doc_id,sentence,text_marked,e1_text,e1_type,e1_start,e1_end,e2_text,e2_type,e2_start,e2_end,p_NoRel,p_HasRel,margin,pred
line1,The clinical profile for Patient 21 includes abnormal thalamic signal intensity and eyelids were positioned lower than normal. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient 21 includes [E1]abnormal thalamic signal intensity[/E1] and eyelids were positioned lower than normal. Genetic analysis of the [E2]POLG[/E2] gene confirmed the diagnosis.,POLG,GENE_VARIANT,151,155,abnormal thalamic signal intensity,HPO_TERM,45,79,0.76895005,0.23104997,-0.5379001,0
line1,The clinical profile for Patient 21 includes abnormal thalamic signal intensity and eyelids were positioned lower than normal. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient 21 includes abnormal thalamic signal intensity and [E1]eyelids were positioned lower than normal[/E1]. Genetic analysis of the [E2]POLG[/E2] gene confirmed the diagnosis.,POLG,GENE_VARIANT,151,155,eyelids were positioned lower than normal,HPO_TERM,84,125,0.7798349,0.22016506,-0.55966985,0
line2,The clinical profile for Patient 22 includes COX-deficient muscle fibers and abnormal thalamic signal intensity. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient 22 includes [E1]COX-deficient muscle fibers[/E1] and abnormal thalamic signal intensity. Genetic analysis of the [E2]POLG[/E2] gene confirmed the diagnosis.,POLG,GENE_VARIANT,137,141,COX-deficient muscle fibers,HPO_TERM,45,72,0.72925633,0.27074364,-0.4585127,0
line2,The clinical profile for Patient 22 includes COX-deficient muscle fibers and abnormal thalamic signal intensity. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient 22 includes COX-deficient muscle fibers and [E1]abnormal thalamic signal intensity[/E1]. Genetic analysis of the [E2]POLG[/E2] gene confirmed the diagnosis.,POLG,GENE_VARIANT,137,141,abnormal thalamic signal intensity,HPO_TERM,77,111,0.763317,0.23668304,-0.526634,0
line3,"We report the case of Patient 23, who has a history of seizure-like activity. Examination also revealed a parkinsonian syndrome. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient 23, who has a history of [E1]seizure-like activity[/E1]. Examination also revealed a parkinsonian syndrome. The underlying cause was traced to a mutation in the [E2]POLG[/E2] gene.",POLG,GENE_VARIANT,182,186,seizure-like activity,HPO_TERM,55,76,0.41803256,0.5819675,0.16393492,1
line3,"We report the case of Patient 23, who has a history of seizure-like activity. Examination also revealed a parkinsonian syndrome. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient 23, who has a history of seizure-like activity. Examination also revealed [E1]a parkinsonian syndrome[/E1]. The underlying cause was traced to a mutation in the [E2]POLG[/E2] gene.",POLG,GENE_VARIANT,182,186,a parkinsonian syndrome,HPO_TERM,104,127,0.47312188,0.52687806,0.053756177,1
line4,"We report the case of Patient 24, who has a history of bilateral ptosis. Examination also revealed cytochrome c oxidase-negative muscle fibers. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient 24, who has a history of [E1]bilateral ptosis[/E1]. Examination also revealed cytochrome c oxidase-negative muscle fibers. The underlying cause was traced to a mutation in the [E2]POLG[/E2] gene.",POLG,GENE_VARIANT,197,201,bilateral ptosis,HPO_TERM,55,71,0.41906646,0.5809335,0.16186705,1
line4,"We report the case of Patient 24, who has a history of bilateral ptosis. Examination also revealed cytochrome c oxidase-negative muscle fibers. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient 24, who has a history of bilateral ptosis. Examination also revealed [E1]cytochrome c oxidase-negative muscle fibers[/E1]. The underlying cause was traced to a mutation in the [E2]POLG[/E2] gene.",POLG,GENE_VARIANT,197,201,cytochrome c oxidase-negative muscle fibers,HPO_TERM,99,142,0.3569161,0.64308393,0.28616783,1
line5,Patient 25 was evaluated for an increased lactate level. The patient also presented with an adult onset and slowness of movement and a resting tremor. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 25 was evaluated for [E1]an increased lactate le[/E1]vel. The patient also presented with an adult onset and slowness of movement and a resting tremor. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,176,180,an increased lactate le,HPO_TERM,29,52,0.83282423,0.16717578,-0.66564846,0
line5,Patient 25 was evaluated for an increased lactate level. The patient also presented with an adult onset and slowness of movement and a resting tremor. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 25 was evaluated for an increased lactate level. The patient also presented wi[E1]th an adult ons[/E1]et and slowness of movement and a resting tremor. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,176,180,th an adult ons,HPO_TERM,86,101,0.84413946,0.15586054,-0.6882789,0
line5,Patient 25 was evaluated for an increased lactate level. The patient also presented with an adult onset and slowness of movement and a resting tremor. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 25 was evaluated for an increased lactate level. The patient also presented with an adult onset an[E1]d slowness of movement and a resting tr[/E1]emor. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,176,180,d slowness of movement and a resting tr,HPO_TERM,106,145,0.8589281,0.14107189,-0.71785617,0
line6,"This report details Patient 26, a patient with a pediatric-onset disorder. Further investigation showed slurred, consistent with dysarthria and a buildup of lactate in his bloodstream. A known variant in the POLG gene was identified.","This report details Patient 26, a patient with [E1]a pediatric-onset disorder[/E1]. Further investigation showed slurred, consistent with dysarthria and a buildup of lactate in his bloodstream. A known variant in t[E2]he P[/E2]OLG gene was identified.",he P,GENE_VARIANT,205,209,a pediatric-onset disorder,HPO_TERM,47,73,0.8292358,0.17076422,-0.6584716,0
line6,"This report details Patient 26, a patient with a pediatric-onset disorder. Further investigation showed slurred, consistent with dysarthria and a buildup of lactate in his bloodstream. A known variant in the POLG gene was identified.","This report details Patient 26, a patient with a pediatric-onset disorder. Further investigation showed [E1]slurred, consistent with dysarthr[/E1]ia and a buildup of lactate in his bloodstream. A known variant in t[E2]he P[/E2]OLG gene was identified.",he P,GENE_VARIANT,205,209,"slurred, consistent with dysarthr",HPO_TERM,104,137,0.8057888,0.19421117,-0.61157763,0
line6,"This report details Patient 26, a patient with a pediatric-onset disorder. Further investigation showed slurred, consistent with dysarthria and a buildup of lactate in his bloodstream. A known variant in the POLG gene was identified.","This report details Patient 26, a patient with a pediatric-onset disorder. Further investigation showed slurred, consistent with dysarthria an[E1]d a buildup of lactate in his bloodstre[/E1]am. A known variant in t[E2]he P[/E2]OLG gene was identified.",he P,GENE_VARIANT,205,209,d a buildup of lactate in his bloodstre,HPO_TERM,142,181,0.8083983,0.19160166,-0.6167966,0
line7,The primary symptoms for Patient 27 were a buildup of lactate in his bloodstream and a clinical syndrome resembling Parkinson's disease. Analysis of the POLG gene was performed.,The primary symptoms for Patient 27 were a [E1]buildup of lactate in his bloodstream a[/E1]nd a clinical syndrome resembling Parkinson's disease. Analysis of the POLG g[E2]ene [/E2]was performed.,ene ,GENE_VARIANT,159,163,buildup of lactate in his bloodstream a,HPO_TERM,43,82,0.83984053,0.1601594,-0.6796811,0
line7,The primary symptoms for Patient 27 were a buildup of lactate in his bloodstream and a clinical syndrome resembling Parkinson's disease. Analysis of the POLG gene was performed.,The primary symptoms for Patient 27 were a buildup of lactate in his bloodstream and a [E1]clinical syndrome resembling Parkinson's disea[/E1]se. Analysis of the POLG g[E2]ene [/E2]was performed.,ene ,GENE_VARIANT,159,163,clinical syndrome resembling Parkinson's disea,HPO_TERM,87,133,0.8479549,0.15204506,-0.69590986,0
line8,"We report the case of Patient 28, who has a history of an increased lactate level. Examination also revealed a buildup of lactate in his bloodstream. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient 28, who has a history of [E1]an increased lactate le[/E1]vel. Examination also revealed a buildup of lactate in his bloodstream. The underlying cause was traced to a mutation in t[E2]he P[/E2]OLG gene.",he P,GENE_VARIANT,200,204,an increased lactate le,HPO_TERM,55,78,0.7702933,0.2297067,-0.5405866,0
line8,"We report the case of Patient 28, who has a history of an increased lactate level. Examination also revealed a buildup of lactate in his bloodstream. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient 28, who has a history of an increased lactate level. Examination also reveal[E1]ed a buildup of lactate in his bloodstr[/E1]eam. The underlying cause was traced to a mutation in t[E2]he P[/E2]OLG gene.",he P,GENE_VARIANT,200,204,ed a buildup of lactate in his bloodstr,HPO_TERM,106,145,0.72478795,0.27521205,-0.4495759,0
line9,Patient 29 was evaluated for an adult onset. The patient also presented with features of parkinsonism and a buildup of lactate in his bloodstream. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 29 was evaluated for an adult onset. The patient also presented with f[E1]eatures of parkinsonis[/E1]m and a buildup of lactate in his bloodstream. Subsequent sequencing of the[E2] POL[/E2]G gene revealed a pathogenic variant., POL,GENE_VARIANT,175,179,eatures of parkinsonis,HPO_TERM,78,100,0.8357742,0.16422579,-0.67154837,0
line9,Patient 29 was evaluated for an adult onset. The patient also presented with features of parkinsonism and a buildup of lactate in his bloodstream. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 29 was evaluated for an adult onset. The patient also presented with features of parkinsonism and[E1] a buildup of lactate in his bloodstrea[/E1]m. Subsequent sequencing of the[E2] POL[/E2]G gene revealed a pathogenic variant., POL,GENE_VARIANT,175,179, a buildup of lactate in his bloodstrea,HPO_TERM,105,144,0.84440774,0.15559229,-0.6888155,0
line10,"This report details Patient 30, a patient with a pediatric-onset disorder. Further investigation showed a deficiency in cytochrome c oxidase and an atypical thalamic signal. A known variant in the POLG gene was identified.","This report details Patient 30, a patient with [E1]a pediatric-onset disorder[/E1]. Further investigation showed a deficiency in cytochrome c oxidase and an atypical thalamic signal. A known variant in th[E2]e PO[/E2]LG gene was identified.",e PO,GENE_VARIANT,195,199,a pediatric-onset disorder,HPO_TERM,47,73,0.8370169,0.16298313,-0.67403376,0
line10,"This report details Patient 30, a patient with a pediatric-onset disorder. Further investigation showed a deficiency in cytochrome c oxidase and an atypical thalamic signal. A known variant in the POLG gene was identified.","This report details Patient 30, a patient with a pediatric-onset disorder. Further investigation showed [E1]a deficiency in cytochrome c oxidase [/E1]and an atypical thalamic signal. A known variant in th[E2]e PO[/E2]LG gene was identified.",e PO,GENE_VARIANT,195,199,a deficiency in cytochrome c oxidase ,HPO_TERM,104,141,0.8148505,0.18514949,-0.629701,0
line10,"This report details Patient 30, a patient with a pediatric-onset disorder. Further investigation showed a deficiency in cytochrome c oxidase and an atypical thalamic signal. A known variant in the POLG gene was identified.","This report details Patient 30, a patient with a pediatric-onset disorder. Further investigation showed a deficiency in cytochrome c oxidase and a[E1]n atypical thalamic signa[/E1]l. A known variant in th[E2]e PO[/E2]LG gene was identified.",e PO,GENE_VARIANT,195,199,n atypical thalamic signa,HPO_TERM,146,171,0.82726884,0.17273118,-0.6545377,0
line11,"This report details Patient 31, a patient with drooping of both upper eyelids. Further investigation showed unclear or mumbled speech and an atypical thalamic signal. A known variant in the POLG gene was identified.","This report details Patient 31, a patient with [E1]drooping of both upper eyelids[/E1]. Further investigation showed unclear or mumbled speech and an atypical thalamic signal. A known variant in t[E2]he P[/E2]OLG gene was identified.",he P,GENE_VARIANT,187,191,drooping of both upper eyelids,HPO_TERM,47,77,0.79534525,0.2046548,-0.59069043,0
line11,"This report details Patient 31, a patient with drooping of both upper eyelids. Further investigation showed unclear or mumbled speech and an atypical thalamic signal. A known variant in the POLG gene was identified.","This report details Patient 31, a patient with drooping of both upper eyelids. Further investigation showed [E1]unclear or mumbled speech[/E1] and an atypical thalamic signal. A known variant in t[E2]he P[/E2]OLG gene was identified.",he P,GENE_VARIANT,187,191,unclear or mumbled speech,HPO_TERM,108,133,0.79248387,0.20751615,-0.58496773,0
line11,"This report details Patient 31, a patient with drooping of both upper eyelids. Further investigation showed unclear or mumbled speech and an atypical thalamic signal. A known variant in the POLG gene was identified.","This report details Patient 31, a patient with drooping of both upper eyelids. Further investigation showed unclear or mumbled speech and [E1]an atypical thalamic sign[/E1]al. A known variant in t[E2]he P[/E2]OLG gene was identified.",he P,GENE_VARIANT,187,191,an atypical thalamic sign,HPO_TERM,138,163,0.82413685,0.17586318,-0.6482737,0
line12,The primary symptoms for Patient 32 were a seizure and a parkinsonian syndrome. Analysis of the POLG gene was performed.,The primary symptoms for Patient 32 were a [E1]seizure a[/E1]nd a parkinsonian syndrome. Analysis of the POLG gene[E2] was[/E2] performed., was,GENE_VARIANT,105,109,seizure a,HPO_TERM,43,52,0.8346651,0.16533494,-0.6693302,0
line13,"We report the case of Patient 33, who has a history of slowness of movement and a resting tremor. Examination also revealed unclear or mumbled speech. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient 33, who has a history of [E1]slowness of movement and a resting trem[/E1]or. Examination also revealed unclear or mumbled speech. The underlying cause was traced to a mutation in th[E2]e PO[/E2]LG gene.",e PO,GENE_VARIANT,202,206,slowness of movement and a resting trem,HPO_TERM,55,94,0.60524654,0.39475343,-0.21049312,0
line13,"We report the case of Patient 33, who has a history of slowness of movement and a resting tremor. Examination also revealed unclear or mumbled speech. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient 33, who has a history of slowness of movement and a resting tremor. Examination also reveale[E1]d unclear or mumbled spee[/E1]ch. The underlying cause was traced to a mutation in th[E2]e PO[/E2]LG gene.",e PO,GENE_VARIANT,202,206,d unclear or mumbled spee,HPO_TERM,122,147,0.4626731,0.53732693,0.074653834,1
line14,The clinical profile for Patient 34 includes epilepsy and an atypical thalamic signal. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient 34 includes [E1]epilepsy[/E1] and an atypical thalamic signal. Genetic analysis of th[E2]e PO[/E2]LG gene confirmed the diagnosis.,e PO,GENE_VARIANT,109,113,epilepsy,HPO_TERM,45,53,0.84589046,0.15410955,-0.6917809,0
line14,The clinical profile for Patient 34 includes epilepsy and an atypical thalamic signal. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient 34 includes epilepsy and [E1]an atypical thalamic sign[/E1]al. Genetic analysis of th[E2]e PO[/E2]LG gene confirmed the diagnosis.,e PO,GENE_VARIANT,109,113,an atypical thalamic sign,HPO_TERM,58,83,0.87069297,0.12930703,-0.74138594,0
line15,"Patient 35 was evaluated for a pediatric-onset disorder. The patient also presented with slurred, consistent with dysarthria and hyperlactatemia. Subsequent sequencing of the POLG gene revealed a pathogenic variant.","Patient 35 was evaluated for [E1]a pediatric-onset disorder[/E1]. The patient also presented with slurred, consistent with dysarthria and hyperlactatemia. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.",he P,GENE_VARIANT,172,176,a pediatric-onset disorder,HPO_TERM,29,55,0.8309815,0.16901845,-0.66196305,0
line15,"Patient 35 was evaluated for a pediatric-onset disorder. The patient also presented with slurred, consistent with dysarthria and hyperlactatemia. Subsequent sequencing of the POLG gene revealed a pathogenic variant.","Patient 35 was evaluated for a pediatric-onset disorder. The patient also presented with [E1]slurred, consistent with dysarthr[/E1]ia and hyperlactatemia. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.",he P,GENE_VARIANT,172,176,"slurred, consistent with dysarthr",HPO_TERM,89,122,0.82211924,0.17788076,-0.6442385,0
line15,"Patient 35 was evaluated for a pediatric-onset disorder. The patient also presented with slurred, consistent with dysarthria and hyperlactatemia. Subsequent sequencing of the POLG gene revealed a pathogenic variant.","Patient 35 was evaluated for a pediatric-onset disorder. The patient also presented with slurred, consistent with dysarthria an[E1]d hyperlactate[/E1]mia. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.",he P,GENE_VARIANT,172,176,d hyperlactate,HPO_TERM,127,141,0.84638405,0.15361595,-0.6927681,0
line16,"This report details Patient 36, a patient with a clinical syndrome resembling Parkinson's disease. Further investigation showed a parkinsonian syndrome and a buildup of lactate in his bloodstream. A known variant in the POLG gene was identified.","This report details Patient 36, a patient with [E1]a clinical syndrome resembling Parkinson's dis[/E1]ease. Further investigation showed a parkinsonian syndrome and a buildup of lactate in his bloodstream. A known variant i[E2]n th[/E2]e POLG gene was identified.",n th,GENE_VARIANT,214,218,a clinical syndrome resembling Parkinson's dis,HPO_TERM,47,93,0.86356187,0.13643812,-0.72712374,0
line16,"This report details Patient 36, a patient with a clinical syndrome resembling Parkinson's disease. Further investigation showed a parkinsonian syndrome and a buildup of lactate in his bloodstream. A known variant in the POLG gene was identified.","This report details Patient 36, a patient with a clinical syndrome resembling Parkinson's disease. Further investigation sho[E1]wed a parkinsonian syn[/E1]drome and a buildup of lactate in his bloodstream. A known variant i[E2]n th[/E2]e POLG gene was identified.",n th,GENE_VARIANT,214,218,wed a parkinsonian syn,HPO_TERM,124,146,0.84948117,0.15051886,-0.69896233,0
line16,"This report details Patient 36, a patient with a clinical syndrome resembling Parkinson's disease. Further investigation showed a parkinsonian syndrome and a buildup of lactate in his bloodstream. A known variant in the POLG gene was identified.","This report details Patient 36, a patient with a clinical syndrome resembling Parkinson's disease. Further investigation showed a parkinsonian syndrome[E1] and a buildup of lactate in his bloods[/E1]tream. A known variant i[E2]n th[/E2]e POLG gene was identified.",n th,GENE_VARIANT,214,218, and a buildup of lactate in his bloods,HPO_TERM,151,190,0.86797833,0.13202168,-0.73595667,0
line17,The primary symptoms for Patient 37 were a condition that affects the muscles used for speech and epilepsy. Analysis of the POLG gene was performed.,The primary symptoms for Patient 37 were a [E1]condition that affects the muscles used for speech [/E1]and epilepsy. Analysis of the POLG gene[E2] was[/E2] performed., was,GENE_VARIANT,133,137,condition that affects the muscles used for speech ,HPO_TERM,43,94,0.82808363,0.17191643,-0.6561672,0
line18,The clinical profile for Patient 38 includes a pediatric-onset disorder and motor speech difficulties. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient 38 includes [E1]a pediatric-onset disorder[/E1] and motor speech difficulties. Genetic analysis of th[E2]e PO[/E2]LG gene confirmed the diagnosis.,e PO,GENE_VARIANT,125,129,a pediatric-onset disorder,HPO_TERM,45,71,0.8473668,0.15263312,-0.6947337,0
line18,The clinical profile for Patient 38 includes a pediatric-onset disorder and motor speech difficulties. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient 38 includes a pediatric-onset disorder and [E1]motor speech difficulti[/E1]es. Genetic analysis of th[E2]e PO[/E2]LG gene confirmed the diagnosis.,e PO,GENE_VARIANT,125,129,motor speech difficulti,HPO_TERM,76,99,0.8299798,0.17002021,-0.65995955,0
line19,The primary symptoms for Patient 39 were an atypical thalamic signal and signs of parkinsonism. Analysis of the POLG gene was performed.,The primary symptoms for Patient 39 were an[E1] atypical thalamic signal[/E1] and signs of parkinsonism. Analysis of the POLG ge[E2]ne w[/E2]as performed.,ne w,GENE_VARIANT,119,123, atypical thalamic signal,HPO_TERM,43,68,0.7540384,0.2459616,-0.5080768,0
line19,The primary symptoms for Patient 39 were an atypical thalamic signal and signs of parkinsonism. Analysis of the POLG gene was performed.,The primary symptoms for Patient 39 were an atypical thalamic signal and [E1]signs of parkinsonis[/E1]m. Analysis of the POLG ge[E2]ne w[/E2]as performed.,ne w,GENE_VARIANT,119,123,signs of parkinsonis,HPO_TERM,73,93,0.8258575,0.17414245,-0.65171504,0
line20,"The clinical profile for Patient 40 includes an increased lactate level and slurred, consistent with dysarthria. Genetic analysis of the POLG gene confirmed the diagnosis.","The clinical profile for Patient 40 includes [E1]an increased lactate le[/E1]vel and slurred, consistent with dysarthria. Genetic analysis of[E2] the[/E2] POLG gene confirmed the diagnosis.", the,GENE_VARIANT,132,136,an increased lactate le,HPO_TERM,45,68,0.84164876,0.15835123,-0.6832975,0
line20,"The clinical profile for Patient 40 includes an increased lactate level and slurred, consistent with dysarthria. Genetic analysis of the POLG gene confirmed the diagnosis.","The clinical profile for Patient 40 includes an increased lactate level a[E1]nd slurred, consistent with dysar[/E1]thria. Genetic analysis of[E2] the[/E2] POLG gene confirmed the diagnosis.", the,GENE_VARIANT,132,136,"nd slurred, consistent with dysar",HPO_TERM,73,106,0.8526367,0.14736328,-0.7052734,0
line21,"This report details Patient 41, a patient with a late-onset variant of the condition. Further investigation showed an increased lactate level and hyperlactatemia. A known variant in the POLG gene was identified.","This report details Patient 41, a patient with [E1]a late-onset variant of the condition[/E1]. Further investigation showed an increased lactate level and hyperlactatemia. A known variant in[E2] the[/E2] POLG gene was identified.", the,GENE_VARIANT,181,185,a late-onset variant of the condition,HPO_TERM,47,84,0.80720127,0.19279882,-0.6144024,0
line21,"This report details Patient 41, a patient with a late-onset variant of the condition. Further investigation showed an increased lactate level and hyperlactatemia. A known variant in the POLG gene was identified.","This report details Patient 41, a patient with a late-onset variant of the condition. Further investigation showed [E1]an increased lactate le[/E1]vel and hyperlactatemia. A known variant in[E2] the[/E2] POLG gene was identified.", the,GENE_VARIANT,181,185,an increased lactate le,HPO_TERM,115,138,0.78527355,0.21472637,-0.57054716,0
line21,"This report details Patient 41, a patient with a late-onset variant of the condition. Further investigation showed an increased lactate level and hyperlactatemia. A known variant in the POLG gene was identified.","This report details Patient 41, a patient with a late-onset variant of the condition. Further investigation showed an increased lactate level a[E1]nd hyperlactat[/E1]emia. A known variant in[E2] the[/E2] POLG gene was identified.", the,GENE_VARIANT,181,185,nd hyperlactat,HPO_TERM,143,157,0.8098885,0.19011152,-0.61977696,0
line22,Patient 42 was evaluated for an increased lactate level. The patient also presented with a buildup of lactate in his bloodstream and an adult onset. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 42 was evaluated for [E1]an increased lactate le[/E1]vel. The patient also presented with a buildup of lactate in his bloodstream and an adult onset. Subsequent sequencing of th[E2]e PO[/E2]LG gene revealed a pathogenic variant.,e PO,GENE_VARIANT,176,180,an increased lactate le,HPO_TERM,29,52,0.88339114,0.11660891,-0.7667822,0
line22,Patient 42 was evaluated for an increased lactate level. The patient also presented with a buildup of lactate in his bloodstream and an adult onset. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 42 was evaluated for an increased lactate level. The patient also presented wi[E1]th a buildup of lactate in his bloodstr[/E1]eam and an adult onset. Subsequent sequencing of th[E2]e PO[/E2]LG gene revealed a pathogenic variant.,e PO,GENE_VARIANT,176,180,th a buildup of lactate in his bloodstr,HPO_TERM,86,125,0.88153046,0.11846947,-0.763061,0
line22,Patient 42 was evaluated for an increased lactate level. The patient also presented with a buildup of lactate in his bloodstream and an adult onset. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 42 was evaluated for an increased lactate level. The patient also presented with a buildup of lactate in his bloodstream a[E1]nd an adult ons[/E1]et. Subsequent sequencing of th[E2]e PO[/E2]LG gene revealed a pathogenic variant.,e PO,GENE_VARIANT,176,180,nd an adult ons,HPO_TERM,130,145,0.89071,0.10929002,-0.78142,0
line23,"This report details Patient 43, a patient with a seizure. Further investigation showed a buildup of lactate in his bloodstream and a parkinsonian syndrome. A known variant in the POLG gene was identified.","This report details Patient 43, a patient with [E1]a seizure[/E1]. Further investigation showed a buildup of lactate in his bloodstream and a parkinsonian syndrome. A known variant in th[E2]e PO[/E2]LG gene was identified.",e PO,GENE_VARIANT,177,181,a seizure,HPO_TERM,47,56,0.83648854,0.16351146,-0.6729771,0
line23,"This report details Patient 43, a patient with a seizure. Further investigation showed a buildup of lactate in his bloodstream and a parkinsonian syndrome. A known variant in the POLG gene was identified.","This report details Patient 43, a patient with a seizure. Further investigation showed [E1]a buildup of lactate in his bloodstream[/E1] and a parkinsonian syndrome. A known variant in th[E2]e PO[/E2]LG gene was identified.",e PO,GENE_VARIANT,177,181,a buildup of lactate in his bloodstream,HPO_TERM,87,126,0.84417903,0.15582098,-0.68835807,0
line23,"This report details Patient 43, a patient with a seizure. Further investigation showed a buildup of lactate in his bloodstream and a parkinsonian syndrome. A known variant in the POLG gene was identified.","This report details Patient 43, a patient with a seizure. Further investigation showed a buildup of lactate in his bloodstream and [E1]a parkinsonian syndrom[/E1]e. A known variant in th[E2]e PO[/E2]LG gene was identified.",e PO,GENE_VARIANT,177,181,a parkinsonian syndrom,HPO_TERM,131,153,0.85034144,0.14965852,-0.70068294,0
line24,Patient 44 was evaluated for drooping of both upper eyelids. The patient also presented with an increased lactate level and a buildup of lactate in his bloodstream. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 44 was evaluated for [E1]drooping of both upper eyelids[/E1]. The patient also presented with an increased lactate level and a buildup of lactate in his bloodstream. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,191,195,drooping of both upper eyelids,HPO_TERM,29,59,0.8691225,0.13087748,-0.738245,0
line24,Patient 44 was evaluated for drooping of both upper eyelids. The patient also presented with an increased lactate level and a buildup of lactate in his bloodstream. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 44 was evaluated for drooping of both upper eyelids. The patient also presented with [E1]an increased lactate le[/E1]vel and a buildup of lactate in his bloodstream. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,191,195,an increased lactate le,HPO_TERM,93,116,0.8693831,0.13061687,-0.7387662,0
line24,Patient 44 was evaluated for drooping of both upper eyelids. The patient also presented with an increased lactate level and a buildup of lactate in his bloodstream. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 44 was evaluated for drooping of both upper eyelids. The patient also presented with an increased lactate level a[E1]nd a buildup of lactate in his bloodstr[/E1]eam. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,191,195,nd a buildup of lactate in his bloodstr,HPO_TERM,121,160,0.8840156,0.1159844,-0.76803124,0
line25,The primary symptoms for Patient 45 were a clinical syndrome resembling Parkinson's disease and an abnormal thalamic MRI signal. Analysis of the POLG gene was performed.,The primary symptoms for Patient 45 were a [E1]clinical syndrome resembling Parkinson's disea[/E1]se and an abnormal thalamic MRI signal. Analysis of the POLG[E2] gen[/E2]e was performed., gen,GENE_VARIANT,149,153,clinical syndrome resembling Parkinson's disea,HPO_TERM,43,89,0.8510709,0.14892913,-0.70214176,0
line25,The primary symptoms for Patient 45 were a clinical syndrome resembling Parkinson's disease and an abnormal thalamic MRI signal. Analysis of the POLG gene was performed.,The primary symptoms for Patient 45 were a clinical syndrome resembling Parkinson's disease an[E1]d an abnormal thalamic MRI si[/E1]gnal. Analysis of the POLG[E2] gen[/E2]e was performed., gen,GENE_VARIANT,149,153,d an abnormal thalamic MRI si,HPO_TERM,94,123,0.8575149,0.14248505,-0.71502984,0
line26,Patient 46 was evaluated for bilateral ptosis. The patient also presented with an increased lactate level and hyperlactatemia. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 46 was evaluated for [E1]bilateral ptosis[/E1]. The patient also presented with an increased lactate level and hyperlactatemia. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,152,156,bilateral ptosis,HPO_TERM,29,45,0.8495228,0.15047716,-0.69904566,0
line26,Patient 46 was evaluated for bilateral ptosis. The patient also presented with an increased lactate level and hyperlactatemia. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 46 was evaluated for bilateral ptosis. The patient also presented with [E1]an increased lactate le[/E1]vel and hyperlactatemia. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,152,156,an increased lactate le,HPO_TERM,79,102,0.8541769,0.14582317,-0.7083537,0
line26,Patient 46 was evaluated for bilateral ptosis. The patient also presented with an increased lactate level and hyperlactatemia. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 46 was evaluated for bilateral ptosis. The patient also presented with an increased lactate level a[E1]nd hyperlactat[/E1]emia. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,152,156,nd hyperlactat,HPO_TERM,107,121,0.86322,0.13678004,-0.72643995,0
line27,Patient 47 was evaluated for a seizure. The patient also presented with an atypical thalamic signal and a buildup of lactate in his bloodstream. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 47 was evaluated for [E1]a seizure[/E1]. The patient also presented with an atypical thalamic signal and a buildup of lactate in his bloodstream. Subsequent sequencing of th[E2]e PO[/E2]LG gene revealed a pathogenic variant.,e PO,GENE_VARIANT,172,176,a seizure,HPO_TERM,29,38,0.8692397,0.13076037,-0.7384793,0
line27,Patient 47 was evaluated for a seizure. The patient also presented with an atypical thalamic signal and a buildup of lactate in his bloodstream. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 47 was evaluated for a seizure. The patient also presented with [E1]an atypical thalamic sign[/E1]al and a buildup of lactate in his bloodstream. Subsequent sequencing of th[E2]e PO[/E2]LG gene revealed a pathogenic variant.,e PO,GENE_VARIANT,172,176,an atypical thalamic sign,HPO_TERM,72,97,0.8711918,0.12880829,-0.7423835,0
line27,Patient 47 was evaluated for a seizure. The patient also presented with an atypical thalamic signal and a buildup of lactate in his bloodstream. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 47 was evaluated for a seizure. The patient also presented with an atypical thalamic signal an[E1]d a buildup of lactate in his bloodstre[/E1]am. Subsequent sequencing of th[E2]e PO[/E2]LG gene revealed a pathogenic variant.,e PO,GENE_VARIANT,172,176,d a buildup of lactate in his bloodstre,HPO_TERM,102,141,0.86936,0.13063996,-0.73872006,0
line28,"Patient 48 was evaluated for slurred, consistent with dysarthria. The patient also presented with hyperlactatemia and an atypical thalamic signal. Subsequent sequencing of the POLG gene revealed a pathogenic variant.","Patient 48 was evaluated for [E1]slurred, consistent with dysarthr[/E1]ia. The patient also presented with hyperlactatemia and an atypical thalamic signal. Subsequent sequencing of[E2] the[/E2] POLG gene revealed a pathogenic variant.", the,GENE_VARIANT,171,175,"slurred, consistent with dysarthr",HPO_TERM,29,62,0.8028732,0.1971268,-0.6057464,0
line28,"Patient 48 was evaluated for slurred, consistent with dysarthria. The patient also presented with hyperlactatemia and an atypical thalamic signal. Subsequent sequencing of the POLG gene revealed a pathogenic variant.","Patient 48 was evaluated for slurred, consistent with dysarthria. The patient also presented wit[E1]h hyperlactate[/E1]mia and an atypical thalamic signal. Subsequent sequencing of[E2] the[/E2] POLG gene revealed a pathogenic variant.", the,GENE_VARIANT,171,175,h hyperlactate,HPO_TERM,96,110,0.80661327,0.19338667,-0.6132266,0
line28,"Patient 48 was evaluated for slurred, consistent with dysarthria. The patient also presented with hyperlactatemia and an atypical thalamic signal. Subsequent sequencing of the POLG gene revealed a pathogenic variant.","Patient 48 was evaluated for slurred, consistent with dysarthria. The patient also presented with hyperlactatemia a[E1]nd an atypical thalamic s[/E1]ignal. Subsequent sequencing of[E2] the[/E2] POLG gene revealed a pathogenic variant.", the,GENE_VARIANT,171,175,nd an atypical thalamic s,HPO_TERM,115,140,0.82508856,0.17491144,-0.6501771,0
line29,The primary symptoms for Patient 49 were bilateral ptosis and a seizure. Analysis of the POLG gene was performed.,The primary symptoms for Patient 49 were bi[E1]lateral ptosis a[/E1]nd a seizure. Analysis of the POLG gene [E2]was [/E2]performed.,was ,GENE_VARIANT,99,103,lateral ptosis a,HPO_TERM,43,59,0.8411162,0.15888385,-0.6822323,0
line30,The primary symptoms for Patient 50 were an atypical thalamic signal and drooping of both upper eyelids. Analysis of the POLG gene was performed.,The primary symptoms for Patient 50 were an[E1] atypical thalamic signal[/E1] and drooping of both upper eyelids. Analysis of the POLG gen[E2]e wa[/E2]s performed.,e wa,GENE_VARIANT,129,133, atypical thalamic signal,HPO_TERM,43,68,0.77148503,0.22851501,-0.54297,0
line30,The primary symptoms for Patient 50 were an atypical thalamic signal and drooping of both upper eyelids. Analysis of the POLG gene was performed.,The primary symptoms for Patient 50 were an atypical thalamic signal and [E1]drooping of both upper eyelids[/E1]. Analysis of the POLG gen[E2]e wa[/E2]s performed.,e wa,GENE_VARIANT,129,133,drooping of both upper eyelids,HPO_TERM,73,103,0.79185367,0.20814638,-0.5837073,0
line31,"This report details Patient 51, a patient with a pediatric-onset disorder. Further investigation showed drooping of both upper eyelids and an adult onset. A known variant in the POLG gene was identified.","This report details Patient 51, a patient with [E1]a pediatric-onset disorder[/E1]. Further investigation showed drooping of both upper eyelids and an adult onset. A known variant in the [E2]POLG[/E2] gene was identified.",POLG,GENE_VARIANT,178,182,a pediatric-onset disorder,HPO_TERM,47,73,0.7698372,0.2301628,-0.5396744,0
line31,"This report details Patient 51, a patient with a pediatric-onset disorder. Further investigation showed drooping of both upper eyelids and an adult onset. A known variant in the POLG gene was identified.","This report details Patient 51, a patient with a pediatric-onset disorder. Further investigation showed [E1]drooping of both upper eyelids[/E1] and an adult onset. A known variant in the [E2]POLG[/E2] gene was identified.",POLG,GENE_VARIANT,178,182,drooping of both upper eyelids,HPO_TERM,104,134,0.7488366,0.2511634,-0.49767318,0
line32,The clinical profile for Patient 52 includes a clinical syndrome resembling Parkinson's disease and an atypical thalamic signal. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient 52 includes [E1]a clinical syndrome resembling Parkinson's dis[/E1]ease and an atypical thalamic signal. Genetic analysis o[E2]f th[/E2]e POLG gene confirmed the diagnosis.,f th,GENE_VARIANT,147,151,a clinical syndrome resembling Parkinson's dis,HPO_TERM,45,91,0.8338802,0.16611977,-0.66776043,0
line32,The clinical profile for Patient 52 includes a clinical syndrome resembling Parkinson's disease and an atypical thalamic signal. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient 52 includes a clinical syndrome resembling Parkinson's disease [E1]and an atypical thalamic [/E1]signal. Genetic analysis o[E2]f th[/E2]e POLG gene confirmed the diagnosis.,f th,GENE_VARIANT,147,151,and an atypical thalamic ,HPO_TERM,96,121,0.843332,0.156668,-0.686664,0
line33,The primary symptoms for Patient 53 were bilateral ptosis and poor articulation. Analysis of the POLG gene was performed.,The primary symptoms for Patient 53 were bi[E1]lateral ptosis a[/E1]nd poor articulation. Analysis of the POLG gene [E2]was [/E2]performed.,was ,GENE_VARIANT,107,111,lateral ptosis a,HPO_TERM,43,59,0.8286015,0.17139852,-0.65720296,0
line34,"This report details Patient 54, a patient with a late-onset variant of the condition. Further investigation showed signs of parkinsonism and an atypical thalamic signal. A known variant in the POLG gene was identified.","This report details Patient 54, a patient with [E1]a late-onset variant of the condition[/E1]. Further investigation showed signs of parkinsonism and an atypical thalamic signal. A known variant in [E2]the [/E2]POLG gene was identified.",the ,GENE_VARIANT,189,193,a late-onset variant of the condition,HPO_TERM,47,84,0.7785034,0.22149661,-0.55700684,0
line34,"This report details Patient 54, a patient with a late-onset variant of the condition. Further investigation showed signs of parkinsonism and an atypical thalamic signal. A known variant in the POLG gene was identified.","This report details Patient 54, a patient with a late-onset variant of the condition. Further investigation showed [E1]signs of parkinsonis[/E1]m and an atypical thalamic signal. A known variant in [E2]the [/E2]POLG gene was identified.",the ,GENE_VARIANT,189,193,signs of parkinsonis,HPO_TERM,115,135,0.7757774,0.22422267,-0.55155474,0
line34,"This report details Patient 54, a patient with a late-onset variant of the condition. Further investigation showed signs of parkinsonism and an atypical thalamic signal. A known variant in the POLG gene was identified.","This report details Patient 54, a patient with a late-onset variant of the condition. Further investigation showed signs of parkinsonism and[E1] an atypical thalamic sig[/E1]nal. A known variant in [E2]the [/E2]POLG gene was identified.",the ,GENE_VARIANT,189,193, an atypical thalamic sig,HPO_TERM,140,165,0.78561467,0.21438529,-0.5712294,0
line35,"We report the case of Patient 55, who has a history of an elevated hepatic transaminase concentration. Examination also revealed signs of parkinsonism. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient 55, who has a history of [E1]an elevated hepatic transaminase concentra[/E1]tion. Examination also revealed signs of parkinsonism. The underlying cause was traced to a mutation in[E2] the[/E2] POLG gene.", the,GENE_VARIANT,200,204,an elevated hepatic transaminase concentra,HPO_TERM,55,97,0.50448674,0.49551317,-0.008973569,0
line35,"We report the case of Patient 55, who has a history of an elevated hepatic transaminase concentration. Examination also revealed signs of parkinsonism. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient 55, who has a history of an elevated hepatic transaminase concentration. Examination also revea[E1]led signs of parkins[/E1]onism. The underlying cause was traced to a mutation in[E2] the[/E2] POLG gene.", the,GENE_VARIANT,200,204,led signs of parkins,HPO_TERM,125,145,0.54595995,0.45404005,-0.0919199,0
line36,"Patient 56 was evaluated for an atypical thalamic signal. The patient also presented with slurred, consistent with dysarthria and a buildup of lactate in his bloodstream. Subsequent sequencing of the POLG gene revealed a pathogenic variant.","Patient 56 was evaluated for [E1]an atypical thalamic sign[/E1]al. The patient also presented with slurred, consistent with dysarthria and a buildup of lactate in his bloodstream. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.",the ,GENE_VARIANT,196,200,an atypical thalamic sign,HPO_TERM,29,54,0.8335493,0.16645068,-0.66709864,0
line36,"Patient 56 was evaluated for an atypical thalamic signal. The patient also presented with slurred, consistent with dysarthria and a buildup of lactate in his bloodstream. Subsequent sequencing of the POLG gene revealed a pathogenic variant.","Patient 56 was evaluated for an atypical thalamic signal. The patient also presented wit[E1]h slurred, consistent with dysart[/E1]hria and a buildup of lactate in his bloodstream. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.",the ,GENE_VARIANT,196,200,"h slurred, consistent with dysart",HPO_TERM,88,121,0.8294939,0.17050612,-0.65898776,0
line36,"Patient 56 was evaluated for an atypical thalamic signal. The patient also presented with slurred, consistent with dysarthria and a buildup of lactate in his bloodstream. Subsequent sequencing of the POLG gene revealed a pathogenic variant.","Patient 56 was evaluated for an atypical thalamic signal. The patient also presented with slurred, consistent with dysarthria [E1]and a buildup of lactate in his bloodst[/E1]ream. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.",the ,GENE_VARIANT,196,200,and a buildup of lactate in his bloodst,HPO_TERM,126,165,0.8166321,0.18336792,-0.6332642,0
line37,The clinical profile for Patient 57 includes hyperlactatemia and a late-onset variant of the condition. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient 57 includes [E1]hyperlactatemi[/E1]a and a late-onset variant of the condition. Genetic analysis of the[E2] POL[/E2]G gene confirmed the diagnosis., POL,GENE_VARIANT,127,131,hyperlactatemi,HPO_TERM,45,59,0.832252,0.16774788,-0.6645042,0
line37,The clinical profile for Patient 57 includes hyperlactatemia and a late-onset variant of the condition. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient 57 includes hyperlactatemia and[E1] a late-onset variant of the conditio[/E1]n. Genetic analysis of the[E2] POL[/E2]G gene confirmed the diagnosis., POL,GENE_VARIANT,127,131, a late-onset variant of the conditio,HPO_TERM,64,101,0.86257887,0.13742116,-0.72515774,0
line38,The clinical profile for Patient 58 includes an increased lactate level and a buildup of lactate in his bloodstream. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient 58 includes [E1]an increased lactate le[/E1]vel and a buildup of lactate in his bloodstream. Genetic analysis of t[E2]he P[/E2]OLG gene confirmed the diagnosis.,he P,GENE_VARIANT,138,142,an increased lactate le,HPO_TERM,45,68,0.8693031,0.13069695,-0.73860615,0
line38,The clinical profile for Patient 58 includes an increased lactate level and a buildup of lactate in his bloodstream. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient 58 includes an increased lactate level a[E1]nd a buildup of lactate in his bloodstr[/E1]eam. Genetic analysis of t[E2]he P[/E2]OLG gene confirmed the diagnosis.,he P,GENE_VARIANT,138,142,nd a buildup of lactate in his bloodstr,HPO_TERM,73,112,0.87236166,0.12763834,-0.7447233,0
line39,"We report the case of Patient 59, who has a history of a clinical syndrome resembling Parkinson's disease. Examination also revealed slowness of movement and a resting tremor. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient 59, who has a history of [E1]a clinical syndrome resembling Parkinson's dis[/E1]ease. Examination also revealed slowness of movement and a resting tremor. The underlying cause was traced to a mutation i[E2]n th[/E2]e POLG gene.",n th,GENE_VARIANT,223,227,a clinical syndrome resembling Parkinson's dis,HPO_TERM,55,101,0.48224634,0.51775366,0.03550732,1
line39,"We report the case of Patient 59, who has a history of a clinical syndrome resembling Parkinson's disease. Examination also revealed slowness of movement and a resting tremor. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient 59, who has a history of a clinical syndrome resembling Parkinson's disease. Examination also revea[E1]led slowness of movement and a resting [/E1]tremor. The underlying cause was traced to a mutation i[E2]n th[/E2]e POLG gene.",n th,GENE_VARIANT,223,227,led slowness of movement and a resting ,HPO_TERM,129,168,0.532848,0.467152,-0.065696,0
line40,The clinical profile for Patient 60 includes a pediatric-onset disorder and an atypical thalamic signal. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient 60 includes [E1]a pediatric-onset disorder[/E1] and an atypical thalamic signal. Genetic analysis of th[E2]e PO[/E2]LG gene confirmed the diagnosis.,e PO,GENE_VARIANT,127,131,a pediatric-onset disorder,HPO_TERM,45,71,0.83654046,0.16345951,-0.6730809,0
line40,The clinical profile for Patient 60 includes a pediatric-onset disorder and an atypical thalamic signal. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient 60 includes a pediatric-onset disorder and [E1]an atypical thalamic sign[/E1]al. Genetic analysis of th[E2]e PO[/E2]LG gene confirmed the diagnosis.,e PO,GENE_VARIANT,127,131,an atypical thalamic sign,HPO_TERM,76,101,0.8574924,0.1425076,-0.7149848,0
line41,The primary symptoms for Patient 61 were an adult onset and an increased lactate level. Analysis of the POLG gene was performed.,The primary symptoms for Patient 61 were an[E1] adult onset an[/E1]d an increased lactate level. Analysis of the POLG gen[E2]e wa[/E2]s performed.,e wa,GENE_VARIANT,112,116, adult onset an,HPO_TERM,43,58,0.78037304,0.21962702,-0.560746,0
line41,The primary symptoms for Patient 61 were an adult onset and an increased lactate level. Analysis of the POLG gene was performed.,The primary symptoms for Patient 61 were an adult onset and an [E1]increased lactate level[/E1]. Analysis of the POLG gen[E2]e wa[/E2]s performed.,e wa,GENE_VARIANT,112,116,increased lactate level,HPO_TERM,63,86,0.7698475,0.23015253,-0.53969496,0
line42,Patient 62 was evaluated for a seizure disorder. The patient also presented with an increased lactate level and an elevated level of lactate in the blood. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 62 was evaluated for a seizure disorder. The patient also presented with an [E1]increased lactate level[/E1] and an elevated level of lactate in the blood. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,181,185,increased lactate level,HPO_TERM,84,107,0.8451524,0.15484764,-0.69030476,0
line42,Patient 62 was evaluated for a seizure disorder. The patient also presented with an increased lactate level and an elevated level of lactate in the blood. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 62 was evaluated for a seizure disorder. The patient also presented with an increased lactate level and [E1]an elevated level of lactate in the bl[/E1]ood. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,181,185,an elevated level of lactate in the bl,HPO_TERM,112,150,0.86225986,0.13774012,-0.7245197,0
line43,The primary symptoms for Patient 63 were bilateral ptosis and signs of parkinsonism. Analysis of the POLG gene was performed.,The primary symptoms for Patient 63 were bi[E1]lateral ptosis a[/E1]nd signs of parkinsonism. Analysis of the POLG gene[E2] was[/E2] performed., was,GENE_VARIANT,110,114,lateral ptosis a,HPO_TERM,43,59,0.81430346,0.18569654,-0.6286069,0
line44,Patient 64 was evaluated for parkinsonism. The patient also presented with an atypical thalamic signal and signs of parkinsonism. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 64 was evaluated for [E1]parkinsonism[/E1]. The patient also presented with an atypical thalamic signal and signs of parkinsonism. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,156,160,parkinsonism,HPO_TERM,29,41,0.84974754,0.15025246,-0.6994951,0
line44,Patient 64 was evaluated for parkinsonism. The patient also presented with an atypical thalamic signal and signs of parkinsonism. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 64 was evaluated for parkinsonism. The patient also presented with [E1]an atypical thalamic sign[/E1]al and signs of parkinsonism. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,156,160,an atypical thalamic sign,HPO_TERM,75,100,0.843338,0.15666199,-0.686676,0
line44,Patient 64 was evaluated for parkinsonism. The patient also presented with an atypical thalamic signal and signs of parkinsonism. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 64 was evaluated for parkinsonism. The patient also presented with an atypical thalamic signal an[E1]d signs of parkinson[/E1]ism. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,156,160,d signs of parkinson,HPO_TERM,105,125,0.85128117,0.1487189,-0.7025623,0
line45,"This report details Patient 65, a patient with disease manifestation was in the pre-adolescent period. Further investigation showed an abnormal thalamic MRI signal and an atypical thalamic signal. A known variant in the POLG gene was identified.","This report details Patient 65, a patient with [E1]disease manifestation was in the pre-adolescent p[/E1]eriod. Further investigation showed an abnormal thalamic MRI signal and an atypical thalamic signal. A known varia[E2]nt i[/E2]n the POLG gene was identified.",nt i,GENE_VARIANT,210,214,disease manifestation was in the pre-adolescent p,HPO_TERM,47,96,0.8882133,0.11178669,-0.77642655,0
line45,"This report details Patient 65, a patient with disease manifestation was in the pre-adolescent period. Further investigation showed an abnormal thalamic MRI signal and an atypical thalamic signal. A known variant in the POLG gene was identified.","This report details Patient 65, a patient with disease manifestation was in the pre-adolescent period. Further investigation sh[E1]owed an abnormal thalamic MRI[/E1] signal and an atypical thalamic signal. A known varia[E2]nt i[/E2]n the POLG gene was identified.",nt i,GENE_VARIANT,210,214,owed an abnormal thalamic MRI,HPO_TERM,127,156,0.88044983,0.11955018,-0.76089966,0
line45,"This report details Patient 65, a patient with disease manifestation was in the pre-adolescent period. Further investigation showed an abnormal thalamic MRI signal and an atypical thalamic signal. A known variant in the POLG gene was identified.","This report details Patient 65, a patient with disease manifestation was in the pre-adolescent period. Further investigation showed an abnormal thalamic MRI sign[E1]al and an atypical thalam[/E1]ic signal. A known varia[E2]nt i[/E2]n the POLG gene was identified.",nt i,GENE_VARIANT,210,214,al and an atypical thalam,HPO_TERM,161,186,0.876478,0.123521954,-0.75295603,0
line46,The primary symptoms for Patient 66 were a condition that affects the muscles used for speech and bradykinesia and rigidity. Analysis of the POLG gene was performed.,The primary symptoms for Patient 66 were a [E1]condition that affects the muscles used for speech [/E1]and bradykinesia and rigidity. Analysis of the POLG gen[E2]e wa[/E2]s performed.,e wa,GENE_VARIANT,149,153,condition that affects the muscles used for speech ,HPO_TERM,43,94,0.6921761,0.30782396,-0.38435215,0
line46,The primary symptoms for Patient 66 were a condition that affects the muscles used for speech and bradykinesia and rigidity. Analysis of the POLG gene was performed.,The primary symptoms for Patient 66 were a condition that affects the muscles used for speech and b[E1]radykinesia and rigidity[/E1]. Analysis of the POLG gen[E2]e wa[/E2]s performed.,e wa,GENE_VARIANT,149,153,radykinesia and rigidity,HPO_TERM,99,123,0.71822345,0.28177652,-0.43644693,0
line47,Patient 67 was evaluated for an atypical thalamic signal. The patient also presented with a buildup of lactate in his bloodstream and a seizure. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 67 was evaluated for [E1]an atypical thalamic sign[/E1]al. The patient also presented with a buildup of lactate in his bloodstream and a seizure. Subsequent sequencing of th[E2]e PO[/E2]LG gene revealed a pathogenic variant.,e PO,GENE_VARIANT,172,176,an atypical thalamic sign,HPO_TERM,29,54,0.8639735,0.13602653,-0.727947,0
line47,Patient 67 was evaluated for an atypical thalamic signal. The patient also presented with a buildup of lactate in his bloodstream and a seizure. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 67 was evaluated for an atypical thalamic signal. The patient also presented wit[E1]h a buildup of lactate in his bloodstre[/E1]am and a seizure. Subsequent sequencing of th[E2]e PO[/E2]LG gene revealed a pathogenic variant.,e PO,GENE_VARIANT,172,176,h a buildup of lactate in his bloodstre,HPO_TERM,88,127,0.8515346,0.14846535,-0.70306927,0
line47,Patient 67 was evaluated for an atypical thalamic signal. The patient also presented with a buildup of lactate in his bloodstream and a seizure. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 67 was evaluated for an atypical thalamic signal. The patient also presented with a buildup of lactate in his bloodstream an[E1]d a seizu[/E1]re. Subsequent sequencing of th[E2]e PO[/E2]LG gene revealed a pathogenic variant.,e PO,GENE_VARIANT,172,176,d a seizu,HPO_TERM,132,141,0.8809929,0.1190071,-0.7619858,0
line48,"We report the case of Patient 68, who has a history of an atypical thalamic signal. Examination also revealed an elevated level of lactate in the blood. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient 68, who has a history of [E1]an atypical thalamic sign[/E1]al. Examination also revealed an elevated level of lactate in the blood. The underlying cause was traced to a mutation in[E2] the[/E2] POLG gene.", the,GENE_VARIANT,201,205,an atypical thalamic sign,HPO_TERM,55,80,0.5668231,0.4331769,-0.13364622,0
line48,"We report the case of Patient 68, who has a history of an atypical thalamic signal. Examination also revealed an elevated level of lactate in the blood. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient 68, who has a history of an atypical thalamic signal. Examination also reveale[E1]d an elevated level of lactate in the [/E1]blood. The underlying cause was traced to a mutation in[E2] the[/E2] POLG gene.", the,GENE_VARIANT,201,205,d an elevated level of lactate in the ,HPO_TERM,108,146,0.66493434,0.33506563,-0.3298687,0
line49,Patient 69 was evaluated for an atypical thalamic signal. The patient also presented with a pediatric-onset disorder and an abnormal thalamic MRI signal. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 69 was evaluated for [E1]an atypical thalamic sign[/E1]al. The patient also presented with a pediatric-onset disorder and an abnormal thalamic MRI signal. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,179,183,an atypical thalamic sign,HPO_TERM,29,54,0.79497814,0.20502183,-0.5899563,0
line49,Patient 69 was evaluated for an atypical thalamic signal. The patient also presented with a pediatric-onset disorder and an abnormal thalamic MRI signal. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 69 was evaluated for an atypical thalamic signal. The patient also presented wit[E1]h a pediatric-onset disord[/E1]er and an abnormal thalamic MRI signal. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,179,183,h a pediatric-onset disord,HPO_TERM,88,114,0.8315688,0.16843127,-0.6631375,0
line49,Patient 69 was evaluated for an atypical thalamic signal. The patient also presented with a pediatric-onset disorder and an abnormal thalamic MRI signal. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 69 was evaluated for an atypical thalamic signal. The patient also presented with a pediatric-onset disorder an[E1]d an abnormal thalamic MRI si[/E1]gnal. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,179,183,d an abnormal thalamic MRI si,HPO_TERM,119,148,0.8216326,0.17836735,-0.64326525,0
line50,The primary symptoms for Patient 70 were a parkinsonian syndrome and a clinical syndrome resembling Parkinson's disease. Analysis of the POLG gene was performed.,The primary symptoms for Patient 70 were a [E1]parkinsonian syndrome [/E1]and a clinical syndrome resembling Parkinson's disease. Analysis of the POLG [E2]gene[/E2] was performed.,gene,GENE_VARIANT,142,146,parkinsonian syndrome ,HPO_TERM,43,65,0.795984,0.20401604,-0.591968,0
line50,The primary symptoms for Patient 70 were a parkinsonian syndrome and a clinical syndrome resembling Parkinson's disease. Analysis of the POLG gene was performed.,The primary symptoms for Patient 70 were a parkinsonian syndrome and a[E1] clinical syndrome resembling Parkinson's dise[/E1]ase. Analysis of the POLG [E2]gene[/E2] was performed.,gene,GENE_VARIANT,142,146, clinical syndrome resembling Parkinson's dise,HPO_TERM,70,116,0.7793481,0.22065191,-0.55869615,0
line51,The clinical profile for Patient 71 includes a buildup of lactate in his bloodstream and an adult onset. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient 71 includes [E1]a buildup of lactate in his bloodstream[/E1] and an adult onset. Genetic analysis of the P[E2]OLG [/E2]gene confirmed the diagnosis.,OLG ,GENE_VARIANT,130,134,a buildup of lactate in his bloodstream,HPO_TERM,45,84,0.8379492,0.16205078,-0.67589843,0
line52,Patient 72 was evaluated for an adult onset. The patient also presented with hyperlactatemia and a condition that affects the muscles used for speech. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 72 was evaluated for an adult onset. The patient also presented with h[E1]yperlactatemia[/E1] and a condition that affects the muscles used for speech. Subsequent sequencing of the[E2] POL[/E2]G gene revealed a pathogenic variant., POL,GENE_VARIANT,179,183,yperlactatemia,HPO_TERM,78,92,0.83182794,0.16817209,-0.6636559,0
line52,Patient 72 was evaluated for an adult onset. The patient also presented with hyperlactatemia and a condition that affects the muscles used for speech. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 72 was evaluated for an adult onset. The patient also presented with hyperlactatemia and [E1]a condition that affects the muscles used for speec[/E1]h. Subsequent sequencing of the[E2] POL[/E2]G gene revealed a pathogenic variant., POL,GENE_VARIANT,179,183,a condition that affects the muscles used for speec,HPO_TERM,97,148,0.83394915,0.16605082,-0.6678983,0
line53,The clinical profile for Patient 73 includes a seizure and an adult onset. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient 73 includes [E1]a seizure[/E1] and an adult onset. Genetic analysis of the P[E2]OLG [/E2]gene confirmed the diagnosis.,OLG ,GENE_VARIANT,100,104,a seizure,HPO_TERM,45,54,0.77740204,0.22259802,-0.554804,0
line54,"This report details Patient 74, a patient with an increased lactate level. Further investigation showed hyperlactatemia and an atypical thalamic signal. A known variant in the POLG gene was identified.","This report details Patient 74, a patient with [E1]an increased lactate le[/E1]vel. Further investigation showed hyperlactatemia and an atypical thalamic signal. A known variant [E2]in t[/E2]he POLG gene was identified.",in t,GENE_VARIANT,169,173,an increased lactate le,HPO_TERM,47,70,0.8260018,0.17399812,-0.6520037,0
line54,"This report details Patient 74, a patient with an increased lactate level. Further investigation showed hyperlactatemia and an atypical thalamic signal. A known variant in the POLG gene was identified.","This report details Patient 74, a patient with an increased lactate level. Further investigation show[E1]ed hyperlactat[/E1]emia and an atypical thalamic signal. A known variant [E2]in t[/E2]he POLG gene was identified.",in t,GENE_VARIANT,169,173,ed hyperlactat,HPO_TERM,101,115,0.8069362,0.1930638,-0.6138724,0
line54,"This report details Patient 74, a patient with an increased lactate level. Further investigation showed hyperlactatemia and an atypical thalamic signal. A known variant in the POLG gene was identified.","This report details Patient 74, a patient with an increased lactate level. Further investigation showed hyperlactatemia [E1]and an atypical thalamic [/E1]signal. A known variant [E2]in t[/E2]he POLG gene was identified.",in t,GENE_VARIANT,169,173,and an atypical thalamic ,HPO_TERM,120,145,0.8153959,0.18460406,-0.63079184,0
line55,"We report the case of Patient 75, who has a history of an elevated hepatic transaminase concentration. Examination also revealed an adult onset. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient 75, who has a history of [E1]an elevated hepatic transaminase concentra[/E1]tion. Examination also revealed an adult onset. The underlying cause was traced to a mutation in t[E2]he P[/E2]OLG gene.",he P,GENE_VARIANT,195,199,an elevated hepatic transaminase concentra,HPO_TERM,55,97,0.5239,0.4761,-0.047799975,0
line55,"We report the case of Patient 75, who has a history of an elevated hepatic transaminase concentration. Examination also revealed an adult onset. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient 75, who has a history of an elevated hepatic transaminase concentration. Examination also revea[E1]led an adult on[/E1]set. The underlying cause was traced to a mutation in t[E2]he P[/E2]OLG gene.",he P,GENE_VARIANT,195,199,led an adult on,HPO_TERM,125,140,0.700594,0.299406,-0.40118802,0
line56,"We report the case of Patient 76, who has a history of hyperlactatemia. Examination also revealed an adult onset. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient 76, who has a history of [E1]hyperlactatemi[/E1]a. Examination also revealed an adult onset. The underlying cause was traced to a mutation in the [E2]POLG[/E2] gene.",POLG,GENE_VARIANT,167,171,hyperlactatemi,HPO_TERM,55,69,0.50408775,0.4959122,-0.008175552,0
line56,"We report the case of Patient 76, who has a history of hyperlactatemia. Examination also revealed an adult onset. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient 76, who has a history of hyperlactatemia. Examination also revealed[E1] an adult onset[/E1]. The underlying cause was traced to a mutation in the [E2]POLG[/E2] gene.",POLG,GENE_VARIANT,167,171, an adult onset,HPO_TERM,97,112,0.365227,0.63477296,0.26954594,1
line57,Patient 77 was evaluated for a pediatric-onset disorder. The patient also presented with an atypical thalamic signal and a buildup of lactate in his bloodstream. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 77 was evaluated for [E1]a pediatric-onset disorder[/E1]. The patient also presented with an atypical thalamic signal and a buildup of lactate in his bloodstream. Subsequent sequencing of th[E2]e PO[/E2]LG gene revealed a pathogenic variant.,e PO,GENE_VARIANT,189,193,a pediatric-onset disorder,HPO_TERM,29,55,0.86666083,0.13333915,-0.73332167,0
line57,Patient 77 was evaluated for a pediatric-onset disorder. The patient also presented with an atypical thalamic signal and a buildup of lactate in his bloodstream. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 77 was evaluated for a pediatric-onset disorder. The patient also presented with [E1]an atypical thalamic sign[/E1]al and a buildup of lactate in his bloodstream. Subsequent sequencing of th[E2]e PO[/E2]LG gene revealed a pathogenic variant.,e PO,GENE_VARIANT,189,193,an atypical thalamic sign,HPO_TERM,89,114,0.86254174,0.13745824,-0.7250835,0
line57,Patient 77 was evaluated for a pediatric-onset disorder. The patient also presented with an atypical thalamic signal and a buildup of lactate in his bloodstream. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 77 was evaluated for a pediatric-onset disorder. The patient also presented with an atypical thalamic signal an[E1]d a buildup of lactate in his bloodstre[/E1]am. Subsequent sequencing of th[E2]e PO[/E2]LG gene revealed a pathogenic variant.,e PO,GENE_VARIANT,189,193,d a buildup of lactate in his bloodstre,HPO_TERM,119,158,0.8643217,0.1356783,-0.7286434,0
line58,"Patient 78 was evaluated for slurred, consistent with dysarthria. The patient also presented with a diagnosis of a seizure disorder and an atypical thalamic signal. Subsequent sequencing of the POLG gene revealed a pathogenic variant.","Patient 78 was evaluated for [E1]slurred, consistent with dysarthr[/E1]ia. The patient also presented with a diagnosis of a seizure disorder and an atypical thalamic signal. Subsequent sequencing o[E2]f th[/E2]e POLG gene revealed a pathogenic variant.",f th,GENE_VARIANT,188,192,"slurred, consistent with dysarthr",HPO_TERM,29,62,0.8194668,0.18053316,-0.63893366,0
line58,"Patient 78 was evaluated for slurred, consistent with dysarthria. The patient also presented with a diagnosis of a seizure disorder and an atypical thalamic signal. Subsequent sequencing of the POLG gene revealed a pathogenic variant.","Patient 78 was evaluated for slurred, consistent with dysarthria. The patient also presented wit[E1]h a diagnosis of a seizure diso[/E1]rder and an atypical thalamic signal. Subsequent sequencing o[E2]f th[/E2]e POLG gene revealed a pathogenic variant.",f th,GENE_VARIANT,188,192,h a diagnosis of a seizure diso,HPO_TERM,96,127,0.8517316,0.1482684,-0.7034632,0
line58,"Patient 78 was evaluated for slurred, consistent with dysarthria. The patient also presented with a diagnosis of a seizure disorder and an atypical thalamic signal. Subsequent sequencing of the POLG gene revealed a pathogenic variant.","Patient 78 was evaluated for slurred, consistent with dysarthria. The patient also presented with a diagnosis of a seizure disorder [E1]and an atypical thalamic [/E1]signal. Subsequent sequencing o[E2]f th[/E2]e POLG gene revealed a pathogenic variant.",f th,GENE_VARIANT,188,192,and an atypical thalamic ,HPO_TERM,132,157,0.7992465,0.20075355,-0.5984929,0
line59,"This report details Patient 79, a patient with an atypical thalamic signal. Further investigation showed bilateral ptosis and signs of parkinsonism. A known variant in the POLG gene was identified.","This report details Patient 79, a patient with [E1]an atypical thalamic sign[/E1]al. Further investigation showed bilateral ptosis and signs of parkinsonism. A known variant in [E2]the [/E2]POLG gene was identified.",the ,GENE_VARIANT,168,172,an atypical thalamic sign,HPO_TERM,47,72,0.7788718,0.22112821,-0.55774355,0
line59,"This report details Patient 79, a patient with an atypical thalamic signal. Further investigation showed bilateral ptosis and signs of parkinsonism. A known variant in the POLG gene was identified.","This report details Patient 79, a patient with an atypical thalamic signal. Further investigation showe[E1]d bilateral ptos[/E1]is and signs of parkinsonism. A known variant in [E2]the [/E2]POLG gene was identified.",the ,GENE_VARIANT,168,172,d bilateral ptos,HPO_TERM,103,119,0.78114206,0.21885794,-0.5622841,0
line59,"This report details Patient 79, a patient with an atypical thalamic signal. Further investigation showed bilateral ptosis and signs of parkinsonism. A known variant in the POLG gene was identified.","This report details Patient 79, a patient with an atypical thalamic signal. Further investigation showed bilateral ptosis an[E1]d signs of parkinson[/E1]ism. A known variant in [E2]the [/E2]POLG gene was identified.",the ,GENE_VARIANT,168,172,d signs of parkinson,HPO_TERM,124,144,0.7786245,0.22137555,-0.55724895,0
line60,The clinical profile for Patient 80 includes signs of parkinsonism and a seizure. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient 80 includes [E1]signs of parkinsonis[/E1]m and a seizure. Genetic analysis of the[E2] POL[/E2]G gene confirmed the diagnosis., POL,GENE_VARIANT,105,109,signs of parkinsonis,HPO_TERM,45,65,0.821357,0.17864297,-0.642714,0
line60,The clinical profile for Patient 80 includes signs of parkinsonism and a seizure. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient 80 includes signs of parkinsonism and[E1] a seizur[/E1]e. Genetic analysis of the[E2] POL[/E2]G gene confirmed the diagnosis., POL,GENE_VARIANT,105,109, a seizur,HPO_TERM,70,79,0.85645187,0.14354813,-0.71290374,0
line61,The primary symptoms for Patient 81 were an abnormal thalamic MRI signal and an atypical thalamic signal. Analysis of the POLG gene was performed.,The primary symptoms for Patient 81 were an[E1] abnormal thalamic MRI signal[/E1] and an atypical thalamic signal. Analysis of the POLG g[E2]ene [/E2]was performed.,ene ,GENE_VARIANT,128,132, abnormal thalamic MRI signal,HPO_TERM,43,72,0.8075368,0.19246319,-0.61507356,0
line61,The primary symptoms for Patient 81 were an abnormal thalamic MRI signal and an atypical thalamic signal. Analysis of the POLG gene was performed.,The primary symptoms for Patient 81 were an abnormal thalamic MRI signal and [E1]an atypical thalamic sign[/E1]al. Analysis of the POLG g[E2]ene [/E2]was performed.,ene ,GENE_VARIANT,128,132,an atypical thalamic sign,HPO_TERM,77,102,0.84802043,0.15197958,-0.69604087,0
line62,The clinical profile for Patient 82 includes a clinical syndrome resembling Parkinson's disease and an atypical thalamic signal. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient 82 includes [E1]a clinical syndrome resembling Parkinson's dis[/E1]ease and an atypical thalamic signal. Genetic analysis o[E2]f th[/E2]e POLG gene confirmed the diagnosis.,f th,GENE_VARIANT,147,151,a clinical syndrome resembling Parkinson's dis,HPO_TERM,45,91,0.83010846,0.16989157,-0.6602169,0
line62,The clinical profile for Patient 82 includes a clinical syndrome resembling Parkinson's disease and an atypical thalamic signal. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient 82 includes a clinical syndrome resembling Parkinson's disease [E1]and an atypical thalamic [/E1]signal. Genetic analysis o[E2]f th[/E2]e POLG gene confirmed the diagnosis.,f th,GENE_VARIANT,147,151,and an atypical thalamic ,HPO_TERM,96,121,0.8406058,0.15939419,-0.6812116,0
line63,"We report the case of Patient 83, who has a history of an abnormal thalamic MRI signal. Examination also revealed an adult onset. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient 83, who has a history of [E1]an abnormal thalamic MRI sign[/E1]al. Examination also revealed an adult onset. The underlying cause was traced to a mutation in the[E2] POL[/E2]G gene.", POL,GENE_VARIANT,182,186,an abnormal thalamic MRI sign,HPO_TERM,55,84,0.47437066,0.5256294,0.051258743,1
line63,"We report the case of Patient 83, who has a history of an abnormal thalamic MRI signal. Examination also revealed an adult onset. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient 83, who has a history of an abnormal thalamic MRI signal. Examination also reveale[E1]d an adult onse[/E1]t. The underlying cause was traced to a mutation in the[E2] POL[/E2]G gene.", POL,GENE_VARIANT,182,186,d an adult onse,HPO_TERM,112,127,0.56952685,0.43047318,-0.13905367,0
line64,"We report the case of Patient 84, who has a history of an elevated hepatic transaminase concentration. Examination also revealed a buildup of lactate in his bloodstream. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient 84, who has a history of [E1]an elevated hepatic transaminase concentra[/E1]tion. Examination also revealed a buildup of lactate in his bloodstream. The underlying cause was traced to a mutation in [E2]the [/E2]POLG gene.",the ,GENE_VARIANT,219,223,an elevated hepatic transaminase concentra,HPO_TERM,55,97,0.5238866,0.4761134,-0.047773212,0
line64,"We report the case of Patient 84, who has a history of an elevated hepatic transaminase concentration. Examination also revealed a buildup of lactate in his bloodstream. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient 84, who has a history of an elevated hepatic transaminase concentration. Examination also revea[E1]led a buildup of lactate in his bloodst[/E1]ream. The underlying cause was traced to a mutation in [E2]the [/E2]POLG gene.",the ,GENE_VARIANT,219,223,led a buildup of lactate in his bloodst,HPO_TERM,125,164,0.61769634,0.38230368,-0.23539266,0
line65,Patient 85 was evaluated for a condition that affects the muscles used for speech. The patient also presented with an atypical thalamic signal and signs of parkinsonism. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 85 was evaluated for [E1]a condition that affects the muscles used for speec[/E1]h. The patient also presented with an atypical thalamic signal and signs of parkinsonism. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,195,199,a condition that affects the muscles used for speec,HPO_TERM,29,80,0.79533595,0.20466407,-0.5906719,0
line65,Patient 85 was evaluated for a condition that affects the muscles used for speech. The patient also presented with an atypical thalamic signal and signs of parkinsonism. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 85 was evaluated for a condition that affects the muscles used for speech. The patient also presented with[E1] an atypical thalamic sig[/E1]nal and signs of parkinsonism. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,195,199, an atypical thalamic sig,HPO_TERM,114,139,0.80813813,0.19186182,-0.6162763,0
line65,Patient 85 was evaluated for a condition that affects the muscles used for speech. The patient also presented with an atypical thalamic signal and signs of parkinsonism. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 85 was evaluated for a condition that affects the muscles used for speech. The patient also presented with an atypical thalamic signal a[E1]nd signs of parkinso[/E1]nism. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,195,199,nd signs of parkinso,HPO_TERM,144,164,0.7885147,0.21148531,-0.57702935,0
line66,Patient 86 was evaluated for an adult onset. The patient also presented with a buildup of lactate in his bloodstream and signs of parkinsonism. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 86 was evaluated for an adult onset. The patient also presented with a[E1] buildup of lactate in his bloodstream [/E1]and signs of parkinsonism. Subsequent sequencing of the [E2]POLG[/E2] gene revealed a pathogenic variant.,POLG,GENE_VARIANT,173,177, buildup of lactate in his bloodstream ,HPO_TERM,78,117,0.81779695,0.18220298,-0.63559395,0
line66,Patient 86 was evaluated for an adult onset. The patient also presented with a buildup of lactate in his bloodstream and signs of parkinsonism. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 86 was evaluated for an adult onset. The patient also presented with a buildup of lactate in his bloodstream and s[E1]igns of parkinsonism[/E1]. Subsequent sequencing of the [E2]POLG[/E2] gene revealed a pathogenic variant.,POLG,GENE_VARIANT,173,177,igns of parkinsonism,HPO_TERM,122,142,0.80071896,0.19928102,-0.6014379,0
line67,Patient 87 was evaluated for bradykinesia and rigidity. The patient also presented with a pediatric-onset disorder and hyperlactatemia. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 87 was evaluated for [E1]bradykinesia and rigidit[/E1]y. The patient also presented with a pediatric-onset disorder and hyperlactatemia. Subsequent sequencing of th[E2]e PO[/E2]LG gene revealed a pathogenic variant.,e PO,GENE_VARIANT,163,167,bradykinesia and rigidit,HPO_TERM,29,53,0.8580309,0.14196905,-0.71606183,0
line67,Patient 87 was evaluated for bradykinesia and rigidity. The patient also presented with a pediatric-onset disorder and hyperlactatemia. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 87 was evaluated for bradykinesia and rigidity. The patient also presented with[E1] a pediatric-onset disorde[/E1]r and hyperlactatemia. Subsequent sequencing of th[E2]e PO[/E2]LG gene revealed a pathogenic variant.,e PO,GENE_VARIANT,163,167, a pediatric-onset disorde,HPO_TERM,87,113,0.8616478,0.13835227,-0.7232955,0
line67,Patient 87 was evaluated for bradykinesia and rigidity. The patient also presented with a pediatric-onset disorder and hyperlactatemia. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 87 was evaluated for bradykinesia and rigidity. The patient also presented with a pediatric-onset disorder and[E1] hyperlactatem[/E1]ia. Subsequent sequencing of th[E2]e PO[/E2]LG gene revealed a pathogenic variant.,e PO,GENE_VARIANT,163,167, hyperlactatem,HPO_TERM,118,132,0.8659409,0.1340591,-0.73188186,0
line68,The primary symptoms for Patient 88 were hyperlactatemia and a seizure disorder. Analysis of the POLG gene was performed.,The primary symptoms for Patient 88 were hy[E1]perlactatemia [/E1]and a seizure disorder. Analysis of the POLG gene wa[E2]s pe[/E2]rformed.,s pe,GENE_VARIANT,109,113,perlactatemia ,HPO_TERM,43,57,0.839676,0.16032395,-0.67935205,0
line70,"This report details Patient 90, a patient with a pediatric-onset disorder. Further investigation showed unclear or mumbled speech and an adult onset. A known variant in the POLG gene was identified.","This report details Patient 90, a patient with [E1]a pediatric-onset disorder[/E1]. Further investigation showed unclear or mumbled speech and an adult onset. A known variant in the [E2]POLG[/E2] gene was identified.",POLG,GENE_VARIANT,173,177,a pediatric-onset disorder,HPO_TERM,47,73,0.7485489,0.2514511,-0.49709782,0
line70,"This report details Patient 90, a patient with a pediatric-onset disorder. Further investigation showed unclear or mumbled speech and an adult onset. A known variant in the POLG gene was identified.","This report details Patient 90, a patient with a pediatric-onset disorder. Further investigation showed [E1]unclear or mumbled speech[/E1] and an adult onset. A known variant in the [E2]POLG[/E2] gene was identified.",POLG,GENE_VARIANT,173,177,unclear or mumbled speech,HPO_TERM,104,129,0.72711486,0.27288514,-0.4542297,0
line71,Patient 91 was evaluated for an atypical thalamic signal. The patient also presented with an elevated hepatic transaminase concentration and bilateral ptosis. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 91 was evaluated for [E1]an atypical thalamic sign[/E1]al. The patient also presented with an elevated hepatic transaminase concentration and bilateral ptosis. Subsequent sequencing o[E2]f th[/E2]e POLG gene revealed a pathogenic variant.,f th,GENE_VARIANT,182,186,an atypical thalamic sign,HPO_TERM,29,54,0.8537322,0.14626779,-0.70746446,0
line71,Patient 91 was evaluated for an atypical thalamic signal. The patient also presented with an elevated hepatic transaminase concentration and bilateral ptosis. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 91 was evaluated for an atypical thalamic signal. The patient also presented wit[E1]h an elevated hepatic transaminase concent[/E1]ration and bilateral ptosis. Subsequent sequencing o[E2]f th[/E2]e POLG gene revealed a pathogenic variant.,f th,GENE_VARIANT,182,186,h an elevated hepatic transaminase concent,HPO_TERM,88,130,0.853465,0.14653493,-0.7069301,0
line71,Patient 91 was evaluated for an atypical thalamic signal. The patient also presented with an elevated hepatic transaminase concentration and bilateral ptosis. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 91 was evaluated for an atypical thalamic signal. The patient also presented with an elevated hepatic transaminase concentratio[E1]n and bilateral [/E1]ptosis. Subsequent sequencing o[E2]f th[/E2]e POLG gene revealed a pathogenic variant.,f th,GENE_VARIANT,182,186,n and bilateral ,HPO_TERM,135,151,0.8550449,0.14495502,-0.71008986,0
line72,"Patient 92 was evaluated for an adult onset. The patient also presented with a seizure disorder and slurred, consistent with dysarthria. Subsequent sequencing of the POLG gene revealed a pathogenic variant.","Patient 92 was evaluated for an adult onset. The patient also presented with a[E1] seizure disorder and[/E1] slurred, consistent with dysarthria. Subsequent sequencing of the PO[E2]LG g[/E2]ene revealed a pathogenic variant.",LG g,GENE_VARIANT,168,172, seizure disorder and,HPO_TERM,78,99,0.86785334,0.1321466,-0.73570675,0
line73,The primary symptoms for Patient 93 were a seizure disorder and poor articulation. Analysis of the POLG gene was performed.,The primary symptoms for Patient 93 were a [E1]seizure disorder and [/E1]poor articulation. Analysis of the POLG gene was[E2] per[/E2]formed., per,GENE_VARIANT,112,116,seizure disorder and ,HPO_TERM,43,64,0.8455244,0.15447564,-0.69104874,0
line74,The clinical profile for Patient 94 includes a seizure disorder and an adult onset. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient 94 includes [E1]a seizure disorder an[/E1]d an adult onset. Genetic analysis of the POLG[E2] gen[/E2]e confirmed the diagnosis., gen,GENE_VARIANT,112,116,a seizure disorder an,HPO_TERM,45,66,0.861756,0.13824399,-0.72351205,0
line75,The primary symptoms for Patient 95 were a buildup of lactate in his bloodstream and an adult onset. Analysis of the POLG gene was performed.,The primary symptoms for Patient 95 were a [E1]buildup of lactate in his bloodstream a[/E1]nd an adult onset. Analysis of the POLG gene w[E2]as p[/E2]erformed.,as p,GENE_VARIANT,128,132,buildup of lactate in his bloodstream a,HPO_TERM,43,82,0.8789663,0.12103374,-0.75793254,0
line76,"This report details Patient 96, a patient with a condition that affects the muscles used for speech. Further investigation showed an atypical thalamic signal and an elevated hepatic transaminase concentration. A known variant in the POLG gene was identified.","This report details Patient 96, a patient with [E1]a condition that affects the muscles used for speec[/E1]h. Further investigation showed an atypical thalamic signal and an elevated hepatic transaminase concentration. A known variant[E2] in [/E2]the POLG gene was identified.", in ,GENE_VARIANT,225,229,a condition that affects the muscles used for speec,HPO_TERM,47,98,0.8407642,0.15923579,-0.68152845,0
line76,"This report details Patient 96, a patient with a condition that affects the muscles used for speech. Further investigation showed an atypical thalamic signal and an elevated hepatic transaminase concentration. A known variant in the POLG gene was identified.","This report details Patient 96, a patient with a condition that affects the muscles used for speech. Further investigation showed[E1] an atypical thalamic sig[/E1]nal and an elevated hepatic transaminase concentration. A known variant[E2] in [/E2]the POLG gene was identified.", in ,GENE_VARIANT,225,229, an atypical thalamic sig,HPO_TERM,129,154,0.8385809,0.16141917,-0.67716175,0
line76,"This report details Patient 96, a patient with a condition that affects the muscles used for speech. Further investigation showed an atypical thalamic signal and an elevated hepatic transaminase concentration. A known variant in the POLG gene was identified.","This report details Patient 96, a patient with a condition that affects the muscles used for speech. Further investigation showed an atypical thalamic signal a[E1]nd an elevated hepatic transaminase concen[/E1]tration. A known variant[E2] in [/E2]the POLG gene was identified.", in ,GENE_VARIANT,225,229,nd an elevated hepatic transaminase concen,HPO_TERM,159,201,0.8367378,0.16326222,-0.6734756,0
line77,"We report the case of Patient 97, who has a history of an elevated hepatic transaminase concentration. Examination also revealed poor articulation. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient 97, who has a history of [E1]an elevated hepatic transaminase concentra[/E1]tion. Examination also revealed poor articulation. The underlying cause was traced to a mutation in [E2]the [/E2]POLG gene.",the ,GENE_VARIANT,197,201,an elevated hepatic transaminase concentra,HPO_TERM,55,97,0.49684185,0.5031582,0.006316364,1
line77,"We report the case of Patient 97, who has a history of an elevated hepatic transaminase concentration. Examination also revealed poor articulation. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient 97, who has a history of an elevated hepatic transaminase concentration. Examination also revea[E1]led poor articula[/E1]tion. The underlying cause was traced to a mutation in [E2]the [/E2]POLG gene.",the ,GENE_VARIANT,197,201,led poor articula,HPO_TERM,125,142,0.59201825,0.40798172,-0.18403652,0
line78,"We report the case of Patient 98, who has a history of a seizure. Examination also revealed poor articulation. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient 98, who has a history of [E1]a seizure[/E1]. Examination also revealed poor articulation. The underlying cause was traced to a mutation in the [E2]POLG[/E2] gene.",POLG,GENE_VARIANT,164,168,a seizure,HPO_TERM,55,64,0.42902616,0.5709739,0.14194772,1
line78,"We report the case of Patient 98, who has a history of a seizure. Examination also revealed poor articulation. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient 98, who has a history of a seizure. Examination also revealed [E1]poor articulation[/E1]. The underlying cause was traced to a mutation in the [E2]POLG[/E2] gene.",POLG,GENE_VARIANT,164,168,poor articulation,HPO_TERM,92,109,0.3836157,0.61638427,0.23276857,1
line79,"This report details Patient 99, a patient with an adult onset. Further investigation showed an abnormal thalamic MRI signal and an atypical thalamic signal. A known variant in the POLG gene was identified.","This report details Patient 99, a patient with an adult onset. Further investigation showed a[E1]n abnormal thalamic MRI signa[/E1]l and an atypical thalamic signal. A known variant in [E2]the [/E2]POLG gene was identified.",the ,GENE_VARIANT,176,180,n abnormal thalamic MRI signa,HPO_TERM,93,122,0.7832153,0.2167847,-0.56643057,0
line79,"This report details Patient 99, a patient with an adult onset. Further investigation showed an abnormal thalamic MRI signal and an atypical thalamic signal. A known variant in the POLG gene was identified.","This report details Patient 99, a patient with an adult onset. Further investigation showed an abnormal thalamic MRI signal and[E1] an atypical thalamic sig[/E1]nal. A known variant in [E2]the [/E2]POLG gene was identified.",the ,GENE_VARIANT,176,180, an atypical thalamic sig,HPO_TERM,127,152,0.8018816,0.19811839,-0.6037632,0
line80,Patient 100 was evaluated for a seizure. The patient also presented with an increased lactate level and a late-onset variant of the condition. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 100 was evaluated for [E1]a seizure[/E1]. The patient also presented with an increased lactate level and a late-onset variant of the condition. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,169,173,a seizure,HPO_TERM,30,39,0.8534284,0.14657162,-0.7068568,0
line80,Patient 100 was evaluated for a seizure. The patient also presented with an increased lactate level and a late-onset variant of the condition. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 100 was evaluated for a seizure. The patient also presented with [E1]an increased lactate le[/E1]vel and a late-onset variant of the condition. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,169,173,an increased lactate le,HPO_TERM,73,96,0.8540792,0.1459208,-0.7081584,0
line80,Patient 100 was evaluated for a seizure. The patient also presented with an increased lactate level and a late-onset variant of the condition. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 100 was evaluated for a seizure. The patient also presented with an increased lactate level a[E1]nd a late-onset variant of the condit[/E1]ion. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,169,173,nd a late-onset variant of the condit,HPO_TERM,101,138,0.8764283,0.123571716,-0.7528566,0
line81,"We report the case of Patient 101, who has a history of an elevated level of lactate in the blood. Examination also revealed a pediatric-onset disorder. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient 101, who has a history of [E1]an elevated level of lactate in the bl[/E1]ood. Examination also revealed a pediatric-onset disorder. The underlying cause was traced to a mutation in t[E2]he P[/E2]OLG gene.",he P,GENE_VARIANT,203,207,an elevated level of lactate in the bl,HPO_TERM,56,94,0.41616192,0.58383805,0.16767612,1
line81,"We report the case of Patient 101, who has a history of an elevated level of lactate in the blood. Examination also revealed a pediatric-onset disorder. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient 101, who has a history of an elevated level of lactate in the blood. Examination also reveal[E1]ed a pediatric-onset disor[/E1]der. The underlying cause was traced to a mutation in t[E2]he P[/E2]OLG gene.",he P,GENE_VARIANT,203,207,ed a pediatric-onset disor,HPO_TERM,122,148,0.68109345,0.31890652,-0.36218694,0
line82,"This report details Patient 102, a patient with bilateral ptosis. Further investigation showed signs of parkinsonism and a buildup of lactate in his bloodstream. A known variant in the POLG gene was identified.","This report details Patient 102, a patient with [E1]bilateral ptosis[/E1]. Further investigation showed signs of parkinsonism and a buildup of lactate in his bloodstream. A known variant in th[E2]e PO[/E2]LG gene was identified.",e PO,GENE_VARIANT,183,187,bilateral ptosis,HPO_TERM,48,64,0.83283675,0.16716327,-0.6656735,0
line82,"This report details Patient 102, a patient with bilateral ptosis. Further investigation showed signs of parkinsonism and a buildup of lactate in his bloodstream. A known variant in the POLG gene was identified.","This report details Patient 102, a patient with bilateral ptosis. Further investigation showed [E1]signs of parkinsonis[/E1]m and a buildup of lactate in his bloodstream. A known variant in th[E2]e PO[/E2]LG gene was identified.",e PO,GENE_VARIANT,183,187,signs of parkinsonis,HPO_TERM,95,115,0.8541937,0.1458063,-0.7083874,0
line82,"This report details Patient 102, a patient with bilateral ptosis. Further investigation showed signs of parkinsonism and a buildup of lactate in his bloodstream. A known variant in the POLG gene was identified.","This report details Patient 102, a patient with bilateral ptosis. Further investigation showed signs of parkinsonism and[E1] a buildup of lactate in his bloodstrea[/E1]m. A known variant in th[E2]e PO[/E2]LG gene was identified.",e PO,GENE_VARIANT,183,187, a buildup of lactate in his bloodstrea,HPO_TERM,120,159,0.84800166,0.15199831,-0.6960033,0
line83,"We report the case of Patient 103, who has a history of an atypical thalamic signal. Examination also revealed an elevated level of lactate in the blood. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient 103, who has a history of [E1]an atypical thalamic sign[/E1]al. Examination also revealed an elevated level of lactate in the blood. The underlying cause was traced to a mutation in[E2] the[/E2] POLG gene.", the,GENE_VARIANT,202,206,an atypical thalamic sign,HPO_TERM,56,81,0.5504452,0.44955477,-0.10089043,0
line83,"We report the case of Patient 103, who has a history of an atypical thalamic signal. Examination also revealed an elevated level of lactate in the blood. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient 103, who has a history of an atypical thalamic signal. Examination also reveale[E1]d an elevated level of lactate in the [/E1]blood. The underlying cause was traced to a mutation in[E2] the[/E2] POLG gene.", the,GENE_VARIANT,202,206,d an elevated level of lactate in the ,HPO_TERM,109,147,0.66511756,0.33488235,-0.3302352,0
line84,The clinical profile for Patient 104 includes an increased lactate level and a pediatric-onset disorder. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient 104 includes [E1]an increased lactate le[/E1]vel and a pediatric-onset disorder. Genetic analysis of t[E2]he P[/E2]OLG gene confirmed the diagnosis.,he P,GENE_VARIANT,126,130,an increased lactate le,HPO_TERM,46,69,0.85740906,0.14259095,-0.7148181,0
line84,The clinical profile for Patient 104 includes an increased lactate level and a pediatric-onset disorder. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient 104 includes an increased lactate level a[E1]nd a pediatric-onset disor[/E1]der. Genetic analysis of t[E2]he P[/E2]OLG gene confirmed the diagnosis.,he P,GENE_VARIANT,126,130,nd a pediatric-onset disor,HPO_TERM,74,100,0.8732265,0.12677345,-0.74645305,0
line85,"We report the case of Patient 105, who has a history of epilepsy. Examination also revealed an elevated hepatic transaminase concentration. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient 105, who has a history of [E1]epilepsy[/E1]. Examination also revealed an elevated hepatic transaminase concentration. The underlying cause was traced to a mutation in [E2]the [/E2]POLG gene.",the ,GENE_VARIANT,189,193,epilepsy,HPO_TERM,56,64,0.42774326,0.57225674,0.14451349,1
line85,"We report the case of Patient 105, who has a history of epilepsy. Examination also revealed an elevated hepatic transaminase concentration. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient 105, who has a history of epilepsy. Examination also revealed [E1]an elevated hepatic transaminase concentra[/E1]tion. The underlying cause was traced to a mutation in [E2]the [/E2]POLG gene.",the ,GENE_VARIANT,189,193,an elevated hepatic transaminase concentra,HPO_TERM,92,134,0.29627508,0.7037249,0.40744984,1
line86,"This report details Patient 106, a patient with hyperlactatemia. Further investigation showed an elevated level of lactate in the blood and a clinical syndrome resembling Parkinson's disease. A known variant in the POLG gene was identified.","This report details Patient 106, a patient with [E1]hyperlactatemi[/E1]a. Further investigation showed an elevated level of lactate in the blood and a clinical syndrome resembling Parkinson's disease. A known varian[E2]t in[/E2] the POLG gene was identified.",t in,GENE_VARIANT,206,210,hyperlactatemi,HPO_TERM,48,62,0.8588096,0.14119042,-0.7176192,0
line86,"This report details Patient 106, a patient with hyperlactatemia. Further investigation showed an elevated level of lactate in the blood and a clinical syndrome resembling Parkinson's disease. A known variant in the POLG gene was identified.","This report details Patient 106, a patient with hyperlactatemia. Further investigation showed[E1] an elevated level of lactate in the b[/E1]lood and a clinical syndrome resembling Parkinson's disease. A known varian[E2]t in[/E2] the POLG gene was identified.",t in,GENE_VARIANT,206,210, an elevated level of lactate in the b,HPO_TERM,93,131,0.8555812,0.14441869,-0.71116257,0
line86,"This report details Patient 106, a patient with hyperlactatemia. Further investigation showed an elevated level of lactate in the blood and a clinical syndrome resembling Parkinson's disease. A known variant in the POLG gene was identified.","This report details Patient 106, a patient with hyperlactatemia. Further investigation showed an elevated level of lactate in the blood [E1]and a clinical syndrome resembling Parkinson's[/E1] disease. A known varian[E2]t in[/E2] the POLG gene was identified.",t in,GENE_VARIANT,206,210,and a clinical syndrome resembling Parkinson's,HPO_TERM,136,182,0.8461313,0.15386862,-0.6922627,0
line87,Patient 107 was evaluated for a buildup of lactate in his bloodstream. The patient also presented with an elevated hepatic transaminase concentration and a seizure. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 107 was evaluated for [E1]a buildup of lactate in his bloodstream[/E1]. The patient also presented with an elevated hepatic transaminase concentration and a seizure. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,190,194,a buildup of lactate in his bloodstream,HPO_TERM,30,69,0.8369278,0.16307227,-0.6738555,0
line87,Patient 107 was evaluated for a buildup of lactate in his bloodstream. The patient also presented with an elevated hepatic transaminase concentration and a seizure. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 107 was evaluated for a buildup of lactate in his bloodstream. The patient also presented with [E1]an elevated hepatic transaminase concentra[/E1]tion and a seizure. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,190,194,an elevated hepatic transaminase concentra,HPO_TERM,103,145,0.84770525,0.15229471,-0.69541055,0
line87,Patient 107 was evaluated for a buildup of lactate in his bloodstream. The patient also presented with an elevated hepatic transaminase concentration and a seizure. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 107 was evaluated for a buildup of lactate in his bloodstream. The patient also presented with an elevated hepatic transaminase concentration [E1]and a sei[/E1]zure. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,190,194,and a sei,HPO_TERM,150,159,0.86815053,0.13184945,-0.73630106,0
line88,Patient 108 was evaluated for an adult onset. The patient also presented with a clinical syndrome resembling Parkinson's disease and an abnormal thalamic MRI signal. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 108 was evaluated for an adult onset. The patient also presented with a[E1] clinical syndrome resembling Parkinson's dise[/E1]ase and an abnormal thalamic MRI signal. Subsequent sequencing of[E2] the[/E2] POLG gene revealed a pathogenic variant., the,GENE_VARIANT,190,194, clinical syndrome resembling Parkinson's dise,HPO_TERM,79,125,0.6987608,0.30123922,-0.3975216,0
line88,Patient 108 was evaluated for an adult onset. The patient also presented with a clinical syndrome resembling Parkinson's disease and an abnormal thalamic MRI signal. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 108 was evaluated for an adult onset. The patient also presented with a clinical syndrome resembling Parkinson's disease a[E1]nd an abnormal thalamic MRI s[/E1]ignal. Subsequent sequencing of[E2] the[/E2] POLG gene revealed a pathogenic variant., the,GENE_VARIANT,190,194,nd an abnormal thalamic MRI s,HPO_TERM,130,159,0.81500417,0.18499584,-0.63000834,0
line89,The clinical profile for Patient 109 includes an adult onset and an increased lactate level. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient 109 includes [E1]an adult onset [/E1]and an increased lactate level. Genetic analysis of th[E2]e PO[/E2]LG gene confirmed the diagnosis.,e PO,GENE_VARIANT,115,119,an adult onset ,HPO_TERM,46,61,0.85421187,0.1457882,-0.7084237,0
line89,The clinical profile for Patient 109 includes an adult onset and an increased lactate level. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient 109 includes an adult onset and a[E1]n increased lactate lev[/E1]el. Genetic analysis of th[E2]e PO[/E2]LG gene confirmed the diagnosis.,e PO,GENE_VARIANT,115,119,n increased lactate lev,HPO_TERM,66,89,0.86774796,0.13225202,-0.7354959,0
line90,Patient 110 was evaluated for unclear or mumbled speech. The patient also presented with hyperlactatemia and a condition that affects the muscles used for speech. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 110 was evaluated for [E1]unclear or mumbled speech[/E1]. The patient also presented with hyperlactatemia and a condition that affects the muscles used for speech. Subsequent sequencing of th[E2]e PO[/E2]LG gene revealed a pathogenic variant.,e PO,GENE_VARIANT,190,194,unclear or mumbled speech,HPO_TERM,30,55,0.8609091,0.13909085,-0.72181827,0
line90,Patient 110 was evaluated for unclear or mumbled speech. The patient also presented with hyperlactatemia and a condition that affects the muscles used for speech. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 110 was evaluated for unclear or mumbled speech. The patient also presented with [E1]hyperlactatemi[/E1]a and a condition that affects the muscles used for speech. Subsequent sequencing of th[E2]e PO[/E2]LG gene revealed a pathogenic variant.,e PO,GENE_VARIANT,190,194,hyperlactatemi,HPO_TERM,89,103,0.8646505,0.13534951,-0.729301,0
line90,Patient 110 was evaluated for unclear or mumbled speech. The patient also presented with hyperlactatemia and a condition that affects the muscles used for speech. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 110 was evaluated for unclear or mumbled speech. The patient also presented with hyperlactatemia and[E1] a condition that affects the muscles used for spee[/E1]ch. Subsequent sequencing of th[E2]e PO[/E2]LG gene revealed a pathogenic variant.,e PO,GENE_VARIANT,190,194, a condition that affects the muscles used for spee,HPO_TERM,108,159,0.86234534,0.13765474,-0.7246906,0
line91,Patient 111 was evaluated for an atypical thalamic signal. The patient also presented with an adult onset and an abnormal thalamic MRI signal. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 111 was evaluated for [E1]an atypical thalamic sign[/E1]al. The patient also presented with an adult onset and an abnormal thalamic MRI signal. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,169,173,an atypical thalamic sign,HPO_TERM,30,55,0.82355714,0.17644288,-0.6471143,0
line91,Patient 111 was evaluated for an atypical thalamic signal. The patient also presented with an adult onset and an abnormal thalamic MRI signal. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 111 was evaluated for an atypical thalamic signal. The patient also presented wit[E1]h an adult onse[/E1]t and an abnormal thalamic MRI signal. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,169,173,h an adult onse,HPO_TERM,89,104,0.85119236,0.14880763,-0.7023847,0
line91,Patient 111 was evaluated for an atypical thalamic signal. The patient also presented with an adult onset and an abnormal thalamic MRI signal. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 111 was evaluated for an atypical thalamic signal. The patient also presented with an adult onset and[E1] an abnormal thalamic MRI sig[/E1]nal. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,169,173, an abnormal thalamic MRI sig,HPO_TERM,109,138,0.8321154,0.16788457,-0.6642308,0
line92,The clinical profile for Patient 112 includes an abnormal thalamic MRI signal and poor articulation. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient 112 includes [E1]an abnormal thalamic MRI sign[/E1]al and poor articulation. Genetic analysis of th[E2]e PO[/E2]LG gene confirmed the diagnosis.,e PO,GENE_VARIANT,123,127,an abnormal thalamic MRI sign,HPO_TERM,46,75,0.8326985,0.16730146,-0.66539705,0
line92,The clinical profile for Patient 112 includes an abnormal thalamic MRI signal and poor articulation. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient 112 includes an abnormal thalamic MRI signal an[E1]d poor articulati[/E1]on. Genetic analysis of th[E2]e PO[/E2]LG gene confirmed the diagnosis.,e PO,GENE_VARIANT,123,127,d poor articulati,HPO_TERM,80,97,0.85018176,0.14981826,-0.7003635,0
line93,Patient 113 was evaluated for an adult onset. The patient also presented with an abnormal thalamic MRI signal and poor articulation. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 113 was evaluated for an adult onset. The patient also presented with a[E1]n abnormal thalamic MRI signa[/E1]l and poor articulation. Subsequent sequencing of the[E2] POL[/E2]G gene revealed a pathogenic variant., POL,GENE_VARIANT,161,165,n abnormal thalamic MRI signa,HPO_TERM,79,108,0.81666476,0.18333524,-0.6333295,0
line93,Patient 113 was evaluated for an adult onset. The patient also presented with an abnormal thalamic MRI signal and poor articulation. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 113 was evaluated for an adult onset. The patient also presented with an abnormal thalamic MRI signal and[E1] poor articulatio[/E1]n. Subsequent sequencing of the[E2] POL[/E2]G gene revealed a pathogenic variant., POL,GENE_VARIANT,161,165, poor articulatio,HPO_TERM,113,130,0.83904815,0.16095187,-0.6780963,0
line94,"This report details Patient 114, a patient with an adult onset. Further investigation showed a buildup of lactate in his bloodstream and an abnormal thalamic MRI signal. A known variant in the POLG gene was identified.","This report details Patient 114, a patient with an adult onset. Further investigation showed a[E1] buildup of lactate in his bloodstream [/E1]and an abnormal thalamic MRI signal. A known variant in th[E2]e PO[/E2]LG gene was identified.",e PO,GENE_VARIANT,191,195, buildup of lactate in his bloodstream ,HPO_TERM,94,133,0.834851,0.16514897,-0.66970205,0
line94,"This report details Patient 114, a patient with an adult onset. Further investigation showed a buildup of lactate in his bloodstream and an abnormal thalamic MRI signal. A known variant in the POLG gene was identified.","This report details Patient 114, a patient with an adult onset. Further investigation showed a buildup of lactate in his bloodstream and a[E1]n abnormal thalamic MRI signa[/E1]l. A known variant in th[E2]e PO[/E2]LG gene was identified.",e PO,GENE_VARIANT,191,195,n abnormal thalamic MRI signa,HPO_TERM,138,167,0.846414,0.15358593,-0.6928281,0
line95,"We report the case of Patient 115, who has a history of an atypical thalamic signal. Examination also revealed parkinsonism. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient 115, who has a history of [E1]an atypical thalamic sign[/E1]al. Examination also revealed parkinsonism. The underlying cause was traced to a mutation in th[E2]e PO[/E2]LG gene.",e PO,GENE_VARIANT,176,180,an atypical thalamic sign,HPO_TERM,56,81,0.65666586,0.34333417,-0.3133317,0
line95,"We report the case of Patient 115, who has a history of an atypical thalamic signal. Examination also revealed parkinsonism. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient 115, who has a history of an atypical thalamic signal. Examination also reveale[E1]d parkinsoni[/E1]sm. The underlying cause was traced to a mutation in th[E2]e PO[/E2]LG gene.",e PO,GENE_VARIANT,176,180,d parkinsoni,HPO_TERM,109,121,0.64804703,0.35195294,-0.2960941,0
line96,"We report the case of Patient 116, who has a history of drooping of both upper eyelids. Examination also revealed an abnormal thalamic MRI signal. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient 116, who has a history of [E1]drooping of both upper eyelids[/E1]. Examination also revealed an abnormal thalamic MRI signal. The underlying cause was traced to a mutation in th[E2]e PO[/E2]LG gene.",e PO,GENE_VARIANT,198,202,drooping of both upper eyelids,HPO_TERM,56,86,0.4386308,0.56136924,0.12273845,1
line96,"We report the case of Patient 116, who has a history of drooping of both upper eyelids. Examination also revealed an abnormal thalamic MRI signal. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient 116, who has a history of drooping of both upper eyelids. Examination also revealed [E1]an abnormal thalamic MRI sign[/E1]al. The underlying cause was traced to a mutation in th[E2]e PO[/E2]LG gene.",e PO,GENE_VARIANT,198,202,an abnormal thalamic MRI sign,HPO_TERM,114,143,0.3519935,0.64800656,0.29601306,1
line97,The primary symptoms for Patient 117 were a buildup of lactate in his bloodstream and signs of parkinsonism. Analysis of the POLG gene was performed.,The primary symptoms for Patient 117 were a [E1]buildup of lactate in his bloodstream a[/E1]nd signs of parkinsonism. Analysis of the POLG gene[E2] was[/E2] performed., was,GENE_VARIANT,134,138,buildup of lactate in his bloodstream a,HPO_TERM,44,83,0.8494995,0.15050049,-0.69899905,0
line98,The primary symptoms for Patient 118 were an adult onset and an abnormal thalamic MRI signal. Analysis of the POLG gene was performed.,The primary symptoms for Patient 118 were an[E1] adult onset an[/E1]d an abnormal thalamic MRI signal. Analysis of the POLG gene[E2] was[/E2] performed., was,GENE_VARIANT,119,123, adult onset an,HPO_TERM,44,59,0.81945175,0.18054824,-0.6389035,0
line99,Patient 119 was evaluated for an atypical thalamic signal. The patient also presented with an abnormal thalamic MRI signal and an adult onset. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 119 was evaluated for [E1]an atypical thalamic sign[/E1]al. The patient also presented with an abnormal thalamic MRI signal and an adult onset. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,169,173,an atypical thalamic sign,HPO_TERM,30,55,0.8128749,0.1871251,-0.6257498,0
line99,Patient 119 was evaluated for an atypical thalamic signal. The patient also presented with an abnormal thalamic MRI signal and an adult onset. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 119 was evaluated for an atypical thalamic signal. The patient also presented wit[E1]h an abnormal thalamic MRI si[/E1]gnal and an adult onset. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,169,173,h an abnormal thalamic MRI si,HPO_TERM,89,118,0.83255434,0.16744566,-0.6651087,0
line99,Patient 119 was evaluated for an atypical thalamic signal. The patient also presented with an abnormal thalamic MRI signal and an adult onset. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 119 was evaluated for an atypical thalamic signal. The patient also presented with an abnormal thalamic MRI signal [E1]and an adult on[/E1]set. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,169,173,and an adult on,HPO_TERM,123,138,0.8251623,0.17483768,-0.6503246,0
line100,The clinical profile for Patient 120 includes a buildup of lactate in his bloodstream and an adult onset. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient 120 includes [E1]a buildup of lactate in his bloodstream[/E1] and an adult onset. Genetic analysis of the P[E2]OLG [/E2]gene confirmed the diagnosis.,OLG ,GENE_VARIANT,131,135,a buildup of lactate in his bloodstream,HPO_TERM,46,85,0.84622586,0.15377413,-0.6924517,0
line101,"This report details Patient 121, a patient with a pediatric-onset disorder. Further investigation showed a buildup of lactate in his bloodstream and hyperlactatemia. A known variant in the POLG gene was identified.","This report details Patient 121, a patient with [E1]a pediatric-onset disorder[/E1]. Further investigation showed a buildup of lactate in his bloodstream and hyperlactatemia. A known variant in th[E2]e PO[/E2]LG gene was identified.",e PO,GENE_VARIANT,187,191,a pediatric-onset disorder,HPO_TERM,48,74,0.8554606,0.1445394,-0.71092117,0
line101,"This report details Patient 121, a patient with a pediatric-onset disorder. Further investigation showed a buildup of lactate in his bloodstream and hyperlactatemia. A known variant in the POLG gene was identified.","This report details Patient 121, a patient with a pediatric-onset disorder. Further investigation showed [E1]a buildup of lactate in his bloodstream[/E1] and hyperlactatemia. A known variant in th[E2]e PO[/E2]LG gene was identified.",e PO,GENE_VARIANT,187,191,a buildup of lactate in his bloodstream,HPO_TERM,105,144,0.8416659,0.1583341,-0.68333185,0
line101,"This report details Patient 121, a patient with a pediatric-onset disorder. Further investigation showed a buildup of lactate in his bloodstream and hyperlactatemia. A known variant in the POLG gene was identified.","This report details Patient 121, a patient with a pediatric-onset disorder. Further investigation showed a buildup of lactate in his bloodstream and [E1]hyperlactatemi[/E1]a. A known variant in th[E2]e PO[/E2]LG gene was identified.",e PO,GENE_VARIANT,187,191,hyperlactatemi,HPO_TERM,149,163,0.86248213,0.13751794,-0.7249642,0
line102,The primary symptoms for Patient 122 were an atypical thalamic signal and signs of parkinsonism. Analysis of the POLG gene was performed.,The primary symptoms for Patient 122 were an[E1] atypical thalamic signal[/E1] and signs of parkinsonism. Analysis of the POLG ge[E2]ne w[/E2]as performed.,ne w,GENE_VARIANT,120,124, atypical thalamic signal,HPO_TERM,44,69,0.75237644,0.24762358,-0.5047529,0
line102,The primary symptoms for Patient 122 were an atypical thalamic signal and signs of parkinsonism. Analysis of the POLG gene was performed.,The primary symptoms for Patient 122 were an atypical thalamic signal and [E1]signs of parkinsonis[/E1]m. Analysis of the POLG ge[E2]ne w[/E2]as performed.,ne w,GENE_VARIANT,120,124,signs of parkinsonis,HPO_TERM,74,94,0.82559836,0.17440158,-0.6511968,0
line103,Patient 123 was evaluated for an adult onset. The patient also presented with an atypical thalamic signal and an elevated level of lactate in the blood. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 123 was evaluated for an adult onset. The patient also presented with a[E1]n atypical thalamic signa[/E1]l and an elevated level of lactate in the blood. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,178,182,n atypical thalamic signa,HPO_TERM,79,104,0.8147284,0.1852716,-0.62945676,0
line103,Patient 123 was evaluated for an adult onset. The patient also presented with an atypical thalamic signal and an elevated level of lactate in the blood. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 123 was evaluated for an adult onset. The patient also presented with an atypical thalamic signal and[E1] an elevated level of lactate in the b[/E1]lood. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,178,182, an elevated level of lactate in the b,HPO_TERM,109,147,0.8175795,0.18242048,-0.635159,0
line104,"We report the case of Patient 124, who has a history of poor articulation. Examination also revealed an elevated hepatic transaminase concentration. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient 124, who has a history of [E1]poor articulation[/E1]. Examination also revealed an elevated hepatic transaminase concentration. The underlying cause was traced to a mutation in [E2]the [/E2]POLG gene.",the ,GENE_VARIANT,198,202,poor articulation,HPO_TERM,56,73,0.38443938,0.61556065,0.23112127,1
line104,"We report the case of Patient 124, who has a history of poor articulation. Examination also revealed an elevated hepatic transaminase concentration. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient 124, who has a history of poor articulation. Examination also revealed [E1]an elevated hepatic transaminase concentra[/E1]tion. The underlying cause was traced to a mutation in [E2]the [/E2]POLG gene.",the ,GENE_VARIANT,198,202,an elevated hepatic transaminase concentra,HPO_TERM,101,143,0.25776574,0.74223423,0.4844685,1
line105,"This report details Patient 125, a patient with an atypical thalamic signal. Further investigation showed an adult onset and drooping of both upper eyelids. A known variant in the POLG gene was identified.","This report details Patient 125, a patient with [E1]an atypical thalamic sign[/E1]al. Further investigation showed an adult onset and drooping of both upper eyelids. A known variant in th[E2]e PO[/E2]LG gene was identified.",e PO,GENE_VARIANT,178,182,an atypical thalamic sign,HPO_TERM,48,73,0.8368603,0.16313973,-0.6737206,0
line105,"This report details Patient 125, a patient with an atypical thalamic signal. Further investigation showed an adult onset and drooping of both upper eyelids. A known variant in the POLG gene was identified.","This report details Patient 125, a patient with an atypical thalamic signal. Further investigation showe[E1]d an adult onse[/E1]t and drooping of both upper eyelids. A known variant in th[E2]e PO[/E2]LG gene was identified.",e PO,GENE_VARIANT,178,182,d an adult onse,HPO_TERM,104,119,0.825784,0.17421599,-0.65156806,0
line105,"This report details Patient 125, a patient with an atypical thalamic signal. Further investigation showed an adult onset and drooping of both upper eyelids. A known variant in the POLG gene was identified.","This report details Patient 125, a patient with an atypical thalamic signal. Further investigation showed an adult onset and[E1] drooping of both upper eyelid[/E1]s. A known variant in th[E2]e PO[/E2]LG gene was identified.",e PO,GENE_VARIANT,178,182, drooping of both upper eyelid,HPO_TERM,124,154,0.8250766,0.17492346,-0.6501531,0
line106,"This report details Patient 126, a patient with unclear or mumbled speech. Further investigation showed an elevated hepatic transaminase concentration and an adult onset. A known variant in the POLG gene was identified.","This report details Patient 126, a patient with [E1]unclear or mumbled speech[/E1]. Further investigation showed an elevated hepatic transaminase concentration and an adult onset. A known variant in [E2]the [/E2]POLG gene was identified.",the ,GENE_VARIANT,190,194,unclear or mumbled speech,HPO_TERM,48,73,0.7670904,0.23290963,-0.53418076,0
line106,"This report details Patient 126, a patient with unclear or mumbled speech. Further investigation showed an elevated hepatic transaminase concentration and an adult onset. A known variant in the POLG gene was identified.","This report details Patient 126, a patient with unclear or mumbled speech. Further investigation showed [E1]an elevated hepatic transaminase concentra[/E1]tion and an adult onset. A known variant in [E2]the [/E2]POLG gene was identified.",the ,GENE_VARIANT,190,194,an elevated hepatic transaminase concentra,HPO_TERM,104,146,0.7954125,0.20458744,-0.590825,0
line106,"This report details Patient 126, a patient with unclear or mumbled speech. Further investigation showed an elevated hepatic transaminase concentration and an adult onset. A known variant in the POLG gene was identified.","This report details Patient 126, a patient with unclear or mumbled speech. Further investigation showed an elevated hepatic transaminase concentration [E1]and an adult on[/E1]set. A known variant in [E2]the [/E2]POLG gene was identified.",the ,GENE_VARIANT,190,194,and an adult on,HPO_TERM,151,166,0.8183054,0.18169463,-0.63661075,0
line107,"We report the case of Patient 127, who has a history of an elevated level of lactate in the blood. Examination also revealed an atypical thalamic signal. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient 127, who has a history of [E1]an elevated level of lactate in the bl[/E1]ood. Examination also revealed an atypical thalamic signal. The underlying cause was traced to a mutation in[E2] the[/E2] POLG gene.", the,GENE_VARIANT,202,206,an elevated level of lactate in the bl,HPO_TERM,56,94,0.3986309,0.60136914,0.20273826,1
line107,"We report the case of Patient 127, who has a history of an elevated level of lactate in the blood. Examination also revealed an atypical thalamic signal. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient 127, who has a history of an elevated level of lactate in the blood. Examination also reveal[E1]ed an atypical thalamic s[/E1]ignal. The underlying cause was traced to a mutation in[E2] the[/E2] POLG gene.", the,GENE_VARIANT,202,206,ed an atypical thalamic s,HPO_TERM,122,147,0.53491914,0.4650809,-0.069838256,0
line108,"We report the case of Patient 128, who has a history of signs of parkinsonism. Examination also revealed an adult onset. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient 128, who has a history of [E1]signs of parkinsonis[/E1]m. Examination also revealed an adult onset. The underlying cause was traced to a mutation in the [E2]POLG[/E2] gene.",POLG,GENE_VARIANT,174,178,signs of parkinsonis,HPO_TERM,56,76,0.49802923,0.50197077,0.003941536,1
line108,"We report the case of Patient 128, who has a history of signs of parkinsonism. Examination also revealed an adult onset. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient 128, who has a history of signs of parkinsonism. Examination also revealed[E1] an adult onset[/E1]. The underlying cause was traced to a mutation in the [E2]POLG[/E2] gene.",POLG,GENE_VARIANT,174,178, an adult onset,HPO_TERM,104,119,0.51675266,0.48324737,-0.03350529,0
line109,The clinical profile for Patient 129 includes a seizure and signs of parkinsonism. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient 129 includes [E1]a seizure[/E1] and signs of parkinsonism. Genetic analysis of the[E2] POL[/E2]G gene confirmed the diagnosis., POL,GENE_VARIANT,106,110,a seizure,HPO_TERM,46,55,0.825368,0.17463194,-0.65073603,0
line109,The clinical profile for Patient 129 includes a seizure and signs of parkinsonism. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient 129 includes a seizure and [E1]signs of parkinsonis[/E1]m. Genetic analysis of the[E2] POL[/E2]G gene confirmed the diagnosis., POL,GENE_VARIANT,106,110,signs of parkinsonis,HPO_TERM,60,80,0.8488059,0.15119408,-0.6976118,0
line110,Patient 130 was evaluated for drooping of both upper eyelids. The patient also presented with an atypical thalamic signal and an adult onset. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 130 was evaluated for [E1]drooping of both upper eyelids[/E1]. The patient also presented with an atypical thalamic signal and an adult onset. Subsequent sequencing of the[E2] POL[/E2]G gene revealed a pathogenic variant., POL,GENE_VARIANT,170,174,drooping of both upper eyelids,HPO_TERM,30,60,0.8179093,0.18209064,-0.63581866,0
line110,Patient 130 was evaluated for drooping of both upper eyelids. The patient also presented with an atypical thalamic signal and an adult onset. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 130 was evaluated for drooping of both upper eyelids. The patient also presented with [E1]an atypical thalamic sign[/E1]al and an adult onset. Subsequent sequencing of the[E2] POL[/E2]G gene revealed a pathogenic variant., POL,GENE_VARIANT,170,174,an atypical thalamic sign,HPO_TERM,94,119,0.8118304,0.18816958,-0.6236608,0
line110,Patient 130 was evaluated for drooping of both upper eyelids. The patient also presented with an atypical thalamic signal and an adult onset. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 130 was evaluated for drooping of both upper eyelids. The patient also presented with an atypical thalamic signal an[E1]d an adult onse[/E1]t. Subsequent sequencing of the[E2] POL[/E2]G gene revealed a pathogenic variant., POL,GENE_VARIANT,170,174,d an adult onse,HPO_TERM,124,139,0.8536762,0.1463238,-0.7073524,0
line111,"We report the case of Patient 131, who has a history of an elevated level of lactate in the blood. Examination also revealed a pediatric-onset disorder. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient 131, who has a history of [E1]an elevated level of lactate in the bl[/E1]ood. Examination also revealed a pediatric-onset disorder. The underlying cause was traced to a mutation in t[E2]he P[/E2]OLG gene.",he P,GENE_VARIANT,203,207,an elevated level of lactate in the bl,HPO_TERM,56,94,0.42913982,0.57086015,0.14172032,1
line111,"We report the case of Patient 131, who has a history of an elevated level of lactate in the blood. Examination also revealed a pediatric-onset disorder. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient 131, who has a history of an elevated level of lactate in the blood. Examination also reveal[E1]ed a pediatric-onset disor[/E1]der. The underlying cause was traced to a mutation in t[E2]he P[/E2]OLG gene.",he P,GENE_VARIANT,203,207,ed a pediatric-onset disor,HPO_TERM,122,148,0.68885875,0.31114125,-0.3777175,0
line112,Patient 132 was evaluated for signs of parkinsonism. The patient also presented with hyperlactatemia and a seizure. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 132 was evaluated for [E1]signs of parkinsonis[/E1]m. The patient also presented with hyperlactatemia and a seizure. Subsequent sequencing of th[E2]e PO[/E2]LG gene revealed a pathogenic variant.,e PO,GENE_VARIANT,143,147,signs of parkinsonis,HPO_TERM,30,50,0.87405896,0.125941,-0.748118,0
line112,Patient 132 was evaluated for signs of parkinsonism. The patient also presented with hyperlactatemia and a seizure. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 132 was evaluated for signs of parkinsonism. The patient also presented with[E1] hyperlactatem[/E1]ia and a seizure. Subsequent sequencing of th[E2]e PO[/E2]LG gene revealed a pathogenic variant.,e PO,GENE_VARIANT,143,147, hyperlactatem,HPO_TERM,84,98,0.8672027,0.1327973,-0.7344054,0
line112,Patient 132 was evaluated for signs of parkinsonism. The patient also presented with hyperlactatemia and a seizure. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 132 was evaluated for signs of parkinsonism. The patient also presented with hyperlactatemia an[E1]d a seizu[/E1]re. Subsequent sequencing of th[E2]e PO[/E2]LG gene revealed a pathogenic variant.,e PO,GENE_VARIANT,143,147,d a seizu,HPO_TERM,103,112,0.8860924,0.11390751,-0.7721849,0
line113,Patient 133 was evaluated for an atypical thalamic signal. The patient also presented with bilateral ptosis and signs of parkinsonism. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 133 was evaluated for [E1]an atypical thalamic sign[/E1]al. The patient also presented with bilateral ptosis and signs of parkinsonism. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,161,165,an atypical thalamic sign,HPO_TERM,30,55,0.8391513,0.16084863,-0.6783027,0
line113,Patient 133 was evaluated for an atypical thalamic signal. The patient also presented with bilateral ptosis and signs of parkinsonism. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 133 was evaluated for an atypical thalamic signal. The patient also presented wit[E1]h bilateral ptos[/E1]is and signs of parkinsonism. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,161,165,h bilateral ptos,HPO_TERM,89,105,0.8337078,0.16629215,-0.6674157,0
line113,Patient 133 was evaluated for an atypical thalamic signal. The patient also presented with bilateral ptosis and signs of parkinsonism. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 133 was evaluated for an atypical thalamic signal. The patient also presented with bilateral ptosis an[E1]d signs of parkinson[/E1]ism. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,161,165,d signs of parkinson,HPO_TERM,110,130,0.8315782,0.16842188,-0.66315633,0
line114,"We report the case of Patient 134, who has a history of an atypical thalamic signal. Examination also revealed an abnormal thalamic MRI signal. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient 134, who has a history of [E1]an atypical thalamic sign[/E1]al. Examination also revealed an abnormal thalamic MRI signal. The underlying cause was traced to a mutation in [E2]the [/E2]POLG gene.",the ,GENE_VARIANT,193,197,an atypical thalamic sign,HPO_TERM,56,81,0.36578605,0.634214,0.26842794,1
line114,"We report the case of Patient 134, who has a history of an atypical thalamic signal. Examination also revealed an abnormal thalamic MRI signal. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient 134, who has a history of an atypical thalamic signal. Examination also reveale[E1]d an abnormal thalamic MRI si[/E1]gnal. The underlying cause was traced to a mutation in [E2]the [/E2]POLG gene.",the ,GENE_VARIANT,193,197,d an abnormal thalamic MRI si,HPO_TERM,109,138,0.4866339,0.5133661,0.026732206,1
line115,"This report details Patient 135, a patient with a seizure disorder. Further investigation showed an increased lactate level and slurred, consistent with dysarthria. A known variant in the POLG gene was identified.","This report details Patient 135, a patient with a seizure disorder. Further investigation showed an [E1]increased lactate level[/E1] and slurred, consistent with dysarthria. A known variant in t[E2]he P[/E2]OLG gene was identified.",he P,GENE_VARIANT,185,189,increased lactate level,HPO_TERM,100,123,0.80147356,0.19852638,-0.6029472,0
line115,"This report details Patient 135, a patient with a seizure disorder. Further investigation showed an increased lactate level and slurred, consistent with dysarthria. A known variant in the POLG gene was identified.","This report details Patient 135, a patient with a seizure disorder. Further investigation showed an increased lactate level and [E1]slurred, consistent with dysarthr[/E1]ia. A known variant in t[E2]he P[/E2]OLG gene was identified.",he P,GENE_VARIANT,185,189,"slurred, consistent with dysarthr",HPO_TERM,128,161,0.8090964,0.19090356,-0.61819285,0
line116,The primary symptoms for Patient 136 were a pediatric-onset disorder and a buildup of lactate in his bloodstream. Analysis of the POLG gene was performed.,The primary symptoms for Patient 136 were a [E1]pediatric-onset disorder a[/E1]nd a buildup of lactate in his bloodstream. Analysis of the POLG gene [E2]was [/E2]performed.,was ,GENE_VARIANT,140,144,pediatric-onset disorder a,HPO_TERM,44,70,0.8623676,0.13763238,-0.7247352,0
line117,"We report the case of Patient 137, who has a history of an atypical thalamic signal. Examination also revealed drooping of both upper eyelids. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient 137, who has a history of [E1]an atypical thalamic sign[/E1]al. Examination also revealed drooping of both upper eyelids. The underlying cause was traced to a mutation in th[E2]e PO[/E2]LG gene.",e PO,GENE_VARIANT,194,198,an atypical thalamic sign,HPO_TERM,56,81,0.6705447,0.3294553,-0.3410894,0
line117,"We report the case of Patient 137, who has a history of an atypical thalamic signal. Examination also revealed drooping of both upper eyelids. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient 137, who has a history of an atypical thalamic signal. Examination also reveale[E1]d drooping of both upper eyeli[/E1]ds. The underlying cause was traced to a mutation in th[E2]e PO[/E2]LG gene.",e PO,GENE_VARIANT,194,198,d drooping of both upper eyeli,HPO_TERM,109,139,0.5286027,0.47139725,-0.05720547,0
line118,The primary symptoms for Patient 138 were an atypical thalamic signal and an abnormal thalamic MRI signal. Analysis of the POLG gene was performed.,The primary symptoms for Patient 138 were an[E1] atypical thalamic signal[/E1] and an abnormal thalamic MRI signal. Analysis of the POLG g[E2]ene [/E2]was performed.,ene ,GENE_VARIANT,129,133, atypical thalamic signal,HPO_TERM,44,69,0.8100704,0.18992959,-0.6201408,0
line118,The primary symptoms for Patient 138 were an atypical thalamic signal and an abnormal thalamic MRI signal. Analysis of the POLG gene was performed.,The primary symptoms for Patient 138 were an atypical thalamic signal and [E1]an abnormal thalamic MRI sign[/E1]al. Analysis of the POLG g[E2]ene [/E2]was performed.,ene ,GENE_VARIANT,129,133,an abnormal thalamic MRI sign,HPO_TERM,74,103,0.8504299,0.1495701,-0.7008598,0
line119,"This report details Patient 139, a patient with poor articulation. Further investigation showed hyperlactatemia and a seizure. A known variant in the POLG gene was identified.","This report details Patient 139, a patient with [E1]poor articulation[/E1]. Further investigation showed hyperlactatemia and a seizure. A known variant in th[E2]e PO[/E2]LG gene was identified.",e PO,GENE_VARIANT,148,152,poor articulation,HPO_TERM,48,65,0.8373912,0.16260877,-0.6747824,0
line119,"This report details Patient 139, a patient with poor articulation. Further investigation showed hyperlactatemia and a seizure. A known variant in the POLG gene was identified.","This report details Patient 139, a patient with poor articulation. Further investigation showed [E1]hyperlactatemi[/E1]a and a seizure. A known variant in th[E2]e PO[/E2]LG gene was identified.",e PO,GENE_VARIANT,148,152,hyperlactatemi,HPO_TERM,96,110,0.84973156,0.15026844,-0.6994631,0
line119,"This report details Patient 139, a patient with poor articulation. Further investigation showed hyperlactatemia and a seizure. A known variant in the POLG gene was identified.","This report details Patient 139, a patient with poor articulation. Further investigation showed hyperlactatemia and[E1] a seizur[/E1]e. A known variant in th[E2]e PO[/E2]LG gene was identified.",e PO,GENE_VARIANT,148,152, a seizur,HPO_TERM,115,124,0.8814534,0.11854659,-0.7629068,0
line120,"This report details Patient 140, a patient with hyperlactatemia. Further investigation showed a clinical syndrome resembling Parkinson's disease and an adult onset. A known variant in the POLG gene was identified.","This report details Patient 140, a patient with [E1]hyperlactatemi[/E1]a. Further investigation showed a clinical syndrome resembling Parkinson's disease and an adult onset. A known variant in[E2] the[/E2] POLG gene was identified.", the,GENE_VARIANT,183,187,hyperlactatemi,HPO_TERM,48,62,0.78605837,0.21394165,-0.57211673,0
line120,"This report details Patient 140, a patient with hyperlactatemia. Further investigation showed a clinical syndrome resembling Parkinson's disease and an adult onset. A known variant in the POLG gene was identified.","This report details Patient 140, a patient with hyperlactatemia. Further investigation showed[E1] a clinical syndrome resembling Parkinson's di[/E1]sease and an adult onset. A known variant in[E2] the[/E2] POLG gene was identified.", the,GENE_VARIANT,183,187, a clinical syndrome resembling Parkinson's di,HPO_TERM,93,139,0.7472868,0.25271323,-0.49457356,0
line120,"This report details Patient 140, a patient with hyperlactatemia. Further investigation showed a clinical syndrome resembling Parkinson's disease and an adult onset. A known variant in the POLG gene was identified.","This report details Patient 140, a patient with hyperlactatemia. Further investigation showed a clinical syndrome resembling Parkinson's disease[E1] and an adult o[/E1]nset. A known variant in[E2] the[/E2] POLG gene was identified.", the,GENE_VARIANT,183,187, and an adult o,HPO_TERM,144,159,0.8055129,0.19448708,-0.6110258,0
line121,"We report the case of Patient 141, who has a history of an elevated hepatic transaminase concentration. Examination also revealed an abnormal thalamic MRI signal. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient 141, who has a history of [E1]an elevated hepatic transaminase concentra[/E1]tion. Examination also revealed an abnormal thalamic MRI signal. The underlying cause was traced to a mutation i[E2]n th[/E2]e POLG gene.",n th,GENE_VARIANT,210,214,an elevated hepatic transaminase concentra,HPO_TERM,56,98,0.51891714,0.48108286,-0.037834287,0
line121,"We report the case of Patient 141, who has a history of an elevated hepatic transaminase concentration. Examination also revealed an abnormal thalamic MRI signal. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient 141, who has a history of an elevated hepatic transaminase concentration. Examination also revea[E1]led an abnormal thalamic MRI [/E1]signal. The underlying cause was traced to a mutation i[E2]n th[/E2]e POLG gene.",n th,GENE_VARIANT,210,214,led an abnormal thalamic MRI ,HPO_TERM,126,155,0.6406339,0.35936612,-0.28126776,0
line122,The primary symptoms for Patient 142 were an elevated hepatic transaminase concentration and an adult onset. Analysis of the POLG gene was performed.,The primary symptoms for Patient 142 were an[E1] elevated hepatic transaminase concentrati[/E1]on and an adult onset. Analysis of the POLG ge[E2]ne w[/E2]as performed.,ne w,GENE_VARIANT,132,136, elevated hepatic transaminase concentrati,HPO_TERM,44,86,0.7948593,0.20514072,-0.5897186,0
line122,The primary symptoms for Patient 142 were an elevated hepatic transaminase concentration and an adult onset. Analysis of the POLG gene was performed.,The primary symptoms for Patient 142 were an elevated hepatic transaminase concentration an[E1]d an adult onse[/E1]t. Analysis of the POLG ge[E2]ne w[/E2]as performed.,ne w,GENE_VARIANT,132,136,d an adult onse,HPO_TERM,91,106,0.817849,0.18215106,-0.6356979,0
line123,The clinical profile for Patient 143 includes an elevated level of lactate in the blood and an adult onset. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient 143 includes [E1]an elevated level of lactate in the bl[/E1]ood and an adult onset. Genetic analysis of th[E2]e PO[/E2]LG gene confirmed the diagnosis.,e PO,GENE_VARIANT,130,134,an elevated level of lactate in the bl,HPO_TERM,46,84,0.843175,0.15682499,-0.68635,0
line123,The clinical profile for Patient 143 includes an elevated level of lactate in the blood and an adult onset. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient 143 includes an elevated level of lactate in the blood a[E1]nd an adult ons[/E1]et. Genetic analysis of th[E2]e PO[/E2]LG gene confirmed the diagnosis.,e PO,GENE_VARIANT,130,134,nd an adult ons,HPO_TERM,89,104,0.87185395,0.1281461,-0.74370784,0
line124,"This report details Patient 144, a patient with an abnormal thalamic MRI signal. Further investigation showed an adult onset and slurred, consistent with dysarthria. A known variant in the POLG gene was identified.","This report details Patient 144, a patient with [E1]an abnormal thalamic MRI sign[/E1]al. Further investigation showed an adult onset and slurred, consistent with dysarthria. A known variant in [E2]the [/E2]POLG gene was identified.",the ,GENE_VARIANT,185,189,an abnormal thalamic MRI sign,HPO_TERM,48,77,0.7629071,0.23709294,-0.5258142,0
line124,"This report details Patient 144, a patient with an abnormal thalamic MRI signal. Further investigation showed an adult onset and slurred, consistent with dysarthria. A known variant in the POLG gene was identified.","This report details Patient 144, a patient with an abnormal thalamic MRI signal. Further investigation showe[E1]d an adult onse[/E1]t and slurred, consistent with dysarthria. A known variant in [E2]the [/E2]POLG gene was identified.",the ,GENE_VARIANT,185,189,d an adult onse,HPO_TERM,108,123,0.76488996,0.23511001,-0.5297799,0
line124,"This report details Patient 144, a patient with an abnormal thalamic MRI signal. Further investigation showed an adult onset and slurred, consistent with dysarthria. A known variant in the POLG gene was identified.","This report details Patient 144, a patient with an abnormal thalamic MRI signal. Further investigation showed an adult onset and[E1] slurred, consistent with dysarth[/E1]ria. A known variant in [E2]the [/E2]POLG gene was identified.",the ,GENE_VARIANT,185,189," slurred, consistent with dysarth",HPO_TERM,128,161,0.74898225,0.25101775,-0.4979645,0
line125,The clinical profile for Patient 145 includes hyperlactatemia and an atypical thalamic signal. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient 145 includes [E1]hyperlactatemi[/E1]a and an atypical thalamic signal. Genetic analysis of t[E2]he P[/E2]OLG gene confirmed the diagnosis.,he P,GENE_VARIANT,116,120,hyperlactatemi,HPO_TERM,46,60,0.8484446,0.15155546,-0.6968891,0
line125,The clinical profile for Patient 145 includes hyperlactatemia and an atypical thalamic signal. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient 145 includes hyperlactatemia and[E1] an atypical thalamic sig[/E1]nal. Genetic analysis of t[E2]he P[/E2]OLG gene confirmed the diagnosis.,he P,GENE_VARIANT,116,120, an atypical thalamic sig,HPO_TERM,65,90,0.8647788,0.13522115,-0.72955763,0
line126,Patient 146 was evaluated for poor articulation. The patient also presented with an elevated hepatic transaminase concentration and a seizure disorder. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 146 was evaluated for [E1]poor articulation[/E1]. The patient also presented with an elevated hepatic transaminase concentration and a seizure disorder. Subsequent sequencing of the[E2] POL[/E2]G gene revealed a pathogenic variant., POL,GENE_VARIANT,180,184,poor articulation,HPO_TERM,30,47,0.8201964,0.17980358,-0.6403928,0
line126,Patient 146 was evaluated for poor articulation. The patient also presented with an elevated hepatic transaminase concentration and a seizure disorder. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 146 was evaluated for poor articulation. The patient also presented with [E1]an elevated hepatic transaminase concentra[/E1]tion and a seizure disorder. Subsequent sequencing of the[E2] POL[/E2]G gene revealed a pathogenic variant., POL,GENE_VARIANT,180,184,an elevated hepatic transaminase concentra,HPO_TERM,81,123,0.81411916,0.18588085,-0.6282383,0
line126,Patient 146 was evaluated for poor articulation. The patient also presented with an elevated hepatic transaminase concentration and a seizure disorder. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 146 was evaluated for poor articulation. The patient also presented with an elevated hepatic transaminase concentration [E1]and a seizure disorde[/E1]r. Subsequent sequencing of the[E2] POL[/E2]G gene revealed a pathogenic variant., POL,GENE_VARIANT,180,184,and a seizure disorde,HPO_TERM,128,149,0.8313226,0.16867742,-0.6626452,0
line127,The clinical profile for Patient 147 includes a buildup of lactate in his bloodstream and an atypical thalamic signal. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient 147 includes [E1]a buildup of lactate in his bloodstream[/E1] and an atypical thalamic signal. Genetic analysis of th[E2]e PO[/E2]LG gene confirmed the diagnosis.,e PO,GENE_VARIANT,141,145,a buildup of lactate in his bloodstream,HPO_TERM,46,85,0.8586988,0.14130123,-0.7173976,0
line127,The clinical profile for Patient 147 includes a buildup of lactate in his bloodstream and an atypical thalamic signal. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient 147 includes a buildup of lactate in his bloodstream and [E1]an atypical thalamic sign[/E1]al. Genetic analysis of th[E2]e PO[/E2]LG gene confirmed the diagnosis.,e PO,GENE_VARIANT,141,145,an atypical thalamic sign,HPO_TERM,90,115,0.8681427,0.13185732,-0.7362854,0
line128,"We report the case of Patient 148, who has a history of an increased lactate level. Examination also revealed an elevated hepatic transaminase concentration. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient 148, who has a history of [E1]an increased lactate le[/E1]vel. Examination also revealed an elevated hepatic transaminase concentration. The underlying cause was traced to a mutation [E2]in t[/E2]he POLG gene.",in t,GENE_VARIANT,204,208,an increased lactate le,HPO_TERM,56,79,0.63531053,0.36468944,-0.2706211,0
line128,"We report the case of Patient 148, who has a history of an increased lactate level. Examination also revealed an elevated hepatic transaminase concentration. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient 148, who has a history of an increased lactate level. Examination also reveal[E1]ed an elevated hepatic transaminase concen[/E1]tration. The underlying cause was traced to a mutation [E2]in t[/E2]he POLG gene.",in t,GENE_VARIANT,204,208,ed an elevated hepatic transaminase concen,HPO_TERM,107,149,0.7109125,0.28908744,-0.42182508,0
line129,The primary symptoms for Patient 149 were unclear or mumbled speech and an abnormal thalamic MRI signal. Analysis of the POLG gene was performed.,The primary symptoms for Patient 149 were un[E1]clear or mumbled speech a[/E1]nd an abnormal thalamic MRI signal. Analysis of the POLG gen[E2]e wa[/E2]s performed.,e wa,GENE_VARIANT,129,133,clear or mumbled speech a,HPO_TERM,44,69,0.7634671,0.23653291,-0.52693415,0
line129,The primary symptoms for Patient 149 were unclear or mumbled speech and an abnormal thalamic MRI signal. Analysis of the POLG gene was performed.,The primary symptoms for Patient 149 were unclear or mumbled speech and an[E1] abnormal thalamic MRI signal[/E1]. Analysis of the POLG gen[E2]e wa[/E2]s performed.,e wa,GENE_VARIANT,129,133, abnormal thalamic MRI signal,HPO_TERM,74,103,0.7359306,0.26406935,-0.47186127,0
line130,"This report details Patient 150, a patient with a late-onset variant of the condition. Further investigation showed an atypical thalamic signal and signs of parkinsonism. A known variant in the POLG gene was identified.","This report details Patient 150, a patient with [E1]a late-onset variant of the condition[/E1]. Further investigation showed an atypical thalamic signal and signs of parkinsonism. A known variant in [E2]the[/E2] POLG gene was identified.",the,GENE_VARIANT,190,193,a late-onset variant of the condition,HPO_TERM,48,85,0.7801184,0.21988153,-0.5602369,0
line130,"This report details Patient 150, a patient with a late-onset variant of the condition. Further investigation showed an atypical thalamic signal and signs of parkinsonism. A known variant in the POLG gene was identified.","This report details Patient 150, a patient with a late-onset variant of the condition. Further investigation showed [E1]an atypical thalamic sign[/E1]al and signs of parkinsonism. A known variant in [E2]the[/E2] POLG gene was identified.",the,GENE_VARIANT,190,193,an atypical thalamic sign,HPO_TERM,116,141,0.7556379,0.24436209,-0.51127577,0
line130,"This report details Patient 150, a patient with a late-onset variant of the condition. Further investigation showed an atypical thalamic signal and signs of parkinsonism. A known variant in the POLG gene was identified.","This report details Patient 150, a patient with a late-onset variant of the condition. Further investigation showed an atypical thalamic signal an[E1]d signs of parkinson[/E1]ism. A known variant in [E2]the[/E2] POLG gene was identified.",the,GENE_VARIANT,190,193,d signs of parkinson,HPO_TERM,146,166,0.7823256,0.21767434,-0.56465125,0
line131,The clinical profile for Patient 151 includes a seizure and an adult onset. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient 151 includes [E1]a seizure[/E1] and an adult onset. Genetic analysis of the P[E2]OLG [/E2]gene confirmed the diagnosis.,OLG ,GENE_VARIANT,101,105,a seizure,HPO_TERM,46,55,0.7903106,0.20968945,-0.5806212,0
line132,"We report the case of Patient 152, who has a history of hyperlactatemia. Examination also revealed a pediatric-onset disorder. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient 152, who has a history of [E1]hyperlactatemi[/E1]a. Examination also revealed a pediatric-onset disorder. The underlying cause was traced to a mutation in the[E2] POL[/E2]G gene.", POL,GENE_VARIANT,179,183,hyperlactatemi,HPO_TERM,56,70,0.5557865,0.44421345,-0.11157304,0
line132,"We report the case of Patient 152, who has a history of hyperlactatemia. Examination also revealed a pediatric-onset disorder. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient 152, who has a history of hyperlactatemia. Examination also revealed[E1] a pediatric-onset disorde[/E1]r. The underlying cause was traced to a mutation in the[E2] POL[/E2]G gene.", POL,GENE_VARIANT,179,183, a pediatric-onset disorde,HPO_TERM,98,124,0.3733223,0.62667763,0.25335532,1
line134,"This report details Patient 154, a patient with a pediatric-onset disorder. Further investigation showed hyperlactatemia and a buildup of lactate in his bloodstream. A known variant in the POLG gene was identified.","This report details Patient 154, a patient with [E1]a pediatric-onset disorder[/E1]. Further investigation showed hyperlactatemia and a buildup of lactate in his bloodstream. A known variant in th[E2]e PO[/E2]LG gene was identified.",e PO,GENE_VARIANT,187,191,a pediatric-onset disorder,HPO_TERM,48,74,0.8559755,0.14402443,-0.7119511,0
line134,"This report details Patient 154, a patient with a pediatric-onset disorder. Further investigation showed hyperlactatemia and a buildup of lactate in his bloodstream. A known variant in the POLG gene was identified.","This report details Patient 154, a patient with a pediatric-onset disorder. Further investigation showed [E1]hyperlactatemi[/E1]a and a buildup of lactate in his bloodstream. A known variant in th[E2]e PO[/E2]LG gene was identified.",e PO,GENE_VARIANT,187,191,hyperlactatemi,HPO_TERM,105,119,0.8511754,0.14882462,-0.7023508,0
line134,"This report details Patient 154, a patient with a pediatric-onset disorder. Further investigation showed hyperlactatemia and a buildup of lactate in his bloodstream. A known variant in the POLG gene was identified.","This report details Patient 154, a patient with a pediatric-onset disorder. Further investigation showed hyperlactatemia and[E1] a buildup of lactate in his bloodstrea[/E1]m. A known variant in th[E2]e PO[/E2]LG gene was identified.",e PO,GENE_VARIANT,187,191, a buildup of lactate in his bloodstrea,HPO_TERM,124,163,0.85419804,0.14580196,-0.7083961,0
line135,"This report details Patient 155, a patient with an elevated hepatic transaminase concentration. Further investigation showed a pediatric-onset disorder and an abnormal thalamic MRI signal. A known variant in the POLG gene was identified.","This report details Patient 155, a patient with [E1]an elevated hepatic transaminase concentra[/E1]tion. Further investigation showed a pediatric-onset disorder and an abnormal thalamic MRI signal. A known variant [E2]in t[/E2]he POLG gene was identified.",in t,GENE_VARIANT,205,209,an elevated hepatic transaminase concentra,HPO_TERM,48,90,0.82075906,0.17924094,-0.6415181,0
line135,"This report details Patient 155, a patient with an elevated hepatic transaminase concentration. Further investigation showed a pediatric-onset disorder and an abnormal thalamic MRI signal. A known variant in the POLG gene was identified.","This report details Patient 155, a patient with an elevated hepatic transaminase concentration. Further investigation sho[E1]wed a pediatric-onset diso[/E1]rder and an abnormal thalamic MRI signal. A known variant [E2]in t[/E2]he POLG gene was identified.",in t,GENE_VARIANT,205,209,wed a pediatric-onset diso,HPO_TERM,121,147,0.8196086,0.1803914,-0.63921726,0
line135,"This report details Patient 155, a patient with an elevated hepatic transaminase concentration. Further investigation showed a pediatric-onset disorder and an abnormal thalamic MRI signal. A known variant in the POLG gene was identified.","This report details Patient 155, a patient with an elevated hepatic transaminase concentration. Further investigation showed a pediatric-onset disorder [E1]and an abnormal thalamic MRI [/E1]signal. A known variant [E2]in t[/E2]he POLG gene was identified.",in t,GENE_VARIANT,205,209,and an abnormal thalamic MRI ,HPO_TERM,152,181,0.8012404,0.19875956,-0.6024808,0
line136,"This report details Patient 156, a patient with an increased lactate level. Further investigation showed an atypical thalamic signal and an elevated hepatic transaminase concentration. A known variant in the POLG gene was identified.","This report details Patient 156, a patient with [E1]an increased lactate le[/E1]vel. Further investigation showed an atypical thalamic signal and an elevated hepatic transaminase concentration. A known varia[E2]nt i[/E2]n the POLG gene was identified.",nt i,GENE_VARIANT,198,202,an increased lactate le,HPO_TERM,48,71,0.8864475,0.113552436,-0.77289504,0
line136,"This report details Patient 156, a patient with an increased lactate level. Further investigation showed an atypical thalamic signal and an elevated hepatic transaminase concentration. A known variant in the POLG gene was identified.","This report details Patient 156, a patient with an increased lactate level. Further investigation show[E1]ed an atypical thalamic s[/E1]ignal and an elevated hepatic transaminase concentration. A known varia[E2]nt i[/E2]n the POLG gene was identified.",nt i,GENE_VARIANT,198,202,ed an atypical thalamic s,HPO_TERM,102,127,0.8798398,0.120160185,-0.7596796,0
line136,"This report details Patient 156, a patient with an increased lactate level. Further investigation showed an atypical thalamic signal and an elevated hepatic transaminase concentration. A known variant in the POLG gene was identified.","This report details Patient 156, a patient with an increased lactate level. Further investigation showed an atypical thalamic signal[E1] and an elevated hepatic transaminase conc[/E1]entration. A known varia[E2]nt i[/E2]n the POLG gene was identified.",nt i,GENE_VARIANT,198,202, and an elevated hepatic transaminase conc,HPO_TERM,132,174,0.8837391,0.11626087,-0.7674782,0
line137,Patient 157 was evaluated for a pediatric-onset disorder. The patient also presented with an atypical thalamic signal and an elevated level of lactate in the blood. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 157 was evaluated for [E1]a pediatric-onset disorder[/E1]. The patient also presented with an atypical thalamic signal and an elevated level of lactate in the blood. Subsequent sequencing of[E2] the[/E2] POLG gene revealed a pathogenic variant., the,GENE_VARIANT,189,193,a pediatric-onset disorder,HPO_TERM,30,56,0.80670166,0.19329835,-0.6134033,0
line137,Patient 157 was evaluated for a pediatric-onset disorder. The patient also presented with an atypical thalamic signal and an elevated level of lactate in the blood. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 157 was evaluated for a pediatric-onset disorder. The patient also presented with [E1]an atypical thalamic sign[/E1]al and an elevated level of lactate in the blood. Subsequent sequencing of[E2] the[/E2] POLG gene revealed a pathogenic variant., the,GENE_VARIANT,189,193,an atypical thalamic sign,HPO_TERM,90,115,0.79631174,0.2036883,-0.5926235,0
line137,Patient 157 was evaluated for a pediatric-onset disorder. The patient also presented with an atypical thalamic signal and an elevated level of lactate in the blood. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 157 was evaluated for a pediatric-onset disorder. The patient also presented with an atypical thalamic signal an[E1]d an elevated level of lactate in the [/E1]blood. Subsequent sequencing of[E2] the[/E2] POLG gene revealed a pathogenic variant., the,GENE_VARIANT,189,193,d an elevated level of lactate in the ,HPO_TERM,120,158,0.8175645,0.1824355,-0.635129,0
line138,"This report details Patient 158, a patient with a seizure. Further investigation showed hyperlactatemia and an adult onset. A known variant in the POLG gene was identified.","This report details Patient 158, a patient with [E1]a seizure[/E1]. Further investigation showed hyperlactatemia and an adult onset. A known variant in the[E2] POL[/E2]G gene was identified.", POL,GENE_VARIANT,146,150,a seizure,HPO_TERM,48,57,0.7974984,0.20250164,-0.59499675,0
line138,"This report details Patient 158, a patient with a seizure. Further investigation showed hyperlactatemia and an adult onset. A known variant in the POLG gene was identified.","This report details Patient 158, a patient with a seizure. Further investigation showed [E1]hyperlactatemi[/E1]a and an adult onset. A known variant in the[E2] POL[/E2]G gene was identified.", POL,GENE_VARIANT,146,150,hyperlactatemi,HPO_TERM,88,102,0.81427366,0.18572636,-0.6285473,0
line138,"This report details Patient 158, a patient with a seizure. Further investigation showed hyperlactatemia and an adult onset. A known variant in the POLG gene was identified.","This report details Patient 158, a patient with a seizure. Further investigation showed hyperlactatemia and[E1] an adult onset[/E1]. A known variant in the[E2] POL[/E2]G gene was identified.", POL,GENE_VARIANT,146,150, an adult onset,HPO_TERM,107,122,0.822706,0.177294,-0.64541197,0
line139,The primary symptoms for Patient 159 were an atypical thalamic signal and signs of parkinsonism. Analysis of the POLG gene was performed.,The primary symptoms for Patient 159 were an[E1] atypical thalamic signal[/E1] and signs of parkinsonism. Analysis of the POLG ge[E2]ne w[/E2]as performed.,ne w,GENE_VARIANT,120,124, atypical thalamic signal,HPO_TERM,44,69,0.7492849,0.25071508,-0.49856985,0
line139,The primary symptoms for Patient 159 were an atypical thalamic signal and signs of parkinsonism. Analysis of the POLG gene was performed.,The primary symptoms for Patient 159 were an atypical thalamic signal and [E1]signs of parkinsonis[/E1]m. Analysis of the POLG ge[E2]ne w[/E2]as performed.,ne w,GENE_VARIANT,120,124,signs of parkinsonis,HPO_TERM,74,94,0.8248601,0.17513984,-0.64972025,0
line140,The primary symptoms for Patient 160 were an atypical thalamic signal and a buildup of lactate in his bloodstream. Analysis of the POLG gene was performed.,The primary symptoms for Patient 160 were an[E1] atypical thalamic signal[/E1] and a buildup of lactate in his bloodstream. Analysis of the POLG gen[E2]e wa[/E2]s performed.,e wa,GENE_VARIANT,139,143, atypical thalamic signal,HPO_TERM,44,69,0.79746246,0.2025375,-0.5949249,0
line140,The primary symptoms for Patient 160 were an atypical thalamic signal and a buildup of lactate in his bloodstream. Analysis of the POLG gene was performed.,The primary symptoms for Patient 160 were an atypical thalamic signal and [E1]a buildup of lactate in his bloodstream[/E1]. Analysis of the POLG gen[E2]e wa[/E2]s performed.,e wa,GENE_VARIANT,139,143,a buildup of lactate in his bloodstream,HPO_TERM,74,113,0.8101208,0.18987922,-0.6202416,0
line141,"We report the case of Patient 161, who has a history of an elevated hepatic transaminase concentration. Examination also revealed an atypical thalamic signal. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient 161, who has a history of [E1]an elevated hepatic transaminase concentra[/E1]tion. Examination also revealed an atypical thalamic signal. The underlying cause was traced to a mutation i[E2]n th[/E2]e POLG gene.",n th,GENE_VARIANT,206,210,an elevated hepatic transaminase concentra,HPO_TERM,56,98,0.6420912,0.3579088,-0.28418243,0
line141,"We report the case of Patient 161, who has a history of an elevated hepatic transaminase concentration. Examination also revealed an atypical thalamic signal. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient 161, who has a history of an elevated hepatic transaminase concentration. Examination also revea[E1]led an atypical thalamic [/E1]signal. The underlying cause was traced to a mutation i[E2]n th[/E2]e POLG gene.",n th,GENE_VARIANT,206,210,led an atypical thalamic ,HPO_TERM,126,151,0.7250921,0.27490786,-0.45018426,0
line142,The clinical profile for Patient 162 includes an adult onset and an abnormal thalamic MRI signal. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient 162 includes [E1]an adult onset [/E1]and an abnormal thalamic MRI signal. Genetic analysis of the[E2] POL[/E2]G gene confirmed the diagnosis., POL,GENE_VARIANT,121,125,an adult onset ,HPO_TERM,46,61,0.8052146,0.19478542,-0.61042917,0
line142,The clinical profile for Patient 162 includes an adult onset and an abnormal thalamic MRI signal. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient 162 includes an adult onset and a[E1]n abnormal thalamic MRI signa[/E1]l. Genetic analysis of the[E2] POL[/E2]G gene confirmed the diagnosis., POL,GENE_VARIANT,121,125,n abnormal thalamic MRI signa,HPO_TERM,66,95,0.8242419,0.17575812,-0.64848375,0
line143,"This report details Patient 163, a patient with a seizure. Further investigation showed an elevated hepatic transaminase concentration and an abnormal thalamic MRI signal. A known variant in the POLG gene was identified.","This report details Patient 163, a patient with [E1]a seizure[/E1]. Further investigation showed an elevated hepatic transaminase concentration and an abnormal thalamic MRI signal. A known variant [E2]in t[/E2]he POLG gene was identified.",in t,GENE_VARIANT,188,192,a seizure,HPO_TERM,48,57,0.82526475,0.17473532,-0.65052944,0
line143,"This report details Patient 163, a patient with a seizure. Further investigation showed an elevated hepatic transaminase concentration and an abnormal thalamic MRI signal. A known variant in the POLG gene was identified.","This report details Patient 163, a patient with a seizure. Further investigation showed [E1]an elevated hepatic transaminase concentra[/E1]tion and an abnormal thalamic MRI signal. A known variant [E2]in t[/E2]he POLG gene was identified.",in t,GENE_VARIANT,188,192,an elevated hepatic transaminase concentra,HPO_TERM,88,130,0.83502764,0.1649724,-0.67005527,0
line143,"This report details Patient 163, a patient with a seizure. Further investigation showed an elevated hepatic transaminase concentration and an abnormal thalamic MRI signal. A known variant in the POLG gene was identified.","This report details Patient 163, a patient with a seizure. Further investigation showed an elevated hepatic transaminase concentration [E1]and an abnormal thalamic MRI [/E1]signal. A known variant [E2]in t[/E2]he POLG gene was identified.",in t,GENE_VARIANT,188,192,and an abnormal thalamic MRI ,HPO_TERM,135,164,0.82372576,0.17627428,-0.64745146,0
line144,"We report the case of Patient 164, who has a history of a clinical syndrome resembling Parkinson's disease. Examination also revealed an atypical thalamic signal. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient 164, who has a history of [E1]a clinical syndrome resembling Parkinson's dis[/E1]ease. Examination also revealed an atypical thalamic signal. The underlying cause was traced to a mutation i[E2]n th[/E2]e POLG gene.",n th,GENE_VARIANT,210,214,a clinical syndrome resembling Parkinson's dis,HPO_TERM,56,102,0.62193847,0.37806153,-0.24387693,0
line144,"We report the case of Patient 164, who has a history of a clinical syndrome resembling Parkinson's disease. Examination also revealed an atypical thalamic signal. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient 164, who has a history of a clinical syndrome resembling Parkinson's disease. Examination also revea[E1]led an atypical thalamic [/E1]signal. The underlying cause was traced to a mutation i[E2]n th[/E2]e POLG gene.",n th,GENE_VARIANT,210,214,led an atypical thalamic ,HPO_TERM,130,155,0.6979664,0.30203366,-0.39593273,0
line145,"We report the case of Patient 165, who has a history of a buildup of lactate in his bloodstream. Examination also revealed a pediatric-onset disorder. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient 165, who has a history of [E1]a buildup of lactate in his bloodstream[/E1]. Examination also revealed a pediatric-onset disorder. The underlying cause was traced to a mutation in the [E2]POLG[/E2] gene.",POLG,GENE_VARIANT,204,208,a buildup of lactate in his bloodstream,HPO_TERM,56,95,0.54172796,0.45827207,-0.08345589,0
line145,"We report the case of Patient 165, who has a history of a buildup of lactate in his bloodstream. Examination also revealed a pediatric-onset disorder. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient 165, who has a history of a buildup of lactate in his bloodstream. Examination also revealed [E1]a pediatric-onset disorder[/E1]. The underlying cause was traced to a mutation in the [E2]POLG[/E2] gene.",POLG,GENE_VARIANT,204,208,a pediatric-onset disorder,HPO_TERM,123,149,0.5247711,0.47522894,-0.04954216,0
line146,The primary symptoms for Patient 166 were a condition that affects the muscles used for speech and an adult onset. Analysis of the POLG gene was performed.,The primary symptoms for Patient 166 were a [E1]condition that affects the muscles used for speech [/E1]and an adult onset. Analysis of the POLG gene [E2]was [/E2]performed.,was ,GENE_VARIANT,141,145,condition that affects the muscles used for speech ,HPO_TERM,44,95,0.8272053,0.17279473,-0.6544106,0
line147,"This report details Patient 167, a patient with an abnormal thalamic MRI signal. Further investigation showed hyperlactatemia and a seizure. A known variant in the POLG gene was identified.","This report details Patient 167, a patient with [E1]an abnormal thalamic MRI sign[/E1]al. Further investigation showed hyperlactatemia and a seizure. A known variant in [E2]the [/E2]POLG gene was identified.",the ,GENE_VARIANT,160,164,an abnormal thalamic MRI sign,HPO_TERM,48,77,0.7735989,0.22640106,-0.5471978,0
line147,"This report details Patient 167, a patient with an abnormal thalamic MRI signal. Further investigation showed hyperlactatemia and a seizure. A known variant in the POLG gene was identified.","This report details Patient 167, a patient with an abnormal thalamic MRI signal. Further investigation showe[E1]d hyperlactate[/E1]mia and a seizure. A known variant in [E2]the [/E2]POLG gene was identified.",the ,GENE_VARIANT,160,164,d hyperlactate,HPO_TERM,108,122,0.7668989,0.2331012,-0.5337977,0
line147,"This report details Patient 167, a patient with an abnormal thalamic MRI signal. Further investigation showed hyperlactatemia and a seizure. A known variant in the POLG gene was identified.","This report details Patient 167, a patient with an abnormal thalamic MRI signal. Further investigation showed hyperlactatemia a[E1]nd a seiz[/E1]ure. A known variant in [E2]the [/E2]POLG gene was identified.",the ,GENE_VARIANT,160,164,nd a seiz,HPO_TERM,127,136,0.7906282,0.20937183,-0.5812564,0
line148,The clinical profile for Patient 168 includes an elevated level of lactate in the blood and signs of parkinsonism. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient 168 includes [E1]an elevated level of lactate in the bl[/E1]ood and signs of parkinsonism. Genetic analysis of [E2]the [/E2]POLG gene confirmed the diagnosis.,the ,GENE_VARIANT,135,139,an elevated level of lactate in the bl,HPO_TERM,46,84,0.83456886,0.16543117,-0.6691377,0
line148,The clinical profile for Patient 168 includes an elevated level of lactate in the blood and signs of parkinsonism. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient 168 includes an elevated level of lactate in the blood a[E1]nd signs of parkinso[/E1]nism. Genetic analysis of [E2]the [/E2]POLG gene confirmed the diagnosis.,the ,GENE_VARIANT,135,139,nd signs of parkinso,HPO_TERM,89,109,0.83221143,0.16778858,-0.66442287,0
line149,"This report details Patient 169, a patient with a buildup of lactate in his bloodstream. Further investigation showed an abnormal thalamic MRI signal and an atypical thalamic signal. A known variant in the POLG gene was identified.","This report details Patient 169, a patient with [E1]a buildup of lactate in his bloodstream[/E1]. Further investigation showed an abnormal thalamic MRI signal and an atypical thalamic signal. A known variant in[E2] the[/E2] POLG gene was identified.", the,GENE_VARIANT,201,205,a buildup of lactate in his bloodstream,HPO_TERM,48,87,0.79094064,0.20905934,-0.5818813,0
line149,"This report details Patient 169, a patient with a buildup of lactate in his bloodstream. Further investigation showed an abnormal thalamic MRI signal and an atypical thalamic signal. A known variant in the POLG gene was identified.","This report details Patient 169, a patient with a buildup of lactate in his bloodstream. Further investigation showed [E1]an abnormal thalamic MRI sign[/E1]al and an atypical thalamic signal. A known variant in[E2] the[/E2] POLG gene was identified.", the,GENE_VARIANT,201,205,an abnormal thalamic MRI sign,HPO_TERM,118,147,0.80801076,0.19198917,-0.6160216,0
line149,"This report details Patient 169, a patient with a buildup of lactate in his bloodstream. Further investigation showed an abnormal thalamic MRI signal and an atypical thalamic signal. A known variant in the POLG gene was identified.","This report details Patient 169, a patient with a buildup of lactate in his bloodstream. Further investigation showed an abnormal thalamic MRI signal an[E1]d an atypical thalamic si[/E1]gnal. A known variant in[E2] the[/E2] POLG gene was identified.", the,GENE_VARIANT,201,205,d an atypical thalamic si,HPO_TERM,152,177,0.81796795,0.18203203,-0.6359359,0
line150,The clinical profile for Patient 170 includes a seizure disorder and hyperlactatemia. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient 170 includes [E1]a seizure disorder an[/E1]d hyperlactatemia. Genetic analysis of the PO[E2]LG g[/E2]ene confirmed the diagnosis.,LG g,GENE_VARIANT,112,116,a seizure disorder an,HPO_TERM,46,67,0.8737993,0.12620069,-0.74759865,0
line151,The clinical profile for Patient 171 includes a seizure disorder and hyperlactatemia. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient 171 includes [E1]a seizure disorder an[/E1]d hyperlactatemia. Genetic analysis of the PO[E2]LG g[/E2]ene confirmed the diagnosis.,LG g,GENE_VARIANT,112,116,a seizure disorder an,HPO_TERM,46,67,0.87437665,0.12562333,-0.7487533,0
line152,"We report the case of Patient 172, who has a history of an abnormal thalamic MRI signal. Examination also revealed a pediatric-onset disorder. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient 172, who has a history of [E1]an abnormal thalamic MRI sign[/E1]al. Examination also revealed a pediatric-onset disorder. The underlying cause was traced to a mutation in th[E2]e PO[/E2]LG gene.",e PO,GENE_VARIANT,194,198,an abnormal thalamic MRI sign,HPO_TERM,56,85,0.4268962,0.5731038,0.14620757,1
line152,"We report the case of Patient 172, who has a history of an abnormal thalamic MRI signal. Examination also revealed a pediatric-onset disorder. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient 172, who has a history of an abnormal thalamic MRI signal. Examination also reveale[E1]d a pediatric-onset disord[/E1]er. The underlying cause was traced to a mutation in th[E2]e PO[/E2]LG gene.",e PO,GENE_VARIANT,194,198,d a pediatric-onset disord,HPO_TERM,113,139,0.5716735,0.4283265,-0.14334702,0
line153,Patient 173 was evaluated for an increased lactate level. The patient also presented with an elevated level of lactate in the blood and drooping of both upper eyelids. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 173 was evaluated for [E1]an increased lactate le[/E1]vel. The patient also presented with an elevated level of lactate in the blood and drooping of both upper eyelids. Subsequent sequencing o[E2]f th[/E2]e POLG gene revealed a pathogenic variant.,f th,GENE_VARIANT,191,195,an increased lactate le,HPO_TERM,30,53,0.8632504,0.13674966,-0.72650075,0
line153,Patient 173 was evaluated for an increased lactate level. The patient also presented with an elevated level of lactate in the blood and drooping of both upper eyelids. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 173 was evaluated for an increased lactate level. The patient also presented wi[E1]th an elevated level of lactate in the[/E1] blood and drooping of both upper eyelids. Subsequent sequencing o[E2]f th[/E2]e POLG gene revealed a pathogenic variant.,f th,GENE_VARIANT,191,195,th an elevated level of lactate in the,HPO_TERM,87,125,0.87438744,0.12561257,-0.7487749,0
line153,Patient 173 was evaluated for an increased lactate level. The patient also presented with an elevated level of lactate in the blood and drooping of both upper eyelids. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 173 was evaluated for an increased lactate level. The patient also presented with an elevated level of lactate in the bloo[E1]d and drooping of both upper e[/E1]yelids. Subsequent sequencing o[E2]f th[/E2]e POLG gene revealed a pathogenic variant.,f th,GENE_VARIANT,191,195,d and drooping of both upper e,HPO_TERM,130,160,0.8544367,0.14556333,-0.7088734,0
line154,The primary symptoms for Patient 174 were signs of parkinsonism and a buildup of lactate in his bloodstream. Analysis of the POLG gene was performed.,The primary symptoms for Patient 174 were si[E1]gns of parkinsonism [/E1]and a buildup of lactate in his bloodstream. Analysis of the POLG gene[E2] was[/E2] performed., was,GENE_VARIANT,134,138,gns of parkinsonism ,HPO_TERM,44,64,0.8489791,0.15102093,-0.6979582,0
line155,Patient 175 was evaluated for an atypical thalamic signal. The patient also presented with poor articulation and signs of parkinsonism. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 175 was evaluated for [E1]an atypical thalamic sign[/E1]al. The patient also presented with poor articulation and signs of parkinsonism. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,162,166,an atypical thalamic sign,HPO_TERM,30,55,0.8421364,0.15786366,-0.6842727,0
line155,Patient 175 was evaluated for an atypical thalamic signal. The patient also presented with poor articulation and signs of parkinsonism. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 175 was evaluated for an atypical thalamic signal. The patient also presented wit[E1]h poor articulati[/E1]on and signs of parkinsonism. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,162,166,h poor articulati,HPO_TERM,89,106,0.8415636,0.15843642,-0.68312716,0
line155,Patient 175 was evaluated for an atypical thalamic signal. The patient also presented with poor articulation and signs of parkinsonism. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 175 was evaluated for an atypical thalamic signal. The patient also presented with poor articulation an[E1]d signs of parkinson[/E1]ism. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,162,166,d signs of parkinson,HPO_TERM,111,131,0.835256,0.16474402,-0.67051196,0
line156,The clinical profile for Patient 176 includes an elevated level of lactate in the blood and hyperlactatemia. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient 176 includes [E1]an elevated level of lactate in the bl[/E1]ood and hyperlactatemia. Genetic analysis of [E2]the [/E2]POLG gene confirmed the diagnosis.,the ,GENE_VARIANT,129,133,an elevated level of lactate in the bl,HPO_TERM,46,84,0.83373207,0.16626792,-0.66746414,0
line156,The clinical profile for Patient 176 includes an elevated level of lactate in the blood and hyperlactatemia. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient 176 includes an elevated level of lactate in the blood a[E1]nd hyperlactat[/E1]emia. Genetic analysis of [E2]the [/E2]POLG gene confirmed the diagnosis.,the ,GENE_VARIANT,129,133,nd hyperlactat,HPO_TERM,89,103,0.8608251,0.1391749,-0.72165024,0
line157,Patient 177 was evaluated for a seizure. The patient also presented with an atypical thalamic signal and signs of parkinsonism. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 177 was evaluated for [E1]a seizure[/E1]. The patient also presented with an atypical thalamic signal and signs of parkinsonism. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,154,158,a seizure,HPO_TERM,30,39,0.83351547,0.1664845,-0.66703093,0
line157,Patient 177 was evaluated for a seizure. The patient also presented with an atypical thalamic signal and signs of parkinsonism. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 177 was evaluated for a seizure. The patient also presented with [E1]an atypical thalamic sign[/E1]al and signs of parkinsonism. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,154,158,an atypical thalamic sign,HPO_TERM,73,98,0.82818174,0.17181826,-0.6563635,0
line157,Patient 177 was evaluated for a seizure. The patient also presented with an atypical thalamic signal and signs of parkinsonism. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 177 was evaluated for a seizure. The patient also presented with an atypical thalamic signal an[E1]d signs of parkinson[/E1]ism. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,154,158,d signs of parkinson,HPO_TERM,103,123,0.83185387,0.16814612,-0.66370773,0
line158,"Patient 178 was evaluated for slurred, consistent with dysarthria. The patient also presented with an elevated hepatic transaminase concentration and a seizure disorder. Subsequent sequencing of the POLG gene revealed a pathogenic variant.","Patient 178 was evaluated for [E1]slurred, consistent with dysarthr[/E1]ia. The patient also presented with an elevated hepatic transaminase concentration and a seizure disorder. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.",he P,GENE_VARIANT,196,200,"slurred, consistent with dysarthr",HPO_TERM,30,63,0.8034563,0.19654366,-0.6069126,0
line158,"Patient 178 was evaluated for slurred, consistent with dysarthria. The patient also presented with an elevated hepatic transaminase concentration and a seizure disorder. Subsequent sequencing of the POLG gene revealed a pathogenic variant.","Patient 178 was evaluated for slurred, consistent with dysarthria. The patient also presented wit[E1]h an elevated hepatic transaminase concent[/E1]ration and a seizure disorder. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.",he P,GENE_VARIANT,196,200,h an elevated hepatic transaminase concent,HPO_TERM,97,139,0.8310226,0.16897744,-0.6620452,0
line158,"Patient 178 was evaluated for slurred, consistent with dysarthria. The patient also presented with an elevated hepatic transaminase concentration and a seizure disorder. Subsequent sequencing of the POLG gene revealed a pathogenic variant.","Patient 178 was evaluated for slurred, consistent with dysarthria. The patient also presented with an elevated hepatic transaminase concentratio[E1]n and a seizure disor[/E1]der. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.",he P,GENE_VARIANT,196,200,n and a seizure disor,HPO_TERM,144,165,0.82960004,0.17039995,-0.6592001,0
line159,"This report details Patient 179, a patient with a buildup of lactate in his bloodstream. Further investigation showed an elevated level of lactate in the blood and signs of parkinsonism. A known variant in the POLG gene was identified.","This report details Patient 179, a patient with [E1]a buildup of lactate in his bloodstream[/E1]. Further investigation showed an elevated level of lactate in the blood and signs of parkinsonism. A known variant in[E2] the[/E2] POLG gene was identified.", the,GENE_VARIANT,205,209,a buildup of lactate in his bloodstream,HPO_TERM,48,87,0.79889154,0.20110849,-0.5977831,0
line159,"This report details Patient 179, a patient with a buildup of lactate in his bloodstream. Further investigation showed an elevated level of lactate in the blood and signs of parkinsonism. A known variant in the POLG gene was identified.","This report details Patient 179, a patient with a buildup of lactate in his bloodstream. Further investigation showed [E1]an elevated level of lactate in the bl[/E1]ood and signs of parkinsonism. A known variant in[E2] the[/E2] POLG gene was identified.", the,GENE_VARIANT,205,209,an elevated level of lactate in the bl,HPO_TERM,118,156,0.81509936,0.1849007,-0.63019866,0
line159,"This report details Patient 179, a patient with a buildup of lactate in his bloodstream. Further investigation showed an elevated level of lactate in the blood and signs of parkinsonism. A known variant in the POLG gene was identified.","This report details Patient 179, a patient with a buildup of lactate in his bloodstream. Further investigation showed an elevated level of lactate in the blood a[E1]nd signs of parkinso[/E1]nism. A known variant in[E2] the[/E2] POLG gene was identified.", the,GENE_VARIANT,205,209,nd signs of parkinso,HPO_TERM,161,181,0.79565084,0.20434918,-0.5913017,0
line160,Patient 180 was evaluated for unclear or mumbled speech. The patient also presented with a pediatric-onset disorder and an elevated level of lactate in the blood. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 180 was evaluated for [E1]unclear or mumbled speech[/E1]. The patient also presented with a pediatric-onset disorder and an elevated level of lactate in the blood. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,189,193,unclear or mumbled speech,HPO_TERM,30,55,0.8056532,0.19434676,-0.6113064,0
line160,Patient 180 was evaluated for unclear or mumbled speech. The patient also presented with a pediatric-onset disorder and an elevated level of lactate in the blood. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 180 was evaluated for unclear or mumbled speech. The patient also presented with [E1]a pediatric-onset disorder[/E1] and an elevated level of lactate in the blood. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,189,193,a pediatric-onset disorder,HPO_TERM,89,115,0.7952901,0.20470986,-0.5905802,0
line160,Patient 180 was evaluated for unclear or mumbled speech. The patient also presented with a pediatric-onset disorder and an elevated level of lactate in the blood. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 180 was evaluated for unclear or mumbled speech. The patient also presented with a pediatric-onset disorder and [E1]an elevated level of lactate in the bl[/E1]ood. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,189,193,an elevated level of lactate in the bl,HPO_TERM,120,158,0.8170295,0.1829706,-0.6340589,0
line161,"We report the case of Patient 181, who has a history of an abnormal thalamic MRI signal. Examination also revealed a buildup of lactate in his bloodstream. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient 181, who has a history of [E1]an abnormal thalamic MRI sign[/E1]al. Examination also revealed a buildup of lactate in his bloodstream. The underlying cause was traced to a mutation in th[E2]e PO[/E2]LG gene.",e PO,GENE_VARIANT,207,211,an abnormal thalamic MRI sign,HPO_TERM,56,85,0.6962886,0.3037114,-0.39257717,0
line161,"We report the case of Patient 181, who has a history of an abnormal thalamic MRI signal. Examination also revealed a buildup of lactate in his bloodstream. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient 181, who has a history of an abnormal thalamic MRI signal. Examination also reveale[E1]d a buildup of lactate in his bloodstre[/E1]am. The underlying cause was traced to a mutation in th[E2]e PO[/E2]LG gene.",e PO,GENE_VARIANT,207,211,d a buildup of lactate in his bloodstre,HPO_TERM,113,152,0.73418975,0.26581025,-0.4683795,0
line162,"We report the case of Patient 182, who has a history of slurred, consistent with dysarthria. Examination also revealed hyperlactatemia. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient 182, who has a history of [E1]slurred, consistent with dysarthr[/E1]ia. Examination also revealed hyperlactatemia. The underlying cause was traced to a mutation in t[E2]he P[/E2]OLG gene.",he P,GENE_VARIANT,186,190,"slurred, consistent with dysarthr",HPO_TERM,56,89,0.5648068,0.43519318,-0.12961364,0
line162,"We report the case of Patient 182, who has a history of slurred, consistent with dysarthria. Examination also revealed hyperlactatemia. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient 182, who has a history of slurred, consistent with dysarthria. Examination also reveale[E1]d hyperlactate[/E1]mia. The underlying cause was traced to a mutation in t[E2]he P[/E2]OLG gene.",he P,GENE_VARIANT,186,190,d hyperlactate,HPO_TERM,117,131,0.5002273,0.4997728,-0.00045448542,0
line163,"We report the case of Patient 183, who has a history of slurred, consistent with dysarthria. Examination also revealed an adult onset. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient 183, who has a history of [E1]slurred, consistent with dysarthr[/E1]ia. Examination also revealed an adult onset. The underlying cause was traced to a mutation in the[E2] POL[/E2]G gene.", POL,GENE_VARIANT,187,191,"slurred, consistent with dysarthr",HPO_TERM,56,89,0.39056846,0.6094315,0.21886304,1
line163,"We report the case of Patient 183, who has a history of slurred, consistent with dysarthria. Examination also revealed an adult onset. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient 183, who has a history of slurred, consistent with dysarthria. Examination also reveale[E1]d an adult onse[/E1]t. The underlying cause was traced to a mutation in the[E2] POL[/E2]G gene.", POL,GENE_VARIANT,187,191,d an adult onse,HPO_TERM,117,132,0.63692343,0.36307657,-0.27384686,0
line164,Patient 184 was evaluated for an adult onset. The patient also presented with an elevated hepatic transaminase concentration and hyperlactatemia. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 184 was evaluated for an adult onset. The patient also presented with a[E1]n elevated hepatic transaminase concentrat[/E1]ion and hyperlactatemia. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,171,175,n elevated hepatic transaminase concentrat,HPO_TERM,79,121,0.81965667,0.18034334,-0.63931334,0
line164,Patient 184 was evaluated for an adult onset. The patient also presented with an elevated hepatic transaminase concentration and hyperlactatemia. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 184 was evaluated for an adult onset. The patient also presented with an elevated hepatic transaminase concentration a[E1]nd hyperlactat[/E1]emia. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,171,175,nd hyperlactat,HPO_TERM,126,140,0.8467529,0.15324707,-0.6935058,0
line165,"We report the case of Patient 185, who has a history of an increased lactate level. Examination also revealed an adult onset. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient 185, who has a history of [E1]an increased lactate le[/E1]vel. Examination also revealed an adult onset. The underlying cause was traced to a mutation in th[E2]e PO[/E2]LG gene.",e PO,GENE_VARIANT,177,181,an increased lactate le,HPO_TERM,56,79,0.66559976,0.3344002,-0.33119956,0
line165,"We report the case of Patient 185, who has a history of an increased lactate level. Examination also revealed an adult onset. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient 185, who has a history of an increased lactate level. Examination also reveal[E1]ed an adult ons[/E1]et. The underlying cause was traced to a mutation in th[E2]e PO[/E2]LG gene.",e PO,GENE_VARIANT,177,181,ed an adult ons,HPO_TERM,107,122,0.75677204,0.24322797,-0.5135441,0
line166,"We report the case of Patient 186, who has a history of a clinical syndrome resembling Parkinson's disease. Examination also revealed a seizure. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient 186, who has a history of [E1]a clinical syndrome resembling Parkinson's dis[/E1]ease. Examination also revealed a seizure. The underlying cause was traced to a mutation in [E2]the [/E2]POLG gene.",the ,GENE_VARIANT,194,198,a clinical syndrome resembling Parkinson's dis,HPO_TERM,56,102,0.4032574,0.5967425,0.19348511,1
line166,"We report the case of Patient 186, who has a history of a clinical syndrome resembling Parkinson's disease. Examination also revealed a seizure. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient 186, who has a history of a clinical syndrome resembling Parkinson's disease. Examination also revea[E1]led a sei[/E1]zure. The underlying cause was traced to a mutation in [E2]the [/E2]POLG gene.",the ,GENE_VARIANT,194,198,led a sei,HPO_TERM,130,139,0.6535173,0.34648272,-0.30703458,0
line167,"Patient 187 was evaluated for slurred, consistent with dysarthria. The patient also presented with hyperlactatemia and an adult onset. Subsequent sequencing of the POLG gene revealed a pathogenic variant.","Patient 187 was evaluated for [E1]slurred, consistent with dysarthr[/E1]ia. The patient also presented with hyperlactatemia and an adult onset. Subsequent sequencing of th[E2]e PO[/E2]LG gene revealed a pathogenic variant.",e PO,GENE_VARIANT,162,166,"slurred, consistent with dysarthr",HPO_TERM,30,63,0.8567442,0.14325576,-0.71348846,0
line167,"Patient 187 was evaluated for slurred, consistent with dysarthria. The patient also presented with hyperlactatemia and an adult onset. Subsequent sequencing of the POLG gene revealed a pathogenic variant.","Patient 187 was evaluated for slurred, consistent with dysarthria. The patient also presented wit[E1]h hyperlactate[/E1]mia and an adult onset. Subsequent sequencing of th[E2]e PO[/E2]LG gene revealed a pathogenic variant.",e PO,GENE_VARIANT,162,166,h hyperlactate,HPO_TERM,97,111,0.8499113,0.15008873,-0.69982255,0
line167,"Patient 187 was evaluated for slurred, consistent with dysarthria. The patient also presented with hyperlactatemia and an adult onset. Subsequent sequencing of the POLG gene revealed a pathogenic variant.","Patient 187 was evaluated for slurred, consistent with dysarthria. The patient also presented with hyperlactatemia a[E1]nd an adult ons[/E1]et. Subsequent sequencing of th[E2]e PO[/E2]LG gene revealed a pathogenic variant.",e PO,GENE_VARIANT,162,166,nd an adult ons,HPO_TERM,116,131,0.8794631,0.12053697,-0.7589261,0
line168,"The clinical profile for Patient 188 includes an elevated level of lactate in the blood and slurred, consistent with dysarthria. Genetic analysis of the POLG gene confirmed the diagnosis.","The clinical profile for Patient 188 includes [E1]an elevated level of lactate in the bl[/E1]ood and slurred, consistent with dysarthria. Genetic analysis of[E2] the[/E2] POLG gene confirmed the diagnosis.", the,GENE_VARIANT,148,152,an elevated level of lactate in the bl,HPO_TERM,46,84,0.8084518,0.19154823,-0.61690354,0
line168,"The clinical profile for Patient 188 includes an elevated level of lactate in the blood and slurred, consistent with dysarthria. Genetic analysis of the POLG gene confirmed the diagnosis.","The clinical profile for Patient 188 includes an elevated level of lactate in the blood a[E1]nd slurred, consistent with dysar[/E1]thria. Genetic analysis of[E2] the[/E2] POLG gene confirmed the diagnosis.", the,GENE_VARIANT,148,152,"nd slurred, consistent with dysar",HPO_TERM,89,122,0.85293907,0.14706096,-0.70587814,0
line169,The primary symptoms for Patient 189 were an abnormal thalamic MRI signal and poor articulation. Analysis of the POLG gene was performed.,The primary symptoms for Patient 189 were an[E1] abnormal thalamic MRI signal[/E1] and poor articulation. Analysis of the POLG gen[E2]e wa[/E2]s performed.,e wa,GENE_VARIANT,121,125, abnormal thalamic MRI signal,HPO_TERM,44,73,0.7518572,0.24814276,-0.50371444,0
line169,The primary symptoms for Patient 189 were an abnormal thalamic MRI signal and poor articulation. Analysis of the POLG gene was performed.,The primary symptoms for Patient 189 were an abnormal thalamic MRI signal and [E1]poor articulation[/E1]. Analysis of the POLG gen[E2]e wa[/E2]s performed.,e wa,GENE_VARIANT,121,125,poor articulation,HPO_TERM,78,95,0.7879804,0.21201965,-0.57596076,0
line170,The clinical profile for Patient 190 includes an elevated hepatic transaminase concentration and an adult onset. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient 190 includes [E1]an elevated hepatic transaminase concentra[/E1]tion and an adult onset. Genetic analysis of t[E2]he P[/E2]OLG gene confirmed the diagnosis.,he P,GENE_VARIANT,134,138,an elevated hepatic transaminase concentra,HPO_TERM,46,88,0.8319922,0.16800778,-0.6639844,0
line170,The clinical profile for Patient 190 includes an elevated hepatic transaminase concentration and an adult onset. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient 190 includes an elevated hepatic transaminase concentration [E1]and an adult on[/E1]set. Genetic analysis of t[E2]he P[/E2]OLG gene confirmed the diagnosis.,he P,GENE_VARIANT,134,138,and an adult on,HPO_TERM,93,108,0.86443037,0.13556965,-0.72886074,0
line171,Patient 191 was evaluated for a pediatric-onset disorder. The patient also presented with signs of parkinsonism and bilateral ptosis. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 191 was evaluated for [E1]a pediatric-onset disorder[/E1]. The patient also presented with signs of parkinsonism and bilateral ptosis. Subsequent sequencing of the[E2] POL[/E2]G gene revealed a pathogenic variant., POL,GENE_VARIANT,162,166,a pediatric-onset disorder,HPO_TERM,30,56,0.8193901,0.1806099,-0.63878024,0
line171,Patient 191 was evaluated for a pediatric-onset disorder. The patient also presented with signs of parkinsonism and bilateral ptosis. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 191 was evaluated for a pediatric-onset disorder. The patient also presented with [E1]signs of parkinsonis[/E1]m and bilateral ptosis. Subsequent sequencing of the[E2] POL[/E2]G gene revealed a pathogenic variant., POL,GENE_VARIANT,162,166,signs of parkinsonis,HPO_TERM,90,110,0.7957243,0.20427568,-0.5914486,0
line171,Patient 191 was evaluated for a pediatric-onset disorder. The patient also presented with signs of parkinsonism and bilateral ptosis. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 191 was evaluated for a pediatric-onset disorder. The patient also presented with signs of parkinsonism and[E1] bilateral ptosi[/E1]s. Subsequent sequencing of the[E2] POL[/E2]G gene revealed a pathogenic variant., POL,GENE_VARIANT,162,166, bilateral ptosi,HPO_TERM,115,131,0.8291509,0.17084908,-0.65830183,0
line172,The primary symptoms for Patient 192 were an atypical thalamic signal and signs of parkinsonism. Analysis of the POLG gene was performed.,The primary symptoms for Patient 192 were an[E1] atypical thalamic signal[/E1] and signs of parkinsonism. Analysis of the POLG ge[E2]ne w[/E2]as performed.,ne w,GENE_VARIANT,120,124, atypical thalamic signal,HPO_TERM,44,69,0.74941945,0.25058052,-0.49883893,0
line172,The primary symptoms for Patient 192 were an atypical thalamic signal and signs of parkinsonism. Analysis of the POLG gene was performed.,The primary symptoms for Patient 192 were an atypical thalamic signal and [E1]signs of parkinsonis[/E1]m. Analysis of the POLG ge[E2]ne w[/E2]as performed.,ne w,GENE_VARIANT,120,124,signs of parkinsonis,HPO_TERM,74,94,0.8260684,0.17393158,-0.6521368,0
line173,"We report the case of Patient 193, who has a history of an abnormal thalamic MRI signal. Examination also revealed signs of parkinsonism. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient 193, who has a history of [E1]an abnormal thalamic MRI sign[/E1]al. Examination also revealed signs of parkinsonism. The underlying cause was traced to a mutation in t[E2]he P[/E2]OLG gene.",he P,GENE_VARIANT,188,192,an abnormal thalamic MRI sign,HPO_TERM,56,85,0.5991875,0.40081248,-0.19837502,0
line173,"We report the case of Patient 193, who has a history of an abnormal thalamic MRI signal. Examination also revealed signs of parkinsonism. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient 193, who has a history of an abnormal thalamic MRI signal. Examination also reveale[E1]d signs of parkinson[/E1]ism. The underlying cause was traced to a mutation in t[E2]he P[/E2]OLG gene.",he P,GENE_VARIANT,188,192,d signs of parkinson,HPO_TERM,113,133,0.38486472,0.61513525,0.23027053,1
line174,The clinical profile for Patient 194 includes drooping of both upper eyelids and an adult onset. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient 194 includes [E1]drooping of both upper eyelids[/E1] and an adult onset. Genetic analysis of the P[E2]OLG [/E2]gene confirmed the diagnosis.,OLG ,GENE_VARIANT,122,126,drooping of both upper eyelids,HPO_TERM,46,76,0.7816351,0.21836492,-0.5632702,0
line175,"We report the case of Patient 195, who has a history of a seizure. Examination also revealed an elevated hepatic transaminase concentration. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient 195, who has a history of [E1]a seizure[/E1]. Examination also revealed an elevated hepatic transaminase concentration. The underlying cause was traced to a mutation in [E2]the [/E2]POLG gene.",the ,GENE_VARIANT,190,194,a seizure,HPO_TERM,56,65,0.48219943,0.51780057,0.03560114,1
line175,"We report the case of Patient 195, who has a history of a seizure. Examination also revealed an elevated hepatic transaminase concentration. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient 195, who has a history of a seizure. Examination also revealed [E1]an elevated hepatic transaminase concentra[/E1]tion. The underlying cause was traced to a mutation in [E2]the [/E2]POLG gene.",the ,GENE_VARIANT,190,194,an elevated hepatic transaminase concentra,HPO_TERM,93,135,0.38842243,0.6115776,0.22315514,1
line176,The clinical profile for Patient 196 includes an adult onset and signs of parkinsonism. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient 196 includes [E1]an adult onset [/E1]and signs of parkinsonism. Genetic analysis of the [E2]POLG[/E2] gene confirmed the diagnosis.,POLG,GENE_VARIANT,112,116,an adult onset ,HPO_TERM,46,61,0.78179437,0.2182057,-0.5635887,0
line176,The clinical profile for Patient 196 includes an adult onset and signs of parkinsonism. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient 196 includes an adult onset and s[E1]igns of parkinsonism[/E1]. Genetic analysis of the [E2]POLG[/E2] gene confirmed the diagnosis.,POLG,GENE_VARIANT,112,116,igns of parkinsonism,HPO_TERM,66,86,0.7955663,0.20443368,-0.59113264,0
line177,"This report details Patient 197, a patient with a pediatric-onset disorder. Further investigation showed an abnormal thalamic MRI signal and an adult onset. A known variant in the POLG gene was identified.","This report details Patient 197, a patient with [E1]a pediatric-onset disorder[/E1]. Further investigation showed an abnormal thalamic MRI signal and an adult onset. A known variant in th[E2]e PO[/E2]LG gene was identified.",e PO,GENE_VARIANT,178,182,a pediatric-onset disorder,HPO_TERM,48,74,0.8170554,0.18294466,-0.63411075,0
line177,"This report details Patient 197, a patient with a pediatric-onset disorder. Further investigation showed an abnormal thalamic MRI signal and an adult onset. A known variant in the POLG gene was identified.","This report details Patient 197, a patient with a pediatric-onset disorder. Further investigation showed [E1]an abnormal thalamic MRI sign[/E1]al and an adult onset. A known variant in th[E2]e PO[/E2]LG gene was identified.",e PO,GENE_VARIANT,178,182,an abnormal thalamic MRI sign,HPO_TERM,105,134,0.81203955,0.18796046,-0.6240791,0
line177,"This report details Patient 197, a patient with a pediatric-onset disorder. Further investigation showed an abnormal thalamic MRI signal and an adult onset. A known variant in the POLG gene was identified.","This report details Patient 197, a patient with a pediatric-onset disorder. Further investigation showed an abnormal thalamic MRI signal an[E1]d an adult onse[/E1]t. A known variant in th[E2]e PO[/E2]LG gene was identified.",e PO,GENE_VARIANT,178,182,d an adult onse,HPO_TERM,139,154,0.8375051,0.1624949,-0.6750102,0
line178,The primary symptoms for Patient 198 were an elevated hepatic transaminase concentration and an increased lactate level. Analysis of the POLG gene was performed.,The primary symptoms for Patient 198 were an[E1] elevated hepatic transaminase concentrati[/E1]on and an increased lactate level. Analysis of the POL[E2]G ge[/E2]ne was performed.,G ge,GENE_VARIANT,140,144, elevated hepatic transaminase concentrati,HPO_TERM,44,86,0.8220023,0.17799771,-0.6440046,0
line178,The primary symptoms for Patient 198 were an elevated hepatic transaminase concentration and an increased lactate level. Analysis of the POLG gene was performed.,The primary symptoms for Patient 198 were an elevated hepatic transaminase concentration an[E1]d an increased lactate [/E1]level. Analysis of the POL[E2]G ge[/E2]ne was performed.,G ge,GENE_VARIANT,140,144,d an increased lactate ,HPO_TERM,91,114,0.8181519,0.18184806,-0.63630384,0
line179,The primary symptoms for Patient 199 were hyperlactatemia and an atypical thalamic signal. Analysis of the POLG gene was performed.,The primary symptoms for Patient 199 were hy[E1]perlactatemia [/E1]and an atypical thalamic signal. Analysis of the POLG ge[E2]ne w[/E2]as performed.,ne w,GENE_VARIANT,114,118,perlactatemia ,HPO_TERM,44,58,0.79706436,0.20293564,-0.5941287,0
line179,The primary symptoms for Patient 199 were hyperlactatemia and an atypical thalamic signal. Analysis of the POLG gene was performed.,The primary symptoms for Patient 199 were hyperlactatemia and a[E1]n atypical thalamic signa[/E1]l. Analysis of the POLG ge[E2]ne w[/E2]as performed.,ne w,GENE_VARIANT,114,118,n atypical thalamic signa,HPO_TERM,63,88,0.8413998,0.15860023,-0.6827996,0
line180,The primary symptoms for Patient 200 were a buildup of lactate in his bloodstream and an adult onset. Analysis of the POLG gene was performed.,The primary symptoms for Patient 200 were a [E1]buildup of lactate in his bloodstream a[/E1]nd an adult onset. Analysis of the POLG gene w[E2]as p[/E2]erformed.,as p,GENE_VARIANT,129,133,buildup of lactate in his bloodstream a,HPO_TERM,44,83,0.8812222,0.118777804,-0.7624444,0
line181,"We report the case of Patient 201, who has a history of an abnormal thalamic MRI signal. Examination also revealed an elevated level of lactate in the blood. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient 201, who has a history of [E1]an abnormal thalamic MRI sign[/E1]al. Examination also revealed an elevated level of lactate in the blood. The underlying cause was traced to a mutation in[E2] the[/E2] POLG gene.", the,GENE_VARIANT,206,210,an abnormal thalamic MRI sign,HPO_TERM,56,85,0.42068067,0.57931936,0.15863869,1
line181,"We report the case of Patient 201, who has a history of an abnormal thalamic MRI signal. Examination also revealed an elevated level of lactate in the blood. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient 201, who has a history of an abnormal thalamic MRI signal. Examination also reveale[E1]d an elevated level of lactate in the [/E1]blood. The underlying cause was traced to a mutation in[E2] the[/E2] POLG gene.", the,GENE_VARIANT,206,210,d an elevated level of lactate in the ,HPO_TERM,113,151,0.54432887,0.45567113,-0.08865774,0
line182,"This report details Patient 202, a patient with a pediatric-onset disorder. Further investigation showed an abnormal thalamic MRI signal and an elevated hepatic transaminase concentration. A known variant in the POLG gene was identified.","This report details Patient 202, a patient with [E1]a pediatric-onset disorder[/E1]. Further investigation showed an abnormal thalamic MRI signal and an elevated hepatic transaminase concentration. A known variant [E2]in t[/E2]he POLG gene was identified.",in t,GENE_VARIANT,205,209,a pediatric-onset disorder,HPO_TERM,48,74,0.8100844,0.18991558,-0.6201688,0
line182,"This report details Patient 202, a patient with a pediatric-onset disorder. Further investigation showed an abnormal thalamic MRI signal and an elevated hepatic transaminase concentration. A known variant in the POLG gene was identified.","This report details Patient 202, a patient with a pediatric-onset disorder. Further investigation showed [E1]an abnormal thalamic MRI sign[/E1]al and an elevated hepatic transaminase concentration. A known variant [E2]in t[/E2]he POLG gene was identified.",in t,GENE_VARIANT,205,209,an abnormal thalamic MRI sign,HPO_TERM,105,134,0.81299424,0.18700579,-0.6259885,0
line182,"This report details Patient 202, a patient with a pediatric-onset disorder. Further investigation showed an abnormal thalamic MRI signal and an elevated hepatic transaminase concentration. A known variant in the POLG gene was identified.","This report details Patient 202, a patient with a pediatric-onset disorder. Further investigation showed an abnormal thalamic MRI signal an[E1]d an elevated hepatic transaminase concent[/E1]ration. A known variant [E2]in t[/E2]he POLG gene was identified.",in t,GENE_VARIANT,205,209,d an elevated hepatic transaminase concent,HPO_TERM,139,181,0.8149933,0.18500671,-0.62998664,0
line183,"We report the case of Patient 203, who has a history of a seizure. Examination also revealed an adult onset. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient 203, who has a history of [E1]a seizure[/E1]. Examination also revealed an adult onset. The underlying cause was traced to a mutation in the P[E2]OLG [/E2]gene.",OLG ,GENE_VARIANT,163,167,a seizure,HPO_TERM,56,65,0.49679536,0.50320464,0.0064092875,1
line184,"We report the case of Patient 204, who has a history of a buildup of lactate in his bloodstream. Examination also revealed an adult onset. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient 204, who has a history of [E1]a buildup of lactate in his bloodstream[/E1]. Examination also revealed an adult onset. The underlying cause was traced to a mutation in the P[E2]OLG [/E2]gene.",OLG ,GENE_VARIANT,193,197,a buildup of lactate in his bloodstream,HPO_TERM,56,95,0.5932214,0.4067786,-0.18644282,0
line185,Patient 205 was evaluated for poor articulation. The patient also presented with hyperlactatemia and an atypical thalamic signal. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 205 was evaluated for [E1]poor articulation[/E1]. The patient also presented with hyperlactatemia and an atypical thalamic signal. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,156,160,poor articulation,HPO_TERM,30,47,0.83382624,0.16617377,-0.6676525,0
line185,Patient 205 was evaluated for poor articulation. The patient also presented with hyperlactatemia and an atypical thalamic signal. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 205 was evaluated for poor articulation. The patient also presented with [E1]hyperlactatemi[/E1]a and an atypical thalamic signal. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,156,160,hyperlactatemi,HPO_TERM,81,95,0.8369614,0.16303858,-0.6739228,0
line185,Patient 205 was evaluated for poor articulation. The patient also presented with hyperlactatemia and an atypical thalamic signal. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 205 was evaluated for poor articulation. The patient also presented with hyperlactatemia and[E1] an atypical thalamic sig[/E1]nal. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,156,160, an atypical thalamic sig,HPO_TERM,100,125,0.846373,0.15362696,-0.69274604,0
line186,Patient 206 was evaluated for a pediatric-onset disorder. The patient also presented with an elevated hepatic transaminase concentration and an atypical thalamic signal. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 206 was evaluated for [E1]a pediatric-onset disorder[/E1]. The patient also presented with an elevated hepatic transaminase concentration and an atypical thalamic signal. Subsequent sequencing o[E2]f th[/E2]e POLG gene revealed a pathogenic variant.,f th,GENE_VARIANT,193,197,a pediatric-onset disorder,HPO_TERM,30,56,0.834603,0.16539702,-0.669206,0
line186,Patient 206 was evaluated for a pediatric-onset disorder. The patient also presented with an elevated hepatic transaminase concentration and an atypical thalamic signal. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 206 was evaluated for a pediatric-onset disorder. The patient also presented with [E1]an elevated hepatic transaminase concentra[/E1]tion and an atypical thalamic signal. Subsequent sequencing o[E2]f th[/E2]e POLG gene revealed a pathogenic variant.,f th,GENE_VARIANT,193,197,an elevated hepatic transaminase concentra,HPO_TERM,90,132,0.8147839,0.18521616,-0.62956774,0
line186,Patient 206 was evaluated for a pediatric-onset disorder. The patient also presented with an elevated hepatic transaminase concentration and an atypical thalamic signal. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 206 was evaluated for a pediatric-onset disorder. The patient also presented with an elevated hepatic transaminase concentration [E1]and an atypical thalamic [/E1]signal. Subsequent sequencing o[E2]f th[/E2]e POLG gene revealed a pathogenic variant.,f th,GENE_VARIANT,193,197,and an atypical thalamic ,HPO_TERM,137,162,0.822427,0.177573,-0.64485395,0
line187,Patient 207 was evaluated for a pediatric-onset disorder. The patient also presented with an atypical thalamic signal and an elevated hepatic transaminase concentration. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 207 was evaluated for [E1]a pediatric-onset disorder[/E1]. The patient also presented with an atypical thalamic signal and an elevated hepatic transaminase concentration. Subsequent sequencing o[E2]f th[/E2]e POLG gene revealed a pathogenic variant.,f th,GENE_VARIANT,193,197,a pediatric-onset disorder,HPO_TERM,30,56,0.82918936,0.1708106,-0.6583788,0
line187,Patient 207 was evaluated for a pediatric-onset disorder. The patient also presented with an atypical thalamic signal and an elevated hepatic transaminase concentration. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 207 was evaluated for a pediatric-onset disorder. The patient also presented with [E1]an atypical thalamic sign[/E1]al and an elevated hepatic transaminase concentration. Subsequent sequencing o[E2]f th[/E2]e POLG gene revealed a pathogenic variant.,f th,GENE_VARIANT,193,197,an atypical thalamic sign,HPO_TERM,90,115,0.8281008,0.17189917,-0.6562016,0
line187,Patient 207 was evaluated for a pediatric-onset disorder. The patient also presented with an atypical thalamic signal and an elevated hepatic transaminase concentration. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 207 was evaluated for a pediatric-onset disorder. The patient also presented with an atypical thalamic signal an[E1]d an elevated hepatic transaminase concent[/E1]ration. Subsequent sequencing o[E2]f th[/E2]e POLG gene revealed a pathogenic variant.,f th,GENE_VARIANT,193,197,d an elevated hepatic transaminase concent,HPO_TERM,120,162,0.8434041,0.15659584,-0.6868083,0
line188,"This report details Patient 208, a patient with hyperlactatemia. Further investigation showed an elevated level of lactate in the blood and signs of parkinsonism. A known variant in the POLG gene was identified.","This report details Patient 208, a patient with [E1]hyperlactatemi[/E1]a. Further investigation showed an elevated level of lactate in the blood and signs of parkinsonism. A known variant i[E2]n th[/E2]e POLG gene was identified.",n th,GENE_VARIANT,180,184,hyperlactatemi,HPO_TERM,48,62,0.85740775,0.1425923,-0.71481544,0
line188,"This report details Patient 208, a patient with hyperlactatemia. Further investigation showed an elevated level of lactate in the blood and signs of parkinsonism. A known variant in the POLG gene was identified.","This report details Patient 208, a patient with hyperlactatemia. Further investigation showed[E1] an elevated level of lactate in the b[/E1]lood and signs of parkinsonism. A known variant i[E2]n th[/E2]e POLG gene was identified.",n th,GENE_VARIANT,180,184, an elevated level of lactate in the b,HPO_TERM,93,131,0.8489536,0.1510464,-0.6979072,0
line188,"This report details Patient 208, a patient with hyperlactatemia. Further investigation showed an elevated level of lactate in the blood and signs of parkinsonism. A known variant in the POLG gene was identified.","This report details Patient 208, a patient with hyperlactatemia. Further investigation showed an elevated level of lactate in the blood [E1]and signs of parkins[/E1]onism. A known variant i[E2]n th[/E2]e POLG gene was identified.",n th,GENE_VARIANT,180,184,and signs of parkins,HPO_TERM,136,156,0.84230447,0.15769558,-0.6846089,0
line189,Patient 209 was evaluated for an increased lactate level. The patient also presented with an elevated level of lactate in the blood and signs of parkinsonism. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 209 was evaluated for [E1]an increased lactate le[/E1]vel. The patient also presented with an elevated level of lactate in the blood and signs of parkinsonism. Subsequent sequencing [E2]of t[/E2]he POLG gene revealed a pathogenic variant.,of t,GENE_VARIANT,181,185,an increased lactate le,HPO_TERM,30,53,0.8507979,0.14920205,-0.70159584,0
line189,Patient 209 was evaluated for an increased lactate level. The patient also presented with an elevated level of lactate in the blood and signs of parkinsonism. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 209 was evaluated for an increased lactate level. The patient also presented wi[E1]th an elevated level of lactate in the[/E1] blood and signs of parkinsonism. Subsequent sequencing [E2]of t[/E2]he POLG gene revealed a pathogenic variant.,of t,GENE_VARIANT,181,185,th an elevated level of lactate in the,HPO_TERM,87,125,0.85769176,0.14230824,-0.7153835,0
line189,Patient 209 was evaluated for an increased lactate level. The patient also presented with an elevated level of lactate in the blood and signs of parkinsonism. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient 209 was evaluated for an increased lactate level. The patient also presented with an elevated level of lactate in the bloo[E1]d and signs of parki[/E1]nsonism. Subsequent sequencing [E2]of t[/E2]he POLG gene revealed a pathogenic variant.,of t,GENE_VARIANT,181,185,d and signs of parki,HPO_TERM,130,150,0.8553189,0.14468108,-0.7106378,0
line190,"This report details Patient 210, a patient with bilateral ptosis. Further investigation showed an increased lactate level and slurred, consistent with dysarthria. A known variant in the POLG gene was identified.","This report details Patient 210, a patient with [E1]bilateral ptosis[/E1]. Further investigation showed an increased lactate level and slurred, consistent with dysarthria. A known variant i[E2]n th[/E2]e POLG gene was identified.",n th,GENE_VARIANT,180,184,bilateral ptosis,HPO_TERM,48,64,0.82434756,0.17565243,-0.6486951,0
line190,"This report details Patient 210, a patient with bilateral ptosis. Further investigation showed an increased lactate level and slurred, consistent with dysarthria. A known variant in the POLG gene was identified.","This report details Patient 210, a patient with bilateral ptosis. Further investigation showed [E1]an increased lactate le[/E1]vel and slurred, consistent with dysarthria. A known variant i[E2]n th[/E2]e POLG gene was identified.",n th,GENE_VARIANT,180,184,an increased lactate le,HPO_TERM,95,118,0.8349417,0.16505836,-0.6698833,0
line190,"This report details Patient 210, a patient with bilateral ptosis. Further investigation showed an increased lactate level and slurred, consistent with dysarthria. A known variant in the POLG gene was identified.","This report details Patient 210, a patient with bilateral ptosis. Further investigation showed an increased lactate level a[E1]nd slurred, consistent with dysar[/E1]thria. A known variant i[E2]n th[/E2]e POLG gene was identified.",n th,GENE_VARIANT,180,184,"nd slurred, consistent with dysar",HPO_TERM,123,156,0.8565555,0.14344448,-0.71311104,0
line191,The clinical profile for Patient 211 includes an adult onset and an increased lactate level. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient 211 includes [E1]an adult onset [/E1]and an increased lactate level. Genetic analysis of th[E2]e PO[/E2]LG gene confirmed the diagnosis.,e PO,GENE_VARIANT,115,119,an adult onset ,HPO_TERM,46,61,0.85241437,0.14758566,-0.70482874,0
line191,The clinical profile for Patient 211 includes an adult onset and an increased lactate level. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient 211 includes an adult onset and a[E1]n increased lactate lev[/E1]el. Genetic analysis of th[E2]e PO[/E2]LG gene confirmed the diagnosis.,e PO,GENE_VARIANT,115,119,n increased lactate lev,HPO_TERM,66,89,0.8656265,0.13437346,-0.731253,0
line192,"This report details Patient 212, a patient with a seizure disorder. Further investigation showed an abnormal thalamic MRI signal and poor articulation. A known variant in the POLG gene was identified.","This report details Patient 212, a patient with a seizure disorder. Further investigation showed an [E1]abnormal thalamic MRI signal [/E1]and poor articulation. A known variant in the [E2]POLG[/E2] gene was identified.",POLG,GENE_VARIANT,175,179,abnormal thalamic MRI signal ,HPO_TERM,100,129,0.718996,0.28100404,-0.43799195,0
line193,"This report details Patient 213, a patient with a seizure disorder. Further investigation showed hyperlactatemia and a seizure. A known variant in the POLG gene was identified.","This report details Patient 213, a patient with a seizure disorder. Further investigation showed hyp[E1]erlactatemia a[/E1]nd a seizure. A known variant in the P[E2]OLG [/E2]gene was identified.",OLG ,GENE_VARIANT,152,156,erlactatemia a,HPO_TERM,100,114,0.7995605,0.20043947,-0.59912103,0
line194,"We report the case of Patient 214, who has a history of an abnormal thalamic MRI signal. Examination also revealed hyperlactatemia. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient 214, who has a history of [E1]an abnormal thalamic MRI sign[/E1]al. Examination also revealed hyperlactatemia. The underlying cause was traced to a mutation in t[E2]he P[/E2]OLG gene.",he P,GENE_VARIANT,182,186,an abnormal thalamic MRI sign,HPO_TERM,56,85,0.562753,0.437247,-0.12550601,0
line194,"We report the case of Patient 214, who has a history of an abnormal thalamic MRI signal. Examination also revealed hyperlactatemia. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient 214, who has a history of an abnormal thalamic MRI signal. Examination also reveale[E1]d hyperlactate[/E1]mia. The underlying cause was traced to a mutation in t[E2]he P[/E2]OLG gene.",he P,GENE_VARIANT,182,186,d hyperlactate,HPO_TERM,113,127,0.38209894,0.617901,0.23580208,1
line195,The clinical profile for Patient 215 includes an abnormal thalamic MRI signal and a seizure. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient 215 includes [E1]an abnormal thalamic MRI sign[/E1]al and a seizure. Genetic analysis of th[E2]e PO[/E2]LG gene confirmed the diagnosis.,e PO,GENE_VARIANT,115,119,an abnormal thalamic MRI sign,HPO_TERM,46,75,0.8441125,0.15588741,-0.6882251,0
line195,The clinical profile for Patient 215 includes an abnormal thalamic MRI signal and a seizure. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient 215 includes an abnormal thalamic MRI signal an[E1]d a seizu[/E1]re. Genetic analysis of th[E2]e PO[/E2]LG gene confirmed the diagnosis.,e PO,GENE_VARIANT,115,119,d a seizu,HPO_TERM,80,89,0.8572066,0.14279349,-0.7144131,0
line196,"We report the case of Patient 216, who has a history of an elevated hepatic transaminase concentration. Examination also revealed a pediatric-onset disorder. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient 216, who has a history of [E1]an elevated hepatic transaminase concentra[/E1]tion. Examination also revealed a pediatric-onset disorder. The underlying cause was traced to a mutation in [E2]the [/E2]POLG gene.",the ,GENE_VARIANT,207,211,an elevated hepatic transaminase concentra,HPO_TERM,56,98,0.31591338,0.6840866,0.36817324,1
line196,"We report the case of Patient 216, who has a history of an elevated hepatic transaminase concentration. Examination also revealed a pediatric-onset disorder. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient 216, who has a history of an elevated hepatic transaminase concentration. Examination also revea[E1]led a pediatric-onset diso[/E1]rder. The underlying cause was traced to a mutation in [E2]the [/E2]POLG gene.",the ,GENE_VARIANT,207,211,led a pediatric-onset diso,HPO_TERM,126,152,0.50165796,0.49834207,-0.0033158958,0
line197,"We report the case of Patient 217, who has a history of An elevated concentration of liver transaminases. Examination also revealed a history of recurrent seizures. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient 217, who has a history of [E1]An elevated concentration of liver transaminases[/E1]. Examination also revealed a history of recurrent seizures. The underlying cause was traced to a mutation in the [E2]POLG[/E2] gene.",POLG,GENE_VARIANT,218,222,An elevated concentration of liver transaminases,HPO_TERM,56,104,0.5329496,0.46705034,-0.06589928,0
line197,"We report the case of Patient 217, who has a history of An elevated concentration of liver transaminases. Examination also revealed a history of recurrent seizures. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient 217, who has a history of An elevated concentration of liver transaminases. Examination also revealed [E1]a history of recurrent seizures[/E1]. The underlying cause was traced to a mutation in the [E2]POLG[/E2] gene.",POLG,GENE_VARIANT,218,222,a history of recurrent seizures,HPO_TERM,132,163,0.5565527,0.44344738,-0.11310533,0
line198,"This report details Patient 218, a patient with a late-onset variant of the condition. Further investigation showed unclear or mumbled speech and hepatic enzyme levels were above the normal range. A known variant in the POLG gene was identified.","This report details Patient 218, a patient with [E1]a late-onset variant of the condition[/E1]. Further investigation showed unclear or mumbled speech and hepatic enzyme levels were above the normal range. A known variant in [E2]the [/E2]POLG gene was identified.",the ,GENE_VARIANT,216,220,a late-onset variant of the condition,HPO_TERM,48,85,0.78252316,0.21747686,-0.5650463,0
line198,"This report details Patient 218, a patient with a late-onset variant of the condition. Further investigation showed unclear or mumbled speech and hepatic enzyme levels were above the normal range. A known variant in the POLG gene was identified.","This report details Patient 218, a patient with a late-onset variant of the condition. Further investigation showed [E1]unclear or mumbled speech[/E1] and hepatic enzyme levels were above the normal range. A known variant in [E2]the [/E2]POLG gene was identified.",the ,GENE_VARIANT,216,220,unclear or mumbled speech,HPO_TERM,116,141,0.7283592,0.27164075,-0.45671847,0
line198,"This report details Patient 218, a patient with a late-onset variant of the condition. Further investigation showed unclear or mumbled speech and hepatic enzyme levels were above the normal range. A known variant in the POLG gene was identified.","This report details Patient 218, a patient with a late-onset variant of the condition. Further investigation showed unclear or mumbled speech and [E1]hepatic enzyme levels were above the normal ra[/E1]nge. A known variant in [E2]the [/E2]POLG gene was identified.",the ,GENE_VARIANT,216,220,hepatic enzyme levels were above the normal ra,HPO_TERM,146,192,0.76049244,0.23950757,-0.5209849,0
line199,The clinical profile for Patient 219 includes a pediatric-onset disorder and drooping of both upper eyelids. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient 219 includes [E1]a pediatric-onset disorder[/E1] and drooping of both upper eyelids. Genetic analysis of the [E2]POLG[/E2] gene confirmed the diagnosis.,POLG,GENE_VARIANT,133,137,a pediatric-onset disorder,HPO_TERM,46,72,0.7619395,0.2380605,-0.52387905,0
line199,The clinical profile for Patient 219 includes a pediatric-onset disorder and drooping of both upper eyelids. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient 219 includes a pediatric-onset disorder and [E1]drooping of both upper eyelids[/E1]. Genetic analysis of the [E2]POLG[/E2] gene confirmed the diagnosis.,POLG,GENE_VARIANT,133,137,drooping of both upper eyelids,HPO_TERM,77,107,0.7736403,0.22635965,-0.5472806,0
line200,"We report the case of Patient X0, who has a history of myoclonic jerks. Examination also revealed a presentation in infancy. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient X0, who has a history of [E1]myoclonic jerks[/E1]. Examination also revealed a presentation in infancy. The underlying cause was traced to a mutation in the [E2]POLG[/E2] gene.",POLG,GENE_VARIANT,178,182,myoclonic jerks,HPO_TERM,55,70,0.6071442,0.39285585,-0.21428832,0
line200,"We report the case of Patient X0, who has a history of myoclonic jerks. Examination also revealed a presentation in infancy. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient X0, who has a history of myoclonic jerks. Examination also revealed [E1]a presentation in infancy[/E1]. The underlying cause was traced to a mutation in the [E2]POLG[/E2] gene.",POLG,GENE_VARIANT,178,182,a presentation in infancy,HPO_TERM,98,123,0.5797234,0.42027655,-0.15944687,0
line201,"We report the case of Patient X1, who has a history of a diagnosis of ataxia. Examination also revealed generalized hypotonia. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient X1, who has a history of [E1]a diagnosis of ataxia[/E1]. Examination also revealed generalized hypotonia. The underlying cause was traced to a mutation in the [E2]POLG[/E2] gene.",POLG,GENE_VARIANT,180,184,a diagnosis of ataxia,HPO_TERM,55,76,0.5745817,0.42541823,-0.14916345,0
line201,"We report the case of Patient X1, who has a history of a diagnosis of ataxia. Examination also revealed generalized hypotonia. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient X1, who has a history of a diagnosis of ataxia. Examination also revealed [E1]generalized hypotonia[/E1]. The underlying cause was traced to a mutation in the [E2]POLG[/E2] gene.",POLG,GENE_VARIANT,180,184,generalized hypotonia,HPO_TERM,104,125,0.52067435,0.47932568,-0.041348666,0
line202,"We report the case of Patient X2, who has a history of oropharyngeal dysphagia. Examination also revealed Mitochondrial proliferation leading to ragged-red fibers. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient X2, who has a history of [E1]oropharyngeal dysphagia[/E1]. Examination also revealed Mitochondrial proliferation leading to ragged-red fibers. The underlying cause was traced to a mutation in t[E2]he P[/E2]OLG gene.",he P,GENE_VARIANT,214,218,oropharyngeal dysphagia,HPO_TERM,55,78,0.4764207,0.5235793,0.0471586,1
line202,"We report the case of Patient X2, who has a history of oropharyngeal dysphagia. Examination also revealed Mitochondrial proliferation leading to ragged-red fibers. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient X2, who has a history of oropharyngeal dysphagia. Examination also revealed [E1]Mitochondrial proliferation leading to ragged-red fib[/E1]ers. The underlying cause was traced to a mutation in t[E2]he P[/E2]OLG gene.",he P,GENE_VARIANT,214,218,Mitochondrial proliferation leading to ragged-red fib,HPO_TERM,106,159,0.29733452,0.70266545,0.40533093,1
line203,Patient X3 was evaluated for a diagnosis of ataxia. The patient also presented with abnormal EMG findings of a myopathic nature and myoclonic jerks. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X3 was evaluated for [E1]a diagnosis of ataxi[/E1]a. The patient also presented with abnormal EMG findings of a myopathic nature and myoclonic jerks. Subsequent sequencing of the P[E2]OLG [/E2]gene revealed a pathogenic variant.,OLG ,GENE_VARIANT,179,183,a diagnosis of ataxi,HPO_TERM,29,49,0.7927875,0.20721257,-0.5855749,0
line203,Patient X3 was evaluated for a diagnosis of ataxia. The patient also presented with abnormal EMG findings of a myopathic nature and myoclonic jerks. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X3 was evaluated for a diagnosis of ataxia. The patient also presented with[E1] abnormal EMG findings of a myopathic nature [/E1]and myoclonic jerks. Subsequent sequencing of the P[E2]OLG [/E2]gene revealed a pathogenic variant.,OLG ,GENE_VARIANT,179,183, abnormal EMG findings of a myopathic nature ,HPO_TERM,83,128,0.7884408,0.21155925,-0.5768816,0
line204,"This report details Patient X4, a patient with myoclonic jerks. Further investigation showed a presentation in infancy and an inability to swallow properly. A known variant in the POLG gene was identified.","This report details Patient X4, a patient with [E1]myoclonic jerks[/E1]. Further investigation showed a presentation in infancy and an inability to swallow properly. A known variant in t[E2]he P[/E2]OLG gene was identified.",he P,GENE_VARIANT,177,181,myoclonic jerks,HPO_TERM,47,62,0.79600215,0.20399791,-0.59200424,0
line204,"This report details Patient X4, a patient with myoclonic jerks. Further investigation showed a presentation in infancy and an inability to swallow properly. A known variant in the POLG gene was identified.","This report details Patient X4, a patient with myoclonic jerks. Further investigation showed [E1]a presentation in infancy[/E1] and an inability to swallow properly. A known variant in t[E2]he P[/E2]OLG gene was identified.",he P,GENE_VARIANT,177,181,a presentation in infancy,HPO_TERM,93,118,0.7987095,0.20129049,-0.597419,0
line204,"This report details Patient X4, a patient with myoclonic jerks. Further investigation showed a presentation in infancy and an inability to swallow properly. A known variant in the POLG gene was identified.","This report details Patient X4, a patient with myoclonic jerks. Further investigation showed a presentation in infancy and [E1]an inability to swallow proper[/E1]ly. A known variant in t[E2]he P[/E2]OLG gene was identified.",he P,GENE_VARIANT,177,181,an inability to swallow proper,HPO_TERM,123,153,0.8152654,0.18473461,-0.63053083,0
line205,"We report the case of Patient X5, who has a history of an inability to swallow properly. Examination also revealed a lack of voluntary coordination of muscle movements. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient X5, who has a history of [E1]an inability to swallow proper[/E1]ly. Examination also revealed a lack of voluntary coordination of muscle movements. The underlying cause was traced to a mutation in t[E2]he P[/E2]OLG gene.",he P,GENE_VARIANT,219,223,an inability to swallow proper,HPO_TERM,55,85,0.4541933,0.54580677,0.09161347,1
line205,"We report the case of Patient X5, who has a history of an inability to swallow properly. Examination also revealed a lack of voluntary coordination of muscle movements. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient X5, who has a history of an inability to swallow properly. Examination also reveale[E1]d a lack of voluntary coordination of muscle moveme[/E1]nts. The underlying cause was traced to a mutation in t[E2]he P[/E2]OLG gene.",he P,GENE_VARIANT,219,223,d a lack of voluntary coordination of muscle moveme,HPO_TERM,113,164,0.5328121,0.46718785,-0.06562427,0
line206,Patient X6 was evaluated for infantile hypotonia. The patient also presented with a complaint of dysphagia and problems with balance and coordination. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X6 was evaluated for [E1]infantile hypotonia[/E1]. The patient also presented with a complaint of dysphagia and problems with balance and coordination. Subsequent sequencing o[E2]f th[/E2]e POLG gene revealed a pathogenic variant.,f th,GENE_VARIANT,174,178,infantile hypotonia,HPO_TERM,29,48,0.8501103,0.14988966,-0.70022064,0
line206,Patient X6 was evaluated for infantile hypotonia. The patient also presented with a complaint of dysphagia and problems with balance and coordination. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X6 was evaluated for infantile hypotonia. The patient also presented with [E1]a complaint of dysphag[/E1]ia and problems with balance and coordination. Subsequent sequencing o[E2]f th[/E2]e POLG gene revealed a pathogenic variant.,f th,GENE_VARIANT,174,178,a complaint of dysphag,HPO_TERM,82,104,0.846205,0.15379502,-0.69241,0
line206,Patient X6 was evaluated for infantile hypotonia. The patient also presented with a complaint of dysphagia and problems with balance and coordination. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X6 was evaluated for infantile hypotonia. The patient also presented with a complaint of dysphagia an[E1]d problems with balance and coordi[/E1]nation. Subsequent sequencing o[E2]f th[/E2]e POLG gene revealed a pathogenic variant.,f th,GENE_VARIANT,174,178,d problems with balance and coordi,HPO_TERM,109,143,0.823419,0.176581,-0.64683795,0
line207,"We report the case of Patient X7, who has a history of a diagnosis of ataxia. Examination also revealed decreased muscle tone. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient X7, who has a history of [E1]a diagnosis of ataxia[/E1]. Examination also revealed decreased muscle tone. The underlying cause was traced to a mutation in th[E2]e PO[/E2]LG gene.",e PO,GENE_VARIANT,178,182,a diagnosis of ataxia,HPO_TERM,55,76,0.70548356,0.29451644,-0.4109671,0
line207,"We report the case of Patient X7, who has a history of a diagnosis of ataxia. Examination also revealed decreased muscle tone. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient X7, who has a history of a diagnosis of ataxia. Examination also revealed [E1]decreased muscle to[/E1]ne. The underlying cause was traced to a mutation in th[E2]e PO[/E2]LG gene.",e PO,GENE_VARIANT,178,182,decreased muscle to,HPO_TERM,104,123,0.5417379,0.4582621,-0.08347583,0
line208,"This report details Patient X8, a patient with a lack of voluntary coordination of muscle movements. Further investigation showed myoclonic activity and a diagnosis of external ophthalmoplegia. A known variant in the POLG gene was identified.","This report details Patient X8, a patient with [E1]a lack of voluntary coordination of muscle movement[/E1]s. Further investigation showed myoclonic activity and a diagnosis of external ophthalmoplegia. A known variant in[E2] the[/E2] POLG gene was identified.", the,GENE_VARIANT,212,216,a lack of voluntary coordination of muscle movement,HPO_TERM,47,98,0.78000706,0.21999292,-0.5600141,0
line208,"This report details Patient X8, a patient with a lack of voluntary coordination of muscle movements. Further investigation showed myoclonic activity and a diagnosis of external ophthalmoplegia. A known variant in the POLG gene was identified.","This report details Patient X8, a patient with a lack of voluntary coordination of muscle movements. Further investigation showed[E1] myoclonic activi[/E1]ty and a diagnosis of external ophthalmoplegia. A known variant in[E2] the[/E2] POLG gene was identified.", the,GENE_VARIANT,212,216, myoclonic activi,HPO_TERM,129,146,0.8105938,0.18940625,-0.62118757,0
line208,"This report details Patient X8, a patient with a lack of voluntary coordination of muscle movements. Further investigation showed myoclonic activity and a diagnosis of external ophthalmoplegia. A known variant in the POLG gene was identified.","This report details Patient X8, a patient with a lack of voluntary coordination of muscle movements. Further investigation showed myoclonic activity an[E1]d a diagnosis of external ophthalmopl[/E1]egia. A known variant in[E2] the[/E2] POLG gene was identified.", the,GENE_VARIANT,212,216,d a diagnosis of external ophthalmopl,HPO_TERM,151,188,0.8068901,0.19310996,-0.61378014,0
line209,"This report details Patient X9, a patient with an infantile onset. Further investigation showed myoclonic seizures and a state of low muscle tone. A known variant in the POLG gene was identified.","This report details Patient X9, a patient with [E1]an infantile onse[/E1]t. Further investigation showed myoclonic seizures and a state of low muscle tone. A known variant in[E2] the[/E2] POLG gene was identified.", the,GENE_VARIANT,165,169,an infantile onse,HPO_TERM,47,64,0.7504613,0.24953872,-0.50092256,0
line209,"This report details Patient X9, a patient with an infantile onset. Further investigation showed myoclonic seizures and a state of low muscle tone. A known variant in the POLG gene was identified.","This report details Patient X9, a patient with an infantile onset. Further investigation showed[E1] myoclonic seizur[/E1]es and a state of low muscle tone. A known variant in[E2] the[/E2] POLG gene was identified.", the,GENE_VARIANT,165,169, myoclonic seizur,HPO_TERM,95,112,0.74207014,0.2579299,-0.48414025,0
line209,"This report details Patient X9, a patient with an infantile onset. Further investigation showed myoclonic seizures and a state of low muscle tone. A known variant in the POLG gene was identified.","This report details Patient X9, a patient with an infantile onset. Further investigation showed myoclonic seizures an[E1]d a state of low muscle [/E1]tone. A known variant in[E2] the[/E2] POLG gene was identified.", the,GENE_VARIANT,165,169,d a state of low muscle ,HPO_TERM,117,141,0.741489,0.25851104,-0.48297796,0
line210,Patient X10 was evaluated for difficulty swallowing. The patient also presented with an infantile onset and a sensation of food getting stuck. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X10 was evaluated for [E1]difficulty swallowing[/E1]. The patient also presented with an infantile onset and a sensation of food getting stuck. Subsequent sequencing of th[E2]e PO[/E2]LG gene revealed a pathogenic variant.,e PO,GENE_VARIANT,170,174,difficulty swallowing,HPO_TERM,30,51,0.8607388,0.1392612,-0.7214776,0
line210,Patient X10 was evaluated for difficulty swallowing. The patient also presented with an infantile onset and a sensation of food getting stuck. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X10 was evaluated for difficulty swallowing. The patient also presented with [E1]an infantile onse[/E1]t and a sensation of food getting stuck. Subsequent sequencing of th[E2]e PO[/E2]LG gene revealed a pathogenic variant.,e PO,GENE_VARIANT,170,174,an infantile onse,HPO_TERM,85,102,0.86493886,0.13506107,-0.72987777,0
line210,Patient X10 was evaluated for difficulty swallowing. The patient also presented with an infantile onset and a sensation of food getting stuck. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X10 was evaluated for difficulty swallowing. The patient also presented with an infantile onset and[E1] a sensation of food getting stu[/E1]ck. Subsequent sequencing of th[E2]e PO[/E2]LG gene revealed a pathogenic variant.,e PO,GENE_VARIANT,170,174, a sensation of food getting stu,HPO_TERM,107,139,0.86061466,0.13938533,-0.7212293,0
line211,Patient X11 was evaluated for a diagnosis of external ophthalmoplegia. The patient also presented with infantile hypotonia and an infantile onset. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X11 was evaluated for [E1]a diagnosis of external ophthalmopleg[/E1]ia. The patient also presented with infantile hypotonia and an infantile onset. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,173,177,a diagnosis of external ophthalmopleg,HPO_TERM,30,67,0.8612472,0.13875282,-0.72249436,0
line211,Patient X11 was evaluated for a diagnosis of external ophthalmoplegia. The patient also presented with infantile hypotonia and an infantile onset. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X11 was evaluated for a diagnosis of external ophthalmoplegia. The patient also presented wit[E1]h infantile hypoton[/E1]ia and an infantile onset. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,173,177,h infantile hypoton,HPO_TERM,101,120,0.8489646,0.15103544,-0.69792914,0
line211,Patient X11 was evaluated for a diagnosis of external ophthalmoplegia. The patient also presented with infantile hypotonia and an infantile onset. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X11 was evaluated for a diagnosis of external ophthalmoplegia. The patient also presented with infantile hypotonia an[E1]d an infantile on[/E1]set. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,173,177,d an infantile on,HPO_TERM,125,142,0.8633115,0.13668853,-0.726623,0
line212,"We report the case of Patient X12, who has a history of myoclonic seizures. Examination also revealed problems with swallowing. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient X12, who has a history of [E1]myoclonic seizure[/E1]s. Examination also revealed problems with swallowing. The underlying cause was traced to a mutation in t[E2]he P[/E2]OLG gene.",he P,GENE_VARIANT,178,182,myoclonic seizure,HPO_TERM,56,73,0.68385017,0.31614983,-0.36770034,0
line212,"We report the case of Patient X12, who has a history of myoclonic seizures. Examination also revealed problems with swallowing. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient X12, who has a history of myoclonic seizures. Examination also revealed[E1] problems with swallow[/E1]ing. The underlying cause was traced to a mutation in t[E2]he P[/E2]OLG gene.",he P,GENE_VARIANT,178,182, problems with swallow,HPO_TERM,101,123,0.67195874,0.32804126,-0.3439175,0
line213,The primary symptoms for Patient X13 were a sensation of food getting stuck and an infantile onset. Analysis of the POLG gene was performed.,The primary symptoms for Patient X13 were a [E1]sensation of food getting stuck [/E1]and an infantile onset. Analysis of the POLG gen[E2]e wa[/E2]s performed.,e wa,GENE_VARIANT,124,128,sensation of food getting stuck ,HPO_TERM,44,76,0.8131342,0.18686584,-0.6262684,0
line213,The primary symptoms for Patient X13 were a sensation of food getting stuck and an infantile onset. Analysis of the POLG gene was performed.,The primary symptoms for Patient X13 were a sensation of food getting stuck and a[E1]n infantile onset[/E1]. Analysis of the POLG gen[E2]e wa[/E2]s performed.,e wa,GENE_VARIANT,124,128,n infantile onset,HPO_TERM,81,98,0.81033754,0.18966241,-0.62067515,0
line214,"We report the case of Patient X14, who has a history of an increased CSF protein concentration. Examination also revealed a diagnosis of external ophthalmoplegia. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient X14, who has a history of [E1]an increased CSF protein concentra[/E1]tion. Examination also revealed a diagnosis of external ophthalmoplegia. The underlying cause was traced to a mutation i[E2]n th[/E2]e POLG gene.",n th,GENE_VARIANT,210,214,an increased CSF protein concentra,HPO_TERM,56,90,0.74306554,0.25693443,-0.4861311,0
line214,"We report the case of Patient X14, who has a history of an increased CSF protein concentration. Examination also revealed a diagnosis of external ophthalmoplegia. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient X14, who has a history of an increased CSF protein concentration. Examination also revea[E1]led a diagnosis of external ophthalmo[/E1]plegia. The underlying cause was traced to a mutation i[E2]n th[/E2]e POLG gene.",n th,GENE_VARIANT,210,214,led a diagnosis of external ophthalmo,HPO_TERM,118,155,0.78544545,0.21455449,-0.57089096,0
line215,The clinical profile for Patient X15 includes an inability to swallow properly and a complaint of dysphagia. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient X15 includes [E1]an inability to swallow proper[/E1]ly and a complaint of dysphagia. Genetic analysis of [E2]the [/E2]POLG gene confirmed the diagnosis.,the ,GENE_VARIANT,129,133,an inability to swallow proper,HPO_TERM,46,76,0.8323847,0.16761535,-0.66476935,0
line215,The clinical profile for Patient X15 includes an inability to swallow properly and a complaint of dysphagia. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient X15 includes an inability to swallow properly an[E1]d a complaint of dysph[/E1]agia. Genetic analysis of [E2]the [/E2]POLG gene confirmed the diagnosis.,the ,GENE_VARIANT,129,133,d a complaint of dysph,HPO_TERM,81,103,0.8290205,0.17097953,-0.658041,0
line216,"We report the case of Patient X16, who has a history of a diagnosis of sensory axonal neuropathy. Examination also revealed difficulty swallowing. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient X16, who has a history of [E1]a diagnosis of sensory axonal neuropathy[/E1]. Examination also revealed difficulty swallowing. The underlying cause was traced to a mutation in the [E2]POLG[/E2] gene.",POLG,GENE_VARIANT,200,204,a diagnosis of sensory axonal neuropathy,HPO_TERM,56,96,0.5415927,0.45840725,-0.083185464,0
line216,"We report the case of Patient X16, who has a history of a diagnosis of sensory axonal neuropathy. Examination also revealed difficulty swallowing. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient X16, who has a history of a diagnosis of sensory axonal neuropathy. Examination also revealed [E1]difficulty swallowing[/E1]. The underlying cause was traced to a mutation in the [E2]POLG[/E2] gene.",POLG,GENE_VARIANT,200,204,difficulty swallowing,HPO_TERM,124,145,0.3905004,0.6094996,0.21899918,1
line217,"This report details Patient X17, a patient with a lack of voluntary coordination of muscle movements. Further investigation showed an increased CSF protein concentration and problems with balance and coordination. A known variant in the POLG gene was identified.","This report details Patient X17, a patient with [E1]a lack of voluntary coordination of muscle movement[/E1]s. Further investigation showed an increased CSF protein concentration and problems with balance and coordination. A known varia[E2]nt i[/E2]n the POLG gene was identified.",nt i,GENE_VARIANT,227,231,a lack of voluntary coordination of muscle movement,HPO_TERM,48,99,0.8715524,0.12844768,-0.7431047,0
line217,"This report details Patient X17, a patient with a lack of voluntary coordination of muscle movements. Further investigation showed an increased CSF protein concentration and problems with balance and coordination. A known variant in the POLG gene was identified.","This report details Patient X17, a patient with a lack of voluntary coordination of muscle movements. Further investigation showed[E1] an increased CSF protein concentr[/E1]ation and problems with balance and coordination. A known varia[E2]nt i[/E2]n the POLG gene was identified.",nt i,GENE_VARIANT,227,231, an increased CSF protein concentr,HPO_TERM,130,164,0.8638036,0.1361964,-0.72760725,0
line217,"This report details Patient X17, a patient with a lack of voluntary coordination of muscle movements. Further investigation showed an increased CSF protein concentration and problems with balance and coordination. A known variant in the POLG gene was identified.","This report details Patient X17, a patient with a lack of voluntary coordination of muscle movements. Further investigation showed an increased CSF protein concentration[E1] and problems with balance and coo[/E1]rdination. A known varia[E2]nt i[/E2]n the POLG gene was identified.",nt i,GENE_VARIANT,227,231, and problems with balance and coo,HPO_TERM,169,203,0.8730365,0.12696347,-0.746073,0
line218,Patient X18 was evaluated for a state of low muscle tone. The patient also presented with an increased CSF protein concentration and myoclonus. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X18 was evaluated for [E1]a state of low muscle to[/E1]ne. The patient also presented with an increased CSF protein concentration and myoclonus. Subsequent sequencing o[E2]f th[/E2]e POLG gene revealed a pathogenic variant.,f th,GENE_VARIANT,167,171,a state of low muscle to,HPO_TERM,30,54,0.8598772,0.14012273,-0.7197545,0
line218,Patient X18 was evaluated for a state of low muscle tone. The patient also presented with an increased CSF protein concentration and myoclonus. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X18 was evaluated for a state of low muscle tone. The patient also presented wit[E1]h an increased CSF protein concent[/E1]ration and myoclonus. Subsequent sequencing o[E2]f th[/E2]e POLG gene revealed a pathogenic variant.,f th,GENE_VARIANT,167,171,h an increased CSF protein concent,HPO_TERM,88,122,0.8628777,0.13712232,-0.7257554,0
line218,Patient X18 was evaluated for a state of low muscle tone. The patient also presented with an increased CSF protein concentration and myoclonus. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X18 was evaluated for a state of low muscle tone. The patient also presented with an increased CSF protein concentratio[E1]n and myo[/E1]clonus. Subsequent sequencing o[E2]f th[/E2]e POLG gene revealed a pathogenic variant.,f th,GENE_VARIANT,167,171,n and myo,HPO_TERM,127,136,0.8669316,0.13306838,-0.73386323,0
line219,The clinical profile for Patient X19 includes a finding of ragged-red fibers and a reduction in muscle tone. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient X19 includes [E1]a finding of ragged-red fiber[/E1]s and a reduction in muscle tone. Genetic analysis of th[E2]e PO[/E2]LG gene confirmed the diagnosis.,e PO,GENE_VARIANT,131,135,a finding of ragged-red fiber,HPO_TERM,46,75,0.8521731,0.14782684,-0.70434624,0
line219,The clinical profile for Patient X19 includes a finding of ragged-red fibers and a reduction in muscle tone. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient X19 includes a finding of ragged-red fibers and[E1] a reduction in muscle to[/E1]ne. Genetic analysis of th[E2]e PO[/E2]LG gene confirmed the diagnosis.,e PO,GENE_VARIANT,131,135, a reduction in muscle to,HPO_TERM,80,105,0.85215366,0.14784642,-0.70430726,0
line220,Patient X20 was evaluated for myoclonus. The patient also presented with an infantile onset and EMG evidence of myopathy. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X20 was evaluated for [E1]myoclonus[/E1]. The patient also presented with an infantile onset and EMG evidence of myopathy. Subsequent sequencing of the[E2] POL[/E2]G gene revealed a pathogenic variant., POL,GENE_VARIANT,150,154,myoclonus,HPO_TERM,30,39,0.8387719,0.16122808,-0.6775438,0
line220,Patient X20 was evaluated for myoclonus. The patient also presented with an infantile onset and EMG evidence of myopathy. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X20 was evaluated for myoclonus. The patient also presented with [E1]an infantile onse[/E1]t and EMG evidence of myopathy. Subsequent sequencing of the[E2] POL[/E2]G gene revealed a pathogenic variant., POL,GENE_VARIANT,150,154,an infantile onse,HPO_TERM,73,90,0.8556881,0.14431192,-0.7113762,0
line220,Patient X20 was evaluated for myoclonus. The patient also presented with an infantile onset and EMG evidence of myopathy. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X20 was evaluated for myoclonus. The patient also presented with an infantile onset and[E1] EMG evidence of myopath[/E1]y. Subsequent sequencing of the[E2] POL[/E2]G gene revealed a pathogenic variant., POL,GENE_VARIANT,150,154, EMG evidence of myopath,HPO_TERM,95,119,0.8460714,0.15392853,-0.6921429,0
line221,"We report the case of Patient X21, who has a history of myoclonic jerks. Examination also revealed an infantile onset. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient X21, who has a history of [E1]myoclonic jerks[/E1]. Examination also revealed an infantile onset. The underlying cause was traced to a mutation in the[E2] POL[/E2]G gene.", POL,GENE_VARIANT,171,175,myoclonic jerks,HPO_TERM,56,71,0.50980717,0.4901928,-0.019614369,0
line221,"We report the case of Patient X21, who has a history of myoclonic jerks. Examination also revealed an infantile onset. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient X21, who has a history of myoclonic jerks. Examination also revealed [E1]an infantile onse[/E1]t. The underlying cause was traced to a mutation in the[E2] POL[/E2]G gene.", POL,GENE_VARIANT,171,175,an infantile onse,HPO_TERM,99,116,0.4377802,0.5622198,0.1244396,1
line222,The primary symptoms for Patient X22 were unsteady gait and poor coordination and a complaint of dysphagia. Analysis of the POLG gene was performed.,The primary symptoms for Patient X22 were un[E1]steady gait and poor coordination[/E1] and a complaint of dysphagia. Analysis of the POLG g[E2]ene [/E2]was performed.,ene ,GENE_VARIANT,130,134,steady gait and poor coordination,HPO_TERM,44,77,0.7875882,0.21241179,-0.57517636,0
line222,The primary symptoms for Patient X22 were unsteady gait and poor coordination and a complaint of dysphagia. Analysis of the POLG gene was performed.,The primary symptoms for Patient X22 were unsteady gait and poor coordination and [E1]a complaint of dysphag[/E1]ia. Analysis of the POLG g[E2]ene [/E2]was performed.,ene ,GENE_VARIANT,130,134,a complaint of dysphag,HPO_TERM,82,104,0.81971854,0.18028137,-0.6394372,0
line223,"This report details Patient X23, a patient with a condition affecting eye movement. Further investigation showed an increased CSF protein concentration and a diagnosis of ataxia. A known variant in the POLG gene was identified.","This report details Patient X23, a patient with [E1]a condition affecting eye movemen[/E1]t. Further investigation showed an increased CSF protein concentration and a diagnosis of ataxia. A known variant[E2] in [/E2]the POLG gene was identified.", in ,GENE_VARIANT,194,198,a condition affecting eye movemen,HPO_TERM,48,81,0.8480918,0.15190819,-0.69618356,0
line223,"This report details Patient X23, a patient with a condition affecting eye movement. Further investigation showed an increased CSF protein concentration and a diagnosis of ataxia. A known variant in the POLG gene was identified.","This report details Patient X23, a patient with a condition affecting eye movement. Further investigation showed[E1] an increased CSF protein concentr[/E1]ation and a diagnosis of ataxia. A known variant[E2] in [/E2]the POLG gene was identified.", in ,GENE_VARIANT,194,198, an increased CSF protein concentr,HPO_TERM,112,146,0.83829737,0.16170262,-0.67659473,0
line223,"This report details Patient X23, a patient with a condition affecting eye movement. Further investigation showed an increased CSF protein concentration and a diagnosis of ataxia. A known variant in the POLG gene was identified.","This report details Patient X23, a patient with a condition affecting eye movement. Further investigation showed an increased CSF protein concentration[E1] and a diagnosis of[/E1] ataxia. A known variant[E2] in [/E2]the POLG gene was identified.", in ,GENE_VARIANT,194,198, and a diagnosis of,HPO_TERM,151,170,0.83463836,0.16536166,-0.6692767,0
line224,The primary symptoms for Patient X24 were myoclonus and an infantile onset. Analysis of the POLG gene was performed.,The primary symptoms for Patient X24 were my[E1]oclonus a[/E1]nd an infantile onset. Analysis of the POLG gene[E2] was[/E2] performed., was,GENE_VARIANT,101,105,oclonus a,HPO_TERM,44,53,0.85483754,0.1451625,-0.7096751,0
line225,"This report details Patient X25, a patient with myoclonic jerks. Further investigation showed hypotonia and difficulty swallowing. A known variant in the POLG gene was identified.","This report details Patient X25, a patient with [E1]myoclonic jerks[/E1]. Further investigation showed hypotonia and difficulty swallowing. A known variant in the[E2] POL[/E2]G gene was identified.", POL,GENE_VARIANT,153,157,myoclonic jerks,HPO_TERM,48,63,0.75561345,0.2443866,-0.51122683,0
line225,"This report details Patient X25, a patient with myoclonic jerks. Further investigation showed hypotonia and difficulty swallowing. A known variant in the POLG gene was identified.","This report details Patient X25, a patient with myoclonic jerks. Further investigation showed [E1]hypotonia[/E1] and difficulty swallowing. A known variant in the[E2] POL[/E2]G gene was identified.", POL,GENE_VARIANT,153,157,hypotonia,HPO_TERM,94,103,0.76690257,0.23309742,-0.53380513,0
line225,"This report details Patient X25, a patient with myoclonic jerks. Further investigation showed hypotonia and difficulty swallowing. A known variant in the POLG gene was identified.","This report details Patient X25, a patient with myoclonic jerks. Further investigation showed hypotonia and [E1]difficulty swallowing[/E1]. A known variant in the[E2] POL[/E2]G gene was identified.", POL,GENE_VARIANT,153,157,difficulty swallowing,HPO_TERM,108,129,0.7759746,0.22402537,-0.5519492,0
line226,"This report details Patient X26, a patient with myoclonic jerks. Further investigation showed a complaint of dysphagia and problems with balance and coordination. A known variant in the POLG gene was identified.","This report details Patient X26, a patient with [E1]myoclonic jerks[/E1]. Further investigation showed a complaint of dysphagia and problems with balance and coordination. A known variant [E2]in t[/E2]he POLG gene was identified.",in t,GENE_VARIANT,179,183,myoclonic jerks,HPO_TERM,48,63,0.74183196,0.25816807,-0.4836639,0
line226,"This report details Patient X26, a patient with myoclonic jerks. Further investigation showed a complaint of dysphagia and problems with balance and coordination. A known variant in the POLG gene was identified.","This report details Patient X26, a patient with myoclonic jerks. Further investigation showed [E1]a complaint of dysphag[/E1]ia and problems with balance and coordination. A known variant [E2]in t[/E2]he POLG gene was identified.",in t,GENE_VARIANT,179,183,a complaint of dysphag,HPO_TERM,94,116,0.77685994,0.22314014,-0.5537198,0
line226,"This report details Patient X26, a patient with myoclonic jerks. Further investigation showed a complaint of dysphagia and problems with balance and coordination. A known variant in the POLG gene was identified.","This report details Patient X26, a patient with myoclonic jerks. Further investigation showed a complaint of dysphagia an[E1]d problems with balance and coordi[/E1]nation. A known variant [E2]in t[/E2]he POLG gene was identified.",in t,GENE_VARIANT,179,183,d problems with balance and coordi,HPO_TERM,121,155,0.7248652,0.27513483,-0.44973037,0
line227,Patient X27 was evaluated for a notable lack of muscle tone. The patient also presented with an infantile onset and a complaint of dysphagia. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X27 was evaluated for [E1]a notable lack of muscle ton[/E1]e. The patient also presented with an infantile onset and a complaint of dysphagia. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,167,171,a notable lack of muscle ton,HPO_TERM,30,58,0.8185661,0.18143392,-0.63713217,0
line227,Patient X27 was evaluated for a notable lack of muscle tone. The patient also presented with an infantile onset and a complaint of dysphagia. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X27 was evaluated for a notable lack of muscle tone. The patient also presented with[E1] an infantile ons[/E1]et and a complaint of dysphagia. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,167,171, an infantile ons,HPO_TERM,92,109,0.82062745,0.1793725,-0.64125496,0
line227,Patient X27 was evaluated for a notable lack of muscle tone. The patient also presented with an infantile onset and a complaint of dysphagia. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X27 was evaluated for a notable lack of muscle tone. The patient also presented with an infantile onset an[E1]d a complaint of dysph[/E1]agia. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,167,171,d a complaint of dysph,HPO_TERM,114,136,0.82678497,0.1732151,-0.6535699,0
line228,"We report the case of Patient X28, who has a history of myoclonic jerks. Examination also revealed a diagnosis of ataxia. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient X28, who has a history of [E1]myoclonic jerks[/E1]. Examination also revealed a diagnosis of ataxia. The underlying cause was traced to a mutation in th[E2]e PO[/E2]LG gene.",e PO,GENE_VARIANT,173,177,myoclonic jerks,HPO_TERM,56,71,0.66628295,0.33371708,-0.33256587,0
line228,"We report the case of Patient X28, who has a history of myoclonic jerks. Examination also revealed a diagnosis of ataxia. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient X28, who has a history of myoclonic jerks. Examination also revealed [E1]a diagnosis of atax[/E1]ia. The underlying cause was traced to a mutation in th[E2]e PO[/E2]LG gene.",e PO,GENE_VARIANT,173,177,a diagnosis of atax,HPO_TERM,99,118,0.58829623,0.4117038,-0.17659244,0
line229,Patient X29 was evaluated for an increased CSF protein concentration. The patient also presented with a state of low muscle tone and problems with swallowing. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X29 was evaluated for [E1]an increased CSF protein concentra[/E1]tion. The patient also presented with a state of low muscle tone and problems with swallowing. Subsequent sequencing[E2] of [/E2]the POLG gene revealed a pathogenic variant., of ,GENE_VARIANT,180,184,an increased CSF protein concentra,HPO_TERM,30,64,0.8638551,0.13614485,-0.72771025,0
line229,Patient X29 was evaluated for an increased CSF protein concentration. The patient also presented with a state of low muscle tone and problems with swallowing. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X29 was evaluated for an increased CSF protein concentration. The patient also presented w[E1]ith a state of low muscl[/E1]e tone and problems with swallowing. Subsequent sequencing[E2] of [/E2]the POLG gene revealed a pathogenic variant., of ,GENE_VARIANT,180,184,ith a state of low muscl,HPO_TERM,98,122,0.86942863,0.13057144,-0.7388572,0
line229,Patient X29 was evaluated for an increased CSF protein concentration. The patient also presented with a state of low muscle tone and problems with swallowing. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X29 was evaluated for an increased CSF protein concentration. The patient also presented with a state of low muscle ton[E1]e and problems with sw[/E1]allowing. Subsequent sequencing[E2] of [/E2]the POLG gene revealed a pathogenic variant., of ,GENE_VARIANT,180,184,e and problems with sw,HPO_TERM,127,149,0.86167645,0.13832356,-0.7233529,0
line230,"We report the case of Patient X30, who has a history of difficulty swallowing. Examination also revealed a notable lack of muscle tone. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient X30, who has a history of [E1]difficulty swallowing[/E1]. Examination also revealed a notable lack of muscle tone. The underlying cause was traced to a mutation in the[E2] POL[/E2]G gene.", POL,GENE_VARIANT,188,192,difficulty swallowing,HPO_TERM,56,77,0.5071527,0.49284726,-0.014305413,0
line230,"We report the case of Patient X30, who has a history of difficulty swallowing. Examination also revealed a notable lack of muscle tone. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient X30, who has a history of difficulty swallowing. Examination also revealed [E1]a notable lack of muscle ton[/E1]e. The underlying cause was traced to a mutation in the[E2] POL[/E2]G gene.", POL,GENE_VARIANT,188,192,a notable lack of muscle ton,HPO_TERM,105,133,0.20898327,0.7910167,0.5820334,1
line231,The primary symptoms for Patient X31 were a sensation of food getting stuck and a complaint of dysphagia. Analysis of the POLG gene was performed.,The primary symptoms for Patient X31 were a [E1]sensation of food getting stuck [/E1]and a complaint of dysphagia. Analysis of the POLG ge[E2]ne w[/E2]as performed.,ne w,GENE_VARIANT,129,133,sensation of food getting stuck ,HPO_TERM,44,76,0.8047221,0.1952779,-0.60944414,0
line231,The primary symptoms for Patient X31 were a sensation of food getting stuck and a complaint of dysphagia. Analysis of the POLG gene was performed.,The primary symptoms for Patient X31 were a sensation of food getting stuck and a[E1] complaint of dysphagi[/E1]a. Analysis of the POLG ge[E2]ne w[/E2]as performed.,ne w,GENE_VARIANT,129,133, complaint of dysphagi,HPO_TERM,81,103,0.814124,0.18587604,-0.628248,0
line232,The clinical profile for Patient X32 includes a diagnosis of ataxia and an infantile onset. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient X32 includes [E1]a diagnosis of atax[/E1]ia and an infantile onset. Genetic analysis of t[E2]he P[/E2]OLG gene confirmed the diagnosis.,he P,GENE_VARIANT,113,117,a diagnosis of atax,HPO_TERM,46,65,0.85471684,0.14528318,-0.7094337,0
line232,The clinical profile for Patient X32 includes a diagnosis of ataxia and an infantile onset. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient X32 includes a diagnosis of ataxia an[E1]d an infantile on[/E1]set. Genetic analysis of t[E2]he P[/E2]OLG gene confirmed the diagnosis.,he P,GENE_VARIANT,113,117,d an infantile on,HPO_TERM,70,87,0.8647657,0.13523425,-0.72953147,0
line233,The clinical profile for Patient X33 includes a diagnosis of sensory axonal neuropathy and myoclonic jerks. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient X33 includes [E1]a diagnosis of sensory axonal neuropathy[/E1] and myoclonic jerks. Genetic analysis of the [E2]POLG[/E2] gene confirmed the diagnosis.,POLG,GENE_VARIANT,132,136,a diagnosis of sensory axonal neuropathy,HPO_TERM,46,86,0.8244586,0.17554143,-0.6489172,0
line233,The clinical profile for Patient X33 includes a diagnosis of sensory axonal neuropathy and myoclonic jerks. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient X33 includes a diagnosis of sensory axonal neuropathy and [E1]myoclonic jerks[/E1]. Genetic analysis of the [E2]POLG[/E2] gene confirmed the diagnosis.,POLG,GENE_VARIANT,132,136,myoclonic jerks,HPO_TERM,91,106,0.83195007,0.16804999,-0.6639001,0
line234,The primary symptoms for Patient X34 were a diagnosis of ataxia and EMG: myopathic abnormalities. Analysis of the POLG gene was performed.,The primary symptoms for Patient X34 were a [E1]diagnosis of ataxia[/E1] and EMG: myopathic abnormalities. Analysis of the POLG gen[E2]e wa[/E2]s performed.,e wa,GENE_VARIANT,122,126,diagnosis of ataxia,HPO_TERM,44,63,0.8333151,0.16668487,-0.6666302,0
line234,The primary symptoms for Patient X34 were a diagnosis of ataxia and EMG: myopathic abnormalities. Analysis of the POLG gene was performed.,The primary symptoms for Patient X34 were a diagnosis of ataxia and [E1]EMG: myopathic abnormalities[/E1]. Analysis of the POLG gen[E2]e wa[/E2]s performed.,e wa,GENE_VARIANT,122,126,EMG: myopathic abnormalities,HPO_TERM,68,96,0.8454905,0.15450945,-0.69098103,0
line235,Patient X35 was evaluated for a lack of voluntary coordination of muscle movements. The patient also presented with myoclonic jerks and a state of low muscle tone. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X35 was evaluated for [E1]a lack of voluntary coordination of muscle movement[/E1]s. The patient also presented with myoclonic jerks and a state of low muscle tone. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,190,194,a lack of voluntary coordination of muscle movement,HPO_TERM,30,81,0.85773957,0.14226042,-0.71547914,0
line235,Patient X35 was evaluated for a lack of voluntary coordination of muscle movements. The patient also presented with myoclonic jerks and a state of low muscle tone. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X35 was evaluated for a lack of voluntary coordination of muscle movements. The patient also presented with[E1] myoclonic jerk[/E1]s and a state of low muscle tone. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,190,194, myoclonic jerk,HPO_TERM,115,130,0.85904807,0.1409519,-0.71809614,0
line235,Patient X35 was evaluated for a lack of voluntary coordination of muscle movements. The patient also presented with myoclonic jerks and a state of low muscle tone. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X35 was evaluated for a lack of voluntary coordination of muscle movements. The patient also presented with myoclonic jerks and[E1] a state of low muscle t[/E1]one. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,190,194, a state of low muscle t,HPO_TERM,135,159,0.8646315,0.13536854,-0.72926295,0
line236,The primary symptoms for Patient X36 were an increased CSF protein concentration and a lack of voluntary coordination of muscle movements. Analysis of the POLG gene was performed.,The primary symptoms for Patient X36 were an[E1] increased CSF protein concentrati[/E1]on and a lack of voluntary coordination of muscle movements. Analysis of the POLG [E2]gene[/E2] was performed.,gene,GENE_VARIANT,160,164, increased CSF protein concentrati,HPO_TERM,44,78,0.824283,0.17571695,-0.64856607,0
line236,The primary symptoms for Patient X36 were an increased CSF protein concentration and a lack of voluntary coordination of muscle movements. Analysis of the POLG gene was performed.,The primary symptoms for Patient X36 were an increased CSF protein concentration an[E1]d a lack of voluntary coordination of muscle moveme[/E1]nts. Analysis of the POLG [E2]gene[/E2] was performed.,gene,GENE_VARIANT,160,164,d a lack of voluntary coordination of muscle moveme,HPO_TERM,83,134,0.8322941,0.1677059,-0.6645882,0
line237,"We report the case of Patient X37, who has a history of myoclonic seizures. Examination also revealed ragged-red fibers on muscle biopsy. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient X37, who has a history of [E1]myoclonic seizure[/E1]s. Examination also revealed ragged-red fibers on muscle biopsy. The underlying cause was traced to a mutation in the[E2] POL[/E2]G gene.", POL,GENE_VARIANT,190,194,myoclonic seizure,HPO_TERM,56,73,0.49800825,0.50199175,0.0039834976,1
line237,"We report the case of Patient X37, who has a history of myoclonic seizures. Examination also revealed ragged-red fibers on muscle biopsy. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient X37, who has a history of myoclonic seizures. Examination also revealed[E1] ragged-red fibers on muscle biops[/E1]y. The underlying cause was traced to a mutation in the[E2] POL[/E2]G gene.", POL,GENE_VARIANT,190,194, ragged-red fibers on muscle biops,HPO_TERM,101,135,0.5058552,0.4941448,-0.011710405,0
line238,The clinical profile for Patient X38 includes a complaint of dysphagia and an infantile onset. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient X38 includes [E1]a complaint of dysphag[/E1]ia and an infantile onset. Genetic analysis of t[E2]he P[/E2]OLG gene confirmed the diagnosis.,he P,GENE_VARIANT,116,120,a complaint of dysphag,HPO_TERM,46,68,0.84311837,0.1568816,-0.68623674,0
line238,The clinical profile for Patient X38 includes a complaint of dysphagia and an infantile onset. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient X38 includes a complaint of dysphagia an[E1]d an infantile on[/E1]set. Genetic analysis of t[E2]he P[/E2]OLG gene confirmed the diagnosis.,he P,GENE_VARIANT,116,120,d an infantile on,HPO_TERM,73,90,0.8526966,0.14730346,-0.70539314,0
line239,"This report details Patient X39, a patient with a lack of voluntary coordination of muscle movements. Further investigation showed myoclonic jerks and problems with balance and coordination. A known variant in the POLG gene was identified.","This report details Patient X39, a patient with [E1]a lack of voluntary coordination of muscle movement[/E1]s. Further investigation showed myoclonic jerks and problems with balance and coordination. A known variant i[E2]n th[/E2]e POLG gene was identified.",n th,GENE_VARIANT,208,212,a lack of voluntary coordination of muscle movement,HPO_TERM,48,99,0.8222442,0.17775579,-0.64448845,0
line239,"This report details Patient X39, a patient with a lack of voluntary coordination of muscle movements. Further investigation showed myoclonic jerks and problems with balance and coordination. A known variant in the POLG gene was identified.","This report details Patient X39, a patient with a lack of voluntary coordination of muscle movements. Further investigation showed[E1] myoclonic jerk[/E1]s and problems with balance and coordination. A known variant i[E2]n th[/E2]e POLG gene was identified.",n th,GENE_VARIANT,208,212, myoclonic jerk,HPO_TERM,130,145,0.82344735,0.17655267,-0.6468947,0
line239,"This report details Patient X39, a patient with a lack of voluntary coordination of muscle movements. Further investigation showed myoclonic jerks and problems with balance and coordination. A known variant in the POLG gene was identified.","This report details Patient X39, a patient with a lack of voluntary coordination of muscle movements. Further investigation showed myoclonic jerks and[E1] problems with balance and coordin[/E1]ation. A known variant i[E2]n th[/E2]e POLG gene was identified.",n th,GENE_VARIANT,208,212, problems with balance and coordin,HPO_TERM,150,184,0.80866766,0.19133233,-0.6173353,0
line240,The clinical profile for Patient X40 includes problems with swallowing and EMG results showing myopathic abnormalities. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient X40 includes [E1]problems with swallowi[/E1]ng and EMG results showing myopathic abnormalities. Genetic analysis of[E2] the[/E2] POLG gene confirmed the diagnosis., the,GENE_VARIANT,139,143,problems with swallowi,HPO_TERM,46,68,0.86885166,0.13114838,-0.73770326,0
line240,The clinical profile for Patient X40 includes problems with swallowing and EMG results showing myopathic abnormalities. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient X40 includes problems with swallowing an[E1]d EMG results showing myopathic abnormal[/E1]ities. Genetic analysis of[E2] the[/E2] POLG gene confirmed the diagnosis., the,GENE_VARIANT,139,143,d EMG results showing myopathic abnormal,HPO_TERM,73,113,0.8641027,0.1358973,-0.72820544,0
line241,"This report details Patient X41, a patient with a presentation in infancy. Further investigation showed a diagnosis of external ophthalmoplegia and a diagnosis of ataxia. A known variant in the POLG gene was identified.","This report details Patient X41, a patient with [E1]a presentation in infancy[/E1]. Further investigation showed a diagnosis of external ophthalmoplegia and a diagnosis of ataxia. A known variant in[E2] the[/E2] POLG gene was identified.", the,GENE_VARIANT,189,193,a presentation in infancy,HPO_TERM,48,73,0.80895853,0.19104144,-0.61791706,0
line241,"This report details Patient X41, a patient with a presentation in infancy. Further investigation showed a diagnosis of external ophthalmoplegia and a diagnosis of ataxia. A known variant in the POLG gene was identified.","This report details Patient X41, a patient with a presentation in infancy. Further investigation showed [E1]a diagnosis of external ophthalmopleg[/E1]ia and a diagnosis of ataxia. A known variant in[E2] the[/E2] POLG gene was identified.", the,GENE_VARIANT,189,193,a diagnosis of external ophthalmopleg,HPO_TERM,104,141,0.82277846,0.1772215,-0.6455569,0
line241,"This report details Patient X41, a patient with a presentation in infancy. Further investigation showed a diagnosis of external ophthalmoplegia and a diagnosis of ataxia. A known variant in the POLG gene was identified.","This report details Patient X41, a patient with a presentation in infancy. Further investigation showed a diagnosis of external ophthalmoplegia an[E1]d a diagnosis of at[/E1]axia. A known variant in[E2] the[/E2] POLG gene was identified.", the,GENE_VARIANT,189,193,d a diagnosis of at,HPO_TERM,146,165,0.8035011,0.19649892,-0.6070022,0
line242,"We report the case of Patient X42, who has a history of a diagnosis of external ophthalmoplegia. Examination also revealed problems with balance and coordination. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient X42, who has a history of [E1]a diagnosis of external ophthalmopleg[/E1]ia. Examination also revealed problems with balance and coordination. The underlying cause was traced to a mutation i[E2]n th[/E2]e POLG gene.",n th,GENE_VARIANT,210,214,a diagnosis of external ophthalmopleg,HPO_TERM,56,93,0.75399303,0.24600703,-0.507986,0
line242,"We report the case of Patient X42, who has a history of a diagnosis of external ophthalmoplegia. Examination also revealed problems with balance and coordination. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient X42, who has a history of a diagnosis of external ophthalmoplegia. Examination also reveale[E1]d problems with balance and coordi[/E1]nation. The underlying cause was traced to a mutation i[E2]n th[/E2]e POLG gene.",n th,GENE_VARIANT,210,214,d problems with balance and coordi,HPO_TERM,121,155,0.6944793,0.30552077,-0.3889585,0
line243,"We report the case of Patient X43, who has a history of an infantile onset. Examination also revealed a state of low muscle tone. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient X43, who has a history of [E1]an infantile onse[/E1]t. Examination also revealed a state of low muscle tone. The underlying cause was traced to a mutation in t[E2]he P[/E2]OLG gene.",he P,GENE_VARIANT,180,184,an infantile onse,HPO_TERM,56,73,0.51018065,0.4898193,-0.020361364,0
line243,"We report the case of Patient X43, who has a history of an infantile onset. Examination also revealed a state of low muscle tone. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient X43, who has a history of an infantile onset. Examination also revealed[E1] a state of low muscle t[/E1]one. The underlying cause was traced to a mutation in t[E2]he P[/E2]OLG gene.",he P,GENE_VARIANT,180,184, a state of low muscle t,HPO_TERM,101,125,0.6072482,0.39275175,-0.21449643,0
line244,The primary symptoms for Patient X44 were a complaint of dysphagia and problems with balance and coordination. Analysis of the POLG gene was performed.,The primary symptoms for Patient X44 were a [E1]complaint of dysphagia[/E1] and problems with balance and coordination. Analysis of the POLG[E2] gen[/E2]e was performed., gen,GENE_VARIANT,131,135,complaint of dysphagia,HPO_TERM,44,66,0.8040276,0.19597246,-0.6080552,0
line244,The primary symptoms for Patient X44 were a complaint of dysphagia and problems with balance and coordination. Analysis of the POLG gene was performed.,The primary symptoms for Patient X44 were a complaint of dysphagia and [E1]problems with balance and coordina[/E1]tion. Analysis of the POLG[E2] gen[/E2]e was performed., gen,GENE_VARIANT,131,135,problems with balance and coordina,HPO_TERM,71,105,0.79990876,0.20009118,-0.5998176,0
line245,"We report the case of Patient X45, who has a history of an increased CSF protein concentration. Examination also revealed problems with swallowing. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient X45, who has a history of [E1]an increased CSF protein concentra[/E1]tion. Examination also revealed problems with swallowing. The underlying cause was traced to a mutation i[E2]n th[/E2]e POLG gene.",n th,GENE_VARIANT,195,199,an increased CSF protein concentra,HPO_TERM,56,90,0.78191984,0.21808015,-0.5638397,0
line245,"We report the case of Patient X45, who has a history of an increased CSF protein concentration. Examination also revealed problems with swallowing. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient X45, who has a history of an increased CSF protein concentration. Examination also revea[E1]led problems with swal[/E1]lowing. The underlying cause was traced to a mutation i[E2]n th[/E2]e POLG gene.",n th,GENE_VARIANT,195,199,led problems with swal,HPO_TERM,118,140,0.74118,0.25882,-0.48236,0
line246,The clinical profile for Patient X46 includes a complaint of dysphagia and myoclonic jerks. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient X46 includes [E1]a complaint of dysphag[/E1]ia and myoclonic jerks. Genetic analysis of th[E2]e PO[/E2]LG gene confirmed the diagnosis.,e PO,GENE_VARIANT,114,118,a complaint of dysphag,HPO_TERM,46,68,0.8600472,0.1399528,-0.72009444,0
line246,The clinical profile for Patient X46 includes a complaint of dysphagia and myoclonic jerks. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient X46 includes a complaint of dysphagia an[E1]d myoclonic jer[/E1]ks. Genetic analysis of th[E2]e PO[/E2]LG gene confirmed the diagnosis.,e PO,GENE_VARIANT,114,118,d myoclonic jer,HPO_TERM,73,88,0.8636989,0.13630116,-0.72739774,0
line247,Patient X47 was evaluated for choking or coughing while eating. The patient also presented with a lack of voluntary coordination of muscle movements and a complaint of dysphagia. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X47 was evaluated for [E1]choking or coughing while eati[/E1]ng. The patient also presented with a lack of voluntary coordination of muscle movements and a complaint of dysphagia. Subsequent sequencing of[E2] the[/E2] POLG gene revealed a pathogenic variant., the,GENE_VARIANT,203,207,choking or coughing while eati,HPO_TERM,30,60,0.8240784,0.1759216,-0.64815676,0
line247,Patient X47 was evaluated for choking or coughing while eating. The patient also presented with a lack of voluntary coordination of muscle movements and a complaint of dysphagia. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X47 was evaluated for choking or coughing while eating. The patient also presented wit[E1]h a lack of voluntary coordination of muscle moveme[/E1]nts and a complaint of dysphagia. Subsequent sequencing of[E2] the[/E2] POLG gene revealed a pathogenic variant., the,GENE_VARIANT,203,207,h a lack of voluntary coordination of muscle moveme,HPO_TERM,94,145,0.8273221,0.17267786,-0.65464425,0
line247,Patient X47 was evaluated for choking or coughing while eating. The patient also presented with a lack of voluntary coordination of muscle movements and a complaint of dysphagia. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X47 was evaluated for choking or coughing while eating. The patient also presented with a lack of voluntary coordination of muscle movements a[E1]nd a complaint of dysp[/E1]hagia. Subsequent sequencing of[E2] the[/E2] POLG gene revealed a pathogenic variant., the,GENE_VARIANT,203,207,nd a complaint of dysp,HPO_TERM,150,172,0.8172387,0.18276125,-0.63447744,0
line248,Patient X48 was evaluated for myoclonic seizures. The patient also presented with a diagnosis of external ophthalmoplegia and problems with balance and coordination. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X48 was evaluated for [E1]myoclonic seizure[/E1]s. The patient also presented with a diagnosis of external ophthalmoplegia and problems with balance and coordination. Subsequent sequencing [E2]of t[/E2]he POLG gene revealed a pathogenic variant.,of t,GENE_VARIANT,188,192,myoclonic seizure,HPO_TERM,30,47,0.8484272,0.15157287,-0.6968543,0
line248,Patient X48 was evaluated for myoclonic seizures. The patient also presented with a diagnosis of external ophthalmoplegia and problems with balance and coordination. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X48 was evaluated for myoclonic seizures. The patient also presented with[E1] a diagnosis of external ophthalmople[/E1]gia and problems with balance and coordination. Subsequent sequencing [E2]of t[/E2]he POLG gene revealed a pathogenic variant.,of t,GENE_VARIANT,188,192, a diagnosis of external ophthalmople,HPO_TERM,81,118,0.8141377,0.18586229,-0.6282754,0
line248,Patient X48 was evaluated for myoclonic seizures. The patient also presented with a diagnosis of external ophthalmoplegia and problems with balance and coordination. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X48 was evaluated for myoclonic seizures. The patient also presented with a diagnosis of external ophthalmoplegia a[E1]nd problems with balance and coord[/E1]ination. Subsequent sequencing [E2]of t[/E2]he POLG gene revealed a pathogenic variant.,of t,GENE_VARIANT,188,192,nd problems with balance and coord,HPO_TERM,123,157,0.8353014,0.16469862,-0.6706028,0
line249,The primary symptoms for Patient X49 were problems with balance and coordination and a condition affecting eye movement. Analysis of the POLG gene was performed.,The primary symptoms for Patient X49 were pr[E1]oblems with balance and coordinati[/E1]on and a condition affecting eye movement. Analysis of the POLG [E2]gene[/E2] was performed.,gene,GENE_VARIANT,142,146,oblems with balance and coordinati,HPO_TERM,44,78,0.8013882,0.19861175,-0.60277647,0
line249,The primary symptoms for Patient X49 were problems with balance and coordination and a condition affecting eye movement. Analysis of the POLG gene was performed.,The primary symptoms for Patient X49 were problems with balance and coordination an[E1]d a condition affecting eye movem[/E1]ent. Analysis of the POLG [E2]gene[/E2] was performed.,gene,GENE_VARIANT,142,146,d a condition affecting eye movem,HPO_TERM,83,116,0.81484735,0.18515271,-0.62969464,0
line250,The primary symptoms for Patient X50 were myoclonic seizures and an increased CSF protein concentration. Analysis of the POLG gene was performed.,The primary symptoms for Patient X50 were my[E1]oclonic seizures [/E1]and an increased CSF protein concentration. Analysis of the POLG [E2]gene[/E2] was performed.,gene,GENE_VARIANT,126,130,oclonic seizures ,HPO_TERM,44,61,0.81936854,0.18063146,-0.6387371,0
line250,The primary symptoms for Patient X50 were myoclonic seizures and an increased CSF protein concentration. Analysis of the POLG gene was performed.,The primary symptoms for Patient X50 were myoclonic seizures and a[E1]n increased CSF protein concentrat[/E1]ion. Analysis of the POLG [E2]gene[/E2] was performed.,gene,GENE_VARIANT,126,130,n increased CSF protein concentrat,HPO_TERM,66,100,0.8242311,0.17576885,-0.64846224,0
line251,"We report the case of Patient X51, who has a history of an infantile onset. Examination also revealed a state of low muscle tone. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient X51, who has a history of [E1]an infantile onse[/E1]t. Examination also revealed a state of low muscle tone. The underlying cause was traced to a mutation in t[E2]he P[/E2]OLG gene.",he P,GENE_VARIANT,180,184,an infantile onse,HPO_TERM,56,73,0.50023127,0.49976873,-0.00046253204,0
line251,"We report the case of Patient X51, who has a history of an infantile onset. Examination also revealed a state of low muscle tone. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient X51, who has a history of an infantile onset. Examination also revealed[E1] a state of low muscle t[/E1]one. The underlying cause was traced to a mutation in t[E2]he P[/E2]OLG gene.",he P,GENE_VARIANT,180,184, a state of low muscle t,HPO_TERM,101,125,0.5979581,0.40204188,-0.1959162,0
line252,Patient X52 was evaluated for a lack of voluntary coordination of muscle movements. The patient also presented with an increased CSF protein concentration and myoclonic jerks. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X52 was evaluated for [E1]a lack of voluntary coordination of muscle movement[/E1]s. The patient also presented with an increased CSF protein concentration and myoclonic jerks. Subsequent sequencing of[E2] the[/E2] POLG gene revealed a pathogenic variant., the,GENE_VARIANT,200,204,a lack of voluntary coordination of muscle movement,HPO_TERM,30,81,0.819517,0.18048303,-0.639034,0
line252,Patient X52 was evaluated for a lack of voluntary coordination of muscle movements. The patient also presented with an increased CSF protein concentration and myoclonic jerks. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X52 was evaluated for a lack of voluntary coordination of muscle movements. The patient also presented with[E1] an increased CSF protein concentr[/E1]ation and myoclonic jerks. Subsequent sequencing of[E2] the[/E2] POLG gene revealed a pathogenic variant., the,GENE_VARIANT,200,204, an increased CSF protein concentr,HPO_TERM,115,149,0.8075415,0.19245851,-0.615083,0
line252,Patient X52 was evaluated for a lack of voluntary coordination of muscle movements. The patient also presented with an increased CSF protein concentration and myoclonic jerks. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X52 was evaluated for a lack of voluntary coordination of muscle movements. The patient also presented with an increased CSF protein concentration[E1] and myoclonic [/E1]jerks. Subsequent sequencing of[E2] the[/E2] POLG gene revealed a pathogenic variant., the,GENE_VARIANT,200,204, and myoclonic ,HPO_TERM,154,169,0.8098021,0.19019791,-0.61960423,0
line253,The clinical profile for Patient X53 includes paralysis of the external eye muscles and ragged-red fibers on muscle biopsy. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient X53 includes [E1]paralysis of the external eye muscl[/E1]es and ragged-red fibers on muscle biopsy. Genetic analysis of th[E2]e PO[/E2]LG gene confirmed the diagnosis.,e PO,GENE_VARIANT,146,150,paralysis of the external eye muscl,HPO_TERM,46,81,0.84562486,0.15437514,-0.6912497,0
line253,The clinical profile for Patient X53 includes paralysis of the external eye muscles and ragged-red fibers on muscle biopsy. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient X53 includes paralysis of the external eye muscles an[E1]d ragged-red fibers on muscle biop[/E1]sy. Genetic analysis of th[E2]e PO[/E2]LG gene confirmed the diagnosis.,e PO,GENE_VARIANT,146,150,d ragged-red fibers on muscle biop,HPO_TERM,86,120,0.8607728,0.13922714,-0.72154564,0
line254,"We report the case of Patient X54, who has a history of a diagnosis of external ophthalmoplegia. Examination also revealed myoclonic seizures. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient X54, who has a history of [E1]a diagnosis of external ophthalmopleg[/E1]ia. Examination also revealed myoclonic seizures. The underlying cause was traced to a mutation in t[E2]he P[/E2]OLG gene.",he P,GENE_VARIANT,193,197,a diagnosis of external ophthalmopleg,HPO_TERM,56,93,0.6696013,0.3303987,-0.3392026,0
line254,"We report the case of Patient X54, who has a history of a diagnosis of external ophthalmoplegia. Examination also revealed myoclonic seizures. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient X54, who has a history of a diagnosis of external ophthalmoplegia. Examination also reveale[E1]d myoclonic seizu[/E1]res. The underlying cause was traced to a mutation in t[E2]he P[/E2]OLG gene.",he P,GENE_VARIANT,193,197,d myoclonic seizu,HPO_TERM,121,138,0.47424722,0.5257527,0.051505506,1
line255,The primary symptoms for Patient X55 were a diagnosis of ataxia and an increased CSF protein concentration. Analysis of the POLG gene was performed.,The primary symptoms for Patient X55 were a [E1]diagnosis of ataxia[/E1] and an increased CSF protein concentration. Analysis of the POLG[E2] gen[/E2]e was performed., gen,GENE_VARIANT,128,132,diagnosis of ataxia,HPO_TERM,44,63,0.85803103,0.14196903,-0.716062,0
line255,The primary symptoms for Patient X55 were a diagnosis of ataxia and an increased CSF protein concentration. Analysis of the POLG gene was performed.,The primary symptoms for Patient X55 were a diagnosis of ataxia and [E1]an increased CSF protein concentra[/E1]tion. Analysis of the POLG[E2] gen[/E2]e was performed., gen,GENE_VARIANT,128,132,an increased CSF protein concentra,HPO_TERM,68,102,0.8616591,0.13834096,-0.72331816,0
line256,The clinical profile for Patient X56 includes a diagnosis of ataxia and a diagnosis of external ophthalmoplegia. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient X56 includes [E1]a diagnosis of atax[/E1]ia and a diagnosis of external ophthalmoplegia. Genetic analysis of [E2]the [/E2]POLG gene confirmed the diagnosis.,the ,GENE_VARIANT,133,137,a diagnosis of atax,HPO_TERM,46,65,0.8521855,0.1478145,-0.704371,0
line256,The clinical profile for Patient X56 includes a diagnosis of ataxia and a diagnosis of external ophthalmoplegia. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient X56 includes a diagnosis of ataxia an[E1]d a diagnosis of external ophthalmopl[/E1]egia. Genetic analysis of [E2]the [/E2]POLG gene confirmed the diagnosis.,the ,GENE_VARIANT,133,137,d a diagnosis of external ophthalmopl,HPO_TERM,70,107,0.84968364,0.15031636,-0.6993673,0
line257,"This report details Patient X57, a patient with a diagnosis of external ophthalmoplegia. Further investigation showed myoclonic jerks and an infantile onset. A known variant in the POLG gene was identified.","This report details Patient X57, a patient with [E1]a diagnosis of external ophthalmopleg[/E1]ia. Further investigation showed myoclonic jerks and an infantile onset. A known variant in [E2]the [/E2]POLG gene was identified.",the ,GENE_VARIANT,177,181,a diagnosis of external ophthalmopleg,HPO_TERM,48,85,0.7882119,0.21178812,-0.57642376,0
line257,"This report details Patient X57, a patient with a diagnosis of external ophthalmoplegia. Further investigation showed myoclonic jerks and an infantile onset. A known variant in the POLG gene was identified.","This report details Patient X57, a patient with a diagnosis of external ophthalmoplegia. Further investigation showe[E1]d myoclonic jer[/E1]ks and an infantile onset. A known variant in [E2]the [/E2]POLG gene was identified.",the ,GENE_VARIANT,177,181,d myoclonic jer,HPO_TERM,116,131,0.7990277,0.20097235,-0.59805536,0
line257,"This report details Patient X57, a patient with a diagnosis of external ophthalmoplegia. Further investigation showed myoclonic jerks and an infantile onset. A known variant in the POLG gene was identified.","This report details Patient X57, a patient with a diagnosis of external ophthalmoplegia. Further investigation showed myoclonic jerks an[E1]d an infantile on[/E1]set. A known variant in [E2]the [/E2]POLG gene was identified.",the ,GENE_VARIANT,177,181,d an infantile on,HPO_TERM,136,153,0.78003234,0.21996771,-0.5600646,0
line258,"We report the case of Patient X58, who has a history of a state of low muscle tone. Examination also revealed myoclonic seizures. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient X58, who has a history of [E1]a state of low muscle to[/E1]ne. Examination also revealed myoclonic seizures. The underlying cause was traced to a mutation in t[E2]he P[/E2]OLG gene.",he P,GENE_VARIANT,180,184,a state of low muscle to,HPO_TERM,56,80,0.50958,0.49042,-0.019160002,0
line258,"We report the case of Patient X58, who has a history of a state of low muscle tone. Examination also revealed myoclonic seizures. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient X58, who has a history of a state of low muscle tone. Examination also reveale[E1]d myoclonic seizu[/E1]res. The underlying cause was traced to a mutation in t[E2]he P[/E2]OLG gene.",he P,GENE_VARIANT,180,184,d myoclonic seizu,HPO_TERM,108,125,0.34684148,0.65315855,0.30631706,1
line259,Patient X59 was evaluated for ataxia. The patient also presented with a state of low muscle tone and problems with balance and coordination. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X59 was evaluated for [E1]ataxia[/E1]. The patient also presented with a state of low muscle tone and problems with balance and coordination. Subsequent sequencing o[E2]f th[/E2]e POLG gene revealed a pathogenic variant.,f th,GENE_VARIANT,164,168,ataxia,HPO_TERM,30,36,0.85125077,0.14874928,-0.7025015,0
line259,Patient X59 was evaluated for ataxia. The patient also presented with a state of low muscle tone and problems with balance and coordination. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X59 was evaluated for ataxia. The patient also presented with [E1]a state of low muscle to[/E1]ne and problems with balance and coordination. Subsequent sequencing o[E2]f th[/E2]e POLG gene revealed a pathogenic variant.,f th,GENE_VARIANT,164,168,a state of low muscle to,HPO_TERM,70,94,0.83646935,0.16353068,-0.6729387,0
line259,Patient X59 was evaluated for ataxia. The patient also presented with a state of low muscle tone and problems with balance and coordination. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X59 was evaluated for ataxia. The patient also presented with a state of low muscle tone an[E1]d problems with balance and coordi[/E1]nation. Subsequent sequencing o[E2]f th[/E2]e POLG gene revealed a pathogenic variant.,f th,GENE_VARIANT,164,168,d problems with balance and coordi,HPO_TERM,99,133,0.8412773,0.15872271,-0.6825546,0
line260,Patient X60 was evaluated for myoclonic jerks. The patient also presented with problems with balance and coordination and a lack of voluntary coordination of muscle movements. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X60 was evaluated for [E1]myoclonic jerks[/E1]. The patient also presented with problems with balance and coordination and a lack of voluntary coordination of muscle movements. Subsequent sequencing of[E2] the[/E2] POLG gene revealed a pathogenic variant., the,GENE_VARIANT,200,204,myoclonic jerks,HPO_TERM,30,45,0.8197672,0.18023281,-0.63953435,0
line260,Patient X60 was evaluated for myoclonic jerks. The patient also presented with problems with balance and coordination and a lack of voluntary coordination of muscle movements. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X60 was evaluated for myoclonic jerks. The patient also presented with [E1]problems with balance and coordina[/E1]tion and a lack of voluntary coordination of muscle movements. Subsequent sequencing of[E2] the[/E2] POLG gene revealed a pathogenic variant., the,GENE_VARIANT,200,204,problems with balance and coordina,HPO_TERM,79,113,0.79872596,0.20127407,-0.5974519,0
line260,Patient X60 was evaluated for myoclonic jerks. The patient also presented with problems with balance and coordination and a lack of voluntary coordination of muscle movements. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X60 was evaluated for myoclonic jerks. The patient also presented with problems with balance and coordination [E1]and a lack of voluntary coordination of muscle move[/E1]ments. Subsequent sequencing of[E2] the[/E2] POLG gene revealed a pathogenic variant., the,GENE_VARIANT,200,204,and a lack of voluntary coordination of muscle move,HPO_TERM,118,169,0.8168406,0.18315944,-0.6336812,0
line261,"This report details Patient X61, a patient with myoclonic jerks. Further investigation showed a presentation in infancy and EMG: myopathic abnormalities. A known variant in the POLG gene was identified.","This report details Patient X61, a patient with [E1]myoclonic jerks[/E1]. Further investigation showed a presentation in infancy and EMG: myopathic abnormalities. A known variant in the[E2] POL[/E2]G gene was identified.", POL,GENE_VARIANT,176,180,myoclonic jerks,HPO_TERM,48,63,0.80251044,0.19748957,-0.6050209,0
line261,"This report details Patient X61, a patient with myoclonic jerks. Further investigation showed a presentation in infancy and EMG: myopathic abnormalities. A known variant in the POLG gene was identified.","This report details Patient X61, a patient with myoclonic jerks. Further investigation showed [E1]a presentation in infancy[/E1] and EMG: myopathic abnormalities. A known variant in the[E2] POL[/E2]G gene was identified.", POL,GENE_VARIANT,176,180,a presentation in infancy,HPO_TERM,94,119,0.81115216,0.18884784,-0.6223043,0
line261,"This report details Patient X61, a patient with myoclonic jerks. Further investigation showed a presentation in infancy and EMG: myopathic abnormalities. A known variant in the POLG gene was identified.","This report details Patient X61, a patient with myoclonic jerks. Further investigation showed a presentation in infancy and [E1]EMG: myopathic abnormalities[/E1]. A known variant in the[E2] POL[/E2]G gene was identified.", POL,GENE_VARIANT,176,180,EMG: myopathic abnormalities,HPO_TERM,124,152,0.8210658,0.17893425,-0.64213157,0
line262,Patient X62 was evaluated for an infantile onset. The patient also presented with a complaint of dysphagia and problems with balance and coordination. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X62 was evaluated for [E1]an infantile onse[/E1]t. The patient also presented with a complaint of dysphagia and problems with balance and coordination. Subsequent sequencing [E2]of t[/E2]he POLG gene revealed a pathogenic variant.,of t,GENE_VARIANT,173,177,an infantile onse,HPO_TERM,30,47,0.8499398,0.15006015,-0.69987965,0
line262,Patient X62 was evaluated for an infantile onset. The patient also presented with a complaint of dysphagia and problems with balance and coordination. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X62 was evaluated for an infantile onset. The patient also presented with[E1] a complaint of dyspha[/E1]gia and problems with balance and coordination. Subsequent sequencing [E2]of t[/E2]he POLG gene revealed a pathogenic variant.,of t,GENE_VARIANT,173,177, a complaint of dyspha,HPO_TERM,81,103,0.77845645,0.2215435,-0.55691296,0
line262,Patient X62 was evaluated for an infantile onset. The patient also presented with a complaint of dysphagia and problems with balance and coordination. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X62 was evaluated for an infantile onset. The patient also presented with a complaint of dysphagia a[E1]nd problems with balance and coord[/E1]ination. Subsequent sequencing [E2]of t[/E2]he POLG gene revealed a pathogenic variant.,of t,GENE_VARIANT,173,177,nd problems with balance and coord,HPO_TERM,108,142,0.79873824,0.20126173,-0.5974765,0
line263,Patient X63 was evaluated for an increased CSF protein concentration. The patient also presented with a lack of voluntary coordination of muscle movements and a complaint of dysphagia. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X63 was evaluated for [E1]an increased CSF protein concentra[/E1]tion. The patient also presented with a lack of voluntary coordination of muscle movements and a complaint of dysphagia. Subsequent sequencing [E2]of t[/E2]he POLG gene revealed a pathogenic variant.,of t,GENE_VARIANT,207,211,an increased CSF protein concentra,HPO_TERM,30,64,0.8548169,0.14518309,-0.7096338,0
line263,Patient X63 was evaluated for an increased CSF protein concentration. The patient also presented with a lack of voluntary coordination of muscle movements and a complaint of dysphagia. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X63 was evaluated for an increased CSF protein concentration. The patient also presented w[E1]ith a lack of voluntary coordination of muscle move[/E1]ments and a complaint of dysphagia. Subsequent sequencing [E2]of t[/E2]he POLG gene revealed a pathogenic variant.,of t,GENE_VARIANT,207,211,ith a lack of voluntary coordination of muscle move,HPO_TERM,98,149,0.85476166,0.14523835,-0.7095233,0
line263,Patient X63 was evaluated for an increased CSF protein concentration. The patient also presented with a lack of voluntary coordination of muscle movements and a complaint of dysphagia. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X63 was evaluated for an increased CSF protein concentration. The patient also presented with a lack of voluntary coordination of muscle movements[E1] and a complaint of dy[/E1]sphagia. Subsequent sequencing [E2]of t[/E2]he POLG gene revealed a pathogenic variant.,of t,GENE_VARIANT,207,211, and a complaint of dy,HPO_TERM,154,176,0.8449446,0.15505539,-0.6898892,0
line264,The primary symptoms for Patient X64 were myoclonic seizures and a state of low muscle tone. Analysis of the POLG gene was performed.,The primary symptoms for Patient X64 were my[E1]oclonic seizures [/E1]and a state of low muscle tone. Analysis of the POLG ge[E2]ne w[/E2]as performed.,ne w,GENE_VARIANT,116,120,oclonic seizures ,HPO_TERM,44,61,0.80071014,0.1992898,-0.60142034,0
line264,The primary symptoms for Patient X64 were myoclonic seizures and a state of low muscle tone. Analysis of the POLG gene was performed.,The primary symptoms for Patient X64 were myoclonic seizures and a[E1] state of low muscle ton[/E1]e. Analysis of the POLG ge[E2]ne w[/E2]as performed.,ne w,GENE_VARIANT,116,120, state of low muscle ton,HPO_TERM,66,90,0.83171415,0.16828589,-0.66342825,0
line265,Patient X65 was evaluated for choking or coughing while eating. The patient also presented with a complaint of dysphagia and a state of low muscle tone. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X65 was evaluated for [E1]choking or coughing while eati[/E1]ng. The patient also presented with a complaint of dysphagia and a state of low muscle tone. Subsequent sequencing o[E2]f th[/E2]e POLG gene revealed a pathogenic variant.,f th,GENE_VARIANT,176,180,choking or coughing while eati,HPO_TERM,30,60,0.84650797,0.15349196,-0.693016,0
line265,Patient X65 was evaluated for choking or coughing while eating. The patient also presented with a complaint of dysphagia and a state of low muscle tone. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X65 was evaluated for choking or coughing while eating. The patient also presented wit[E1]h a complaint of dysph[/E1]agia and a state of low muscle tone. Subsequent sequencing o[E2]f th[/E2]e POLG gene revealed a pathogenic variant.,f th,GENE_VARIANT,176,180,h a complaint of dysph,HPO_TERM,94,116,0.84882736,0.15117258,-0.6976548,0
line265,Patient X65 was evaluated for choking or coughing while eating. The patient also presented with a complaint of dysphagia and a state of low muscle tone. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X65 was evaluated for choking or coughing while eating. The patient also presented with a complaint of dysphagia [E1]and a state of low muscl[/E1]e tone. Subsequent sequencing o[E2]f th[/E2]e POLG gene revealed a pathogenic variant.,f th,GENE_VARIANT,176,180,and a state of low muscl,HPO_TERM,121,145,0.818413,0.18158697,-0.63682604,0
line266,"We report the case of Patient X66, who has a history of problems with swallowing. Examination also revealed myoclonic jerks. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient X66, who has a history of [E1]problems with swallowi[/E1]ng. Examination also revealed myoclonic jerks. The underlying cause was traced to a mutation in th[E2]e PO[/E2]LG gene.",e PO,GENE_VARIANT,176,180,problems with swallowi,HPO_TERM,56,78,0.75829506,0.24170494,-0.5165901,0
line266,"We report the case of Patient X66, who has a history of problems with swallowing. Examination also revealed myoclonic jerks. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient X66, who has a history of problems with swallowing. Examination also reveale[E1]d myoclonic jer[/E1]ks. The underlying cause was traced to a mutation in th[E2]e PO[/E2]LG gene.",e PO,GENE_VARIANT,176,180,d myoclonic jer,HPO_TERM,106,121,0.72536016,0.27463984,-0.4507203,0
line267,Patient X67 was evaluated for incoordinated movements. The patient also presented with hypotonia and myoclonic jerks. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X67 was evaluated for [E1]incoordinated movement[/E1]s. The patient also presented with hypotonia and myoclonic jerks. Subsequent sequencing of the[E2] POL[/E2]G gene revealed a pathogenic variant., POL,GENE_VARIANT,146,150,incoordinated movement,HPO_TERM,30,52,0.8466165,0.15338357,-0.69323295,0
line267,Patient X67 was evaluated for incoordinated movements. The patient also presented with hypotonia and myoclonic jerks. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X67 was evaluated for incoordinated movements. The patient also presented with[E1] hypotoni[/E1]a and myoclonic jerks. Subsequent sequencing of the[E2] POL[/E2]G gene revealed a pathogenic variant., POL,GENE_VARIANT,146,150, hypotoni,HPO_TERM,86,95,0.82121664,0.17878342,-0.6424332,0
line267,Patient X67 was evaluated for incoordinated movements. The patient also presented with hypotonia and myoclonic jerks. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X67 was evaluated for incoordinated movements. The patient also presented with hypotonia and[E1] myoclonic jerk[/E1]s. Subsequent sequencing of the[E2] POL[/E2]G gene revealed a pathogenic variant., POL,GENE_VARIANT,146,150, myoclonic jerk,HPO_TERM,100,115,0.8399682,0.16003181,-0.6799364,0
line268,Patient X68 was evaluated for hypotonia. The patient also presented with a presentation in infancy and a diagnosis of external ophthalmoplegia. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X68 was evaluated for [E1]hypotonia[/E1]. The patient also presented with a presentation in infancy and a diagnosis of external ophthalmoplegia. Subsequent sequencing of th[E2]e PO[/E2]LG gene revealed a pathogenic variant.,e PO,GENE_VARIANT,171,175,hypotonia,HPO_TERM,30,39,0.8724171,0.12758291,-0.7448342,0
line268,Patient X68 was evaluated for hypotonia. The patient also presented with a presentation in infancy and a diagnosis of external ophthalmoplegia. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X68 was evaluated for hypotonia. The patient also presented with [E1]a presentation in infancy[/E1] and a diagnosis of external ophthalmoplegia. Subsequent sequencing of th[E2]e PO[/E2]LG gene revealed a pathogenic variant.,e PO,GENE_VARIANT,171,175,a presentation in infancy,HPO_TERM,73,98,0.87266916,0.1273309,-0.74533826,0
line268,Patient X68 was evaluated for hypotonia. The patient also presented with a presentation in infancy and a diagnosis of external ophthalmoplegia. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X68 was evaluated for hypotonia. The patient also presented with a presentation in infancy and [E1]a diagnosis of external ophthalmopleg[/E1]ia. Subsequent sequencing of th[E2]e PO[/E2]LG gene revealed a pathogenic variant.,e PO,GENE_VARIANT,171,175,a diagnosis of external ophthalmopleg,HPO_TERM,103,140,0.87818265,0.12181733,-0.7563653,0
line269,The primary symptoms for Patient X69 were a complaint of dysphagia and a lack of voluntary coordination of muscle movements. Analysis of the POLG gene was performed.,The primary symptoms for Patient X69 were a [E1]complaint of dysphagia[/E1] and a lack of voluntary coordination of muscle movements. Analysis of the POLG ge[E2]ne w[/E2]as performed.,ne w,GENE_VARIANT,148,152,complaint of dysphagia,HPO_TERM,44,66,0.77403504,0.225965,-0.5480701,0
line269,The primary symptoms for Patient X69 were a complaint of dysphagia and a lack of voluntary coordination of muscle movements. Analysis of the POLG gene was performed.,The primary symptoms for Patient X69 were a complaint of dysphagia and [E1]a lack of voluntary coordination of muscle movement[/E1]s. Analysis of the POLG ge[E2]ne w[/E2]as performed.,ne w,GENE_VARIANT,148,152,a lack of voluntary coordination of muscle movement,HPO_TERM,71,122,0.7972654,0.20273466,-0.59453076,0
line270,Patient X70 was evaluated for a state of low muscle tone. The patient also presented with problems with balance and coordination and a complaint of dysphagia. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X70 was evaluated for [E1]a state of low muscle to[/E1]ne. The patient also presented with problems with balance and coordination and a complaint of dysphagia. Subsequent sequencing[E2] of [/E2]the POLG gene revealed a pathogenic variant., of ,GENE_VARIANT,180,184,a state of low muscle to,HPO_TERM,30,54,0.83772516,0.16227485,-0.6754503,0
line270,Patient X70 was evaluated for a state of low muscle tone. The patient also presented with problems with balance and coordination and a complaint of dysphagia. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X70 was evaluated for a state of low muscle tone. The patient also presented wit[E1]h problems with balance and coordi[/E1]nation and a complaint of dysphagia. Subsequent sequencing[E2] of [/E2]the POLG gene revealed a pathogenic variant., of ,GENE_VARIANT,180,184,h problems with balance and coordi,HPO_TERM,88,122,0.82756346,0.17243648,-0.655127,0
line270,Patient X70 was evaluated for a state of low muscle tone. The patient also presented with problems with balance and coordination and a complaint of dysphagia. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X70 was evaluated for a state of low muscle tone. The patient also presented with problems with balance and coordinatio[E1]n and a complaint of d[/E1]ysphagia. Subsequent sequencing[E2] of [/E2]the POLG gene revealed a pathogenic variant., of ,GENE_VARIANT,180,184,n and a complaint of d,HPO_TERM,127,149,0.837516,0.16248403,-0.67503196,0
line271,The clinical profile for Patient X71 includes difficulty swallowing and an infantile onset. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient X71 includes [E1]difficulty swallowing[/E1] and an infantile onset. Genetic analysis of the[E2] POL[/E2]G gene confirmed the diagnosis., POL,GENE_VARIANT,115,119,difficulty swallowing,HPO_TERM,46,67,0.8140918,0.18590823,-0.6281836,0
line271,The clinical profile for Patient X71 includes difficulty swallowing and an infantile onset. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient X71 includes difficulty swallowing and [E1]an infantile onse[/E1]t. Genetic analysis of the[E2] POL[/E2]G gene confirmed the diagnosis., POL,GENE_VARIANT,115,119,an infantile onse,HPO_TERM,72,89,0.8573454,0.14265461,-0.7146908,0
line272,The clinical profile for Patient X72 includes an increased CSF protein concentration and myoclonic jerks. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient X72 includes [E1]an increased CSF protein concentra[/E1]tion and myoclonic jerks. Genetic analysis of [E2]the [/E2]POLG gene confirmed the diagnosis.,the ,GENE_VARIANT,126,130,an increased CSF protein concentra,HPO_TERM,46,80,0.84611726,0.15388268,-0.6922346,0
line272,The clinical profile for Patient X72 includes an increased CSF protein concentration and myoclonic jerks. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient X72 includes an increased CSF protein concentration [E1]and myoclonic j[/E1]erks. Genetic analysis of [E2]the [/E2]POLG gene confirmed the diagnosis.,the ,GENE_VARIANT,126,130,and myoclonic j,HPO_TERM,85,100,0.857373,0.14262693,-0.71474606,0
line273,"This report details Patient X73, a patient with myoclonic jerks. Further investigation showed difficulty swallowing and a lack of voluntary coordination of muscle movements. A known variant in the POLG gene was identified.","This report details Patient X73, a patient with [E1]myoclonic jerks[/E1]. Further investigation showed difficulty swallowing and a lack of voluntary coordination of muscle movements. A known variant in th[E2]e PO[/E2]LG gene was identified.",e PO,GENE_VARIANT,195,199,myoclonic jerks,HPO_TERM,48,63,0.802477,0.19752307,-0.60495394,0
line273,"This report details Patient X73, a patient with myoclonic jerks. Further investigation showed difficulty swallowing and a lack of voluntary coordination of muscle movements. A known variant in the POLG gene was identified.","This report details Patient X73, a patient with myoclonic jerks. Further investigation showed [E1]difficulty swallowing[/E1] and a lack of voluntary coordination of muscle movements. A known variant in th[E2]e PO[/E2]LG gene was identified.",e PO,GENE_VARIANT,195,199,difficulty swallowing,HPO_TERM,94,115,0.8100311,0.18996881,-0.6200623,0
line273,"This report details Patient X73, a patient with myoclonic jerks. Further investigation showed difficulty swallowing and a lack of voluntary coordination of muscle movements. A known variant in the POLG gene was identified.","This report details Patient X73, a patient with myoclonic jerks. Further investigation showed difficulty swallowing and [E1]a lack of voluntary coordination of muscle movement[/E1]s. A known variant in th[E2]e PO[/E2]LG gene was identified.",e PO,GENE_VARIANT,195,199,a lack of voluntary coordination of muscle movement,HPO_TERM,120,171,0.8156928,0.1843072,-0.63138556,0
line274,"This report details Patient X74, a patient with a state of low muscle tone. Further investigation showed a presentation in infancy and a complaint of dysphagia. A known variant in the POLG gene was identified.","This report details Patient X74, a patient with [E1]a state of low muscle to[/E1]ne. Further investigation showed a presentation in infancy and a complaint of dysphagia. A known variant in[E2] the[/E2] POLG gene was identified.", the,GENE_VARIANT,179,183,a state of low muscle to,HPO_TERM,48,72,0.763816,0.23618399,-0.527632,0
line274,"This report details Patient X74, a patient with a state of low muscle tone. Further investigation showed a presentation in infancy and a complaint of dysphagia. A known variant in the POLG gene was identified.","This report details Patient X74, a patient with a state of low muscle tone. Further investigation showe[E1]d a presentation in infan[/E1]cy and a complaint of dysphagia. A known variant in[E2] the[/E2] POLG gene was identified.", the,GENE_VARIANT,179,183,d a presentation in infan,HPO_TERM,103,128,0.78037745,0.21962261,-0.56075484,0
line274,"This report details Patient X74, a patient with a state of low muscle tone. Further investigation showed a presentation in infancy and a complaint of dysphagia. A known variant in the POLG gene was identified.","This report details Patient X74, a patient with a state of low muscle tone. Further investigation showed a presentation in infancy an[E1]d a complaint of dysph[/E1]agia. A known variant in[E2] the[/E2] POLG gene was identified.", the,GENE_VARIANT,179,183,d a complaint of dysph,HPO_TERM,133,155,0.78768104,0.21231888,-0.57536215,0
line275,"This report details Patient X75, a patient with a diagnosis of external ophthalmoplegia. Further investigation showed myoclonic seizures and a presentation in infancy. A known variant in the POLG gene was identified.","This report details Patient X75, a patient with [E1]a diagnosis of external ophthalmopleg[/E1]ia. Further investigation showed myoclonic seizures and a presentation in infancy. A known variant in [E2]the [/E2]POLG gene was identified.",the ,GENE_VARIANT,187,191,a diagnosis of external ophthalmopleg,HPO_TERM,48,85,0.77503496,0.224965,-0.5500699,0
line275,"This report details Patient X75, a patient with a diagnosis of external ophthalmoplegia. Further investigation showed myoclonic seizures and a presentation in infancy. A known variant in the POLG gene was identified.","This report details Patient X75, a patient with a diagnosis of external ophthalmoplegia. Further investigation showe[E1]d myoclonic seizu[/E1]res and a presentation in infancy. A known variant in [E2]the [/E2]POLG gene was identified.",the ,GENE_VARIANT,187,191,d myoclonic seizu,HPO_TERM,116,133,0.77726567,0.22273432,-0.55453134,0
line275,"This report details Patient X75, a patient with a diagnosis of external ophthalmoplegia. Further investigation showed myoclonic seizures and a presentation in infancy. A known variant in the POLG gene was identified.","This report details Patient X75, a patient with a diagnosis of external ophthalmoplegia. Further investigation showed myoclonic seizures a[E1]nd a presentation in infa[/E1]ncy. A known variant in [E2]the [/E2]POLG gene was identified.",the ,GENE_VARIANT,187,191,nd a presentation in infa,HPO_TERM,138,163,0.79859954,0.20140043,-0.5971991,0
line276,Patient X76 was evaluated for a diagnosis of external ophthalmoplegia. The patient also presented with a diagnosis of ataxia and EMG: myopathic abnormalities. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X76 was evaluated for [E1]a diagnosis of external ophthalmopleg[/E1]ia. The patient also presented with a diagnosis of ataxia and EMG: myopathic abnormalities. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,184,188,a diagnosis of external ophthalmopleg,HPO_TERM,30,67,0.85298675,0.14701322,-0.7059735,0
line276,Patient X76 was evaluated for a diagnosis of external ophthalmoplegia. The patient also presented with a diagnosis of ataxia and EMG: myopathic abnormalities. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X76 was evaluated for a diagnosis of external ophthalmoplegia. The patient also presented wit[E1]h a diagnosis of at[/E1]axia and EMG: myopathic abnormalities. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,184,188,h a diagnosis of at,HPO_TERM,101,120,0.8650879,0.13491203,-0.7301759,0
line276,Patient X76 was evaluated for a diagnosis of external ophthalmoplegia. The patient also presented with a diagnosis of ataxia and EMG: myopathic abnormalities. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X76 was evaluated for a diagnosis of external ophthalmoplegia. The patient also presented with a diagnosis of ataxia [E1]and EMG: myopathic abnormali[/E1]ties. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,184,188,and EMG: myopathic abnormali,HPO_TERM,125,153,0.85447663,0.14552343,-0.7089532,0
line277,"We report the case of Patient X77, who has a history of myoclonic jerks. Examination also revealed an infantile onset. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient X77, who has a history of [E1]myoclonic jerks[/E1]. Examination also revealed an infantile onset. The underlying cause was traced to a mutation in the[E2] POL[/E2]G gene.", POL,GENE_VARIANT,171,175,myoclonic jerks,HPO_TERM,56,71,0.4654665,0.53453344,0.06906694,1
line277,"We report the case of Patient X77, who has a history of myoclonic jerks. Examination also revealed an infantile onset. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient X77, who has a history of myoclonic jerks. Examination also revealed [E1]an infantile onse[/E1]t. The underlying cause was traced to a mutation in the[E2] POL[/E2]G gene.", POL,GENE_VARIANT,171,175,an infantile onse,HPO_TERM,99,116,0.39314538,0.60685456,0.21370918,1
line278,The clinical profile for Patient X78 includes myoclonic jerks and an infantile onset. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient X78 includes [E1]myoclonic jerks[/E1] and an infantile onset. Genetic analysis of the[E2] POL[/E2]G gene confirmed the diagnosis., POL,GENE_VARIANT,109,113,myoclonic jerks,HPO_TERM,46,61,0.8087082,0.19129181,-0.6174164,0
line278,The clinical profile for Patient X78 includes myoclonic jerks and an infantile onset. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient X78 includes myoclonic jerks and [E1]an infantile onse[/E1]t. Genetic analysis of the[E2] POL[/E2]G gene confirmed the diagnosis., POL,GENE_VARIANT,109,113,an infantile onse,HPO_TERM,66,83,0.8627427,0.13725726,-0.72548544,0
line279,The primary symptoms for Patient X79 were myoclonic seizures and a lack of voluntary coordination of muscle movements. Analysis of the POLG gene was performed.,The primary symptoms for Patient X79 were my[E1]oclonic seizures [/E1]and a lack of voluntary coordination of muscle movements. Analysis of the POLG gen[E2]e wa[/E2]s performed.,e wa,GENE_VARIANT,143,147,oclonic seizures ,HPO_TERM,44,61,0.7793354,0.22066458,-0.5586708,0
line279,The primary symptoms for Patient X79 were myoclonic seizures and a lack of voluntary coordination of muscle movements. Analysis of the POLG gene was performed.,The primary symptoms for Patient X79 were myoclonic seizures and a[E1] lack of voluntary coordination of muscle movements[/E1]. Analysis of the POLG gen[E2]e wa[/E2]s performed.,e wa,GENE_VARIANT,143,147, lack of voluntary coordination of muscle movements,HPO_TERM,66,117,0.7820291,0.2179709,-0.5640582,0
line280,The primary symptoms for Patient X80 were a diagnosis of ataxia and problems with balance and coordination. Analysis of the POLG gene was performed.,The primary symptoms for Patient X80 were a [E1]diagnosis of ataxia[/E1] and problems with balance and coordination. Analysis of the POLG[E2] gen[/E2]e was performed., gen,GENE_VARIANT,128,132,diagnosis of ataxia,HPO_TERM,44,63,0.82413435,0.1758656,-0.64826876,0
line280,The primary symptoms for Patient X80 were a diagnosis of ataxia and problems with balance and coordination. Analysis of the POLG gene was performed.,The primary symptoms for Patient X80 were a diagnosis of ataxia and [E1]problems with balance and coordina[/E1]tion. Analysis of the POLG[E2] gen[/E2]e was performed., gen,GENE_VARIANT,128,132,problems with balance and coordina,HPO_TERM,68,102,0.8179972,0.18200278,-0.63599443,0
line281,"We report the case of Patient X81, who has a history of an increased CSF protein concentration. Examination also revealed ataxia. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient X81, who has a history of [E1]an increased CSF protein concentra[/E1]tion. Examination also revealed ataxia. The underlying cause was traced to a mutation in [E2]the [/E2]POLG gene.",the ,GENE_VARIANT,179,183,an increased CSF protein concentra,HPO_TERM,56,90,0.3259308,0.6740692,0.34813842,1
line281,"We report the case of Patient X81, who has a history of an increased CSF protein concentration. Examination also revealed ataxia. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient X81, who has a history of an increased CSF protein concentration. Examination also revea[E1]led at[/E1]axia. The underlying cause was traced to a mutation in [E2]the [/E2]POLG gene.",the ,GENE_VARIANT,179,183,led at,HPO_TERM,118,124,0.36875117,0.63124883,0.26249766,1
line282,Patient X82 was evaluated for hypotonia. The patient also presented with an infantile onset and myoclonic jerks. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X82 was evaluated for [E1]hypotonia[/E1]. The patient also presented with an infantile onset and myoclonic jerks. Subsequent sequencing of the[E2] POL[/E2]G gene revealed a pathogenic variant., POL,GENE_VARIANT,141,145,hypotonia,HPO_TERM,30,39,0.83555585,0.16444421,-0.67111164,0
line282,Patient X82 was evaluated for hypotonia. The patient also presented with an infantile onset and myoclonic jerks. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X82 was evaluated for hypotonia. The patient also presented with [E1]an infantile onse[/E1]t and myoclonic jerks. Subsequent sequencing of the[E2] POL[/E2]G gene revealed a pathogenic variant., POL,GENE_VARIANT,141,145,an infantile onse,HPO_TERM,73,90,0.8431398,0.1568602,-0.68627965,0
line282,Patient X82 was evaluated for hypotonia. The patient also presented with an infantile onset and myoclonic jerks. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X82 was evaluated for hypotonia. The patient also presented with an infantile onset and[E1] myoclonic jerk[/E1]s. Subsequent sequencing of the[E2] POL[/E2]G gene revealed a pathogenic variant., POL,GENE_VARIANT,141,145, myoclonic jerk,HPO_TERM,95,110,0.8374056,0.16259436,-0.67481124,0
line283,Patient X83 was evaluated for choking or coughing while eating. The patient also presented with an increased CSF protein concentration and myoclonic jerks. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X83 was evaluated for [E1]choking or coughing while eati[/E1]ng. The patient also presented with an increased CSF protein concentration and myoclonic jerks. Subsequent sequencing o[E2]f th[/E2]e POLG gene revealed a pathogenic variant.,f th,GENE_VARIANT,179,183,choking or coughing while eati,HPO_TERM,30,60,0.87069446,0.12930562,-0.74138886,0
line283,Patient X83 was evaluated for choking or coughing while eating. The patient also presented with an increased CSF protein concentration and myoclonic jerks. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X83 was evaluated for choking or coughing while eating. The patient also presented wit[E1]h an increased CSF protein concent[/E1]ration and myoclonic jerks. Subsequent sequencing o[E2]f th[/E2]e POLG gene revealed a pathogenic variant.,f th,GENE_VARIANT,179,183,h an increased CSF protein concent,HPO_TERM,94,128,0.8660655,0.1339345,-0.732131,0
line283,Patient X83 was evaluated for choking or coughing while eating. The patient also presented with an increased CSF protein concentration and myoclonic jerks. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X83 was evaluated for choking or coughing while eating. The patient also presented with an increased CSF protein concentratio[E1]n and myoclonic[/E1] jerks. Subsequent sequencing o[E2]f th[/E2]e POLG gene revealed a pathogenic variant.,f th,GENE_VARIANT,179,183,n and myoclonic,HPO_TERM,133,148,0.8678501,0.13214992,-0.7357002,0
line284,The clinical profile for Patient X84 includes a lack of voluntary coordination of muscle movements and a presentation in infancy. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient X84 includes [E1]a lack of voluntary coordination of muscle movement[/E1]s and a presentation in infancy. Genetic analysis of the[E2] POL[/E2]G gene confirmed the diagnosis., POL,GENE_VARIANT,153,157,a lack of voluntary coordination of muscle movement,HPO_TERM,46,97,0.8177229,0.18227711,-0.63544583,0
line284,The clinical profile for Patient X84 includes a lack of voluntary coordination of muscle movements and a presentation in infancy. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient X84 includes a lack of voluntary coordination of muscle movements and[E1] a presentation in infanc[/E1]y. Genetic analysis of the[E2] POL[/E2]G gene confirmed the diagnosis., POL,GENE_VARIANT,153,157, a presentation in infanc,HPO_TERM,102,127,0.84906286,0.15093713,-0.6981257,0
line285,The primary symptoms for Patient X85 were an infantile onset and a condition affecting eye movement. Analysis of the POLG gene was performed.,The primary symptoms for Patient X85 were an[E1] infantile onset [/E1]and a condition affecting eye movement. Analysis of the POLG gen[E2]e wa[/E2]s performed.,e wa,GENE_VARIANT,125,129, infantile onset ,HPO_TERM,44,61,0.7547604,0.24523957,-0.5095208,0
line285,The primary symptoms for Patient X85 were an infantile onset and a condition affecting eye movement. Analysis of the POLG gene was performed.,The primary symptoms for Patient X85 were an infantile onset and a[E1] condition affecting eye movement[/E1]. Analysis of the POLG gen[E2]e wa[/E2]s performed.,e wa,GENE_VARIANT,125,129, condition affecting eye movement,HPO_TERM,66,99,0.7142099,0.28579015,-0.42841977,0
line286,The clinical profile for Patient X86 includes myoclonic seizures and a lack of voluntary coordination of muscle movements. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient X86 includes [E1]myoclonic seizure[/E1]s and a lack of voluntary coordination of muscle movements. Genetic analysis of th[E2]e PO[/E2]LG gene confirmed the diagnosis.,e PO,GENE_VARIANT,145,149,myoclonic seizure,HPO_TERM,46,63,0.85391647,0.14608356,-0.70783293,0
line286,The clinical profile for Patient X86 includes myoclonic seizures and a lack of voluntary coordination of muscle movements. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient X86 includes myoclonic seizures and[E1] a lack of voluntary coordination of muscle movemen[/E1]ts. Genetic analysis of th[E2]e PO[/E2]LG gene confirmed the diagnosis.,e PO,GENE_VARIANT,145,149, a lack of voluntary coordination of muscle movemen,HPO_TERM,68,119,0.8582806,0.14171934,-0.71656126,0
line287,The primary symptoms for Patient X87 were a presentation in infancy and EMG: myopathic abnormalities. Analysis of the POLG gene was performed.,The primary symptoms for Patient X87 were a [E1]presentation in infancy a[/E1]nd EMG: myopathic abnormalities. Analysis of the POLG gene [E2]was [/E2]performed.,was ,GENE_VARIANT,128,132,presentation in infancy a,HPO_TERM,44,69,0.86948216,0.13051786,-0.7389643,0
line288,The clinical profile for Patient X88 includes myoclonic seizures and myoclonic jerks. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient X88 includes [E1]myoclonic seizure[/E1]s and myoclonic jerks. Genetic analysis of the[E2] POL[/E2]G gene confirmed the diagnosis., POL,GENE_VARIANT,109,113,myoclonic seizure,HPO_TERM,46,63,0.82514936,0.17485063,-0.6502987,0
line288,The clinical profile for Patient X88 includes myoclonic seizures and myoclonic jerks. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient X88 includes myoclonic seizures and[E1] myoclonic jerk[/E1]s. Genetic analysis of the[E2] POL[/E2]G gene confirmed the diagnosis., POL,GENE_VARIANT,109,113, myoclonic jerk,HPO_TERM,68,83,0.8403928,0.15960722,-0.6807856,0
line289,"This report details Patient X89, a patient with a state of low muscle tone. Further investigation showed hypotonia and myoclonic jerks. A known variant in the POLG gene was identified.","This report details Patient X89, a patient with [E1]a state of low muscle to[/E1]ne. Further investigation showed hypotonia and myoclonic jerks. A known variant in t[E2]he P[/E2]OLG gene was identified.",he P,GENE_VARIANT,156,160,a state of low muscle to,HPO_TERM,48,72,0.7798655,0.22013448,-0.559731,0
line289,"This report details Patient X89, a patient with a state of low muscle tone. Further investigation showed hypotonia and myoclonic jerks. A known variant in the POLG gene was identified.","This report details Patient X89, a patient with a state of low muscle tone. Further investigation showe[E1]d hypoton[/E1]ia and myoclonic jerks. A known variant in t[E2]he P[/E2]OLG gene was identified.",he P,GENE_VARIANT,156,160,d hypoton,HPO_TERM,103,112,0.7934439,0.20655614,-0.5868878,0
line289,"This report details Patient X89, a patient with a state of low muscle tone. Further investigation showed hypotonia and myoclonic jerks. A known variant in the POLG gene was identified.","This report details Patient X89, a patient with a state of low muscle tone. Further investigation showed hypotonia an[E1]d myoclonic jer[/E1]ks. A known variant in t[E2]he P[/E2]OLG gene was identified.",he P,GENE_VARIANT,156,160,d myoclonic jer,HPO_TERM,117,132,0.82376885,0.17623119,-0.64753765,0
line290,The primary symptoms for Patient X90 were a condition affecting eye movement and myoclonic jerks. Analysis of the POLG gene was performed.,The primary symptoms for Patient X90 were a [E1]condition affecting eye movement [/E1]and myoclonic jerks. Analysis of the POLG gene[E2] was[/E2] performed., was,GENE_VARIANT,123,127,condition affecting eye movement ,HPO_TERM,44,77,0.82067835,0.17932166,-0.6413567,0
line291,"This report details Patient X91, a patient with myoclonic jerks. Further investigation showed a presentation in infancy and a condition affecting eye movement. A known variant in the POLG gene was identified.","This report details Patient X91, a patient with [E1]myoclonic jerks[/E1]. Further investigation showed a presentation in infancy and a condition affecting eye movement. A known variant in th[E2]e PO[/E2]LG gene was identified.",e PO,GENE_VARIANT,181,185,myoclonic jerks,HPO_TERM,48,63,0.8281908,0.17180917,-0.6563816,0
line291,"This report details Patient X91, a patient with myoclonic jerks. Further investigation showed a presentation in infancy and a condition affecting eye movement. A known variant in the POLG gene was identified.","This report details Patient X91, a patient with myoclonic jerks. Further investigation showed [E1]a presentation in infancy[/E1] and a condition affecting eye movement. A known variant in th[E2]e PO[/E2]LG gene was identified.",e PO,GENE_VARIANT,181,185,a presentation in infancy,HPO_TERM,94,119,0.83276135,0.16723868,-0.6655227,0
line291,"This report details Patient X91, a patient with myoclonic jerks. Further investigation showed a presentation in infancy and a condition affecting eye movement. A known variant in the POLG gene was identified.","This report details Patient X91, a patient with myoclonic jerks. Further investigation showed a presentation in infancy and [E1]a condition affecting eye movemen[/E1]t. A known variant in th[E2]e PO[/E2]LG gene was identified.",e PO,GENE_VARIANT,181,185,a condition affecting eye movemen,HPO_TERM,124,157,0.83957654,0.16042343,-0.6791531,0
line292,"This report details Patient X92, a patient with myoclonic jerks. Further investigation showed difficulty swallowing and an infantile onset. A known variant in the POLG gene was identified.","This report details Patient X92, a patient with [E1]myoclonic jerks[/E1]. Further investigation showed difficulty swallowing and an infantile onset. A known variant in th[E2]e PO[/E2]LG gene was identified.",e PO,GENE_VARIANT,161,165,myoclonic jerks,HPO_TERM,48,63,0.81794953,0.18205048,-0.63589907,0
line292,"This report details Patient X92, a patient with myoclonic jerks. Further investigation showed difficulty swallowing and an infantile onset. A known variant in the POLG gene was identified.","This report details Patient X92, a patient with myoclonic jerks. Further investigation showed [E1]difficulty swallowing[/E1] and an infantile onset. A known variant in th[E2]e PO[/E2]LG gene was identified.",e PO,GENE_VARIANT,161,165,difficulty swallowing,HPO_TERM,94,115,0.82458013,0.17541985,-0.64916027,0
line292,"This report details Patient X92, a patient with myoclonic jerks. Further investigation showed difficulty swallowing and an infantile onset. A known variant in the POLG gene was identified.","This report details Patient X92, a patient with myoclonic jerks. Further investigation showed difficulty swallowing and [E1]an infantile onse[/E1]t. A known variant in th[E2]e PO[/E2]LG gene was identified.",e PO,GENE_VARIANT,161,165,an infantile onse,HPO_TERM,120,137,0.84381074,0.1561892,-0.68762153,0
line293,"We report the case of Patient X93, who has a history of myoclonic seizures. Examination also revealed EMG: myopathic abnormalities. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient X93, who has a history of [E1]myoclonic seizure[/E1]s. Examination also revealed EMG: myopathic abnormalities. The underlying cause was traced to a mutation in the[E2] POL[/E2]G gene.", POL,GENE_VARIANT,184,188,myoclonic seizure,HPO_TERM,56,73,0.5689166,0.43108335,-0.13783327,0
line293,"We report the case of Patient X93, who has a history of myoclonic seizures. Examination also revealed EMG: myopathic abnormalities. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient X93, who has a history of myoclonic seizures. Examination also revealed[E1] EMG: myopathic abnormalitie[/E1]s. The underlying cause was traced to a mutation in the[E2] POL[/E2]G gene.", POL,GENE_VARIANT,184,188, EMG: myopathic abnormalitie,HPO_TERM,101,129,0.5914052,0.4085948,-0.18281043,0
line294,The clinical profile for Patient X94 includes myoclonic jerks and incoordinated movements. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient X94 includes [E1]myoclonic jerks[/E1] and incoordinated movements. Genetic analysis of the[E2] POL[/E2]G gene confirmed the diagnosis., POL,GENE_VARIANT,114,118,myoclonic jerks,HPO_TERM,46,61,0.8042764,0.19572356,-0.6085528,0
line294,The clinical profile for Patient X94 includes myoclonic jerks and incoordinated movements. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient X94 includes myoclonic jerks and [E1]incoordinated movement[/E1]s. Genetic analysis of the[E2] POL[/E2]G gene confirmed the diagnosis., POL,GENE_VARIANT,114,118,incoordinated movement,HPO_TERM,66,88,0.8295553,0.17044476,-0.65911055,0
line295,"We report the case of Patient X95, who has a history of a diagnosis of ataxia. Examination also revealed problems with swallowing. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient X95, who has a history of [E1]a diagnosis of ataxia[/E1]. Examination also revealed problems with swallowing. The underlying cause was traced to a mutation in th[E2]e PO[/E2]LG gene.",e PO,GENE_VARIANT,182,186,a diagnosis of ataxia,HPO_TERM,56,77,0.7735964,0.22640358,-0.5471928,0
line295,"We report the case of Patient X95, who has a history of a diagnosis of ataxia. Examination also revealed problems with swallowing. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient X95, who has a history of a diagnosis of ataxia. Examination also revealed [E1]problems with swallowi[/E1]ng. The underlying cause was traced to a mutation in th[E2]e PO[/E2]LG gene.",e PO,GENE_VARIANT,182,186,problems with swallowi,HPO_TERM,105,127,0.79585135,0.20414868,-0.5917027,0
line296,"We report the case of Patient X96, who has a history of a presentation in infancy. Examination also revealed a diagnosis of ataxia. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient X96, who has a history of [E1]a presentation in infancy[/E1]. Examination also revealed a diagnosis of ataxia. The underlying cause was traced to a mutation in th[E2]e PO[/E2]LG gene.",e PO,GENE_VARIANT,183,187,a presentation in infancy,HPO_TERM,56,81,0.7328694,0.26713052,-0.46573886,0
line296,"We report the case of Patient X96, who has a history of a presentation in infancy. Examination also revealed a diagnosis of ataxia. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient X96, who has a history of a presentation in infancy. Examination also revealed [E1]a diagnosis of atax[/E1]ia. The underlying cause was traced to a mutation in th[E2]e PO[/E2]LG gene.",e PO,GENE_VARIANT,183,187,a diagnosis of atax,HPO_TERM,109,128,0.671684,0.32831597,-0.34336805,0
line297,Patient X97 was evaluated for a complaint of dysphagia. The patient also presented with myoclonic jerks and an infantile onset. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X97 was evaluated for [E1]a complaint of dysphag[/E1]ia. The patient also presented with myoclonic jerks and an infantile onset. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,154,158,a complaint of dysphag,HPO_TERM,30,52,0.8150404,0.18495953,-0.6300809,0
line297,Patient X97 was evaluated for a complaint of dysphagia. The patient also presented with myoclonic jerks and an infantile onset. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X97 was evaluated for a complaint of dysphagia. The patient also presented wit[E1]h myoclonic jer[/E1]ks and an infantile onset. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,154,158,h myoclonic jer,HPO_TERM,86,101,0.7926673,0.20733264,-0.58533466,0
line297,Patient X97 was evaluated for a complaint of dysphagia. The patient also presented with myoclonic jerks and an infantile onset. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X97 was evaluated for a complaint of dysphagia. The patient also presented with myoclonic jerks an[E1]d an infantile on[/E1]set. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,154,158,d an infantile on,HPO_TERM,106,123,0.83435917,0.16564082,-0.66871834,0
line298,"This report details Patient X98, a patient with myoclonic jerks. Further investigation showed a diagnosis of external ophthalmoplegia and myoclonic seizures. A known variant in the POLG gene was identified.","This report details Patient X98, a patient with [E1]myoclonic jerks[/E1]. Further investigation showed a diagnosis of external ophthalmoplegia and myoclonic seizures. A known variant in [E2]the [/E2]POLG gene was identified.",the ,GENE_VARIANT,177,181,myoclonic jerks,HPO_TERM,48,63,0.72415626,0.2758437,-0.44831255,0
line298,"This report details Patient X98, a patient with myoclonic jerks. Further investigation showed a diagnosis of external ophthalmoplegia and myoclonic seizures. A known variant in the POLG gene was identified.","This report details Patient X98, a patient with myoclonic jerks. Further investigation showed [E1]a diagnosis of external ophthalmopleg[/E1]ia and myoclonic seizures. A known variant in [E2]the [/E2]POLG gene was identified.",the ,GENE_VARIANT,177,181,a diagnosis of external ophthalmopleg,HPO_TERM,94,131,0.80270237,0.19729765,-0.60540473,0
line298,"This report details Patient X98, a patient with myoclonic jerks. Further investigation showed a diagnosis of external ophthalmoplegia and myoclonic seizures. A known variant in the POLG gene was identified.","This report details Patient X98, a patient with myoclonic jerks. Further investigation showed a diagnosis of external ophthalmoplegia an[E1]d myoclonic seizu[/E1]res. A known variant in [E2]the [/E2]POLG gene was identified.",the ,GENE_VARIANT,177,181,d myoclonic seizu,HPO_TERM,136,153,0.781439,0.218561,-0.562878,0
line299,The primary symptoms for Patient X99 were problems with balance and coordination and a condition affecting eye movement. Analysis of the POLG gene was performed.,The primary symptoms for Patient X99 were pr[E1]oblems with balance and coordinati[/E1]on and a condition affecting eye movement. Analysis of the POLG [E2]gene[/E2] was performed.,gene,GENE_VARIANT,142,146,oblems with balance and coordinati,HPO_TERM,44,78,0.7981546,0.20184535,-0.59630924,0
line299,The primary symptoms for Patient X99 were problems with balance and coordination and a condition affecting eye movement. Analysis of the POLG gene was performed.,The primary symptoms for Patient X99 were problems with balance and coordination an[E1]d a condition affecting eye movem[/E1]ent. Analysis of the POLG [E2]gene[/E2] was performed.,gene,GENE_VARIANT,142,146,d a condition affecting eye movem,HPO_TERM,83,116,0.8111194,0.1888806,-0.62223876,0
line300,The clinical profile for Patient X100 includes ataxia and a presentation in infancy. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient X100 includes [E1]ataxia[/E1] and a presentation in infancy. Genetic analysis of the [E2]POLG[/E2] gene confirmed the diagnosis.,POLG,GENE_VARIANT,109,113,ataxia,HPO_TERM,47,53,0.7878993,0.21210068,-0.57579863,0
line300,The clinical profile for Patient X100 includes ataxia and a presentation in infancy. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient X100 includes ataxia and [E1]a presentation in infancy[/E1]. Genetic analysis of the [E2]POLG[/E2] gene confirmed the diagnosis.,POLG,GENE_VARIANT,109,113,a presentation in infancy,HPO_TERM,58,83,0.82441854,0.17558144,-0.6488371,0
line301,Patient X101 was evaluated for myoclonic jerks. The patient also presented with problems with swallowing and a diagnosis of external ophthalmoplegia. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X101 was evaluated for [E1]myoclonic jerks[/E1]. The patient also presented with problems with swallowing and a diagnosis of external ophthalmoplegia. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,175,179,myoclonic jerks,HPO_TERM,31,46,0.84757525,0.15242472,-0.6951505,0
line301,Patient X101 was evaluated for myoclonic jerks. The patient also presented with problems with swallowing and a diagnosis of external ophthalmoplegia. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X101 was evaluated for myoclonic jerks. The patient also presented with [E1]problems with swallowi[/E1]ng and a diagnosis of external ophthalmoplegia. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,175,179,problems with swallowi,HPO_TERM,80,102,0.84232926,0.1576707,-0.6846585,0
line301,Patient X101 was evaluated for myoclonic jerks. The patient also presented with problems with swallowing and a diagnosis of external ophthalmoplegia. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X101 was evaluated for myoclonic jerks. The patient also presented with problems with swallowing an[E1]d a diagnosis of external ophthalmopl[/E1]egia. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,175,179,d a diagnosis of external ophthalmopl,HPO_TERM,107,144,0.8466035,0.1533965,-0.693207,0
line302,Patient X102 was evaluated for difficulty swallowing. The patient also presented with problems with balance and coordination and an increased CSF protein concentration. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X102 was evaluated for [E1]difficulty swallowing[/E1]. The patient also presented with problems with balance and coordination and an increased CSF protein concentration. Subsequent sequencing[E2] of [/E2]the POLG gene revealed a pathogenic variant., of ,GENE_VARIANT,190,194,difficulty swallowing,HPO_TERM,31,52,0.8497288,0.15027119,-0.69945765,0
line302,Patient X102 was evaluated for difficulty swallowing. The patient also presented with problems with balance and coordination and an increased CSF protein concentration. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X102 was evaluated for difficulty swallowing. The patient also presented with [E1]problems with balance and coordina[/E1]tion and an increased CSF protein concentration. Subsequent sequencing[E2] of [/E2]the POLG gene revealed a pathogenic variant., of ,GENE_VARIANT,190,194,problems with balance and coordina,HPO_TERM,86,120,0.84311974,0.15688026,-0.6862395,0
line302,Patient X102 was evaluated for difficulty swallowing. The patient also presented with problems with balance and coordination and an increased CSF protein concentration. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X102 was evaluated for difficulty swallowing. The patient also presented with problems with balance and coordination [E1]and an increased CSF protein conce[/E1]ntration. Subsequent sequencing[E2] of [/E2]the POLG gene revealed a pathogenic variant., of ,GENE_VARIANT,190,194,and an increased CSF protein conce,HPO_TERM,125,159,0.8452262,0.15477376,-0.69045246,0
line303,Patient X103 was evaluated for a diagnosis of external ophthalmoplegia. The patient also presented with a complaint of dysphagia and problems with balance and coordination. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X103 was evaluated for [E1]a diagnosis of external ophthalmopleg[/E1]ia. The patient also presented with a complaint of dysphagia and problems with balance and coordination. Subsequent sequencing[E2] of [/E2]the POLG gene revealed a pathogenic variant., of ,GENE_VARIANT,194,198,a diagnosis of external ophthalmopleg,HPO_TERM,31,68,0.8303909,0.16960905,-0.6607818,0
line303,Patient X103 was evaluated for a diagnosis of external ophthalmoplegia. The patient also presented with a complaint of dysphagia and problems with balance and coordination. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X103 was evaluated for a diagnosis of external ophthalmoplegia. The patient also presented wit[E1]h a complaint of dysph[/E1]agia and problems with balance and coordination. Subsequent sequencing[E2] of [/E2]the POLG gene revealed a pathogenic variant., of ,GENE_VARIANT,194,198,h a complaint of dysph,HPO_TERM,102,124,0.81985486,0.18014519,-0.63970965,0
line303,Patient X103 was evaluated for a diagnosis of external ophthalmoplegia. The patient also presented with a complaint of dysphagia and problems with balance and coordination. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X103 was evaluated for a diagnosis of external ophthalmoplegia. The patient also presented with a complaint of dysphagia [E1]and problems with balance and coor[/E1]dination. Subsequent sequencing[E2] of [/E2]the POLG gene revealed a pathogenic variant., of ,GENE_VARIANT,194,198,and problems with balance and coor,HPO_TERM,129,163,0.8091843,0.19081576,-0.61836857,0
line304,"We report the case of Patient X104, who has a history of an increased CSF protein concentration. Examination also revealed an infantile onset. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient X104, who has a history of [E1]an increased CSF protein concentra[/E1]tion. Examination also revealed an infantile onset. The underlying cause was traced to a mutation in[E2] the[/E2] POLG gene.", the,GENE_VARIANT,191,195,an increased CSF protein concentra,HPO_TERM,57,91,0.3927583,0.6072417,0.21448338,1
line304,"We report the case of Patient X104, who has a history of an increased CSF protein concentration. Examination also revealed an infantile onset. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient X104, who has a history of an increased CSF protein concentration. Examination also revea[E1]led an infantile [/E1]onset. The underlying cause was traced to a mutation in[E2] the[/E2] POLG gene.", the,GENE_VARIANT,191,195,led an infantile ,HPO_TERM,119,136,0.43665576,0.56334424,0.12668848,1
line305,The clinical profile for Patient X105 includes a lack of voluntary coordination of muscle movements and a complaint of dysphagia. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient X105 includes [E1]a lack of voluntary coordination of muscle movement[/E1]s and a complaint of dysphagia. Genetic analysis of t[E2]he P[/E2]OLG gene confirmed the diagnosis.,he P,GENE_VARIANT,151,155,a lack of voluntary coordination of muscle movement,HPO_TERM,47,98,0.83863175,0.1613682,-0.67726356,0
line305,The clinical profile for Patient X105 includes a lack of voluntary coordination of muscle movements and a complaint of dysphagia. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient X105 includes a lack of voluntary coordination of muscle movements and[E1] a complaint of dyspha[/E1]gia. Genetic analysis of t[E2]he P[/E2]OLG gene confirmed the diagnosis.,he P,GENE_VARIANT,151,155, a complaint of dyspha,HPO_TERM,103,125,0.8352462,0.16475384,-0.67049235,0
line306,Patient X106 was evaluated for a condition affecting eye movement. The patient also presented with a state of low muscle tone and problems with balance and coordination. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X106 was evaluated for [E1]a condition affecting eye movemen[/E1]t. The patient also presented with a state of low muscle tone and problems with balance and coordination. Subsequent sequencing [E2]of t[/E2]he POLG gene revealed a pathogenic variant.,of t,GENE_VARIANT,192,196,a condition affecting eye movemen,HPO_TERM,31,64,0.8690827,0.13091725,-0.73816544,0
line306,Patient X106 was evaluated for a condition affecting eye movement. The patient also presented with a state of low muscle tone and problems with balance and coordination. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X106 was evaluated for a condition affecting eye movement. The patient also presented with[E1] a state of low muscle t[/E1]one and problems with balance and coordination. Subsequent sequencing [E2]of t[/E2]he POLG gene revealed a pathogenic variant.,of t,GENE_VARIANT,192,196, a state of low muscle t,HPO_TERM,98,122,0.84237915,0.15762085,-0.6847583,0
line306,Patient X106 was evaluated for a condition affecting eye movement. The patient also presented with a state of low muscle tone and problems with balance and coordination. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X106 was evaluated for a condition affecting eye movement. The patient also presented with a state of low muscle tone a[E1]nd problems with balance and coord[/E1]ination. Subsequent sequencing [E2]of t[/E2]he POLG gene revealed a pathogenic variant.,of t,GENE_VARIANT,192,196,nd problems with balance and coord,HPO_TERM,127,161,0.8344873,0.16551268,-0.66897464,0
line307,Patient X107 was evaluated for a lack of voluntary coordination of muscle movements. The patient also presented with a complaint of dysphagia and ataxia. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X107 was evaluated for [E1]a lack of voluntary coordination of muscle movement[/E1]s. The patient also presented with a complaint of dysphagia and ataxia. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,180,184,a lack of voluntary coordination of muscle movement,HPO_TERM,31,82,0.834577,0.16542296,-0.66915405,0
line307,Patient X107 was evaluated for a lack of voluntary coordination of muscle movements. The patient also presented with a complaint of dysphagia and ataxia. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X107 was evaluated for a lack of voluntary coordination of muscle movements. The patient also presented with[E1] a complaint of dyspha[/E1]gia and ataxia. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,180,184, a complaint of dyspha,HPO_TERM,116,138,0.7985042,0.20149584,-0.59700835,0
line307,Patient X107 was evaluated for a lack of voluntary coordination of muscle movements. The patient also presented with a complaint of dysphagia and ataxia. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X107 was evaluated for a lack of voluntary coordination of muscle movements. The patient also presented with a complaint of dysphagia a[E1]nd ata[/E1]xia. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,180,184,nd ata,HPO_TERM,143,149,0.85427046,0.14572954,-0.7085409,0
line308,The clinical profile for Patient X108 includes myoclonic jerks and hypotonia. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient X108 includes [E1]myoclonic jerks[/E1] and hypotonia. Genetic analysis of the [E2]POLG[/E2] gene confirmed the diagnosis.,POLG,GENE_VARIANT,102,106,myoclonic jerks,HPO_TERM,47,62,0.7935458,0.20645426,-0.5870915,0
line308,The clinical profile for Patient X108 includes myoclonic jerks and hypotonia. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient X108 includes myoclonic jerks and [E1]hypotonia[/E1]. Genetic analysis of the [E2]POLG[/E2] gene confirmed the diagnosis.,POLG,GENE_VARIANT,102,106,hypotonia,HPO_TERM,67,76,0.80734545,0.1926546,-0.61469084,0
line309,"We report the case of Patient X109, who has a history of myoclonic seizures. Examination also revealed a complaint of dysphagia. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient X109, who has a history of [E1]myoclonic seizure[/E1]s. Examination also revealed a complaint of dysphagia. The underlying cause was traced to a mutation in t[E2]he P[/E2]OLG gene.",he P,GENE_VARIANT,179,183,myoclonic seizure,HPO_TERM,57,74,0.33726454,0.6627354,0.32547086,1
line309,"We report the case of Patient X109, who has a history of myoclonic seizures. Examination also revealed a complaint of dysphagia. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient X109, who has a history of myoclonic seizures. Examination also revealed[E1] a complaint of dyspha[/E1]gia. The underlying cause was traced to a mutation in t[E2]he P[/E2]OLG gene.",he P,GENE_VARIANT,179,183, a complaint of dyspha,HPO_TERM,102,124,0.19942579,0.80057424,0.6011485,1
line310,The primary symptoms for Patient X110 were myoclonic jerks and a state of low muscle tone. Analysis of the POLG gene was performed.,The primary symptoms for Patient X110 were m[E1]yoclonic jerks [/E1]and a state of low muscle tone. Analysis of the POLG ge[E2]ne w[/E2]as performed.,ne w,GENE_VARIANT,114,118,yoclonic jerks ,HPO_TERM,44,59,0.79599345,0.20400652,-0.5919869,0
line310,The primary symptoms for Patient X110 were myoclonic jerks and a state of low muscle tone. Analysis of the POLG gene was performed.,The primary symptoms for Patient X110 were myoclonic jerks and a[E1] state of low muscle ton[/E1]e. Analysis of the POLG ge[E2]ne w[/E2]as performed.,ne w,GENE_VARIANT,114,118, state of low muscle ton,HPO_TERM,64,88,0.81932026,0.18067977,-0.6386405,0
line311,"We report the case of Patient X111, who has a history of myoclonic seizures. Examination also revealed incoordinated movements. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient X111, who has a history of [E1]myoclonic seizure[/E1]s. Examination also revealed incoordinated movements. The underlying cause was traced to a mutation in th[E2]e PO[/E2]LG gene.",e PO,GENE_VARIANT,179,183,myoclonic seizure,HPO_TERM,57,74,0.4442094,0.55579054,0.11158115,1
line311,"We report the case of Patient X111, who has a history of myoclonic seizures. Examination also revealed incoordinated movements. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient X111, who has a history of myoclonic seizures. Examination also revealed[E1] incoordinated movemen[/E1]ts. The underlying cause was traced to a mutation in th[E2]e PO[/E2]LG gene.",e PO,GENE_VARIANT,179,183, incoordinated movemen,HPO_TERM,102,124,0.5175267,0.48247328,-0.035053402,0
line312,"We report the case of Patient X112, who has a history of an increased CSF protein concentration. Examination also revealed a state of low muscle tone. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient X112, who has a history of [E1]an increased CSF protein concentra[/E1]tion. Examination also revealed a state of low muscle tone. The underlying cause was traced to a mutation i[E2]n th[/E2]e POLG gene.",n th,GENE_VARIANT,198,202,an increased CSF protein concentra,HPO_TERM,57,91,0.72917444,0.27082556,-0.45834887,0
line312,"We report the case of Patient X112, who has a history of an increased CSF protein concentration. Examination also revealed a state of low muscle tone. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient X112, who has a history of an increased CSF protein concentration. Examination also revea[E1]led a state of low muscl[/E1]e tone. The underlying cause was traced to a mutation i[E2]n th[/E2]e POLG gene.",n th,GENE_VARIANT,198,202,led a state of low muscl,HPO_TERM,119,143,0.7386159,0.26138416,-0.4772317,0
line313,The primary symptoms for Patient X113 were problems with swallowing and a diagnosis of external ophthalmoplegia. Analysis of the POLG gene was performed.,The primary symptoms for Patient X113 were pr[E1]oblems with swallowing[/E1] and a diagnosis of external ophthalmoplegia. Analysis of the POLG g[E2]ene [/E2]was performed.,ene ,GENE_VARIANT,135,139,oblems with swallowing,HPO_TERM,45,67,0.8183248,0.18167529,-0.6366495,0
line313,The primary symptoms for Patient X113 were problems with swallowing and a diagnosis of external ophthalmoplegia. Analysis of the POLG gene was performed.,The primary symptoms for Patient X113 were problems with swallowing and [E1]a diagnosis of external ophthalmopleg[/E1]ia. Analysis of the POLG g[E2]ene [/E2]was performed.,ene ,GENE_VARIANT,135,139,a diagnosis of external ophthalmopleg,HPO_TERM,72,109,0.84348625,0.15651381,-0.68697244,0
line314,Patient X114 was evaluated for difficulty swallowing. The patient also presented with hypotonia and myoclonic jerks. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X114 was evaluated for [E1]difficulty swallowing[/E1]. The patient also presented with hypotonia and myoclonic jerks. Subsequent sequencing of the [E2]POLG[/E2] gene revealed a pathogenic variant.,POLG,GENE_VARIANT,146,150,difficulty swallowing,HPO_TERM,31,52,0.8208682,0.17913184,-0.6417364,0
line314,Patient X114 was evaluated for difficulty swallowing. The patient also presented with hypotonia and myoclonic jerks. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X114 was evaluated for difficulty swallowing. The patient also presented with [E1]hypotonia[/E1] and myoclonic jerks. Subsequent sequencing of the [E2]POLG[/E2] gene revealed a pathogenic variant.,POLG,GENE_VARIANT,146,150,hypotonia,HPO_TERM,86,95,0.8033423,0.19665766,-0.6066846,0
line314,Patient X114 was evaluated for difficulty swallowing. The patient also presented with hypotonia and myoclonic jerks. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X114 was evaluated for difficulty swallowing. The patient also presented with hypotonia and [E1]myoclonic jerks[/E1]. Subsequent sequencing of the [E2]POLG[/E2] gene revealed a pathogenic variant.,POLG,GENE_VARIANT,146,150,myoclonic jerks,HPO_TERM,100,115,0.8206325,0.1793675,-0.64126503,0
line315,"This report details Patient X115, a patient with a complaint of dysphagia. Further investigation showed hypotonia and myoclonic seizures. A known variant in the POLG gene was identified.","This report details Patient X115, a patient with [E1]a complaint of dysphag[/E1]ia. Further investigation showed hypotonia and myoclonic seizures. A known variant in [E2]the [/E2]POLG gene was identified.",the ,GENE_VARIANT,157,161,a complaint of dysphag,HPO_TERM,49,71,0.72430444,0.27569553,-0.4486089,0
line315,"This report details Patient X115, a patient with a complaint of dysphagia. Further investigation showed hypotonia and myoclonic seizures. A known variant in the POLG gene was identified.","This report details Patient X115, a patient with a complaint of dysphagia. Further investigation showe[E1]d hypoton[/E1]ia and myoclonic seizures. A known variant in [E2]the [/E2]POLG gene was identified.",the ,GENE_VARIANT,157,161,d hypoton,HPO_TERM,102,111,0.7559735,0.24402645,-0.51194704,0
line315,"This report details Patient X115, a patient with a complaint of dysphagia. Further investigation showed hypotonia and myoclonic seizures. A known variant in the POLG gene was identified.","This report details Patient X115, a patient with a complaint of dysphagia. Further investigation showed hypotonia an[E1]d myoclonic seizu[/E1]res. A known variant in [E2]the [/E2]POLG gene was identified.",the ,GENE_VARIANT,157,161,d myoclonic seizu,HPO_TERM,116,133,0.73695546,0.2630445,-0.47391096,0
line316,The primary symptoms for Patient X116 were problems with balance and coordination and a condition affecting eye movement. Analysis of the POLG gene was performed.,The primary symptoms for Patient X116 were pr[E1]oblems with balance and coordinati[/E1]on and a condition affecting eye movement. Analysis of the POLG [E2]gene[/E2] was performed.,gene,GENE_VARIANT,143,147,oblems with balance and coordinati,HPO_TERM,45,79,0.80382067,0.19617933,-0.60764134,0
line316,The primary symptoms for Patient X116 were problems with balance and coordination and a condition affecting eye movement. Analysis of the POLG gene was performed.,The primary symptoms for Patient X116 were problems with balance and coordination an[E1]d a condition affecting eye movem[/E1]ent. Analysis of the POLG [E2]gene[/E2] was performed.,gene,GENE_VARIANT,143,147,d a condition affecting eye movem,HPO_TERM,84,117,0.81339425,0.1866057,-0.62678856,0
line317,Patient X117 was evaluated for a diagnosis of external ophthalmoplegia. The patient also presented with myoclonic seizures and an increased CSF protein concentration. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X117 was evaluated for [E1]a diagnosis of external ophthalmopleg[/E1]ia. The patient also presented with myoclonic seizures and an increased CSF protein concentration. Subsequent sequencing [E2]of t[/E2]he POLG gene revealed a pathogenic variant.,of t,GENE_VARIANT,189,193,a diagnosis of external ophthalmopleg,HPO_TERM,31,68,0.86628985,0.13371012,-0.7325797,0
line317,Patient X117 was evaluated for a diagnosis of external ophthalmoplegia. The patient also presented with myoclonic seizures and an increased CSF protein concentration. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X117 was evaluated for a diagnosis of external ophthalmoplegia. The patient also presented wit[E1]h myoclonic seizu[/E1]res and an increased CSF protein concentration. Subsequent sequencing [E2]of t[/E2]he POLG gene revealed a pathogenic variant.,of t,GENE_VARIANT,189,193,h myoclonic seizu,HPO_TERM,102,119,0.83957803,0.16042197,-0.67915606,0
line317,Patient X117 was evaluated for a diagnosis of external ophthalmoplegia. The patient also presented with myoclonic seizures and an increased CSF protein concentration. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X117 was evaluated for a diagnosis of external ophthalmoplegia. The patient also presented with myoclonic seizures a[E1]nd an increased CSF protein concen[/E1]tration. Subsequent sequencing [E2]of t[/E2]he POLG gene revealed a pathogenic variant.,of t,GENE_VARIANT,189,193,nd an increased CSF protein concen,HPO_TERM,124,158,0.8726754,0.12732455,-0.74535084,0
line318,Patient X118 was evaluated for an infantile onset. The patient also presented with a complaint of dysphagia and a state of low muscle tone. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X118 was evaluated for [E1]an infantile onse[/E1]t. The patient also presented with a complaint of dysphagia and a state of low muscle tone. Subsequent sequencing of[E2] the[/E2] POLG gene revealed a pathogenic variant., the,GENE_VARIANT,164,168,an infantile onse,HPO_TERM,31,48,0.82812476,0.17187527,-0.6562495,0
line318,Patient X118 was evaluated for an infantile onset. The patient also presented with a complaint of dysphagia and a state of low muscle tone. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X118 was evaluated for an infantile onset. The patient also presented with[E1] a complaint of dyspha[/E1]gia and a state of low muscle tone. Subsequent sequencing of[E2] the[/E2] POLG gene revealed a pathogenic variant., the,GENE_VARIANT,164,168, a complaint of dyspha,HPO_TERM,82,104,0.76070875,0.23929119,-0.52141756,0
line318,Patient X118 was evaluated for an infantile onset. The patient also presented with a complaint of dysphagia and a state of low muscle tone. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X118 was evaluated for an infantile onset. The patient also presented with a complaint of dysphagia a[E1]nd a state of low muscle[/E1] tone. Subsequent sequencing of[E2] the[/E2] POLG gene revealed a pathogenic variant., the,GENE_VARIANT,164,168,nd a state of low muscle,HPO_TERM,109,133,0.81622154,0.18377848,-0.6324431,0
line319,"This report details Patient X119, a patient with a state of low muscle tone. Further investigation showed difficulty swallowing and an infantile onset. A known variant in the POLG gene was identified.","This report details Patient X119, a patient with [E1]a state of low muscle to[/E1]ne. Further investigation showed difficulty swallowing and an infantile onset. A known variant in [E2]the [/E2]POLG gene was identified.",the ,GENE_VARIANT,171,175,a state of low muscle to,HPO_TERM,49,73,0.7775006,0.22249945,-0.5550012,0
line319,"This report details Patient X119, a patient with a state of low muscle tone. Further investigation showed difficulty swallowing and an infantile onset. A known variant in the POLG gene was identified.","This report details Patient X119, a patient with a state of low muscle tone. Further investigation showe[E1]d difficulty swallowi[/E1]ng and an infantile onset. A known variant in [E2]the [/E2]POLG gene was identified.",the ,GENE_VARIANT,171,175,d difficulty swallowi,HPO_TERM,104,125,0.80355275,0.1964472,-0.60710555,0
line319,"This report details Patient X119, a patient with a state of low muscle tone. Further investigation showed difficulty swallowing and an infantile onset. A known variant in the POLG gene was identified.","This report details Patient X119, a patient with a state of low muscle tone. Further investigation showed difficulty swallowing an[E1]d an infantile on[/E1]set. A known variant in [E2]the [/E2]POLG gene was identified.",the ,GENE_VARIANT,171,175,d an infantile on,HPO_TERM,130,147,0.8000826,0.19991733,-0.6001653,0
line320,Patient X120 was evaluated for myoclonic seizures. The patient also presented with a diagnosis of external ophthalmoplegia and an infantile onset. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X120 was evaluated for [E1]myoclonic seizure[/E1]s. The patient also presented with a diagnosis of external ophthalmoplegia and an infantile onset. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,172,176,myoclonic seizure,HPO_TERM,31,48,0.8363808,0.16361924,-0.67276156,0
line320,Patient X120 was evaluated for myoclonic seizures. The patient also presented with a diagnosis of external ophthalmoplegia and an infantile onset. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X120 was evaluated for myoclonic seizures. The patient also presented with[E1] a diagnosis of external ophthalmople[/E1]gia and an infantile onset. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,172,176, a diagnosis of external ophthalmople,HPO_TERM,82,119,0.79490906,0.20509094,-0.5898181,0
line320,Patient X120 was evaluated for myoclonic seizures. The patient also presented with a diagnosis of external ophthalmoplegia and an infantile onset. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X120 was evaluated for myoclonic seizures. The patient also presented with a diagnosis of external ophthalmoplegia a[E1]nd an infantile o[/E1]nset. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,172,176,nd an infantile o,HPO_TERM,124,141,0.84148794,0.15851213,-0.6829758,0
line321,The clinical profile for Patient X121 includes a diagnosis of sensory axonal neuropathy and a state of low muscle tone. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient X121 includes [E1]a diagnosis of sensory axonal neuropathy[/E1] and a state of low muscle tone. Genetic analysis of th[E2]e PO[/E2]LG gene confirmed the diagnosis.,e PO,GENE_VARIANT,142,146,a diagnosis of sensory axonal neuropathy,HPO_TERM,47,87,0.8762202,0.12377984,-0.7524404,0
line321,The clinical profile for Patient X121 includes a diagnosis of sensory axonal neuropathy and a state of low muscle tone. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient X121 includes a diagnosis of sensory axonal neuropathy and [E1]a state of low muscle to[/E1]ne. Genetic analysis of th[E2]e PO[/E2]LG gene confirmed the diagnosis.,e PO,GENE_VARIANT,142,146,a state of low muscle to,HPO_TERM,92,116,0.8792163,0.12078367,-0.7584326,0
line322,Patient X122 was evaluated for a state of low muscle tone. The patient also presented with a diagnosis of external ophthalmoplegia and myoclonic jerks. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X122 was evaluated for [E1]a state of low muscle to[/E1]ne. The patient also presented with a diagnosis of external ophthalmoplegia and myoclonic jerks. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,177,181,a state of low muscle to,HPO_TERM,31,55,0.83198875,0.16801123,-0.6639775,0
line322,Patient X122 was evaluated for a state of low muscle tone. The patient also presented with a diagnosis of external ophthalmoplegia and myoclonic jerks. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X122 was evaluated for a state of low muscle tone. The patient also presented wit[E1]h a diagnosis of external ophthalmopl[/E1]egia and myoclonic jerks. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,177,181,h a diagnosis of external ophthalmopl,HPO_TERM,89,126,0.85299504,0.14700495,-0.7059901,0
line322,Patient X122 was evaluated for a state of low muscle tone. The patient also presented with a diagnosis of external ophthalmoplegia and myoclonic jerks. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X122 was evaluated for a state of low muscle tone. The patient also presented with a diagnosis of external ophthalmoplegia [E1]and myoclonic j[/E1]erks. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,177,181,and myoclonic j,HPO_TERM,131,146,0.82924104,0.170759,-0.658482,0
line323,"We report the case of Patient X123, who has a history of a state of low muscle tone. Examination also revealed a diagnosis of sensory axonal neuropathy. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient X123, who has a history of [E1]a state of low muscle to[/E1]ne. Examination also revealed a diagnosis of sensory axonal neuropathy. The underlying cause was traced to a mutation in th[E2]e PO[/E2]LG gene.",e PO,GENE_VARIANT,204,208,a state of low muscle to,HPO_TERM,57,81,0.62796146,0.37203857,-0.25592288,0
line323,"We report the case of Patient X123, who has a history of a state of low muscle tone. Examination also revealed a diagnosis of sensory axonal neuropathy. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient X123, who has a history of a state of low muscle tone. Examination also reveale[E1]d a diagnosis of sensory axonal neuropat[/E1]hy. The underlying cause was traced to a mutation in th[E2]e PO[/E2]LG gene.",e PO,GENE_VARIANT,204,208,d a diagnosis of sensory axonal neuropat,HPO_TERM,109,149,0.79574895,0.20425105,-0.5914979,0
line324,The clinical profile for Patient X124 includes myoclonic jerks and a diagnosis of ataxia. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient X124 includes [E1]myoclonic jerks[/E1] and a diagnosis of ataxia. Genetic analysis of th[E2]e PO[/E2]LG gene confirmed the diagnosis.,e PO,GENE_VARIANT,112,116,myoclonic jerks,HPO_TERM,47,62,0.8653491,0.13465083,-0.7306983,0
line324,The clinical profile for Patient X124 includes myoclonic jerks and a diagnosis of ataxia. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient X124 includes myoclonic jerks and [E1]a diagnosis of atax[/E1]ia. Genetic analysis of th[E2]e PO[/E2]LG gene confirmed the diagnosis.,e PO,GENE_VARIANT,112,116,a diagnosis of atax,HPO_TERM,67,86,0.8755374,0.1244626,-0.7510748,0
line325,Patient X125 was evaluated for a diagnosis of external ophthalmoplegia. The patient also presented with problems with swallowing and a presentation in infancy. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X125 was evaluated for [E1]a diagnosis of external ophthalmopleg[/E1]ia. The patient also presented with problems with swallowing and a presentation in infancy. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,185,189,a diagnosis of external ophthalmopleg,HPO_TERM,31,68,0.8509229,0.14907709,-0.70184577,0
line325,Patient X125 was evaluated for a diagnosis of external ophthalmoplegia. The patient also presented with problems with swallowing and a presentation in infancy. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X125 was evaluated for a diagnosis of external ophthalmoplegia. The patient also presented wit[E1]h problems with swallo[/E1]wing and a presentation in infancy. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,185,189,h problems with swallo,HPO_TERM,102,124,0.82787806,0.17212193,-0.6557561,0
line325,Patient X125 was evaluated for a diagnosis of external ophthalmoplegia. The patient also presented with problems with swallowing and a presentation in infancy. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X125 was evaluated for a diagnosis of external ophthalmoplegia. The patient also presented with problems with swallowing [E1]and a presentation in inf[/E1]ancy. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,185,189,and a presentation in inf,HPO_TERM,129,154,0.8382246,0.1617754,-0.6764492,0
line326,Patient X126 was evaluated for a condition affecting eye movement. The patient also presented with an increased CSF protein concentration and myoclonic jerks. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X126 was evaluated for [E1]a condition affecting eye movemen[/E1]t. The patient also presented with an increased CSF protein concentration and myoclonic jerks. Subsequent sequencing of[E2] the[/E2] POLG gene revealed a pathogenic variant., the,GENE_VARIANT,183,187,a condition affecting eye movemen,HPO_TERM,31,64,0.8405813,0.15941875,-0.68116254,0
line326,Patient X126 was evaluated for a condition affecting eye movement. The patient also presented with an increased CSF protein concentration and myoclonic jerks. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X126 was evaluated for a condition affecting eye movement. The patient also presented with[E1] an increased CSF protein concentr[/E1]ation and myoclonic jerks. Subsequent sequencing of[E2] the[/E2] POLG gene revealed a pathogenic variant., the,GENE_VARIANT,183,187, an increased CSF protein concentr,HPO_TERM,98,132,0.8005455,0.19945453,-0.60109097,0
line326,Patient X126 was evaluated for a condition affecting eye movement. The patient also presented with an increased CSF protein concentration and myoclonic jerks. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X126 was evaluated for a condition affecting eye movement. The patient also presented with an increased CSF protein concentration[E1] and myoclonic [/E1]jerks. Subsequent sequencing of[E2] the[/E2] POLG gene revealed a pathogenic variant., the,GENE_VARIANT,183,187, and myoclonic ,HPO_TERM,137,152,0.8179831,0.18201694,-0.6359662,0
line327,The primary symptoms for Patient X127 were myoclonic seizures and an increased CSF protein concentration. Analysis of the POLG gene was performed.,The primary symptoms for Patient X127 were my[E1]oclonic seizures [/E1]and an increased CSF protein concentration. Analysis of the POLG [E2]gene[/E2] was performed.,gene,GENE_VARIANT,127,131,oclonic seizures ,HPO_TERM,45,62,0.81689817,0.18310183,-0.63379633,0
line327,The primary symptoms for Patient X127 were myoclonic seizures and an increased CSF protein concentration. Analysis of the POLG gene was performed.,The primary symptoms for Patient X127 were myoclonic seizures and a[E1]n increased CSF protein concentrat[/E1]ion. Analysis of the POLG [E2]gene[/E2] was performed.,gene,GENE_VARIANT,127,131,n increased CSF protein concentrat,HPO_TERM,67,101,0.82327515,0.17672487,-0.6465503,0
line328,Patient X128 was evaluated for a state of low muscle tone. The patient also presented with an infantile onset and myoclonic jerks. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X128 was evaluated for [E1]a state of low muscle to[/E1]ne. The patient also presented with an infantile onset and myoclonic jerks. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,157,161,a state of low muscle to,HPO_TERM,31,55,0.83816606,0.16183394,-0.6763321,0
line328,Patient X128 was evaluated for a state of low muscle tone. The patient also presented with an infantile onset and myoclonic jerks. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X128 was evaluated for a state of low muscle tone. The patient also presented wit[E1]h an infantile on[/E1]set and myoclonic jerks. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,157,161,h an infantile on,HPO_TERM,89,106,0.8520733,0.14792669,-0.7041466,0
line328,Patient X128 was evaluated for a state of low muscle tone. The patient also presented with an infantile onset and myoclonic jerks. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X128 was evaluated for a state of low muscle tone. The patient also presented with an infantile onset a[E1]nd myoclonic je[/E1]rks. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,157,161,nd myoclonic je,HPO_TERM,111,126,0.8582511,0.14174895,-0.71650213,0
line329,The clinical profile for Patient X129 includes a state of low muscle tone and problems with balance and coordination. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient X129 includes [E1]a state of low muscle to[/E1]ne and problems with balance and coordination. Genetic analysis o[E2]f th[/E2]e POLG gene confirmed the diagnosis.,f th,GENE_VARIANT,136,140,a state of low muscle to,HPO_TERM,47,71,0.8319053,0.16809468,-0.6638106,0
line329,The clinical profile for Patient X129 includes a state of low muscle tone and problems with balance and coordination. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient X129 includes a state of low muscle tone an[E1]d problems with balance and coordi[/E1]nation. Genetic analysis o[E2]f th[/E2]e POLG gene confirmed the diagnosis.,f th,GENE_VARIANT,136,140,d problems with balance and coordi,HPO_TERM,76,110,0.8464909,0.15350908,-0.69298184,0
line330,Patient X130 was evaluated for difficulty swallowing. The patient also presented with a presentation in infancy and a diagnosis of external ophthalmoplegia. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X130 was evaluated for [E1]difficulty swallowing[/E1]. The patient also presented with a presentation in infancy and a diagnosis of external ophthalmoplegia. Subsequent sequencing of th[E2]e PO[/E2]LG gene revealed a pathogenic variant.,e PO,GENE_VARIANT,184,188,difficulty swallowing,HPO_TERM,31,52,0.8730397,0.12696029,-0.74607944,0
line330,Patient X130 was evaluated for difficulty swallowing. The patient also presented with a presentation in infancy and a diagnosis of external ophthalmoplegia. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X130 was evaluated for difficulty swallowing. The patient also presented with [E1]a presentation in infancy[/E1] and a diagnosis of external ophthalmoplegia. Subsequent sequencing of th[E2]e PO[/E2]LG gene revealed a pathogenic variant.,e PO,GENE_VARIANT,184,188,a presentation in infancy,HPO_TERM,86,111,0.87413484,0.12586518,-0.7482697,0
line330,Patient X130 was evaluated for difficulty swallowing. The patient also presented with a presentation in infancy and a diagnosis of external ophthalmoplegia. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X130 was evaluated for difficulty swallowing. The patient also presented with a presentation in infancy and [E1]a diagnosis of external ophthalmopleg[/E1]ia. Subsequent sequencing of th[E2]e PO[/E2]LG gene revealed a pathogenic variant.,e PO,GENE_VARIANT,184,188,a diagnosis of external ophthalmopleg,HPO_TERM,116,153,0.87497324,0.12502675,-0.7499465,0
line331,The clinical profile for Patient X131 includes a condition affecting eye movement and a diagnosis of ataxia. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient X131 includes [E1]a condition affecting eye movemen[/E1]t and a diagnosis of ataxia. Genetic analysis of t[E2]he P[/E2]OLG gene confirmed the diagnosis.,he P,GENE_VARIANT,130,134,a condition affecting eye movemen,HPO_TERM,47,80,0.87527204,0.12472797,-0.7505441,0
line331,The clinical profile for Patient X131 includes a condition affecting eye movement and a diagnosis of ataxia. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient X131 includes a condition affecting eye movement and[E1] a diagnosis of ata[/E1]xia. Genetic analysis of t[E2]he P[/E2]OLG gene confirmed the diagnosis.,he P,GENE_VARIANT,130,134, a diagnosis of ata,HPO_TERM,85,104,0.8660596,0.13394043,-0.7321192,0
line332,The primary symptoms for Patient X132 were problems with swallowing and a lack of voluntary coordination of muscle movements. Analysis of the POLG gene was performed.,The primary symptoms for Patient X132 were pr[E1]oblems with swallowing[/E1] and a lack of voluntary coordination of muscle movements. Analysis of the POLG ge[E2]ne w[/E2]as performed.,ne w,GENE_VARIANT,149,153,oblems with swallowing,HPO_TERM,45,67,0.79929477,0.20070523,-0.59858954,0
line332,The primary symptoms for Patient X132 were problems with swallowing and a lack of voluntary coordination of muscle movements. Analysis of the POLG gene was performed.,The primary symptoms for Patient X132 were problems with swallowing and [E1]a lack of voluntary coordination of muscle movement[/E1]s. Analysis of the POLG ge[E2]ne w[/E2]as performed.,ne w,GENE_VARIANT,149,153,a lack of voluntary coordination of muscle movement,HPO_TERM,72,123,0.790359,0.20964104,-0.580718,0
line333,Patient X133 was evaluated for an increased CSF protein concentration. The patient also presented with a diagnosis of sensory axonal neuropathy and a diagnosis of ataxia. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X133 was evaluated for [E1]an increased CSF protein concentra[/E1]tion. The patient also presented with a diagnosis of sensory axonal neuropathy and a diagnosis of ataxia. Subsequent sequencing o[E2]f th[/E2]e POLG gene revealed a pathogenic variant.,f th,GENE_VARIANT,194,198,an increased CSF protein concentra,HPO_TERM,31,65,0.8657252,0.13427483,-0.7314504,0
line333,Patient X133 was evaluated for an increased CSF protein concentration. The patient also presented with a diagnosis of sensory axonal neuropathy and a diagnosis of ataxia. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X133 was evaluated for an increased CSF protein concentration. The patient also presented w[E1]ith a diagnosis of sensory axonal neurop[/E1]athy and a diagnosis of ataxia. Subsequent sequencing o[E2]f th[/E2]e POLG gene revealed a pathogenic variant.,f th,GENE_VARIANT,194,198,ith a diagnosis of sensory axonal neurop,HPO_TERM,99,139,0.86948305,0.13051693,-0.7389661,0
line333,Patient X133 was evaluated for an increased CSF protein concentration. The patient also presented with a diagnosis of sensory axonal neuropathy and a diagnosis of ataxia. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X133 was evaluated for an increased CSF protein concentration. The patient also presented with a diagnosis of sensory axonal neuropathy [E1]and a diagnosis of [/E1]ataxia. Subsequent sequencing o[E2]f th[/E2]e POLG gene revealed a pathogenic variant.,f th,GENE_VARIANT,194,198,and a diagnosis of ,HPO_TERM,144,163,0.8610761,0.13892382,-0.7221523,0
line334,"This report details Patient X134, a patient with myoclonic jerks. Further investigation showed a presentation in infancy and a diagnosis of external ophthalmoplegia. A known variant in the POLG gene was identified.","This report details Patient X134, a patient with [E1]myoclonic jerks[/E1]. Further investigation showed a presentation in infancy and a diagnosis of external ophthalmoplegia. A known variant in t[E2]he P[/E2]OLG gene was identified.",he P,GENE_VARIANT,186,190,myoclonic jerks,HPO_TERM,49,64,0.8299565,0.17004353,-0.65991294,0
line334,"This report details Patient X134, a patient with myoclonic jerks. Further investigation showed a presentation in infancy and a diagnosis of external ophthalmoplegia. A known variant in the POLG gene was identified.","This report details Patient X134, a patient with myoclonic jerks. Further investigation showed [E1]a presentation in infancy[/E1] and a diagnosis of external ophthalmoplegia. A known variant in t[E2]he P[/E2]OLG gene was identified.",he P,GENE_VARIANT,186,190,a presentation in infancy,HPO_TERM,95,120,0.8367939,0.16320607,-0.6735878,0
line334,"This report details Patient X134, a patient with myoclonic jerks. Further investigation showed a presentation in infancy and a diagnosis of external ophthalmoplegia. A known variant in the POLG gene was identified.","This report details Patient X134, a patient with myoclonic jerks. Further investigation showed a presentation in infancy and [E1]a diagnosis of external ophthalmopleg[/E1]ia. A known variant in t[E2]he P[/E2]OLG gene was identified.",he P,GENE_VARIANT,186,190,a diagnosis of external ophthalmopleg,HPO_TERM,125,162,0.84619033,0.1538097,-0.69238067,0
line335,"We report the case of Patient X135, who has a history of myoclonic seizures. Examination also revealed a diagnosis of sensory axonal neuropathy. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient X135, who has a history of [E1]myoclonic seizure[/E1]s. Examination also revealed a diagnosis of sensory axonal neuropathy. The underlying cause was traced to a mutation in the[E2] POL[/E2]G gene.", POL,GENE_VARIANT,197,201,myoclonic seizure,HPO_TERM,57,74,0.64615947,0.35384053,-0.29231894,0
line335,"We report the case of Patient X135, who has a history of myoclonic seizures. Examination also revealed a diagnosis of sensory axonal neuropathy. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient X135, who has a history of myoclonic seizures. Examination also revealed[E1] a diagnosis of sensory axonal neuropath[/E1]y. The underlying cause was traced to a mutation in the[E2] POL[/E2]G gene.", POL,GENE_VARIANT,197,201, a diagnosis of sensory axonal neuropath,HPO_TERM,102,142,0.63026977,0.36973026,-0.2605395,0
line336,The clinical profile for Patient X136 includes a state of low muscle tone and a diagnosis of sensory axonal neuropathy. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient X136 includes [E1]a state of low muscle to[/E1]ne and a diagnosis of sensory axonal neuropathy. Genetic analysis of th[E2]e PO[/E2]LG gene confirmed the diagnosis.,e PO,GENE_VARIANT,142,146,a state of low muscle to,HPO_TERM,47,71,0.86916107,0.1308389,-0.73832214,0
line336,The clinical profile for Patient X136 includes a state of low muscle tone and a diagnosis of sensory axonal neuropathy. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient X136 includes a state of low muscle tone an[E1]d a diagnosis of sensory axonal neuropat[/E1]hy. Genetic analysis of th[E2]e PO[/E2]LG gene confirmed the diagnosis.,e PO,GENE_VARIANT,142,146,d a diagnosis of sensory axonal neuropat,HPO_TERM,76,116,0.88505304,0.114946924,-0.77010614,0
line337,The clinical profile for Patient X137 includes difficulty swallowing and hypotonia. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient X137 includes [E1]difficulty swallowing[/E1] and hypotonia. Genetic analysis of the [E2]POLG[/E2] gene confirmed the diagnosis.,POLG,GENE_VARIANT,108,112,difficulty swallowing,HPO_TERM,47,68,0.79841495,0.20158508,-0.5968299,0
line337,The clinical profile for Patient X137 includes difficulty swallowing and hypotonia. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient X137 includes difficulty swallowing and [E1]hypotonia[/E1]. Genetic analysis of the [E2]POLG[/E2] gene confirmed the diagnosis.,POLG,GENE_VARIANT,108,112,hypotonia,HPO_TERM,73,82,0.81333756,0.18666244,-0.6266751,0
line338,The primary symptoms for Patient X138 were a diagnosis of ataxia and hypotonia. Analysis of the POLG gene was performed.,The primary symptoms for Patient X138 were a [E1]diagnosis of ataxia[/E1] and hypotonia. Analysis of the POLG gen[E2]e wa[/E2]s performed.,e wa,GENE_VARIANT,104,108,diagnosis of ataxia,HPO_TERM,45,64,0.80501336,0.1949866,-0.6100268,0
line338,The primary symptoms for Patient X138 were a diagnosis of ataxia and hypotonia. Analysis of the POLG gene was performed.,The primary symptoms for Patient X138 were a diagnosis of ataxia and [E1]hypotonia[/E1]. Analysis of the POLG gen[E2]e wa[/E2]s performed.,e wa,GENE_VARIANT,104,108,hypotonia,HPO_TERM,69,78,0.8026289,0.19737113,-0.60525775,0
line339,The clinical profile for Patient X139 includes a diagnosis of external ophthalmoplegia and ataxia. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient X139 includes [E1]a diagnosis of external ophthalmopleg[/E1]ia and ataxia. Genetic analysis of th[E2]e PO[/E2]LG gene confirmed the diagnosis.,e PO,GENE_VARIANT,121,125,a diagnosis of external ophthalmopleg,HPO_TERM,47,84,0.8704959,0.12950404,-0.7409919,0
line339,The clinical profile for Patient X139 includes a diagnosis of external ophthalmoplegia and ataxia. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient X139 includes a diagnosis of external ophthalmoplegia an[E1]d atax[/E1]ia. Genetic analysis of th[E2]e PO[/E2]LG gene confirmed the diagnosis.,e PO,GENE_VARIANT,121,125,d atax,HPO_TERM,89,95,0.8784919,0.12150818,-0.7569837,0
line340,"We report the case of Patient X140, who has a history of a diagnosis of external ophthalmoplegia. Examination also revealed a diagnosis of ataxia. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient X140, who has a history of [E1]a diagnosis of external ophthalmopleg[/E1]ia. Examination also revealed a diagnosis of ataxia. The underlying cause was traced to a mutation in [E2]the [/E2]POLG gene.",the ,GENE_VARIANT,196,200,a diagnosis of external ophthalmopleg,HPO_TERM,57,94,0.62118405,0.37881595,-0.2423681,0
line340,"We report the case of Patient X140, who has a history of a diagnosis of external ophthalmoplegia. Examination also revealed a diagnosis of ataxia. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient X140, who has a history of a diagnosis of external ophthalmoplegia. Examination also reveale[E1]d a diagnosis of at[/E1]axia. The underlying cause was traced to a mutation in [E2]the [/E2]POLG gene.",the ,GENE_VARIANT,196,200,d a diagnosis of at,HPO_TERM,122,141,0.6826713,0.31732866,-0.36534265,0
line341,Patient X141 was evaluated for myoclonic seizures. The patient also presented with a diagnosis of external ophthalmoplegia and myoclonic jerks. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X141 was evaluated for [E1]myoclonic seizure[/E1]s. The patient also presented with a diagnosis of external ophthalmoplegia and myoclonic jerks. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,170,174,myoclonic seizure,HPO_TERM,31,48,0.8605946,0.13940534,-0.72118926,0
line341,Patient X141 was evaluated for myoclonic seizures. The patient also presented with a diagnosis of external ophthalmoplegia and myoclonic jerks. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X141 was evaluated for myoclonic seizures. The patient also presented with[E1] a diagnosis of external ophthalmople[/E1]gia and myoclonic jerks. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,170,174, a diagnosis of external ophthalmople,HPO_TERM,82,119,0.826524,0.17347597,-0.65304804,0
line341,Patient X141 was evaluated for myoclonic seizures. The patient also presented with a diagnosis of external ophthalmoplegia and myoclonic jerks. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X141 was evaluated for myoclonic seizures. The patient also presented with a diagnosis of external ophthalmoplegia a[E1]nd myoclonic je[/E1]rks. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,170,174,nd myoclonic je,HPO_TERM,124,139,0.8634987,0.13650139,-0.7269973,0
line342,Patient X142 was evaluated for a state of low muscle tone. The patient also presented with myoclonic jerks and a diagnosis of external ophthalmoplegia. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X142 was evaluated for [E1]a state of low muscle to[/E1]ne. The patient also presented with myoclonic jerks and a diagnosis of external ophthalmoplegia. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,177,181,a state of low muscle to,HPO_TERM,31,55,0.83335096,0.1666491,-0.66670185,0
line342,Patient X142 was evaluated for a state of low muscle tone. The patient also presented with myoclonic jerks and a diagnosis of external ophthalmoplegia. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X142 was evaluated for a state of low muscle tone. The patient also presented wit[E1]h myoclonic jer[/E1]ks and a diagnosis of external ophthalmoplegia. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,177,181,h myoclonic jer,HPO_TERM,89,104,0.84106725,0.15893279,-0.68213445,0
line342,Patient X142 was evaluated for a state of low muscle tone. The patient also presented with myoclonic jerks and a diagnosis of external ophthalmoplegia. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X142 was evaluated for a state of low muscle tone. The patient also presented with myoclonic jerks an[E1]d a diagnosis of external ophthalmopl[/E1]egia. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,177,181,d a diagnosis of external ophthalmopl,HPO_TERM,109,146,0.8397669,0.16023305,-0.67953384,0
line343,The clinical profile for Patient X143 includes problems with balance and coordination and a diagnosis of ataxia. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient X143 includes [E1]problems with balance and coordina[/E1]tion and a diagnosis of ataxia. Genetic analysis o[E2]f th[/E2]e POLG gene confirmed the diagnosis.,f th,GENE_VARIANT,131,135,problems with balance and coordina,HPO_TERM,47,81,0.8511511,0.14884889,-0.7023022,0
line343,The clinical profile for Patient X143 includes problems with balance and coordination and a diagnosis of ataxia. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient X143 includes problems with balance and coordination [E1]and a diagnosis of [/E1]ataxia. Genetic analysis o[E2]f th[/E2]e POLG gene confirmed the diagnosis.,f th,GENE_VARIANT,131,135,and a diagnosis of ,HPO_TERM,86,105,0.85554653,0.14445353,-0.711093,0
line344,The primary symptoms for Patient X144 were myoclonic jerks and a diagnosis of external ophthalmoplegia. Analysis of the POLG gene was performed.,The primary symptoms for Patient X144 were my[E1]oclonic jerks a[/E1]nd a diagnosis of external ophthalmoplegia. Analysis of the POLG gen[E2]e wa[/E2]s performed.,e wa,GENE_VARIANT,128,132,oclonic jerks a,HPO_TERM,45,60,0.80021435,0.19978562,-0.6004287,0
line344,The primary symptoms for Patient X144 were myoclonic jerks and a diagnosis of external ophthalmoplegia. Analysis of the POLG gene was performed.,The primary symptoms for Patient X144 were myoclonic jerks and a [E1]diagnosis of external ophthalmoplegia[/E1]. Analysis of the POLG gen[E2]e wa[/E2]s performed.,e wa,GENE_VARIANT,128,132,diagnosis of external ophthalmoplegia,HPO_TERM,65,102,0.81665975,0.18334025,-0.6333195,0
line345,"We report the case of Patient X145, who has a history of problems with balance and coordination. Examination also revealed myoclonic seizures. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient X145, who has a history of [E1]problems with balance and coordina[/E1]tion. Examination also revealed myoclonic seizures. The underlying cause was traced to a mutation in[E2] the[/E2] POLG gene.", the,GENE_VARIANT,191,195,problems with balance and coordina,HPO_TERM,57,91,0.43273664,0.56726336,0.13452673,1
line345,"We report the case of Patient X145, who has a history of problems with balance and coordination. Examination also revealed myoclonic seizures. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient X145, who has a history of problems with balance and coordination. Examination also revea[E1]led myoclonic sei[/E1]zures. The underlying cause was traced to a mutation in[E2] the[/E2] POLG gene.", the,GENE_VARIANT,191,195,led myoclonic sei,HPO_TERM,119,136,0.3798154,0.6201846,0.2403692,1
line346,The primary symptoms for Patient X146 were myoclonic seizures and EMG: myopathic abnormalities. Analysis of the POLG gene was performed.,The primary symptoms for Patient X146 were my[E1]oclonic seizures [/E1]and EMG: myopathic abnormalities. Analysis of the POLG gene[E2] was[/E2] performed., was,GENE_VARIANT,121,125,oclonic seizures ,HPO_TERM,45,62,0.85527515,0.14472488,-0.7105503,0
line347,"We report the case of Patient X147, who has a history of myoclonic jerks. Examination also revealed EMG: myopathic abnormalities. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient X147, who has a history of [E1]myoclonic jerks[/E1]. Examination also revealed EMG: myopathic abnormalities. The underlying cause was traced to a mutation in the [E2]POLG[/E2] gene.",POLG,GENE_VARIANT,183,187,myoclonic jerks,HPO_TERM,57,72,0.45896584,0.54103416,0.082068324,1
line347,"We report the case of Patient X147, who has a history of myoclonic jerks. Examination also revealed EMG: myopathic abnormalities. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient X147, who has a history of myoclonic jerks. Examination also revealed [E1]EMG: myopathic abnormalities[/E1]. The underlying cause was traced to a mutation in the [E2]POLG[/E2] gene.",POLG,GENE_VARIANT,183,187,EMG: myopathic abnormalities,HPO_TERM,100,128,0.3816692,0.6183309,0.2366617,1
line348,"We report the case of Patient X148, who has a history of incoordinated movements. Examination also revealed a diagnosis of external ophthalmoplegia. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient X148, who has a history of [E1]incoordinated movement[/E1]s. Examination also revealed a diagnosis of external ophthalmoplegia. The underlying cause was traced to a mutation in t[E2]he P[/E2]OLG gene.",he P,GENE_VARIANT,199,203,incoordinated movement,HPO_TERM,57,79,0.5533647,0.44663534,-0.10672936,0
line348,"We report the case of Patient X148, who has a history of incoordinated movements. Examination also revealed a diagnosis of external ophthalmoplegia. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient X148, who has a history of incoordinated movements. Examination also revealed[E1] a diagnosis of external ophthalmople[/E1]gia. The underlying cause was traced to a mutation in t[E2]he P[/E2]OLG gene.",he P,GENE_VARIANT,199,203, a diagnosis of external ophthalmople,HPO_TERM,107,144,0.34666112,0.65333885,0.30667773,1
line349,"We report the case of Patient X149, who has a history of hypotonia. Examination also revealed an infantile onset. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient X149, who has a history of [E1]hypotonia[/E1]. Examination also revealed an infantile onset. The underlying cause was traced to a mutation in the[E2] POL[/E2]G gene.", POL,GENE_VARIANT,166,170,hypotonia,HPO_TERM,57,66,0.55066186,0.4493381,-0.10132375,0
line349,"We report the case of Patient X149, who has a history of hypotonia. Examination also revealed an infantile onset. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient X149, who has a history of hypotonia. Examination also revealed [E1]an infantile onse[/E1]t. The underlying cause was traced to a mutation in the[E2] POL[/E2]G gene.", POL,GENE_VARIANT,166,170,an infantile onse,HPO_TERM,94,111,0.4929555,0.50704455,0.014089048,1
line350,The primary symptoms for Patient X150 were a diagnosis of ataxia and an increased CSF protein concentration. Analysis of the POLG gene was performed.,The primary symptoms for Patient X150 were a[E1] diagnosis of ataxi[/E1]a and an increased CSF protein concentration. Analysis of the POL[E2]G ge[/E2]ne was performed.,G ge,GENE_VARIANT,128,132, diagnosis of ataxi,HPO_TERM,44,63,0.8600629,0.13993709,-0.7201258,0
line350,The primary symptoms for Patient X150 were a diagnosis of ataxia and an increased CSF protein concentration. Analysis of the POLG gene was performed.,The primary symptoms for Patient X150 were a diagnosis of ataxia and[E1] an increased CSF protein concentr[/E1]ation. Analysis of the POL[E2]G ge[/E2]ne was performed.,G ge,GENE_VARIANT,128,132, an increased CSF protein concentr,HPO_TERM,68,102,0.85078895,0.14921105,-0.7015779,0
line351,The clinical profile for Patient X151 includes ataxia and a diagnosis of external ophthalmoplegia. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient X151 includes [E1]ataxia[/E1] and a diagnosis of external ophthalmoplegia. Genetic analysis of th[E2]e PO[/E2]LG gene confirmed the diagnosis.,e PO,GENE_VARIANT,121,125,ataxia,HPO_TERM,47,53,0.86724037,0.13275962,-0.73448074,0
line351,The clinical profile for Patient X151 includes ataxia and a diagnosis of external ophthalmoplegia. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient X151 includes ataxia and [E1]a diagnosis of external ophthalmopleg[/E1]ia. Genetic analysis of th[E2]e PO[/E2]LG gene confirmed the diagnosis.,e PO,GENE_VARIANT,121,125,a diagnosis of external ophthalmopleg,HPO_TERM,58,95,0.8782821,0.12171783,-0.7565643,0
line352,The clinical profile for Patient X152 includes a diagnosis of ataxia and hypotonia. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient X152 includes [E1]a diagnosis of atax[/E1]ia and hypotonia. Genetic analysis of th[E2]e PO[/E2]LG gene confirmed the diagnosis.,e PO,GENE_VARIANT,106,110,a diagnosis of atax,HPO_TERM,47,66,0.86578095,0.13421904,-0.7315619,0
line352,The clinical profile for Patient X152 includes a diagnosis of ataxia and hypotonia. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient X152 includes a diagnosis of ataxia an[E1]d hypoton[/E1]ia. Genetic analysis of th[E2]e PO[/E2]LG gene confirmed the diagnosis.,e PO,GENE_VARIANT,106,110,d hypoton,HPO_TERM,71,80,0.87905204,0.12094798,-0.7581041,0
line353,The clinical profile for Patient X153 includes an infantile onset and EMG results showing myopathic abnormalities. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient X153 includes [E1]an infantile onse[/E1]t and EMG results showing myopathic abnormalities. Genetic analysis of [E2]the [/E2]POLG gene confirmed the diagnosis.,the ,GENE_VARIANT,135,139,an infantile onse,HPO_TERM,47,64,0.8730807,0.12691937,-0.7461613,0
line353,The clinical profile for Patient X153 includes an infantile onset and EMG results showing myopathic abnormalities. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient X153 includes an infantile onset and[E1] EMG results showing myopathic abnormali[/E1]ties. Genetic analysis of [E2]the [/E2]POLG gene confirmed the diagnosis.,the ,GENE_VARIANT,135,139, EMG results showing myopathic abnormali,HPO_TERM,69,109,0.8711351,0.12886482,-0.7422703,0
line354,"This report details Patient X154, a patient with a state of low muscle tone. Further investigation showed a presentation in infancy and EMG: myopathic abnormalities. A known variant in the POLG gene was identified.","This report details Patient X154, a patient with [E1]a state of low muscle to[/E1]ne. Further investigation showed a presentation in infancy and EMG: myopathic abnormalities. A known variant in t[E2]he P[/E2]OLG gene was identified.",he P,GENE_VARIANT,186,190,a state of low muscle to,HPO_TERM,49,73,0.8452424,0.15475762,-0.69048476,0
line354,"This report details Patient X154, a patient with a state of low muscle tone. Further investigation showed a presentation in infancy and EMG: myopathic abnormalities. A known variant in the POLG gene was identified.","This report details Patient X154, a patient with a state of low muscle tone. Further investigation showe[E1]d a presentation in infan[/E1]cy and EMG: myopathic abnormalities. A known variant in t[E2]he P[/E2]OLG gene was identified.",he P,GENE_VARIANT,186,190,d a presentation in infan,HPO_TERM,104,129,0.8462322,0.15376782,-0.69246435,0
line354,"This report details Patient X154, a patient with a state of low muscle tone. Further investigation showed a presentation in infancy and EMG: myopathic abnormalities. A known variant in the POLG gene was identified.","This report details Patient X154, a patient with a state of low muscle tone. Further investigation showed a presentation in infancy an[E1]d EMG: myopathic abnormaliti[/E1]es. A known variant in t[E2]he P[/E2]OLG gene was identified.",he P,GENE_VARIANT,186,190,d EMG: myopathic abnormaliti,HPO_TERM,134,162,0.8601957,0.13980432,-0.7203914,0
line355,The primary symptoms for Patient X155 were incoordinated movements and a diagnosis of external ophthalmoplegia. Analysis of the POLG gene was performed.,The primary symptoms for Patient X155 were in[E1]coordinated movements [/E1]and a diagnosis of external ophthalmoplegia. Analysis of the POLG ge[E2]ne w[/E2]as performed.,ne w,GENE_VARIANT,135,139,coordinated movements ,HPO_TERM,45,67,0.80467594,0.19532411,-0.6093518,0
line355,The primary symptoms for Patient X155 were incoordinated movements and a diagnosis of external ophthalmoplegia. Analysis of the POLG gene was performed.,The primary symptoms for Patient X155 were incoordinated movements and a[E1] diagnosis of external ophthalmoplegi[/E1]a. Analysis of the POLG ge[E2]ne w[/E2]as performed.,ne w,GENE_VARIANT,135,139, diagnosis of external ophthalmoplegi,HPO_TERM,72,109,0.8465213,0.15347865,-0.69304264,0
line356,"This report details Patient X156, a patient with a diagnosis of external ophthalmoplegia. Further investigation showed a state of low muscle tone and problems with swallowing. A known variant in the POLG gene was identified.","This report details Patient X156, a patient with [E1]a diagnosis of external ophthalmopleg[/E1]ia. Further investigation showed a state of low muscle tone and problems with swallowing. A known variant [E2]in t[/E2]he POLG gene was identified.",in t,GENE_VARIANT,192,196,a diagnosis of external ophthalmopleg,HPO_TERM,49,86,0.84286785,0.15713213,-0.6857357,0
line356,"This report details Patient X156, a patient with a diagnosis of external ophthalmoplegia. Further investigation showed a state of low muscle tone and problems with swallowing. A known variant in the POLG gene was identified.","This report details Patient X156, a patient with a diagnosis of external ophthalmoplegia. Further investigation showe[E1]d a state of low muscle [/E1]tone and problems with swallowing. A known variant [E2]in t[/E2]he POLG gene was identified.",in t,GENE_VARIANT,192,196,d a state of low muscle ,HPO_TERM,117,141,0.82692325,0.17307675,-0.6538465,0
line356,"This report details Patient X156, a patient with a diagnosis of external ophthalmoplegia. Further investigation showed a state of low muscle tone and problems with swallowing. A known variant in the POLG gene was identified.","This report details Patient X156, a patient with a diagnosis of external ophthalmoplegia. Further investigation showed a state of low muscle tone [E1]and problems with swal[/E1]lowing. A known variant [E2]in t[/E2]he POLG gene was identified.",in t,GENE_VARIANT,192,196,and problems with swal,HPO_TERM,146,168,0.8187489,0.18125115,-0.6374977,0
line357,"This report details Patient X157, a patient with a state of low muscle tone. Further investigation showed a complaint of dysphagia and an increased CSF protein concentration. A known variant in the POLG gene was identified.","This report details Patient X157, a patient with [E1]a state of low muscle to[/E1]ne. Further investigation showed a complaint of dysphagia and an increased CSF protein concentration. A known varian[E2]t in[/E2] the POLG gene was identified.",t in,GENE_VARIANT,189,193,a state of low muscle to,HPO_TERM,49,73,0.8531417,0.14685826,-0.70628345,0
line357,"This report details Patient X157, a patient with a state of low muscle tone. Further investigation showed a complaint of dysphagia and an increased CSF protein concentration. A known variant in the POLG gene was identified.","This report details Patient X157, a patient with a state of low muscle tone. Further investigation showe[E1]d a complaint of dysph[/E1]agia and an increased CSF protein concentration. A known varian[E2]t in[/E2] the POLG gene was identified.",t in,GENE_VARIANT,189,193,d a complaint of dysph,HPO_TERM,104,126,0.8560106,0.1439894,-0.71202123,0
line357,"This report details Patient X157, a patient with a state of low muscle tone. Further investigation showed a complaint of dysphagia and an increased CSF protein concentration. A known variant in the POLG gene was identified.","This report details Patient X157, a patient with a state of low muscle tone. Further investigation showed a complaint of dysphagia [E1]and an increased CSF protein conce[/E1]ntration. A known varian[E2]t in[/E2] the POLG gene was identified.",t in,GENE_VARIANT,189,193,and an increased CSF protein conce,HPO_TERM,131,165,0.8478319,0.15216814,-0.69566375,0
line358,Patient X158 was evaluated for myoclonic jerks. The patient also presented with a diagnosis of sensory axonal neuropathy and myoclonus. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X158 was evaluated for [E1]myoclonic jerks[/E1]. The patient also presented with a diagnosis of sensory axonal neuropathy and myoclonus. Subsequent sequencing of the [E2]POLG[/E2] gene revealed a pathogenic variant.,POLG,GENE_VARIANT,165,169,myoclonic jerks,HPO_TERM,31,46,0.81390953,0.18609045,-0.62781906,0
line358,Patient X158 was evaluated for myoclonic jerks. The patient also presented with a diagnosis of sensory axonal neuropathy and myoclonus. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X158 was evaluated for myoclonic jerks. The patient also presented with [E1]a diagnosis of sensory axonal neuropathy[/E1] and myoclonus. Subsequent sequencing of the [E2]POLG[/E2] gene revealed a pathogenic variant.,POLG,GENE_VARIANT,165,169,a diagnosis of sensory axonal neuropathy,HPO_TERM,80,120,0.8124119,0.18758811,-0.6248238,0
line358,Patient X158 was evaluated for myoclonic jerks. The patient also presented with a diagnosis of sensory axonal neuropathy and myoclonus. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X158 was evaluated for myoclonic jerks. The patient also presented with a diagnosis of sensory axonal neuropathy and [E1]myoclonus[/E1]. Subsequent sequencing of the [E2]POLG[/E2] gene revealed a pathogenic variant.,POLG,GENE_VARIANT,165,169,myoclonus,HPO_TERM,125,134,0.8098052,0.19019474,-0.6196105,0
line359,The clinical profile for Patient X159 includes myoclonic seizures and a lack of voluntary coordination of muscle movements. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient X159 includes [E1]myoclonic seizure[/E1]s and a lack of voluntary coordination of muscle movements. Genetic analysis of th[E2]e PO[/E2]LG gene confirmed the diagnosis.,e PO,GENE_VARIANT,146,150,myoclonic seizure,HPO_TERM,47,64,0.8529551,0.14704487,-0.7059102,0
line359,The clinical profile for Patient X159 includes myoclonic seizures and a lack of voluntary coordination of muscle movements. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient X159 includes myoclonic seizures and[E1] a lack of voluntary coordination of muscle movemen[/E1]ts. Genetic analysis of th[E2]e PO[/E2]LG gene confirmed the diagnosis.,e PO,GENE_VARIANT,146,150, a lack of voluntary coordination of muscle movemen,HPO_TERM,69,120,0.8626312,0.1373688,-0.7252624,0
line360,The primary symptoms for Patient X160 were an increased CSF protein concentration and problems with swallowing. Analysis of the POLG gene was performed.,The primary symptoms for Patient X160 were a[E1]n increased CSF protein concentrat[/E1]ion and problems with swallowing. Analysis of the POL[E2]G ge[/E2]ne was performed.,G ge,GENE_VARIANT,131,135,n increased CSF protein concentrat,HPO_TERM,44,78,0.8361024,0.16389762,-0.6722048,0
line360,The primary symptoms for Patient X160 were an increased CSF protein concentration and problems with swallowing. Analysis of the POLG gene was performed.,The primary symptoms for Patient X160 were an increased CSF protein concentration a[E1]nd problems with swall[/E1]owing. Analysis of the POL[E2]G ge[/E2]ne was performed.,G ge,GENE_VARIANT,131,135,nd problems with swall,HPO_TERM,83,105,0.8415792,0.15842079,-0.6831584,0
line361,Patient X161 was evaluated for a diagnosis of external ophthalmoplegia. The patient also presented with myoclonic jerks and a state of low muscle tone. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X161 was evaluated for [E1]a diagnosis of external ophthalmopleg[/E1]ia. The patient also presented with myoclonic jerks and a state of low muscle tone. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,177,181,a diagnosis of external ophthalmopleg,HPO_TERM,31,68,0.83861625,0.16138369,-0.67723256,0
line361,Patient X161 was evaluated for a diagnosis of external ophthalmoplegia. The patient also presented with myoclonic jerks and a state of low muscle tone. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X161 was evaluated for a diagnosis of external ophthalmoplegia. The patient also presented wit[E1]h myoclonic jer[/E1]ks and a state of low muscle tone. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,177,181,h myoclonic jer,HPO_TERM,102,117,0.82410616,0.17589383,-0.6482123,0
line361,Patient X161 was evaluated for a diagnosis of external ophthalmoplegia. The patient also presented with myoclonic jerks and a state of low muscle tone. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X161 was evaluated for a diagnosis of external ophthalmoplegia. The patient also presented with myoclonic jerks an[E1]d a state of low muscle [/E1]tone. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,177,181,d a state of low muscle ,HPO_TERM,122,146,0.8128541,0.18714587,-0.6257082,0
line362,The clinical profile for Patient X162 includes a presentation in infancy and a diagnosis of ataxia. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient X162 includes [E1]a presentation in infancy[/E1] and a diagnosis of ataxia. Genetic analysis of th[E2]e PO[/E2]LG gene confirmed the diagnosis.,e PO,GENE_VARIANT,122,126,a presentation in infancy,HPO_TERM,47,72,0.8656413,0.13435863,-0.73128265,0
line362,The clinical profile for Patient X162 includes a presentation in infancy and a diagnosis of ataxia. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient X162 includes a presentation in infancy and [E1]a diagnosis of atax[/E1]ia. Genetic analysis of th[E2]e PO[/E2]LG gene confirmed the diagnosis.,e PO,GENE_VARIANT,122,126,a diagnosis of atax,HPO_TERM,77,96,0.8727419,0.1272582,-0.7454837,0
line363,The clinical profile for Patient X163 includes difficulty swallowing and myoclonic jerks. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient X163 includes [E1]difficulty swallowing[/E1] and myoclonic jerks. Genetic analysis of the [E2]POLG[/E2] gene confirmed the diagnosis.,POLG,GENE_VARIANT,114,118,difficulty swallowing,HPO_TERM,47,68,0.789741,0.21025908,-0.5794819,0
line363,The clinical profile for Patient X163 includes difficulty swallowing and myoclonic jerks. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient X163 includes difficulty swallowing and [E1]myoclonic jerks[/E1]. Genetic analysis of the [E2]POLG[/E2] gene confirmed the diagnosis.,POLG,GENE_VARIANT,114,118,myoclonic jerks,HPO_TERM,73,88,0.8180287,0.1819713,-0.6360574,0
line364,Patient X164 was evaluated for difficulty swallowing. The patient also presented with a diagnosis of external ophthalmoplegia and myoclonic jerks. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X164 was evaluated for [E1]difficulty swallowing[/E1]. The patient also presented with a diagnosis of external ophthalmoplegia and myoclonic jerks. Subsequent sequencing of th[E2]e PO[/E2]LG gene revealed a pathogenic variant.,e PO,GENE_VARIANT,174,178,difficulty swallowing,HPO_TERM,31,52,0.8685698,0.13143022,-0.7371396,0
line364,Patient X164 was evaluated for difficulty swallowing. The patient also presented with a diagnosis of external ophthalmoplegia and myoclonic jerks. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X164 was evaluated for difficulty swallowing. The patient also presented with [E1]a diagnosis of external ophthalmopleg[/E1]ia and myoclonic jerks. Subsequent sequencing of th[E2]e PO[/E2]LG gene revealed a pathogenic variant.,e PO,GENE_VARIANT,174,178,a diagnosis of external ophthalmopleg,HPO_TERM,86,123,0.86105615,0.13894387,-0.7221123,0
line364,Patient X164 was evaluated for difficulty swallowing. The patient also presented with a diagnosis of external ophthalmoplegia and myoclonic jerks. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X164 was evaluated for difficulty swallowing. The patient also presented with a diagnosis of external ophthalmoplegia an[E1]d myoclonic jer[/E1]ks. Subsequent sequencing of th[E2]e PO[/E2]LG gene revealed a pathogenic variant.,e PO,GENE_VARIANT,174,178,d myoclonic jer,HPO_TERM,128,143,0.86630887,0.1336912,-0.7326177,0
line365,Patient X165 was evaluated for myoclonic seizures. The patient also presented with myoclonus and a diagnosis of sensory axonal neuropathy. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X165 was evaluated for [E1]myoclonic seizure[/E1]s. The patient also presented with myoclonus and a diagnosis of sensory axonal neuropathy. Subsequent sequencing of the[E2] POL[/E2]G gene revealed a pathogenic variant., POL,GENE_VARIANT,167,171,myoclonic seizure,HPO_TERM,31,48,0.8529796,0.14702041,-0.7059592,0
line365,Patient X165 was evaluated for myoclonic seizures. The patient also presented with myoclonus and a diagnosis of sensory axonal neuropathy. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X165 was evaluated for myoclonic seizures. The patient also presented with[E1] myoclonu[/E1]s and a diagnosis of sensory axonal neuropathy. Subsequent sequencing of the[E2] POL[/E2]G gene revealed a pathogenic variant., POL,GENE_VARIANT,167,171, myoclonu,HPO_TERM,82,91,0.8342036,0.16579644,-0.66840714,0
line365,Patient X165 was evaluated for myoclonic seizures. The patient also presented with myoclonus and a diagnosis of sensory axonal neuropathy. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X165 was evaluated for myoclonic seizures. The patient also presented with myoclonus and[E1] a diagnosis of sensory axonal neuropath[/E1]y. Subsequent sequencing of the[E2] POL[/E2]G gene revealed a pathogenic variant., POL,GENE_VARIANT,167,171, a diagnosis of sensory axonal neuropath,HPO_TERM,96,136,0.8464554,0.1535447,-0.6929107,0
line366,"This report details Patient X166, a patient with problems with balance and coordination. Further investigation showed a complaint of dysphagia and an increased CSF protein concentration. A known variant in the POLG gene was identified.","This report details Patient X166, a patient with [E1]problems with balance and coordina[/E1]tion. Further investigation showed a complaint of dysphagia and an increased CSF protein concentration. A known vari[E2]ant [/E2]in the POLG gene was identified.",ant ,GENE_VARIANT,199,203,problems with balance and coordina,HPO_TERM,49,83,0.8320523,0.16794774,-0.6641046,0
line366,"This report details Patient X166, a patient with problems with balance and coordination. Further investigation showed a complaint of dysphagia and an increased CSF protein concentration. A known variant in the POLG gene was identified.","This report details Patient X166, a patient with problems with balance and coordination. Further investigation sho[E1]wed a complaint of dys[/E1]phagia and an increased CSF protein concentration. A known vari[E2]ant [/E2]in the POLG gene was identified.",ant ,GENE_VARIANT,199,203,wed a complaint of dys,HPO_TERM,114,136,0.8541481,0.1458519,-0.7082962,0
line366,"This report details Patient X166, a patient with problems with balance and coordination. Further investigation showed a complaint of dysphagia and an increased CSF protein concentration. A known variant in the POLG gene was identified.","This report details Patient X166, a patient with problems with balance and coordination. Further investigation showed a complaint of dysphagi[E1]a and an increased CSF protein con[/E1]centration. A known vari[E2]ant [/E2]in the POLG gene was identified.",ant ,GENE_VARIANT,199,203,a and an increased CSF protein con,HPO_TERM,141,175,0.8445263,0.15547372,-0.6890526,0
line367,"We report the case of Patient X167, who has a history of incoordinated movements. Examination also revealed myoclonic jerks. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient X167, who has a history of [E1]incoordinated movement[/E1]s. Examination also revealed myoclonic jerks. The underlying cause was traced to a mutation in the[E2] POL[/E2]G gene.", POL,GENE_VARIANT,177,181,incoordinated movement,HPO_TERM,57,79,0.40415823,0.59584177,0.19168353,1
line367,"We report the case of Patient X167, who has a history of incoordinated movements. Examination also revealed myoclonic jerks. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient X167, who has a history of incoordinated movements. Examination also revealed[E1] myoclonic jerk[/E1]s. The underlying cause was traced to a mutation in the[E2] POL[/E2]G gene.", POL,GENE_VARIANT,177,181, myoclonic jerk,HPO_TERM,107,122,0.3065412,0.6934588,0.3869176,1
line368,The primary symptoms for Patient X168 were myoclonic jerks and a diagnosis of ataxia. Analysis of the POLG gene was performed.,The primary symptoms for Patient X168 were my[E1]oclonic jerks a[/E1]nd a diagnosis of ataxia. Analysis of the POLG gen[E2]e wa[/E2]s performed.,e wa,GENE_VARIANT,110,114,oclonic jerks a,HPO_TERM,45,60,0.81140256,0.18859747,-0.6228051,0
line368,The primary symptoms for Patient X168 were myoclonic jerks and a diagnosis of ataxia. Analysis of the POLG gene was performed.,The primary symptoms for Patient X168 were myoclonic jerks and a [E1]diagnosis of ataxia[/E1]. Analysis of the POLG gen[E2]e wa[/E2]s performed.,e wa,GENE_VARIANT,110,114,diagnosis of ataxia,HPO_TERM,65,84,0.80572397,0.19427606,-0.61144793,0
line369,Patient X169 was evaluated for ataxia. The patient also presented with hypotonia and myoclonic jerks. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X169 was evaluated for [E1]ataxia[/E1]. The patient also presented with hypotonia and myoclonic jerks. Subsequent sequencing of the [E2]POLG[/E2] gene revealed a pathogenic variant.,POLG,GENE_VARIANT,131,135,ataxia,HPO_TERM,31,37,0.8019274,0.19807257,-0.60385484,0
line369,Patient X169 was evaluated for ataxia. The patient also presented with hypotonia and myoclonic jerks. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X169 was evaluated for ataxia. The patient also presented with [E1]hypotonia[/E1] and myoclonic jerks. Subsequent sequencing of the [E2]POLG[/E2] gene revealed a pathogenic variant.,POLG,GENE_VARIANT,131,135,hypotonia,HPO_TERM,71,80,0.7820791,0.2179209,-0.5641582,0
line369,Patient X169 was evaluated for ataxia. The patient also presented with hypotonia and myoclonic jerks. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X169 was evaluated for ataxia. The patient also presented with hypotonia and [E1]myoclonic jerks[/E1]. Subsequent sequencing of the [E2]POLG[/E2] gene revealed a pathogenic variant.,POLG,GENE_VARIANT,131,135,myoclonic jerks,HPO_TERM,85,100,0.7989065,0.20109347,-0.597813,0
line370,Patient X170 was evaluated for a diagnosis of ataxia. The patient also presented with a diagnosis of external ophthalmoplegia and a lack of voluntary coordination of muscle movements. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X170 was evaluated for [E1]a diagnosis of atax[/E1]ia. The patient also presented with a diagnosis of external ophthalmoplegia and a lack of voluntary coordination of muscle movements. Subsequent sequencing of[E2] the[/E2] POLG gene revealed a pathogenic variant., the,GENE_VARIANT,208,212,a diagnosis of atax,HPO_TERM,31,50,0.8355955,0.16440457,-0.6711909,0
line370,Patient X170 was evaluated for a diagnosis of ataxia. The patient also presented with a diagnosis of external ophthalmoplegia and a lack of voluntary coordination of muscle movements. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X170 was evaluated for a diagnosis of ataxia. The patient also presented wit[E1]h a diagnosis of external ophthalmopl[/E1]egia and a lack of voluntary coordination of muscle movements. Subsequent sequencing of[E2] the[/E2] POLG gene revealed a pathogenic variant., the,GENE_VARIANT,208,212,h a diagnosis of external ophthalmopl,HPO_TERM,84,121,0.84308183,0.15691811,-0.6861637,0
line370,Patient X170 was evaluated for a diagnosis of ataxia. The patient also presented with a diagnosis of external ophthalmoplegia and a lack of voluntary coordination of muscle movements. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X170 was evaluated for a diagnosis of ataxia. The patient also presented with a diagnosis of external ophthalmoplegia [E1]and a lack of voluntary coordination of muscle move[/E1]ments. Subsequent sequencing of[E2] the[/E2] POLG gene revealed a pathogenic variant., the,GENE_VARIANT,208,212,and a lack of voluntary coordination of muscle move,HPO_TERM,126,177,0.81946987,0.18053013,-0.63893974,0
line371,The primary symptoms for Patient X171 were a presentation in infancy and a diagnosis of ataxia. Analysis of the POLG gene was performed.,The primary symptoms for Patient X171 were a [E1]presentation in infancy a[/E1]nd a diagnosis of ataxia. Analysis of the POLG gen[E2]e wa[/E2]s performed.,e wa,GENE_VARIANT,120,124,presentation in infancy a,HPO_TERM,45,70,0.8410411,0.15895893,-0.6820822,0
line371,The primary symptoms for Patient X171 were a presentation in infancy and a diagnosis of ataxia. Analysis of the POLG gene was performed.,The primary symptoms for Patient X171 were a presentation in infancy and a [E1]diagnosis of ataxia[/E1]. Analysis of the POLG gen[E2]e wa[/E2]s performed.,e wa,GENE_VARIANT,120,124,diagnosis of ataxia,HPO_TERM,75,94,0.8352362,0.16476382,-0.6704724,0
line372,"This report details Patient X172, a patient with ataxia. Further investigation showed a diagnosis of external ophthalmoplegia and a complaint of dysphagia. A known variant in the POLG gene was identified.","This report details Patient X172, a patient with [E1]ataxia[/E1]. Further investigation showed a diagnosis of external ophthalmoplegia and a complaint of dysphagia. A known variant in[E2] the[/E2] POLG gene was identified.", the,GENE_VARIANT,174,178,ataxia,HPO_TERM,49,55,0.7683532,0.23164672,-0.5367065,0
line372,"This report details Patient X172, a patient with ataxia. Further investigation showed a diagnosis of external ophthalmoplegia and a complaint of dysphagia. A known variant in the POLG gene was identified.","This report details Patient X172, a patient with ataxia. Further investigation showed [E1]a diagnosis of external ophthalmopleg[/E1]ia and a complaint of dysphagia. A known variant in[E2] the[/E2] POLG gene was identified.", the,GENE_VARIANT,174,178,a diagnosis of external ophthalmopleg,HPO_TERM,86,123,0.81421554,0.18578441,-0.62843114,0
line372,"This report details Patient X172, a patient with ataxia. Further investigation showed a diagnosis of external ophthalmoplegia and a complaint of dysphagia. A known variant in the POLG gene was identified.","This report details Patient X172, a patient with ataxia. Further investigation showed a diagnosis of external ophthalmoplegia an[E1]d a complaint of dysph[/E1]agia. A known variant in[E2] the[/E2] POLG gene was identified.", the,GENE_VARIANT,174,178,d a complaint of dysph,HPO_TERM,128,150,0.8035899,0.19641009,-0.60717976,0
line373,"We report the case of Patient X173, who has a history of myoclonic jerks. Examination also revealed a diagnosis of external ophthalmoplegia. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient X173, who has a history of [E1]myoclonic jerks[/E1]. Examination also revealed a diagnosis of external ophthalmoplegia. The underlying cause was traced to a mutation in th[E2]e PO[/E2]LG gene.",e PO,GENE_VARIANT,192,196,myoclonic jerks,HPO_TERM,57,72,0.6645651,0.33543488,-0.3291302,0
line373,"We report the case of Patient X173, who has a history of myoclonic jerks. Examination also revealed a diagnosis of external ophthalmoplegia. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient X173, who has a history of myoclonic jerks. Examination also revealed [E1]a diagnosis of external ophthalmopleg[/E1]ia. The underlying cause was traced to a mutation in th[E2]e PO[/E2]LG gene.",e PO,GENE_VARIANT,192,196,a diagnosis of external ophthalmopleg,HPO_TERM,100,137,0.63180006,0.36819988,-0.26360017,0
line374,Patient X174 was evaluated for ataxia. The patient also presented with myoclonus and an infantile onset. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X174 was evaluated for [E1]ataxia[/E1]. The patient also presented with myoclonus and an infantile onset. Subsequent sequencing of the[E2] POL[/E2]G gene revealed a pathogenic variant., POL,GENE_VARIANT,133,137,ataxia,HPO_TERM,31,37,0.8295548,0.17044526,-0.65910953,0
line374,Patient X174 was evaluated for ataxia. The patient also presented with myoclonus and an infantile onset. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X174 was evaluated for ataxia. The patient also presented with [E1]myoclonus[/E1] and an infantile onset. Subsequent sequencing of the[E2] POL[/E2]G gene revealed a pathogenic variant., POL,GENE_VARIANT,133,137,myoclonus,HPO_TERM,71,80,0.80703706,0.19296293,-0.6140741,0
line374,Patient X174 was evaluated for ataxia. The patient also presented with myoclonus and an infantile onset. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X174 was evaluated for ataxia. The patient also presented with myoclonus and [E1]an infantile onse[/E1]t. Subsequent sequencing of the[E2] POL[/E2]G gene revealed a pathogenic variant., POL,GENE_VARIANT,133,137,an infantile onse,HPO_TERM,85,102,0.8463937,0.15360625,-0.69278747,0
line375,"We report the case of Patient X175, who has a history of hypotonia. Examination also revealed a presentation in infancy. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient X175, who has a history of [E1]hypotonia[/E1]. Examination also revealed a presentation in infancy. The underlying cause was traced to a mutation in the [E2]POLG[/E2] gene.",POLG,GENE_VARIANT,174,178,hypotonia,HPO_TERM,57,66,0.6007645,0.39923552,-0.201529,0
line375,"We report the case of Patient X175, who has a history of hypotonia. Examination also revealed a presentation in infancy. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient X175, who has a history of hypotonia. Examination also revealed [E1]a presentation in infancy[/E1]. The underlying cause was traced to a mutation in the [E2]POLG[/E2] gene.",POLG,GENE_VARIANT,174,178,a presentation in infancy,HPO_TERM,94,119,0.564842,0.43515807,-0.12968391,0
line376,The primary symptoms for Patient X176 were myoclonic seizures and a lack of voluntary coordination of muscle movements. Analysis of the POLG gene was performed.,The primary symptoms for Patient X176 were my[E1]oclonic seizures [/E1]and a lack of voluntary coordination of muscle movements. Analysis of the POLG gen[E2]e wa[/E2]s performed.,e wa,GENE_VARIANT,144,148,oclonic seizures ,HPO_TERM,45,62,0.79352266,0.20647736,-0.5870453,0
line376,The primary symptoms for Patient X176 were myoclonic seizures and a lack of voluntary coordination of muscle movements. Analysis of the POLG gene was performed.,The primary symptoms for Patient X176 were myoclonic seizures and a[E1] lack of voluntary coordination of muscle movements[/E1]. Analysis of the POLG gen[E2]e wa[/E2]s performed.,e wa,GENE_VARIANT,144,148, lack of voluntary coordination of muscle movements,HPO_TERM,67,118,0.7955041,0.20449597,-0.5910081,0
line377,"This report details Patient X177, a patient with hypotonia. Further investigation showed a lack of voluntary coordination of muscle movements and a presentation in infancy. A known variant in the POLG gene was identified.","This report details Patient X177, a patient with [E1]hypotonia[/E1]. Further investigation showed a lack of voluntary coordination of muscle movements and a presentation in infancy. A known variant in th[E2]e PO[/E2]LG gene was identified.",e PO,GENE_VARIANT,194,198,hypotonia,HPO_TERM,49,58,0.8218758,0.17812419,-0.6437516,0
line377,"This report details Patient X177, a patient with hypotonia. Further investigation showed a lack of voluntary coordination of muscle movements and a presentation in infancy. A known variant in the POLG gene was identified.","This report details Patient X177, a patient with hypotonia. Further investigation showed [E1]a lack of voluntary coordination of muscle movement[/E1]s and a presentation in infancy. A known variant in th[E2]e PO[/E2]LG gene was identified.",e PO,GENE_VARIANT,194,198,a lack of voluntary coordination of muscle movement,HPO_TERM,89,140,0.8268128,0.17318723,-0.6536256,0
line377,"This report details Patient X177, a patient with hypotonia. Further investigation showed a lack of voluntary coordination of muscle movements and a presentation in infancy. A known variant in the POLG gene was identified.","This report details Patient X177, a patient with hypotonia. Further investigation showed a lack of voluntary coordination of muscle movements and[E1] a presentation in infanc[/E1]y. A known variant in th[E2]e PO[/E2]LG gene was identified.",e PO,GENE_VARIANT,194,198, a presentation in infanc,HPO_TERM,145,170,0.8448693,0.15513064,-0.6897387,0
line378,Patient X178 was evaluated for myoclonic jerks. The patient also presented with a diagnosis of external ophthalmoplegia and a complaint of dysphagia. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X178 was evaluated for [E1]myoclonic jerks[/E1]. The patient also presented with a diagnosis of external ophthalmoplegia and a complaint of dysphagia. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,175,179,myoclonic jerks,HPO_TERM,31,46,0.78936225,0.21063772,-0.5787245,0
line378,Patient X178 was evaluated for myoclonic jerks. The patient also presented with a diagnosis of external ophthalmoplegia and a complaint of dysphagia. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X178 was evaluated for myoclonic jerks. The patient also presented with [E1]a diagnosis of external ophthalmopleg[/E1]ia and a complaint of dysphagia. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,175,179,a diagnosis of external ophthalmopleg,HPO_TERM,80,117,0.823416,0.17658398,-0.646832,0
line378,Patient X178 was evaluated for myoclonic jerks. The patient also presented with a diagnosis of external ophthalmoplegia and a complaint of dysphagia. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X178 was evaluated for myoclonic jerks. The patient also presented with a diagnosis of external ophthalmoplegia an[E1]d a complaint of dysph[/E1]agia. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,175,179,d a complaint of dysph,HPO_TERM,122,144,0.8192784,0.1807216,-0.63855684,0
line379,The primary symptoms for Patient X179 were hypotonia and problems with swallowing. Analysis of the POLG gene was performed.,The primary symptoms for Patient X179 were hy[E1]potonia a[/E1]nd problems with swallowing. Analysis of the POLG gen[E2]e wa[/E2]s performed.,e wa,GENE_VARIANT,107,111,potonia a,HPO_TERM,45,54,0.77798724,0.22201273,-0.5559745,0
line379,The primary symptoms for Patient X179 were hypotonia and problems with swallowing. Analysis of the POLG gene was performed.,The primary symptoms for Patient X179 were hypotonia and pr[E1]oblems with swallowing[/E1]. Analysis of the POLG gen[E2]e wa[/E2]s performed.,e wa,GENE_VARIANT,107,111,oblems with swallowing,HPO_TERM,59,81,0.7692666,0.23073338,-0.5385332,0
line380,The clinical profile for Patient X180 includes an infantile onset and a diagnosis of sensory axonal neuropathy. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient X180 includes [E1]an infantile onse[/E1]t and a diagnosis of sensory axonal neuropathy. Genetic analysis of the[E2] POL[/E2]G gene confirmed the diagnosis., POL,GENE_VARIANT,135,139,an infantile onse,HPO_TERM,47,64,0.85798687,0.14201313,-0.71597373,0
line380,The clinical profile for Patient X180 includes an infantile onset and a diagnosis of sensory axonal neuropathy. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient X180 includes an infantile onset and[E1] a diagnosis of sensory axonal neuropath[/E1]y. Genetic analysis of the[E2] POL[/E2]G gene confirmed the diagnosis., POL,GENE_VARIANT,135,139, a diagnosis of sensory axonal neuropath,HPO_TERM,69,109,0.857864,0.142136,-0.71572804,0
line381,Patient X181 was evaluated for a state of low muscle tone. The patient also presented with problems with swallowing and ataxia. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X181 was evaluated for [E1]a state of low muscle to[/E1]ne. The patient also presented with problems with swallowing and ataxia. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,153,157,a state of low muscle to,HPO_TERM,31,55,0.826884,0.17311606,-0.65376794,0
line381,Patient X181 was evaluated for a state of low muscle tone. The patient also presented with problems with swallowing and ataxia. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X181 was evaluated for a state of low muscle tone. The patient also presented wit[E1]h problems with swallo[/E1]wing and ataxia. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,153,157,h problems with swallo,HPO_TERM,89,111,0.81007457,0.18992548,-0.6201491,0
line381,Patient X181 was evaluated for a state of low muscle tone. The patient also presented with problems with swallowing and ataxia. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X181 was evaluated for a state of low muscle tone. The patient also presented with problems with swallowing [E1]and at[/E1]axia. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,153,157,and at,HPO_TERM,116,122,0.83327675,0.16672325,-0.6665535,0
line382,Patient X182 was evaluated for an increased CSF protein concentration. The patient also presented with problems with balance and coordination and a diagnosis of sensory axonal neuropathy. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X182 was evaluated for [E1]an increased CSF protein concentra[/E1]tion. The patient also presented with problems with balance and coordination and a diagnosis of sensory axonal neuropathy. Subsequent sequencing[E2] of [/E2]the POLG gene revealed a pathogenic variant., of ,GENE_VARIANT,209,213,an increased CSF protein concentra,HPO_TERM,31,65,0.8572337,0.14276631,-0.7144674,0
line382,Patient X182 was evaluated for an increased CSF protein concentration. The patient also presented with problems with balance and coordination and a diagnosis of sensory axonal neuropathy. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X182 was evaluated for an increased CSF protein concentration. The patient also presented w[E1]ith problems with balance and coor[/E1]dination and a diagnosis of sensory axonal neuropathy. Subsequent sequencing[E2] of [/E2]the POLG gene revealed a pathogenic variant., of ,GENE_VARIANT,209,213,ith problems with balance and coor,HPO_TERM,99,133,0.8566381,0.14336193,-0.71327615,0
line382,Patient X182 was evaluated for an increased CSF protein concentration. The patient also presented with problems with balance and coordination and a diagnosis of sensory axonal neuropathy. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X182 was evaluated for an increased CSF protein concentration. The patient also presented with problems with balance and coordinat[E1]ion and a diagnosis of sensory axonal ne[/E1]uropathy. Subsequent sequencing[E2] of [/E2]the POLG gene revealed a pathogenic variant., of ,GENE_VARIANT,209,213,ion and a diagnosis of sensory axonal ne,HPO_TERM,138,178,0.8430987,0.15690127,-0.6861974,0
line383,"We report the case of Patient X183, who has a history of a diagnosis of external ophthalmoplegia. Examination also revealed incoordinated movements. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient X183, who has a history of [E1]a diagnosis of external ophthalmopleg[/E1]ia. Examination also revealed incoordinated movements. The underlying cause was traced to a mutation in t[E2]he P[/E2]OLG gene.",he P,GENE_VARIANT,199,203,a diagnosis of external ophthalmopleg,HPO_TERM,57,94,0.6315904,0.36840954,-0.26318088,0
line383,"We report the case of Patient X183, who has a history of a diagnosis of external ophthalmoplegia. Examination also revealed incoordinated movements. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient X183, who has a history of a diagnosis of external ophthalmoplegia. Examination also reveale[E1]d incoordinated moveme[/E1]nts. The underlying cause was traced to a mutation in t[E2]he P[/E2]OLG gene.",he P,GENE_VARIANT,199,203,d incoordinated moveme,HPO_TERM,122,144,0.758576,0.24142395,-0.517152,0
line384,Patient X184 was evaluated for a diagnosis of external ophthalmoplegia. The patient also presented with a diagnosis of ataxia and problems with swallowing. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X184 was evaluated for [E1]a diagnosis of external ophthalmopleg[/E1]ia. The patient also presented with a diagnosis of ataxia and problems with swallowing. Subsequent sequencing o[E2]f th[/E2]e POLG gene revealed a pathogenic variant.,f th,GENE_VARIANT,179,183,a diagnosis of external ophthalmopleg,HPO_TERM,31,68,0.8641488,0.13585122,-0.7282976,0
line384,Patient X184 was evaluated for a diagnosis of external ophthalmoplegia. The patient also presented with a diagnosis of ataxia and problems with swallowing. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X184 was evaluated for a diagnosis of external ophthalmoplegia. The patient also presented wit[E1]h a diagnosis of at[/E1]axia and problems with swallowing. Subsequent sequencing o[E2]f th[/E2]e POLG gene revealed a pathogenic variant.,f th,GENE_VARIANT,179,183,h a diagnosis of at,HPO_TERM,102,121,0.85833657,0.14166345,-0.71667314,0
line384,Patient X184 was evaluated for a diagnosis of external ophthalmoplegia. The patient also presented with a diagnosis of ataxia and problems with swallowing. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X184 was evaluated for a diagnosis of external ophthalmoplegia. The patient also presented with a diagnosis of ataxia [E1]and problems with swal[/E1]lowing. Subsequent sequencing o[E2]f th[/E2]e POLG gene revealed a pathogenic variant.,f th,GENE_VARIANT,179,183,and problems with swal,HPO_TERM,126,148,0.84522706,0.15477298,-0.69045407,0
line385,Patient X185 was evaluated for myoclonic jerks. The patient also presented with hypotonia and myoclonus. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X185 was evaluated for [E1]myoclonic jerks[/E1]. The patient also presented with hypotonia and myoclonus. Subsequent sequencing of the [E2]POLG[/E2] gene revealed a pathogenic variant.,POLG,GENE_VARIANT,134,138,myoclonic jerks,HPO_TERM,31,46,0.8304561,0.16954394,-0.66091216,0
line385,Patient X185 was evaluated for myoclonic jerks. The patient also presented with hypotonia and myoclonus. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X185 was evaluated for myoclonic jerks. The patient also presented with [E1]hypotonia[/E1] and myoclonus. Subsequent sequencing of the [E2]POLG[/E2] gene revealed a pathogenic variant.,POLG,GENE_VARIANT,134,138,hypotonia,HPO_TERM,80,89,0.8164133,0.18358676,-0.6328265,0
line385,Patient X185 was evaluated for myoclonic jerks. The patient also presented with hypotonia and myoclonus. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X185 was evaluated for myoclonic jerks. The patient also presented with hypotonia and [E1]myoclonus[/E1]. Subsequent sequencing of the [E2]POLG[/E2] gene revealed a pathogenic variant.,POLG,GENE_VARIANT,134,138,myoclonus,HPO_TERM,94,103,0.82146823,0.17853175,-0.64293647,0
line386,"We report the case of Patient X186, who has a history of myoclonic seizures. Examination also revealed a state of low muscle tone. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient X186, who has a history of [E1]myoclonic seizure[/E1]s. Examination also revealed a state of low muscle tone. The underlying cause was traced to a mutation in t[E2]he P[/E2]OLG gene.",he P,GENE_VARIANT,181,185,myoclonic seizure,HPO_TERM,57,74,0.5609663,0.43903372,-0.121932596,0
line386,"We report the case of Patient X186, who has a history of myoclonic seizures. Examination also revealed a state of low muscle tone. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient X186, who has a history of myoclonic seizures. Examination also revealed[E1] a state of low muscle t[/E1]one. The underlying cause was traced to a mutation in t[E2]he P[/E2]OLG gene.",he P,GENE_VARIANT,181,185, a state of low muscle t,HPO_TERM,102,126,0.6030874,0.39691257,-0.20617485,0
line387,The primary symptoms for Patient X187 were a complaint of dysphagia and problems with swallowing. Analysis of the POLG gene was performed.,The primary symptoms for Patient X187 were a [E1]complaint of dysphagia[/E1] and problems with swallowing. Analysis of the POLG g[E2]ene [/E2]was performed.,ene ,GENE_VARIANT,120,124,complaint of dysphagia,HPO_TERM,45,67,0.7817642,0.21823582,-0.5635284,0
line387,The primary symptoms for Patient X187 were a complaint of dysphagia and problems with swallowing. Analysis of the POLG gene was performed.,The primary symptoms for Patient X187 were a complaint of dysphagia and [E1]problems with swallowi[/E1]ng. Analysis of the POLG g[E2]ene [/E2]was performed.,ene ,GENE_VARIANT,120,124,problems with swallowi,HPO_TERM,72,94,0.8026926,0.19730738,-0.6053852,0
line388,"We report the case of Patient X188, who has a history of a condition affecting eye movement. Examination also revealed a presentation in infancy. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient X188, who has a history of [E1]a condition affecting eye movemen[/E1]t. Examination also revealed a presentation in infancy. The underlying cause was traced to a mutation in the[E2] POL[/E2]G gene.", POL,GENE_VARIANT,198,202,a condition affecting eye movemen,HPO_TERM,57,90,0.7081347,0.2918652,-0.4162695,0
line388,"We report the case of Patient X188, who has a history of a condition affecting eye movement. Examination also revealed a presentation in infancy. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient X188, who has a history of a condition affecting eye movement. Examination also revealed[E1] a presentation in infanc[/E1]y. The underlying cause was traced to a mutation in the[E2] POL[/E2]G gene.", POL,GENE_VARIANT,198,202, a presentation in infanc,HPO_TERM,118,143,0.64223284,0.3577672,-0.28446564,0
line389,The clinical profile for Patient X189 includes myoclonic jerks and incoordinated movements. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient X189 includes [E1]myoclonic jerks[/E1] and incoordinated movements. Genetic analysis of the[E2] POL[/E2]G gene confirmed the diagnosis., POL,GENE_VARIANT,115,119,myoclonic jerks,HPO_TERM,47,62,0.8083332,0.19166683,-0.6166664,0
line389,The clinical profile for Patient X189 includes myoclonic jerks and incoordinated movements. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient X189 includes myoclonic jerks and [E1]incoordinated movement[/E1]s. Genetic analysis of the[E2] POL[/E2]G gene confirmed the diagnosis., POL,GENE_VARIANT,115,119,incoordinated movement,HPO_TERM,67,89,0.83299005,0.16700993,-0.6659801,0
line390,"This report details Patient X190, a patient with hypotonia. Further investigation showed a diagnosis of sensory axonal neuropathy and myoclonus. A known variant in the POLG gene was identified.","This report details Patient X190, a patient with [E1]hypotonia[/E1]. Further investigation showed a diagnosis of sensory axonal neuropathy and myoclonus. A known variant in the[E2] POL[/E2]G gene was identified.", POL,GENE_VARIANT,167,171,hypotonia,HPO_TERM,49,58,0.7978254,0.20217463,-0.5956508,0
line390,"This report details Patient X190, a patient with hypotonia. Further investigation showed a diagnosis of sensory axonal neuropathy and myoclonus. A known variant in the POLG gene was identified.","This report details Patient X190, a patient with hypotonia. Further investigation showed [E1]a diagnosis of sensory axonal neuropathy[/E1] and myoclonus. A known variant in the[E2] POL[/E2]G gene was identified.", POL,GENE_VARIANT,167,171,a diagnosis of sensory axonal neuropathy,HPO_TERM,89,129,0.81069195,0.18930803,-0.6213839,0
line390,"This report details Patient X190, a patient with hypotonia. Further investigation showed a diagnosis of sensory axonal neuropathy and myoclonus. A known variant in the POLG gene was identified.","This report details Patient X190, a patient with hypotonia. Further investigation showed a diagnosis of sensory axonal neuropathy and [E1]myoclonus[/E1]. A known variant in the[E2] POL[/E2]G gene was identified.", POL,GENE_VARIANT,167,171,myoclonus,HPO_TERM,134,143,0.8096427,0.19035731,-0.61928535,0
line391,"We report the case of Patient X191, who has a history of a diagnosis of external ophthalmoplegia. Examination also revealed incoordinated movements. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient X191, who has a history of [E1]a diagnosis of external ophthalmopleg[/E1]ia. Examination also revealed incoordinated movements. The underlying cause was traced to a mutation in t[E2]he P[/E2]OLG gene.",he P,GENE_VARIANT,199,203,a diagnosis of external ophthalmopleg,HPO_TERM,57,94,0.6466788,0.35332122,-0.29335758,0
line391,"We report the case of Patient X191, who has a history of a diagnosis of external ophthalmoplegia. Examination also revealed incoordinated movements. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient X191, who has a history of a diagnosis of external ophthalmoplegia. Examination also reveale[E1]d incoordinated moveme[/E1]nts. The underlying cause was traced to a mutation in t[E2]he P[/E2]OLG gene.",he P,GENE_VARIANT,199,203,d incoordinated moveme,HPO_TERM,122,144,0.7695189,0.23048109,-0.5390378,0
line392,"This report details Patient X192, a patient with problems with swallowing. Further investigation showed a presentation in infancy and myoclonic jerks. A known variant in the POLG gene was identified.","This report details Patient X192, a patient with [E1]problems with swallowi[/E1]ng. Further investigation showed a presentation in infancy and myoclonic jerks. A known variant in t[E2]he P[/E2]OLG gene was identified.",he P,GENE_VARIANT,171,175,problems with swallowi,HPO_TERM,49,71,0.81252056,0.18747942,-0.6250411,0
line392,"This report details Patient X192, a patient with problems with swallowing. Further investigation showed a presentation in infancy and myoclonic jerks. A known variant in the POLG gene was identified.","This report details Patient X192, a patient with problems with swallowing. Further investigation showe[E1]d a presentation in infan[/E1]cy and myoclonic jerks. A known variant in t[E2]he P[/E2]OLG gene was identified.",he P,GENE_VARIANT,171,175,d a presentation in infan,HPO_TERM,102,127,0.80902696,0.19097304,-0.6180539,0
line392,"This report details Patient X192, a patient with problems with swallowing. Further investigation showed a presentation in infancy and myoclonic jerks. A known variant in the POLG gene was identified.","This report details Patient X192, a patient with problems with swallowing. Further investigation showed a presentation in infancy an[E1]d myoclonic jer[/E1]ks. A known variant in t[E2]he P[/E2]OLG gene was identified.",he P,GENE_VARIANT,171,175,d myoclonic jer,HPO_TERM,132,147,0.8360376,0.1639624,-0.67207515,0
line393,Patient X193 was evaluated for a state of low muscle tone. The patient also presented with myoclonic seizures and incoordinated movements. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X193 was evaluated for [E1]a state of low muscle to[/E1]ne. The patient also presented with myoclonic seizures and incoordinated movements. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,164,168,a state of low muscle to,HPO_TERM,31,55,0.810193,0.18980695,-0.62038606,0
line393,Patient X193 was evaluated for a state of low muscle tone. The patient also presented with myoclonic seizures and incoordinated movements. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X193 was evaluated for a state of low muscle tone. The patient also presented wit[E1]h myoclonic seizu[/E1]res and incoordinated movements. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,164,168,h myoclonic seizu,HPO_TERM,89,106,0.7778812,0.22211877,-0.5557624,0
line393,Patient X193 was evaluated for a state of low muscle tone. The patient also presented with myoclonic seizures and incoordinated movements. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X193 was evaluated for a state of low muscle tone. The patient also presented with myoclonic seizures a[E1]nd incoordinated movem[/E1]ents. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,164,168,nd incoordinated movem,HPO_TERM,111,133,0.8478874,0.15211254,-0.69577485,0
line394,The primary symptoms for Patient X194 were a presentation in infancy and a diagnosis of ataxia. Analysis of the POLG gene was performed.,The primary symptoms for Patient X194 were a [E1]presentation in infancy a[/E1]nd a diagnosis of ataxia. Analysis of the POLG gen[E2]e wa[/E2]s performed.,e wa,GENE_VARIANT,120,124,presentation in infancy a,HPO_TERM,45,70,0.83498937,0.16501065,-0.66997874,0
line394,The primary symptoms for Patient X194 were a presentation in infancy and a diagnosis of ataxia. Analysis of the POLG gene was performed.,The primary symptoms for Patient X194 were a presentation in infancy and a [E1]diagnosis of ataxia[/E1]. Analysis of the POLG gen[E2]e wa[/E2]s performed.,e wa,GENE_VARIANT,120,124,diagnosis of ataxia,HPO_TERM,75,94,0.8321844,0.16781561,-0.66436875,0
line395,The primary symptoms for Patient X195 were myoclonic seizures and an increased CSF protein concentration. Analysis of the POLG gene was performed.,The primary symptoms for Patient X195 were my[E1]oclonic seizures [/E1]and an increased CSF protein concentration. Analysis of the POLG [E2]gene[/E2] was performed.,gene,GENE_VARIANT,127,131,oclonic seizures ,HPO_TERM,45,62,0.8258133,0.17418674,-0.6516266,0
line395,The primary symptoms for Patient X195 were myoclonic seizures and an increased CSF protein concentration. Analysis of the POLG gene was performed.,The primary symptoms for Patient X195 were myoclonic seizures and a[E1]n increased CSF protein concentrat[/E1]ion. Analysis of the POLG [E2]gene[/E2] was performed.,gene,GENE_VARIANT,127,131,n increased CSF protein concentrat,HPO_TERM,67,101,0.8335482,0.16645183,-0.6670964,0
line396,The clinical profile for Patient X196 includes a raised CSF protein level and swallowing difficulties. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient X196 includes [E1]a raised CSF protein level[/E1] and swallowing difficulties. Genetic analysis of the [E2]POLG[/E2] gene confirmed the diagnosis.,POLG,GENE_VARIANT,127,131,a raised CSF protein level,HPO_TERM,47,73,0.83203286,0.1679671,-0.6640658,0
line396,The clinical profile for Patient X196 includes a raised CSF protein level and swallowing difficulties. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient X196 includes a raised CSF protein level and [E1]swallowing difficulties[/E1]. Genetic analysis of the [E2]POLG[/E2] gene confirmed the diagnosis.,POLG,GENE_VARIANT,127,131,swallowing difficulties,HPO_TERM,78,101,0.8400029,0.15999714,-0.6800058,0
line397,The primary symptoms for Patient X197 were external ophthalmoplegia and the patient was hypotonic. Analysis of the POLG gene was performed.,The primary symptoms for Patient X197 were [E1]external ophthalmoplegia[/E1] and the patient was hypotonic. Analysis of the [E2]POLG[/E2] gene was performed.,POLG,GENE_VARIANT,115,119,external ophthalmoplegia,HPO_TERM,43,67,0.8438864,0.1561136,-0.68777275,0
line397,The primary symptoms for Patient X197 were external ophthalmoplegia and the patient was hypotonic. Analysis of the POLG gene was performed.,The primary symptoms for Patient X197 were external ophthalmoplegia and [E1]the patient was hypotonic[/E1]. Analysis of the [E2]POLG[/E2] gene was performed.,POLG,GENE_VARIANT,115,119,the patient was hypotonic,HPO_TERM,72,97,0.85564995,0.1443501,-0.71129984,0
line398,Patient X198 was evaluated for a history of myoclonus. The patient also presented with swallowing difficulties and classic ragged-red fibers. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X198 was evaluated for [E1]a history of myoclonus[/E1]. The patient also presented with swallowing difficulties and classic ragged-red fibers. Subsequent sequencing of the [E2]POLG[/E2] gene revealed a pathogenic variant.,POLG,GENE_VARIANT,171,175,a history of myoclonus,HPO_TERM,31,53,0.8256106,0.17438945,-0.65122116,0
line398,Patient X198 was evaluated for a history of myoclonus. The patient also presented with swallowing difficulties and classic ragged-red fibers. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X198 was evaluated for a history of myoclonus. The patient also presented with [E1]swallowing difficulties[/E1] and classic ragged-red fibers. Subsequent sequencing of the [E2]POLG[/E2] gene revealed a pathogenic variant.,POLG,GENE_VARIANT,171,175,swallowing difficulties,HPO_TERM,87,110,0.8014175,0.19858247,-0.60283506,0
line398,Patient X198 was evaluated for a history of myoclonus. The patient also presented with swallowing difficulties and classic ragged-red fibers. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X198 was evaluated for a history of myoclonus. The patient also presented with swallowing difficulties and [E1]classic ragged-red fibers[/E1]. Subsequent sequencing of the [E2]POLG[/E2] gene revealed a pathogenic variant.,POLG,GENE_VARIANT,171,175,classic ragged-red fibers,HPO_TERM,115,140,0.8172405,0.18275955,-0.63448095,0
line399,Patient X199 was evaluated for an increased CSF protein concentration. The patient also presented with a lack of voluntary coordination of muscle movements and problems with swallowing. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X199 was evaluated for [E1]an increased CSF protein concentra[/E1]tion. The patient also presented with a lack of voluntary coordination of muscle movements and problems with swallowing. Subsequent sequencing [E2]of t[/E2]he POLG gene revealed a pathogenic variant.,of t,GENE_VARIANT,208,212,an increased CSF protein concentra,HPO_TERM,31,65,0.8714719,0.12852813,-0.74294376,0
line399,Patient X199 was evaluated for an increased CSF protein concentration. The patient also presented with a lack of voluntary coordination of muscle movements and problems with swallowing. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X199 was evaluated for an increased CSF protein concentration. The patient also presented w[E1]ith a lack of voluntary coordination of muscle move[/E1]ments and problems with swallowing. Subsequent sequencing [E2]of t[/E2]he POLG gene revealed a pathogenic variant.,of t,GENE_VARIANT,208,212,ith a lack of voluntary coordination of muscle move,HPO_TERM,99,150,0.86065817,0.13934185,-0.72131634,0
line399,Patient X199 was evaluated for an increased CSF protein concentration. The patient also presented with a lack of voluntary coordination of muscle movements and problems with swallowing. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient X199 was evaluated for an increased CSF protein concentration. The patient also presented with a lack of voluntary coordination of muscle movements[E1] and problems with swa[/E1]llowing. Subsequent sequencing [E2]of t[/E2]he POLG gene revealed a pathogenic variant.,of t,GENE_VARIANT,208,212, and problems with swa,HPO_TERM,155,177,0.85585177,0.14414826,-0.71170354,0
line400,"This report details Patient Z0, a patient with abnormal findings on diffusion-weighted imaging. Further investigation showed a progressive slowness of movement and a reduction in complex IV activity. A known variant in the POLG gene was identified.","This report details Patient Z0, a patient with [E1]abnormal findings on diffusion-weighted imaging[/E1]. Further investigation showed a progressive slowness of movement and a reduction in complex IV activity. A known variant in the [E2]POLG[/E2] gene was identified.",POLG,GENE_VARIANT,223,227,abnormal findings on diffusion-weighted imaging,HPO_TERM,47,94,0.67009383,0.32990617,-0.34018767,0
line400,"This report details Patient Z0, a patient with abnormal findings on diffusion-weighted imaging. Further investigation showed a progressive slowness of movement and a reduction in complex IV activity. A known variant in the POLG gene was identified.","This report details Patient Z0, a patient with abnormal findings on diffusion-weighted imaging. Further investigation showed [E1]a progressive slowness of movement[/E1] and a reduction in complex IV activity. A known variant in the [E2]POLG[/E2] gene was identified.",POLG,GENE_VARIANT,223,227,a progressive slowness of movement,HPO_TERM,125,159,0.6710047,0.32899532,-0.3420094,0
line400,"This report details Patient Z0, a patient with abnormal findings on diffusion-weighted imaging. Further investigation showed a progressive slowness of movement and a reduction in complex IV activity. A known variant in the POLG gene was identified.","This report details Patient Z0, a patient with abnormal findings on diffusion-weighted imaging. Further investigation showed a progressive slowness of movement and [E1]a reduction in complex IV activity[/E1]. A known variant in the [E2]POLG[/E2] gene was identified.",POLG,GENE_VARIANT,223,227,a reduction in complex IV activity,HPO_TERM,164,198,0.71800333,0.2819967,-0.43600664,0
line401,"We report the case of Patient Z1, who has a history of elevated ALT enzymatic activity. Examination also revealed a partial deficiency of complex I. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Z1, who has a history of [E1]elevated ALT enzymatic activity[/E1]. Examination also revealed a partial deficiency of complex I. The underlying cause was traced to a mutation in the [E2]POLG[/E2] gene.",POLG,GENE_VARIANT,202,206,elevated ALT enzymatic activity,HPO_TERM,55,86,0.63739425,0.36260575,-0.2747885,0
line401,"We report the case of Patient Z1, who has a history of elevated ALT enzymatic activity. Examination also revealed a partial deficiency of complex I. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Z1, who has a history of elevated ALT enzymatic activity. Examination also revealed [E1]a partial deficiency of complex I[/E1]. The underlying cause was traced to a mutation in the [E2]POLG[/E2] gene.",POLG,GENE_VARIANT,202,206,a partial deficiency of complex I,HPO_TERM,114,147,0.6207219,0.3792781,-0.24144378,0
line402,Patient Z2 was evaluated for impaired function of mitochondrial complex I. The patient also presented with impaired function of mitochondrial complex IV and reduced mitochondrial DNA content in muscle. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z2 was evaluated for [E1]impaired function of mitochondrial complex [/E1]I. The patient also presented with impaired function of mitochondrial complex IV and reduced mitochondrial DNA content in muscle. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,227,231,impaired function of mitochondrial complex ,HPO_TERM,29,72,0.8425407,0.15745936,-0.6850813,0
line402,Patient Z2 was evaluated for impaired function of mitochondrial complex I. The patient also presented with impaired function of mitochondrial complex IV and reduced mitochondrial DNA content in muscle. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z2 was evaluated for impaired function of mitochondrial complex I. The patient also presented with[E1] impaired function of mitochondrial complex[/E1] IV and reduced mitochondrial DNA content in muscle. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,227,231, impaired function of mitochondrial complex,HPO_TERM,106,149,0.8461574,0.15384264,-0.69231474,0
line402,Patient Z2 was evaluated for impaired function of mitochondrial complex I. The patient also presented with impaired function of mitochondrial complex IV and reduced mitochondrial DNA content in muscle. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z2 was evaluated for impaired function of mitochondrial complex I. The patient also presented with impaired function of mitochondrial complex IV a[E1]nd reduced mitochondrial DNA content in mu[/E1]scle. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,227,231,nd reduced mitochondrial DNA content in mu,HPO_TERM,154,196,0.85154396,0.14845608,-0.70308787,0
line403,"This report details Patient Z3, a patient with a defect in mitochondrial complex I. Further investigation showed abnormal findings on diffusion-weighted imaging and slowness of movement. A known variant in the POLG gene was identified.","This report details Patient Z3, a patient with [E1]a defect in mitochondrial complex [/E1]I. Further investigation showed abnormal findings on diffusion-weighted imaging and slowness of movement. A known variant in t[E2]he P[/E2]OLG gene was identified.",he P,GENE_VARIANT,207,211,a defect in mitochondrial complex ,HPO_TERM,47,81,0.7605787,0.23942126,-0.52115744,0
line403,"This report details Patient Z3, a patient with a defect in mitochondrial complex I. Further investigation showed abnormal findings on diffusion-weighted imaging and slowness of movement. A known variant in the POLG gene was identified.","This report details Patient Z3, a patient with a defect in mitochondrial complex I. Further investigation showed[E1] abnormal findings on diffusion-weighted imagin[/E1]g and slowness of movement. A known variant in t[E2]he P[/E2]OLG gene was identified.",he P,GENE_VARIANT,207,211, abnormal findings on diffusion-weighted imagin,HPO_TERM,112,159,0.7912341,0.208766,-0.5824681,0
line403,"This report details Patient Z3, a patient with a defect in mitochondrial complex I. Further investigation showed abnormal findings on diffusion-weighted imaging and slowness of movement. A known variant in the POLG gene was identified.","This report details Patient Z3, a patient with a defect in mitochondrial complex I. Further investigation showed abnormal findings on diffusion-weighted imaging and[E1] slowness of moveme[/E1]nt. A known variant in t[E2]he P[/E2]OLG gene was identified.",he P,GENE_VARIANT,207,211, slowness of moveme,HPO_TERM,164,183,0.8254256,0.17457439,-0.65085125,0
line404,The primary symptoms for Patient Z4 were a severe reduction of mtDNA in muscle and abnormal morphology of the cerebral cortex. Analysis of the POLG gene was performed.,The primary symptoms for Patient Z4 were a [E1]severe reduction of mtDNA in muscle and[/E1] abnormal morphology of the cerebral cortex. Analysis of the POLG gene w[E2]as p[/E2]erformed.,as p,GENE_VARIANT,154,158,severe reduction of mtDNA in muscle and,HPO_TERM,43,82,0.8590824,0.14091758,-0.7181648,0
line405,The primary symptoms for Patient Z5 were a reduction in complex I activity and slowness of movement. Analysis of the POLG gene was performed.,The primary symptoms for Patient Z5 were a [E1]reduction in complex I activity a[/E1]nd slowness of movement. Analysis of the POLG gene[E2] was[/E2] performed., was,GENE_VARIANT,126,130,reduction in complex I activity a,HPO_TERM,43,76,0.8446921,0.15530784,-0.6893843,0
line406,Patient Z6 was evaluated for elevated alanine aminotransferase. The patient also presented with abnormal DWI signal on brain MRI and a defect in mitochondrial complex I. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z6 was evaluated for [E1]elevated alanine aminotransferase[/E1]. The patient also presented with abnormal DWI signal on brain MRI and a defect in mitochondrial complex I. Subsequent sequencing of th[E2]e PO[/E2]LG gene revealed a pathogenic variant.,e PO,GENE_VARIANT,197,201,elevated alanine aminotransferase,HPO_TERM,29,62,0.86294687,0.13705313,-0.72589374,0
line406,Patient Z6 was evaluated for elevated alanine aminotransferase. The patient also presented with abnormal DWI signal on brain MRI and a defect in mitochondrial complex I. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z6 was evaluated for elevated alanine aminotransferase. The patient also presented with [E1]abnormal DWI signal on brain MR[/E1]I and a defect in mitochondrial complex I. Subsequent sequencing of th[E2]e PO[/E2]LG gene revealed a pathogenic variant.,e PO,GENE_VARIANT,197,201,abnormal DWI signal on brain MR,HPO_TERM,96,127,0.8735611,0.12643893,-0.74712217,0
line406,Patient Z6 was evaluated for elevated alanine aminotransferase. The patient also presented with abnormal DWI signal on brain MRI and a defect in mitochondrial complex I. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z6 was evaluated for elevated alanine aminotransferase. The patient also presented with abnormal DWI signal on brain MRI and[E1] a defect in mitochondrial complex[/E1] I. Subsequent sequencing of th[E2]e PO[/E2]LG gene revealed a pathogenic variant.,e PO,GENE_VARIANT,197,201, a defect in mitochondrial complex,HPO_TERM,132,166,0.8633838,0.1366162,-0.72676766,0
line407,The primary symptoms for Patient Z7 were slowness of movement and a defect in mitochondrial complex I. Analysis of the POLG gene was performed.,The primary symptoms for Patient Z7 were sl[E1]owness of movement [/E1]and a defect in mitochondrial complex I. Analysis of the POLG gen[E2]e wa[/E2]s performed.,e wa,GENE_VARIANT,127,131,owness of movement ,HPO_TERM,43,62,0.85567194,0.14432806,-0.7113439,0
line407,The primary symptoms for Patient Z7 were slowness of movement and a defect in mitochondrial complex I. Analysis of the POLG gene was performed.,The primary symptoms for Patient Z7 were slowness of movement and a[E1] defect in mitochondrial complex I[/E1]. Analysis of the POLG gen[E2]e wa[/E2]s performed.,e wa,GENE_VARIANT,127,131, defect in mitochondrial complex I,HPO_TERM,67,101,0.8599192,0.1400808,-0.7198384,0
line408,Patient Z8 was evaluated for slowness of movement. The patient also presented with low complex I enzymatic activity and a decrease in mitochondrial DNA in the muscles. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z8 was evaluated for [E1]slowness of movemen[/E1]t. The patient also presented with low complex I enzymatic activity and a decrease in mitochondrial DNA in the muscles. Subsequent sequencing of th[E2]e PO[/E2]LG gene revealed a pathogenic variant.,e PO,GENE_VARIANT,195,199,slowness of movemen,HPO_TERM,29,48,0.88014054,0.11985944,-0.7602811,0
line408,Patient Z8 was evaluated for slowness of movement. The patient also presented with low complex I enzymatic activity and a decrease in mitochondrial DNA in the muscles. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z8 was evaluated for slowness of movement. The patient also presented with[E1] low complex I enzymatic activ[/E1]ity and a decrease in mitochondrial DNA in the muscles. Subsequent sequencing of th[E2]e PO[/E2]LG gene revealed a pathogenic variant.,e PO,GENE_VARIANT,195,199, low complex I enzymatic activ,HPO_TERM,82,112,0.87421584,0.12578414,-0.7484317,0
line408,Patient Z8 was evaluated for slowness of movement. The patient also presented with low complex I enzymatic activity and a decrease in mitochondrial DNA in the muscles. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z8 was evaluated for slowness of movement. The patient also presented with low complex I enzymatic activity a[E1]nd a decrease in mitochondrial DNA in the muscl[/E1]es. Subsequent sequencing of th[E2]e PO[/E2]LG gene revealed a pathogenic variant.,e PO,GENE_VARIANT,195,199,nd a decrease in mitochondrial DNA in the muscl,HPO_TERM,117,164,0.88155144,0.11844859,-0.7631028,0
line409,"This report details Patient Z9, a patient with a congenital malformation of the cerebral cortex. Further investigation showed a rise in AST concentration and a partial deficiency of complex I. A known variant in the POLG gene was identified.","This report details Patient Z9, a patient with a congenital malformation of the cerebral cortex. Further investigation showed a[E1] rise in AST concentration[/E1] and a partial deficiency of complex I. A known variant in the[E2] POL[/E2]G gene was identified.", POL,GENE_VARIANT,215,219, rise in AST concentration,HPO_TERM,127,153,0.7958585,0.20414153,-0.591717,0
line409,"This report details Patient Z9, a patient with a congenital malformation of the cerebral cortex. Further investigation showed a rise in AST concentration and a partial deficiency of complex I. A known variant in the POLG gene was identified.","This report details Patient Z9, a patient with a congenital malformation of the cerebral cortex. Further investigation showed a rise in AST concentration and [E1]a partial deficiency of complex I[/E1]. A known variant in the[E2] POL[/E2]G gene was identified.", POL,GENE_VARIANT,215,219,a partial deficiency of complex I,HPO_TERM,158,191,0.8086337,0.1913663,-0.6172674,0
line410,The clinical profile for Patient Z10 includes an increase in the serum level of alanine aminotransferase and a severe reduction of mtDNA in muscle. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Z10 includes [E1]an increase in the serum level of alanine aminotransferase and [/E1]a severe reduction of mtDNA in muscle. Genetic analysis of the POLG ge[E2]ne c[/E2]onfirmed the diagnosis.,ne c,GENE_VARIANT,179,183,an increase in the serum level of alanine aminotransferase and ,HPO_TERM,46,109,0.8777371,0.12226295,-0.75547415,0
line411,The primary symptoms for Patient Z11 were a defect in mitochondrial complex I and areas of restricted diffusion on brain DWI. Analysis of the POLG gene was performed.,The primary symptoms for Patient Z11 were a [E1]defect in mitochondrial complex I [/E1]and areas of restricted diffusion on brain DWI. Analysis of the POLG gene [E2]was [/E2]performed.,was ,GENE_VARIANT,152,156,defect in mitochondrial complex I ,HPO_TERM,44,78,0.84837687,0.15162316,-0.69675374,0
line412,The clinical profile for Patient Z12 includes a severe reduction of mtDNA in muscle and a defect in mitochondrial complex I. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Z12 includes [E1]a severe reduction of mtDNA in muscle a[/E1]nd a defect in mitochondrial complex I. Genetic analysis of the P[E2]OLG [/E2]gene confirmed the diagnosis.,OLG ,GENE_VARIANT,150,154,a severe reduction of mtDNA in muscle a,HPO_TERM,46,85,0.8308148,0.16918527,-0.6616295,0
line413,Patient Z13 was evaluated for slowness of movement. The patient also presented with bradykinesia and high levels of alanine aminotransferase. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z13 was evaluated for [E1]slowness of movemen[/E1]t. The patient also presented with bradykinesia and high levels of alanine aminotransferase. Subsequent sequencing of the[E2] POL[/E2]G gene revealed a pathogenic variant., POL,GENE_VARIANT,170,174,slowness of movemen,HPO_TERM,30,49,0.86576444,0.1342356,-0.7315288,0
line413,Patient Z13 was evaluated for slowness of movement. The patient also presented with bradykinesia and high levels of alanine aminotransferase. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z13 was evaluated for slowness of movement. The patient also presented with[E1] bradykinesi[/E1]a and high levels of alanine aminotransferase. Subsequent sequencing of the[E2] POL[/E2]G gene revealed a pathogenic variant., POL,GENE_VARIANT,170,174, bradykinesi,HPO_TERM,83,95,0.859599,0.14040099,-0.719198,0
line413,Patient Z13 was evaluated for slowness of movement. The patient also presented with bradykinesia and high levels of alanine aminotransferase. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z13 was evaluated for slowness of movement. The patient also presented with bradykinesia and[E1] high levels of alanine aminotransferas[/E1]e. Subsequent sequencing of the[E2] POL[/E2]G gene revealed a pathogenic variant., POL,GENE_VARIANT,170,174, high levels of alanine aminotransferas,HPO_TERM,100,139,0.86963844,0.1303616,-0.7392768,0
line414,Patient Z14 was evaluated for multiple deletions in the mitochondrial DNA. The patient also presented with an accumulation of multiple mtDNA deletions and a defect in mitochondrial complex I. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z14 was evaluated for [E1]multiple deletions in the mitochondrial D[/E1]NA. The patient also presented with an accumulation of multiple mtDNA deletions and a defect in mitochondrial complex I. Subsequent sequencing of[E2] the[/E2] POLG gene revealed a pathogenic variant., the,GENE_VARIANT,216,220,multiple deletions in the mitochondrial D,HPO_TERM,30,71,0.8233961,0.1766039,-0.6467922,0
line414,Patient Z14 was evaluated for multiple deletions in the mitochondrial DNA. The patient also presented with an accumulation of multiple mtDNA deletions and a defect in mitochondrial complex I. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z14 was evaluated for multiple deletions in the mitochondrial DNA. The patient also presented wit[E1]h an accumulation of multiple mtDNA delet[/E1]ions and a defect in mitochondrial complex I. Subsequent sequencing of[E2] the[/E2] POLG gene revealed a pathogenic variant., the,GENE_VARIANT,216,220,h an accumulation of multiple mtDNA delet,HPO_TERM,105,146,0.83787745,0.16212253,-0.6757549,0
line414,Patient Z14 was evaluated for multiple deletions in the mitochondrial DNA. The patient also presented with an accumulation of multiple mtDNA deletions and a defect in mitochondrial complex I. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z14 was evaluated for multiple deletions in the mitochondrial DNA. The patient also presented with an accumulation of multiple mtDNA deletions [E1]and a defect in mitochondrial comp[/E1]lex I. Subsequent sequencing of[E2] the[/E2] POLG gene revealed a pathogenic variant., the,GENE_VARIANT,216,220,and a defect in mitochondrial comp,HPO_TERM,151,185,0.8418683,0.15813172,-0.68373656,0
line415,The primary symptoms for Patient Z15 were a decrease in mitochondrial DNA in the muscles and slowness of movement. Analysis of the POLG gene was performed.,The primary symptoms for Patient Z15 were a [E1]decrease in mitochondrial DNA in the muscles an[/E1]d slowness of movement. Analysis of the POLG gene [E2]was [/E2]performed.,was ,GENE_VARIANT,141,145,decrease in mitochondrial DNA in the muscles an,HPO_TERM,44,91,0.8460186,0.15398142,-0.6920372,0
line416,The clinical profile for Patient Z16 includes low levels of mitochondrial DNA in muscle and bradykinesia. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Z16 includes [E1]low levels of mitochondrial DNA in muscle a[/E1]nd bradykinesia. Genetic analysis of the PO[E2]LG g[/E2]ene confirmed the diagnosis.,LG g,GENE_VARIANT,132,136,low levels of mitochondrial DNA in muscle a,HPO_TERM,46,89,0.8853233,0.114676744,-0.7706466,0
line417,Patient Z17 was evaluated for a low copy number of mtDNA in muscle tissue. The patient also presented with abnormal DWI signal on brain MRI and a partial deficiency of complex I. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z17 was evaluated for [E1]a low copy number of mtDNA in muscle tissu[/E1]e. The patient also presented with abnormal DWI signal on brain MRI and a partial deficiency of complex I. Subsequent sequencing of th[E2]e PO[/E2]LG gene revealed a pathogenic variant.,e PO,GENE_VARIANT,206,210,a low copy number of mtDNA in muscle tissu,HPO_TERM,30,72,0.8751759,0.12482408,-0.7503518,0
line417,Patient Z17 was evaluated for a low copy number of mtDNA in muscle tissue. The patient also presented with abnormal DWI signal on brain MRI and a partial deficiency of complex I. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z17 was evaluated for a low copy number of mtDNA in muscle tissue. The patient also presented with[E1] abnormal DWI signal on brain M[/E1]RI and a partial deficiency of complex I. Subsequent sequencing of th[E2]e PO[/E2]LG gene revealed a pathogenic variant.,e PO,GENE_VARIANT,206,210, abnormal DWI signal on brain M,HPO_TERM,106,137,0.87609136,0.123908594,-0.7521828,0
line417,Patient Z17 was evaluated for a low copy number of mtDNA in muscle tissue. The patient also presented with abnormal DWI signal on brain MRI and a partial deficiency of complex I. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z17 was evaluated for a low copy number of mtDNA in muscle tissue. The patient also presented with abnormal DWI signal on brain MRI an[E1]d a partial deficiency of complex[/E1] I. Subsequent sequencing of th[E2]e PO[/E2]LG gene revealed a pathogenic variant.,e PO,GENE_VARIANT,206,210,d a partial deficiency of complex,HPO_TERM,142,175,0.884066,0.11593395,-0.76813203,0
line418,"We report the case of Patient Z18, who has a history of deficient cytochrome c oxidase activity. Examination also revealed bradykinesia. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Z18, who has a history of [E1]deficient cytochrome c oxidase activit[/E1]y. Examination also revealed bradykinesia. The underlying cause was traced to a mutation in the[E2] POL[/E2]G gene.", POL,GENE_VARIANT,189,193,deficient cytochrome c oxidase activit,HPO_TERM,56,94,0.49029523,0.5097048,0.019409597,1
line418,"We report the case of Patient Z18, who has a history of deficient cytochrome c oxidase activity. Examination also revealed bradykinesia. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Z18, who has a history of deficient cytochrome c oxidase activity. Examination also revealed[E1] bradykinesi[/E1]a. The underlying cause was traced to a mutation in the[E2] POL[/E2]G gene.", POL,GENE_VARIANT,189,193, bradykinesi,HPO_TERM,122,134,0.5001292,0.49987084,-0.00025838614,0
line419,Patient Z19 was evaluated for an increase in the serum level of alanine aminotransferase. The patient also presented with areas of restricted diffusion on brain DWI and a rise in AST concentration. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z19 was evaluated for an increase in the serum level of alanine aminotransferase. The patient also presented with a[E1]reas of restricted diffusion on brain DWI a[/E1]nd a rise in AST concentration. Subsequent sequencing of the P[E2]OLG [/E2]gene revealed a pathogenic variant.,OLG ,GENE_VARIANT,228,232,reas of restricted diffusion on brain DWI a,HPO_TERM,123,166,0.8658471,0.13415289,-0.7316942,0
line420,Patient Z20 was evaluated for elevated alanine aminotransferase. The patient also presented with bradykinesia and slowness of movement. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z20 was evaluated for [E1]elevated alanine aminotransferase[/E1]. The patient also presented with bradykinesia and slowness of movement. Subsequent sequencing of the[E2] POL[/E2]G gene revealed a pathogenic variant., POL,GENE_VARIANT,164,168,elevated alanine aminotransferase,HPO_TERM,30,63,0.86162865,0.13837138,-0.7232573,0
line420,Patient Z20 was evaluated for elevated alanine aminotransferase. The patient also presented with bradykinesia and slowness of movement. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z20 was evaluated for elevated alanine aminotransferase. The patient also presented with [E1]bradykinesia[/E1] and slowness of movement. Subsequent sequencing of the[E2] POL[/E2]G gene revealed a pathogenic variant., POL,GENE_VARIANT,164,168,bradykinesia,HPO_TERM,97,109,0.8576503,0.1423497,-0.71530056,0
line420,Patient Z20 was evaluated for elevated alanine aminotransferase. The patient also presented with bradykinesia and slowness of movement. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z20 was evaluated for elevated alanine aminotransferase. The patient also presented with bradykinesia and [E1]slowness of movemen[/E1]t. Subsequent sequencing of the[E2] POL[/E2]G gene revealed a pathogenic variant., POL,GENE_VARIANT,164,168,slowness of movemen,HPO_TERM,114,133,0.8687175,0.1312825,-0.737435,0
line421,Patient Z21 was evaluated for a rise in AST concentration. The patient also presented with a partial deficiency of complex I and a defect in mitochondrial complex I. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z21 was evaluated for [E1]a rise in AST concentratio[/E1]n. The patient also presented with a partial deficiency of complex I and a defect in mitochondrial complex I. Subsequent sequencing of th[E2]e PO[/E2]LG gene revealed a pathogenic variant.,e PO,GENE_VARIANT,193,197,a rise in AST concentratio,HPO_TERM,30,56,0.89663714,0.10336283,-0.7932743,0
line421,Patient Z21 was evaluated for a rise in AST concentration. The patient also presented with a partial deficiency of complex I and a defect in mitochondrial complex I. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z21 was evaluated for a rise in AST concentration. The patient also presented with[E1] a partial deficiency of complex [/E1]I and a defect in mitochondrial complex I. Subsequent sequencing of th[E2]e PO[/E2]LG gene revealed a pathogenic variant.,e PO,GENE_VARIANT,193,197, a partial deficiency of complex ,HPO_TERM,90,123,0.8896672,0.11033282,-0.7793344,0
line421,Patient Z21 was evaluated for a rise in AST concentration. The patient also presented with a partial deficiency of complex I and a defect in mitochondrial complex I. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z21 was evaluated for a rise in AST concentration. The patient also presented with a partial deficiency of complex I and[E1] a defect in mitochondrial complex[/E1] I. Subsequent sequencing of th[E2]e PO[/E2]LG gene revealed a pathogenic variant.,e PO,GENE_VARIANT,193,197, a defect in mitochondrial complex,HPO_TERM,128,162,0.8910713,0.108928606,-0.7821427,0
line422,"This report details Patient Z22, a patient with a reduction in complex IV activity. Further investigation showed slowness of movement and an increase in CSF lactate. A known variant in the POLG gene was identified.","This report details Patient Z22, a patient with [E1]a reduction in complex IV activity[/E1]. Further investigation showed slowness of movement and an increase in CSF lactate. A known variant i[E2]n th[/E2]e POLG gene was identified.",n th,GENE_VARIANT,183,187,a reduction in complex IV activity,HPO_TERM,48,82,0.8419336,0.15806642,-0.6838672,0
line422,"This report details Patient Z22, a patient with a reduction in complex IV activity. Further investigation showed slowness of movement and an increase in CSF lactate. A known variant in the POLG gene was identified.","This report details Patient Z22, a patient with a reduction in complex IV activity. Further investigation showed [E1]slowness of movemen[/E1]t and an increase in CSF lactate. A known variant i[E2]n th[/E2]e POLG gene was identified.",n th,GENE_VARIANT,183,187,slowness of movemen,HPO_TERM,113,132,0.8573112,0.14268887,-0.7146223,0
line422,"This report details Patient Z22, a patient with a reduction in complex IV activity. Further investigation showed slowness of movement and an increase in CSF lactate. A known variant in the POLG gene was identified.","This report details Patient Z22, a patient with a reduction in complex IV activity. Further investigation showed slowness of movement and[E1] an increase in CSF la[/E1]ctate. A known variant i[E2]n th[/E2]e POLG gene was identified.",n th,GENE_VARIANT,183,187, an increase in CSF la,HPO_TERM,137,159,0.8389592,0.1610408,-0.67791843,0
line423,The clinical profile for Patient Z23 includes high levels of alanine aminotransferase and bradykinesia. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Z23 includes [E1]high levels of alanine aminotransferase[/E1] and bradykinesia. Genetic analysis of the [E2]POLG[/E2] gene confirmed the diagnosis.,POLG,GENE_VARIANT,128,132,high levels of alanine aminotransferase,HPO_TERM,46,85,0.8262895,0.1737105,-0.65257895,0
line423,The clinical profile for Patient Z23 includes high levels of alanine aminotransferase and bradykinesia. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Z23 includes high levels of alanine aminotransferase and [E1]bradykinesia[/E1]. Genetic analysis of the [E2]POLG[/E2] gene confirmed the diagnosis.,POLG,GENE_VARIANT,128,132,bradykinesia,HPO_TERM,90,102,0.8373104,0.16268964,-0.67462075,0
line424,The clinical profile for Patient Z24 includes a defect in mitochondrial complex I and a progressive slowness of movement. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Z24 includes [E1]a defect in mitochondrial complex [/E1]I and a progressive slowness of movement. Genetic analysis of the[E2] POL[/E2]G gene confirmed the diagnosis., POL,GENE_VARIANT,145,149,a defect in mitochondrial complex ,HPO_TERM,46,80,0.8278389,0.17216118,-0.65567774,0
line424,The clinical profile for Patient Z24 includes a defect in mitochondrial complex I and a progressive slowness of movement. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Z24 includes a defect in mitochondrial complex I and[E1] a progressive slowness of movemen[/E1]t. Genetic analysis of the[E2] POL[/E2]G gene confirmed the diagnosis., POL,GENE_VARIANT,145,149, a progressive slowness of movemen,HPO_TERM,85,119,0.86199594,0.1380041,-0.7239919,0
line425,"We report the case of Patient Z25, who has a history of high levels of aspartate aminotransferase. Examination also revealed a low copy number of mtDNA in muscle tissue. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Z25, who has a history of [E1]high levels of aspartate aminotransfera[/E1]se. Examination also revealed a low copy number of mtDNA in muscle tissue. The underlying cause was traced to a mutation in t[E2]he P[/E2]OLG gene.",he P,GENE_VARIANT,220,224,high levels of aspartate aminotransfera,HPO_TERM,56,95,0.6024305,0.3975695,-0.20486102,0
line425,"We report the case of Patient Z25, who has a history of high levels of aspartate aminotransferase. Examination also revealed a low copy number of mtDNA in muscle tissue. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Z25, who has a history of high levels of aspartate aminotransferase. Examination also reveale[E1]d a low copy number of mtDNA in muscle tis[/E1]sue. The underlying cause was traced to a mutation in t[E2]he P[/E2]OLG gene.",he P,GENE_VARIANT,220,224,d a low copy number of mtDNA in muscle tis,HPO_TERM,123,165,0.60882187,0.39117816,-0.21764371,0
line426,The clinical profile for Patient Z26 includes a low copy number of mtDNA in muscle tissue and low complex I enzymatic activity. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Z26 includes [E1]a low copy number of mtDNA in muscle tissu[/E1]e and low complex I enzymatic activity. Genetic analysis of t[E2]he P[/E2]OLG gene confirmed the diagnosis.,he P,GENE_VARIANT,149,153,a low copy number of mtDNA in muscle tissu,HPO_TERM,46,88,0.87372506,0.126275,-0.74745005,0
line426,The clinical profile for Patient Z26 includes a low copy number of mtDNA in muscle tissue and low complex I enzymatic activity. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Z26 includes a low copy number of mtDNA in muscle tissue and[E1] low complex I enzymatic activ[/E1]ity. Genetic analysis of t[E2]he P[/E2]OLG gene confirmed the diagnosis.,he P,GENE_VARIANT,149,153, low complex I enzymatic activ,HPO_TERM,93,123,0.87625307,0.12374692,-0.75250614,0
line427,The clinical profile for Patient Z27 includes an accumulation of multiple mtDNA deletions and a partial deficiency of complex I. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Z27 includes [E1]an accumulation of multiple mtDNA deletio[/E1]ns and a partial deficiency of complex I. Genetic analysis of th[E2]e PO[/E2]LG gene confirmed the diagnosis.,e PO,GENE_VARIANT,151,155,an accumulation of multiple mtDNA deletio,HPO_TERM,46,87,0.8737311,0.126269,-0.7474621,0
line427,The clinical profile for Patient Z27 includes an accumulation of multiple mtDNA deletions and a partial deficiency of complex I. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Z27 includes an accumulation of multiple mtDNA deletions an[E1]d a partial deficiency of complex[/E1] I. Genetic analysis of th[E2]e PO[/E2]LG gene confirmed the diagnosis.,e PO,GENE_VARIANT,151,155,d a partial deficiency of complex,HPO_TERM,92,125,0.87029535,0.12970465,-0.7405907,0
line428,Patient Z28 was evaluated for slowness of movement. The patient also presented with a quantitative defect of mitochondrial DNA in muscle and high levels of alanine aminotransferase. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z28 was evaluated for [E1]slowness of movemen[/E1]t. The patient also presented with a quantitative defect of mitochondrial DNA in muscle and high levels of alanine aminotransferase. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,208,212,slowness of movemen,HPO_TERM,30,49,0.87692076,0.12307921,-0.7538415,0
line428,Patient Z28 was evaluated for slowness of movement. The patient also presented with a quantitative defect of mitochondrial DNA in muscle and high levels of alanine aminotransferase. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z28 was evaluated for slowness of movement. The patient also presented with[E1] a quantitative defect of mitochondrial DNA in mus[/E1]cle and high levels of alanine aminotransferase. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,208,212, a quantitative defect of mitochondrial DNA in mus,HPO_TERM,83,133,0.85615414,0.1438458,-0.71230835,0
line428,Patient Z28 was evaluated for slowness of movement. The patient also presented with a quantitative defect of mitochondrial DNA in muscle and high levels of alanine aminotransferase. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z28 was evaluated for slowness of movement. The patient also presented with a quantitative defect of mitochondrial DNA in muscle a[E1]nd high levels of alanine aminotransfer[/E1]ase. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,208,212,nd high levels of alanine aminotransfer,HPO_TERM,138,177,0.87872964,0.12127041,-0.7574592,0
line429,"We report the case of Patient Z29, who has a history of high ALT levels. Examination also revealed a rise in AST concentration. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Z29, who has a history of [E1]high ALT leve[/E1]ls. Examination also revealed a rise in AST concentration. The underlying cause was traced to a mutation in t[E2]he P[/E2]OLG gene.",he P,GENE_VARIANT,178,182,high ALT leve,HPO_TERM,56,69,0.76992226,0.23007777,-0.5398445,0
line429,"We report the case of Patient Z29, who has a history of high ALT levels. Examination also revealed a rise in AST concentration. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Z29, who has a history of high ALT levels. Examination also reveale[E1]d a rise in AST concentrat[/E1]ion. The underlying cause was traced to a mutation in t[E2]he P[/E2]OLG gene.",he P,GENE_VARIANT,178,182,d a rise in AST concentrat,HPO_TERM,97,123,0.75597596,0.24402401,-0.5119519,0
line430,Patient Z30 was evaluated for a severe reduction of mtDNA in muscle. The patient also presented with a rise in AST concentration and areas of restricted diffusion on brain DWI. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z30 was evaluated for a severe reduction of mtDNA in muscle. The patient also presented with a [E1]rise in AST concentration [/E1]and areas of restricted diffusion on brain DWI. Subsequent sequencing of the PO[E2]LG g[/E2]ene revealed a pathogenic variant.,LG g,GENE_VARIANT,208,212,rise in AST concentration ,HPO_TERM,103,129,0.8818727,0.11812724,-0.7637455,0
line431,Patient Z31 was evaluated for a defect in mitochondrial complex I. The patient also presented with a partial deficiency of complex I and an accumulation of multiple mtDNA deletions. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z31 was evaluated for [E1]a defect in mitochondrial complex [/E1]I. The patient also presented with a partial deficiency of complex I and an accumulation of multiple mtDNA deletions. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,208,212,a defect in mitochondrial complex ,HPO_TERM,30,64,0.8588356,0.14116439,-0.71767116,0
line431,Patient Z31 was evaluated for a defect in mitochondrial complex I. The patient also presented with a partial deficiency of complex I and an accumulation of multiple mtDNA deletions. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z31 was evaluated for a defect in mitochondrial complex I. The patient also presented with[E1] a partial deficiency of complex [/E1]I and an accumulation of multiple mtDNA deletions. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,208,212, a partial deficiency of complex ,HPO_TERM,98,131,0.86170936,0.13829063,-0.7234187,0
line431,Patient Z31 was evaluated for a defect in mitochondrial complex I. The patient also presented with a partial deficiency of complex I and an accumulation of multiple mtDNA deletions. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z31 was evaluated for a defect in mitochondrial complex I. The patient also presented with a partial deficiency of complex I and[E1] an accumulation of multiple mtDNA deleti[/E1]ons. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,208,212, an accumulation of multiple mtDNA deleti,HPO_TERM,136,177,0.86730206,0.13269794,-0.7346041,0
line432,The primary symptoms for Patient Z32 were a quantitative defect of mitochondrial DNA in muscle and a progressive slowness of movement. Analysis of the POLG gene was performed.,The primary symptoms for Patient Z32 were a [E1]quantitative defect of mitochondrial DNA in muscle[/E1] and a progressive slowness of movement. Analysis of the POLG gen[E2]e wa[/E2]s performed.,e wa,GENE_VARIANT,159,163,quantitative defect of mitochondrial DNA in muscle,HPO_TERM,44,94,0.8384249,0.16157508,-0.67684984,0
line432,The primary symptoms for Patient Z32 were a quantitative defect of mitochondrial DNA in muscle and a progressive slowness of movement. Analysis of the POLG gene was performed.,The primary symptoms for Patient Z32 were a quantitative defect of mitochondrial DNA in muscle and [E1]a progressive slowness of movement[/E1]. Analysis of the POLG gen[E2]e wa[/E2]s performed.,e wa,GENE_VARIANT,159,163,a progressive slowness of movement,HPO_TERM,99,133,0.83906513,0.16093491,-0.6781302,0
line433,The primary symptoms for Patient Z33 were a severe reduction of mtDNA in muscle and an increase in CSF lactate. Analysis of the POLG gene was performed.,The primary symptoms for Patient Z33 were a [E1]severe reduction of mtDNA in muscle and[/E1] an increase in CSF lactate. Analysis of the POLG gen[E2]e wa[/E2]s performed.,e wa,GENE_VARIANT,136,140,severe reduction of mtDNA in muscle and,HPO_TERM,44,83,0.8118124,0.18818757,-0.6236248,0
line433,The primary symptoms for Patient Z33 were a severe reduction of mtDNA in muscle and an increase in CSF lactate. Analysis of the POLG gene was performed.,The primary symptoms for Patient Z33 were a severe reduction of mtDNA in muscle and an i[E1]ncrease in CSF lactate[/E1]. Analysis of the POLG gen[E2]e wa[/E2]s performed.,e wa,GENE_VARIANT,136,140,ncrease in CSF lactate,HPO_TERM,88,110,0.825434,0.17456599,-0.65086806,0
line434,The primary symptoms for Patient Z34 were a partial deficiency of complex I and a reduction in complex I activity. Analysis of the POLG gene was performed.,The primary symptoms for Patient Z34 were a [E1]partial deficiency of complex I a[/E1]nd a reduction in complex I activity. Analysis of the POLG gene [E2]was [/E2]performed.,was ,GENE_VARIANT,141,145,partial deficiency of complex I a,HPO_TERM,44,77,0.8538265,0.14617355,-0.707653,0
line435,Patient Z35 was evaluated for a general slowing of physical movements. The patient also presented with a reduction in complex I activity and multiple deletions in the mitochondrial DNA. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z35 was evaluated for [E1]a general slowing of physical movement[/E1]s. The patient also presented with a reduction in complex I activity and multiple deletions in the mitochondrial DNA. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,212,216,a general slowing of physical movement,HPO_TERM,30,68,0.86036265,0.13963741,-0.72072524,0
line435,Patient Z35 was evaluated for a general slowing of physical movements. The patient also presented with a reduction in complex I activity and multiple deletions in the mitochondrial DNA. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z35 was evaluated for a general slowing of physical movements. The patient also presented with[E1] a reduction in complex I activit[/E1]y and multiple deletions in the mitochondrial DNA. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,212,216, a reduction in complex I activit,HPO_TERM,102,135,0.8603877,0.13961232,-0.72077537,0
line435,Patient Z35 was evaluated for a general slowing of physical movements. The patient also presented with a reduction in complex I activity and multiple deletions in the mitochondrial DNA. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z35 was evaluated for a general slowing of physical movements. The patient also presented with a reduction in complex I activity and[E1] multiple deletions in the mitochondrial [/E1]DNA. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,212,216, multiple deletions in the mitochondrial ,HPO_TERM,140,181,0.8521853,0.14781465,-0.7043707,0
line436,"This report details Patient Z36, a patient with bradykinesia. Further investigation showed a reduction in complex I activity and a decrease in mitochondrial DNA in the muscles. A known variant in the POLG gene was identified.","This report details Patient Z36, a patient with [E1]bradykinesia[/E1]. Further investigation showed a reduction in complex I activity and a decrease in mitochondrial DNA in the muscles. A known variant in the [E2]POLG[/E2] gene was identified.",POLG,GENE_VARIANT,200,204,bradykinesia,HPO_TERM,48,60,0.6866382,0.31336176,-0.3732764,0
line436,"This report details Patient Z36, a patient with bradykinesia. Further investigation showed a reduction in complex I activity and a decrease in mitochondrial DNA in the muscles. A known variant in the POLG gene was identified.","This report details Patient Z36, a patient with bradykinesia. Further investigation showed [E1]a reduction in complex I activity[/E1] and a decrease in mitochondrial DNA in the muscles. A known variant in the [E2]POLG[/E2] gene was identified.",POLG,GENE_VARIANT,200,204,a reduction in complex I activity,HPO_TERM,91,124,0.67545795,0.32454208,-0.35091588,0
line437,"This report details Patient Z37, a patient with elevated aspartate aminotransferase. Further investigation showed a quantitative defect of mitochondrial DNA in muscle and elevated lactate in CSF. A known variant in the POLG gene was identified.","This report details Patient Z37, a patient with [E1]elevated aspartate aminotransferase[/E1]. Further investigation showed a quantitative defect of mitochondrial DNA in muscle and elevated lactate in CSF. A known variant in[E2] the[/E2] POLG gene was identified.", the,GENE_VARIANT,214,218,elevated aspartate aminotransferase,HPO_TERM,48,83,0.77501005,0.22498994,-0.5500201,0
line437,"This report details Patient Z37, a patient with elevated aspartate aminotransferase. Further investigation showed a quantitative defect of mitochondrial DNA in muscle and elevated lactate in CSF. A known variant in the POLG gene was identified.","This report details Patient Z37, a patient with elevated aspartate aminotransferase. Further investigation showed [E1]a quantitative defect of mitochondrial DNA in musc[/E1]le and elevated lactate in CSF. A known variant in[E2] the[/E2] POLG gene was identified.", the,GENE_VARIANT,214,218,a quantitative defect of mitochondrial DNA in musc,HPO_TERM,114,164,0.8194739,0.18052605,-0.63894784,0
line437,"This report details Patient Z37, a patient with elevated aspartate aminotransferase. Further investigation showed a quantitative defect of mitochondrial DNA in muscle and elevated lactate in CSF. A known variant in the POLG gene was identified.","This report details Patient Z37, a patient with elevated aspartate aminotransferase. Further investigation showed a quantitative defect of mitochondrial DNA in muscle an[E1]d elevated lactate in[/E1] CSF. A known variant in[E2] the[/E2] POLG gene was identified.", the,GENE_VARIANT,214,218,d elevated lactate in,HPO_TERM,169,190,0.81051,0.18949004,-0.62101996,0
line438,"This report details Patient Z38, a patient with a severe reduction of mtDNA in muscle. Further investigation showed an abnormal thalamic MRI signal and an elevated circulating aspartate aminotransferase concentration. A known variant in the POLG gene was identified.","This report details Patient Z38, a patient with a severe reduction of mtDNA in muscle. Further investigation showed an[E1] abnormal thalamic MRI signal[/E1] and an elevated circulating aspartate aminotransferase concentration. A known variant i[E2]n th[/E2]e POLG gene was identified.",n th,GENE_VARIANT,235,239, abnormal thalamic MRI signal,HPO_TERM,118,147,0.8289997,0.17100032,-0.6579994,0
line438,"This report details Patient Z38, a patient with a severe reduction of mtDNA in muscle. Further investigation showed an abnormal thalamic MRI signal and an elevated circulating aspartate aminotransferase concentration. A known variant in the POLG gene was identified.","This report details Patient Z38, a patient with a severe reduction of mtDNA in muscle. Further investigation showed an abnormal thalamic MRI signal and [E1]an elevated circulating aspartate aminotransferase concentr[/E1]ation. A known variant i[E2]n th[/E2]e POLG gene was identified.",n th,GENE_VARIANT,235,239,an elevated circulating aspartate aminotransferase concentr,HPO_TERM,152,211,0.8411785,0.15882146,-0.682357,0
line439,"We report the case of Patient Z39, who has a history of an abnormal thalamic MRI signal. Examination also revealed slowness of movement. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Z39, who has a history of [E1]an abnormal thalamic MRI sign[/E1]al. Examination also revealed slowness of movement. The underlying cause was traced to a mutation in t[E2]he P[/E2]OLG gene.",he P,GENE_VARIANT,187,191,an abnormal thalamic MRI sign,HPO_TERM,56,85,0.3887244,0.6112757,0.22255129,1
line439,"We report the case of Patient Z39, who has a history of an abnormal thalamic MRI signal. Examination also revealed slowness of movement. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Z39, who has a history of an abnormal thalamic MRI signal. Examination also reveale[E1]d slowness of movem[/E1]ent. The underlying cause was traced to a mutation in t[E2]he P[/E2]OLG gene.",he P,GENE_VARIANT,187,191,d slowness of movem,HPO_TERM,113,132,0.3099065,0.69009346,0.38018695,1
line440,Patient Z40 was evaluated for slowness of movement. The patient also presented with areas of restricted diffusion on brain DWI and an increase in CSF lactate. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z40 was evaluated for [E1]slowness of movemen[/E1]t. The patient also presented with areas of restricted diffusion on brain DWI and an increase in CSF lactate. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,184,188,slowness of movemen,HPO_TERM,30,49,0.84440875,0.15559132,-0.68881744,0
line440,Patient Z40 was evaluated for slowness of movement. The patient also presented with areas of restricted diffusion on brain DWI and an increase in CSF lactate. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z40 was evaluated for slowness of movement. The patient also presented with[E1] areas of restricted diffusion on brain DWI[/E1] and an increase in CSF lactate. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,184,188, areas of restricted diffusion on brain DWI,HPO_TERM,83,126,0.8177931,0.18220694,-0.63558614,0
line440,Patient Z40 was evaluated for slowness of movement. The patient also presented with areas of restricted diffusion on brain DWI and an increase in CSF lactate. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z40 was evaluated for slowness of movement. The patient also presented with areas of restricted diffusion on brain DWI and [E1]an increase in CSF lac[/E1]tate. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,184,188,an increase in CSF lac,HPO_TERM,131,153,0.82962453,0.17037553,-0.659249,0
line441,The clinical profile for Patient Z41 includes a congenital malformation of the cerebral cortex and high levels of aspartate aminotransferase. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Z41 includes [E1]a congenital malformation of the cerebral cortex [/E1]and high levels of aspartate aminotransferase. Genetic analysis of the[E2] POL[/E2]G gene confirmed the diagnosis., POL,GENE_VARIANT,165,169,a congenital malformation of the cerebral cortex ,HPO_TERM,46,95,0.83685994,0.16314004,-0.6737199,0
line441,The clinical profile for Patient Z41 includes a congenital malformation of the cerebral cortex and high levels of aspartate aminotransferase. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Z41 includes a congenital malformation of the cerebral cortex and h[E1]igh levels of aspartate aminotransferas[/E1]e. Genetic analysis of the[E2] POL[/E2]G gene confirmed the diagnosis., POL,GENE_VARIANT,165,169,igh levels of aspartate aminotransferas,HPO_TERM,100,139,0.8556137,0.14438629,-0.7112274,0
line442,"This report details Patient Z42, a patient with abnormally high ALT levels. Further investigation showed complex I deficiency and slowness of movement. A known variant in the POLG gene was identified.","This report details Patient Z42, a patient with [E1]abnormally high ALT leve[/E1]ls. Further investigation showed complex I deficiency and slowness of movement. A known variant in[E2] the[/E2] POLG gene was identified.", the,GENE_VARIANT,170,174,abnormally high ALT leve,HPO_TERM,48,72,0.7716912,0.22830881,-0.5433824,0
line442,"This report details Patient Z42, a patient with abnormally high ALT levels. Further investigation showed complex I deficiency and slowness of movement. A known variant in the POLG gene was identified.","This report details Patient Z42, a patient with abnormally high ALT levels. Further investigation showe[E1]d complex I deficie[/E1]ncy and slowness of movement. A known variant in[E2] the[/E2] POLG gene was identified.", the,GENE_VARIANT,170,174,d complex I deficie,HPO_TERM,103,122,0.7864655,0.21353443,-0.5729311,0
line442,"This report details Patient Z42, a patient with abnormally high ALT levels. Further investigation showed complex I deficiency and slowness of movement. A known variant in the POLG gene was identified.","This report details Patient Z42, a patient with abnormally high ALT levels. Further investigation showed complex I deficiency a[E1]nd slowness of move[/E1]ment. A known variant in[E2] the[/E2] POLG gene was identified.", the,GENE_VARIANT,170,174,nd slowness of move,HPO_TERM,127,146,0.8123811,0.18761893,-0.6247622,0
line443,Patient Z43 was evaluated for multiple deletions in the mitochondrial DNA. The patient also presented with a reduction in complex IV activity and high levels of alanine aminotransferase. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z43 was evaluated for [E1]multiple deletions in the mitochondrial D[/E1]NA. The patient also presented with a reduction in complex IV activity and high levels of alanine aminotransferase. Subsequent sequencing of th[E2]e PO[/E2]LG gene revealed a pathogenic variant.,e PO,GENE_VARIANT,214,218,multiple deletions in the mitochondrial D,HPO_TERM,30,71,0.88257307,0.11742698,-0.7651461,0
line443,Patient Z43 was evaluated for multiple deletions in the mitochondrial DNA. The patient also presented with a reduction in complex IV activity and high levels of alanine aminotransferase. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z43 was evaluated for multiple deletions in the mitochondrial DNA. The patient also presented wit[E1]h a reduction in complex IV activi[/E1]ty and high levels of alanine aminotransferase. Subsequent sequencing of th[E2]e PO[/E2]LG gene revealed a pathogenic variant.,e PO,GENE_VARIANT,214,218,h a reduction in complex IV activi,HPO_TERM,105,139,0.8934779,0.10652206,-0.78695583,0
line443,Patient Z43 was evaluated for multiple deletions in the mitochondrial DNA. The patient also presented with a reduction in complex IV activity and high levels of alanine aminotransferase. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z43 was evaluated for multiple deletions in the mitochondrial DNA. The patient also presented with a reduction in complex IV activity an[E1]d high levels of alanine aminotransfera[/E1]se. Subsequent sequencing of th[E2]e PO[/E2]LG gene revealed a pathogenic variant.,e PO,GENE_VARIANT,214,218,d high levels of alanine aminotransfera,HPO_TERM,144,183,0.8919707,0.10802925,-0.78394145,0
line444,The clinical profile for Patient Z44 includes a defect in mitochondrial complex I and a reduction in complex I activity. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Z44 includes [E1]a defect in mitochondrial complex [/E1]I and a reduction in complex I activity. Genetic analysis of the[E2] POL[/E2]G gene confirmed the diagnosis., POL,GENE_VARIANT,144,148,a defect in mitochondrial complex ,HPO_TERM,46,80,0.8214284,0.17857157,-0.64285684,0
line444,The clinical profile for Patient Z44 includes a defect in mitochondrial complex I and a reduction in complex I activity. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Z44 includes a defect in mitochondrial complex I and[E1] a reduction in complex I activit[/E1]y. Genetic analysis of the[E2] POL[/E2]G gene confirmed the diagnosis., POL,GENE_VARIANT,144,148, a reduction in complex I activit,HPO_TERM,85,118,0.8566821,0.1433179,-0.71336424,0
line445,The primary symptoms for Patient Z45 were a rise in AST concentration and a severe reduction of mtDNA in muscle. Analysis of the POLG gene was performed.,The primary symptoms for Patient Z45 were a [E1]rise in AST concentration [/E1]and a severe reduction of mtDNA in muscle. Analysis of the POLG gene w[E2]as p[/E2]erformed.,as p,GENE_VARIANT,140,144,rise in AST concentration ,HPO_TERM,44,70,0.8757652,0.124234766,-0.7515304,0
line446,"We report the case of Patient Z46, a patient with a history of reduced mitochondrial DNA content in muscle. Examination also revealed slowness of movement. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Z46, a patient with a hist[E1]ory of reduced mitochondrial DNA content i[/E1]n muscle. Examination also revealed slowness of movement. The underlying cause was traced to a mutatio[E2]n in[/E2] the POLG gene.",n in,GENE_VARIANT,200,204,ory of reduced mitochondrial DNA content i,HPO_TERM,56,98,0.8397874,0.16021264,-0.6795748,0
line446,"We report the case of Patient Z46, a patient with a history of reduced mitochondrial DNA content in muscle. Examination also revealed slowness of movement. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Z46, a patient with a history of reduced mitochondrial DNA content in muscle. Examination also r[E1]evealed slowness of[/E1] movement. The underlying cause was traced to a mutatio[E2]n in[/E2] the POLG gene.",n in,GENE_VARIANT,200,204,evealed slowness of,HPO_TERM,126,145,0.819563,0.18043707,-0.6391259,0
line447,Patient Z47 was evaluated for a low copy number of mtDNA in muscle tissue. The patient also presented with slowness of movement and abnormal cortical architecture. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z47 was evaluated for [E1]a low copy number of mtDNA in muscle tissu[/E1]e. The patient also presented with slowness of movement and abnormal cortical architecture. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,190,194,a low copy number of mtDNA in muscle tissu,HPO_TERM,30,72,0.8243407,0.17565936,-0.64868134,0
line447,Patient Z47 was evaluated for a low copy number of mtDNA in muscle tissue. The patient also presented with slowness of movement and abnormal cortical architecture. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z47 was evaluated for a low copy number of mtDNA in muscle tissue. The patient also presented with[E1] slowness of moveme[/E1]nt and abnormal cortical architecture. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,190,194, slowness of moveme,HPO_TERM,106,125,0.8411876,0.15881242,-0.6823752,0
line447,Patient Z47 was evaluated for a low copy number of mtDNA in muscle tissue. The patient also presented with slowness of movement and abnormal cortical architecture. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z47 was evaluated for a low copy number of mtDNA in muscle tissue. The patient also presented with slowness of movement an[E1]d abnormal cortical architect[/E1]ure. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,190,194,d abnormal cortical architect,HPO_TERM,130,159,0.84166867,0.1583313,-0.68333733,0
line448,The primary symptoms for Patient Z48 were a partial deficiency of complex I and an elevated CSF lactate level. Analysis of the POLG gene was performed.,The primary symptoms for Patient Z48 were a [E1]partial deficiency of complex I a[/E1]nd an elevated CSF lactate level. Analysis of the POLG g[E2]ene [/E2]was performed.,ene ,GENE_VARIANT,133,137,partial deficiency of complex I a,HPO_TERM,44,77,0.8500425,0.1499575,-0.70008504,0
line448,The primary symptoms for Patient Z48 were a partial deficiency of complex I and an elevated CSF lactate level. Analysis of the POLG gene was performed.,The primary symptoms for Patient Z48 were a partial deficiency of complex I and an[E1] elevated CSF lactate lev[/E1]el. Analysis of the POLG g[E2]ene [/E2]was performed.,ene ,GENE_VARIANT,133,137, elevated CSF lactate lev,HPO_TERM,82,107,0.8709248,0.1290752,-0.74184954,0
line449,The primary symptoms for Patient Z49 were an abnormal thalamic MRI signal and multiple mitochondrial DNA deletions. Analysis of the POLG gene was performed.,The primary symptoms for Patient Z49 were an[E1] abnormal thalamic MRI signal[/E1] and multiple mitochondrial DNA deletions. Analysis of the POLG ge[E2]ne w[/E2]as performed.,ne w,GENE_VARIANT,139,143, abnormal thalamic MRI signal,HPO_TERM,44,73,0.8387684,0.1612315,-0.6775369,0
line449,The primary symptoms for Patient Z49 were an abnormal thalamic MRI signal and multiple mitochondrial DNA deletions. Analysis of the POLG gene was performed.,The primary symptoms for Patient Z49 were an abnormal thalamic MRI signal and [E1]multiple mitochondrial DNA deletion[/E1]s. Analysis of the POLG ge[E2]ne w[/E2]as performed.,ne w,GENE_VARIANT,139,143,multiple mitochondrial DNA deletion,HPO_TERM,78,113,0.88884914,0.11115087,-0.7776983,0
line450,Patient Z50 was evaluated for abnormal findings on diffusion-weighted imaging. The patient also presented with bradykinesia and high AST levels. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z50 was evaluated for [E1]abnormal findings on diffusion-weighted imaging[/E1]. The patient also presented with bradykinesia and high AST levels. Subsequent sequencing of the[E2] POL[/E2]G gene revealed a pathogenic variant., POL,GENE_VARIANT,173,177,abnormal findings on diffusion-weighted imaging,HPO_TERM,30,77,0.85351723,0.14648281,-0.7070344,0
line450,Patient Z50 was evaluated for abnormal findings on diffusion-weighted imaging. The patient also presented with bradykinesia and high AST levels. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z50 was evaluated for abnormal findings on diffusion-weighted imaging. The patient also presented with [E1]bradykinesia[/E1] and high AST levels. Subsequent sequencing of the[E2] POL[/E2]G gene revealed a pathogenic variant., POL,GENE_VARIANT,173,177,bradykinesia,HPO_TERM,111,123,0.8600923,0.13990773,-0.72018456,0
line450,Patient Z50 was evaluated for abnormal findings on diffusion-weighted imaging. The patient also presented with bradykinesia and high AST levels. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z50 was evaluated for abnormal findings on diffusion-weighted imaging. The patient also presented with bradykinesia and [E1]high AST level[/E1]s. Subsequent sequencing of the[E2] POL[/E2]G gene revealed a pathogenic variant., POL,GENE_VARIANT,173,177,high AST level,HPO_TERM,128,142,0.87467426,0.12532578,-0.74934846,0
line451,"We report the case of Patient Z51, who has a history of slowness of movement. Examination also revealed areas of restricted diffusion on brain DWI. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Z51, who has a history of [E1]slowness of movemen[/E1]t. Examination also revealed areas of restricted diffusion on brain DWI. The underlying cause was traced to a mutation in the [E2]POLG[/E2] gene.",POLG,GENE_VARIANT,201,205,slowness of movemen,HPO_TERM,56,75,0.36557612,0.6344239,0.2688478,1
line451,"We report the case of Patient Z51, who has a history of slowness of movement. Examination also revealed areas of restricted diffusion on brain DWI. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Z51, who has a history of slowness of movement. Examination also revealed[E1] areas of restricted diffusion on brain DWI[/E1]. The underlying cause was traced to a mutation in the [E2]POLG[/E2] gene.",POLG,GENE_VARIANT,201,205, areas of restricted diffusion on brain DWI,HPO_TERM,103,146,0.1728898,0.82711023,0.65422046,1
line452,"This report details Patient Z52, a patient with slowness of movement. Further investigation showed a low copy number of mtDNA in muscle tissue and a defect in mitochondrial complex I. A known variant in the POLG gene was identified.","This report details Patient Z52, a patient with [E1]slowness of movemen[/E1]t. Further investigation showed a low copy number of mtDNA in muscle tissue and a defect in mitochondrial complex I. A known variant in [E2]the [/E2]POLG gene was identified.",the ,GENE_VARIANT,203,207,slowness of movemen,HPO_TERM,48,67,0.77154994,0.22845006,-0.5430999,0
line452,"This report details Patient Z52, a patient with slowness of movement. Further investigation showed a low copy number of mtDNA in muscle tissue and a defect in mitochondrial complex I. A known variant in the POLG gene was identified.","This report details Patient Z52, a patient with slowness of movement. Further investigation showed[E1] a low copy number of mtDNA in muscle tiss[/E1]ue and a defect in mitochondrial complex I. A known variant in [E2]the [/E2]POLG gene was identified.",the ,GENE_VARIANT,203,207, a low copy number of mtDNA in muscle tiss,HPO_TERM,98,140,0.7665811,0.23341887,-0.53316224,0
line452,"This report details Patient Z52, a patient with slowness of movement. Further investigation showed a low copy number of mtDNA in muscle tissue and a defect in mitochondrial complex I. A known variant in the POLG gene was identified.","This report details Patient Z52, a patient with slowness of movement. Further investigation showed a low copy number of mtDNA in muscle tissue an[E1]d a defect in mitochondrial comple[/E1]x I. A known variant in [E2]the [/E2]POLG gene was identified.",the ,GENE_VARIANT,203,207,d a defect in mitochondrial comple,HPO_TERM,145,179,0.8284585,0.17154153,-0.656917,0
line453,Patient Z53 was evaluated for slowness of movement. The patient also presented with a congenital malformation of the cerebral cortex and an elevated CSF lactate level. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z53 was evaluated for [E1]slowness of movemen[/E1]t. The patient also presented with a congenital malformation of the cerebral cortex and an elevated CSF lactate level. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,193,197,slowness of movemen,HPO_TERM,30,49,0.8433776,0.15662238,-0.6867552,0
line453,Patient Z53 was evaluated for slowness of movement. The patient also presented with a congenital malformation of the cerebral cortex and an elevated CSF lactate level. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z53 was evaluated for slowness of movement. The patient also presented with[E1] a congenital malformation of the cerebral cortex[/E1] and an elevated CSF lactate level. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,193,197, a congenital malformation of the cerebral cortex,HPO_TERM,83,132,0.78018934,0.21981071,-0.5603786,0
line453,Patient Z53 was evaluated for slowness of movement. The patient also presented with a congenital malformation of the cerebral cortex and an elevated CSF lactate level. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z53 was evaluated for slowness of movement. The patient also presented with a congenital malformation of the cerebral cortex and [E1]an elevated CSF lactate l[/E1]evel. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,193,197,an elevated CSF lactate l,HPO_TERM,137,162,0.81526023,0.1847398,-0.63052046,0
line454,The primary symptoms for Patient Z54 were an accumulation of multiple mtDNA deletions and a partial deficiency of complex I. Analysis of the POLG gene was performed.,The primary symptoms for Patient Z54 were an[E1] accumulation of multiple mtDNA deletions[/E1] and a partial deficiency of complex I. Analysis of the POLG gen[E2]e wa[/E2]s performed.,e wa,GENE_VARIANT,149,153, accumulation of multiple mtDNA deletions,HPO_TERM,44,85,0.85390574,0.14609426,-0.7078115,0
line454,The primary symptoms for Patient Z54 were an accumulation of multiple mtDNA deletions and a partial deficiency of complex I. Analysis of the POLG gene was performed.,The primary symptoms for Patient Z54 were an accumulation of multiple mtDNA deletions and [E1]a partial deficiency of complex I[/E1]. Analysis of the POLG gen[E2]e wa[/E2]s performed.,e wa,GENE_VARIANT,149,153,a partial deficiency of complex I,HPO_TERM,90,123,0.85672295,0.14327702,-0.7134459,0
line455,"This report details Patient Z55, a patient with high levels of aspartate aminotransferase. Further investigation showed bradykinesia and an elevated CSF lactate level. A known variant in the POLG gene was identified.","This report details Patient Z55, a patient with [E1]high levels of aspartate aminotransfera[/E1]se. Further investigation showed bradykinesia and an elevated CSF lactate level. A known variant [E2]in t[/E2]he POLG gene was identified.",in t,GENE_VARIANT,184,188,high levels of aspartate aminotransfera,HPO_TERM,48,87,0.8425623,0.15743761,-0.6851247,0
line455,"This report details Patient Z55, a patient with high levels of aspartate aminotransferase. Further investigation showed bradykinesia and an elevated CSF lactate level. A known variant in the POLG gene was identified.","This report details Patient Z55, a patient with high levels of aspartate aminotransferase. Further investigation showe[E1]d bradykines[/E1]ia and an elevated CSF lactate level. A known variant [E2]in t[/E2]he POLG gene was identified.",in t,GENE_VARIANT,184,188,d bradykines,HPO_TERM,118,130,0.8357752,0.16422482,-0.6715504,0
line455,"This report details Patient Z55, a patient with high levels of aspartate aminotransferase. Further investigation showed bradykinesia and an elevated CSF lactate level. A known variant in the POLG gene was identified.","This report details Patient Z55, a patient with high levels of aspartate aminotransferase. Further investigation showed bradykinesia an[E1]d an elevated CSF lactate[/E1] level. A known variant [E2]in t[/E2]he POLG gene was identified.",in t,GENE_VARIANT,184,188,d an elevated CSF lactate,HPO_TERM,135,160,0.8360273,0.16397263,-0.6720547,0
line456,Patient Z56 was evaluated for a low copy number of mtDNA in muscle tissue. The patient also presented with an elevated circulating aspartate aminotransferase concentration and slowness of movement. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z56 was evaluated for [E1]a low copy number of mtDNA in muscle tissu[/E1]e. The patient also presented with an elevated circulating aspartate aminotransferase concentration and slowness of movement. Subsequent sequencing [E2]of t[/E2]he POLG gene revealed a pathogenic variant.,of t,GENE_VARIANT,220,224,a low copy number of mtDNA in muscle tissu,HPO_TERM,30,72,0.8630479,0.13695212,-0.7260958,0
line456,Patient Z56 was evaluated for a low copy number of mtDNA in muscle tissue. The patient also presented with an elevated circulating aspartate aminotransferase concentration and slowness of movement. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z56 was evaluated for a low copy number of mtDNA in muscle tissue. The patient also presented with[E1] an elevated circulating aspartate aminotransferase concent[/E1]ration and slowness of movement. Subsequent sequencing [E2]of t[/E2]he POLG gene revealed a pathogenic variant.,of t,GENE_VARIANT,220,224, an elevated circulating aspartate aminotransferase concent,HPO_TERM,106,165,0.8566632,0.14333677,-0.71332645,0
line456,Patient Z56 was evaluated for a low copy number of mtDNA in muscle tissue. The patient also presented with an elevated circulating aspartate aminotransferase concentration and slowness of movement. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z56 was evaluated for a low copy number of mtDNA in muscle tissue. The patient also presented with an elevated circulating aspartate aminotransferase concentratio[E1]n and slowness of m[/E1]ovement. Subsequent sequencing [E2]of t[/E2]he POLG gene revealed a pathogenic variant.,of t,GENE_VARIANT,220,224,n and slowness of m,HPO_TERM,170,189,0.87401515,0.12598482,-0.7480303,0
line457,The primary symptoms for Patient Z57 were a structural malformation of the brain's outer layer and high ALT levels. Analysis of the POLG gene was performed.,The primary symptoms for Patient Z57 were a [E1]structural malformation of the brain's outer layer a[/E1]nd high ALT levels. Analysis of the POLG gen[E2]e wa[/E2]s performed.,e wa,GENE_VARIANT,140,144,structural malformation of the brain's outer layer a,HPO_TERM,44,96,0.79822123,0.20177878,-0.59644246,0
line457,The primary symptoms for Patient Z57 were a structural malformation of the brain's outer layer and high ALT levels. Analysis of the POLG gene was performed.,The primary symptoms for Patient Z57 were a structural malformation of the brain's outer layer and hi[E1]gh ALT levels[/E1]. Analysis of the POLG gen[E2]e wa[/E2]s performed.,e wa,GENE_VARIANT,140,144,gh ALT levels,HPO_TERM,101,114,0.7295597,0.2704403,-0.4591194,0
line458,Patient Z58 was evaluated for high AST levels. The patient also presented with an accumulation of multiple mtDNA deletions and a rise in AST concentration. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z58 was evaluated for [E1]high AST level[/E1]s. The patient also presented with an accumulation of multiple mtDNA deletions and a rise in AST concentration. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,181,185,high AST level,HPO_TERM,30,44,0.87671626,0.123283744,-0.7534325,0
line458,Patient Z58 was evaluated for high AST levels. The patient also presented with an accumulation of multiple mtDNA deletions and a rise in AST concentration. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z58 was evaluated for high AST levels. The patient also presented with[E1] an accumulation of multiple mtDNA deleti[/E1]ons and a rise in AST concentration. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,181,185, an accumulation of multiple mtDNA deleti,HPO_TERM,78,119,0.8511427,0.14885733,-0.7022854,0
line458,Patient Z58 was evaluated for high AST levels. The patient also presented with an accumulation of multiple mtDNA deletions and a rise in AST concentration. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z58 was evaluated for high AST levels. The patient also presented with an accumulation of multiple mtDNA deletions a[E1]nd a rise in AST concentra[/E1]tion. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,181,185,nd a rise in AST concentra,HPO_TERM,124,150,0.88043976,0.11956025,-0.7608795,0
line459,The primary symptoms for Patient Z59 were an increase in the serum level of aspartate aminotransferase and bradykinesia. Analysis of the POLG gene was performed.,The primary symptoms for Patient Z59 were an[E1] increase in the serum level of aspartate aminotransferase [/E1]and bradykinesia. Analysis of the POLG gene[E2] was[/E2] performed., was,GENE_VARIANT,146,150, increase in the serum level of aspartate aminotransferase ,HPO_TERM,44,103,0.83167213,0.16832788,-0.66334426,0
line460,"This report details Patient Z60, a patient with an accumulation of multiple mtDNA deletions. Further investigation showed high levels of alanine aminotransferase and an elevated CSF lactate level. A known variant in the POLG gene was identified.","This report details Patient Z60, a patient with [E1]an accumulation of multiple mtDNA deletio[/E1]ns. Further investigation showed high levels of alanine aminotransferase and an elevated CSF lactate level. A known variant [E2]in t[/E2]he POLG gene was identified.",in t,GENE_VARIANT,213,217,an accumulation of multiple mtDNA deletio,HPO_TERM,48,89,0.8406658,0.15933424,-0.6813316,0
line460,"This report details Patient Z60, a patient with an accumulation of multiple mtDNA deletions. Further investigation showed high levels of alanine aminotransferase and an elevated CSF lactate level. A known variant in the POLG gene was identified.","This report details Patient Z60, a patient with an accumulation of multiple mtDNA deletions. Further investigation showe[E1]d high levels of alanine aminotransfera[/E1]se and an elevated CSF lactate level. A known variant [E2]in t[/E2]he POLG gene was identified.",in t,GENE_VARIANT,213,217,d high levels of alanine aminotransfera,HPO_TERM,120,159,0.83983046,0.16016956,-0.6796609,0
line460,"This report details Patient Z60, a patient with an accumulation of multiple mtDNA deletions. Further investigation showed high levels of alanine aminotransferase and an elevated CSF lactate level. A known variant in the POLG gene was identified.","This report details Patient Z60, a patient with an accumulation of multiple mtDNA deletions. Further investigation showed high levels of alanine aminotransferase an[E1]d an elevated CSF lactate[/E1] level. A known variant [E2]in t[/E2]he POLG gene was identified.",in t,GENE_VARIANT,213,217,d an elevated CSF lactate,HPO_TERM,164,189,0.8383241,0.16167593,-0.6766482,0
line461,The clinical profile for Patient Z61 includes multiple deletions in the mitochondrial DNA and a severe reduction of mtDNA in muscle. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Z61 includes [E1]multiple deletions in the mitochondrial D[/E1]NA and a severe reduction of mtDNA in muscle. Genetic analysis of the [E2]POLG[/E2] gene confirmed the diagnosis.,POLG,GENE_VARIANT,157,161,multiple deletions in the mitochondrial D,HPO_TERM,46,87,0.78519624,0.2148038,-0.57039243,0
line461,The clinical profile for Patient Z61 includes multiple deletions in the mitochondrial DNA and a severe reduction of mtDNA in muscle. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Z61 includes multiple deletions in the mitochondrial DNA an[E1]d a severe reduction of mtDNA in muscle[/E1]. Genetic analysis of the [E2]POLG[/E2] gene confirmed the diagnosis.,POLG,GENE_VARIANT,157,161,d a severe reduction of mtDNA in muscle,HPO_TERM,92,131,0.813279,0.18672104,-0.62655795,0
line462,Patient Z62 was evaluated for an accumulation of multiple mtDNA deletions. The patient also presented with an elevated circulating aspartate aminotransferase concentration and a quantitative defect of mitochondrial DNA in muscle. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z62 was evaluated for [E1]an accumulation of multiple mtDNA deletio[/E1]ns. The patient also presented with an elevated circulating aspartate aminotransferase concentration and a quantitative defect of mitochondrial DNA in muscle. Subsequent sequencin[E2]g of[/E2] the POLG gene revealed a pathogenic variant.,g of,GENE_VARIANT,250,254,an accumulation of multiple mtDNA deletio,HPO_TERM,30,71,0.8741243,0.12587576,-0.7482485,0
line462,Patient Z62 was evaluated for an accumulation of multiple mtDNA deletions. The patient also presented with an elevated circulating aspartate aminotransferase concentration and a quantitative defect of mitochondrial DNA in muscle. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z62 was evaluated for an accumulation of multiple mtDNA deletions. The patient also presented wit[E1]h an elevated circulating aspartate aminotransferase concen[/E1]tration and a quantitative defect of mitochondrial DNA in muscle. Subsequent sequencin[E2]g of[/E2] the POLG gene revealed a pathogenic variant.,g of,GENE_VARIANT,250,254,h an elevated circulating aspartate aminotransferase concen,HPO_TERM,105,164,0.87617844,0.12382157,-0.7523569,0
line462,Patient Z62 was evaluated for an accumulation of multiple mtDNA deletions. The patient also presented with an elevated circulating aspartate aminotransferase concentration and a quantitative defect of mitochondrial DNA in muscle. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z62 was evaluated for an accumulation of multiple mtDNA deletions. The patient also presented with an elevated circulating aspartate aminotransferase concentrati[E1]on and a quantitative defect of mitochondrial DNA [/E1]in muscle. Subsequent sequencin[E2]g of[/E2] the POLG gene revealed a pathogenic variant.,g of,GENE_VARIANT,250,254,on and a quantitative defect of mitochondrial DNA ,HPO_TERM,169,219,0.86752915,0.1324708,-0.73505837,0
line463,The clinical profile for Patient Z63 includes a reduction in complex I activity and slowness of movement. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Z63 includes [E1]a reduction in complex I activity[/E1] and slowness of movement. Genetic analysis of the[E2] POL[/E2]G gene confirmed the diagnosis., POL,GENE_VARIANT,129,133,a reduction in complex I activity,HPO_TERM,46,79,0.7996791,0.2003209,-0.5993582,0
line463,The clinical profile for Patient Z63 includes a reduction in complex I activity and slowness of movement. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Z63 includes a reduction in complex I activity and [E1]slowness of movemen[/E1]t. Genetic analysis of the[E2] POL[/E2]G gene confirmed the diagnosis., POL,GENE_VARIANT,129,133,slowness of movemen,HPO_TERM,84,103,0.8501698,0.14983027,-0.7003395,0
line464,"This report details Patient Z64, a patient with a partial deficiency of complex I. Further investigation showed a reduction in complex IV activity and slowness of movement. A known variant in the POLG gene was identified.","This report details Patient Z64, a patient with [E1]a partial deficiency of complex I[/E1]. Further investigation showed a reduction in complex IV activity and slowness of movement. A known variant in th[E2]e PO[/E2]LG gene was identified.",e PO,GENE_VARIANT,194,198,a partial deficiency of complex I,HPO_TERM,48,81,0.82664204,0.17335792,-0.65328413,0
line464,"This report details Patient Z64, a patient with a partial deficiency of complex I. Further investigation showed a reduction in complex IV activity and slowness of movement. A known variant in the POLG gene was identified.","This report details Patient Z64, a patient with a partial deficiency of complex I. Further investigation showed [E1]a reduction in complex IV activity[/E1] and slowness of movement. A known variant in th[E2]e PO[/E2]LG gene was identified.",e PO,GENE_VARIANT,194,198,a reduction in complex IV activity,HPO_TERM,112,146,0.83172303,0.16827694,-0.66344607,0
line464,"This report details Patient Z64, a patient with a partial deficiency of complex I. Further investigation showed a reduction in complex IV activity and slowness of movement. A known variant in the POLG gene was identified.","This report details Patient Z64, a patient with a partial deficiency of complex I. Further investigation showed a reduction in complex IV activity and [E1]slowness of movemen[/E1]t. A known variant in th[E2]e PO[/E2]LG gene was identified.",e PO,GENE_VARIANT,194,198,slowness of movemen,HPO_TERM,151,170,0.8486365,0.15136354,-0.69727296,0
line465,Patient Z65 was evaluated for an increase in CSF lactate. The patient also presented with complex I deficiency and multiple mitochondrial DNA deletions. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z65 was evaluated for [E1]an increase in CSF lac[/E1]tate. The patient also presented with complex I deficiency and multiple mitochondrial DNA deletions. Subsequent sequencing o[E2]f th[/E2]e POLG gene revealed a pathogenic variant.,f th,GENE_VARIANT,176,180,an increase in CSF lac,HPO_TERM,30,52,0.8767509,0.12324907,-0.75350183,0
line465,Patient Z65 was evaluated for an increase in CSF lactate. The patient also presented with complex I deficiency and multiple mitochondrial DNA deletions. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z65 was evaluated for an increase in CSF lactate. The patient also presented w[E1]ith complex I defic[/E1]iency and multiple mitochondrial DNA deletions. Subsequent sequencing o[E2]f th[/E2]e POLG gene revealed a pathogenic variant.,f th,GENE_VARIANT,176,180,ith complex I defic,HPO_TERM,86,105,0.8789174,0.1210826,-0.7578348,0
line465,Patient Z65 was evaluated for an increase in CSF lactate. The patient also presented with complex I deficiency and multiple mitochondrial DNA deletions. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z65 was evaluated for an increase in CSF lactate. The patient also presented with complex I deficiency[E1] and multiple mitochondrial DNA del[/E1]etions. Subsequent sequencing o[E2]f th[/E2]e POLG gene revealed a pathogenic variant.,f th,GENE_VARIANT,176,180, and multiple mitochondrial DNA del,HPO_TERM,110,145,0.8768494,0.123150624,-0.75369877,0
line466,Patient Z66 was evaluated for a congenital malformation of the cerebral cortex. The patient also presented with a partial deficiency of complex I and a defect in mitochondrial complex I. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z66 was evaluated for a congenital malformation of the cerebral cortex. The patient also presented with a[E1] partial deficiency of complex I [/E1]and a defect in mitochondrial complex I. Subsequent sequencing of the [E2]POLG[/E2] gene revealed a pathogenic variant.,POLG,GENE_VARIANT,216,220, partial deficiency of complex I ,HPO_TERM,113,146,0.74997723,0.25002277,-0.49995446,0
line466,Patient Z66 was evaluated for a congenital malformation of the cerebral cortex. The patient also presented with a partial deficiency of complex I and a defect in mitochondrial complex I. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z66 was evaluated for a congenital malformation of the cerebral cortex. The patient also presented with a partial deficiency of complex I and a[E1] defect in mitochondrial complex I[/E1]. Subsequent sequencing of the [E2]POLG[/E2] gene revealed a pathogenic variant.,POLG,GENE_VARIANT,216,220, defect in mitochondrial complex I,HPO_TERM,151,185,0.74560857,0.25439146,-0.4912171,0
line467,"This report details Patient Z67, a patient with elevated ALT enzymatic activity. Further investigation showed a partial deficiency of complex I and deficient cytochrome c oxidase activity. A known variant in the POLG gene was identified.","This report details Patient Z67, a patient with [E1]elevated ALT enzymatic activity[/E1]. Further investigation showed a partial deficiency of complex I and deficient cytochrome c oxidase activity. A known variant in th[E2]e PO[/E2]LG gene was identified.",e PO,GENE_VARIANT,210,214,elevated ALT enzymatic activity,HPO_TERM,48,79,0.85229045,0.14770958,-0.7045809,0
line467,"This report details Patient Z67, a patient with elevated ALT enzymatic activity. Further investigation showed a partial deficiency of complex I and deficient cytochrome c oxidase activity. A known variant in the POLG gene was identified.","This report details Patient Z67, a patient with elevated ALT enzymatic activity. Further investigation showed [E1]a partial deficiency of complex I[/E1] and deficient cytochrome c oxidase activity. A known variant in th[E2]e PO[/E2]LG gene was identified.",e PO,GENE_VARIANT,210,214,a partial deficiency of complex I,HPO_TERM,110,143,0.8448558,0.15514421,-0.6897116,0
line467,"This report details Patient Z67, a patient with elevated ALT enzymatic activity. Further investigation showed a partial deficiency of complex I and deficient cytochrome c oxidase activity. A known variant in the POLG gene was identified.","This report details Patient Z67, a patient with elevated ALT enzymatic activity. Further investigation showed a partial deficiency of complex I and [E1]deficient cytochrome c oxidase activit[/E1]y. A known variant in th[E2]e PO[/E2]LG gene was identified.",e PO,GENE_VARIANT,210,214,deficient cytochrome c oxidase activit,HPO_TERM,148,186,0.8453502,0.15464976,-0.6907004,0
line468,The primary symptoms for Patient Z68 were high ALT levels and a partial deficiency of complex I. Analysis of the POLG gene was performed.,The primary symptoms for Patient Z68 were hi[E1]gh ALT levels [/E1]and a partial deficiency of complex I. Analysis of the POLG gene[E2] was[/E2] performed., was,GENE_VARIANT,122,126,gh ALT levels ,HPO_TERM,44,58,0.8738634,0.12613663,-0.7477268,0
line469,The primary symptoms for Patient Z69 were a low copy number of mtDNA in muscle tissue and low complex I enzymatic activity. Analysis of the POLG gene was performed.,The primary symptoms for Patient Z69 were a [E1]low copy number of mtDNA in muscle tissue [/E1]and low complex I enzymatic activity. Analysis of the POLG ge[E2]ne w[/E2]as performed.,ne w,GENE_VARIANT,147,151,low copy number of mtDNA in muscle tissue ,HPO_TERM,44,86,0.84899235,0.15100767,-0.6979847,0
line469,The primary symptoms for Patient Z69 were a low copy number of mtDNA in muscle tissue and low complex I enzymatic activity. Analysis of the POLG gene was performed.,The primary symptoms for Patient Z69 were a low copy number of mtDNA in muscle tissue and l[E1]ow complex I enzymatic activit[/E1]y. Analysis of the POLG ge[E2]ne w[/E2]as performed.,ne w,GENE_VARIANT,147,151,ow complex I enzymatic activit,HPO_TERM,91,121,0.8810254,0.11897464,-0.76205075,0
line470,The primary symptoms for Patient Z70 were an abnormal thalamic MRI signal and an elevated CSF lactate level. Analysis of the POLG gene was performed.,The primary symptoms for Patient Z70 were an[E1] abnormal thalamic MRI signal[/E1] and an elevated CSF lactate level. Analysis of the POLG[E2] gen[/E2]e was performed., gen,GENE_VARIANT,129,133, abnormal thalamic MRI signal,HPO_TERM,44,73,0.8572003,0.14279963,-0.7144007,0
line470,The primary symptoms for Patient Z70 were an abnormal thalamic MRI signal and an elevated CSF lactate level. Analysis of the POLG gene was performed.,The primary symptoms for Patient Z70 were an abnormal thalamic MRI signal and [E1]an elevated CSF lactate l[/E1]evel. Analysis of the POLG[E2] gen[/E2]e was performed., gen,GENE_VARIANT,129,133,an elevated CSF lactate l,HPO_TERM,78,103,0.86563,0.13437003,-0.73125994,0
line471,"This report details Patient Z71, a patient with complex I deficiency. Further investigation showed a partial deficiency of complex I and an elevated CSF lactate level. A known variant in the POLG gene was identified.","This report details Patient Z71, a patient with [E1]complex I deficienc[/E1]y. Further investigation showed a partial deficiency of complex I and an elevated CSF lactate level. A known variant i[E2]n th[/E2]e POLG gene was identified.",n th,GENE_VARIANT,185,189,complex I deficienc,HPO_TERM,48,67,0.86504287,0.13495716,-0.73008573,0
line471,"This report details Patient Z71, a patient with complex I deficiency. Further investigation showed a partial deficiency of complex I and an elevated CSF lactate level. A known variant in the POLG gene was identified.","This report details Patient Z71, a patient with complex I deficiency. Further investigation showed[E1] a partial deficiency of complex [/E1]I and an elevated CSF lactate level. A known variant i[E2]n th[/E2]e POLG gene was identified.",n th,GENE_VARIANT,185,189, a partial deficiency of complex ,HPO_TERM,98,131,0.85198814,0.14801183,-0.7039763,0
line471,"This report details Patient Z71, a patient with complex I deficiency. Further investigation showed a partial deficiency of complex I and an elevated CSF lactate level. A known variant in the POLG gene was identified.","This report details Patient Z71, a patient with complex I deficiency. Further investigation showed a partial deficiency of complex I and[E1] an elevated CSF lactate [/E1]level. A known variant i[E2]n th[/E2]e POLG gene was identified.",n th,GENE_VARIANT,185,189, an elevated CSF lactate ,HPO_TERM,136,161,0.8493215,0.15067855,-0.69864297,0
line472,"We report the case of Patient Z72, who has a history of slowness of movement. Examination also revealed low complex I enzymatic activity. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Z72, who has a history of [E1]slowness of movemen[/E1]t. Examination also revealed low complex I enzymatic activity. The underlying cause was traced to a mutation in t[E2]he P[/E2]OLG gene.",he P,GENE_VARIANT,188,192,slowness of movemen,HPO_TERM,56,75,0.69026226,0.30973777,-0.3805245,0
line472,"We report the case of Patient Z72, who has a history of slowness of movement. Examination also revealed low complex I enzymatic activity. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Z72, who has a history of slowness of movement. Examination also revealed[E1] low complex I enzymatic activ[/E1]ity. The underlying cause was traced to a mutation in t[E2]he P[/E2]OLG gene.",he P,GENE_VARIANT,188,192, low complex I enzymatic activ,HPO_TERM,103,133,0.56556576,0.43443426,-0.1311315,0
line473,The clinical profile for Patient Z73 includes a reduction in complex I activity and slowness of movement. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Z73 includes [E1]a reduction in complex I activity[/E1] and slowness of movement. Genetic analysis of the[E2] POL[/E2]G gene confirmed the diagnosis., POL,GENE_VARIANT,129,133,a reduction in complex I activity,HPO_TERM,46,79,0.797289,0.20271102,-0.594578,0
line473,The clinical profile for Patient Z73 includes a reduction in complex I activity and slowness of movement. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Z73 includes a reduction in complex I activity and [E1]slowness of movemen[/E1]t. Genetic analysis of the[E2] POL[/E2]G gene confirmed the diagnosis., POL,GENE_VARIANT,129,133,slowness of movemen,HPO_TERM,84,103,0.8503894,0.14961052,-0.7007789,0
line474,The primary symptoms for Patient Z74 were an elevated CSF lactate level and cytochrome c oxidase deficiency. Analysis of the POLG gene was performed.,The primary symptoms for Patient Z74 were an[E1] elevated CSF lactate lev[/E1]el and cytochrome c oxidase deficiency. Analysis of the POLG [E2]gene[/E2] was performed.,gene,GENE_VARIANT,130,134, elevated CSF lactate lev,HPO_TERM,44,69,0.8505404,0.14945963,-0.7010808,0
line474,The primary symptoms for Patient Z74 were an elevated CSF lactate level and cytochrome c oxidase deficiency. Analysis of the POLG gene was performed.,The primary symptoms for Patient Z74 were an elevated CSF lactate level an[E1]d cytochrome c oxidase deficie[/E1]ncy. Analysis of the POLG [E2]gene[/E2] was performed.,gene,GENE_VARIANT,130,134,d cytochrome c oxidase deficie,HPO_TERM,74,104,0.86392784,0.13607214,-0.7278557,0
line475,The primary symptoms for Patient Z75 were an abnormal thalamic MRI signal and an accumulation of multiple mtDNA deletions. Analysis of the POLG gene was performed.,The primary symptoms for Patient Z75 were an[E1] abnormal thalamic MRI signal[/E1] and an accumulation of multiple mtDNA deletions. Analysis of the POLG g[E2]ene [/E2]was performed.,ene ,GENE_VARIANT,145,149, abnormal thalamic MRI signal,HPO_TERM,44,73,0.8429845,0.15701544,-0.68596905,0
line475,The primary symptoms for Patient Z75 were an abnormal thalamic MRI signal and an accumulation of multiple mtDNA deletions. Analysis of the POLG gene was performed.,The primary symptoms for Patient Z75 were an abnormal thalamic MRI signal and [E1]an accumulation of multiple mtDNA deletio[/E1]ns. Analysis of the POLG g[E2]ene [/E2]was performed.,ene ,GENE_VARIANT,145,149,an accumulation of multiple mtDNA deletio,HPO_TERM,78,119,0.87493014,0.12506987,-0.7498603,0
line476,The clinical profile for Patient Z76 includes increased ALT in the blood and high ALT levels. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Z76 includes [E1]increased ALT in the bl[/E1]ood and high ALT levels. Genetic analysis of [E2]the [/E2]POLG gene confirmed the diagnosis.,the ,GENE_VARIANT,114,118,increased ALT in the bl,HPO_TERM,46,69,0.8460872,0.15391272,-0.6921745,0
line476,The clinical profile for Patient Z76 includes increased ALT in the blood and high ALT levels. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Z76 includes increased ALT in the blood a[E1]nd high ALT le[/E1]vels. Genetic analysis of [E2]the [/E2]POLG gene confirmed the diagnosis.,the ,GENE_VARIANT,114,118,nd high ALT le,HPO_TERM,74,88,0.8851567,0.11484333,-0.7703134,0
line477,The clinical profile for Patient Z77 includes the presence of multiple mtDNA deletions and a reduction in complex IV activity. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Z77 includes [E1]the presence of multiple mtDNA deletion[/E1]s and a reduction in complex IV activity. Genetic analysis of the[E2] POL[/E2]G gene confirmed the diagnosis., POL,GENE_VARIANT,150,154,the presence of multiple mtDNA deletion,HPO_TERM,46,85,0.85818225,0.14181773,-0.7163645,0
line477,The clinical profile for Patient Z77 includes the presence of multiple mtDNA deletions and a reduction in complex IV activity. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Z77 includes the presence of multiple mtDNA deletions and[E1] a reduction in complex IV activit[/E1]y. Genetic analysis of the[E2] POL[/E2]G gene confirmed the diagnosis., POL,GENE_VARIANT,150,154, a reduction in complex IV activit,HPO_TERM,90,124,0.8538708,0.14612912,-0.7077417,0
line478,"We report the case of Patient Z78, who has a history of an abnormal thalamic MRI signal. Examination also revealed complex I deficiency. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Z78, who has a history of [E1]an abnormal thalamic MRI sign[/E1]al. Examination also revealed complex I deficiency. The underlying cause was traced to a mutation in t[E2]he P[/E2]OLG gene.",he P,GENE_VARIANT,187,191,an abnormal thalamic MRI sign,HPO_TERM,56,85,0.42058742,0.5794125,0.1588251,1
line478,"We report the case of Patient Z78, who has a history of an abnormal thalamic MRI signal. Examination also revealed complex I deficiency. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Z78, who has a history of an abnormal thalamic MRI signal. Examination also reveale[E1]d complex I deficie[/E1]ncy. The underlying cause was traced to a mutation in t[E2]he P[/E2]OLG gene.",he P,GENE_VARIANT,187,191,d complex I deficie,HPO_TERM,113,132,0.44610617,0.5538938,0.10778764,1
line479,Patient Z79 was evaluated for reduced mitochondrial DNA content in muscle. The patient also presented with areas of restricted diffusion on brain DWI and a rise in AST concentration. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z79 was evaluated for [E1]reduced mitochondrial DNA content in muscl[/E1]e. The patient also presented with areas of restricted diffusion on brain DWI and a rise in AST concentration. Subsequent sequencing of the[E2] POL[/E2]G gene revealed a pathogenic variant., POL,GENE_VARIANT,211,215,reduced mitochondrial DNA content in muscl,HPO_TERM,30,72,0.8718893,0.12811069,-0.7437786,0
line479,Patient Z79 was evaluated for reduced mitochondrial DNA content in muscle. The patient also presented with areas of restricted diffusion on brain DWI and a rise in AST concentration. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z79 was evaluated for reduced mitochondrial DNA content in muscle. The patient also presented with[E1] areas of restricted diffusion on brain DWI[/E1] and a rise in AST concentration. Subsequent sequencing of the[E2] POL[/E2]G gene revealed a pathogenic variant., POL,GENE_VARIANT,211,215, areas of restricted diffusion on brain DWI,HPO_TERM,106,149,0.8442211,0.15577894,-0.6884422,0
line479,Patient Z79 was evaluated for reduced mitochondrial DNA content in muscle. The patient also presented with areas of restricted diffusion on brain DWI and a rise in AST concentration. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z79 was evaluated for reduced mitochondrial DNA content in muscle. The patient also presented with areas of restricted diffusion on brain DWI and [E1]a rise in AST concentratio[/E1]n. Subsequent sequencing of the[E2] POL[/E2]G gene revealed a pathogenic variant., POL,GENE_VARIANT,211,215,a rise in AST concentratio,HPO_TERM,154,180,0.8643867,0.13561335,-0.72877336,0
line480,The primary symptoms for Patient Z80 were a decrease in mitochondrial DNA in the muscles and a defect in mitochondrial complex I. Analysis of the POLG gene was performed.,The primary symptoms for Patient Z80 were a [E1]decrease in mitochondrial DNA in the muscles an[/E1]d a defect in mitochondrial complex I. Analysis of the POLG gene [E2]was [/E2]performed.,was ,GENE_VARIANT,156,160,decrease in mitochondrial DNA in the muscles an,HPO_TERM,44,91,0.8500727,0.1499273,-0.70014536,0
line481,"We report the case of Patient Z81, who has a history of an elevated CSF lactate level. Examination also revealed difficulty initiating movement. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Z81, who has a history of [E1]an elevated CSF lactate l[/E1]evel. Examination also revealed difficulty initiating movement. The underlying cause was traced to a mutation i[E2]n th[/E2]e POLG gene.",n th,GENE_VARIANT,192,196,an elevated CSF lactate l,HPO_TERM,56,81,0.5922165,0.4077835,-0.18443298,0
line481,"We report the case of Patient Z81, who has a history of an elevated CSF lactate level. Examination also revealed difficulty initiating movement. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Z81, who has a history of an elevated CSF lactate level. Examination also revea[E1]led difficulty initiating mo[/E1]vement. The underlying cause was traced to a mutation i[E2]n th[/E2]e POLG gene.",n th,GENE_VARIANT,192,196,led difficulty initiating mo,HPO_TERM,109,137,0.5862765,0.41372356,-0.17255291,0
line482,The primary symptoms for Patient Z82 were a progressive slowness of movement and an abnormal thalamic MRI signal. Analysis of the POLG gene was performed.,The primary symptoms for Patient Z82 were a [E1]progressive slowness of movement a[/E1]nd an abnormal thalamic MRI signal. Analysis of the POLG gen[E2]e wa[/E2]s performed.,e wa,GENE_VARIANT,138,142,progressive slowness of movement a,HPO_TERM,44,78,0.8180885,0.18191157,-0.6361769,0
line482,The primary symptoms for Patient Z82 were a progressive slowness of movement and an abnormal thalamic MRI signal. Analysis of the POLG gene was performed.,The primary symptoms for Patient Z82 were a progressive slowness of movement and an[E1] abnormal thalamic MRI signal[/E1]. Analysis of the POLG gen[E2]e wa[/E2]s performed.,e wa,GENE_VARIANT,138,142, abnormal thalamic MRI signal,HPO_TERM,83,112,0.78450215,0.21549782,-0.5690043,0
line483,"We report the case of Patient Z83, who has a history of a decrease in mitochondrial DNA in the muscles. Examination also revealed slowness of movement. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Z83, who has a history of a decrease in mitochondrial DNA in the muscles. Examination also revealed s[E1]lowness of movement[/E1]. The underlying cause was traced to a mutation in the [E2]POLG[/E2] gene.",POLG,GENE_VARIANT,205,209,lowness of movement,HPO_TERM,131,150,0.20175922,0.7982408,0.59648156,1
line484,"This report details Patient Z84, a patient with a defect in mitochondrial complex I. Further investigation showed slowness of movement and an accumulation of multiple mtDNA deletions. A known variant in the POLG gene was identified.","This report details Patient Z84, a patient with [E1]a defect in mitochondrial complex [/E1]I. Further investigation showed slowness of movement and an accumulation of multiple mtDNA deletions. A known variant in[E2] the[/E2] POLG gene was identified.", the,GENE_VARIANT,202,206,a defect in mitochondrial complex ,HPO_TERM,48,82,0.7156717,0.28432828,-0.43134344,0
line484,"This report details Patient Z84, a patient with a defect in mitochondrial complex I. Further investigation showed slowness of movement and an accumulation of multiple mtDNA deletions. A known variant in the POLG gene was identified.","This report details Patient Z84, a patient with a defect in mitochondrial complex I. Further investigation showed[E1] slowness of moveme[/E1]nt and an accumulation of multiple mtDNA deletions. A known variant in[E2] the[/E2] POLG gene was identified.", the,GENE_VARIANT,202,206, slowness of moveme,HPO_TERM,113,132,0.7935601,0.20643994,-0.5871202,0
line484,"This report details Patient Z84, a patient with a defect in mitochondrial complex I. Further investigation showed slowness of movement and an accumulation of multiple mtDNA deletions. A known variant in the POLG gene was identified.","This report details Patient Z84, a patient with a defect in mitochondrial complex I. Further investigation showed slowness of movement an[E1]d an accumulation of multiple mtDNA delet[/E1]ions. A known variant in[E2] the[/E2] POLG gene was identified.", the,GENE_VARIANT,202,206,d an accumulation of multiple mtDNA delet,HPO_TERM,137,178,0.7349736,0.2650264,-0.46994722,0
line485,"This report details Patient Z85, a patient with a quantitative defect of mitochondrial DNA in muscle. Further investigation showed a rise in AST concentration and a low copy number of mtDNA in muscle tissue. A known variant in the POLG gene was identified.","This report details Patient Z85, a patient with [E1]a quantitative defect of mitochondrial DNA in musc[/E1]le. Further investigation showed a rise in AST concentration and a low copy number of mtDNA in muscle tissue. A known variant in[E2] the[/E2] POLG gene was identified.", the,GENE_VARIANT,226,230,a quantitative defect of mitochondrial DNA in musc,HPO_TERM,48,98,0.83226997,0.16772999,-0.66454,0
line485,"This report details Patient Z85, a patient with a quantitative defect of mitochondrial DNA in muscle. Further investigation showed a rise in AST concentration and a low copy number of mtDNA in muscle tissue. A known variant in the POLG gene was identified.","This report details Patient Z85, a patient with a quantitative defect of mitochondrial DNA in muscle. Further investigation showe[E1]d a rise in AST concentrat[/E1]ion and a low copy number of mtDNA in muscle tissue. A known variant in[E2] the[/E2] POLG gene was identified.", the,GENE_VARIANT,226,230,d a rise in AST concentrat,HPO_TERM,129,155,0.8174639,0.18253613,-0.63492775,0
line485,"This report details Patient Z85, a patient with a quantitative defect of mitochondrial DNA in muscle. Further investigation showed a rise in AST concentration and a low copy number of mtDNA in muscle tissue. A known variant in the POLG gene was identified.","This report details Patient Z85, a patient with a quantitative defect of mitochondrial DNA in muscle. Further investigation showed a rise in AST concentration a[E1]nd a low copy number of mtDNA in muscle ti[/E1]ssue. A known variant in[E2] the[/E2] POLG gene was identified.", the,GENE_VARIANT,226,230,nd a low copy number of mtDNA in muscle ti,HPO_TERM,160,202,0.83407736,0.16592263,-0.6681547,0
line486,Patient Z86 was evaluated for an increase in CSF lactate. The patient also presented with complex I deficiency and a severe reduction of mtDNA in muscle. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z86 was evaluated for [E1]an increase in CSF lac[/E1]tate. The patient also presented with complex I deficiency and a severe reduction of mtDNA in muscle. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,180,184,an increase in CSF lac,HPO_TERM,30,52,0.8606343,0.13936563,-0.7212687,0
line486,Patient Z86 was evaluated for an increase in CSF lactate. The patient also presented with complex I deficiency and a severe reduction of mtDNA in muscle. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z86 was evaluated for an increase in CSF lactate. The patient also presented w[E1]ith complex I defic[/E1]iency and a severe reduction of mtDNA in muscle. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,180,184,ith complex I defic,HPO_TERM,86,105,0.8767585,0.12324144,-0.7535171,0
line486,Patient Z86 was evaluated for an increase in CSF lactate. The patient also presented with complex I deficiency and a severe reduction of mtDNA in muscle. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z86 was evaluated for an increase in CSF lactate. The patient also presented with complex I deficiency[E1] and a severe reduction of mtDNA in mus[/E1]cle. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,180,184, and a severe reduction of mtDNA in mus,HPO_TERM,110,149,0.87390625,0.12609372,-0.7478125,0
line487,"This report details Patient Z87, a patient with a progressive slowness of movement. Further investigation showed complex I deficiency and an increase in CSF lactate. A known variant in the POLG gene was identified.","This report details Patient Z87, a patient with [E1]a progressive slowness of movement[/E1]. Further investigation showed complex I deficiency and an increase in CSF lactate. A known variant i[E2]n th[/E2]e POLG gene was identified.",n th,GENE_VARIANT,183,187,a progressive slowness of movement,HPO_TERM,48,82,0.82827985,0.17172009,-0.65655977,0
line487,"This report details Patient Z87, a patient with a progressive slowness of movement. Further investigation showed complex I deficiency and an increase in CSF lactate. A known variant in the POLG gene was identified.","This report details Patient Z87, a patient with a progressive slowness of movement. Further investigation showed [E1]complex I deficienc[/E1]y and an increase in CSF lactate. A known variant i[E2]n th[/E2]e POLG gene was identified.",n th,GENE_VARIANT,183,187,complex I deficienc,HPO_TERM,113,132,0.8649546,0.13504547,-0.7299091,0
line487,"This report details Patient Z87, a patient with a progressive slowness of movement. Further investigation showed complex I deficiency and an increase in CSF lactate. A known variant in the POLG gene was identified.","This report details Patient Z87, a patient with a progressive slowness of movement. Further investigation showed complex I deficiency and[E1] an increase in CSF la[/E1]ctate. A known variant i[E2]n th[/E2]e POLG gene was identified.",n th,GENE_VARIANT,183,187, an increase in CSF la,HPO_TERM,137,159,0.82686585,0.17313409,-0.65373176,0
line488,The clinical profile for Patient Z88 includes the occurrence of multiple mtDNA deletions and a defect in mitochondrial complex I. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Z88 includes [E1]the occurrence of multiple mtDNA deletio[/E1]ns and a defect in mitochondrial complex I. Genetic analysis of t[E2]he P[/E2]OLG gene confirmed the diagnosis.,he P,GENE_VARIANT,151,155,the occurrence of multiple mtDNA deletio,HPO_TERM,46,86,0.86583036,0.13416956,-0.7316608,0
line488,The clinical profile for Patient Z88 includes the occurrence of multiple mtDNA deletions and a defect in mitochondrial complex I. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Z88 includes the occurrence of multiple mtDNA deletions an[E1]d a defect in mitochondrial comple[/E1]x I. Genetic analysis of t[E2]he P[/E2]OLG gene confirmed the diagnosis.,he P,GENE_VARIANT,151,155,d a defect in mitochondrial comple,HPO_TERM,91,125,0.8766816,0.123318404,-0.75336325,0
line489,The primary symptoms for Patient Z89 were an elevated CSF lactate level and an abnormal thalamic MRI signal. Analysis of the POLG gene was performed.,The primary symptoms for Patient Z89 were an[E1] elevated CSF lactate lev[/E1]el and an abnormal thalamic MRI signal. Analysis of the POLG[E2] gen[/E2]e was performed., gen,GENE_VARIANT,129,133, elevated CSF lactate lev,HPO_TERM,44,69,0.8683948,0.13160516,-0.73678964,0
line489,The primary symptoms for Patient Z89 were an elevated CSF lactate level and an abnormal thalamic MRI signal. Analysis of the POLG gene was performed.,The primary symptoms for Patient Z89 were an elevated CSF lactate level an[E1]d an abnormal thalamic MRI si[/E1]gnal. Analysis of the POLG[E2] gen[/E2]e was performed., gen,GENE_VARIANT,129,133,d an abnormal thalamic MRI si,HPO_TERM,74,103,0.8727887,0.12721132,-0.7455774,0
line490,The primary symptoms for Patient Z90 were an elevated CSF lactate level and bradykinesia. Analysis of the POLG gene was performed.,The primary symptoms for Patient Z90 were an[E1] elevated CSF lactate lev[/E1]el and bradykinesia. Analysis of the POLG g[E2]ene [/E2]was performed.,ene ,GENE_VARIANT,112,116, elevated CSF lactate lev,HPO_TERM,44,69,0.83213794,0.16786203,-0.6642759,0
line490,The primary symptoms for Patient Z90 were an elevated CSF lactate level and bradykinesia. Analysis of the POLG gene was performed.,The primary symptoms for Patient Z90 were an elevated CSF lactate level an[E1]d bradykines[/E1]ia. Analysis of the POLG g[E2]ene [/E2]was performed.,ene ,GENE_VARIANT,112,116,d bradykines,HPO_TERM,74,86,0.84121764,0.15878236,-0.6824353,0
line491,Patient Z91 was evaluated for a severe reduction of mtDNA in muscle. The patient also presented with an elevated circulating aspartate aminotransferase concentration and slowness of movement. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z91 was evaluated for a severe reduction of mtDNA in muscle. The patient also presented with an[E1] elevated circulating aspartate aminotransferase concentrat[/E1]ion and slowness of movement. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,217,221, elevated circulating aspartate aminotransferase concentrat,HPO_TERM,103,162,0.82676756,0.17323239,-0.6535352,0
line491,Patient Z91 was evaluated for a severe reduction of mtDNA in muscle. The patient also presented with an elevated circulating aspartate aminotransferase concentration and slowness of movement. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z91 was evaluated for a severe reduction of mtDNA in muscle. The patient also presented with an elevated circulating aspartate aminotransferase concentration a[E1]nd slowness of move[/E1]ment. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,217,221,nd slowness of move,HPO_TERM,167,186,0.8579235,0.14207654,-0.71584696,0
line492,"This report details Patient Z92, a patient with a reduction in complex IV activity. Further investigation showed a progressive slowness of movement and abnormal cortical architecture. A known variant in the POLG gene was identified.","This report details Patient Z92, a patient with [E1]a reduction in complex IV activity[/E1]. Further investigation showed a progressive slowness of movement and abnormal cortical architecture. A known variant in t[E2]he P[/E2]OLG gene was identified.",he P,GENE_VARIANT,204,208,a reduction in complex IV activity,HPO_TERM,48,82,0.74157333,0.2584267,-0.48314664,0
line492,"This report details Patient Z92, a patient with a reduction in complex IV activity. Further investigation showed a progressive slowness of movement and abnormal cortical architecture. A known variant in the POLG gene was identified.","This report details Patient Z92, a patient with a reduction in complex IV activity. Further investigation showed [E1]a progressive slowness of movement[/E1] and abnormal cortical architecture. A known variant in t[E2]he P[/E2]OLG gene was identified.",he P,GENE_VARIANT,204,208,a progressive slowness of movement,HPO_TERM,113,147,0.7201475,0.27985254,-0.44029495,0
line492,"This report details Patient Z92, a patient with a reduction in complex IV activity. Further investigation showed a progressive slowness of movement and abnormal cortical architecture. A known variant in the POLG gene was identified.","This report details Patient Z92, a patient with a reduction in complex IV activity. Further investigation showed a progressive slowness of movement and [E1]abnormal cortical architectu[/E1]re. A known variant in t[E2]he P[/E2]OLG gene was identified.",he P,GENE_VARIANT,204,208,abnormal cortical architectu,HPO_TERM,152,180,0.75199586,0.2480041,-0.5039918,0
line493,The primary symptoms for Patient Z93 were a rise in AST concentration and a low copy number of mtDNA in muscle tissue. Analysis of the POLG gene was performed.,The primary symptoms for Patient Z93 were a [E1]rise in AST concentration [/E1]and a low copy number of mtDNA in muscle tissue. Analysis of the POLG gen[E2]e wa[/E2]s performed.,e wa,GENE_VARIANT,143,147,rise in AST concentration ,HPO_TERM,44,70,0.835446,0.16455398,-0.670892,0
line493,The primary symptoms for Patient Z93 were a rise in AST concentration and a low copy number of mtDNA in muscle tissue. Analysis of the POLG gene was performed.,The primary symptoms for Patient Z93 were a rise in AST concentration and a[E1] low copy number of mtDNA in muscle tissue[/E1]. Analysis of the POLG gen[E2]e wa[/E2]s performed.,e wa,GENE_VARIANT,143,147, low copy number of mtDNA in muscle tissue,HPO_TERM,75,117,0.8329342,0.16706575,-0.66586846,0
line494,The clinical profile for Patient Z94 includes high AST levels and an elevated CSF lactate level. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Z94 includes [E1]high AST level[/E1]s and an elevated CSF lactate level. Genetic analysis of[E2] the[/E2] POLG gene confirmed the diagnosis., the,GENE_VARIANT,116,120,high AST level,HPO_TERM,46,60,0.87408996,0.12591006,-0.7481799,0
line494,The clinical profile for Patient Z94 includes high AST levels and an elevated CSF lactate level. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Z94 includes high AST levels and[E1] an elevated CSF lactate [/E1]level. Genetic analysis of[E2] the[/E2] POLG gene confirmed the diagnosis., the,GENE_VARIANT,116,120, an elevated CSF lactate ,HPO_TERM,65,90,0.86929464,0.13070542,-0.7385892,0
line495,"We report the case of Patient Z95, who has a history of slowness of movement. Examination also revealed cytochrome c oxidase deficiency. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Z95, who has a history of [E1]slowness of movemen[/E1]t. Examination also revealed cytochrome c oxidase deficiency. The underlying cause was traced to a mutation in th[E2]e PO[/E2]LG gene.",e PO,GENE_VARIANT,188,192,slowness of movemen,HPO_TERM,56,75,0.68051666,0.3194833,-0.36103335,0
line495,"We report the case of Patient Z95, who has a history of slowness of movement. Examination also revealed cytochrome c oxidase deficiency. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Z95, who has a history of slowness of movement. Examination also revealed[E1] cytochrome c oxidase deficien[/E1]cy. The underlying cause was traced to a mutation in th[E2]e PO[/E2]LG gene.",e PO,GENE_VARIANT,188,192, cytochrome c oxidase deficien,HPO_TERM,103,133,0.51217914,0.4878209,-0.024358243,0
line496,"This report details Patient Z96, a patient with slowness of movement. Further investigation showed deficient cytochrome c oxidase activity and an accumulation of multiple mtDNA deletions. A known variant in the POLG gene was identified.","This report details Patient Z96, a patient with [E1]slowness of movemen[/E1]t. Further investigation showed deficient cytochrome c oxidase activity and an accumulation of multiple mtDNA deletions. A known variant in[E2] the[/E2] POLG gene was identified.", the,GENE_VARIANT,206,210,slowness of movemen,HPO_TERM,48,67,0.731117,0.26888293,-0.46223408,0
line496,"This report details Patient Z96, a patient with slowness of movement. Further investigation showed deficient cytochrome c oxidase activity and an accumulation of multiple mtDNA deletions. A known variant in the POLG gene was identified.","This report details Patient Z96, a patient with slowness of movement. Further investigation showed[E1] deficient cytochrome c oxidase activi[/E1]ty and an accumulation of multiple mtDNA deletions. A known variant in[E2] the[/E2] POLG gene was identified.", the,GENE_VARIANT,206,210, deficient cytochrome c oxidase activi,HPO_TERM,98,136,0.7083253,0.29167467,-0.41665065,0
line496,"This report details Patient Z96, a patient with slowness of movement. Further investigation showed deficient cytochrome c oxidase activity and an accumulation of multiple mtDNA deletions. A known variant in the POLG gene was identified.","This report details Patient Z96, a patient with slowness of movement. Further investigation showed deficient cytochrome c oxidase activity an[E1]d an accumulation of multiple mtDNA delet[/E1]ions. A known variant in[E2] the[/E2] POLG gene was identified.", the,GENE_VARIANT,206,210,d an accumulation of multiple mtDNA delet,HPO_TERM,141,182,0.74140215,0.2585978,-0.48280436,0
line497,Patient Z97 was evaluated for increased CSF lactate. The patient also presented with a progressive slowness of movement and bradykinesia. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z97 was evaluated for [E1]increased CSF lactate[/E1]. The patient also presented with a progressive slowness of movement and bradykinesia. Subsequent sequencing of the [E2]POLG[/E2] gene revealed a pathogenic variant.,POLG,GENE_VARIANT,167,171,increased CSF lactate,HPO_TERM,30,51,0.84932274,0.15067726,-0.6986455,0
line497,Patient Z97 was evaluated for increased CSF lactate. The patient also presented with a progressive slowness of movement and bradykinesia. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z97 was evaluated for increased CSF lactate. The patient also presented with [E1]a progressive slowness of movement[/E1] and bradykinesia. Subsequent sequencing of the [E2]POLG[/E2] gene revealed a pathogenic variant.,POLG,GENE_VARIANT,167,171,a progressive slowness of movement,HPO_TERM,85,119,0.842284,0.15771599,-0.68456805,0
line497,Patient Z97 was evaluated for increased CSF lactate. The patient also presented with a progressive slowness of movement and bradykinesia. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z97 was evaluated for increased CSF lactate. The patient also presented with a progressive slowness of movement and [E1]bradykinesia[/E1]. Subsequent sequencing of the [E2]POLG[/E2] gene revealed a pathogenic variant.,POLG,GENE_VARIANT,167,171,bradykinesia,HPO_TERM,124,136,0.8507815,0.14921851,-0.701563,0
line498,"This report details Patient Z98, a patient with an elevated CSF lactate level. Further investigation showed a progressive slowness of movement and complex I deficiency. A known variant in the POLG gene was identified.","This report details Patient Z98, a patient with [E1]an elevated CSF lactate l[/E1]evel. Further investigation showed a progressive slowness of movement and complex I deficiency. A known variant i[E2]n th[/E2]e POLG gene was identified.",n th,GENE_VARIANT,186,190,an elevated CSF lactate l,HPO_TERM,48,73,0.8363246,0.16367547,-0.6726491,0
line498,"This report details Patient Z98, a patient with an elevated CSF lactate level. Further investigation showed a progressive slowness of movement and complex I deficiency. A known variant in the POLG gene was identified.","This report details Patient Z98, a patient with an elevated CSF lactate level. Further investigation sho[E1]wed a progressive slowness of move[/E1]ment and complex I deficiency. A known variant i[E2]n th[/E2]e POLG gene was identified.",n th,GENE_VARIANT,186,190,wed a progressive slowness of move,HPO_TERM,104,138,0.8459306,0.15406944,-0.69186115,0
line498,"This report details Patient Z98, a patient with an elevated CSF lactate level. Further investigation showed a progressive slowness of movement and complex I deficiency. A known variant in the POLG gene was identified.","This report details Patient Z98, a patient with an elevated CSF lactate level. Further investigation showed a progressive slowness of movement [E1]and complex I defic[/E1]iency. A known variant i[E2]n th[/E2]e POLG gene was identified.",n th,GENE_VARIANT,186,190,and complex I defic,HPO_TERM,143,162,0.8509658,0.14903417,-0.7019316,0
line499,"This report details Patient Z99, a patient with bradykinesia. Further investigation showed a reduction in complex IV activity and high levels of alanine aminotransferase. A known variant in the POLG gene was identified.","This report details Patient Z99, a patient with [E1]bradykinesia[/E1]. Further investigation showed a reduction in complex IV activity and high levels of alanine aminotransferase. A known variant in the[E2] POL[/E2]G gene was identified.", POL,GENE_VARIANT,193,197,bradykinesia,HPO_TERM,48,60,0.79173374,0.2082663,-0.5834674,0
line499,"This report details Patient Z99, a patient with bradykinesia. Further investigation showed a reduction in complex IV activity and high levels of alanine aminotransferase. A known variant in the POLG gene was identified.","This report details Patient Z99, a patient with bradykinesia. Further investigation showed [E1]a reduction in complex IV activity[/E1] and high levels of alanine aminotransferase. A known variant in the[E2] POL[/E2]G gene was identified.", POL,GENE_VARIANT,193,197,a reduction in complex IV activity,HPO_TERM,91,125,0.7914654,0.20853458,-0.5829308,0
line499,"This report details Patient Z99, a patient with bradykinesia. Further investigation showed a reduction in complex IV activity and high levels of alanine aminotransferase. A known variant in the POLG gene was identified.","This report details Patient Z99, a patient with bradykinesia. Further investigation showed a reduction in complex IV activity and [E1]high levels of alanine aminotransferase[/E1]. A known variant in the[E2] POL[/E2]G gene was identified.", POL,GENE_VARIANT,193,197,high levels of alanine aminotransferase,HPO_TERM,130,169,0.7932852,0.20671475,-0.58657044,0
line500,Patient Z100 was evaluated for slowness of movement. The patient also presented with a severe reduction of mtDNA in muscle and a defect in mitochondrial complex I. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z100 was evaluated for [E1]slowness of movemen[/E1]t. The patient also presented with a severe reduction of mtDNA in muscle and a defect in mitochondrial complex I. Subsequent sequencing of the [E2]POLG[/E2] gene revealed a pathogenic variant.,POLG,GENE_VARIANT,193,197,slowness of movemen,HPO_TERM,31,50,0.82415,0.17584993,-0.6483001,0
line500,Patient Z100 was evaluated for slowness of movement. The patient also presented with a severe reduction of mtDNA in muscle and a defect in mitochondrial complex I. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z100 was evaluated for slowness of movement. The patient also presented with[E1] a severe reduction of mtDNA in muscle [/E1]and a defect in mitochondrial complex I. Subsequent sequencing of the [E2]POLG[/E2] gene revealed a pathogenic variant.,POLG,GENE_VARIANT,193,197, a severe reduction of mtDNA in muscle ,HPO_TERM,84,123,0.7950815,0.20491853,-0.590163,0
line500,Patient Z100 was evaluated for slowness of movement. The patient also presented with a severe reduction of mtDNA in muscle and a defect in mitochondrial complex I. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z100 was evaluated for slowness of movement. The patient also presented with a severe reduction of mtDNA in muscle and a[E1] defect in mitochondrial complex I[/E1]. Subsequent sequencing of the [E2]POLG[/E2] gene revealed a pathogenic variant.,POLG,GENE_VARIANT,193,197, defect in mitochondrial complex I,HPO_TERM,128,162,0.80618966,0.1938104,-0.61237925,0
line501,The primary symptoms for Patient Z101 were high levels of alanine aminotransferase and bradykinesia. Analysis of the POLG gene was performed.,The primary symptoms for Patient Z101 were hi[E1]gh levels of alanine aminotransferase a[/E1]nd bradykinesia. Analysis of the POLG gene [E2]was [/E2]performed.,was ,GENE_VARIANT,127,131,gh levels of alanine aminotransferase a,HPO_TERM,45,84,0.8566268,0.14337322,-0.7132536,0
line502,The primary symptoms for Patient Z102 were elevated ALT enzymatic activity and a decrease in mitochondrial DNA in the muscles. Analysis of the POLG gene was performed.,The primary symptoms for Patient Z102 were el[E1]evated ALT enzymatic activity a[/E1]nd a decrease in mitochondrial DNA in the muscles. Analysis of the POLG gene w[E2]as p[/E2]erformed.,as p,GENE_VARIANT,154,158,evated ALT enzymatic activity a,HPO_TERM,45,76,0.86686754,0.13313249,-0.7337351,0
line503,"We report the case of Patient Z103, who has a history of an elevated CSF lactate level. Examination also revealed bradykinesia. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Z103, who has a history of [E1]an elevated CSF lactate l[/E1]evel. Examination also revealed bradykinesia. The underlying cause was traced to a mutation in [E2]the [/E2]POLG gene.",the ,GENE_VARIANT,177,181,an elevated CSF lactate l,HPO_TERM,57,82,0.48574713,0.51425296,0.028505832,1
line503,"We report the case of Patient Z103, who has a history of an elevated CSF lactate level. Examination also revealed bradykinesia. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Z103, who has a history of an elevated CSF lactate level. Examination also revea[E1]led bradykin[/E1]esia. The underlying cause was traced to a mutation in [E2]the [/E2]POLG gene.",the ,GENE_VARIANT,177,181,led bradykin,HPO_TERM,110,122,0.29405704,0.705943,0.41188595,1
line504,"We report the case of Patient Z104, who has a history of a reduction in complex I activity. Examination also revealed abnormal cortical architecture. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Z104, who has a history of [E1]a reduction in complex I activity[/E1]. Examination also revealed abnormal cortical architecture. The underlying cause was traced to a mutation in th[E2]e PO[/E2]LG gene.",e PO,GENE_VARIANT,201,205,a reduction in complex I activity,HPO_TERM,57,90,0.5513431,0.44865692,-0.10268617,0
line504,"We report the case of Patient Z104, who has a history of a reduction in complex I activity. Examination also revealed abnormal cortical architecture. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Z104, who has a history of a reduction in complex I activity. Examination also revealed [E1]abnormal cortical architectu[/E1]re. The underlying cause was traced to a mutation in th[E2]e PO[/E2]LG gene.",e PO,GENE_VARIANT,201,205,abnormal cortical architectu,HPO_TERM,118,146,0.39566863,0.6043314,0.20866275,1
line505,"This report details Patient Z105, a patient with reduced mitochondrial DNA content in muscle. Further investigation showed a partial deficiency of complex I and high AST levels. A known variant in the POLG gene was identified.","This report details Patient Z105, a patient with [E1]reduced mitochondrial DNA content in muscl[/E1]e. Further investigation showed a partial deficiency of complex I and high AST levels. A known variant in t[E2]he P[/E2]OLG gene was identified.",he P,GENE_VARIANT,198,202,reduced mitochondrial DNA content in muscl,HPO_TERM,49,91,0.8502642,0.14973582,-0.7005284,0
line505,"This report details Patient Z105, a patient with reduced mitochondrial DNA content in muscle. Further investigation showed a partial deficiency of complex I and high AST levels. A known variant in the POLG gene was identified.","This report details Patient Z105, a patient with reduced mitochondrial DNA content in muscle. Further investigation showed[E1] a partial deficiency of complex [/E1]I and high AST levels. A known variant in t[E2]he P[/E2]OLG gene was identified.",he P,GENE_VARIANT,198,202, a partial deficiency of complex ,HPO_TERM,122,155,0.8191498,0.18085024,-0.6382996,0
line505,"This report details Patient Z105, a patient with reduced mitochondrial DNA content in muscle. Further investigation showed a partial deficiency of complex I and high AST levels. A known variant in the POLG gene was identified.","This report details Patient Z105, a patient with reduced mitochondrial DNA content in muscle. Further investigation showed a partial deficiency of complex I and[E1] high AST leve[/E1]ls. A known variant in t[E2]he P[/E2]OLG gene was identified.",he P,GENE_VARIANT,198,202, high AST leve,HPO_TERM,160,174,0.8555823,0.14441766,-0.71116465,0
line506,Patient Z106 was evaluated for abnormally high AST levels. The patient also presented with a defect in mitochondrial complex I and slowness of movement. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z106 was evaluated for [E1]abnormally high AST leve[/E1]ls. The patient also presented with a defect in mitochondrial complex I and slowness of movement. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,178,182,abnormally high AST leve,HPO_TERM,31,55,0.8501669,0.14983307,-0.70033383,0
line506,Patient Z106 was evaluated for abnormally high AST levels. The patient also presented with a defect in mitochondrial complex I and slowness of movement. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z106 was evaluated for abnormally high AST levels. The patient also presented wit[E1]h a defect in mitochondrial comple[/E1]x I and slowness of movement. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,178,182,h a defect in mitochondrial comple,HPO_TERM,89,123,0.8581315,0.14186846,-0.71626306,0
line506,Patient Z106 was evaluated for abnormally high AST levels. The patient also presented with a defect in mitochondrial complex I and slowness of movement. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z106 was evaluated for abnormally high AST levels. The patient also presented with a defect in mitochondrial complex I a[E1]nd slowness of move[/E1]ment. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,178,182,nd slowness of move,HPO_TERM,128,147,0.86324316,0.1367568,-0.7264864,0
line507,The primary symptoms for Patient Z107 were elevated aspartate aminotransferase and multiple mitochondrial DNA deletions. Analysis of the POLG gene was performed.,The primary symptoms for Patient Z107 were el[E1]evated aspartate aminotransferase a[/E1]nd multiple mitochondrial DNA deletions. Analysis of the POLG gene[E2] was[/E2] performed., was,GENE_VARIANT,146,150,evated aspartate aminotransferase a,HPO_TERM,45,80,0.8590447,0.14095534,-0.71808934,0
line508,"We report the case of Patient Z108, who has a history of high levels of alanine aminotransferase. Examination also revealed a decrease in mitochondrial DNA in the muscles. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Z108, who has a history of [E1]high levels of alanine aminotransferase[/E1]. Examination also revealed a decrease in mitochondrial DNA in the muscles. The underlying cause was traced to a mutation in the P[E2]OLG [/E2]gene.",OLG ,GENE_VARIANT,226,230,high levels of alanine aminotransferase,HPO_TERM,57,96,0.451318,0.548682,0.09736398,1
line509,The clinical profile for Patient Z109 includes a decrease in mitochondrial DNA in the muscles and bradykinesia. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Z109 includes [E1]a decrease in mitochondrial DNA in the muscles [/E1]and bradykinesia. Genetic analysis of the P[E2]OLG [/E2]gene confirmed the diagnosis.,OLG ,GENE_VARIANT,137,141,a decrease in mitochondrial DNA in the muscles ,HPO_TERM,47,94,0.8137221,0.18627788,-0.6274442,0
line510,The primary symptoms for Patient Z110 were elevated alanine aminotransferase and an elevated CSF lactate level. Analysis of the POLG gene was performed.,The primary symptoms for Patient Z110 were el[E1]evated alanine aminotransferase a[/E1]nd an elevated CSF lactate level. Analysis of the POLG g[E2]ene [/E2]was performed.,ene ,GENE_VARIANT,134,138,evated alanine aminotransferase a,HPO_TERM,45,78,0.86100006,0.13899992,-0.7220001,0
line510,The primary symptoms for Patient Z110 were elevated alanine aminotransferase and an elevated CSF lactate level. Analysis of the POLG gene was performed.,The primary symptoms for Patient Z110 were elevated alanine aminotransferase and an[E1] elevated CSF lactate lev[/E1]el. Analysis of the POLG g[E2]ene [/E2]was performed.,ene ,GENE_VARIANT,134,138, elevated CSF lactate lev,HPO_TERM,83,108,0.8693002,0.13069972,-0.7386005,0
line511,The primary symptoms for Patient Z111 were abnormal findings on diffusion-weighted imaging and an elevated CSF lactate level. Analysis of the POLG gene was performed.,The primary symptoms for Patient Z111 were ab[E1]normal findings on diffusion-weighted imaging a[/E1]nd an elevated CSF lactate level. Analysis of the POLG g[E2]ene [/E2]was performed.,ene ,GENE_VARIANT,148,152,normal findings on diffusion-weighted imaging a,HPO_TERM,45,92,0.8503774,0.14962263,-0.70075476,0
line511,The primary symptoms for Patient Z111 were abnormal findings on diffusion-weighted imaging and an elevated CSF lactate level. Analysis of the POLG gene was performed.,The primary symptoms for Patient Z111 were abnormal findings on diffusion-weighted imaging and an[E1] elevated CSF lactate lev[/E1]el. Analysis of the POLG g[E2]ene [/E2]was performed.,ene ,GENE_VARIANT,148,152, elevated CSF lactate lev,HPO_TERM,97,122,0.86006147,0.13993852,-0.72012293,0
line512,"We report the case of Patient Z112, who has a history of a decrease in mitochondrial DNA in the muscles. Examination also revealed elevated lactate in CSF. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Z112, who has a history of a decrease in mitochondrial DNA in the muscles. Examination also revealed e[E1]levated lactate in CS[/E1]F. The underlying cause was traced to a mutation in the[E2] POL[/E2]G gene.", POL,GENE_VARIANT,208,212,levated lactate in CS,HPO_TERM,132,153,0.6761681,0.32383195,-0.35233614,0
line513,"We report the case of Patient Z113, who has a history of an elevated CSF lactate level. Examination also revealed complex I deficiency. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Z113, who has a history of [E1]an elevated CSF lactate l[/E1]evel. Examination also revealed complex I deficiency. The underlying cause was traced to a mutation in[E2] the[/E2] POLG gene.", the,GENE_VARIANT,184,188,an elevated CSF lactate l,HPO_TERM,57,82,0.6201367,0.37986332,-0.24027336,0
line513,"We report the case of Patient Z113, who has a history of an elevated CSF lactate level. Examination also revealed complex I deficiency. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Z113, who has a history of an elevated CSF lactate level. Examination also revea[E1]led complex I defic[/E1]iency. The underlying cause was traced to a mutation in[E2] the[/E2] POLG gene.", the,GENE_VARIANT,184,188,led complex I defic,HPO_TERM,110,129,0.52368903,0.47631097,-0.047378063,0
line514,The primary symptoms for Patient Z114 were abnormal findings on diffusion-weighted imaging and slowness of movement. Analysis of the POLG gene was performed.,The primary symptoms for Patient Z114 were ab[E1]normal findings on diffusion-weighted imaging a[/E1]nd slowness of movement. Analysis of the POLG gene[E2] was[/E2] performed., was,GENE_VARIANT,142,146,normal findings on diffusion-weighted imaging a,HPO_TERM,45,92,0.85811293,0.14188705,-0.71622586,0
line515,"We report the case of Patient Z115, who has a history of a reduction in complex IV activity. Examination also revealed bradykinesia. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Z115, who has a history of [E1]a reduction in complex IV activity[/E1]. Examination also revealed bradykinesia. The underlying cause was traced to a mutation in the [E2]POLG[/E2] gene.",POLG,GENE_VARIANT,186,190,a reduction in complex IV activity,HPO_TERM,57,91,0.56747365,0.43252638,-0.13494727,0
line515,"We report the case of Patient Z115, who has a history of a reduction in complex IV activity. Examination also revealed bradykinesia. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Z115, who has a history of a reduction in complex IV activity. Examination also revealed [E1]bradykinesia[/E1]. The underlying cause was traced to a mutation in the [E2]POLG[/E2] gene.",POLG,GENE_VARIANT,186,190,bradykinesia,HPO_TERM,119,131,0.5331274,0.4668725,-0.066254914,0
line516,Patient Z116 was evaluated for abnormally high AST levels. The patient also presented with multiple mitochondrial DNA deletions and complex I deficiency. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z116 was evaluated for [E1]abnormally high AST leve[/E1]ls. The patient also presented with multiple mitochondrial DNA deletions and complex I deficiency. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,179,183,abnormally high AST leve,HPO_TERM,31,55,0.851981,0.14801903,-0.70396197,0
line516,Patient Z116 was evaluated for abnormally high AST levels. The patient also presented with multiple mitochondrial DNA deletions and complex I deficiency. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z116 was evaluated for abnormally high AST levels. The patient also presented wit[E1]h multiple mitochondrial DNA deleti[/E1]ons and complex I deficiency. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,179,183,h multiple mitochondrial DNA deleti,HPO_TERM,89,124,0.85176367,0.14823632,-0.70352733,0
line516,Patient Z116 was evaluated for abnormally high AST levels. The patient also presented with multiple mitochondrial DNA deletions and complex I deficiency. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z116 was evaluated for abnormally high AST levels. The patient also presented with multiple mitochondrial DNA deletions a[E1]nd complex I defici[/E1]ency. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,179,183,nd complex I defici,HPO_TERM,129,148,0.8766681,0.123331904,-0.7533362,0
line517,"This report details Patient Z117, a patient with slowness of movement. Further investigation showed multiple mitochondrial DNA deletions and high AST levels. A known variant in the POLG gene was identified.","This report details Patient Z117, a patient with [E1]slowness of movemen[/E1]t. Further investigation showed multiple mitochondrial DNA deletions and high AST levels. A known variant in [E2]the [/E2]POLG gene was identified.",the ,GENE_VARIANT,177,181,slowness of movemen,HPO_TERM,49,68,0.7852289,0.21477112,-0.5704578,0
line517,"This report details Patient Z117, a patient with slowness of movement. Further investigation showed multiple mitochondrial DNA deletions and high AST levels. A known variant in the POLG gene was identified.","This report details Patient Z117, a patient with slowness of movement. Further investigation showed[E1] multiple mitochondrial DNA deletio[/E1]ns and high AST levels. A known variant in [E2]the [/E2]POLG gene was identified.",the ,GENE_VARIANT,177,181, multiple mitochondrial DNA deletio,HPO_TERM,99,134,0.8033981,0.1966019,-0.60679615,0
line517,"This report details Patient Z117, a patient with slowness of movement. Further investigation showed multiple mitochondrial DNA deletions and high AST levels. A known variant in the POLG gene was identified.","This report details Patient Z117, a patient with slowness of movement. Further investigation showed multiple mitochondrial DNA deletions an[E1]d high AST lev[/E1]els. A known variant in [E2]the [/E2]POLG gene was identified.",the ,GENE_VARIANT,177,181,d high AST lev,HPO_TERM,139,153,0.84209603,0.15790392,-0.6841921,0
line518,The clinical profile for Patient Z118 includes high levels of alanine aminotransferase and an elevated CSF lactate level. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Z118 includes [E1]high levels of alanine aminotransferase[/E1] and an elevated CSF lactate level. Genetic analysis of [E2]the [/E2]POLG gene confirmed the diagnosis.,the ,GENE_VARIANT,142,146,high levels of alanine aminotransferase,HPO_TERM,47,86,0.8604326,0.13956739,-0.72086525,0
line518,The clinical profile for Patient Z118 includes high levels of alanine aminotransferase and an elevated CSF lactate level. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Z118 includes high levels of alanine aminotransferase and [E1]an elevated CSF lactate l[/E1]evel. Genetic analysis of [E2]the [/E2]POLG gene confirmed the diagnosis.,the ,GENE_VARIANT,142,146,an elevated CSF lactate l,HPO_TERM,91,116,0.8658864,0.1341136,-0.7317728,0
line519,"This report details Patient Z119, a patient with slowness of movement. Further investigation showed a low copy number of mtDNA in muscle tissue and a defect in mitochondrial complex I. A known variant in the POLG gene was identified.","This report details Patient Z119, a patient with [E1]slowness of movemen[/E1]t. Further investigation showed a low copy number of mtDNA in muscle tissue and a defect in mitochondrial complex I. A known variant in [E2]the [/E2]POLG gene was identified.",the ,GENE_VARIANT,204,208,slowness of movemen,HPO_TERM,49,68,0.7778084,0.2221916,-0.55561686,0
line519,"This report details Patient Z119, a patient with slowness of movement. Further investigation showed a low copy number of mtDNA in muscle tissue and a defect in mitochondrial complex I. A known variant in the POLG gene was identified.","This report details Patient Z119, a patient with slowness of movement. Further investigation showed[E1] a low copy number of mtDNA in muscle tiss[/E1]ue and a defect in mitochondrial complex I. A known variant in [E2]the [/E2]POLG gene was identified.",the ,GENE_VARIANT,204,208, a low copy number of mtDNA in muscle tiss,HPO_TERM,99,141,0.76902163,0.2309784,-0.53804326,0
line519,"This report details Patient Z119, a patient with slowness of movement. Further investigation showed a low copy number of mtDNA in muscle tissue and a defect in mitochondrial complex I. A known variant in the POLG gene was identified.","This report details Patient Z119, a patient with slowness of movement. Further investigation showed a low copy number of mtDNA in muscle tissue an[E1]d a defect in mitochondrial comple[/E1]x I. A known variant in [E2]the [/E2]POLG gene was identified.",the ,GENE_VARIANT,204,208,d a defect in mitochondrial comple,HPO_TERM,146,180,0.8291772,0.17082281,-0.6583544,0
line520,Patient Z120 was evaluated for high levels of alanine aminotransferase. The patient also presented with areas of restricted diffusion on brain DWI and a reduction in complex IV activity. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z120 was evaluated for [E1]high levels of alanine aminotransferase[/E1]. The patient also presented with areas of restricted diffusion on brain DWI and a reduction in complex IV activity. Subsequent sequencing of the P[E2]OLG [/E2]gene revealed a pathogenic variant.,OLG ,GENE_VARIANT,217,221,high levels of alanine aminotransferase,HPO_TERM,31,70,0.83236545,0.16763456,-0.6647309,0
line520,Patient Z120 was evaluated for high levels of alanine aminotransferase. The patient also presented with areas of restricted diffusion on brain DWI and a reduction in complex IV activity. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z120 was evaluated for high levels of alanine aminotransferase. The patient also presented with [E1]areas of restricted diffusion on brain DWI [/E1]and a reduction in complex IV activity. Subsequent sequencing of the P[E2]OLG [/E2]gene revealed a pathogenic variant.,OLG ,GENE_VARIANT,217,221,areas of restricted diffusion on brain DWI ,HPO_TERM,104,147,0.81447595,0.18552408,-0.6289519,0
line521,"This report details Patient Z121, a patient with abnormal findings on diffusion-weighted imaging. Further investigation showed slowness of movement and an elevated CSF lactate level. A known variant in the POLG gene was identified.","This report details Patient Z121, a patient with [E1]abnormal findings on diffusion-weighted imaging[/E1]. Further investigation showed slowness of movement and an elevated CSF lactate level. A known variant i[E2]n th[/E2]e POLG gene was identified.",n th,GENE_VARIANT,200,204,abnormal findings on diffusion-weighted imaging,HPO_TERM,49,96,0.82197434,0.17802565,-0.6439487,0
line521,"This report details Patient Z121, a patient with abnormal findings on diffusion-weighted imaging. Further investigation showed slowness of movement and an elevated CSF lactate level. A known variant in the POLG gene was identified.","This report details Patient Z121, a patient with abnormal findings on diffusion-weighted imaging. Further investigation showed [E1]slowness of movemen[/E1]t and an elevated CSF lactate level. A known variant i[E2]n th[/E2]e POLG gene was identified.",n th,GENE_VARIANT,200,204,slowness of movemen,HPO_TERM,127,146,0.8582032,0.1417969,-0.7164063,0
line521,"This report details Patient Z121, a patient with abnormal findings on diffusion-weighted imaging. Further investigation showed slowness of movement and an elevated CSF lactate level. A known variant in the POLG gene was identified.","This report details Patient Z121, a patient with abnormal findings on diffusion-weighted imaging. Further investigation showed slowness of movement and[E1] an elevated CSF lactate [/E1]level. A known variant i[E2]n th[/E2]e POLG gene was identified.",n th,GENE_VARIANT,200,204, an elevated CSF lactate ,HPO_TERM,151,176,0.8394835,0.16051647,-0.678967,0
line522,The primary symptoms for Patient Z122 were complex I deficiency and an accumulation of multiple mtDNA deletions. Analysis of the POLG gene was performed.,The primary symptoms for Patient Z122 were co[E1]mplex I deficiency [/E1]and an accumulation of multiple mtDNA deletions. Analysis of the POLG ge[E2]ne w[/E2]as performed.,ne w,GENE_VARIANT,136,140,mplex I deficiency ,HPO_TERM,45,64,0.8517808,0.1482192,-0.70356154,0
line522,The primary symptoms for Patient Z122 were complex I deficiency and an accumulation of multiple mtDNA deletions. Analysis of the POLG gene was performed.,The primary symptoms for Patient Z122 were complex I deficiency and a[E1]n accumulation of multiple mtDNA deletion[/E1]s. Analysis of the POLG ge[E2]ne w[/E2]as performed.,ne w,GENE_VARIANT,136,140,n accumulation of multiple mtDNA deletion,HPO_TERM,69,110,0.88136053,0.11863951,-0.762721,0
line523,"We report the case of Patient Z123, who has a history of a decrease in mitochondrial DNA in the muscles. Examination also revealed a low copy number of mtDNA in muscle tissue. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Z123, who has a history of a decrease in mitochondrial DNA in the muscles. Examination also revealed a[E1] low copy number of mtDNA in muscle tissue[/E1]. The underlying cause was traced to a mutation in the [E2]POLG[/E2] gene.",POLG,GENE_VARIANT,229,233, low copy number of mtDNA in muscle tissue,HPO_TERM,132,174,0.4912181,0.5087819,0.01756382,1
line524,Patient Z124 was evaluated for multiple mitochondrial DNA deletions. The patient also presented with a defect in mitochondrial complex I and a reduction in complex IV activity. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z124 was evaluated for [E1]multiple mitochondrial DNA deletion[/E1]s. The patient also presented with a defect in mitochondrial complex I and a reduction in complex IV activity. Subsequent sequencing of th[E2]e PO[/E2]LG gene revealed a pathogenic variant.,e PO,GENE_VARIANT,204,208,multiple mitochondrial DNA deletion,HPO_TERM,31,66,0.89019626,0.10980371,-0.7803925,0
line524,Patient Z124 was evaluated for multiple mitochondrial DNA deletions. The patient also presented with a defect in mitochondrial complex I and a reduction in complex IV activity. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z124 was evaluated for multiple mitochondrial DNA deletions. The patient also presented with[E1] a defect in mitochondrial complex[/E1] I and a reduction in complex IV activity. Subsequent sequencing of th[E2]e PO[/E2]LG gene revealed a pathogenic variant.,e PO,GENE_VARIANT,204,208, a defect in mitochondrial complex,HPO_TERM,100,134,0.87273633,0.12726365,-0.74547267,0
line524,Patient Z124 was evaluated for multiple mitochondrial DNA deletions. The patient also presented with a defect in mitochondrial complex I and a reduction in complex IV activity. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z124 was evaluated for multiple mitochondrial DNA deletions. The patient also presented with a defect in mitochondrial complex I an[E1]d a reduction in complex IV activi[/E1]ty. Subsequent sequencing of th[E2]e PO[/E2]LG gene revealed a pathogenic variant.,e PO,GENE_VARIANT,204,208,d a reduction in complex IV activi,HPO_TERM,139,173,0.8935453,0.106454715,-0.7870906,0
line525,The primary symptoms for Patient Z125 were difficulty initiating movement and a reduction in complex IV activity. Analysis of the POLG gene was performed.,The primary symptoms for Patient Z125 were di[E1]fficulty initiating movement[/E1] and a reduction in complex IV activity. Analysis of the POLG gen[E2]e wa[/E2]s performed.,e wa,GENE_VARIANT,138,142,fficulty initiating movement,HPO_TERM,45,73,0.7937508,0.20624916,-0.58750165,0
line525,The primary symptoms for Patient Z125 were difficulty initiating movement and a reduction in complex IV activity. Analysis of the POLG gene was performed.,The primary symptoms for Patient Z125 were difficulty initiating movement and [E1]a reduction in complex IV activity[/E1]. Analysis of the POLG gen[E2]e wa[/E2]s performed.,e wa,GENE_VARIANT,138,142,a reduction in complex IV activity,HPO_TERM,78,112,0.7640102,0.23598981,-0.5280204,0
line526,The clinical profile for Patient Z126 includes an elevated CSF lactate level and cytochrome c oxidase deficiency. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Z126 includes [E1]an elevated CSF lactate l[/E1]evel and cytochrome c oxidase deficiency. Genetic analysis of[E2] the[/E2] POLG gene confirmed the diagnosis., the,GENE_VARIANT,133,137,an elevated CSF lactate l,HPO_TERM,47,72,0.8504566,0.14954334,-0.70091325,0
line526,The clinical profile for Patient Z126 includes an elevated CSF lactate level and cytochrome c oxidase deficiency. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Z126 includes an elevated CSF lactate level [E1]and cytochrome c oxidase defic[/E1]iency. Genetic analysis of[E2] the[/E2] POLG gene confirmed the diagnosis., the,GENE_VARIANT,133,137,and cytochrome c oxidase defic,HPO_TERM,77,107,0.8661383,0.1338617,-0.73227656,0
line527,"This report details Patient Z127, a patient with abnormal cortical architecture. Further investigation showed a reduction in complex IV activity and an elevated CSF lactate level. A known variant in the POLG gene was identified.","This report details Patient Z127, a patient with [E1]abnormal cortical architectu[/E1]re. Further investigation showed a reduction in complex IV activity and an elevated CSF lactate level. A known variant [E2]in t[/E2]he POLG gene was identified.",in t,GENE_VARIANT,196,200,abnormal cortical architectu,HPO_TERM,49,77,0.81606305,0.18393695,-0.6321261,0
line527,"This report details Patient Z127, a patient with abnormal cortical architecture. Further investigation showed a reduction in complex IV activity and an elevated CSF lactate level. A known variant in the POLG gene was identified.","This report details Patient Z127, a patient with abnormal cortical architecture. Further investigation showe[E1]d a reduction in complex IV activi[/E1]ty and an elevated CSF lactate level. A known variant [E2]in t[/E2]he POLG gene was identified.",in t,GENE_VARIANT,196,200,d a reduction in complex IV activi,HPO_TERM,108,142,0.8223199,0.17768006,-0.64463985,0
line527,"This report details Patient Z127, a patient with abnormal cortical architecture. Further investigation showed a reduction in complex IV activity and an elevated CSF lactate level. A known variant in the POLG gene was identified.","This report details Patient Z127, a patient with abnormal cortical architecture. Further investigation showed a reduction in complex IV activity an[E1]d an elevated CSF lactate[/E1] level. A known variant [E2]in t[/E2]he POLG gene was identified.",in t,GENE_VARIANT,196,200,d an elevated CSF lactate,HPO_TERM,147,172,0.8001629,0.19983709,-0.6003258,0
line528,Patient Z128 was evaluated for slowness of movement. The patient also presented with a reduction in complex IV activity and abnormal findings on diffusion-weighted imaging. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z128 was evaluated for [E1]slowness of movemen[/E1]t. The patient also presented with a reduction in complex IV activity and abnormal findings on diffusion-weighted imaging. Subsequent sequencing of the[E2] POL[/E2]G gene revealed a pathogenic variant., POL,GENE_VARIANT,201,205,slowness of movemen,HPO_TERM,31,50,0.8415644,0.15843558,-0.68312883,0
line528,Patient Z128 was evaluated for slowness of movement. The patient also presented with a reduction in complex IV activity and abnormal findings on diffusion-weighted imaging. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z128 was evaluated for slowness of movement. The patient also presented with[E1] a reduction in complex IV activit[/E1]y and abnormal findings on diffusion-weighted imaging. Subsequent sequencing of the[E2] POL[/E2]G gene revealed a pathogenic variant., POL,GENE_VARIANT,201,205, a reduction in complex IV activit,HPO_TERM,84,118,0.8173356,0.18266435,-0.6346713,0
line528,Patient Z128 was evaluated for slowness of movement. The patient also presented with a reduction in complex IV activity and abnormal findings on diffusion-weighted imaging. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z128 was evaluated for slowness of movement. The patient also presented with a reduction in complex IV activity and[E1] abnormal findings on diffusion-weighted imagin[/E1]g. Subsequent sequencing of the[E2] POL[/E2]G gene revealed a pathogenic variant., POL,GENE_VARIANT,201,205, abnormal findings on diffusion-weighted imagin,HPO_TERM,123,170,0.80929095,0.19070908,-0.6185819,0
line529,The clinical profile for Patient Z129 includes abnormally high AST levels and an elevated CSF lactate level. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Z129 includes [E1]abnormally high AST leve[/E1]ls and an elevated CSF lactate level. Genetic analysis o[E2]f th[/E2]e POLG gene confirmed the diagnosis.,f th,GENE_VARIANT,127,131,abnormally high AST leve,HPO_TERM,47,71,0.87888753,0.1211125,-0.757775,0
line529,The clinical profile for Patient Z129 includes abnormally high AST levels and an elevated CSF lactate level. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Z129 includes abnormally high AST levels an[E1]d an elevated CSF lactate[/E1] level. Genetic analysis o[E2]f th[/E2]e POLG gene confirmed the diagnosis.,f th,GENE_VARIANT,127,131,d an elevated CSF lactate,HPO_TERM,76,101,0.8735476,0.12645242,-0.7470952,0
line530,"This report details Patient Z130, a patient with a congenital malformation of the cerebral cortex. Further investigation showed deficient cytochrome c oxidase activity and an elevated CSF lactate level. A known variant in the POLG gene was identified.","This report details Patient Z130, a patient with a congenital malformation of the cerebral cortex. Further investigation showed d[E1]eficient cytochrome c oxidase activity[/E1] and an elevated CSF lactate level. A known variant in[E2] the[/E2] POLG gene was identified.", the,GENE_VARIANT,221,225,eficient cytochrome c oxidase activity,HPO_TERM,129,167,0.71085495,0.28914508,-0.42170987,0
line530,"This report details Patient Z130, a patient with a congenital malformation of the cerebral cortex. Further investigation showed deficient cytochrome c oxidase activity and an elevated CSF lactate level. A known variant in the POLG gene was identified.","This report details Patient Z130, a patient with a congenital malformation of the cerebral cortex. Further investigation showed deficient cytochrome c oxidase activity and [E1]an elevated CSF lactate l[/E1]evel. A known variant in[E2] the[/E2] POLG gene was identified.", the,GENE_VARIANT,221,225,an elevated CSF lactate l,HPO_TERM,172,197,0.7289191,0.27108085,-0.45783824,0
line531,"This report details Patient Z131, a patient with high levels of aspartate aminotransferase. Further investigation showed a defect in mitochondrial complex I and increased CSF lactate. A known variant in the POLG gene was identified.","This report details Patient Z131, a patient with [E1]high levels of aspartate aminotransfera[/E1]se. Further investigation showed a defect in mitochondrial complex I and increased CSF lactate. A known variant in [E2]the [/E2]POLG gene was identified.",the ,GENE_VARIANT,203,207,high levels of aspartate aminotransfera,HPO_TERM,49,88,0.8002981,0.19970189,-0.6005962,0
line531,"This report details Patient Z131, a patient with high levels of aspartate aminotransferase. Further investigation showed a defect in mitochondrial complex I and increased CSF lactate. A known variant in the POLG gene was identified.","This report details Patient Z131, a patient with high levels of aspartate aminotransferase. Further investigation showe[E1]d a defect in mitochondrial comple[/E1]x I and increased CSF lactate. A known variant in [E2]the [/E2]POLG gene was identified.",the ,GENE_VARIANT,203,207,d a defect in mitochondrial comple,HPO_TERM,119,153,0.80191076,0.19808924,-0.6038215,0
line531,"This report details Patient Z131, a patient with high levels of aspartate aminotransferase. Further investigation showed a defect in mitochondrial complex I and increased CSF lactate. A known variant in the POLG gene was identified.","This report details Patient Z131, a patient with high levels of aspartate aminotransferase. Further investigation showed a defect in mitochondrial complex I a[E1]nd increased CSF lact[/E1]ate. A known variant in [E2]the [/E2]POLG gene was identified.",the ,GENE_VARIANT,203,207,nd increased CSF lact,HPO_TERM,158,179,0.8364151,0.16358493,-0.67283016,0
line532,"We report the case of Patient Z132, who has a history of slowness of movement. Examination also revealed a reduction in complex IV activity. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Z132, who has a history of [E1]slowness of movemen[/E1]t. Examination also revealed a reduction in complex IV activity. The underlying cause was traced to a mutation in the[E2] POL[/E2]G gene.", POL,GENE_VARIANT,193,197,slowness of movemen,HPO_TERM,57,76,0.63306916,0.36693084,-0.26613832,0
line532,"We report the case of Patient Z132, who has a history of slowness of movement. Examination also revealed a reduction in complex IV activity. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Z132, who has a history of slowness of movement. Examination also revealed[E1] a reduction in complex IV activit[/E1]y. The underlying cause was traced to a mutation in the[E2] POL[/E2]G gene.", POL,GENE_VARIANT,193,197, a reduction in complex IV activit,HPO_TERM,104,138,0.5794236,0.42057633,-0.15884727,0
line533,Patient Z133 was evaluated for an elevated CSF lactate level. The patient also presented with a partial deficiency of complex I and a defect in mitochondrial complex I. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z133 was evaluated for [E1]an elevated CSF lactate l[/E1]evel. The patient also presented with a partial deficiency of complex I and a defect in mitochondrial complex I. Subsequent sequencing of[E2] the[/E2] POLG gene revealed a pathogenic variant., the,GENE_VARIANT,193,197,an elevated CSF lactate l,HPO_TERM,31,56,0.85507655,0.1449234,-0.71015316,0
line533,Patient Z133 was evaluated for an elevated CSF lactate level. The patient also presented with a partial deficiency of complex I and a defect in mitochondrial complex I. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z133 was evaluated for an elevated CSF lactate level. The patient also presented w[E1]ith a partial deficiency of compl[/E1]ex I and a defect in mitochondrial complex I. Subsequent sequencing of[E2] the[/E2] POLG gene revealed a pathogenic variant., the,GENE_VARIANT,193,197,ith a partial deficiency of compl,HPO_TERM,90,123,0.88011295,0.11988713,-0.76022583,0
line533,Patient Z133 was evaluated for an elevated CSF lactate level. The patient also presented with a partial deficiency of complex I and a defect in mitochondrial complex I. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z133 was evaluated for an elevated CSF lactate level. The patient also presented with a partial deficiency of complex I [E1]and a defect in mitochondrial comp[/E1]lex I. Subsequent sequencing of[E2] the[/E2] POLG gene revealed a pathogenic variant., the,GENE_VARIANT,193,197,and a defect in mitochondrial comp,HPO_TERM,128,162,0.8603538,0.13964623,-0.7207076,0
line534,Patient Z134 was evaluated for high levels of alanine aminotransferase. The patient also presented with abnormal cortical architecture and elevated lactate in CSF. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z134 was evaluated for [E1]high levels of alanine aminotransferase[/E1]. The patient also presented with abnormal cortical architecture and elevated lactate in CSF. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,189,193,high levels of alanine aminotransferase,HPO_TERM,31,70,0.8243166,0.1756834,-0.64863324,0
line534,Patient Z134 was evaluated for high levels of alanine aminotransferase. The patient also presented with abnormal cortical architecture and elevated lactate in CSF. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z134 was evaluated for high levels of alanine aminotransferase. The patient also presented with [E1]abnormal cortical architectu[/E1]re and elevated lactate in CSF. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,189,193,abnormal cortical architectu,HPO_TERM,104,132,0.8301139,0.16988611,-0.6602278,0
line534,Patient Z134 was evaluated for high levels of alanine aminotransferase. The patient also presented with abnormal cortical architecture and elevated lactate in CSF. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z134 was evaluated for high levels of alanine aminotransferase. The patient also presented with abnormal cortical architecture an[E1]d elevated lactate in[/E1] CSF. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,189,193,d elevated lactate in,HPO_TERM,137,158,0.8491111,0.15088889,-0.69822216,0
line535,"This report details Patient Z135, a patient with an increase in CSF lactate. Further investigation showed an elevated circulating aspartate aminotransferase concentration and slowness of movement. A known variant in the POLG gene was identified.","This report details Patient Z135, a patient with [E1]an increase in CSF lac[/E1]tate. Further investigation showed an elevated circulating aspartate aminotransferase concentration and slowness of movement. A known vari[E2]ant [/E2]in the POLG gene was identified.",ant ,GENE_VARIANT,209,213,an increase in CSF lac,HPO_TERM,49,71,0.86941445,0.13058554,-0.7388289,0
line535,"This report details Patient Z135, a patient with an increase in CSF lactate. Further investigation showed an elevated circulating aspartate aminotransferase concentration and slowness of movement. A known variant in the POLG gene was identified.","This report details Patient Z135, a patient with an increase in CSF lactate. Further investigation sho[E1]wed an elevated circulating aspartate aminotransferase conc[/E1]entration and slowness of movement. A known vari[E2]ant [/E2]in the POLG gene was identified.",ant ,GENE_VARIANT,209,213,wed an elevated circulating aspartate aminotransferase conc,HPO_TERM,102,161,0.86758316,0.13241683,-0.7351663,0
line535,"This report details Patient Z135, a patient with an increase in CSF lactate. Further investigation showed an elevated circulating aspartate aminotransferase concentration and slowness of movement. A known variant in the POLG gene was identified.","This report details Patient Z135, a patient with an increase in CSF lactate. Further investigation showed an elevated circulating aspartate aminotransferase concentra[E1]tion and slowness o[/E1]f movement. A known vari[E2]ant [/E2]in the POLG gene was identified.",ant ,GENE_VARIANT,209,213,tion and slowness o,HPO_TERM,166,185,0.8710728,0.12892719,-0.74214566,0
line536,The primary symptoms for Patient Z136 were a partial deficiency of complex I and an elevated CSF lactate level. Analysis of the POLG gene was performed.,The primary symptoms for Patient Z136 were a [E1]partial deficiency of complex I a[/E1]nd an elevated CSF lactate level. Analysis of the POLG g[E2]ene [/E2]was performed.,ene ,GENE_VARIANT,134,138,partial deficiency of complex I a,HPO_TERM,45,78,0.85224366,0.14775634,-0.7044873,0
line536,The primary symptoms for Patient Z136 were a partial deficiency of complex I and an elevated CSF lactate level. Analysis of the POLG gene was performed.,The primary symptoms for Patient Z136 were a partial deficiency of complex I and an[E1] elevated CSF lactate lev[/E1]el. Analysis of the POLG g[E2]ene [/E2]was performed.,ene ,GENE_VARIANT,134,138, elevated CSF lactate lev,HPO_TERM,83,108,0.8677345,0.13226546,-0.73546904,0
line537,"We report the case of Patient Z137, who has a history of an abnormal thalamic MRI signal. Examination also revealed complex I deficiency. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Z137, who has a history of [E1]an abnormal thalamic MRI sign[/E1]al. Examination also revealed complex I deficiency. The underlying cause was traced to a mutation in t[E2]he P[/E2]OLG gene.",he P,GENE_VARIANT,188,192,an abnormal thalamic MRI sign,HPO_TERM,57,86,0.4982816,0.50171846,0.0034368634,1
line537,"We report the case of Patient Z137, who has a history of an abnormal thalamic MRI signal. Examination also revealed complex I deficiency. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Z137, who has a history of an abnormal thalamic MRI signal. Examination also reveale[E1]d complex I deficie[/E1]ncy. The underlying cause was traced to a mutation in t[E2]he P[/E2]OLG gene.",he P,GENE_VARIANT,188,192,d complex I deficie,HPO_TERM,114,133,0.5275073,0.47249272,-0.05501458,0
line538,The primary symptoms for Patient Z138 were abnormally high ALT levels and an elevated CSF lactate level. Analysis of the POLG gene was performed.,The primary symptoms for Patient Z138 were ab[E1]normally high ALT levels[/E1] and an elevated CSF lactate level. Analysis of the POLG[E2] gen[/E2]e was performed., gen,GENE_VARIANT,125,129,normally high ALT levels,HPO_TERM,45,69,0.8701696,0.12983045,-0.74033916,0
line538,The primary symptoms for Patient Z138 were abnormally high ALT levels and an elevated CSF lactate level. Analysis of the POLG gene was performed.,The primary symptoms for Patient Z138 were abnormally high ALT levels and [E1]an elevated CSF lactate l[/E1]evel. Analysis of the POLG[E2] gen[/E2]e was performed., gen,GENE_VARIANT,125,129,an elevated CSF lactate l,HPO_TERM,74,99,0.8654282,0.13457175,-0.7308565,0
line539,The clinical profile for Patient Z139 includes an elevated CSF lactate level and an elevated circulating aspartate aminotransferase concentration. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Z139 includes [E1]an elevated CSF lactate l[/E1]evel and an elevated circulating aspartate aminotransferase concentration. Genetic analysi[E2]s of[/E2] the POLG gene confirmed the diagnosis.,s of,GENE_VARIANT,162,166,an elevated CSF lactate l,HPO_TERM,47,72,0.8692524,0.13074766,-0.7385047,0
line539,The clinical profile for Patient Z139 includes an elevated CSF lactate level and an elevated circulating aspartate aminotransferase concentration. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Z139 includes an elevated CSF lactate level [E1]and an elevated circulating aspartate aminotransferase conc[/E1]entration. Genetic analysi[E2]s of[/E2] the POLG gene confirmed the diagnosis.,s of,GENE_VARIANT,162,166,and an elevated circulating aspartate aminotransferase conc,HPO_TERM,77,136,0.8693511,0.13064891,-0.7387022,0
line540,The clinical profile for Patient Z140 includes an elevated circulating aspartate aminotransferase concentration and slowness of movement. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Z140 includes [E1]an elevated circulating aspartate aminotransferase concentr[/E1]ation and slowness of movement. Genetic analysis o[E2]f th[/E2]e POLG gene confirmed the diagnosis.,f th,GENE_VARIANT,156,160,an elevated circulating aspartate aminotransferase concentr,HPO_TERM,47,106,0.8682068,0.13179319,-0.7364136,0
line540,The clinical profile for Patient Z140 includes an elevated circulating aspartate aminotransferase concentration and slowness of movement. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Z140 includes an elevated circulating aspartate aminotransferase concentration[E1] and slowness of mo[/E1]vement. Genetic analysis o[E2]f th[/E2]e POLG gene confirmed the diagnosis.,f th,GENE_VARIANT,156,160, and slowness of mo,HPO_TERM,111,130,0.87120515,0.12879482,-0.7424103,0
line541,The primary symptoms for Patient Z141 were a reduction in complex IV activity and slowness of movement. Analysis of the POLG gene was performed.,The primary symptoms for Patient Z141 were a [E1]reduction in complex IV activity a[/E1]nd slowness of movement. Analysis of the POLG gene[E2] was[/E2] performed., was,GENE_VARIANT,129,133,reduction in complex IV activity a,HPO_TERM,45,79,0.8506704,0.14932962,-0.7013408,0
line542,"This report details Patient Z142, a patient with a reduction in complex I activity. Further investigation showed a decrease in mitochondrial DNA in the muscles and slowness of movement. A known variant in the POLG gene was identified.","This report details Patient Z142, a patient with [E1]a reduction in complex I activity[/E1]. Further investigation showed a decrease in mitochondrial DNA in the muscles and slowness of movement. A known variant in the[E2] POL[/E2]G gene was identified.", POL,GENE_VARIANT,208,212,a reduction in complex I activity,HPO_TERM,49,82,0.7839282,0.21607177,-0.56785643,0
line542,"This report details Patient Z142, a patient with a reduction in complex I activity. Further investigation showed a decrease in mitochondrial DNA in the muscles and slowness of movement. A known variant in the POLG gene was identified.","This report details Patient Z142, a patient with a reduction in complex I activity. Further investigation showed [E1]a decrease in mitochondrial DNA in the muscles [/E1]and slowness of movement. A known variant in the[E2] POL[/E2]G gene was identified.", POL,GENE_VARIANT,208,212,a decrease in mitochondrial DNA in the muscles ,HPO_TERM,113,160,0.77583134,0.22416863,-0.5516627,0
line542,"This report details Patient Z142, a patient with a reduction in complex I activity. Further investigation showed a decrease in mitochondrial DNA in the muscles and slowness of movement. A known variant in the POLG gene was identified.","This report details Patient Z142, a patient with a reduction in complex I activity. Further investigation showed a decrease in mitochondrial DNA in the muscles and s[E1]lowness of movement[/E1]. A known variant in the[E2] POL[/E2]G gene was identified.", POL,GENE_VARIANT,208,212,lowness of movement,HPO_TERM,165,184,0.78684974,0.21315023,-0.5736995,0
line543,"We report the case of Patient Z143, who has a history of slowness of movement. Examination also revealed elevated lactate in CSF. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Z143, who has a history of [E1]slowness of movemen[/E1]t. Examination also revealed elevated lactate in CSF. The underlying cause was traced to a mutation in t[E2]he P[/E2]OLG gene.",he P,GENE_VARIANT,180,184,slowness of movemen,HPO_TERM,57,76,0.5150312,0.4849688,-0.030062407,0
line543,"We report the case of Patient Z143, who has a history of slowness of movement. Examination also revealed elevated lactate in CSF. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Z143, who has a history of slowness of movement. Examination also revealed[E1] elevated lactate in [/E1]CSF. The underlying cause was traced to a mutation in t[E2]he P[/E2]OLG gene.",he P,GENE_VARIANT,180,184, elevated lactate in ,HPO_TERM,104,125,0.4815896,0.51841044,0.03682086,1
line544,"We report the case of Patient Z144, who has a history of an elevated CSF lactate level. Examination also revealed bradykinesia. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Z144, who has a history of [E1]an elevated CSF lactate l[/E1]evel. Examination also revealed bradykinesia. The underlying cause was traced to a mutation in [E2]the [/E2]POLG gene.",the ,GENE_VARIANT,177,181,an elevated CSF lactate l,HPO_TERM,57,82,0.49195418,0.5080458,0.016091615,1
line544,"We report the case of Patient Z144, who has a history of an elevated CSF lactate level. Examination also revealed bradykinesia. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Z144, who has a history of an elevated CSF lactate level. Examination also revea[E1]led bradykin[/E1]esia. The underlying cause was traced to a mutation in [E2]the [/E2]POLG gene.",the ,GENE_VARIANT,177,181,led bradykin,HPO_TERM,110,122,0.30355468,0.69644535,0.39289066,1
line545,The primary symptoms for Patient Z145 were an elevated CSF lactate level and a decrease in mitochondrial DNA in the muscles. Analysis of the POLG gene was performed.,The primary symptoms for Patient Z145 were an[E1] elevated CSF lactate lev[/E1]el and a decrease in mitochondrial DNA in the muscles. Analysis of the POLG ge[E2]ne w[/E2]as performed.,ne w,GENE_VARIANT,148,152, elevated CSF lactate lev,HPO_TERM,45,70,0.83069974,0.16930026,-0.6613995,0
line545,The primary symptoms for Patient Z145 were an elevated CSF lactate level and a decrease in mitochondrial DNA in the muscles. Analysis of the POLG gene was performed.,The primary symptoms for Patient Z145 were an elevated CSF lactate level an[E1]d a decrease in mitochondrial DNA in the muscle[/E1]s. Analysis of the POLG ge[E2]ne w[/E2]as performed.,ne w,GENE_VARIANT,148,152,d a decrease in mitochondrial DNA in the muscle,HPO_TERM,75,122,0.85245496,0.14754501,-0.7049099,0
line546,Patient Z146 was evaluated for a severe reduction of mtDNA in muscle. The patient also presented with an elevated CSF lactate level and high levels of alanine aminotransferase. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z146 was evaluated for a severe reduction of mtDNA in muscle. The patient also presented with an[E1] elevated CSF lactate lev[/E1]el and high levels of alanine aminotransferase. Subsequent sequencing of th[E2]e PO[/E2]LG gene revealed a pathogenic variant.,e PO,GENE_VARIANT,204,208, elevated CSF lactate lev,HPO_TERM,104,129,0.890592,0.10940799,-0.78118396,0
line546,Patient Z146 was evaluated for a severe reduction of mtDNA in muscle. The patient also presented with an elevated CSF lactate level and high levels of alanine aminotransferase. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z146 was evaluated for a severe reduction of mtDNA in muscle. The patient also presented with an elevated CSF lactate level an[E1]d high levels of alanine aminotransfera[/E1]se. Subsequent sequencing of th[E2]e PO[/E2]LG gene revealed a pathogenic variant.,e PO,GENE_VARIANT,204,208,d high levels of alanine aminotransfera,HPO_TERM,134,173,0.8917363,0.108263746,-0.7834726,0
line547,The primary symptoms for Patient Z147 were slowness of movement and multiple mitochondrial DNA deletions. Analysis of the POLG gene was performed.,The primary symptoms for Patient Z147 were sl[E1]owness of movement [/E1]and multiple mitochondrial DNA deletions. Analysis of the POLG gen[E2]e wa[/E2]s performed.,e wa,GENE_VARIANT,130,134,owness of movement ,HPO_TERM,45,64,0.84593475,0.1540652,-0.69186956,0
line547,The primary symptoms for Patient Z147 were slowness of movement and multiple mitochondrial DNA deletions. Analysis of the POLG gene was performed.,The primary symptoms for Patient Z147 were slowness of movement and m[E1]ultiple mitochondrial DNA deletions[/E1]. Analysis of the POLG gen[E2]e wa[/E2]s performed.,e wa,GENE_VARIANT,130,134,ultiple mitochondrial DNA deletions,HPO_TERM,69,104,0.8364753,0.16352463,-0.6729507,0
line548,The primary symptoms for Patient Z148 were abnormal cortical architecture and slowness of movement. Analysis of the POLG gene was performed.,The primary symptoms for Patient Z148 were ab[E1]normal cortical architecture[/E1] and slowness of movement. Analysis of the POLG ge[E2]ne w[/E2]as performed.,ne w,GENE_VARIANT,123,127,normal cortical architecture,HPO_TERM,45,73,0.7654746,0.23452546,-0.5309492,0
line548,The primary symptoms for Patient Z148 were abnormal cortical architecture and slowness of movement. Analysis of the POLG gene was performed.,The primary symptoms for Patient Z148 were abnormal cortical architecture and [E1]slowness of movemen[/E1]t. Analysis of the POLG ge[E2]ne w[/E2]as performed.,ne w,GENE_VARIANT,123,127,slowness of movemen,HPO_TERM,78,97,0.83510756,0.1648924,-0.67021513,0
line549,"This report details Patient Z149, a patient with a severe reduction of mtDNA in muscle. Further investigation showed multiple mitochondrial DNA deletions and high levels of alanine aminotransferase. A known variant in the POLG gene was identified.","This report details Patient Z149, a patient with a severe reduction of mtDNA in muscle. Further investigation showed mu[E1]ltiple mitochondrial DNA deletions [/E1]and high levels of alanine aminotransferase. A known variant in the [E2]POLG[/E2] gene was identified.",POLG,GENE_VARIANT,222,226,ltiple mitochondrial DNA deletions ,HPO_TERM,119,154,0.74119735,0.25880265,-0.4823947,0
line550,The clinical profile for Patient Z150 includes complex I deficiency and multiple mitochondrial DNA deletions. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Z150 includes [E1]complex I deficienc[/E1]y and multiple mitochondrial DNA deletions. Genetic analysis of th[E2]e PO[/E2]LG gene confirmed the diagnosis.,e PO,GENE_VARIANT,132,136,complex I deficienc,HPO_TERM,47,66,0.86402893,0.13597104,-0.72805786,0
line550,The clinical profile for Patient Z150 includes complex I deficiency and multiple mitochondrial DNA deletions. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Z150 includes complex I deficiency and[E1] multiple mitochondrial DNA deletio[/E1]ns. Genetic analysis of th[E2]e PO[/E2]LG gene confirmed the diagnosis.,e PO,GENE_VARIANT,132,136, multiple mitochondrial DNA deletio,HPO_TERM,71,106,0.8736632,0.12633684,-0.7473264,0
line551,Patient Z151 was evaluated for a severe reduction of mtDNA in muscle. The patient also presented with an accumulation of multiple mtDNA deletions and slowness of movement. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z151 was evaluated for a severe reduction of mtDNA in muscle. The patient also presented with an[E1] accumulation of multiple mtDNA deletions[/E1] and slowness of movement. Subsequent sequencing of the[E2] POL[/E2]G gene revealed a pathogenic variant., POL,GENE_VARIANT,200,204, accumulation of multiple mtDNA deletions,HPO_TERM,104,145,0.7728977,0.22710226,-0.54579544,0
line551,Patient Z151 was evaluated for a severe reduction of mtDNA in muscle. The patient also presented with an accumulation of multiple mtDNA deletions and slowness of movement. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z151 was evaluated for a severe reduction of mtDNA in muscle. The patient also presented with an accumulation of multiple mtDNA deletions and [E1]slowness of movemen[/E1]t. Subsequent sequencing of the[E2] POL[/E2]G gene revealed a pathogenic variant., POL,GENE_VARIANT,200,204,slowness of movemen,HPO_TERM,150,169,0.81760496,0.18239501,-0.6352099,0
line552,"We report the case of Patient Z152, who has a history of slowness of movement. Examination also revealed abnormally high ALT levels. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Z152, who has a history of [E1]slowness of movemen[/E1]t. Examination also revealed abnormally high ALT levels. The underlying cause was traced to a mutation in t[E2]he P[/E2]OLG gene.",he P,GENE_VARIANT,183,187,slowness of movemen,HPO_TERM,57,76,0.38170847,0.6182915,0.23658302,1
line552,"We report the case of Patient Z152, who has a history of slowness of movement. Examination also revealed abnormally high ALT levels. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Z152, who has a history of slowness of movement. Examination also revealed[E1] abnormally high ALT lev[/E1]els. The underlying cause was traced to a mutation in t[E2]he P[/E2]OLG gene.",he P,GENE_VARIANT,183,187, abnormally high ALT lev,HPO_TERM,104,128,0.2472481,0.75275195,0.50550383,1
line553,The primary symptoms for Patient Z153 were a reduction in complex IV activity and an elevated CSF lactate level. Analysis of the POLG gene was performed.,The primary symptoms for Patient Z153 were a [E1]reduction in complex IV activity a[/E1]nd an elevated CSF lactate level. Analysis of the POLG g[E2]ene [/E2]was performed.,ene ,GENE_VARIANT,135,139,reduction in complex IV activity a,HPO_TERM,45,79,0.85404783,0.14595222,-0.7080956,0
line553,The primary symptoms for Patient Z153 were a reduction in complex IV activity and an elevated CSF lactate level. Analysis of the POLG gene was performed.,The primary symptoms for Patient Z153 were a reduction in complex IV activity and an[E1] elevated CSF lactate lev[/E1]el. Analysis of the POLG g[E2]ene [/E2]was performed.,ene ,GENE_VARIANT,135,139, elevated CSF lactate lev,HPO_TERM,84,109,0.84518373,0.1548163,-0.69036746,0
line554,Patient Z154 was evaluated for a low copy number of mtDNA in muscle tissue. The patient also presented with slowness of movement and an elevated CSF lactate level. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z154 was evaluated for [E1]a low copy number of mtDNA in muscle tissu[/E1]e. The patient also presented with slowness of movement and an elevated CSF lactate level. Subsequent sequencing o[E2]f th[/E2]e POLG gene revealed a pathogenic variant.,f th,GENE_VARIANT,187,191,a low copy number of mtDNA in muscle tissu,HPO_TERM,31,73,0.8724537,0.12754631,-0.7449074,0
line554,Patient Z154 was evaluated for a low copy number of mtDNA in muscle tissue. The patient also presented with slowness of movement and an elevated CSF lactate level. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z154 was evaluated for a low copy number of mtDNA in muscle tissue. The patient also presented with[E1] slowness of moveme[/E1]nt and an elevated CSF lactate level. Subsequent sequencing o[E2]f th[/E2]e POLG gene revealed a pathogenic variant.,f th,GENE_VARIANT,187,191, slowness of moveme,HPO_TERM,107,126,0.8800306,0.11996949,-0.7600611,0
line554,Patient Z154 was evaluated for a low copy number of mtDNA in muscle tissue. The patient also presented with slowness of movement and an elevated CSF lactate level. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z154 was evaluated for a low copy number of mtDNA in muscle tissue. The patient also presented with slowness of movement an[E1]d an elevated CSF lactate[/E1] level. Subsequent sequencing o[E2]f th[/E2]e POLG gene revealed a pathogenic variant.,f th,GENE_VARIANT,187,191,d an elevated CSF lactate,HPO_TERM,131,156,0.8768509,0.12314913,-0.7537018,0
line555,The primary symptoms for Patient Z155 were increased ALT in the blood and slowness of movement. Analysis of the POLG gene was performed.,The primary symptoms for Patient Z155 were in[E1]creased ALT in the bloo[/E1]d and slowness of movement. Analysis of the POLG g[E2]ene [/E2]was performed.,ene ,GENE_VARIANT,118,122,creased ALT in the bloo,HPO_TERM,45,68,0.8221112,0.17788878,-0.6442224,0
line555,The primary symptoms for Patient Z155 were increased ALT in the blood and slowness of movement. Analysis of the POLG gene was performed.,The primary symptoms for Patient Z155 were increased ALT in the blood and[E1] slowness of moveme[/E1]nt. Analysis of the POLG g[E2]ene [/E2]was performed.,ene ,GENE_VARIANT,118,122, slowness of moveme,HPO_TERM,73,92,0.8547511,0.14524882,-0.7095023,0
line556,The clinical profile for Patient Z156 includes reduced mitochondrial DNA content in muscle and an elevated CSF lactate level. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Z156 includes [E1]reduced mitochondrial DNA content in muscl[/E1]e and an elevated CSF lactate level. Genetic analysis of[E2] the[/E2] POLG gene confirmed the diagnosis., the,GENE_VARIANT,145,149,reduced mitochondrial DNA content in muscl,HPO_TERM,47,89,0.85340035,0.14659967,-0.7068007,0
line556,The clinical profile for Patient Z156 includes reduced mitochondrial DNA content in muscle and an elevated CSF lactate level. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Z156 includes reduced mitochondrial DNA content in muscle and[E1] an elevated CSF lactate [/E1]level. Genetic analysis of[E2] the[/E2] POLG gene confirmed the diagnosis., the,GENE_VARIANT,145,149, an elevated CSF lactate ,HPO_TERM,94,119,0.83925223,0.1607478,-0.67850447,0
line557,The primary symptoms for Patient Z157 were abnormally high AST levels and an elevated CSF lactate level. Analysis of the POLG gene was performed.,The primary symptoms for Patient Z157 were ab[E1]normally high AST levels[/E1] and an elevated CSF lactate level. Analysis of the POLG[E2] gen[/E2]e was performed., gen,GENE_VARIANT,125,129,normally high AST levels,HPO_TERM,45,69,0.8696942,0.13030586,-0.73938835,0
line557,The primary symptoms for Patient Z157 were abnormally high AST levels and an elevated CSF lactate level. Analysis of the POLG gene was performed.,The primary symptoms for Patient Z157 were abnormally high AST levels and [E1]an elevated CSF lactate l[/E1]evel. Analysis of the POLG[E2] gen[/E2]e was performed., gen,GENE_VARIANT,125,129,an elevated CSF lactate l,HPO_TERM,74,99,0.8648769,0.13512307,-0.72975385,0
line558,Patient Z158 was evaluated for slowness of movement. The patient also presented with a partial deficiency of complex I and a progressive slowness of movement. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z158 was evaluated for [E1]slowness of movemen[/E1]t. The patient also presented with a partial deficiency of complex I and a progressive slowness of movement. Subsequent sequencing of the[E2] POL[/E2]G gene revealed a pathogenic variant., POL,GENE_VARIANT,187,191,slowness of movemen,HPO_TERM,31,50,0.86532265,0.13467737,-0.7306453,0
line558,Patient Z158 was evaluated for slowness of movement. The patient also presented with a partial deficiency of complex I and a progressive slowness of movement. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z158 was evaluated for slowness of movement. The patient also presented with[E1] a partial deficiency of complex [/E1]I and a progressive slowness of movement. Subsequent sequencing of the[E2] POL[/E2]G gene revealed a pathogenic variant., POL,GENE_VARIANT,187,191, a partial deficiency of complex ,HPO_TERM,84,117,0.8231891,0.17681095,-0.64637816,0
line558,Patient Z158 was evaluated for slowness of movement. The patient also presented with a partial deficiency of complex I and a progressive slowness of movement. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z158 was evaluated for slowness of movement. The patient also presented with a partial deficiency of complex I and[E1] a progressive slowness of movemen[/E1]t. Subsequent sequencing of the[E2] POL[/E2]G gene revealed a pathogenic variant., POL,GENE_VARIANT,187,191, a progressive slowness of movemen,HPO_TERM,122,156,0.8577237,0.14227629,-0.7154474,0
line559,The clinical profile for Patient Z159 includes a quantitative defect of mitochondrial DNA in muscle and bradykinesia. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Z159 includes [E1]a quantitative defect of mitochondrial DNA in musc[/E1]le and bradykinesia. Genetic analysis of th[E2]e PO[/E2]LG gene confirmed the diagnosis.,e PO,GENE_VARIANT,140,144,a quantitative defect of mitochondrial DNA in musc,HPO_TERM,47,97,0.86895967,0.13104038,-0.7379193,0
line559,The clinical profile for Patient Z159 includes a quantitative defect of mitochondrial DNA in muscle and bradykinesia. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Z159 includes a quantitative defect of mitochondrial DNA in muscle an[E1]d bradykines[/E1]ia. Genetic analysis of th[E2]e PO[/E2]LG gene confirmed the diagnosis.,e PO,GENE_VARIANT,140,144,d bradykines,HPO_TERM,102,114,0.88469714,0.11530282,-0.76939434,0
line560,"This report details Patient Z160, a patient with a reduction in complex I activity. Further investigation showed a severe reduction of mtDNA in muscle and a quantitative defect of mitochondrial DNA in muscle. A known variant in the POLG gene was identified.","This report details Patient Z160, a patient with [E1]a reduction in complex I activity[/E1]. Further investigation showed a severe reduction of mtDNA in muscle and a quantitative defect of mitochondrial DNA in muscle. A known variant in the[E2] POL[/E2]G gene was identified.", POL,GENE_VARIANT,231,235,a reduction in complex I activity,HPO_TERM,49,82,0.78046227,0.21953773,-0.56092453,0
line560,"This report details Patient Z160, a patient with a reduction in complex I activity. Further investigation showed a severe reduction of mtDNA in muscle and a quantitative defect of mitochondrial DNA in muscle. A known variant in the POLG gene was identified.","This report details Patient Z160, a patient with a reduction in complex I activity. Further investigation showed [E1]a severe reduction of mtDNA in muscle a[/E1]nd a quantitative defect of mitochondrial DNA in muscle. A known variant in the[E2] POL[/E2]G gene was identified.", POL,GENE_VARIANT,231,235,a severe reduction of mtDNA in muscle a,HPO_TERM,113,152,0.782975,0.21702501,-0.56595004,0
line560,"This report details Patient Z160, a patient with a reduction in complex I activity. Further investigation showed a severe reduction of mtDNA in muscle and a quantitative defect of mitochondrial DNA in muscle. A known variant in the POLG gene was identified.","This report details Patient Z160, a patient with a reduction in complex I activity. Further investigation showed a severe reduction of mtDNA in muscle and a [E1]quantitative defect of mitochondrial DNA in muscle[/E1]. A known variant in the[E2] POL[/E2]G gene was identified.", POL,GENE_VARIANT,231,235,quantitative defect of mitochondrial DNA in muscle,HPO_TERM,157,207,0.765401,0.23459901,-0.530802,0
line561,"We report the case of Patient Z161, who has a history of slowness of movement. Examination also revealed an elevated CSF lactate level. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Z161, who has a history of [E1]slowness of movemen[/E1]t. Examination also revealed an elevated CSF lactate level. The underlying cause was traced to a mutation in[E2] the[/E2] POLG gene.", the,GENE_VARIANT,184,188,slowness of movemen,HPO_TERM,57,76,0.37749767,0.6225024,0.24500471,1
line561,"We report the case of Patient Z161, who has a history of slowness of movement. Examination also revealed an elevated CSF lactate level. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Z161, who has a history of slowness of movement. Examination also revealed[E1] an elevated CSF lactate [/E1]level. The underlying cause was traced to a mutation in[E2] the[/E2] POLG gene.", the,GENE_VARIANT,184,188, an elevated CSF lactate ,HPO_TERM,104,129,0.16823176,0.8317682,0.6635364,1
line562,"This report details Patient Z162, a patient with slowness of movement. Further investigation showed abnormally high AST levels and a quantitative defect of mitochondrial DNA in muscle. A known variant in the POLG gene was identified.","This report details Patient Z162, a patient with [E1]slowness of movemen[/E1]t. Further investigation showed abnormally high AST levels and a quantitative defect of mitochondrial DNA in muscle. A known variant i[E2]n th[/E2]e POLG gene was identified.",n th,GENE_VARIANT,202,206,slowness of movemen,HPO_TERM,49,68,0.8506895,0.14931051,-0.70137894,0
line562,"This report details Patient Z162, a patient with slowness of movement. Further investigation showed abnormally high AST levels and a quantitative defect of mitochondrial DNA in muscle. A known variant in the POLG gene was identified.","This report details Patient Z162, a patient with slowness of movement. Further investigation showed[E1] abnormally high AST lev[/E1]els and a quantitative defect of mitochondrial DNA in muscle. A known variant i[E2]n th[/E2]e POLG gene was identified.",n th,GENE_VARIANT,202,206, abnormally high AST lev,HPO_TERM,99,123,0.8581828,0.14181724,-0.7163656,0
line562,"This report details Patient Z162, a patient with slowness of movement. Further investigation showed abnormally high AST levels and a quantitative defect of mitochondrial DNA in muscle. A known variant in the POLG gene was identified.","This report details Patient Z162, a patient with slowness of movement. Further investigation showed abnormally high AST levels a[E1]nd a quantitative defect of mitochondrial DNA in m[/E1]uscle. A known variant i[E2]n th[/E2]e POLG gene was identified.",n th,GENE_VARIANT,202,206,nd a quantitative defect of mitochondrial DNA in m,HPO_TERM,128,178,0.8517084,0.14829157,-0.7034168,0
line563,"We report the case of Patient Z163, who has a history of an elevated CSF lactate level. Examination also revealed multiple mitochondrial DNA deletions. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Z163, who has a history of [E1]an elevated CSF lactate l[/E1]evel. Examination also revealed multiple mitochondrial DNA deletions. The underlying cause was traced to a mutation in[E2] the[/E2] POLG gene.", the,GENE_VARIANT,200,204,an elevated CSF lactate l,HPO_TERM,57,82,0.5120486,0.48795134,-0.024097264,0
line563,"We report the case of Patient Z163, who has a history of an elevated CSF lactate level. Examination also revealed multiple mitochondrial DNA deletions. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Z163, who has a history of an elevated CSF lactate level. Examination also revea[E1]led multiple mitochondrial DNA dele[/E1]tions. The underlying cause was traced to a mutation in[E2] the[/E2] POLG gene.", the,GENE_VARIANT,200,204,led multiple mitochondrial DNA dele,HPO_TERM,110,145,0.4204404,0.57955956,0.15911916,1
line564,Patient Z164 was evaluated for increased CSF lactate. The patient also presented with abnormally high ALT levels and multiple mitochondrial DNA deletions. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z164 was evaluated for [E1]increased CSF lactate[/E1]. The patient also presented with abnormally high ALT levels and multiple mitochondrial DNA deletions. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,181,185,increased CSF lactate,HPO_TERM,31,52,0.8583571,0.1416429,-0.71671414,0
line564,Patient Z164 was evaluated for increased CSF lactate. The patient also presented with abnormally high ALT levels and multiple mitochondrial DNA deletions. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z164 was evaluated for increased CSF lactate. The patient also presented with [E1]abnormally high ALT leve[/E1]ls and multiple mitochondrial DNA deletions. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,181,185,abnormally high ALT leve,HPO_TERM,86,110,0.8698949,0.1301051,-0.73978984,0
line564,Patient Z164 was evaluated for increased CSF lactate. The patient also presented with abnormally high ALT levels and multiple mitochondrial DNA deletions. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z164 was evaluated for increased CSF lactate. The patient also presented with abnormally high ALT levels an[E1]d multiple mitochondrial DNA deleti[/E1]ons. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,181,185,d multiple mitochondrial DNA deleti,HPO_TERM,115,150,0.8891055,0.110894546,-0.77821094,0
line565,"This report details Patient Z165, a patient with mtDNA depletion in muscle. Further investigation showed an increase in CSF lactate and areas of restricted diffusion on brain DWI. A known variant in the POLG gene was identified.","This report details Patient Z165, a patient with [E1]mtDNA depletion in muscl[/E1]e. Further investigation showed an increase in CSF lactate and areas of restricted diffusion on brain DWI. A known variant in[E2] the[/E2] POLG gene was identified.", the,GENE_VARIANT,198,202,mtDNA depletion in muscl,HPO_TERM,49,73,0.7016622,0.2983378,-0.4033244,0
line565,"This report details Patient Z165, a patient with mtDNA depletion in muscle. Further investigation showed an increase in CSF lactate and areas of restricted diffusion on brain DWI. A known variant in the POLG gene was identified.","This report details Patient Z165, a patient with mtDNA depletion in muscle. Further investigation showed[E1] an increase in CSF la[/E1]ctate and areas of restricted diffusion on brain DWI. A known variant in[E2] the[/E2] POLG gene was identified.", the,GENE_VARIANT,198,202, an increase in CSF la,HPO_TERM,104,126,0.72811687,0.2718832,-0.45623368,0
line565,"This report details Patient Z165, a patient with mtDNA depletion in muscle. Further investigation showed an increase in CSF lactate and areas of restricted diffusion on brain DWI. A known variant in the POLG gene was identified.","This report details Patient Z165, a patient with mtDNA depletion in muscle. Further investigation showed an increase in CSF lactate[E1] and areas of restricted diffusion on brain[/E1] DWI. A known variant in[E2] the[/E2] POLG gene was identified.", the,GENE_VARIANT,198,202, and areas of restricted diffusion on brain,HPO_TERM,131,174,0.74139744,0.25860256,-0.48279488,0
line566,"We report the case of Patient Z166, who has a history of deficient cytochrome c oxidase activity. Examination also revealed complex I deficiency. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Z166, who has a history of [E1]deficient cytochrome c oxidase activit[/E1]y. Examination also revealed complex I deficiency. The underlying cause was traced to a mutation in th[E2]e PO[/E2]LG gene.",e PO,GENE_VARIANT,197,201,deficient cytochrome c oxidase activit,HPO_TERM,57,95,0.6181214,0.38187858,-0.2362428,0
line566,"We report the case of Patient Z166, who has a history of deficient cytochrome c oxidase activity. Examination also revealed complex I deficiency. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Z166, who has a history of deficient cytochrome c oxidase activity. Examination also revealed[E1] complex I deficien[/E1]cy. The underlying cause was traced to a mutation in th[E2]e PO[/E2]LG gene.",e PO,GENE_VARIANT,197,201, complex I deficien,HPO_TERM,123,142,0.7301606,0.26983935,-0.46032125,0
line567,"We report the case of Patient Z167, who has a history of complex I deficiency. Examination also revealed an elevated CSF lactate level. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Z167, who has a history of [E1]complex I deficienc[/E1]y. Examination also revealed an elevated CSF lactate level. The underlying cause was traced to a mutation in[E2] the[/E2] POLG gene.", the,GENE_VARIANT,184,188,complex I deficienc,HPO_TERM,57,76,0.549292,0.450708,-0.098584026,0
line567,"We report the case of Patient Z167, who has a history of complex I deficiency. Examination also revealed an elevated CSF lactate level. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Z167, who has a history of complex I deficiency. Examination also revealed[E1] an elevated CSF lactate [/E1]level. The underlying cause was traced to a mutation in[E2] the[/E2] POLG gene.", the,GENE_VARIANT,184,188, an elevated CSF lactate ,HPO_TERM,104,129,0.3739435,0.62605655,0.25211304,1
line568,The primary symptoms for Patient Z168 were slowness of movement and abnormal cortical architecture. Analysis of the POLG gene was performed.,The primary symptoms for Patient Z168 were sl[E1]owness of movement [/E1]and abnormal cortical architecture. Analysis of the POLG ge[E2]ne w[/E2]as performed.,ne w,GENE_VARIANT,123,127,owness of movement ,HPO_TERM,45,64,0.7624627,0.23753731,-0.52492535,0
line568,The primary symptoms for Patient Z168 were slowness of movement and abnormal cortical architecture. Analysis of the POLG gene was performed.,The primary symptoms for Patient Z168 were slowness of movement and a[E1]bnormal cortical architectur[/E1]e. Analysis of the POLG ge[E2]ne w[/E2]as performed.,ne w,GENE_VARIANT,123,127,bnormal cortical architectur,HPO_TERM,69,97,0.82730156,0.17269841,-0.6546031,0
line569,"We report the case of Patient Z169, who has a history of a reduction in complex IV activity. Examination also revealed elevated ALT enzymatic activity. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Z169, who has a history of [E1]a reduction in complex IV activity[/E1]. Examination also revealed elevated ALT enzymatic activity. The underlying cause was traced to a mutation in the [E2]POLG[/E2] gene.",POLG,GENE_VARIANT,205,209,a reduction in complex IV activity,HPO_TERM,57,91,0.6788443,0.32115567,-0.3576886,0
line569,"We report the case of Patient Z169, who has a history of a reduction in complex IV activity. Examination also revealed elevated ALT enzymatic activity. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Z169, who has a history of a reduction in complex IV activity. Examination also revealed [E1]elevated ALT enzymatic activity[/E1]. The underlying cause was traced to a mutation in the [E2]POLG[/E2] gene.",POLG,GENE_VARIANT,205,209,elevated ALT enzymatic activity,HPO_TERM,119,150,0.6477003,0.3522996,-0.2954007,0
line570,The clinical profile for Patient Z170 includes an increase in the serum level of aspartate aminotransferase and slowness of movement. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Z170 includes [E1]an increase in the serum level of aspartate aminotransferas[/E1]e and slowness of movement. Genetic analysis of th[E2]e PO[/E2]LG gene confirmed the diagnosis.,e PO,GENE_VARIANT,156,160,an increase in the serum level of aspartate aminotransferas,HPO_TERM,47,106,0.86318326,0.13681675,-0.7263665,0
line570,The clinical profile for Patient Z170 includes an increase in the serum level of aspartate aminotransferase and slowness of movement. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Z170 includes an increase in the serum level of aspartate aminotransferase and[E1] slowness of moveme[/E1]nt. Genetic analysis of th[E2]e PO[/E2]LG gene confirmed the diagnosis.,e PO,GENE_VARIANT,156,160, slowness of moveme,HPO_TERM,111,130,0.8732466,0.12675333,-0.7464933,0
line571,The primary symptoms for Patient Z171 were a partial deficiency of complex I and an accumulation of multiple mtDNA deletions. Analysis of the POLG gene was performed.,The primary symptoms for Patient Z171 were a [E1]partial deficiency of complex I a[/E1]nd an accumulation of multiple mtDNA deletions. Analysis of the POLG gen[E2]e wa[/E2]s performed.,e wa,GENE_VARIANT,150,154,partial deficiency of complex I a,HPO_TERM,45,78,0.8507512,0.1492487,-0.7015025,0
line571,The primary symptoms for Patient Z171 were a partial deficiency of complex I and an accumulation of multiple mtDNA deletions. Analysis of the POLG gene was performed.,The primary symptoms for Patient Z171 were a partial deficiency of complex I and an[E1] accumulation of multiple mtDNA deletions[/E1]. Analysis of the POLG gen[E2]e wa[/E2]s performed.,e wa,GENE_VARIANT,150,154, accumulation of multiple mtDNA deletions,HPO_TERM,83,124,0.84934735,0.15065263,-0.6986947,0
line572,The clinical profile for Patient Z172 includes a defect in mitochondrial complex I and a reduction in complex IV activity. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Z172 includes [E1]a defect in mitochondrial complex [/E1]I and a reduction in complex IV activity. Genetic analysis of the[E2] POL[/E2]G gene confirmed the diagnosis., POL,GENE_VARIANT,146,150,a defect in mitochondrial complex ,HPO_TERM,47,81,0.8342127,0.16578731,-0.66842544,0
line572,The clinical profile for Patient Z172 includes a defect in mitochondrial complex I and a reduction in complex IV activity. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Z172 includes a defect in mitochondrial complex I and[E1] a reduction in complex IV activit[/E1]y. Genetic analysis of the[E2] POL[/E2]G gene confirmed the diagnosis., POL,GENE_VARIANT,146,150, a reduction in complex IV activit,HPO_TERM,86,120,0.8681325,0.13186745,-0.736265,0
line573,The primary symptoms for Patient Z173 were bradykinesia and slowness of movement. Analysis of the POLG gene was performed.,The primary symptoms for Patient Z173 were br[E1]adykinesia a[/E1]nd slowness of movement. Analysis of the POLG gene[E2] was[/E2] performed., was,GENE_VARIANT,107,111,adykinesia a,HPO_TERM,45,57,0.8529585,0.14704148,-0.705917,0
line574,Patient Z174 was evaluated for a severe reduction of mtDNA in muscle. The patient also presented with abnormal cortical architecture and an elevated CSF lactate level. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z174 was evaluated for a severe reduction of mtDNA in muscle. The patient also presented with ab[E1]normal cortical architecture[/E1] and an elevated CSF lactate level. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,193,197,normal cortical architecture,HPO_TERM,104,132,0.81523055,0.18476945,-0.6304611,0
line574,Patient Z174 was evaluated for a severe reduction of mtDNA in muscle. The patient also presented with abnormal cortical architecture and an elevated CSF lactate level. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z174 was evaluated for a severe reduction of mtDNA in muscle. The patient also presented with abnormal cortical architecture and [E1]an elevated CSF lactate l[/E1]evel. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,193,197,an elevated CSF lactate l,HPO_TERM,137,162,0.8126889,0.1873111,-0.6253778,0
line575,Patient Z175 was evaluated for multiple mitochondrial DNA deletions. The patient also presented with an elevated circulating aspartate aminotransferase concentration and a decrease in mitochondrial DNA in the muscles. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z175 was evaluated for [E1]multiple mitochondrial DNA deletion[/E1]s. The patient also presented with an elevated circulating aspartate aminotransferase concentration and a decrease in mitochondrial DNA in the muscles. Subsequent sequencing of[E2] the[/E2] POLG gene revealed a pathogenic variant., the,GENE_VARIANT,242,246,multiple mitochondrial DNA deletion,HPO_TERM,31,66,0.86773163,0.13226837,-0.73546326,0
line575,Patient Z175 was evaluated for multiple mitochondrial DNA deletions. The patient also presented with an elevated circulating aspartate aminotransferase concentration and a decrease in mitochondrial DNA in the muscles. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z175 was evaluated for multiple mitochondrial DNA deletions. The patient also presented with[E1] an elevated circulating aspartate aminotransferase concent[/E1]ration and a decrease in mitochondrial DNA in the muscles. Subsequent sequencing of[E2] the[/E2] POLG gene revealed a pathogenic variant., the,GENE_VARIANT,242,246, an elevated circulating aspartate aminotransferase concent,HPO_TERM,100,159,0.8385141,0.16148591,-0.6770282,0
line575,Patient Z175 was evaluated for multiple mitochondrial DNA deletions. The patient also presented with an elevated circulating aspartate aminotransferase concentration and a decrease in mitochondrial DNA in the muscles. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z175 was evaluated for multiple mitochondrial DNA deletions. The patient also presented with an elevated circulating aspartate aminotransferase concentratio[E1]n and a decrease in mitochondrial DNA in the mu[/E1]scles. Subsequent sequencing of[E2] the[/E2] POLG gene revealed a pathogenic variant., the,GENE_VARIANT,242,246,n and a decrease in mitochondrial DNA in the mu,HPO_TERM,164,211,0.84738153,0.15261841,-0.6947631,0
line576,"This report details Patient Z176, a patient with a reduction in complex I activity. Further investigation showed a rise in AST concentration and a partial deficiency of complex I. A known variant in the POLG gene was identified.","This report details Patient Z176, a patient with [E1]a reduction in complex I activity[/E1]. Further investigation showed a rise in AST concentration and a partial deficiency of complex I. A known variant in th[E2]e PO[/E2]LG gene was identified.",e PO,GENE_VARIANT,201,205,a reduction in complex I activity,HPO_TERM,49,82,0.86006266,0.13993734,-0.7201253,0
line576,"This report details Patient Z176, a patient with a reduction in complex I activity. Further investigation showed a rise in AST concentration and a partial deficiency of complex I. A known variant in the POLG gene was identified.","This report details Patient Z176, a patient with a reduction in complex I activity. Further investigation showed [E1]a rise in AST concentratio[/E1]n and a partial deficiency of complex I. A known variant in th[E2]e PO[/E2]LG gene was identified.",e PO,GENE_VARIANT,201,205,a rise in AST concentratio,HPO_TERM,113,139,0.86399806,0.13600196,-0.7279961,0
line576,"This report details Patient Z176, a patient with a reduction in complex I activity. Further investigation showed a rise in AST concentration and a partial deficiency of complex I. A known variant in the POLG gene was identified.","This report details Patient Z176, a patient with a reduction in complex I activity. Further investigation showed a rise in AST concentration and[E1] a partial deficiency of complex [/E1]I. A known variant in th[E2]e PO[/E2]LG gene was identified.",e PO,GENE_VARIANT,201,205, a partial deficiency of complex ,HPO_TERM,144,177,0.86061674,0.13938321,-0.72123355,0
line577,The clinical profile for Patient Z177 includes a partial deficiency of complex I and an elevated CSF lactate level. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Z177 includes [E1]a partial deficiency of complex I[/E1] and an elevated CSF lactate level. Genetic analysis of [E2]the [/E2]POLG gene confirmed the diagnosis.,the ,GENE_VARIANT,136,140,a partial deficiency of complex I,HPO_TERM,47,80,0.8603765,0.13962348,-0.720753,0
line577,The clinical profile for Patient Z177 includes a partial deficiency of complex I and an elevated CSF lactate level. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Z177 includes a partial deficiency of complex I and [E1]an elevated CSF lactate l[/E1]evel. Genetic analysis of [E2]the [/E2]POLG gene confirmed the diagnosis.,the ,GENE_VARIANT,136,140,an elevated CSF lactate l,HPO_TERM,85,110,0.85598826,0.1440117,-0.7119765,0
line578,"We report the case of Patient Z178, who has a history of slowness of movement. Examination also revealed multiple mitochondrial DNA deletions. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Z178, who has a history of [E1]slowness of movemen[/E1]t. Examination also revealed multiple mitochondrial DNA deletions. The underlying cause was traced to a mutation in th[E2]e PO[/E2]LG gene.",e PO,GENE_VARIANT,194,198,slowness of movemen,HPO_TERM,57,76,0.5441589,0.45584112,-0.08831775,0
line578,"We report the case of Patient Z178, who has a history of slowness of movement. Examination also revealed multiple mitochondrial DNA deletions. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Z178, who has a history of slowness of movement. Examination also revealed[E1] multiple mitochondrial DNA deletio[/E1]ns. The underlying cause was traced to a mutation in th[E2]e PO[/E2]LG gene.",e PO,GENE_VARIANT,194,198, multiple mitochondrial DNA deletio,HPO_TERM,104,139,0.43823612,0.5617639,0.123527765,1
line579,The primary symptoms for Patient Z179 were a severe reduction of mtDNA in muscle and a partial deficiency of complex I. Analysis of the POLG gene was performed.,The primary symptoms for Patient Z179 were a [E1]severe reduction of mtDNA in muscle and[/E1] a partial deficiency of complex I. Analysis of the POLG gene wa[E2]s pe[/E2]rformed.,s pe,GENE_VARIANT,148,152,severe reduction of mtDNA in muscle and,HPO_TERM,45,84,0.8496792,0.15032084,-0.69935834,0
line580,The clinical profile for Patient Z180 includes reduced mitochondrial DNA content in muscle and an elevated CSF lactate level. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Z180 includes [E1]reduced mitochondrial DNA content in muscl[/E1]e and an elevated CSF lactate level. Genetic analysis of[E2] the[/E2] POLG gene confirmed the diagnosis., the,GENE_VARIANT,145,149,reduced mitochondrial DNA content in muscl,HPO_TERM,47,89,0.85585123,0.14414872,-0.7117025,0
line580,The clinical profile for Patient Z180 includes reduced mitochondrial DNA content in muscle and an elevated CSF lactate level. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Z180 includes reduced mitochondrial DNA content in muscle and[E1] an elevated CSF lactate [/E1]level. Genetic analysis of[E2] the[/E2] POLG gene confirmed the diagnosis., the,GENE_VARIANT,145,149, an elevated CSF lactate ,HPO_TERM,94,119,0.8419674,0.15803263,-0.6839348,0
line581,Patient Z181 was evaluated for a severe reduction of mtDNA in muscle. The patient also presented with a partial deficiency of complex I and bradykinesia. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z181 was evaluated for a severe reduction of mtDNA in muscle. The patient also presented with a [E1]partial deficiency of complex I a[/E1]nd bradykinesia. Subsequent sequencing of the PO[E2]LG g[/E2]ene revealed a pathogenic variant.,LG g,GENE_VARIANT,185,189,partial deficiency of complex I a,HPO_TERM,104,137,0.8846996,0.11530044,-0.76939917,0
line582,"We report the case of Patient Z182, who has a history of complex I deficiency. Examination also revealed an elevated CSF lactate level. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Z182, who has a history of [E1]complex I deficienc[/E1]y. Examination also revealed an elevated CSF lactate level. The underlying cause was traced to a mutation in[E2] the[/E2] POLG gene.", the,GENE_VARIANT,184,188,complex I deficienc,HPO_TERM,57,76,0.5252454,0.47475448,-0.050490946,0
line582,"We report the case of Patient Z182, who has a history of complex I deficiency. Examination also revealed an elevated CSF lactate level. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Z182, who has a history of complex I deficiency. Examination also revealed[E1] an elevated CSF lactate [/E1]level. The underlying cause was traced to a mutation in[E2] the[/E2] POLG gene.", the,GENE_VARIANT,184,188, an elevated CSF lactate ,HPO_TERM,104,129,0.3622003,0.63779974,0.27559945,1
line583,Patient Z183 was evaluated for multiple mitochondrial DNA deletions. The patient also presented with abnormal cortical architecture and slowness of movement. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z183 was evaluated for [E1]multiple mitochondrial DNA deletion[/E1]s. The patient also presented with abnormal cortical architecture and slowness of movement. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,183,187,multiple mitochondrial DNA deletion,HPO_TERM,31,66,0.8464576,0.15354241,-0.6929152,0
line583,Patient Z183 was evaluated for multiple mitochondrial DNA deletions. The patient also presented with abnormal cortical architecture and slowness of movement. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z183 was evaluated for multiple mitochondrial DNA deletions. The patient also presented with[E1] abnormal cortical architect[/E1]ure and slowness of movement. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,183,187, abnormal cortical architect,HPO_TERM,100,128,0.77355295,0.226447,-0.54710597,0
line583,Patient Z183 was evaluated for multiple mitochondrial DNA deletions. The patient also presented with abnormal cortical architecture and slowness of movement. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z183 was evaluated for multiple mitochondrial DNA deletions. The patient also presented with abnormal cortical architecture a[E1]nd slowness of move[/E1]ment. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,183,187,nd slowness of move,HPO_TERM,133,152,0.824403,0.17559698,-0.648806,0
line584,The primary symptoms for Patient Z184 were abnormally high ALT levels and an abnormal thalamic MRI signal. Analysis of the POLG gene was performed.,The primary symptoms for Patient Z184 were ab[E1]normally high ALT levels[/E1] and an abnormal thalamic MRI signal. Analysis of the POLG g[E2]ene [/E2]was performed.,ene ,GENE_VARIANT,129,133,normally high ALT levels,HPO_TERM,45,69,0.855508,0.14449191,-0.7110161,0
line584,The primary symptoms for Patient Z184 were abnormally high ALT levels and an abnormal thalamic MRI signal. Analysis of the POLG gene was performed.,The primary symptoms for Patient Z184 were abnormally high ALT levels and [E1]an abnormal thalamic MRI sign[/E1]al. Analysis of the POLG g[E2]ene [/E2]was performed.,ene ,GENE_VARIANT,129,133,an abnormal thalamic MRI sign,HPO_TERM,74,103,0.8707794,0.12922058,-0.7415588,0
line585,Patient Z185 was evaluated for a severe reduction of mtDNA in muscle. The patient also presented with a partial deficiency of complex I and a reduction in complex IV activity. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z185 was evaluated for a severe reduction of mtDNA in muscle. The patient also presented with a [E1]partial deficiency of complex I a[/E1]nd a reduction in complex IV activity. Subsequent sequencing of the PO[E2]LG g[/E2]ene revealed a pathogenic variant.,LG g,GENE_VARIANT,207,211,partial deficiency of complex I a,HPO_TERM,104,137,0.88739616,0.11260387,-0.7747923,0
line586,Patient Z186 was evaluated for abnormally high AST levels. The patient also presented with a partial deficiency of complex I and complex I deficiency. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z186 was evaluated for [E1]abnormally high AST leve[/E1]ls. The patient also presented with a partial deficiency of complex I and complex I deficiency. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,177,181,abnormally high AST leve,HPO_TERM,31,55,0.8802883,0.11971166,-0.76057667,0
line586,Patient Z186 was evaluated for abnormally high AST levels. The patient also presented with a partial deficiency of complex I and complex I deficiency. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z186 was evaluated for abnormally high AST levels. The patient also presented wit[E1]h a partial deficiency of complex[/E1] I and complex I deficiency. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,177,181,h a partial deficiency of complex,HPO_TERM,89,122,0.8793909,0.12060916,-0.75878173,0
line586,Patient Z186 was evaluated for abnormally high AST levels. The patient also presented with a partial deficiency of complex I and complex I deficiency. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z186 was evaluated for abnormally high AST levels. The patient also presented with a partial deficiency of complex I an[E1]d complex I deficie[/E1]ncy. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,177,181,d complex I deficie,HPO_TERM,127,146,0.8806996,0.11930038,-0.7613992,0
line587,Patient Z187 was evaluated for increased CSF lactate. The patient also presented with slowness of movement and a decrease in mitochondrial DNA in the muscles. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z187 was evaluated for [E1]increased CSF lactate[/E1]. The patient also presented with slowness of movement and a decrease in mitochondrial DNA in the muscles. Subsequent sequencing of the [E2]POLG[/E2] gene revealed a pathogenic variant.,POLG,GENE_VARIANT,188,192,increased CSF lactate,HPO_TERM,31,52,0.83167684,0.16832311,-0.66335374,0
line587,Patient Z187 was evaluated for increased CSF lactate. The patient also presented with slowness of movement and a decrease in mitochondrial DNA in the muscles. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z187 was evaluated for increased CSF lactate. The patient also presented with [E1]slowness of movemen[/E1]t and a decrease in mitochondrial DNA in the muscles. Subsequent sequencing of the [E2]POLG[/E2] gene revealed a pathogenic variant.,POLG,GENE_VARIANT,188,192,slowness of movemen,HPO_TERM,86,105,0.8426074,0.1573926,-0.68521476,0
line587,Patient Z187 was evaluated for increased CSF lactate. The patient also presented with slowness of movement and a decrease in mitochondrial DNA in the muscles. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z187 was evaluated for increased CSF lactate. The patient also presented with slowness of movement and[E1] a decrease in mitochondrial DNA in the muscles[/E1]. Subsequent sequencing of the [E2]POLG[/E2] gene revealed a pathogenic variant.,POLG,GENE_VARIANT,188,192, a decrease in mitochondrial DNA in the muscles,HPO_TERM,110,157,0.83260363,0.16739641,-0.6652072,0
line588,"We report the case of Patient Z188, who has a history of deficient cytochrome c oxidase activity. Examination also revealed an elevated CSF lactate level. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Z188, who has a history of [E1]deficient cytochrome c oxidase activit[/E1]y. Examination also revealed an elevated CSF lactate level. The underlying cause was traced to a mutation in[E2] the[/E2] POLG gene.", the,GENE_VARIANT,203,207,deficient cytochrome c oxidase activit,HPO_TERM,57,95,0.19310227,0.8068977,0.6137954,1
line588,"We report the case of Patient Z188, who has a history of deficient cytochrome c oxidase activity. Examination also revealed an elevated CSF lactate level. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Z188, who has a history of deficient cytochrome c oxidase activity. Examination also revealed[E1] an elevated CSF lactate [/E1]level. The underlying cause was traced to a mutation in[E2] the[/E2] POLG gene.", the,GENE_VARIANT,203,207, an elevated CSF lactate ,HPO_TERM,123,148,0.24952479,0.7504752,0.50095046,1
line589,The clinical profile for Patient Z189 includes bradykinesia and high AST levels. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Z189 includes [E1]bradykinesia[/E1] and high AST levels. Genetic analysis of the[E2] POL[/E2]G gene confirmed the diagnosis., POL,GENE_VARIANT,104,108,bradykinesia,HPO_TERM,47,59,0.8477613,0.15223874,-0.69552255,0
line589,The clinical profile for Patient Z189 includes bradykinesia and high AST levels. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Z189 includes bradykinesia and [E1]high AST level[/E1]s. Genetic analysis of the[E2] POL[/E2]G gene confirmed the diagnosis., POL,GENE_VARIANT,104,108,high AST level,HPO_TERM,64,78,0.8775958,0.122404285,-0.7551915,0
line590,The primary symptoms for Patient Z190 were slowness of movement and an abnormal thalamic MRI signal. Analysis of the POLG gene was performed.,The primary symptoms for Patient Z190 were sl[E1]owness of movement [/E1]and an abnormal thalamic MRI signal. Analysis of the POLG ge[E2]ne w[/E2]as performed.,ne w,GENE_VARIANT,124,128,owness of movement ,HPO_TERM,45,64,0.82072604,0.17927396,-0.6414521,0
line590,The primary symptoms for Patient Z190 were slowness of movement and an abnormal thalamic MRI signal. Analysis of the POLG gene was performed.,The primary symptoms for Patient Z190 were slowness of movement and a[E1]n abnormal thalamic MRI signa[/E1]l. Analysis of the POLG ge[E2]ne w[/E2]as performed.,ne w,GENE_VARIANT,124,128,n abnormal thalamic MRI signa,HPO_TERM,69,98,0.8491612,0.15083879,-0.6983224,0
line591,"We report the case of Patient Z191, who has a history of slowness of movement. Examination also revealed high levels of alanine aminotransferase. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Z191, who has a history of [E1]slowness of movemen[/E1]t. Examination also revealed high levels of alanine aminotransferase. The underlying cause was traced to a mutation in the[E2] POL[/E2]G gene.", POL,GENE_VARIANT,198,202,slowness of movemen,HPO_TERM,57,76,0.62945205,0.37054792,-0.25890413,0
line591,"We report the case of Patient Z191, who has a history of slowness of movement. Examination also revealed high levels of alanine aminotransferase. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Z191, who has a history of slowness of movement. Examination also revealed[E1] high levels of alanine aminotransferas[/E1]e. The underlying cause was traced to a mutation in the[E2] POL[/E2]G gene.", POL,GENE_VARIANT,198,202, high levels of alanine aminotransferas,HPO_TERM,104,143,0.42399406,0.57600594,0.15201187,1
line592,"We report the case of Patient Z192, who has a history of an accumulation of multiple mtDNA deletions. Examination also revealed a decrease in mitochondrial DNA in the muscles. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Z192, who has a history of [E1]an accumulation of multiple mtDNA deletio[/E1]ns. Examination also revealed a decrease in mitochondrial DNA in the muscles. The underlying cause was traced to a mutation in the[E2] POL[/E2]G gene.", POL,GENE_VARIANT,228,232,an accumulation of multiple mtDNA deletio,HPO_TERM,57,98,0.5374123,0.46258774,-0.07482454,0
line592,"We report the case of Patient Z192, who has a history of an accumulation of multiple mtDNA deletions. Examination also revealed a decrease in mitochondrial DNA in the muscles. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Z192, who has a history of an accumulation of multiple mtDNA deletions. Examination also reveale[E1]d a decrease in mitochondrial DNA in the muscle[/E1]s. The underlying cause was traced to a mutation in the[E2] POL[/E2]G gene.", POL,GENE_VARIANT,228,232,d a decrease in mitochondrial DNA in the muscle,HPO_TERM,126,173,0.62364125,0.37635872,-0.24728253,0
line593,"This report details Patient Z193, a patient with a partial deficiency of complex I. Further investigation showed a decrease in mitochondrial DNA in the muscles and a rise in AST concentration. A known variant in the POLG gene was identified.","This report details Patient Z193, a patient with [E1]a partial deficiency of complex I[/E1]. Further investigation showed a decrease in mitochondrial DNA in the muscles and a rise in AST concentration. A known variant in the[E2] POL[/E2]G gene was identified.", POL,GENE_VARIANT,215,219,a partial deficiency of complex I,HPO_TERM,49,82,0.81510013,0.18489984,-0.63020027,0
line593,"This report details Patient Z193, a patient with a partial deficiency of complex I. Further investigation showed a decrease in mitochondrial DNA in the muscles and a rise in AST concentration. A known variant in the POLG gene was identified.","This report details Patient Z193, a patient with a partial deficiency of complex I. Further investigation showed [E1]a decrease in mitochondrial DNA in the muscles [/E1]and a rise in AST concentration. A known variant in the[E2] POL[/E2]G gene was identified.", POL,GENE_VARIANT,215,219,a decrease in mitochondrial DNA in the muscles ,HPO_TERM,113,160,0.8202143,0.17978568,-0.6404286,0
line593,"This report details Patient Z193, a patient with a partial deficiency of complex I. Further investigation showed a decrease in mitochondrial DNA in the muscles and a rise in AST concentration. A known variant in the POLG gene was identified.","This report details Patient Z193, a patient with a partial deficiency of complex I. Further investigation showed a decrease in mitochondrial DNA in the muscles and a[E1] rise in AST concentration[/E1]. A known variant in the[E2] POL[/E2]G gene was identified.", POL,GENE_VARIANT,215,219, rise in AST concentration,HPO_TERM,165,191,0.83278507,0.16721492,-0.66557014,0
line594,The primary symptoms for Patient Z194 were a defect in mitochondrial complex I and cytochrome c oxidase deficiency. Analysis of the POLG gene was performed.,The primary symptoms for Patient Z194 were a [E1]defect in mitochondrial complex I [/E1]and cytochrome c oxidase deficiency. Analysis of the POLG gen[E2]e wa[/E2]s performed.,e wa,GENE_VARIANT,140,144,defect in mitochondrial complex I ,HPO_TERM,45,79,0.84083927,0.15916064,-0.68167865,0
line594,The primary symptoms for Patient Z194 were a defect in mitochondrial complex I and cytochrome c oxidase deficiency. Analysis of the POLG gene was performed.,The primary symptoms for Patient Z194 were a defect in mitochondrial complex I and c[E1]ytochrome c oxidase deficiency[/E1]. Analysis of the POLG gen[E2]e wa[/E2]s performed.,e wa,GENE_VARIANT,140,144,ytochrome c oxidase deficiency,HPO_TERM,84,114,0.8370509,0.1629491,-0.6741018,0
line596,Patient Z196 was evaluated for abnormally high AST levels. The patient also presented with increased CSF lactate and slowness in voluntary movement. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z196 was evaluated for [E1]abnormally high AST leve[/E1]ls. The patient also presented with increased CSF lactate and slowness in voluntary movement. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,175,179,abnormally high AST leve,HPO_TERM,31,55,0.8630894,0.13691063,-0.72617877,0
line596,Patient Z196 was evaluated for abnormally high AST levels. The patient also presented with increased CSF lactate and slowness in voluntary movement. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z196 was evaluated for abnormally high AST levels. The patient also presented wit[E1]h increased CSF lacta[/E1]te and slowness in voluntary movement. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,175,179,h increased CSF lacta,HPO_TERM,89,110,0.86831933,0.13168068,-0.73663867,0
line596,Patient Z196 was evaluated for abnormally high AST levels. The patient also presented with increased CSF lactate and slowness in voluntary movement. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Z196 was evaluated for abnormally high AST levels. The patient also presented with increased CSF lactate an[E1]d slowness in voluntary movem[/E1]ent. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,175,179,d slowness in voluntary movem,HPO_TERM,115,144,0.8708578,0.12914221,-0.74171555,0
line597,"This report details Patient Z197, a patient with a reduction in complex I activity. Further investigation showed deficient cytochrome c oxidase activity and restricted diffusion on cerebral MRI. A known variant in the POLG gene was identified.","This report details Patient Z197, a patient with [E1]a reduction in complex I activity[/E1]. Further investigation showed deficient cytochrome c oxidase activity and restricted diffusion on cerebral MRI. A known variant in the [E2]POLG[/E2] gene was identified.",POLG,GENE_VARIANT,218,222,a reduction in complex I activity,HPO_TERM,49,82,0.7175067,0.2824932,-0.4350135,0
line597,"This report details Patient Z197, a patient with a reduction in complex I activity. Further investigation showed deficient cytochrome c oxidase activity and restricted diffusion on cerebral MRI. A known variant in the POLG gene was identified.","This report details Patient Z197, a patient with a reduction in complex I activity. Further investigation showed [E1]deficient cytochrome c oxidase activity[/E1] and restricted diffusion on cerebral MRI. A known variant in the [E2]POLG[/E2] gene was identified.",POLG,GENE_VARIANT,218,222,deficient cytochrome c oxidase activity,HPO_TERM,113,152,0.7184314,0.28156856,-0.43686286,0
line597,"This report details Patient Z197, a patient with a reduction in complex I activity. Further investigation showed deficient cytochrome c oxidase activity and restricted diffusion on cerebral MRI. A known variant in the POLG gene was identified.","This report details Patient Z197, a patient with a reduction in complex I activity. Further investigation showed deficient cytochrome c oxidase activity and [E1]restricted diffusion on cerebral MRI[/E1]. A known variant in the [E2]POLG[/E2] gene was identified.",POLG,GENE_VARIANT,218,222,restricted diffusion on cerebral MRI,HPO_TERM,157,193,0.7147703,0.28522968,-0.42954063,0
line598,"We report the case of Patient Z198, who has a history of elevated aspartate aminotransferase. Examination also revealed elevated alanine aminotransferase. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Z198, who has a history of [E1]elevated aspartate aminotransferase[/E1]. Examination also revealed elevated alanine aminotransferase. The underlying cause was traced to a mutation in the [E2]POLG[/E2] gene.",POLG,GENE_VARIANT,208,212,elevated aspartate aminotransferase,HPO_TERM,57,92,0.3941941,0.6058059,0.21161178,1
line598,"We report the case of Patient Z198, who has a history of elevated aspartate aminotransferase. Examination also revealed elevated alanine aminotransferase. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Z198, who has a history of elevated aspartate aminotransferase. Examination also revealed [E1]elevated alanine aminotransferase[/E1]. The underlying cause was traced to a mutation in the [E2]POLG[/E2] gene.",POLG,GENE_VARIANT,208,212,elevated alanine aminotransferase,HPO_TERM,120,153,0.27481368,0.7251864,0.45037273,1
line599,"We report the case of Patient Z199, who has a history of complex I deficiency. Examination also revealed a reduction in complex I activity. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Z199, who has a history of [E1]complex I deficienc[/E1]y. Examination also revealed a reduction in complex I activity. The underlying cause was traced to a mutation in the[E2] POL[/E2]G gene.", POL,GENE_VARIANT,192,196,complex I deficienc,HPO_TERM,57,76,0.62343794,0.37656212,-0.24687582,0
line599,"We report the case of Patient Z199, who has a history of complex I deficiency. Examination also revealed a reduction in complex I activity. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Z199, who has a history of complex I deficiency. Examination also revealed[E1] a reduction in complex I activit[/E1]y. The underlying cause was traced to a mutation in the[E2] POL[/E2]G gene.", POL,GENE_VARIANT,192,196, a reduction in complex I activit,HPO_TERM,104,137,0.46121308,0.53878695,0.077573866,1
line600,"We report the case of Patient Y0, who has a history of symptoms of anxiety. Examination also revealed a significant decrease in body weight. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Y0, who has a history of [E1]symptoms of anxiety[/E1]. Examination also revealed a significant decrease in body weight. The underlying cause was traced to a mutation in the [E2]POLG[/E2] gene.",POLG,GENE_VARIANT,194,198,symptoms of anxiety,HPO_TERM,55,74,0.43437472,0.5656253,0.13125059,1
line600,"We report the case of Patient Y0, who has a history of symptoms of anxiety. Examination also revealed a significant decrease in body weight. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Y0, who has a history of symptoms of anxiety. Examination also revealed [E1]a significant decrease in body weight[/E1]. The underlying cause was traced to a mutation in the [E2]POLG[/E2] gene.",POLG,GENE_VARIANT,194,198,a significant decrease in body weight,HPO_TERM,102,139,0.45238623,0.5476138,0.09522757,1
line601,"This report details Patient Y1, a patient with a face with diminished mimetic function. Further investigation showed bilateral tonic-clonic seizures and a significant decrease in body weight. A known variant in the POLG gene was identified.","This report details Patient Y1, a patient with [E1]a face with diminished mimetic function[/E1]. Further investigation showed bilateral tonic-clonic seizures and a significant decrease in body weight. A known variant in the [E2]POLG[/E2] gene was identified.",POLG,GENE_VARIANT,215,219,a face with diminished mimetic function,HPO_TERM,47,86,0.77688336,0.22311665,-0.5537667,0
line601,"This report details Patient Y1, a patient with a face with diminished mimetic function. Further investigation showed bilateral tonic-clonic seizures and a significant decrease in body weight. A known variant in the POLG gene was identified.","This report details Patient Y1, a patient with a face with diminished mimetic function. Further investigation showed [E1]bilateral tonic-clonic seizures[/E1] and a significant decrease in body weight. A known variant in the [E2]POLG[/E2] gene was identified.",POLG,GENE_VARIANT,215,219,bilateral tonic-clonic seizures,HPO_TERM,117,148,0.7593341,0.24066597,-0.5186681,0
line601,"This report details Patient Y1, a patient with a face with diminished mimetic function. Further investigation showed bilateral tonic-clonic seizures and a significant decrease in body weight. A known variant in the POLG gene was identified.","This report details Patient Y1, a patient with a face with diminished mimetic function. Further investigation showed bilateral tonic-clonic seizures and [E1]a significant decrease in body weight[/E1]. A known variant in the [E2]POLG[/E2] gene was identified.",POLG,GENE_VARIANT,215,219,a significant decrease in body weight,HPO_TERM,153,190,0.76804215,0.23195781,-0.53608435,0
line602,"This report details Patient Y2, a patient with episodes of intense anxiety. Further investigation showed insufficient liver function and a decrease in body mass. A known variant in the POLG gene was identified.","This report details Patient Y2, a patient with [E1]episodes of intense anxie[/E1]ty. Further investigation showed insufficient liver function and a decrease in body mass. A known variant in [E2]the [/E2]POLG gene was identified.",the ,GENE_VARIANT,181,185,episodes of intense anxie,HPO_TERM,47,72,0.8005489,0.19945106,-0.6010978,0
line602,"This report details Patient Y2, a patient with episodes of intense anxiety. Further investigation showed insufficient liver function and a decrease in body mass. A known variant in the POLG gene was identified.","This report details Patient Y2, a patient with episodes of intense anxiety. Further investigation showe[E1]d insufficient liver func[/E1]tion and a decrease in body mass. A known variant in [E2]the [/E2]POLG gene was identified.",the ,GENE_VARIANT,181,185,d insufficient liver func,HPO_TERM,103,128,0.7930399,0.20696005,-0.58607984,0
line602,"This report details Patient Y2, a patient with episodes of intense anxiety. Further investigation showed insufficient liver function and a decrease in body mass. A known variant in the POLG gene was identified.","This report details Patient Y2, a patient with episodes of intense anxiety. Further investigation showed insufficient liver function [E1]and a decrease in body [/E1]mass. A known variant in [E2]the [/E2]POLG gene was identified.",the ,GENE_VARIANT,181,185,and a decrease in body ,HPO_TERM,133,156,0.79205376,0.20794621,-0.5841075,0
line603,The primary symptoms for Patient Y3 were a focal-onset seizure and a weak voice. Analysis of the POLG gene was performed.,The primary symptoms for Patient Y3 were a [E1]focal-onset seizure [/E1]and a weak voice. Analysis of the POLG gene[E2] was[/E2] performed., was,GENE_VARIANT,106,110,focal-onset seizure ,HPO_TERM,43,63,0.8149329,0.18506715,-0.62986577,0
line604,Patient Y4 was evaluated for anxiety. The patient also presented with a focal T2 hyperintense thalamic lesion and a weak voice. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y4 was evaluated for [E1]anxiety[/E1]. The patient also presented with a focal T2 hyperintense thalamic lesion and a weak voice. Subsequent sequencing of the[E2] POL[/E2]G gene revealed a pathogenic variant., POL,GENE_VARIANT,156,160,anxiety,HPO_TERM,29,36,0.83962446,0.16037554,-0.6792489,0
line604,Patient Y4 was evaluated for anxiety. The patient also presented with a focal T2 hyperintense thalamic lesion and a weak voice. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y4 was evaluated for anxiety. The patient also presented with [E1]a focal T2 hyperintense thalamic lesio[/E1]n and a weak voice. Subsequent sequencing of the[E2] POL[/E2]G gene revealed a pathogenic variant., POL,GENE_VARIANT,156,160,a focal T2 hyperintense thalamic lesio,HPO_TERM,70,108,0.84034175,0.15965822,-0.6806835,0
line604,Patient Y4 was evaluated for anxiety. The patient also presented with a focal T2 hyperintense thalamic lesion and a weak voice. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y4 was evaluated for anxiety. The patient also presented with a focal T2 hyperintense thalamic lesion and[E1] a weak voic[/E1]e. Subsequent sequencing of the[E2] POL[/E2]G gene revealed a pathogenic variant., POL,GENE_VARIANT,156,160, a weak voic,HPO_TERM,113,125,0.8473659,0.15263407,-0.69473183,0
line605,The primary symptoms for Patient Y5 were a history of anxiety and a focal T2 hyperintense thalamic lesion. Analysis of the POLG gene was performed.,The primary symptoms for Patient Y5 were a [E1]history of anxiety [/E1]and a focal T2 hyperintense thalamic lesion. Analysis of the POLG gen[E2]e wa[/E2]s performed.,e wa,GENE_VARIANT,131,135,history of anxiety ,HPO_TERM,43,62,0.7996666,0.20033342,-0.59933317,0
line605,The primary symptoms for Patient Y5 were a history of anxiety and a focal T2 hyperintense thalamic lesion. Analysis of the POLG gene was performed.,The primary symptoms for Patient Y5 were a history of anxiety and a[E1] focal T2 hyperintense thalamic lesion[/E1]. Analysis of the POLG gen[E2]e wa[/E2]s performed.,e wa,GENE_VARIANT,131,135, focal T2 hyperintense thalamic lesion,HPO_TERM,67,105,0.7966192,0.20338081,-0.59323835,0
line606,"This report details Patient Y6, a patient with a diagnosis of an anxiety disorder. Further investigation showed a focal-onset seizure and decreased liver function. A known variant in the POLG gene was identified.","This report details Patient Y6, a patient with [E1]a diagnosis of an anxiety disor[/E1]der. Further investigation showed a focal-onset seizure and decreased liver function. A known variant in [E2]the [/E2]POLG gene was identified.",the ,GENE_VARIANT,183,187,a diagnosis of an anxiety disor,HPO_TERM,47,78,0.777234,0.22276598,-0.55446804,0
line606,"This report details Patient Y6, a patient with a diagnosis of an anxiety disorder. Further investigation showed a focal-onset seizure and decreased liver function. A known variant in the POLG gene was identified.","This report details Patient Y6, a patient with a diagnosis of an anxiety disorder. Further investigation show[E1]ed a focal-onset sei[/E1]zure and decreased liver function. A known variant in [E2]the [/E2]POLG gene was identified.",the ,GENE_VARIANT,183,187,ed a focal-onset sei,HPO_TERM,109,129,0.768146,0.23185402,-0.53629196,0
line606,"This report details Patient Y6, a patient with a diagnosis of an anxiety disorder. Further investigation showed a focal-onset seizure and decreased liver function. A known variant in the POLG gene was identified.","This report details Patient Y6, a patient with a diagnosis of an anxiety disorder. Further investigation showed a focal-onset seizure [E1]and decreased liver func[/E1]tion. A known variant in [E2]the [/E2]POLG gene was identified.",the ,GENE_VARIANT,183,187,and decreased liver func,HPO_TERM,134,158,0.7711824,0.22881755,-0.54236484,0
line607,Patient Y7 was evaluated for a rhythmic shaking movement. The patient also presented with a soft or quiet voice and a focal T2 hyperintense thalamic lesion. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y7 was evaluated for [E1]a rhythmic shaking movement[/E1]. The patient also presented with a soft or quiet voice and a focal T2 hyperintense thalamic lesion. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,183,187,a rhythmic shaking movement,HPO_TERM,29,56,0.7431107,0.25688928,-0.48622143,0
line607,Patient Y7 was evaluated for a rhythmic shaking movement. The patient also presented with a soft or quiet voice and a focal T2 hyperintense thalamic lesion. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y7 was evaluated for a rhythmic shaking movement. The patient also presented with [E1]a soft or quiet voi[/E1]ce and a focal T2 hyperintense thalamic lesion. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,183,187,a soft or quiet voi,HPO_TERM,90,109,0.7038155,0.29618448,-0.40763104,0
line607,Patient Y7 was evaluated for a rhythmic shaking movement. The patient also presented with a soft or quiet voice and a focal T2 hyperintense thalamic lesion. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y7 was evaluated for a rhythmic shaking movement. The patient also presented with a soft or quiet voice an[E1]d a focal T2 hyperintense thalamic les[/E1]ion. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,183,187,d a focal T2 hyperintense thalamic les,HPO_TERM,114,152,0.79452384,0.20547618,-0.5890477,0
line608,"We report the case of Patient Y8, who has a history of a focal T2 hyperintense thalamic lesion. Examination also revealed a tremor. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Y8, who has a history of [E1]a focal T2 hyperintense thalamic lesio[/E1]n. Examination also revealed a tremor. The underlying cause was traced to a mutation in th[E2]e PO[/E2]LG gene.",e PO,GENE_VARIANT,183,187,a focal T2 hyperintense thalamic lesio,HPO_TERM,55,93,0.6517256,0.34827438,-0.3034512,0
line608,"We report the case of Patient Y8, who has a history of a focal T2 hyperintense thalamic lesion. Examination also revealed a tremor. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Y8, who has a history of a focal T2 hyperintense thalamic lesion. Examination also revealed[E1] a trem[/E1]or. The underlying cause was traced to a mutation in th[E2]e PO[/E2]LG gene.",e PO,GENE_VARIANT,183,187, a trem,HPO_TERM,121,128,0.53722364,0.46277636,-0.074447274,0
line609,The clinical profile for Patient Y9 includes a history of significant weight loss and anxiety. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Y9 includes [E1]a history of significant weight los[/E1]s and anxiety. Genetic analysis of the[E2] POL[/E2]G gene confirmed the diagnosis., POL,GENE_VARIANT,118,122,a history of significant weight los,HPO_TERM,45,80,0.81712556,0.18287435,-0.63425124,0
line609,The clinical profile for Patient Y9 includes a history of significant weight loss and anxiety. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Y9 includes a history of significant weight loss and[E1] anxiet[/E1]y. Genetic analysis of the[E2] POL[/E2]G gene confirmed the diagnosis., POL,GENE_VARIANT,118,122, anxiet,HPO_TERM,85,92,0.8441353,0.15586476,-0.6882705,0
line610,Patient Y10 was evaluated for a weak voice. The patient also presented with seizures originating in one area of the brain and a focal T2 hyperintense thalamic lesion. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y10 was evaluated for [E1]a weak voice[/E1]. The patient also presented with seizures originating in one area of the brain and a focal T2 hyperintense thalamic lesion. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,192,196,a weak voice,HPO_TERM,30,42,0.80644864,0.19355133,-0.6128973,0
line610,Patient Y10 was evaluated for a weak voice. The patient also presented with seizures originating in one area of the brain and a focal T2 hyperintense thalamic lesion. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y10 was evaluated for a weak voice. The patient also presented with [E1]seizures originating in one area of the br[/E1]ain and a focal T2 hyperintense thalamic lesion. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,192,196,seizures originating in one area of the br,HPO_TERM,76,118,0.7612266,0.23877345,-0.5224531,0
line610,Patient Y10 was evaluated for a weak voice. The patient also presented with seizures originating in one area of the brain and a focal T2 hyperintense thalamic lesion. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y10 was evaluated for a weak voice. The patient also presented with seizures originating in one area of the brain a[E1]nd a focal T2 hyperintense thalamic le[/E1]sion. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,192,196,nd a focal T2 hyperintense thalamic le,HPO_TERM,123,161,0.8222121,0.1777879,-0.6444242,0
line611,The primary symptoms for Patient Y11 were a limitation of upgaze and a focal T2 hyperintense thalamic lesion. Analysis of the POLG gene was performed.,The primary symptoms for Patient Y11 were a [E1]limitation of upgaze a[/E1]nd a focal T2 hyperintense thalamic lesion. Analysis of the POLG gene[E2] was[/E2] performed., was,GENE_VARIANT,135,139,limitation of upgaze a,HPO_TERM,44,66,0.8365748,0.16342524,-0.6731496,0
line612,"This report details Patient Y12, a patient with a history of anxiety. Further investigation showed a focal-onset seizure and a focal T2 hyperintense thalamic lesion. A known variant in the POLG gene was identified.","This report details Patient Y12, a patient with [E1]a history of anxiet[/E1]y. Further investigation showed a focal-onset seizure and a focal T2 hyperintense thalamic lesion. A known variant in t[E2]he P[/E2]OLG gene was identified.",he P,GENE_VARIANT,186,190,a history of anxiet,HPO_TERM,48,67,0.74776816,0.25223187,-0.4955363,0
line612,"This report details Patient Y12, a patient with a history of anxiety. Further investigation showed a focal-onset seizure and a focal T2 hyperintense thalamic lesion. A known variant in the POLG gene was identified.","This report details Patient Y12, a patient with a history of anxiety. Further investigation showed[E1] a focal-onset seizu[/E1]re and a focal T2 hyperintense thalamic lesion. A known variant in t[E2]he P[/E2]OLG gene was identified.",he P,GENE_VARIANT,186,190, a focal-onset seizu,HPO_TERM,98,118,0.73571676,0.26428324,-0.47143352,0
line612,"This report details Patient Y12, a patient with a history of anxiety. Further investigation showed a focal-onset seizure and a focal T2 hyperintense thalamic lesion. A known variant in the POLG gene was identified.","This report details Patient Y12, a patient with a history of anxiety. Further investigation showed a focal-onset seizure an[E1]d a focal T2 hyperintense thalamic les[/E1]ion. A known variant in t[E2]he P[/E2]OLG gene was identified.",he P,GENE_VARIANT,186,190,d a focal T2 hyperintense thalamic les,HPO_TERM,123,161,0.77448153,0.22551839,-0.5489631,0
line613,Patient Y13 was evaluated for a partial seizure. The patient also presented with poverty of facial expression and a limitation of upgaze. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y13 was evaluated for [E1]a partial seizur[/E1]e. The patient also presented with poverty of facial expression and a limitation of upgaze. Subsequent sequencing of th[E2]e PO[/E2]LG gene revealed a pathogenic variant.,e PO,GENE_VARIANT,165,169,a partial seizur,HPO_TERM,30,46,0.8903196,0.109680444,-0.7806392,0
line613,Patient Y13 was evaluated for a partial seizure. The patient also presented with poverty of facial expression and a limitation of upgaze. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y13 was evaluated for a partial seizure. The patient also presented with[E1] poverty of facial expressi[/E1]on and a limitation of upgaze. Subsequent sequencing of th[E2]e PO[/E2]LG gene revealed a pathogenic variant.,e PO,GENE_VARIANT,165,169, poverty of facial expressi,HPO_TERM,80,107,0.86947113,0.13052885,-0.73894227,0
line613,Patient Y13 was evaluated for a partial seizure. The patient also presented with poverty of facial expression and a limitation of upgaze. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y13 was evaluated for a partial seizure. The patient also presented with poverty of facial expression an[E1]d a limitation of upga[/E1]ze. Subsequent sequencing of th[E2]e PO[/E2]LG gene revealed a pathogenic variant.,e PO,GENE_VARIANT,165,169,d a limitation of upga,HPO_TERM,112,134,0.8629427,0.1370573,-0.7258854,0
line614,Patient Y14 was evaluated for a soft or quiet voice. The patient also presented with a tremor and bilateral tonic-clonic seizures. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y14 was evaluated for [E1]a soft or quiet voi[/E1]ce. The patient also presented with a tremor and bilateral tonic-clonic seizures. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,157,161,a soft or quiet voi,HPO_TERM,30,49,0.823185,0.17681494,-0.64637005,0
line614,Patient Y14 was evaluated for a soft or quiet voice. The patient also presented with a tremor and bilateral tonic-clonic seizures. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y14 was evaluated for a soft or quiet voice. The patient also presented wit[E1]h a tre[/E1]mor and bilateral tonic-clonic seizures. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,157,161,h a tre,HPO_TERM,83,90,0.85741615,0.1425838,-0.71483237,0
line614,Patient Y14 was evaluated for a soft or quiet voice. The patient also presented with a tremor and bilateral tonic-clonic seizures. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y14 was evaluated for a soft or quiet voice. The patient also presented with a tremor a[E1]nd bilateral tonic-clonic seizu[/E1]res. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,157,161,nd bilateral tonic-clonic seizu,HPO_TERM,95,126,0.824719,0.17528094,-0.6494381,0
line615,"We report the case of Patient Y15, who has a history of a fine tremor. Examination also revealed anxiety. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Y15, who has a history of [E1]a fine tremor[/E1]. Examination also revealed anxiety. The underlying cause was traced to a mutation in the [E2]POLG[/E2] gene.",POLG,GENE_VARIANT,159,163,a fine tremor,HPO_TERM,56,69,0.44728586,0.5527141,0.10542825,1
line615,"We report the case of Patient Y15, who has a history of a fine tremor. Examination also revealed anxiety. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Y15, who has a history of a fine tremor. Examination also revealed [E1]anxiety[/E1]. The underlying cause was traced to a mutation in the [E2]POLG[/E2] gene.",POLG,GENE_VARIANT,159,163,anxiety,HPO_TERM,97,104,0.35402706,0.64597297,0.2919459,1
line616,"This report details Patient Y16, a patient with a focal-onset seizure. Further investigation showed a soft or quiet voice and seizures originating in one area of the brain. A known variant in the POLG gene was identified.","This report details Patient Y16, a patient with [E1]a focal-onset seizur[/E1]e. Further investigation showed a soft or quiet voice and seizures originating in one area of the brain. A known variant i[E2]n th[/E2]e POLG gene was identified.",n th,GENE_VARIANT,190,194,a focal-onset seizur,HPO_TERM,48,68,0.82247066,0.1775293,-0.64494133,0
line616,"This report details Patient Y16, a patient with a focal-onset seizure. Further investigation showed a soft or quiet voice and seizures originating in one area of the brain. A known variant in the POLG gene was identified.","This report details Patient Y16, a patient with a focal-onset seizure. Further investigation showed[E1] a soft or quiet vo[/E1]ice and seizures originating in one area of the brain. A known variant i[E2]n th[/E2]e POLG gene was identified.",n th,GENE_VARIANT,190,194, a soft or quiet vo,HPO_TERM,99,118,0.8082034,0.19179665,-0.61640674,0
line616,"This report details Patient Y16, a patient with a focal-onset seizure. Further investigation showed a soft or quiet voice and seizures originating in one area of the brain. A known variant in the POLG gene was identified.","This report details Patient Y16, a patient with a focal-onset seizure. Further investigation showed a soft or quiet voice a[E1]nd seizures originating in one area of the[/E1] brain. A known variant i[E2]n th[/E2]e POLG gene was identified.",n th,GENE_VARIANT,190,194,nd seizures originating in one area of the,HPO_TERM,123,165,0.81875545,0.18124457,-0.6375109,0
line617,"This report details Patient Y17, a patient with a rhythmic shaking movement. Further investigation showed a partial seizure and a focal T2 hyperintense thalamic lesion. A known variant in the POLG gene was identified.","This report details Patient Y17, a patient with [E1]a rhythmic shaking movement[/E1]. Further investigation showed a partial seizure and a focal T2 hyperintense thalamic lesion. A known variant in th[E2]e PO[/E2]LG gene was identified.",e PO,GENE_VARIANT,190,194,a rhythmic shaking movement,HPO_TERM,48,75,0.7440015,0.25599852,-0.488003,0
line617,"This report details Patient Y17, a patient with a rhythmic shaking movement. Further investigation showed a partial seizure and a focal T2 hyperintense thalamic lesion. A known variant in the POLG gene was identified.","This report details Patient Y17, a patient with a rhythmic shaking movement. Further investigation showed [E1]a partial seizur[/E1]e and a focal T2 hyperintense thalamic lesion. A known variant in th[E2]e PO[/E2]LG gene was identified.",e PO,GENE_VARIANT,190,194,a partial seizur,HPO_TERM,106,122,0.7785754,0.22142465,-0.5571508,0
line617,"This report details Patient Y17, a patient with a rhythmic shaking movement. Further investigation showed a partial seizure and a focal T2 hyperintense thalamic lesion. A known variant in the POLG gene was identified.","This report details Patient Y17, a patient with a rhythmic shaking movement. Further investigation showed a partial seizure and[E1] a focal T2 hyperintense thalamic lesi[/E1]on. A known variant in th[E2]e PO[/E2]LG gene was identified.",e PO,GENE_VARIANT,190,194, a focal T2 hyperintense thalamic lesi,HPO_TERM,127,165,0.78436923,0.21563078,-0.56873846,0
line618,The primary symptoms for Patient Y18 were difficulty looking upwards and seizures with a localized origin. Analysis of the POLG gene was performed.,The primary symptoms for Patient Y18 were di[E1]fficulty looking upwards [/E1]and seizures with a localized origin. Analysis of the POLG gen[E2]e wa[/E2]s performed.,e wa,GENE_VARIANT,131,135,fficulty looking upwards ,HPO_TERM,44,69,0.7741919,0.22580802,-0.5483839,0
line618,The primary symptoms for Patient Y18 were difficulty looking upwards and seizures with a localized origin. Analysis of the POLG gene was performed.,The primary symptoms for Patient Y18 were difficulty looking upwards and s[E1]eizures with a localized origin[/E1]. Analysis of the POLG gen[E2]e wa[/E2]s performed.,e wa,GENE_VARIANT,131,135,eizures with a localized origin,HPO_TERM,74,105,0.76916426,0.23083569,-0.5383286,0
line619,"This report details Patient Y19, a patient with a focal-onset seizure. Further investigation showed a focal bright signal on T2 MRI of the thalamus and a history of significant weight loss. A known variant in the POLG gene was identified.","This report details Patient Y19, a patient with [E1]a focal-onset seizur[/E1]e. Further investigation showed a focal bright signal on T2 MRI of the thalamus and a history of significant weight loss. A known variant in[E2] the[/E2] POLG gene was identified.", the,GENE_VARIANT,208,212,a focal-onset seizur,HPO_TERM,48,68,0.68776786,0.31223223,-0.37553564,0
line619,"This report details Patient Y19, a patient with a focal-onset seizure. Further investigation showed a focal bright signal on T2 MRI of the thalamus and a history of significant weight loss. A known variant in the POLG gene was identified.","This report details Patient Y19, a patient with a focal-onset seizure. Further investigation showed[E1] a focal bright signal on T2 MRI of the thal[/E1]amus and a history of significant weight loss. A known variant in[E2] the[/E2] POLG gene was identified.", the,GENE_VARIANT,208,212, a focal bright signal on T2 MRI of the thal,HPO_TERM,99,143,0.74140096,0.258599,-0.48280194,0
line619,"This report details Patient Y19, a patient with a focal-onset seizure. Further investigation showed a focal bright signal on T2 MRI of the thalamus and a history of significant weight loss. A known variant in the POLG gene was identified.","This report details Patient Y19, a patient with a focal-onset seizure. Further investigation showed a focal bright signal on T2 MRI of the thalamus [E1]and a history of significant weight[/E1] loss. A known variant in[E2] the[/E2] POLG gene was identified.", the,GENE_VARIANT,208,212,and a history of significant weight,HPO_TERM,148,183,0.70691186,0.29308817,-0.4138237,0
line620,The clinical profile for Patient Y20 includes difficulty looking upwards and a partial seizure. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Y20 includes [E1]difficulty looking upward[/E1]s and a partial seizure. Genetic analysis of th[E2]e PO[/E2]LG gene confirmed the diagnosis.,e PO,GENE_VARIANT,118,122,difficulty looking upward,HPO_TERM,46,71,0.8240212,0.1759787,-0.6480425,0
line620,The clinical profile for Patient Y20 includes difficulty looking upwards and a partial seizure. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Y20 includes difficulty looking upwards and[E1] a partial seizu[/E1]re. Genetic analysis of th[E2]e PO[/E2]LG gene confirmed the diagnosis.,e PO,GENE_VARIANT,118,122, a partial seizu,HPO_TERM,76,92,0.84831226,0.15168773,-0.6966245,0
line621,The clinical profile for Patient Y21 includes progressive loss of weight and a tremor. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Y21 includes [E1]progressive loss of weight[/E1] and a tremor. Genetic analysis of the[E2] POL[/E2]G gene confirmed the diagnosis., POL,GENE_VARIANT,110,114,progressive loss of weight,HPO_TERM,46,72,0.8169858,0.18301423,-0.6339716,0
line621,The clinical profile for Patient Y21 includes progressive loss of weight and a tremor. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Y21 includes progressive loss of weight and [E1]a tremo[/E1]r. Genetic analysis of the[E2] POL[/E2]G gene confirmed the diagnosis., POL,GENE_VARIANT,110,114,a tremo,HPO_TERM,77,84,0.83799684,0.16200323,-0.6759936,0
line622,The primary symptoms for Patient Y22 were a tremor and seizures originating in one area of the brain. Analysis of the POLG gene was performed.,The primary symptoms for Patient Y22 were a [E1]tremor [/E1]and seizures originating in one area of the brain. Analysis of the POLG g[E2]ene [/E2]was performed.,ene ,GENE_VARIANT,124,128,tremor ,HPO_TERM,44,51,0.7890783,0.21092165,-0.57815665,0
line622,The primary symptoms for Patient Y22 were a tremor and seizures originating in one area of the brain. Analysis of the POLG gene was performed.,The primary symptoms for Patient Y22 were a tremor and s[E1]eizures originating in one area of the bra[/E1]in. Analysis of the POLG g[E2]ene [/E2]was performed.,ene ,GENE_VARIANT,124,128,eizures originating in one area of the bra,HPO_TERM,56,98,0.7883482,0.21165185,-0.57669634,0
line623,The primary symptoms for Patient Y23 were a focal T2 hyperintense thalamic lesion and a soft or quiet voice. Analysis of the POLG gene was performed.,The primary symptoms for Patient Y23 were a [E1]focal T2 hyperintense thalamic lesion [/E1]and a soft or quiet voice. Analysis of the POLG ge[E2]ne w[/E2]as performed.,ne w,GENE_VARIANT,132,136,focal T2 hyperintense thalamic lesion ,HPO_TERM,44,82,0.7803112,0.21968876,-0.56062245,0
line623,The primary symptoms for Patient Y23 were a focal T2 hyperintense thalamic lesion and a soft or quiet voice. Analysis of the POLG gene was performed.,The primary symptoms for Patient Y23 were a focal T2 hyperintense thalamic lesion and a[E1] soft or quiet voic[/E1]e. Analysis of the POLG ge[E2]ne w[/E2]as performed.,ne w,GENE_VARIANT,132,136, soft or quiet voic,HPO_TERM,87,106,0.83516526,0.16483475,-0.6703305,0
line624,"This report details Patient Y24, a patient with an unexplained drop in weight. Further investigation showed a weak voice and a focal T2 hyperintense thalamic lesion. A known variant in the POLG gene was identified.","This report details Patient Y24, a patient with [E1]an unexplained drop in weight[/E1]. Further investigation showed a weak voice and a focal T2 hyperintense thalamic lesion. A known variant in the[E2] POL[/E2]G gene was identified.", POL,GENE_VARIANT,188,192,an unexplained drop in weight,HPO_TERM,48,77,0.76454896,0.23545112,-0.52909786,0
line624,"This report details Patient Y24, a patient with an unexplained drop in weight. Further investigation showed a weak voice and a focal T2 hyperintense thalamic lesion. A known variant in the POLG gene was identified.","This report details Patient Y24, a patient with an unexplained drop in weight. Further investigation showed [E1]a weak voice[/E1] and a focal T2 hyperintense thalamic lesion. A known variant in the[E2] POL[/E2]G gene was identified.", POL,GENE_VARIANT,188,192,a weak voice,HPO_TERM,108,120,0.768171,0.231829,-0.536342,0
line624,"This report details Patient Y24, a patient with an unexplained drop in weight. Further investigation showed a weak voice and a focal T2 hyperintense thalamic lesion. A known variant in the POLG gene was identified.","This report details Patient Y24, a patient with an unexplained drop in weight. Further investigation showed a weak voice and [E1]a focal T2 hyperintense thalamic lesio[/E1]n. A known variant in the[E2] POL[/E2]G gene was identified.", POL,GENE_VARIANT,188,192,a focal T2 hyperintense thalamic lesio,HPO_TERM,125,163,0.8202568,0.17974325,-0.6405136,0
line625,The primary symptoms for Patient Y25 were bilateral tonic-clonic seizures and a focal-onset seizure. Analysis of the POLG gene was performed.,The primary symptoms for Patient Y25 were bi[E1]lateral tonic-clonic seizures a[/E1]nd a focal-onset seizure. Analysis of the POLG gene[E2] was[/E2] performed., was,GENE_VARIANT,126,130,lateral tonic-clonic seizures a,HPO_TERM,44,75,0.84336287,0.1566372,-0.6867257,0
line626,"We report the case of Patient Y26, who has a history of a decrease in body mass. Examination also revealed a tremor. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Y26, who has a history of [E1]a decrease in body mass[/E1]. Examination also revealed a tremor. The underlying cause was traced to a mutation in the[E2] POL[/E2]G gene.", POL,GENE_VARIANT,169,173,a decrease in body mass,HPO_TERM,56,79,0.50872296,0.491277,-0.017445952,0
line626,"We report the case of Patient Y26, who has a history of a decrease in body mass. Examination also revealed a tremor. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Y26, who has a history of a decrease in body mass. Examination also revealed [E1]a tremo[/E1]r. The underlying cause was traced to a mutation in the[E2] POL[/E2]G gene.", POL,GENE_VARIANT,169,173,a tremo,HPO_TERM,107,114,0.40828374,0.59171623,0.18343249,1
line627,The clinical profile for Patient Y27 includes focal seizures and a focal-onset seizure. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Y27 includes [E1]focal seizures[/E1] and a focal-onset seizure. Genetic analysis of the[E2] POL[/E2]G gene confirmed the diagnosis., POL,GENE_VARIANT,111,115,focal seizures,HPO_TERM,46,60,0.8150115,0.18498847,-0.630023,0
line627,The clinical profile for Patient Y27 includes focal seizures and a focal-onset seizure. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Y27 includes focal seizures and [E1]a focal-onset seizur[/E1]e. Genetic analysis of the[E2] POL[/E2]G gene confirmed the diagnosis., POL,GENE_VARIANT,111,115,a focal-onset seizur,HPO_TERM,65,85,0.844767,0.15523304,-0.68953395,0
line628,Patient Y28 was evaluated for a tremor. The patient also presented with seizures with a localized origin and a focal bright signal on T2 MRI of the thalamus. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y28 was evaluated for [E1]a tremo[/E1]r. The patient also presented with seizures with a localized origin and a focal bright signal on T2 MRI of the thalamus. Subsequent sequencing of[E2] the[/E2] POLG gene revealed a pathogenic variant., the,GENE_VARIANT,182,186,a tremo,HPO_TERM,30,37,0.8011826,0.19881742,-0.6023652,0
line628,Patient Y28 was evaluated for a tremor. The patient also presented with seizures with a localized origin and a focal bright signal on T2 MRI of the thalamus. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y28 was evaluated for a tremor. The patient also presented with[E1] seizures with a localized orig[/E1]in and a focal bright signal on T2 MRI of the thalamus. Subsequent sequencing of[E2] the[/E2] POLG gene revealed a pathogenic variant., the,GENE_VARIANT,182,186, seizures with a localized orig,HPO_TERM,71,102,0.75920486,0.24079517,-0.5184097,0
line628,Patient Y28 was evaluated for a tremor. The patient also presented with seizures with a localized origin and a focal bright signal on T2 MRI of the thalamus. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y28 was evaluated for a tremor. The patient also presented with seizures with a localized origin an[E1]d a focal bright signal on T2 MRI of the tha[/E1]lamus. Subsequent sequencing of[E2] the[/E2] POLG gene revealed a pathogenic variant., the,GENE_VARIANT,182,186,d a focal bright signal on T2 MRI of the tha,HPO_TERM,107,151,0.79657096,0.2034291,-0.59314185,0
line629,"We report the case of Patient Y29, who has a history of hypophonia. Examination also revealed a focal T2 hyperintense thalamic lesion. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Y29, who has a history of [E1]hypophonia[/E1]. Examination also revealed a focal T2 hyperintense thalamic lesion. The underlying cause was traced to a mutation in the[E2] POL[/E2]G gene.", POL,GENE_VARIANT,187,191,hypophonia,HPO_TERM,56,66,0.3640794,0.6359206,0.2718412,1
line629,"We report the case of Patient Y29, who has a history of hypophonia. Examination also revealed a focal T2 hyperintense thalamic lesion. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Y29, who has a history of hypophonia. Examination also revealed [E1]a focal T2 hyperintense thalamic lesio[/E1]n. The underlying cause was traced to a mutation in the[E2] POL[/E2]G gene.", POL,GENE_VARIANT,187,191,a focal T2 hyperintense thalamic lesio,HPO_TERM,94,132,0.3966161,0.60338396,0.20676786,1
line630,Patient Y30 was evaluated for a focal-onset seizure. The patient also presented with feelings of anxiety and seizures with a localized origin. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y30 was evaluated for [E1]a focal-onset seizur[/E1]e. The patient also presented with feelings of anxiety and seizures with a localized origin. Subsequent sequencing of th[E2]e PO[/E2]LG gene revealed a pathogenic variant.,e PO,GENE_VARIANT,170,174,a focal-onset seizur,HPO_TERM,30,50,0.8801505,0.119849466,-0.76030105,0
line630,Patient Y30 was evaluated for a focal-onset seizure. The patient also presented with feelings of anxiety and seizures with a localized origin. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y30 was evaluated for a focal-onset seizure. The patient also presented with[E1] feelings of anxiet[/E1]y and seizures with a localized origin. Subsequent sequencing of th[E2]e PO[/E2]LG gene revealed a pathogenic variant.,e PO,GENE_VARIANT,170,174, feelings of anxiet,HPO_TERM,84,103,0.87170553,0.12829445,-0.74341106,0
line630,Patient Y30 was evaluated for a focal-onset seizure. The patient also presented with feelings of anxiety and seizures with a localized origin. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y30 was evaluated for a focal-onset seizure. The patient also presented with feelings of anxiety and[E1] seizures with a localized orig[/E1]in. Subsequent sequencing of th[E2]e PO[/E2]LG gene revealed a pathogenic variant.,e PO,GENE_VARIANT,170,174, seizures with a localized orig,HPO_TERM,108,139,0.8540139,0.1459861,-0.70802784,0
line631,"This report details Patient Y31, a patient with a weak voice. Further investigation showed a focal-onset seizure and decreased liver function. A known variant in the POLG gene was identified.","This report details Patient Y31, a patient with [E1]a weak voice[/E1]. Further investigation showed a focal-onset seizure and decreased liver function. A known variant in the[E2] POL[/E2]G gene was identified.", POL,GENE_VARIANT,165,169,a weak voice,HPO_TERM,48,60,0.7953684,0.20463161,-0.59073675,0
line631,"This report details Patient Y31, a patient with a weak voice. Further investigation showed a focal-onset seizure and decreased liver function. A known variant in the POLG gene was identified.","This report details Patient Y31, a patient with a weak voice. Further investigation showed [E1]a focal-onset seizur[/E1]e and decreased liver function. A known variant in the[E2] POL[/E2]G gene was identified.", POL,GENE_VARIANT,165,169,a focal-onset seizur,HPO_TERM,91,111,0.8080061,0.19199383,-0.6160123,0
line631,"This report details Patient Y31, a patient with a weak voice. Further investigation showed a focal-onset seizure and decreased liver function. A known variant in the POLG gene was identified.","This report details Patient Y31, a patient with a weak voice. Further investigation showed a focal-onset seizure and[E1] decreased liver functio[/E1]n. A known variant in the[E2] POL[/E2]G gene was identified.", POL,GENE_VARIANT,165,169, decreased liver functio,HPO_TERM,116,140,0.8350197,0.16498034,-0.67003936,0
line632,"We report the case of Patient Y32, who has a history of a very quiet speaking voice. Examination also revealed anxiety. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Y32, who has a history of [E1]a very quiet speaking voic[/E1]e. Examination also revealed anxiety. The underlying cause was traced to a mutation in the[E2] POL[/E2]G gene.", POL,GENE_VARIANT,172,176,a very quiet speaking voic,HPO_TERM,56,82,0.63105077,0.36894932,-0.26210144,0
line632,"We report the case of Patient Y32, who has a history of a very quiet speaking voice. Examination also revealed anxiety. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Y32, who has a history of a very quiet speaking voice. Examination also revealed[E1] anxiet[/E1]y. The underlying cause was traced to a mutation in the[E2] POL[/E2]G gene.", POL,GENE_VARIANT,172,176, anxiet,HPO_TERM,110,117,0.5300695,0.46993056,-0.06013891,0
line633,"We report the case of Patient Y33, who has a history of a very quiet speaking voice. Examination also revealed a history of anxiety. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Y33, who has a history of [E1]a very quiet speaking voic[/E1]e. Examination also revealed a history of anxiety. The underlying cause was traced to a mutation in th[E2]e PO[/E2]LG gene.",e PO,GENE_VARIANT,184,188,a very quiet speaking voic,HPO_TERM,56,82,0.6884647,0.31153524,-0.37692946,0
line633,"We report the case of Patient Y33, who has a history of a very quiet speaking voice. Examination also revealed a history of anxiety. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Y33, who has a history of a very quiet speaking voice. Examination also revealed[E1] a history of anxie[/E1]ty. The underlying cause was traced to a mutation in th[E2]e PO[/E2]LG gene.",e PO,GENE_VARIANT,184,188, a history of anxie,HPO_TERM,110,129,0.5538737,0.44612625,-0.107747465,0
line634,The primary symptoms for Patient Y34 were focal seizures and progressive loss of weight. Analysis of the POLG gene was performed.,The primary symptoms for Patient Y34 were fo[E1]cal seizures a[/E1]nd progressive loss of weight. Analysis of the POLG gene [E2]was [/E2]performed.,was ,GENE_VARIANT,115,119,cal seizures a,HPO_TERM,44,58,0.8363349,0.16366504,-0.6726698,0
line635,"We report the case of Patient Y35, who has a history of a focal bright signal on T2 MRI of the thalamus. Examination also revealed a focal-onset seizure. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Y35, who has a history of [E1]a focal bright signal on T2 MRI of the thala[/E1]mus. Examination also revealed a focal-onset seizure. The underlying cause was traced to a mutation in [E2]the [/E2]POLG gene.",the ,GENE_VARIANT,203,207,a focal bright signal on T2 MRI of the thala,HPO_TERM,56,100,0.17298982,0.82701015,0.6540203,1
line635,"We report the case of Patient Y35, who has a history of a focal bright signal on T2 MRI of the thalamus. Examination also revealed a focal-onset seizure. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Y35, who has a history of a focal bright signal on T2 MRI of the thalamus. Examination also reveal[E1]ed a focal-onset sei[/E1]zure. The underlying cause was traced to a mutation in [E2]the [/E2]POLG gene.",the ,GENE_VARIANT,203,207,ed a focal-onset sei,HPO_TERM,128,148,0.40315437,0.5968456,0.19369125,1
line636,The clinical profile for Patient Y36 includes impaired liver function and a focal T2 hyperintense thalamic lesion. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Y36 includes [E1]impaired liver function[/E1] and a focal T2 hyperintense thalamic lesion. Genetic analysis of the[E2] POL[/E2]G gene confirmed the diagnosis., POL,GENE_VARIANT,138,142,impaired liver function,HPO_TERM,46,69,0.8117836,0.18821643,-0.62356716,0
line636,The clinical profile for Patient Y36 includes impaired liver function and a focal T2 hyperintense thalamic lesion. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Y36 includes impaired liver function and [E1]a focal T2 hyperintense thalamic lesio[/E1]n. Genetic analysis of the[E2] POL[/E2]G gene confirmed the diagnosis., POL,GENE_VARIANT,138,142,a focal T2 hyperintense thalamic lesio,HPO_TERM,74,112,0.84489894,0.15510102,-0.68979794,0
line637,"We report the case of Patient Y37, who has a history of anxiety. Examination also revealed a vertical gaze palsy affecting upgaze. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Y37, who has a history of [E1]anxiety[/E1]. Examination also revealed a vertical gaze palsy affecting upgaze. The underlying cause was traced to a mutation in the[E2] POL[/E2]G gene.", POL,GENE_VARIANT,183,187,anxiety,HPO_TERM,56,63,0.46725938,0.53274065,0.065481275,1
line637,"We report the case of Patient Y37, who has a history of anxiety. Examination also revealed a vertical gaze palsy affecting upgaze. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Y37, who has a history of anxiety. Examination also revealed [E1]a vertical gaze palsy affecting upgaz[/E1]e. The underlying cause was traced to a mutation in the[E2] POL[/E2]G gene.", POL,GENE_VARIANT,183,187,a vertical gaze palsy affecting upgaz,HPO_TERM,91,128,0.45474207,0.5452579,0.09051585,1
line638,The primary symptoms for Patient Y38 were anxiety and a focal bright signal on T2 MRI of the thalamus. Analysis of the POLG gene was performed.,The primary symptoms for Patient Y38 were an[E1]xiety a[/E1]nd a focal bright signal on T2 MRI of the thalamus. Analysis of the POLG ge[E2]ne w[/E2]as performed.,ne w,GENE_VARIANT,126,130,xiety a,HPO_TERM,44,51,0.8066589,0.1933411,-0.61331785,0
line638,The primary symptoms for Patient Y38 were anxiety and a focal bright signal on T2 MRI of the thalamus. Analysis of the POLG gene was performed.,The primary symptoms for Patient Y38 were anxiety and a [E1]focal bright signal on T2 MRI of the thalamu[/E1]s. Analysis of the POLG ge[E2]ne w[/E2]as performed.,ne w,GENE_VARIANT,126,130,focal bright signal on T2 MRI of the thalamu,HPO_TERM,56,100,0.8242961,0.1757039,-0.64859223,0
line639,Patient Y39 was evaluated for an expressionless face. The patient also presented with a soft or quiet voice and a simple partial seizure. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y39 was evaluated for [E1]an expressionless fac[/E1]e. The patient also presented with a soft or quiet voice and a simple partial seizure. Subsequent sequencing of[E2] the[/E2] POLG gene revealed a pathogenic variant., the,GENE_VARIANT,162,166,an expressionless fac,HPO_TERM,30,51,0.83783805,0.16216192,-0.6756761,0
line639,Patient Y39 was evaluated for an expressionless face. The patient also presented with a soft or quiet voice and a simple partial seizure. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y39 was evaluated for an expressionless face. The patient also presented with[E1] a soft or quiet vo[/E1]ice and a simple partial seizure. Subsequent sequencing of[E2] the[/E2] POLG gene revealed a pathogenic variant., the,GENE_VARIANT,162,166, a soft or quiet vo,HPO_TERM,85,104,0.75876826,0.24123174,-0.5175365,0
line639,Patient Y39 was evaluated for an expressionless face. The patient also presented with a soft or quiet voice and a simple partial seizure. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y39 was evaluated for an expressionless face. The patient also presented with a soft or quiet voice a[E1]nd a simple partial se[/E1]izure. Subsequent sequencing of[E2] the[/E2] POLG gene revealed a pathogenic variant., the,GENE_VARIANT,162,166,nd a simple partial se,HPO_TERM,109,131,0.8509749,0.14902502,-0.7019499,0
line640,The primary symptoms for Patient Y40 were a rhythmic shaking movement and a tremor. Analysis of the POLG gene was performed.,The primary symptoms for Patient Y40 were a [E1]rhythmic shaking movement a[/E1]nd a tremor. Analysis of the POLG gene[E2] was[/E2] performed., was,GENE_VARIANT,109,113,rhythmic shaking movement a,HPO_TERM,44,71,0.83092856,0.1690714,-0.6618571,0
line641,"This report details Patient Y41, a patient with a focal-onset seizure. Further investigation showed a vertical gaze palsy affecting upgaze and a weak voice. A known variant in the POLG gene was identified.","This report details Patient Y41, a patient with [E1]a focal-onset seizur[/E1]e. Further investigation showed a vertical gaze palsy affecting upgaze and a weak voice. A known variant in th[E2]e PO[/E2]LG gene was identified.",e PO,GENE_VARIANT,178,182,a focal-onset seizur,HPO_TERM,48,68,0.82144076,0.17855929,-0.64288145,0
line641,"This report details Patient Y41, a patient with a focal-onset seizure. Further investigation showed a vertical gaze palsy affecting upgaze and a weak voice. A known variant in the POLG gene was identified.","This report details Patient Y41, a patient with a focal-onset seizure. Further investigation showed[E1] a vertical gaze palsy affecting upga[/E1]ze and a weak voice. A known variant in th[E2]e PO[/E2]LG gene was identified.",e PO,GENE_VARIANT,178,182, a vertical gaze palsy affecting upga,HPO_TERM,99,136,0.78220797,0.21779206,-0.56441593,0
line641,"This report details Patient Y41, a patient with a focal-onset seizure. Further investigation showed a vertical gaze palsy affecting upgaze and a weak voice. A known variant in the POLG gene was identified.","This report details Patient Y41, a patient with a focal-onset seizure. Further investigation showed a vertical gaze palsy affecting upgaze an[E1]d a weak voi[/E1]ce. A known variant in th[E2]e PO[/E2]LG gene was identified.",e PO,GENE_VARIANT,178,182,d a weak voi,HPO_TERM,141,153,0.81531096,0.18468904,-0.6306219,0
line642,"This report details Patient Y42, a patient with a focal T2 hyperintense thalamic lesion. Further investigation showed a partial seizure and a soft or quiet voice. A known variant in the POLG gene was identified.","This report details Patient Y42, a patient with [E1]a focal T2 hyperintense thalamic lesio[/E1]n. Further investigation showed a partial seizure and a soft or quiet voice. A known variant in [E2]the [/E2]POLG gene was identified.",the ,GENE_VARIANT,182,186,a focal T2 hyperintense thalamic lesio,HPO_TERM,48,86,0.766069,0.23393098,-0.532138,0
line642,"This report details Patient Y42, a patient with a focal T2 hyperintense thalamic lesion. Further investigation showed a partial seizure and a soft or quiet voice. A known variant in the POLG gene was identified.","This report details Patient Y42, a patient with a focal T2 hyperintense thalamic lesion. Further investigation showed[E1] a partial seizu[/E1]re and a soft or quiet voice. A known variant in [E2]the [/E2]POLG gene was identified.",the ,GENE_VARIANT,182,186, a partial seizu,HPO_TERM,117,133,0.72316235,0.27683765,-0.4463247,0
line642,"This report details Patient Y42, a patient with a focal T2 hyperintense thalamic lesion. Further investigation showed a partial seizure and a soft or quiet voice. A known variant in the POLG gene was identified.","This report details Patient Y42, a patient with a focal T2 hyperintense thalamic lesion. Further investigation showed a partial seizure an[E1]d a soft or quiet v[/E1]oice. A known variant in [E2]the [/E2]POLG gene was identified.",the ,GENE_VARIANT,182,186,d a soft or quiet v,HPO_TERM,138,157,0.7526223,0.24737762,-0.5052447,0
line643,The primary symptoms for Patient Y43 were a tremor and an involuntary trembling or shaking. Analysis of the POLG gene was performed.,The primary symptoms for Patient Y43 were a [E1]tremor [/E1]and an involuntary trembling or shaking. Analysis of the POLG gen[E2]e wa[/E2]s performed.,e wa,GENE_VARIANT,116,120,tremor ,HPO_TERM,44,51,0.6710673,0.3289328,-0.3421345,0
line643,The primary symptoms for Patient Y43 were a tremor and an involuntary trembling or shaking. Analysis of the POLG gene was performed.,The primary symptoms for Patient Y43 were a tremor and a[E1]n involuntary trembling or shaking[/E1]. Analysis of the POLG gen[E2]e wa[/E2]s performed.,e wa,GENE_VARIANT,116,120,n involuntary trembling or shaking,HPO_TERM,56,90,0.65671974,0.34328035,-0.3134394,0
line644,The clinical profile for Patient Y44 includes feelings of anxiety and a focal-onset seizure. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Y44 includes [E1]feelings of anxiety[/E1] and a focal-onset seizure. Genetic analysis of the[E2] POL[/E2]G gene confirmed the diagnosis., POL,GENE_VARIANT,116,120,feelings of anxiety,HPO_TERM,46,65,0.82324284,0.17675722,-0.6464856,0
line644,The clinical profile for Patient Y44 includes feelings of anxiety and a focal-onset seizure. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Y44 includes feelings of anxiety and [E1]a focal-onset seizur[/E1]e. Genetic analysis of the[E2] POL[/E2]G gene confirmed the diagnosis., POL,GENE_VARIANT,116,120,a focal-onset seizur,HPO_TERM,70,90,0.8572682,0.1427318,-0.7145364,0
line645,Patient Y45 was evaluated for a resting tremor. The patient also presented with a diagnosis of focal-onset seizures and a decrease in body mass. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y45 was evaluated for [E1]a resting tremo[/E1]r. The patient also presented with a diagnosis of focal-onset seizures and a decrease in body mass. Subsequent sequencing of the[E2] POL[/E2]G gene revealed a pathogenic variant., POL,GENE_VARIANT,173,177,a resting tremo,HPO_TERM,30,45,0.84047854,0.15952149,-0.6809571,0
line645,Patient Y45 was evaluated for a resting tremor. The patient also presented with a diagnosis of focal-onset seizures and a decrease in body mass. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y45 was evaluated for a resting tremor. The patient also presented with[E1] a diagnosis of focal-onset seizure[/E1]s and a decrease in body mass. Subsequent sequencing of the[E2] POL[/E2]G gene revealed a pathogenic variant., POL,GENE_VARIANT,173,177, a diagnosis of focal-onset seizure,HPO_TERM,79,114,0.8402211,0.15977888,-0.6804422,0
line645,Patient Y45 was evaluated for a resting tremor. The patient also presented with a diagnosis of focal-onset seizures and a decrease in body mass. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y45 was evaluated for a resting tremor. The patient also presented with a diagnosis of focal-onset seizures and[E1] a decrease in body mas[/E1]s. Subsequent sequencing of the[E2] POL[/E2]G gene revealed a pathogenic variant., POL,GENE_VARIANT,173,177, a decrease in body mas,HPO_TERM,119,142,0.84058696,0.15941305,-0.6811739,0
line646,The clinical profile for Patient Y46 includes a decrease in body mass and poor liver function. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Y46 includes [E1]a decrease in body mass[/E1] and poor liver function. Genetic analysis of the[E2] POL[/E2]G gene confirmed the diagnosis., POL,GENE_VARIANT,118,122,a decrease in body mass,HPO_TERM,46,69,0.8352986,0.16470145,-0.67059714,0
line646,The clinical profile for Patient Y46 includes a decrease in body mass and poor liver function. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Y46 includes a decrease in body mass and [E1]poor liver functio[/E1]n. Genetic analysis of the[E2] POL[/E2]G gene confirmed the diagnosis., POL,GENE_VARIANT,118,122,poor liver functio,HPO_TERM,74,92,0.86348957,0.13651034,-0.72697926,0
line647,The clinical profile for Patient Y47 includes anxiety and a simple partial seizure. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Y47 includes [E1]anxiety[/E1] and a simple partial seizure. Genetic analysis of th[E2]e PO[/E2]LG gene confirmed the diagnosis.,e PO,GENE_VARIANT,106,110,anxiety,HPO_TERM,46,53,0.8332808,0.16671918,-0.6665616,0
line647,The clinical profile for Patient Y47 includes anxiety and a simple partial seizure. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Y47 includes anxiety and [E1]a simple partial seizu[/E1]re. Genetic analysis of th[E2]e PO[/E2]LG gene confirmed the diagnosis.,e PO,GENE_VARIANT,106,110,a simple partial seizu,HPO_TERM,58,80,0.8589818,0.14101827,-0.7179635,0
line648,"This report details Patient Y48, a patient with impaired liver function. Further investigation showed a focal-onset seizure and a focal T2 hyperintense thalamic lesion. A known variant in the POLG gene was identified.","This report details Patient Y48, a patient with [E1]impaired liver function[/E1]. Further investigation showed a focal-onset seizure and a focal T2 hyperintense thalamic lesion. A known variant in th[E2]e PO[/E2]LG gene was identified.",e PO,GENE_VARIANT,190,194,impaired liver function,HPO_TERM,48,71,0.8071415,0.1928585,-0.61428297,0
line648,"This report details Patient Y48, a patient with impaired liver function. Further investigation showed a focal-onset seizure and a focal T2 hyperintense thalamic lesion. A known variant in the POLG gene was identified.","This report details Patient Y48, a patient with impaired liver function. Further investigation showed [E1]a focal-onset seizur[/E1]e and a focal T2 hyperintense thalamic lesion. A known variant in th[E2]e PO[/E2]LG gene was identified.",e PO,GENE_VARIANT,190,194,a focal-onset seizur,HPO_TERM,102,122,0.83054054,0.16945946,-0.6610811,0
line648,"This report details Patient Y48, a patient with impaired liver function. Further investigation showed a focal-onset seizure and a focal T2 hyperintense thalamic lesion. A known variant in the POLG gene was identified.","This report details Patient Y48, a patient with impaired liver function. Further investigation showed a focal-onset seizure and[E1] a focal T2 hyperintense thalamic lesi[/E1]on. A known variant in th[E2]e PO[/E2]LG gene was identified.",e PO,GENE_VARIANT,190,194, a focal T2 hyperintense thalamic lesi,HPO_TERM,127,165,0.82009417,0.17990579,-0.6401884,0
line649,The clinical profile for Patient Y49 includes a tremor and a weak voice. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Y49 includes [E1]a tremo[/E1]r and a weak voice. Genetic analysis of the[E2] POL[/E2]G gene confirmed the diagnosis., POL,GENE_VARIANT,96,100,a tremo,HPO_TERM,46,53,0.8315738,0.16842622,-0.66314757,0
line649,The clinical profile for Patient Y49 includes a tremor and a weak voice. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Y49 includes a tremor and[E1] a weak voic[/E1]e. Genetic analysis of the[E2] POL[/E2]G gene confirmed the diagnosis., POL,GENE_VARIANT,96,100, a weak voic,HPO_TERM,58,70,0.85422426,0.14577575,-0.7084485,0
line650,Patient Y50 was evaluated for weight loss. The patient also presented with bilateral grand mal seizures and a focal-onset seizure. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y50 was evaluated for [E1]weight loss[/E1]. The patient also presented with bilateral grand mal seizures and a focal-onset seizure. Subsequent sequencing of the[E2] POL[/E2]G gene revealed a pathogenic variant., POL,GENE_VARIANT,159,163,weight loss,HPO_TERM,30,41,0.8131632,0.18683678,-0.62632644,0
line650,Patient Y50 was evaluated for weight loss. The patient also presented with bilateral grand mal seizures and a focal-onset seizure. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y50 was evaluated for weight loss. The patient also presented with [E1]bilateral grand mal seizures[/E1] and a focal-onset seizure. Subsequent sequencing of the[E2] POL[/E2]G gene revealed a pathogenic variant., POL,GENE_VARIANT,159,163,bilateral grand mal seizures,HPO_TERM,75,103,0.807522,0.19247797,-0.615044,0
line650,Patient Y50 was evaluated for weight loss. The patient also presented with bilateral grand mal seizures and a focal-onset seizure. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y50 was evaluated for weight loss. The patient also presented with bilateral grand mal seizures and [E1]a focal-onset seizur[/E1]e. Subsequent sequencing of the[E2] POL[/E2]G gene revealed a pathogenic variant., POL,GENE_VARIANT,159,163,a focal-onset seizur,HPO_TERM,108,128,0.84318304,0.15681696,-0.6863661,0
line651,The primary symptoms for Patient Y51 were bilateral tonic-clonic seizures and a history of anxiety. Analysis of the POLG gene was performed.,The primary symptoms for Patient Y51 were bi[E1]lateral tonic-clonic seizures a[/E1]nd a history of anxiety. Analysis of the POLG gene[E2] was[/E2] performed., was,GENE_VARIANT,125,129,lateral tonic-clonic seizures a,HPO_TERM,44,75,0.8256985,0.17430149,-0.651397,0
line652,Patient Y52 was evaluated for impaired liver function. The patient also presented with seizures with a localized origin and a tremor. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y52 was evaluated for [E1]impaired liver function[/E1]. The patient also presented with seizures with a localized origin and a tremor. Subsequent sequencing of th[E2]e PO[/E2]LG gene revealed a pathogenic variant.,e PO,GENE_VARIANT,161,165,impaired liver function,HPO_TERM,30,53,0.87847954,0.12152047,-0.7569591,0
line652,Patient Y52 was evaluated for impaired liver function. The patient also presented with seizures with a localized origin and a tremor. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y52 was evaluated for impaired liver function. The patient also presented with [E1]seizures with a localized origi[/E1]n and a tremor. Subsequent sequencing of th[E2]e PO[/E2]LG gene revealed a pathogenic variant.,e PO,GENE_VARIANT,161,165,seizures with a localized origi,HPO_TERM,87,118,0.86490536,0.13509466,-0.7298107,0
line652,Patient Y52 was evaluated for impaired liver function. The patient also presented with seizures with a localized origin and a tremor. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y52 was evaluated for impaired liver function. The patient also presented with seizures with a localized origin and[E1] a trem[/E1]or. Subsequent sequencing of th[E2]e PO[/E2]LG gene revealed a pathogenic variant.,e PO,GENE_VARIANT,161,165, a trem,HPO_TERM,123,130,0.87205666,0.12794334,-0.7441133,0
line653,Patient Y53 was evaluated for seizures with a localized origin. The patient also presented with a focal T2 hyperintense thalamic lesion and a soft or quiet voice. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y53 was evaluated for [E1]seizures with a localized origi[/E1]n. The patient also presented with a focal T2 hyperintense thalamic lesion and a soft or quiet voice. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,188,192,seizures with a localized origi,HPO_TERM,30,61,0.78161055,0.21838945,-0.5632211,0
line653,Patient Y53 was evaluated for seizures with a localized origin. The patient also presented with a focal T2 hyperintense thalamic lesion and a soft or quiet voice. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y53 was evaluated for seizures with a localized origin. The patient also presented with[E1] a focal T2 hyperintense thalamic lesi[/E1]on and a soft or quiet voice. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,188,192, a focal T2 hyperintense thalamic lesi,HPO_TERM,95,133,0.7703961,0.22960392,-0.5407922,0
line653,Patient Y53 was evaluated for seizures with a localized origin. The patient also presented with a focal T2 hyperintense thalamic lesion and a soft or quiet voice. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y53 was evaluated for seizures with a localized origin. The patient also presented with a focal T2 hyperintense thalamic lesion an[E1]d a soft or quiet v[/E1]oice. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,188,192,d a soft or quiet v,HPO_TERM,138,157,0.8015269,0.1984731,-0.6030538,0
line654,The primary symptoms for Patient Y54 were bilateral tonic-clonic seizures and a weak voice. Analysis of the POLG gene was performed.,The primary symptoms for Patient Y54 were bi[E1]lateral tonic-clonic seizures a[/E1]nd a weak voice. Analysis of the POLG gene [E2]was [/E2]performed.,was ,GENE_VARIANT,118,122,lateral tonic-clonic seizures a,HPO_TERM,44,75,0.8401735,0.15982649,-0.68034697,0
line655,Patient Y55 was evaluated for a very quiet speaking voice. The patient also presented with a partial seizure and a focal-onset seizure. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y55 was evaluated for [E1]a very quiet speaking voic[/E1]e. The patient also presented with a partial seizure and a focal-onset seizure. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,162,166,a very quiet speaking voic,HPO_TERM,30,56,0.8646658,0.13533421,-0.7293316,0
line655,Patient Y55 was evaluated for a very quiet speaking voice. The patient also presented with a partial seizure and a focal-onset seizure. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y55 was evaluated for a very quiet speaking voice. The patient also presented with[E1] a partial seizu[/E1]re and a focal-onset seizure. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,162,166, a partial seizu,HPO_TERM,90,106,0.79671717,0.20328279,-0.5934344,0
line655,Patient Y55 was evaluated for a very quiet speaking voice. The patient also presented with a partial seizure and a focal-onset seizure. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y55 was evaluated for a very quiet speaking voice. The patient also presented with a partial seizure an[E1]d a focal-onset seiz[/E1]ure. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,162,166,d a focal-onset seiz,HPO_TERM,111,131,0.8481765,0.1518235,-0.69635296,0
line656,Patient Y56 was evaluated for a focal-onset seizure. The patient also presented with a focal T2 hyperintense thalamic lesion and a tremor. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y56 was evaluated for [E1]a focal-onset seizur[/E1]e. The patient also presented with a focal T2 hyperintense thalamic lesion and a tremor. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,165,169,a focal-onset seizur,HPO_TERM,30,50,0.80737036,0.19262964,-0.6147407,0
line656,Patient Y56 was evaluated for a focal-onset seizure. The patient also presented with a focal T2 hyperintense thalamic lesion and a tremor. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y56 was evaluated for a focal-onset seizure. The patient also presented with[E1] a focal T2 hyperintense thalamic lesi[/E1]on and a tremor. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,165,169, a focal T2 hyperintense thalamic lesi,HPO_TERM,84,122,0.77592856,0.22407144,-0.5518571,0
line656,Patient Y56 was evaluated for a focal-onset seizure. The patient also presented with a focal T2 hyperintense thalamic lesion and a tremor. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y56 was evaluated for a focal-onset seizure. The patient also presented with a focal T2 hyperintense thalamic lesion an[E1]d a tre[/E1]mor. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,165,169,d a tre,HPO_TERM,127,134,0.8377111,0.1622889,-0.6754222,0
line657,The clinical profile for Patient Y57 includes difficulty projecting the voice and a focal T2 hyperintense thalamic lesion. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Y57 includes [E1]difficulty projecting the vo[/E1]ice and a focal T2 hyperintense thalamic lesion. Genetic analysis of [E2]the [/E2]POLG gene confirmed the diagnosis.,the ,GENE_VARIANT,143,147,difficulty projecting the vo,HPO_TERM,46,74,0.7757025,0.22429754,-0.55140495,0
line657,The clinical profile for Patient Y57 includes difficulty projecting the voice and a focal T2 hyperintense thalamic lesion. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Y57 includes difficulty projecting the voice a[E1]nd a focal T2 hyperintense thalamic le[/E1]sion. Genetic analysis of [E2]the [/E2]POLG gene confirmed the diagnosis.,the ,GENE_VARIANT,143,147,nd a focal T2 hyperintense thalamic le,HPO_TERM,79,117,0.8240622,0.17593776,-0.64812446,0
line658,Patient Y58 was evaluated for a reduction in facial animation. The patient also presented with paralysis of upward gaze and a tremor. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y58 was evaluated for [E1]a reduction in facial animatio[/E1]n. The patient also presented with paralysis of upward gaze and a tremor. Subsequent sequencing of th[E2]e PO[/E2]LG gene revealed a pathogenic variant.,e PO,GENE_VARIANT,161,165,a reduction in facial animatio,HPO_TERM,30,60,0.86543566,0.13456433,-0.7308713,0
line658,Patient Y58 was evaluated for a reduction in facial animation. The patient also presented with paralysis of upward gaze and a tremor. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y58 was evaluated for a reduction in facial animation. The patient also presented with[E1] paralysis of upward gaz[/E1]e and a tremor. Subsequent sequencing of th[E2]e PO[/E2]LG gene revealed a pathogenic variant.,e PO,GENE_VARIANT,161,165, paralysis of upward gaz,HPO_TERM,94,118,0.8534775,0.14652258,-0.7069549,0
line658,Patient Y58 was evaluated for a reduction in facial animation. The patient also presented with paralysis of upward gaze and a tremor. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y58 was evaluated for a reduction in facial animation. The patient also presented with paralysis of upward gaze and[E1] a trem[/E1]or. Subsequent sequencing of th[E2]e PO[/E2]LG gene revealed a pathogenic variant.,e PO,GENE_VARIANT,161,165, a trem,HPO_TERM,123,130,0.8560414,0.1439586,-0.71208274,0
line659,"We report the case of Patient Y59, who has a history of a very quiet speaking voice. Examination also revealed a tremor. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Y59, who has a history of [E1]a very quiet speaking voic[/E1]e. Examination also revealed a tremor. The underlying cause was traced to a mutation in th[E2]e PO[/E2]LG gene.",e PO,GENE_VARIANT,172,176,a very quiet speaking voic,HPO_TERM,56,82,0.64350283,0.35649717,-0.28700566,0
line659,"We report the case of Patient Y59, who has a history of a very quiet speaking voice. Examination also revealed a tremor. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Y59, who has a history of a very quiet speaking voice. Examination also revealed[E1] a trem[/E1]or. The underlying cause was traced to a mutation in th[E2]e PO[/E2]LG gene.",e PO,GENE_VARIANT,172,176, a trem,HPO_TERM,110,117,0.55057144,0.44942856,-0.10114288,0
line660,"This report details Patient Y60, a patient with a focal-onset seizure. Further investigation showed seizures with a localized origin and a focal T2 hyperintense thalamic lesion. A known variant in the POLG gene was identified.","This report details Patient Y60, a patient with [E1]a focal-onset seizur[/E1]e. Further investigation showed seizures with a localized origin and a focal T2 hyperintense thalamic lesion. A known variant in t[E2]he P[/E2]OLG gene was identified.",he P,GENE_VARIANT,198,202,a focal-onset seizur,HPO_TERM,48,68,0.72634697,0.27365306,-0.4526939,0
line660,"This report details Patient Y60, a patient with a focal-onset seizure. Further investigation showed seizures with a localized origin and a focal T2 hyperintense thalamic lesion. A known variant in the POLG gene was identified.","This report details Patient Y60, a patient with a focal-onset seizure. Further investigation showed[E1] seizures with a localized orig[/E1]in and a focal T2 hyperintense thalamic lesion. A known variant in t[E2]he P[/E2]OLG gene was identified.",he P,GENE_VARIANT,198,202, seizures with a localized orig,HPO_TERM,99,130,0.6979614,0.30203867,-0.39592272,0
line660,"This report details Patient Y60, a patient with a focal-onset seizure. Further investigation showed seizures with a localized origin and a focal T2 hyperintense thalamic lesion. A known variant in the POLG gene was identified.","This report details Patient Y60, a patient with a focal-onset seizure. Further investigation showed seizures with a localized origin an[E1]d a focal T2 hyperintense thalamic les[/E1]ion. A known variant in t[E2]he P[/E2]OLG gene was identified.",he P,GENE_VARIANT,198,202,d a focal T2 hyperintense thalamic les,HPO_TERM,135,173,0.76108545,0.23891449,-0.52217096,0
line661,Patient Y61 was evaluated for seizures with a localized origin. The patient also presented with a soft or quiet voice and seizures with a localized origin. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y61 was evaluated for [E1]seizures with a localized origi[/E1]n. The patient also presented with a soft or quiet voice and seizures with a localized origin. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,181,185,seizures with a localized origi,HPO_TERM,30,61,0.8339847,0.1660154,-0.6679693,0
line661,Patient Y61 was evaluated for seizures with a localized origin. The patient also presented with a soft or quiet voice and seizures with a localized origin. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y61 was evaluated for seizures with a localized origin. The patient also presented with[E1] a soft or quiet vo[/E1]ice and seizures with a localized origin. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,181,185, a soft or quiet vo,HPO_TERM,95,114,0.8153077,0.18469232,-0.63061535,0
line661,Patient Y61 was evaluated for seizures with a localized origin. The patient also presented with a soft or quiet voice and seizures with a localized origin. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y61 was evaluated for seizures with a localized origin. The patient also presented with a soft or quiet voice a[E1]nd seizures with a localized or[/E1]igin. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,181,185,nd seizures with a localized or,HPO_TERM,119,150,0.82591456,0.17408544,-0.6518291,0
line662,The clinical profile for Patient Y62 includes a mask-like facial expression and a tremor. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Y62 includes [E1]a mask-like facial expressio[/E1]n and a tremor. Genetic analysis of th[E2]e PO[/E2]LG gene confirmed the diagnosis.,e PO,GENE_VARIANT,112,116,a mask-like facial expressio,HPO_TERM,46,74,0.8446343,0.15536574,-0.6892686,0
line662,The clinical profile for Patient Y62 includes a mask-like facial expression and a tremor. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Y62 includes a mask-like facial expression and[E1] a trem[/E1]or. Genetic analysis of th[E2]e PO[/E2]LG gene confirmed the diagnosis.,e PO,GENE_VARIANT,112,116, a trem,HPO_TERM,79,86,0.8514376,0.14856239,-0.70287526,0
line663,Patient Y63 was evaluated for a focal-onset seizure. The patient also presented with bilateral grand mal seizures and a focal-onset seizure. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y63 was evaluated for [E1]a focal-onset seizur[/E1]e. The patient also presented with bilateral grand mal seizures and a focal-onset seizure. Subsequent sequencing of th[E2]e PO[/E2]LG gene revealed a pathogenic variant.,e PO,GENE_VARIANT,168,172,a focal-onset seizur,HPO_TERM,30,50,0.84800345,0.15199654,-0.6960069,0
line663,Patient Y63 was evaluated for a focal-onset seizure. The patient also presented with bilateral grand mal seizures and a focal-onset seizure. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y63 was evaluated for a focal-onset seizure. The patient also presented with[E1] bilateral grand mal seizure[/E1]s and a focal-onset seizure. Subsequent sequencing of th[E2]e PO[/E2]LG gene revealed a pathogenic variant.,e PO,GENE_VARIANT,168,172, bilateral grand mal seizure,HPO_TERM,84,112,0.8391336,0.16086638,-0.67826724,0
line663,Patient Y63 was evaluated for a focal-onset seizure. The patient also presented with bilateral grand mal seizures and a focal-onset seizure. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y63 was evaluated for a focal-onset seizure. The patient also presented with bilateral grand mal seizures and[E1] a focal-onset seizu[/E1]re. Subsequent sequencing of th[E2]e PO[/E2]LG gene revealed a pathogenic variant.,e PO,GENE_VARIANT,168,172, a focal-onset seizu,HPO_TERM,117,137,0.808328,0.19167206,-0.61665595,0
line664,The primary symptoms for Patient Y64 were anxiety and a focal T2 hyperintense thalamic lesion. Analysis of the POLG gene was performed.,The primary symptoms for Patient Y64 were an[E1]xiety a[/E1]nd a focal T2 hyperintense thalamic lesion. Analysis of the POLG gene[E2] was[/E2] performed., was,GENE_VARIANT,120,124,xiety a,HPO_TERM,44,51,0.8356483,0.16435169,-0.6712966,0
line665,The primary symptoms for Patient Y65 were a weak voice and a tremor. Analysis of the POLG gene was performed.,The primary symptoms for Patient Y65 were a [E1]weak voice a[/E1]nd a tremor. Analysis of the POLG gene[E2] was[/E2] performed., was,GENE_VARIANT,94,98,weak voice a,HPO_TERM,44,56,0.84172195,0.15827796,-0.683444,0
line666,"We report the case of Patient Y66, who has a history of a focal T2 hyperintense thalamic lesion. Examination also revealed seizures originating in one area of the brain. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Y66, who has a history of [E1]a focal T2 hyperintense thalamic lesio[/E1]n. Examination also revealed seizures originating in one area of the brain. The underlying cause was traced to a mutation in [E2]the [/E2]POLG gene.",the ,GENE_VARIANT,219,223,a focal T2 hyperintense thalamic lesio,HPO_TERM,56,94,0.43744,0.56255996,0.12511995,1
line666,"We report the case of Patient Y66, who has a history of a focal T2 hyperintense thalamic lesion. Examination also revealed seizures originating in one area of the brain. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Y66, who has a history of a focal T2 hyperintense thalamic lesion. Examination also revealed[E1] seizures originating in one area of the b[/E1]rain. The underlying cause was traced to a mutation in [E2]the [/E2]POLG gene.",the ,GENE_VARIANT,219,223, seizures originating in one area of the b,HPO_TERM,122,164,0.26219308,0.7378069,0.47561383,1
line667,"We report the case of Patient Y67, who has a history of a focal T2 hyperintense thalamic lesion. Examination also revealed anxiety. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Y67, who has a history of [E1]a focal T2 hyperintense thalamic lesio[/E1]n. Examination also revealed anxiety. The underlying cause was traced to a mutation in the[E2] POL[/E2]G gene.", POL,GENE_VARIANT,184,188,a focal T2 hyperintense thalamic lesio,HPO_TERM,56,94,0.61431575,0.38568425,-0.2286315,0
line667,"We report the case of Patient Y67, who has a history of a focal T2 hyperintense thalamic lesion. Examination also revealed anxiety. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Y67, who has a history of a focal T2 hyperintense thalamic lesion. Examination also revealed[E1] anxiet[/E1]y. The underlying cause was traced to a mutation in the[E2] POL[/E2]G gene.", POL,GENE_VARIANT,184,188, anxiet,HPO_TERM,122,129,0.48322994,0.51677006,0.03354013,1
line668,The primary symptoms for Patient Y68 were a decrease in body mass and a focal-onset seizure. Analysis of the POLG gene was performed.,The primary symptoms for Patient Y68 were a [E1]decrease in body mass a[/E1]nd a focal-onset seizure. Analysis of the POLG gene[E2] was[/E2] performed., was,GENE_VARIANT,118,122,decrease in body mass a,HPO_TERM,44,67,0.847609,0.15239103,-0.69521797,0
line669,Patient Y69 was evaluated for a weak voice. The patient also presented with a focal T2 hyperintense thalamic lesion and anxiety. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y69 was evaluated for [E1]a weak voice[/E1]. The patient also presented with a focal T2 hyperintense thalamic lesion and anxiety. Subsequent sequencing of the[E2] POL[/E2]G gene revealed a pathogenic variant., POL,GENE_VARIANT,157,161,a weak voice,HPO_TERM,30,42,0.8355269,0.16447315,-0.67105377,0
line669,Patient Y69 was evaluated for a weak voice. The patient also presented with a focal T2 hyperintense thalamic lesion and anxiety. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y69 was evaluated for a weak voice. The patient also presented with [E1]a focal T2 hyperintense thalamic lesio[/E1]n and anxiety. Subsequent sequencing of the[E2] POL[/E2]G gene revealed a pathogenic variant., POL,GENE_VARIANT,157,161,a focal T2 hyperintense thalamic lesio,HPO_TERM,76,114,0.8335097,0.16649035,-0.66701937,0
line669,Patient Y69 was evaluated for a weak voice. The patient also presented with a focal T2 hyperintense thalamic lesion and anxiety. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y69 was evaluated for a weak voice. The patient also presented with a focal T2 hyperintense thalamic lesion and[E1] anxiet[/E1]y. Subsequent sequencing of the[E2] POL[/E2]G gene revealed a pathogenic variant., POL,GENE_VARIANT,157,161, anxiet,HPO_TERM,119,126,0.85494345,0.14505653,-0.7098869,0
line670,Patient Y70 was evaluated for a resting tremor. The patient also presented with feelings of anxiety and a focal bright signal on T2 MRI of the thalamus. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y70 was evaluated for [E1]a resting tremo[/E1]r. The patient also presented with feelings of anxiety and a focal bright signal on T2 MRI of the thalamus. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,178,182,a resting tremo,HPO_TERM,30,45,0.8204441,0.17955592,-0.6408882,0
line670,Patient Y70 was evaluated for a resting tremor. The patient also presented with feelings of anxiety and a focal bright signal on T2 MRI of the thalamus. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y70 was evaluated for a resting tremor. The patient also presented with[E1] feelings of anxiet[/E1]y and a focal bright signal on T2 MRI of the thalamus. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,178,182, feelings of anxiet,HPO_TERM,79,98,0.8242644,0.17573556,-0.6485288,0
line670,Patient Y70 was evaluated for a resting tremor. The patient also presented with feelings of anxiety and a focal bright signal on T2 MRI of the thalamus. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y70 was evaluated for a resting tremor. The patient also presented with feelings of anxiety and[E1] a focal bright signal on T2 MRI of the thal[/E1]amus. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,178,182, a focal bright signal on T2 MRI of the thal,HPO_TERM,103,147,0.81691617,0.18308389,-0.6338323,0
line671,"We report the case of Patient Y71, who has a history of a very quiet speaking voice. Examination also revealed seizures with a localized origin. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Y71, who has a history of [E1]a very quiet speaking voic[/E1]e. Examination also revealed seizures with a localized origin. The underlying cause was traced to a mutation in th[E2]e PO[/E2]LG gene.",e PO,GENE_VARIANT,196,200,a very quiet speaking voic,HPO_TERM,56,82,0.7692322,0.23076782,-0.5384644,0
line671,"We report the case of Patient Y71, who has a history of a very quiet speaking voice. Examination also revealed seizures with a localized origin. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Y71, who has a history of a very quiet speaking voice. Examination also revealed[E1] seizures with a localized orig[/E1]in. The underlying cause was traced to a mutation in th[E2]e PO[/E2]LG gene.",e PO,GENE_VARIANT,196,200, seizures with a localized orig,HPO_TERM,110,141,0.485787,0.514213,0.028426021,1
line672,The clinical profile for Patient Y72 includes a simple partial seizure and anxiety. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Y72 includes [E1]a simple partial seizu[/E1]re and anxiety. Genetic analysis of th[E2]e PO[/E2]LG gene confirmed the diagnosis.,e PO,GENE_VARIANT,106,110,a simple partial seizu,HPO_TERM,46,68,0.8402895,0.15971053,-0.68057895,0
line672,The clinical profile for Patient Y72 includes a simple partial seizure and anxiety. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Y72 includes a simple partial seizure an[E1]d anxie[/E1]ty. Genetic analysis of th[E2]e PO[/E2]LG gene confirmed the diagnosis.,e PO,GENE_VARIANT,106,110,d anxie,HPO_TERM,73,80,0.86467505,0.13532493,-0.7293501,0
line673,"This report details Patient Y73, a patient with impaired liver function. Further investigation showed a weak voice and a focal-onset seizure. A known variant in the POLG gene was identified.","This report details Patient Y73, a patient with [E1]impaired liver function[/E1]. Further investigation showed a weak voice and a focal-onset seizure. A known variant in the[E2] POL[/E2]G gene was identified.", POL,GENE_VARIANT,164,168,impaired liver function,HPO_TERM,48,71,0.8117967,0.1882033,-0.62359345,0
line673,"This report details Patient Y73, a patient with impaired liver function. Further investigation showed a weak voice and a focal-onset seizure. A known variant in the POLG gene was identified.","This report details Patient Y73, a patient with impaired liver function. Further investigation showed [E1]a weak voice[/E1] and a focal-onset seizure. A known variant in the[E2] POL[/E2]G gene was identified.", POL,GENE_VARIANT,164,168,a weak voice,HPO_TERM,102,114,0.8011564,0.19884361,-0.6023128,0
line673,"This report details Patient Y73, a patient with impaired liver function. Further investigation showed a weak voice and a focal-onset seizure. A known variant in the POLG gene was identified.","This report details Patient Y73, a patient with impaired liver function. Further investigation showed a weak voice and [E1]a focal-onset seizur[/E1]e. A known variant in the[E2] POL[/E2]G gene was identified.", POL,GENE_VARIANT,164,168,a focal-onset seizur,HPO_TERM,119,139,0.8189812,0.18101884,-0.63796234,0
line674,The primary symptoms for Patient Y74 were a focal T2 hyperintense thalamic lesion and a weak voice. Analysis of the POLG gene was performed.,The primary symptoms for Patient Y74 were a [E1]focal T2 hyperintense thalamic lesion [/E1]and a weak voice. Analysis of the POLG gene[E2] was[/E2] performed., was,GENE_VARIANT,125,129,focal T2 hyperintense thalamic lesion ,HPO_TERM,44,82,0.7949811,0.20501892,-0.5899622,0
line675,Patient Y75 was evaluated for a history of significant weight loss. The patient also presented with a partial seizure and a focal T2 hyperintense thalamic lesion. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y75 was evaluated for [E1]a history of significant weight los[/E1]s. The patient also presented with a partial seizure and a focal T2 hyperintense thalamic lesion. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,189,193,a history of significant weight los,HPO_TERM,30,65,0.8194697,0.18053026,-0.63893944,0
line675,Patient Y75 was evaluated for a history of significant weight loss. The patient also presented with a partial seizure and a focal T2 hyperintense thalamic lesion. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y75 was evaluated for a history of significant weight loss. The patient also presented with[E1] a partial seizu[/E1]re and a focal T2 hyperintense thalamic lesion. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,189,193, a partial seizu,HPO_TERM,99,115,0.7608733,0.23912665,-0.52174664,0
line675,Patient Y75 was evaluated for a history of significant weight loss. The patient also presented with a partial seizure and a focal T2 hyperintense thalamic lesion. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y75 was evaluated for a history of significant weight loss. The patient also presented with a partial seizure an[E1]d a focal T2 hyperintense thalamic les[/E1]ion. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,189,193,d a focal T2 hyperintense thalamic les,HPO_TERM,120,158,0.7955244,0.20447549,-0.59104896,0
line676,The clinical profile for Patient Y76 includes bilateral tonic-clonic seizures and a history of anxiety. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Y76 includes [E1]bilateral tonic-clonic seizures[/E1] and a history of anxiety. Genetic analysis of the[E2] POL[/E2]G gene confirmed the diagnosis., POL,GENE_VARIANT,127,131,bilateral tonic-clonic seizures,HPO_TERM,46,77,0.8205997,0.17940038,-0.6411993,0
line676,The clinical profile for Patient Y76 includes bilateral tonic-clonic seizures and a history of anxiety. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Y76 includes bilateral tonic-clonic seizures and [E1]a history of anxiet[/E1]y. Genetic analysis of the[E2] POL[/E2]G gene confirmed the diagnosis., POL,GENE_VARIANT,127,131,a history of anxiet,HPO_TERM,82,101,0.8414971,0.15850285,-0.68299425,0
line677,Patient Y77 was evaluated for a focal T2 hyperintense thalamic lesion. The patient also presented with a partial seizure and a decrease in body mass. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y77 was evaluated for [E1]a focal T2 hyperintense thalamic lesio[/E1]n. The patient also presented with a partial seizure and a decrease in body mass. Subsequent sequencing of th[E2]e PO[/E2]LG gene revealed a pathogenic variant.,e PO,GENE_VARIANT,177,181,a focal T2 hyperintense thalamic lesio,HPO_TERM,30,68,0.8481651,0.15183493,-0.6963302,0
line677,Patient Y77 was evaluated for a focal T2 hyperintense thalamic lesion. The patient also presented with a partial seizure and a decrease in body mass. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y77 was evaluated for a focal T2 hyperintense thalamic lesion. The patient also presented with[E1] a partial seizu[/E1]re and a decrease in body mass. Subsequent sequencing of th[E2]e PO[/E2]LG gene revealed a pathogenic variant.,e PO,GENE_VARIANT,177,181, a partial seizu,HPO_TERM,102,118,0.8210052,0.17899477,-0.64201045,0
line677,Patient Y77 was evaluated for a focal T2 hyperintense thalamic lesion. The patient also presented with a partial seizure and a decrease in body mass. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y77 was evaluated for a focal T2 hyperintense thalamic lesion. The patient also presented with a partial seizure an[E1]d a decrease in body ma[/E1]ss. Subsequent sequencing of th[E2]e PO[/E2]LG gene revealed a pathogenic variant.,e PO,GENE_VARIANT,177,181,d a decrease in body ma,HPO_TERM,123,146,0.8408632,0.15913674,-0.68172646,0
line678,"We report the case of Patient Y78, who has a history of poor liver function. Examination also revealed seizures with a localized origin. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Y78, who has a history of [E1]poor liver functio[/E1]n. Examination also revealed seizures with a localized origin. The underlying cause was traced to a mutation in th[E2]e PO[/E2]LG gene.",e PO,GENE_VARIANT,188,192,poor liver functio,HPO_TERM,56,74,0.7855333,0.2144667,-0.5710666,0
line678,"We report the case of Patient Y78, who has a history of poor liver function. Examination also revealed seizures with a localized origin. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Y78, who has a history of poor liver function. Examination also revealed[E1] seizures with a localized orig[/E1]in. The underlying cause was traced to a mutation in th[E2]e PO[/E2]LG gene.",e PO,GENE_VARIANT,188,192, seizures with a localized orig,HPO_TERM,102,133,0.51404446,0.4859555,-0.028088957,0
line679,"This report details Patient Y79, a patient with a focal-onset seizure. Further investigation showed a focal T2 hyperintense thalamic lesion and anxiety. A known variant in the POLG gene was identified.","This report details Patient Y79, a patient with [E1]a focal-onset seizur[/E1]e. Further investigation showed a focal T2 hyperintense thalamic lesion and anxiety. A known variant in th[E2]e PO[/E2]LG gene was identified.",e PO,GENE_VARIANT,174,178,a focal-onset seizur,HPO_TERM,48,68,0.7823773,0.2176227,-0.5647546,0
line679,"This report details Patient Y79, a patient with a focal-onset seizure. Further investigation showed a focal T2 hyperintense thalamic lesion and anxiety. A known variant in the POLG gene was identified.","This report details Patient Y79, a patient with a focal-onset seizure. Further investigation showed[E1] a focal T2 hyperintense thalamic lesi[/E1]on and anxiety. A known variant in th[E2]e PO[/E2]LG gene was identified.",e PO,GENE_VARIANT,174,178, a focal T2 hyperintense thalamic lesi,HPO_TERM,99,137,0.7590573,0.24094264,-0.5181146,0
line679,"This report details Patient Y79, a patient with a focal-onset seizure. Further investigation showed a focal T2 hyperintense thalamic lesion and anxiety. A known variant in the POLG gene was identified.","This report details Patient Y79, a patient with a focal-onset seizure. Further investigation showed a focal T2 hyperintense thalamic lesion an[E1]d anxie[/E1]ty. A known variant in th[E2]e PO[/E2]LG gene was identified.",e PO,GENE_VARIANT,174,178,d anxie,HPO_TERM,142,149,0.8055145,0.19448547,-0.611029,0
line680,"This report details Patient Y80, a patient with a tremor. Further investigation showed a focal-onset seizure and a focal T2 hyperintense thalamic lesion. A known variant in the POLG gene was identified.","This report details Patient Y80, a patient with [E1]a tremo[/E1]r. Further investigation showed a focal-onset seizure and a focal T2 hyperintense thalamic lesion. A known variant in t[E2]he P[/E2]OLG gene was identified.",he P,GENE_VARIANT,174,178,a tremo,HPO_TERM,48,55,0.70360726,0.29639274,-0.40721452,0
line680,"This report details Patient Y80, a patient with a tremor. Further investigation showed a focal-onset seizure and a focal T2 hyperintense thalamic lesion. A known variant in the POLG gene was identified.","This report details Patient Y80, a patient with a tremor. Further investigation showed[E1] a focal-onset seizu[/E1]re and a focal T2 hyperintense thalamic lesion. A known variant in t[E2]he P[/E2]OLG gene was identified.",he P,GENE_VARIANT,174,178, a focal-onset seizu,HPO_TERM,86,106,0.6297308,0.3702692,-0.2594616,0
line680,"This report details Patient Y80, a patient with a tremor. Further investigation showed a focal-onset seizure and a focal T2 hyperintense thalamic lesion. A known variant in the POLG gene was identified.","This report details Patient Y80, a patient with a tremor. Further investigation showed a focal-onset seizure an[E1]d a focal T2 hyperintense thalamic les[/E1]ion. A known variant in t[E2]he P[/E2]OLG gene was identified.",he P,GENE_VARIANT,174,178,d a focal T2 hyperintense thalamic les,HPO_TERM,111,149,0.7403535,0.2596465,-0.48070702,0
line681,Patient Y81 was evaluated for a focal-onset seizure. The patient also presented with a weak voice and a focal-onset seizure. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y81 was evaluated for [E1]a focal-onset seizur[/E1]e. The patient also presented with a weak voice and a focal-onset seizure. Subsequent sequencing of th[E2]e PO[/E2]LG gene revealed a pathogenic variant.,e PO,GENE_VARIANT,152,156,a focal-onset seizur,HPO_TERM,30,50,0.8771439,0.12285612,-0.7542878,0
line681,Patient Y81 was evaluated for a focal-onset seizure. The patient also presented with a weak voice and a focal-onset seizure. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y81 was evaluated for a focal-onset seizure. The patient also presented with[E1] a weak voic[/E1]e and a focal-onset seizure. Subsequent sequencing of th[E2]e PO[/E2]LG gene revealed a pathogenic variant.,e PO,GENE_VARIANT,152,156, a weak voic,HPO_TERM,84,96,0.8622475,0.13775249,-0.72449505,0
line681,Patient Y81 was evaluated for a focal-onset seizure. The patient also presented with a weak voice and a focal-onset seizure. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y81 was evaluated for a focal-onset seizure. The patient also presented with a weak voice and[E1] a focal-onset seizu[/E1]re. Subsequent sequencing of th[E2]e PO[/E2]LG gene revealed a pathogenic variant.,e PO,GENE_VARIANT,152,156, a focal-onset seizu,HPO_TERM,101,121,0.8481547,0.15184526,-0.69630945,0
line682,The primary symptoms for Patient Y82 were a tremor and bilateral tonic-clonic seizures. Analysis of the POLG gene was performed.,The primary symptoms for Patient Y82 were a [E1]tremor [/E1]and bilateral tonic-clonic seizures. Analysis of the POLG gene[E2] was[/E2] performed., was,GENE_VARIANT,113,117,tremor ,HPO_TERM,44,51,0.81712353,0.1828765,-0.63424706,0
line683,Patient Y83 was evaluated for a soft or quiet voice. The patient also presented with a partial seizure and a focal T2 hyperintense thalamic lesion. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y83 was evaluated for [E1]a soft or quiet voi[/E1]ce. The patient also presented with a partial seizure and a focal T2 hyperintense thalamic lesion. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,173,177,a soft or quiet voi,HPO_TERM,30,49,0.7814149,0.21858507,-0.56282985,0
line683,Patient Y83 was evaluated for a soft or quiet voice. The patient also presented with a partial seizure and a focal T2 hyperintense thalamic lesion. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y83 was evaluated for a soft or quiet voice. The patient also presented wit[E1]h a partial seiz[/E1]ure and a focal T2 hyperintense thalamic lesion. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,173,177,h a partial seiz,HPO_TERM,83,99,0.78550714,0.21449287,-0.5710143,0
line683,Patient Y83 was evaluated for a soft or quiet voice. The patient also presented with a partial seizure and a focal T2 hyperintense thalamic lesion. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y83 was evaluated for a soft or quiet voice. The patient also presented with a partial seizure a[E1]nd a focal T2 hyperintense thalamic le[/E1]sion. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,173,177,nd a focal T2 hyperintense thalamic le,HPO_TERM,104,142,0.8044776,0.19552235,-0.6089552,0
line684,Patient Y84 was evaluated for a focal-onset seizure. The patient also presented with a focal T2 hyperintense thalamic lesion and a focal-onset seizure. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y84 was evaluated for [E1]a focal-onset seizur[/E1]e. The patient also presented with a focal T2 hyperintense thalamic lesion and a focal-onset seizure. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,178,182,a focal-onset seizur,HPO_TERM,30,50,0.756725,0.24327496,-0.51345,0
line684,Patient Y84 was evaluated for a focal-onset seizure. The patient also presented with a focal T2 hyperintense thalamic lesion and a focal-onset seizure. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y84 was evaluated for a focal-onset seizure. The patient also presented with[E1] a focal T2 hyperintense thalamic lesi[/E1]on and a focal-onset seizure. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,178,182, a focal T2 hyperintense thalamic lesi,HPO_TERM,84,122,0.7355953,0.2644047,-0.47119057,0
line684,Patient Y84 was evaluated for a focal-onset seizure. The patient also presented with a focal T2 hyperintense thalamic lesion and a focal-onset seizure. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y84 was evaluated for a focal-onset seizure. The patient also presented with a focal T2 hyperintense thalamic lesion an[E1]d a focal-onset seiz[/E1]ure. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,178,182,d a focal-onset seiz,HPO_TERM,127,147,0.74828786,0.25171208,-0.49657577,0
line685,"This report details Patient Y85, a patient with impaired liver function. Further investigation showed a focal-onset seizure and a focal T2 hyperintense thalamic lesion. A known variant in the POLG gene was identified.","This report details Patient Y85, a patient with [E1]impaired liver function[/E1]. Further investigation showed a focal-onset seizure and a focal T2 hyperintense thalamic lesion. A known variant in th[E2]e PO[/E2]LG gene was identified.",e PO,GENE_VARIANT,190,194,impaired liver function,HPO_TERM,48,71,0.8060066,0.19399342,-0.6120132,0
line685,"This report details Patient Y85, a patient with impaired liver function. Further investigation showed a focal-onset seizure and a focal T2 hyperintense thalamic lesion. A known variant in the POLG gene was identified.","This report details Patient Y85, a patient with impaired liver function. Further investigation showed [E1]a focal-onset seizur[/E1]e and a focal T2 hyperintense thalamic lesion. A known variant in th[E2]e PO[/E2]LG gene was identified.",e PO,GENE_VARIANT,190,194,a focal-onset seizur,HPO_TERM,102,122,0.8208314,0.17916864,-0.6416628,0
line685,"This report details Patient Y85, a patient with impaired liver function. Further investigation showed a focal-onset seizure and a focal T2 hyperintense thalamic lesion. A known variant in the POLG gene was identified.","This report details Patient Y85, a patient with impaired liver function. Further investigation showed a focal-onset seizure and[E1] a focal T2 hyperintense thalamic lesi[/E1]on. A known variant in th[E2]e PO[/E2]LG gene was identified.",e PO,GENE_VARIANT,190,194, a focal T2 hyperintense thalamic lesi,HPO_TERM,127,165,0.8157202,0.18427981,-0.6314404,0
line686,"We report the case of Patient Y86, who has a history of a focal T2 hyperintense thalamic lesion. Examination also revealed anxiety. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Y86, who has a history of [E1]a focal T2 hyperintense thalamic lesio[/E1]n. Examination also revealed anxiety. The underlying cause was traced to a mutation in the[E2] POL[/E2]G gene.", POL,GENE_VARIANT,184,188,a focal T2 hyperintense thalamic lesio,HPO_TERM,56,94,0.6371367,0.3628633,-0.2742734,0
line686,"We report the case of Patient Y86, who has a history of a focal T2 hyperintense thalamic lesion. Examination also revealed anxiety. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Y86, who has a history of a focal T2 hyperintense thalamic lesion. Examination also revealed[E1] anxiet[/E1]y. The underlying cause was traced to a mutation in the[E2] POL[/E2]G gene.", POL,GENE_VARIANT,184,188, anxiet,HPO_TERM,122,129,0.4881656,0.51183444,0.023668855,1
line687,The primary symptoms for Patient Y87 were a focal-onset seizure and a focal T2 hyperintense thalamic lesion. Analysis of the POLG gene was performed.,The primary symptoms for Patient Y87 were a [E1]focal-onset seizure [/E1]and a focal T2 hyperintense thalamic lesion. Analysis of the POLG gen[E2]e wa[/E2]s performed.,e wa,GENE_VARIANT,133,137,focal-onset seizure ,HPO_TERM,44,64,0.7645592,0.23544084,-0.52911836,0
line687,The primary symptoms for Patient Y87 were a focal-onset seizure and a focal T2 hyperintense thalamic lesion. Analysis of the POLG gene was performed.,The primary symptoms for Patient Y87 were a focal-onset seizure and a[E1] focal T2 hyperintense thalamic lesion[/E1]. Analysis of the POLG gen[E2]e wa[/E2]s performed.,e wa,GENE_VARIANT,133,137, focal T2 hyperintense thalamic lesion,HPO_TERM,69,107,0.77268505,0.22731493,-0.5453701,0
line688,Patient Y88 was evaluated for a tremor. The patient also presented with seizures with a localized origin and a soft or quiet voice. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y88 was evaluated for [E1]a tremo[/E1]r. The patient also presented with seizures with a localized origin and a soft or quiet voice. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,157,161,a tremo,HPO_TERM,30,37,0.81436753,0.18563248,-0.62873507,0
line688,Patient Y88 was evaluated for a tremor. The patient also presented with seizures with a localized origin and a soft or quiet voice. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y88 was evaluated for a tremor. The patient also presented with[E1] seizures with a localized orig[/E1]in and a soft or quiet voice. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,157,161, seizures with a localized orig,HPO_TERM,71,102,0.7797298,0.22027025,-0.55945957,0
line688,Patient Y88 was evaluated for a tremor. The patient also presented with seizures with a localized origin and a soft or quiet voice. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y88 was evaluated for a tremor. The patient also presented with seizures with a localized origin an[E1]d a soft or quiet v[/E1]oice. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,157,161,d a soft or quiet v,HPO_TERM,107,126,0.8237844,0.17621565,-0.64756876,0
line689,Patient Y89 was evaluated for a tremor. The patient also presented with anxiety and a focal bright signal on T2 MRI of the thalamus. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y89 was evaluated for [E1]a tremo[/E1]r. The patient also presented with anxiety and a focal bright signal on T2 MRI of the thalamus. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,158,162,a tremo,HPO_TERM,30,37,0.8009399,0.19906013,-0.6018798,0
line689,Patient Y89 was evaluated for a tremor. The patient also presented with anxiety and a focal bright signal on T2 MRI of the thalamus. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y89 was evaluated for a tremor. The patient also presented with[E1] anxiet[/E1]y and a focal bright signal on T2 MRI of the thalamus. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,158,162, anxiet,HPO_TERM,71,78,0.8119764,0.18802366,-0.62395275,0
line689,Patient Y89 was evaluated for a tremor. The patient also presented with anxiety and a focal bright signal on T2 MRI of the thalamus. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y89 was evaluated for a tremor. The patient also presented with anxiety and[E1] a focal bright signal on T2 MRI of the thal[/E1]amus. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,158,162, a focal bright signal on T2 MRI of the thal,HPO_TERM,83,127,0.80517834,0.19482167,-0.6103567,0
line690,The primary symptoms for Patient Y90 were a tremor and bilateral tonic-clonic seizures. Analysis of the POLG gene was performed.,The primary symptoms for Patient Y90 were a [E1]tremor [/E1]and bilateral tonic-clonic seizures. Analysis of the POLG gene[E2] was[/E2] performed., was,GENE_VARIANT,113,117,tremor ,HPO_TERM,44,51,0.81179667,0.1882034,-0.6235933,0
line691,Patient Y91 was evaluated for a focal bright signal on T2 MRI of the thalamus. The patient also presented with feelings of anxiety and a focal bright signal on T2 MRI of the thalamus. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y91 was evaluated for [E1]a focal bright signal on T2 MRI of the thala[/E1]mus. The patient also presented with feelings of anxiety and a focal bright signal on T2 MRI of the thalamus. Subsequent sequencing o[E2]f th[/E2]e POLG gene revealed a pathogenic variant.,f th,GENE_VARIANT,207,211,a focal bright signal on T2 MRI of the thala,HPO_TERM,30,74,0.8477509,0.15224907,-0.6955018,0
line691,Patient Y91 was evaluated for a focal bright signal on T2 MRI of the thalamus. The patient also presented with feelings of anxiety and a focal bright signal on T2 MRI of the thalamus. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y91 was evaluated for a focal bright signal on T2 MRI of the thalamus. The patient also presented wi[E1]th feelings of anxi[/E1]ety and a focal bright signal on T2 MRI of the thalamus. Subsequent sequencing o[E2]f th[/E2]e POLG gene revealed a pathogenic variant.,f th,GENE_VARIANT,207,211,th feelings of anxi,HPO_TERM,108,127,0.87011635,0.12988366,-0.7402327,0
line691,Patient Y91 was evaluated for a focal bright signal on T2 MRI of the thalamus. The patient also presented with feelings of anxiety and a focal bright signal on T2 MRI of the thalamus. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y91 was evaluated for a focal bright signal on T2 MRI of the thalamus. The patient also presented with feelings of anxiety a[E1]nd a focal bright signal on T2 MRI of the th[/E1]alamus. Subsequent sequencing o[E2]f th[/E2]e POLG gene revealed a pathogenic variant.,f th,GENE_VARIANT,207,211,nd a focal bright signal on T2 MRI of the th,HPO_TERM,132,176,0.8646885,0.1353115,-0.72937703,0
line692,The clinical profile for Patient Y92 includes poor liver function and a focal T2 hyperintense thalamic lesion. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Y92 includes [E1]poor liver functio[/E1]n and a focal T2 hyperintense thalamic lesion. Genetic analysis of th[E2]e PO[/E2]LG gene confirmed the diagnosis.,e PO,GENE_VARIANT,133,137,poor liver functio,HPO_TERM,46,64,0.8528089,0.1471911,-0.7056178,0
line692,The clinical profile for Patient Y92 includes poor liver function and a focal T2 hyperintense thalamic lesion. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Y92 includes poor liver function and[E1] a focal T2 hyperintense thalamic lesi[/E1]on. Genetic analysis of th[E2]e PO[/E2]LG gene confirmed the diagnosis.,e PO,GENE_VARIANT,133,137, a focal T2 hyperintense thalamic lesi,HPO_TERM,69,107,0.8402616,0.15973844,-0.68052316,0
line693,Patient Y93 was evaluated for bilateral tonic-clonic seizures. The patient also presented with seizures with a localized origin and a partial seizure. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y93 was evaluated for [E1]bilateral tonic-clonic seizures[/E1]. The patient also presented with seizures with a localized origin and a partial seizure. Subsequent sequencing of th[E2]e PO[/E2]LG gene revealed a pathogenic variant.,e PO,GENE_VARIANT,178,182,bilateral tonic-clonic seizures,HPO_TERM,30,61,0.8597587,0.14024128,-0.7195174,0
line693,Patient Y93 was evaluated for bilateral tonic-clonic seizures. The patient also presented with seizures with a localized origin and a partial seizure. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y93 was evaluated for bilateral tonic-clonic seizures. The patient also presented with [E1]seizures with a localized origi[/E1]n and a partial seizure. Subsequent sequencing of th[E2]e PO[/E2]LG gene revealed a pathogenic variant.,e PO,GENE_VARIANT,178,182,seizures with a localized origi,HPO_TERM,95,126,0.83216125,0.1678388,-0.66432244,0
line693,Patient Y93 was evaluated for bilateral tonic-clonic seizures. The patient also presented with seizures with a localized origin and a partial seizure. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y93 was evaluated for bilateral tonic-clonic seizures. The patient also presented with seizures with a localized origin and[E1] a partial seizu[/E1]re. Subsequent sequencing of th[E2]e PO[/E2]LG gene revealed a pathogenic variant.,e PO,GENE_VARIANT,178,182, a partial seizu,HPO_TERM,131,147,0.85453093,0.14546905,-0.70906186,0
line694,The clinical profile for Patient Y94 includes a tremor and a focal-onset seizure. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Y94 includes [E1]a tremo[/E1]r and a focal-onset seizure. Genetic analysis of th[E2]e PO[/E2]LG gene confirmed the diagnosis.,e PO,GENE_VARIANT,104,108,a tremo,HPO_TERM,46,53,0.84660774,0.15339223,-0.6932155,0
line694,The clinical profile for Patient Y94 includes a tremor and a focal-onset seizure. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Y94 includes a tremor and[E1] a focal-onset seizu[/E1]re. Genetic analysis of th[E2]e PO[/E2]LG gene confirmed the diagnosis.,e PO,GENE_VARIANT,104,108, a focal-onset seizu,HPO_TERM,58,78,0.8614322,0.1385678,-0.7228644,0
line695,"This report details Patient Y95, a patient with impaired liver function. Further investigation showed a focal-onset seizure and a tremor. A known variant in the POLG gene was identified.","This report details Patient Y95, a patient with [E1]impaired liver function[/E1]. Further investigation showed a focal-onset seizure and a tremor. A known variant in th[E2]e PO[/E2]LG gene was identified.",e PO,GENE_VARIANT,159,163,impaired liver function,HPO_TERM,48,71,0.8350932,0.16490683,-0.6701864,0
line695,"This report details Patient Y95, a patient with impaired liver function. Further investigation showed a focal-onset seizure and a tremor. A known variant in the POLG gene was identified.","This report details Patient Y95, a patient with impaired liver function. Further investigation showed [E1]a focal-onset seizur[/E1]e and a tremor. A known variant in th[E2]e PO[/E2]LG gene was identified.",e PO,GENE_VARIANT,159,163,a focal-onset seizur,HPO_TERM,102,122,0.8446936,0.15530637,-0.6893872,0
line695,"This report details Patient Y95, a patient with impaired liver function. Further investigation showed a focal-onset seizure and a tremor. A known variant in the POLG gene was identified.","This report details Patient Y95, a patient with impaired liver function. Further investigation showed a focal-onset seizure and[E1] a trem[/E1]or. A known variant in th[E2]e PO[/E2]LG gene was identified.",e PO,GENE_VARIANT,159,163, a trem,HPO_TERM,127,134,0.84652317,0.1534768,-0.69304633,0
line696,The clinical profile for Patient Y96 includes a focal T2 hyperintense thalamic lesion and a weak voice. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Y96 includes [E1]a focal T2 hyperintense thalamic lesio[/E1]n and a weak voice. Genetic analysis of the[E2] POL[/E2]G gene confirmed the diagnosis., POL,GENE_VARIANT,127,131,a focal T2 hyperintense thalamic lesio,HPO_TERM,46,84,0.8330301,0.16696987,-0.6660602,0
line696,The clinical profile for Patient Y96 includes a focal T2 hyperintense thalamic lesion and a weak voice. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Y96 includes a focal T2 hyperintense thalamic lesion and[E1] a weak voic[/E1]e. Genetic analysis of the[E2] POL[/E2]G gene confirmed the diagnosis., POL,GENE_VARIANT,127,131, a weak voic,HPO_TERM,89,101,0.83639276,0.16360722,-0.6727855,0
line697,Patient Y97 was evaluated for a focal T2 hyperintense thalamic lesion. The patient also presented with a partial seizure and a focal bright signal on T2 MRI of the thalamus. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y97 was evaluated for [E1]a focal T2 hyperintense thalamic lesio[/E1]n. The patient also presented with a partial seizure and a focal bright signal on T2 MRI of the thalamus. Subsequent sequencing of[E2] the[/E2] POLG gene revealed a pathogenic variant., the,GENE_VARIANT,198,202,a focal T2 hyperintense thalamic lesio,HPO_TERM,30,68,0.7939121,0.2060879,-0.5878242,0
line697,Patient Y97 was evaluated for a focal T2 hyperintense thalamic lesion. The patient also presented with a partial seizure and a focal bright signal on T2 MRI of the thalamus. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y97 was evaluated for a focal T2 hyperintense thalamic lesion. The patient also presented with[E1] a partial seizu[/E1]re and a focal bright signal on T2 MRI of the thalamus. Subsequent sequencing of[E2] the[/E2] POLG gene revealed a pathogenic variant., the,GENE_VARIANT,198,202, a partial seizu,HPO_TERM,102,118,0.6961655,0.30383447,-0.39233103,0
line697,Patient Y97 was evaluated for a focal T2 hyperintense thalamic lesion. The patient also presented with a partial seizure and a focal bright signal on T2 MRI of the thalamus. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y97 was evaluated for a focal T2 hyperintense thalamic lesion. The patient also presented with a partial seizure an[E1]d a focal bright signal on T2 MRI of the tha[/E1]lamus. Subsequent sequencing of[E2] the[/E2] POLG gene revealed a pathogenic variant., the,GENE_VARIANT,198,202,d a focal bright signal on T2 MRI of the tha,HPO_TERM,123,167,0.7761234,0.2238766,-0.5522468,0
line698,"This report details Patient Y98, a patient with a focal T2 hyperintense thalamic lesion. Further investigation showed seizures with a localized origin and anxiety. A known variant in the POLG gene was identified.","This report details Patient Y98, a patient with [E1]a focal T2 hyperintense thalamic lesio[/E1]n. Further investigation showed seizures with a localized origin and anxiety. A known variant in th[E2]e PO[/E2]LG gene was identified.",e PO,GENE_VARIANT,185,189,a focal T2 hyperintense thalamic lesio,HPO_TERM,48,86,0.8205006,0.17949933,-0.6410013,0
line698,"This report details Patient Y98, a patient with a focal T2 hyperintense thalamic lesion. Further investigation showed seizures with a localized origin and anxiety. A known variant in the POLG gene was identified.","This report details Patient Y98, a patient with a focal T2 hyperintense thalamic lesion. Further investigation showed[E1] seizures with a localized orig[/E1]in and anxiety. A known variant in th[E2]e PO[/E2]LG gene was identified.",e PO,GENE_VARIANT,185,189, seizures with a localized orig,HPO_TERM,117,148,0.7727946,0.22720537,-0.5455892,0
line698,"This report details Patient Y98, a patient with a focal T2 hyperintense thalamic lesion. Further investigation showed seizures with a localized origin and anxiety. A known variant in the POLG gene was identified.","This report details Patient Y98, a patient with a focal T2 hyperintense thalamic lesion. Further investigation showed seizures with a localized origin an[E1]d anxie[/E1]ty. A known variant in th[E2]e PO[/E2]LG gene was identified.",e PO,GENE_VARIANT,185,189,d anxie,HPO_TERM,153,160,0.8280082,0.17199178,-0.6560164,0
line699,The clinical profile for Patient Y99 includes a weak voice and a focal-onset seizure. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Y99 includes [E1]a weak voice[/E1] and a focal-onset seizure. Genetic analysis of the[E2] POL[/E2]G gene confirmed the diagnosis., POL,GENE_VARIANT,109,113,a weak voice,HPO_TERM,46,58,0.8284845,0.17151558,-0.6569689,0
line699,The clinical profile for Patient Y99 includes a weak voice and a focal-onset seizure. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Y99 includes a weak voice and [E1]a focal-onset seizur[/E1]e. Genetic analysis of the[E2] POL[/E2]G gene confirmed the diagnosis., POL,GENE_VARIANT,109,113,a focal-onset seizur,HPO_TERM,63,83,0.86874306,0.13125695,-0.7374861,0
line700,The primary symptoms for Patient Y100 were a soft or quiet voice and a focal-onset seizure. Analysis of the POLG gene was performed.,The primary symptoms for Patient Y100 were a[E1] soft or quiet voic[/E1]e and a focal-onset seizure. Analysis of the POLG g[E2]ene [/E2]was performed.,ene ,GENE_VARIANT,114,118, soft or quiet voic,HPO_TERM,44,63,0.80640155,0.19359848,-0.6128031,0
line700,The primary symptoms for Patient Y100 were a soft or quiet voice and a focal-onset seizure. Analysis of the POLG gene was performed.,The primary symptoms for Patient Y100 were a soft or quiet voice and[E1] a focal-onset seizu[/E1]re. Analysis of the POLG g[E2]ene [/E2]was performed.,ene ,GENE_VARIANT,114,118, a focal-onset seizu,HPO_TERM,68,88,0.7799657,0.22003433,-0.5599314,0
line701,Patient Y101 was evaluated for a focal T2 hyperintense thalamic lesion. The patient also presented with seizures with a localized origin and a focal bright signal on T2 MRI of the thalamus. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y101 was evaluated for [E1]a focal T2 hyperintense thalamic lesio[/E1]n. The patient also presented with seizures with a localized origin and a focal bright signal on T2 MRI of the thalamus. Subsequent sequencing of[E2] the[/E2] POLG gene revealed a pathogenic variant., the,GENE_VARIANT,214,218,a focal T2 hyperintense thalamic lesio,HPO_TERM,31,69,0.8163309,0.18366916,-0.63266176,0
line701,Patient Y101 was evaluated for a focal T2 hyperintense thalamic lesion. The patient also presented with seizures with a localized origin and a focal bright signal on T2 MRI of the thalamus. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y101 was evaluated for a focal T2 hyperintense thalamic lesion. The patient also presented with[E1] seizures with a localized orig[/E1]in and a focal bright signal on T2 MRI of the thalamus. Subsequent sequencing of[E2] the[/E2] POLG gene revealed a pathogenic variant., the,GENE_VARIANT,214,218, seizures with a localized orig,HPO_TERM,103,134,0.7380863,0.26191378,-0.4761725,0
line701,Patient Y101 was evaluated for a focal T2 hyperintense thalamic lesion. The patient also presented with seizures with a localized origin and a focal bright signal on T2 MRI of the thalamus. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y101 was evaluated for a focal T2 hyperintense thalamic lesion. The patient also presented with seizures with a localized origin an[E1]d a focal bright signal on T2 MRI of the tha[/E1]lamus. Subsequent sequencing of[E2] the[/E2] POLG gene revealed a pathogenic variant., the,GENE_VARIANT,214,218,d a focal bright signal on T2 MRI of the tha,HPO_TERM,139,183,0.7994378,0.2005622,-0.59887564,0
line702,Patient Y102 was evaluated for anxiety. The patient also presented with a partial seizure and a soft or quiet voice. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y102 was evaluated for [E1]anxiety[/E1]. The patient also presented with a partial seizure and a soft or quiet voice. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,143,147,anxiety,HPO_TERM,31,38,0.8420248,0.15797526,-0.68404955,0
line702,Patient Y102 was evaluated for anxiety. The patient also presented with a partial seizure and a soft or quiet voice. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y102 was evaluated for anxiety. The patient also presented with [E1]a partial seizur[/E1]e and a soft or quiet voice. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,143,147,a partial seizur,HPO_TERM,72,88,0.8510852,0.14891477,-0.70217043,0
line702,Patient Y102 was evaluated for anxiety. The patient also presented with a partial seizure and a soft or quiet voice. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y102 was evaluated for anxiety. The patient also presented with a partial seizure and[E1] a soft or quiet vo[/E1]ice. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,143,147, a soft or quiet vo,HPO_TERM,93,112,0.8382961,0.16170388,-0.67659223,0
line703,Patient Y103 was evaluated for bilateral grand mal seizures. The patient also presented with a focal T2 hyperintense thalamic lesion and decreased liver function. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y103 was evaluated for [E1]bilateral grand mal seizures[/E1]. The patient also presented with a focal T2 hyperintense thalamic lesion and decreased liver function. Subsequent sequencing of the[E2] POL[/E2]G gene revealed a pathogenic variant., POL,GENE_VARIANT,191,195,bilateral grand mal seizures,HPO_TERM,31,59,0.7836844,0.21631558,-0.5673688,0
line703,Patient Y103 was evaluated for bilateral grand mal seizures. The patient also presented with a focal T2 hyperintense thalamic lesion and decreased liver function. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y103 was evaluated for bilateral grand mal seizures. The patient also presented with [E1]a focal T2 hyperintense thalamic lesio[/E1]n and decreased liver function. Subsequent sequencing of the[E2] POL[/E2]G gene revealed a pathogenic variant., POL,GENE_VARIANT,191,195,a focal T2 hyperintense thalamic lesio,HPO_TERM,93,131,0.7803202,0.21967976,-0.56064045,0
line703,Patient Y103 was evaluated for bilateral grand mal seizures. The patient also presented with a focal T2 hyperintense thalamic lesion and decreased liver function. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y103 was evaluated for bilateral grand mal seizures. The patient also presented with a focal T2 hyperintense thalamic lesion and[E1] decreased liver functio[/E1]n. Subsequent sequencing of the[E2] POL[/E2]G gene revealed a pathogenic variant., POL,GENE_VARIANT,191,195, decreased liver functio,HPO_TERM,136,160,0.78959495,0.21040507,-0.5791899,0
line704,"This report details Patient Y104, a patient with a focal bright signal on T2 MRI of the thalamus. Further investigation showed a weak voice and feelings of anxiety. A known variant in the POLG gene was identified.","This report details Patient Y104, a patient with [E1]a focal bright signal on T2 MRI of the thala[/E1]mus. Further investigation showed a weak voice and feelings of anxiety. A known variant in t[E2]he P[/E2]OLG gene was identified.",he P,GENE_VARIANT,185,189,a focal bright signal on T2 MRI of the thala,HPO_TERM,49,93,0.76936024,0.23063974,-0.5387205,0
line704,"This report details Patient Y104, a patient with a focal bright signal on T2 MRI of the thalamus. Further investigation showed a weak voice and feelings of anxiety. A known variant in the POLG gene was identified.","This report details Patient Y104, a patient with a focal bright signal on T2 MRI of the thalamus. Further investigation show[E1]ed a weak vo[/E1]ice and feelings of anxiety. A known variant in t[E2]he P[/E2]OLG gene was identified.",he P,GENE_VARIANT,185,189,ed a weak vo,HPO_TERM,124,136,0.77019256,0.22980745,-0.5403851,0
line704,"This report details Patient Y104, a patient with a focal bright signal on T2 MRI of the thalamus. Further investigation showed a weak voice and feelings of anxiety. A known variant in the POLG gene was identified.","This report details Patient Y104, a patient with a focal bright signal on T2 MRI of the thalamus. Further investigation showed a weak voice a[E1]nd feelings of anxi[/E1]ety. A known variant in t[E2]he P[/E2]OLG gene was identified.",he P,GENE_VARIANT,185,189,nd feelings of anxi,HPO_TERM,141,160,0.7904939,0.20950612,-0.5809878,0
line705,The primary symptoms for Patient Y105 were feelings of anxiety and a focal T2 hyperintense thalamic lesion. Analysis of the POLG gene was performed.,The primary symptoms for Patient Y105 were f[E1]eelings of anxiety [/E1]and a focal T2 hyperintense thalamic lesion. Analysis of the POLG gen[E2]e wa[/E2]s performed.,e wa,GENE_VARIANT,132,136,eelings of anxiety ,HPO_TERM,44,63,0.83030385,0.16969614,-0.6606077,0
line705,The primary symptoms for Patient Y105 were feelings of anxiety and a focal T2 hyperintense thalamic lesion. Analysis of the POLG gene was performed.,The primary symptoms for Patient Y105 were feelings of anxiety and a[E1] focal T2 hyperintense thalamic lesion[/E1]. Analysis of the POLG gen[E2]e wa[/E2]s performed.,e wa,GENE_VARIANT,132,136, focal T2 hyperintense thalamic lesion,HPO_TERM,68,106,0.79203784,0.20796219,-0.5840757,0
line706,The primary symptoms for Patient Y106 were a very quiet speaking voice and anxiety. Analysis of the POLG gene was performed.,The primary symptoms for Patient Y106 were a[E1] very quiet speaking voice[/E1] and anxiety. Analysis of the POLG gen[E2]e wa[/E2]s performed.,e wa,GENE_VARIANT,108,112, very quiet speaking voice,HPO_TERM,44,70,0.74455726,0.25544277,-0.4891145,0
line706,The primary symptoms for Patient Y106 were a very quiet speaking voice and anxiety. Analysis of the POLG gene was performed.,The primary symptoms for Patient Y106 were a very quiet speaking voice and [E1]anxiety[/E1]. Analysis of the POLG gen[E2]e wa[/E2]s performed.,e wa,GENE_VARIANT,108,112,anxiety,HPO_TERM,75,82,0.7661831,0.23381698,-0.5323661,0
line707,Patient Y107 was evaluated for a simple partial seizure. The patient also presented with a tremor and bilateral tonic-clonic seizures. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y107 was evaluated for [E1]a simple partial seizu[/E1]re. The patient also presented with a tremor and bilateral tonic-clonic seizures. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,161,165,a simple partial seizu,HPO_TERM,31,53,0.8036546,0.19634537,-0.6073092,0
line707,Patient Y107 was evaluated for a simple partial seizure. The patient also presented with a tremor and bilateral tonic-clonic seizures. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y107 was evaluated for a simple partial seizure. The patient also presented wit[E1]h a tre[/E1]mor and bilateral tonic-clonic seizures. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,161,165,h a tre,HPO_TERM,87,94,0.85442585,0.14557414,-0.7088517,0
line707,Patient Y107 was evaluated for a simple partial seizure. The patient also presented with a tremor and bilateral tonic-clonic seizures. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y107 was evaluated for a simple partial seizure. The patient also presented with a tremor a[E1]nd bilateral tonic-clonic seizu[/E1]res. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,161,165,nd bilateral tonic-clonic seizu,HPO_TERM,99,130,0.79032207,0.20967789,-0.5806442,0
line708,"We report the case of Patient Y108, who has a history of a focal bright signal on T2 MRI of the thalamus. Examination also revealed a tremor. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Y108, who has a history of [E1]a focal bright signal on T2 MRI of the thala[/E1]mus. Examination also revealed a tremor. The underlying cause was traced to a mutation in [E2]the [/E2]POLG gene.",the ,GENE_VARIANT,191,195,a focal bright signal on T2 MRI of the thala,HPO_TERM,57,101,0.18331322,0.81668675,0.6333735,1
line708,"We report the case of Patient Y108, who has a history of a focal bright signal on T2 MRI of the thalamus. Examination also revealed a tremor. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Y108, who has a history of a focal bright signal on T2 MRI of the thalamus. Examination also reveal[E1]ed a tr[/E1]emor. The underlying cause was traced to a mutation in [E2]the [/E2]POLG gene.",the ,GENE_VARIANT,191,195,ed a tr,HPO_TERM,129,136,0.45443794,0.545562,0.09112409,1
line709,Patient Y109 was evaluated for bilateral grand mal seizures. The patient also presented with a partial seizure and a tremor. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y109 was evaluated for [E1]bilateral grand mal seizures[/E1]. The patient also presented with a partial seizure and a tremor. Subsequent sequencing of th[E2]e PO[/E2]LG gene revealed a pathogenic variant.,e PO,GENE_VARIANT,152,156,bilateral grand mal seizures,HPO_TERM,31,59,0.86204267,0.1379573,-0.72408533,0
line709,Patient Y109 was evaluated for bilateral grand mal seizures. The patient also presented with a partial seizure and a tremor. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y109 was evaluated for bilateral grand mal seizures. The patient also presented with [E1]a partial seizur[/E1]e and a tremor. Subsequent sequencing of th[E2]e PO[/E2]LG gene revealed a pathogenic variant.,e PO,GENE_VARIANT,152,156,a partial seizur,HPO_TERM,93,109,0.85485464,0.14514539,-0.7097093,0
line709,Patient Y109 was evaluated for bilateral grand mal seizures. The patient also presented with a partial seizure and a tremor. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y109 was evaluated for bilateral grand mal seizures. The patient also presented with a partial seizure and[E1] a trem[/E1]or. Subsequent sequencing of th[E2]e PO[/E2]LG gene revealed a pathogenic variant.,e PO,GENE_VARIANT,152,156, a trem,HPO_TERM,114,121,0.8508868,0.1491132,-0.70177364,0
line710,The clinical profile for Patient Y110 includes bilateral grand mal seizures and a weak voice. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Y110 includes [E1]bilateral grand mal seizures[/E1] and a weak voice. Genetic analysis of the [E2]POLG[/E2] gene confirmed the diagnosis.,POLG,GENE_VARIANT,118,122,bilateral grand mal seizures,HPO_TERM,47,75,0.8093816,0.19061843,-0.6187632,0
line710,The clinical profile for Patient Y110 includes bilateral grand mal seizures and a weak voice. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Y110 includes bilateral grand mal seizures and [E1]a weak voice[/E1]. Genetic analysis of the [E2]POLG[/E2] gene confirmed the diagnosis.,POLG,GENE_VARIANT,118,122,a weak voice,HPO_TERM,80,92,0.8113319,0.18866807,-0.62266386,0
line711,Patient Y111 was evaluated for seizures with a localized origin. The patient also presented with a focal bright signal on T2 MRI of the thalamus and a focal-onset seizure. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y111 was evaluated for [E1]seizures with a localized origi[/E1]n. The patient also presented with a focal bright signal on T2 MRI of the thalamus and a focal-onset seizure. Subsequent sequencing of[E2] the[/E2] POLG gene revealed a pathogenic variant., the,GENE_VARIANT,196,200,seizures with a localized origi,HPO_TERM,31,62,0.7857258,0.21427421,-0.57145154,0
line711,Patient Y111 was evaluated for seizures with a localized origin. The patient also presented with a focal bright signal on T2 MRI of the thalamus and a focal-onset seizure. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y111 was evaluated for seizures with a localized origin. The patient also presented with[E1] a focal bright signal on T2 MRI of the thal[/E1]amus and a focal-onset seizure. Subsequent sequencing of[E2] the[/E2] POLG gene revealed a pathogenic variant., the,GENE_VARIANT,196,200, a focal bright signal on T2 MRI of the thal,HPO_TERM,96,140,0.78886956,0.21113041,-0.5777391,0
line711,Patient Y111 was evaluated for seizures with a localized origin. The patient also presented with a focal bright signal on T2 MRI of the thalamus and a focal-onset seizure. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y111 was evaluated for seizures with a localized origin. The patient also presented with a focal bright signal on T2 MRI of the thalamus [E1]and a focal-onset se[/E1]izure. Subsequent sequencing of[E2] the[/E2] POLG gene revealed a pathogenic variant., the,GENE_VARIANT,196,200,and a focal-onset se,HPO_TERM,145,165,0.7919924,0.20800757,-0.58398485,0
line712,The primary symptoms for Patient Y112 were a tremor and impaired liver function. Analysis of the POLG gene was performed.,The primary symptoms for Patient Y112 were a[E1] tremor[/E1] and impaired liver function. Analysis of the POLG gen[E2]e wa[/E2]s performed.,e wa,GENE_VARIANT,105,109, tremor,HPO_TERM,44,51,0.7685635,0.23143652,-0.537127,0
line712,The primary symptoms for Patient Y112 were a tremor and impaired liver function. Analysis of the POLG gene was performed.,The primary symptoms for Patient Y112 were a tremor and [E1]impaired liver function[/E1]. Analysis of the POLG gen[E2]e wa[/E2]s performed.,e wa,GENE_VARIANT,105,109,impaired liver function,HPO_TERM,56,79,0.77899885,0.22100115,-0.5579977,0
line713,"This report details Patient Y113, a patient with poor liver function. Further investigation showed a focal-onset seizure and a focal T2 hyperintense thalamic lesion. A known variant in the POLG gene was identified.","This report details Patient Y113, a patient with [E1]poor liver functio[/E1]n. Further investigation showed a focal-onset seizure and a focal T2 hyperintense thalamic lesion. A known variant in t[E2]he P[/E2]OLG gene was identified.",he P,GENE_VARIANT,186,190,poor liver functio,HPO_TERM,49,67,0.80187035,0.19812961,-0.60374075,0
line713,"This report details Patient Y113, a patient with poor liver function. Further investigation showed a focal-onset seizure and a focal T2 hyperintense thalamic lesion. A known variant in the POLG gene was identified.","This report details Patient Y113, a patient with poor liver function. Further investigation showed[E1] a focal-onset seizu[/E1]re and a focal T2 hyperintense thalamic lesion. A known variant in t[E2]he P[/E2]OLG gene was identified.",he P,GENE_VARIANT,186,190, a focal-onset seizu,HPO_TERM,98,118,0.65547,0.34453002,-0.31094,0
line713,"This report details Patient Y113, a patient with poor liver function. Further investigation showed a focal-onset seizure and a focal T2 hyperintense thalamic lesion. A known variant in the POLG gene was identified.","This report details Patient Y113, a patient with poor liver function. Further investigation showed a focal-onset seizure an[E1]d a focal T2 hyperintense thalamic les[/E1]ion. A known variant in t[E2]he P[/E2]OLG gene was identified.",he P,GENE_VARIANT,186,190,d a focal T2 hyperintense thalamic les,HPO_TERM,123,161,0.7637722,0.2362278,-0.5275444,0
line714,Patient Y114 was evaluated for a tremor. The patient also presented with a focal bright signal on T2 MRI of the thalamus and a partial seizure. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y114 was evaluated for [E1]a tremo[/E1]r. The patient also presented with a focal bright signal on T2 MRI of the thalamus and a partial seizure. Subsequent sequencing of[E2] the[/E2] POLG gene revealed a pathogenic variant., the,GENE_VARIANT,168,172,a tremo,HPO_TERM,31,38,0.7962758,0.2037242,-0.5925516,0
line714,Patient Y114 was evaluated for a tremor. The patient also presented with a focal bright signal on T2 MRI of the thalamus and a partial seizure. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y114 was evaluated for a tremor. The patient also presented with[E1] a focal bright signal on T2 MRI of the thal[/E1]amus and a partial seizure. Subsequent sequencing of[E2] the[/E2] POLG gene revealed a pathogenic variant., the,GENE_VARIANT,168,172, a focal bright signal on T2 MRI of the thal,HPO_TERM,72,116,0.78731674,0.21268329,-0.5746335,0
line714,Patient Y114 was evaluated for a tremor. The patient also presented with a focal bright signal on T2 MRI of the thalamus and a partial seizure. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y114 was evaluated for a tremor. The patient also presented with a focal bright signal on T2 MRI of the thalamus [E1]and a partial se[/E1]izure. Subsequent sequencing of[E2] the[/E2] POLG gene revealed a pathogenic variant., the,GENE_VARIANT,168,172,and a partial se,HPO_TERM,121,137,0.81470704,0.18529294,-0.6294141,0
line715,"This report details Patient Y115, a patient with impaired liver function. Further investigation showed seizures with a localized origin and a focal-onset seizure. A known variant in the POLG gene was identified.","This report details Patient Y115, a patient with [E1]impaired liver function[/E1]. Further investigation showed seizures with a localized origin and a focal-onset seizure. A known variant in th[E2]e PO[/E2]LG gene was identified.",e PO,GENE_VARIANT,184,188,impaired liver function,HPO_TERM,49,72,0.8368497,0.16315027,-0.67369944,0
line715,"This report details Patient Y115, a patient with impaired liver function. Further investigation showed seizures with a localized origin and a focal-onset seizure. A known variant in the POLG gene was identified.","This report details Patient Y115, a patient with impaired liver function. Further investigation showed [E1]seizures with a localized origi[/E1]n and a focal-onset seizure. A known variant in th[E2]e PO[/E2]LG gene was identified.",e PO,GENE_VARIANT,184,188,seizures with a localized origi,HPO_TERM,103,134,0.8231898,0.17681019,-0.6463796,0
line715,"This report details Patient Y115, a patient with impaired liver function. Further investigation showed seizures with a localized origin and a focal-onset seizure. A known variant in the POLG gene was identified.","This report details Patient Y115, a patient with impaired liver function. Further investigation showed seizures with a localized origin and[E1] a focal-onset seizu[/E1]re. A known variant in th[E2]e PO[/E2]LG gene was identified.",e PO,GENE_VARIANT,184,188, a focal-onset seizu,HPO_TERM,139,159,0.8568484,0.14315149,-0.71369696,0
line716,"This report details Patient Y116, a patient with a tremor. Further investigation showed bilateral grand mal seizures and seizures originating in one area of the brain. A known variant in the POLG gene was identified.","This report details Patient Y116, a patient with [E1]a tremo[/E1]r. Further investigation showed bilateral grand mal seizures and seizures originating in one area of the brain. A known variant in [E2]the [/E2]POLG gene was identified.",the ,GENE_VARIANT,187,191,a tremo,HPO_TERM,49,56,0.66557026,0.33442968,-0.33114058,0
line716,"This report details Patient Y116, a patient with a tremor. Further investigation showed bilateral grand mal seizures and seizures originating in one area of the brain. A known variant in the POLG gene was identified.","This report details Patient Y116, a patient with a tremor. Further investigation showed[E1] bilateral grand mal seizure[/E1]s and seizures originating in one area of the brain. A known variant in [E2]the [/E2]POLG gene was identified.",the ,GENE_VARIANT,187,191, bilateral grand mal seizure,HPO_TERM,87,115,0.72242635,0.2775737,-0.44485265,0
line716,"This report details Patient Y116, a patient with a tremor. Further investigation showed bilateral grand mal seizures and seizures originating in one area of the brain. A known variant in the POLG gene was identified.","This report details Patient Y116, a patient with a tremor. Further investigation showed bilateral grand mal seizures and[E1] seizures originating in one area of the b[/E1]rain. A known variant in [E2]the [/E2]POLG gene was identified.",the ,GENE_VARIANT,187,191, seizures originating in one area of the b,HPO_TERM,120,162,0.69444305,0.30555698,-0.38888606,0
line717,The clinical profile for Patient Y117 includes a focal T2 hyperintense thalamic lesion and a weak voice. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Y117 includes [E1]a focal T2 hyperintense thalamic lesio[/E1]n and a weak voice. Genetic analysis of the[E2] POL[/E2]G gene confirmed the diagnosis., POL,GENE_VARIANT,128,132,a focal T2 hyperintense thalamic lesio,HPO_TERM,47,85,0.8309492,0.16905087,-0.6618983,0
line717,The clinical profile for Patient Y117 includes a focal T2 hyperintense thalamic lesion and a weak voice. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Y117 includes a focal T2 hyperintense thalamic lesion and[E1] a weak voic[/E1]e. Genetic analysis of the[E2] POL[/E2]G gene confirmed the diagnosis., POL,GENE_VARIANT,128,132, a weak voic,HPO_TERM,90,102,0.8338259,0.16617407,-0.66765183,0
line718,"We report the case of Patient Y118, who has a history of anxiety. Examination also revealed a history of significant weight loss. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Y118, who has a history of [E1]anxiety[/E1]. Examination also revealed a history of significant weight loss. The underlying cause was traced to a mutation in the[E2] POL[/E2]G gene.", POL,GENE_VARIANT,182,186,anxiety,HPO_TERM,57,64,0.5093579,0.49064204,-0.018715888,0
line718,"We report the case of Patient Y118, who has a history of anxiety. Examination also revealed a history of significant weight loss. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Y118, who has a history of anxiety. Examination also revealed [E1]a history of significant weight los[/E1]s. The underlying cause was traced to a mutation in the[E2] POL[/E2]G gene.", POL,GENE_VARIANT,182,186,a history of significant weight los,HPO_TERM,92,127,0.59752566,0.4024743,-0.19505134,0
line719,The primary symptoms for Patient Y119 were a weak voice and seizures with a localized origin. Analysis of the POLG gene was performed.,The primary symptoms for Patient Y119 were a [E1]weak voice a[/E1]nd seizures with a localized origin. Analysis of the POLG gene[E2] was[/E2] performed., was,GENE_VARIANT,119,123,weak voice a,HPO_TERM,45,57,0.8572728,0.14272723,-0.7145456,0
line720,The primary symptoms for Patient Y120 were a soft or quiet voice and seizures originating in one area of the brain. Analysis of the POLG gene was performed.,The primary symptoms for Patient Y120 were a[E1] soft or quiet voic[/E1]e and seizures originating in one area of the brain. Analysis of the POLG[E2] gen[/E2]e was performed., gen,GENE_VARIANT,136,140, soft or quiet voic,HPO_TERM,44,63,0.7969421,0.2030579,-0.5938842,0
line720,The primary symptoms for Patient Y120 were a soft or quiet voice and seizures originating in one area of the brain. Analysis of the POLG gene was performed.,The primary symptoms for Patient Y120 were a soft or quiet voice and[E1] seizures originating in one area of the b[/E1]rain. Analysis of the POLG[E2] gen[/E2]e was performed., gen,GENE_VARIANT,136,140, seizures originating in one area of the b,HPO_TERM,68,110,0.7876724,0.21232758,-0.5753448,0
line721,The clinical profile for Patient Y121 includes a focal-onset seizure and a weak voice. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Y121 includes [E1]a focal-onset seizur[/E1]e and a weak voice. Genetic analysis of the[E2] POL[/E2]G gene confirmed the diagnosis., POL,GENE_VARIANT,110,114,a focal-onset seizur,HPO_TERM,47,67,0.8519442,0.14805584,-0.70388836,0
line721,The clinical profile for Patient Y121 includes a focal-onset seizure and a weak voice. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Y121 includes a focal-onset seizure and[E1] a weak voic[/E1]e. Genetic analysis of the[E2] POL[/E2]G gene confirmed the diagnosis., POL,GENE_VARIANT,110,114, a weak voic,HPO_TERM,72,84,0.853066,0.14693399,-0.70613205,0
line722,The primary symptoms for Patient Y122 were bilateral tonic-clonic seizures and a history of anxiety. Analysis of the POLG gene was performed.,The primary symptoms for Patient Y122 were b[E1]ilateral tonic-clonic seizures [/E1]and a history of anxiety. Analysis of the POLG gen[E2]e wa[/E2]s performed.,e wa,GENE_VARIANT,125,129,ilateral tonic-clonic seizures ,HPO_TERM,44,75,0.7664485,0.23355149,-0.532897,0
line722,The primary symptoms for Patient Y122 were bilateral tonic-clonic seizures and a history of anxiety. Analysis of the POLG gene was performed.,The primary symptoms for Patient Y122 were bilateral tonic-clonic seizures and a[E1] history of anxiety[/E1]. Analysis of the POLG gen[E2]e wa[/E2]s performed.,e wa,GENE_VARIANT,125,129, history of anxiety,HPO_TERM,80,99,0.7819644,0.2180355,-0.5639289,0
line723,"This report details Patient Y123, a patient with seizures originating in one area of the brain. Further investigation showed a reduction in facial animation and a weak voice. A known variant in the POLG gene was identified.","This report details Patient Y123, a patient with [E1]seizures originating in one area of the br[/E1]ain. Further investigation showed a reduction in facial animation and a weak voice. A known variant in [E2]the [/E2]POLG gene was identified.",the ,GENE_VARIANT,194,198,seizures originating in one area of the br,HPO_TERM,49,91,0.69700277,0.3029973,-0.39400548,0
line723,"This report details Patient Y123, a patient with seizures originating in one area of the brain. Further investigation showed a reduction in facial animation and a weak voice. A known variant in the POLG gene was identified.","This report details Patient Y123, a patient with seizures originating in one area of the brain. Further investigation show[E1]ed a reduction in facial anima[/E1]tion and a weak voice. A known variant in [E2]the [/E2]POLG gene was identified.",the ,GENE_VARIANT,194,198,ed a reduction in facial anima,HPO_TERM,122,152,0.71521854,0.2847815,-0.43043706,0
line723,"This report details Patient Y123, a patient with seizures originating in one area of the brain. Further investigation showed a reduction in facial animation and a weak voice. A known variant in the POLG gene was identified.","This report details Patient Y123, a patient with seizures originating in one area of the brain. Further investigation showed a reduction in facial animation [E1]and a weak v[/E1]oice. A known variant in [E2]the [/E2]POLG gene was identified.",the ,GENE_VARIANT,194,198,and a weak v,HPO_TERM,157,169,0.6995694,0.3004306,-0.3991388,0
line724,"This report details Patient Y124, a patient with a weak voice. Further investigation showed a reduction in facial animation and a partial seizure. A known variant in the POLG gene was identified.","This report details Patient Y124, a patient with [E1]a weak voice[/E1]. Further investigation showed a reduction in facial animation and a partial seizure. A known variant in th[E2]e PO[/E2]LG gene was identified.",e PO,GENE_VARIANT,168,172,a weak voice,HPO_TERM,49,61,0.79885966,0.20114039,-0.59771925,0
line724,"This report details Patient Y124, a patient with a weak voice. Further investigation showed a reduction in facial animation and a partial seizure. A known variant in the POLG gene was identified.","This report details Patient Y124, a patient with a weak voice. Further investigation showed [E1]a reduction in facial animatio[/E1]n and a partial seizure. A known variant in th[E2]e PO[/E2]LG gene was identified.",e PO,GENE_VARIANT,168,172,a reduction in facial animatio,HPO_TERM,92,122,0.8165854,0.18341456,-0.63317084,0
line724,"This report details Patient Y124, a patient with a weak voice. Further investigation showed a reduction in facial animation and a partial seizure. A known variant in the POLG gene was identified.","This report details Patient Y124, a patient with a weak voice. Further investigation showed a reduction in facial animation and[E1] a partial seizu[/E1]re. A known variant in th[E2]e PO[/E2]LG gene was identified.",e PO,GENE_VARIANT,168,172, a partial seizu,HPO_TERM,127,143,0.84043217,0.15956788,-0.6808643,0
line725,"We report the case of Patient Y125, who has a history of a focal T2 hyperintense thalamic lesion. Examination also revealed seizures originating in one area of the brain. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Y125, who has a history of [E1]a focal T2 hyperintense thalamic lesio[/E1]n. Examination also revealed seizures originating in one area of the brain. The underlying cause was traced to a mutation in [E2]the [/E2]POLG gene.",the ,GENE_VARIANT,220,224,a focal T2 hyperintense thalamic lesio,HPO_TERM,57,95,0.44383612,0.55616385,0.112327725,1
line725,"We report the case of Patient Y125, who has a history of a focal T2 hyperintense thalamic lesion. Examination also revealed seizures originating in one area of the brain. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Y125, who has a history of a focal T2 hyperintense thalamic lesion. Examination also revealed[E1] seizures originating in one area of the b[/E1]rain. The underlying cause was traced to a mutation in [E2]the [/E2]POLG gene.",the ,GENE_VARIANT,220,224, seizures originating in one area of the b,HPO_TERM,123,165,0.27065927,0.72934073,0.45868146,1
line726,"This report details Patient Y126, a patient with bilateral tonic-clonic seizures. Further investigation showed a focal-onset seizure and a partial seizure. A known variant in the POLG gene was identified.","This report details Patient Y126, a patient with [E1]bilateral tonic-clonic seizures[/E1]. Further investigation showed a focal-onset seizure and a partial seizure. A known variant in th[E2]e PO[/E2]LG gene was identified.",e PO,GENE_VARIANT,177,181,bilateral tonic-clonic seizures,HPO_TERM,49,80,0.7774189,0.22258115,-0.55483776,0
line726,"This report details Patient Y126, a patient with bilateral tonic-clonic seizures. Further investigation showed a focal-onset seizure and a partial seizure. A known variant in the POLG gene was identified.","This report details Patient Y126, a patient with bilateral tonic-clonic seizures. Further investigation showed [E1]a focal-onset seizur[/E1]e and a partial seizure. A known variant in th[E2]e PO[/E2]LG gene was identified.",e PO,GENE_VARIANT,177,181,a focal-onset seizur,HPO_TERM,111,131,0.77212465,0.22787537,-0.5442493,0
line726,"This report details Patient Y126, a patient with bilateral tonic-clonic seizures. Further investigation showed a focal-onset seizure and a partial seizure. A known variant in the POLG gene was identified.","This report details Patient Y126, a patient with bilateral tonic-clonic seizures. Further investigation showed a focal-onset seizure and[E1] a partial seizu[/E1]re. A known variant in th[E2]e PO[/E2]LG gene was identified.",e PO,GENE_VARIANT,177,181, a partial seizu,HPO_TERM,136,152,0.8115232,0.18847685,-0.62304634,0
line727,"This report details Patient Y127, a patient with a focal T2 hyperintense thalamic lesion. Further investigation showed a history of anxiety and a focal bright signal on T2 MRI of the thalamus. A known variant in the POLG gene was identified.","This report details Patient Y127, a patient with [E1]a focal T2 hyperintense thalamic lesio[/E1]n. Further investigation showed a history of anxiety and a focal bright signal on T2 MRI of the thalamus. A known variant in[E2] the[/E2] POLG gene was identified.", the,GENE_VARIANT,211,215,a focal T2 hyperintense thalamic lesio,HPO_TERM,49,87,0.724234,0.27576607,-0.4484679,0
line727,"This report details Patient Y127, a patient with a focal T2 hyperintense thalamic lesion. Further investigation showed a history of anxiety and a focal bright signal on T2 MRI of the thalamus. A known variant in the POLG gene was identified.","This report details Patient Y127, a patient with a focal T2 hyperintense thalamic lesion. Further investigation showed[E1] a history of anxie[/E1]ty and a focal bright signal on T2 MRI of the thalamus. A known variant in[E2] the[/E2] POLG gene was identified.", the,GENE_VARIANT,211,215, a history of anxie,HPO_TERM,118,137,0.6615959,0.3384041,-0.3231918,0
line727,"This report details Patient Y127, a patient with a focal T2 hyperintense thalamic lesion. Further investigation showed a history of anxiety and a focal bright signal on T2 MRI of the thalamus. A known variant in the POLG gene was identified.","This report details Patient Y127, a patient with a focal T2 hyperintense thalamic lesion. Further investigation showed a history of anxiety an[E1]d a focal bright signal on T2 MRI of the tha[/E1]lamus. A known variant in[E2] the[/E2] POLG gene was identified.", the,GENE_VARIANT,211,215,d a focal bright signal on T2 MRI of the tha,HPO_TERM,142,186,0.67457867,0.32542136,-0.3491573,0
line728,"We report the case of Patient Y128, who has a history of a decrease in body mass. Examination also revealed a reduction in facial animation. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Y128, who has a history of [E1]a decrease in body mass[/E1]. Examination also revealed a reduction in facial animation. The underlying cause was traced to a mutation in the[E2] POL[/E2]G gene.", POL,GENE_VARIANT,193,197,a decrease in body mass,HPO_TERM,57,80,0.45557404,0.54442596,0.08885193,1
line728,"We report the case of Patient Y128, who has a history of a decrease in body mass. Examination also revealed a reduction in facial animation. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Y128, who has a history of a decrease in body mass. Examination also revealed [E1]a reduction in facial animatio[/E1]n. The underlying cause was traced to a mutation in the[E2] POL[/E2]G gene.", POL,GENE_VARIANT,193,197,a reduction in facial animatio,HPO_TERM,108,138,0.46750236,0.53249764,0.06499529,1
line729,The primary symptoms for Patient Y129 were a focal bright signal on T2 MRI of the thalamus and a history of anxiety. Analysis of the POLG gene was performed.,The primary symptoms for Patient Y129 were a [E1]focal bright signal on T2 MRI of the thalamu[/E1]s and a history of anxiety. Analysis of the POLG g[E2]ene [/E2]was performed.,ene ,GENE_VARIANT,139,143,focal bright signal on T2 MRI of the thalamu,HPO_TERM,45,89,0.8137241,0.18627588,-0.6274482,0
line729,The primary symptoms for Patient Y129 were a focal bright signal on T2 MRI of the thalamus and a history of anxiety. Analysis of the POLG gene was performed.,The primary symptoms for Patient Y129 were a focal bright signal on T2 MRI of the thalamus and[E1] a history of anxie[/E1]ty. Analysis of the POLG g[E2]ene [/E2]was performed.,ene ,GENE_VARIANT,139,143, a history of anxie,HPO_TERM,94,113,0.84172714,0.15827289,-0.6834543,0
line730,Patient Y130 was evaluated for a focal T2 hyperintense thalamic lesion. The patient also presented with a soft or quiet voice and seizures originating in one area of the brain. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y130 was evaluated for [E1]a focal T2 hyperintense thalamic lesio[/E1]n. The patient also presented with a soft or quiet voice and seizures originating in one area of the brain. Subsequent sequencing o[E2]f th[/E2]e POLG gene revealed a pathogenic variant.,f th,GENE_VARIANT,200,204,a focal T2 hyperintense thalamic lesio,HPO_TERM,31,69,0.8564101,0.1435899,-0.7128202,0
line730,Patient Y130 was evaluated for a focal T2 hyperintense thalamic lesion. The patient also presented with a soft or quiet voice and seizures originating in one area of the brain. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y130 was evaluated for a focal T2 hyperintense thalamic lesion. The patient also presented with[E1] a soft or quiet vo[/E1]ice and seizures originating in one area of the brain. Subsequent sequencing o[E2]f th[/E2]e POLG gene revealed a pathogenic variant.,f th,GENE_VARIANT,200,204, a soft or quiet vo,HPO_TERM,103,122,0.80552655,0.19447345,-0.6110531,0
line730,Patient Y130 was evaluated for a focal T2 hyperintense thalamic lesion. The patient also presented with a soft or quiet voice and seizures originating in one area of the brain. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y130 was evaluated for a focal T2 hyperintense thalamic lesion. The patient also presented with a soft or quiet voice a[E1]nd seizures originating in one area of the[/E1] brain. Subsequent sequencing o[E2]f th[/E2]e POLG gene revealed a pathogenic variant.,f th,GENE_VARIANT,200,204,nd seizures originating in one area of the,HPO_TERM,127,169,0.8379282,0.16207178,-0.6758564,0
line731,"This report details Patient Y131, a patient with seizures originating in one area of the brain. Further investigation showed a focal-onset seizure and a focal T2 hyperintense thalamic lesion. A known variant in the POLG gene was identified.","This report details Patient Y131, a patient with [E1]seizures originating in one area of the br[/E1]ain. Further investigation showed a focal-onset seizure and a focal T2 hyperintense thalamic lesion. A known variant in[E2] the[/E2] POLG gene was identified.", the,GENE_VARIANT,210,214,seizures originating in one area of the br,HPO_TERM,49,91,0.68214095,0.31785902,-0.36428192,0
line731,"This report details Patient Y131, a patient with seizures originating in one area of the brain. Further investigation showed a focal-onset seizure and a focal T2 hyperintense thalamic lesion. A known variant in the POLG gene was identified.","This report details Patient Y131, a patient with seizures originating in one area of the brain. Further investigation show[E1]ed a focal-onset sei[/E1]zure and a focal T2 hyperintense thalamic lesion. A known variant in[E2] the[/E2] POLG gene was identified.", the,GENE_VARIANT,210,214,ed a focal-onset sei,HPO_TERM,122,142,0.72677684,0.27322313,-0.4535537,0
line731,"This report details Patient Y131, a patient with seizures originating in one area of the brain. Further investigation showed a focal-onset seizure and a focal T2 hyperintense thalamic lesion. A known variant in the POLG gene was identified.","This report details Patient Y131, a patient with seizures originating in one area of the brain. Further investigation showed a focal-onset seizure [E1]and a focal T2 hyperintense thalamic l[/E1]esion. A known variant in[E2] the[/E2] POLG gene was identified.", the,GENE_VARIANT,210,214,and a focal T2 hyperintense thalamic l,HPO_TERM,147,185,0.68977094,0.310229,-0.37954193,0
line732,Patient Y132 was evaluated for seizures with a localized origin. The patient also presented with a focal bright signal on T2 MRI of the thalamus and a history of anxiety. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y132 was evaluated for [E1]seizures with a localized origi[/E1]n. The patient also presented with a focal bright signal on T2 MRI of the thalamus and a history of anxiety. Subsequent sequencing of[E2] the[/E2] POLG gene revealed a pathogenic variant., the,GENE_VARIANT,195,199,seizures with a localized origi,HPO_TERM,31,62,0.79670995,0.20329003,-0.5934199,0
line732,Patient Y132 was evaluated for seizures with a localized origin. The patient also presented with a focal bright signal on T2 MRI of the thalamus and a history of anxiety. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y132 was evaluated for seizures with a localized origin. The patient also presented with[E1] a focal bright signal on T2 MRI of the thal[/E1]amus and a history of anxiety. Subsequent sequencing of[E2] the[/E2] POLG gene revealed a pathogenic variant., the,GENE_VARIANT,195,199, a focal bright signal on T2 MRI of the thal,HPO_TERM,96,140,0.7991868,0.20081314,-0.59837365,0
line732,Patient Y132 was evaluated for seizures with a localized origin. The patient also presented with a focal bright signal on T2 MRI of the thalamus and a history of anxiety. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y132 was evaluated for seizures with a localized origin. The patient also presented with a focal bright signal on T2 MRI of the thalamus [E1]and a history of an[/E1]xiety. Subsequent sequencing of[E2] the[/E2] POLG gene revealed a pathogenic variant., the,GENE_VARIANT,195,199,and a history of an,HPO_TERM,145,164,0.7978369,0.2021631,-0.5956738,0
line733,Patient Y133 was evaluated for a soft or quiet voice. The patient also presented with a history of anxiety and a focal T2 hyperintense thalamic lesion. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y133 was evaluated for [E1]a soft or quiet voi[/E1]ce. The patient also presented with a history of anxiety and a focal T2 hyperintense thalamic lesion. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,177,181,a soft or quiet voi,HPO_TERM,31,50,0.804035,0.19596507,-0.60806996,0
line733,Patient Y133 was evaluated for a soft or quiet voice. The patient also presented with a history of anxiety and a focal T2 hyperintense thalamic lesion. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y133 was evaluated for a soft or quiet voice. The patient also presented wit[E1]h a history of anxi[/E1]ety and a focal T2 hyperintense thalamic lesion. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,177,181,h a history of anxi,HPO_TERM,84,103,0.8106466,0.18935347,-0.6212931,0
line733,Patient Y133 was evaluated for a soft or quiet voice. The patient also presented with a history of anxiety and a focal T2 hyperintense thalamic lesion. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y133 was evaluated for a soft or quiet voice. The patient also presented with a history of anxiety a[E1]nd a focal T2 hyperintense thalamic le[/E1]sion. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,177,181,nd a focal T2 hyperintense thalamic le,HPO_TERM,108,146,0.8201497,0.17985027,-0.64029944,0
line734,The clinical profile for Patient Y134 includes a focal T2 hyperintense thalamic lesion and a tremor. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Y134 includes [E1]a focal T2 hyperintense thalamic lesio[/E1]n and a tremor. Genetic analysis of th[E2]e PO[/E2]LG gene confirmed the diagnosis.,e PO,GENE_VARIANT,123,127,a focal T2 hyperintense thalamic lesio,HPO_TERM,47,85,0.8437025,0.15629753,-0.687405,0
line734,The clinical profile for Patient Y134 includes a focal T2 hyperintense thalamic lesion and a tremor. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Y134 includes a focal T2 hyperintense thalamic lesion and[E1] a trem[/E1]or. Genetic analysis of th[E2]e PO[/E2]LG gene confirmed the diagnosis.,e PO,GENE_VARIANT,123,127, a trem,HPO_TERM,90,97,0.8491346,0.1508653,-0.6982693,0
line735,"We report the case of Patient Y135, who has a history of a focal bright signal on T2 MRI of the thalamus. Examination also revealed a weak voice. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Y135, who has a history of [E1]a focal bright signal on T2 MRI of the thala[/E1]mus. Examination also revealed a weak voice. The underlying cause was traced to a mutation in t[E2]he P[/E2]OLG gene.",he P,GENE_VARIANT,196,200,a focal bright signal on T2 MRI of the thala,HPO_TERM,57,101,0.32648414,0.67351586,0.3470317,1
line735,"We report the case of Patient Y135, who has a history of a focal bright signal on T2 MRI of the thalamus. Examination also revealed a weak voice. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Y135, who has a history of a focal bright signal on T2 MRI of the thalamus. Examination also reveal[E1]ed a weak vo[/E1]ice. The underlying cause was traced to a mutation in t[E2]he P[/E2]OLG gene.",he P,GENE_VARIANT,196,200,ed a weak vo,HPO_TERM,129,141,0.49086598,0.50913405,0.018268079,1
line736,Patient Y136 was evaluated for poor liver function. The patient also presented with seizures with a localized origin and a focal T2 hyperintense thalamic lesion. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y136 was evaluated for [E1]poor liver functio[/E1]n. The patient also presented with seizures with a localized origin and a focal T2 hyperintense thalamic lesion. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,188,192,poor liver functio,HPO_TERM,31,49,0.8607509,0.13924909,-0.7215018,0
line736,Patient Y136 was evaluated for poor liver function. The patient also presented with seizures with a localized origin and a focal T2 hyperintense thalamic lesion. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y136 was evaluated for poor liver function. The patient also presented with[E1] seizures with a localized orig[/E1]in and a focal T2 hyperintense thalamic lesion. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,188,192, seizures with a localized orig,HPO_TERM,83,114,0.7740608,0.22593924,-0.5481216,0
line736,Patient Y136 was evaluated for poor liver function. The patient also presented with seizures with a localized origin and a focal T2 hyperintense thalamic lesion. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y136 was evaluated for poor liver function. The patient also presented with seizures with a localized origin an[E1]d a focal T2 hyperintense thalamic les[/E1]ion. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,188,192,d a focal T2 hyperintense thalamic les,HPO_TERM,119,157,0.8398187,0.16018125,-0.67963743,0
line737,"We report the case of Patient Y137, who has a history of a tremor. Examination also revealed a simple partial seizure. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Y137, who has a history of [E1]a tremo[/E1]r. Examination also revealed a simple partial seizure. The underlying cause was traced to a mutation in t[E2]he P[/E2]OLG gene.",he P,GENE_VARIANT,169,173,a tremo,HPO_TERM,57,64,0.4290237,0.5709763,0.1419526,1
line737,"We report the case of Patient Y137, who has a history of a tremor. Examination also revealed a simple partial seizure. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Y137, who has a history of a tremor. Examination also revealed[E1] a simple partial seiz[/E1]ure. The underlying cause was traced to a mutation in t[E2]he P[/E2]OLG gene.",he P,GENE_VARIANT,169,173, a simple partial seiz,HPO_TERM,92,114,0.1852661,0.8147339,0.62946784,1
line738,Patient Y138 was evaluated for a partial seizure. The patient also presented with a history of anxiety and a focal T2 hyperintense thalamic lesion. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y138 was evaluated for [E1]a partial seizur[/E1]e. The patient also presented with a history of anxiety and a focal T2 hyperintense thalamic lesion. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,174,178,a partial seizur,HPO_TERM,31,47,0.84236133,0.15763871,-0.6847226,0
line738,Patient Y138 was evaluated for a partial seizure. The patient also presented with a history of anxiety and a focal T2 hyperintense thalamic lesion. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y138 was evaluated for a partial seizure. The patient also presented with[E1] a history of anxie[/E1]ty and a focal T2 hyperintense thalamic lesion. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,174,178, a history of anxie,HPO_TERM,81,100,0.7505579,0.24944213,-0.5011158,0
line738,Patient Y138 was evaluated for a partial seizure. The patient also presented with a history of anxiety and a focal T2 hyperintense thalamic lesion. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y138 was evaluated for a partial seizure. The patient also presented with a history of anxiety an[E1]d a focal T2 hyperintense thalamic les[/E1]ion. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,174,178,d a focal T2 hyperintense thalamic les,HPO_TERM,105,143,0.7880595,0.21194056,-0.57611895,0
line739,Patient Y139 was evaluated for a tremor. The patient also presented with bilateral grand mal seizures and seizures originating in one area of the brain. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y139 was evaluated for [E1]a tremo[/E1]r. The patient also presented with bilateral grand mal seizures and seizures originating in one area of the brain. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,178,182,a tremo,HPO_TERM,31,38,0.8061714,0.19382857,-0.61234283,0
line739,Patient Y139 was evaluated for a tremor. The patient also presented with bilateral grand mal seizures and seizures originating in one area of the brain. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y139 was evaluated for a tremor. The patient also presented with[E1] bilateral grand mal seizure[/E1]s and seizures originating in one area of the brain. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,178,182, bilateral grand mal seizure,HPO_TERM,72,100,0.8228709,0.17712903,-0.6457419,0
line739,Patient Y139 was evaluated for a tremor. The patient also presented with bilateral grand mal seizures and seizures originating in one area of the brain. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y139 was evaluated for a tremor. The patient also presented with bilateral grand mal seizures and[E1] seizures originating in one area of the b[/E1]rain. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,178,182, seizures originating in one area of the b,HPO_TERM,105,147,0.7881037,0.21189632,-0.5762074,0
line740,The primary symptoms for Patient Y140 were a partial seizure and a focal bright signal on T2 MRI of the thalamus. Analysis of the POLG gene was performed.,The primary symptoms for Patient Y140 were a[E1] partial seizure[/E1] and a focal bright signal on T2 MRI of the thalamus. Analysis of the POLG [E2]gene[/E2] was performed.,gene,GENE_VARIANT,135,139, partial seizure,HPO_TERM,44,60,0.80870515,0.19129486,-0.6174103,0
line740,The primary symptoms for Patient Y140 were a partial seizure and a focal bright signal on T2 MRI of the thalamus. Analysis of the POLG gene was performed.,The primary symptoms for Patient Y140 were a partial seizure and [E1]a focal bright signal on T2 MRI of the thala[/E1]mus. Analysis of the POLG [E2]gene[/E2] was performed.,gene,GENE_VARIANT,135,139,a focal bright signal on T2 MRI of the thala,HPO_TERM,65,109,0.8202337,0.17976628,-0.6404674,0
line741,"We report the case of Patient Y141, who has a history of a soft or quiet voice. Examination also revealed a simple partial seizure. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Y141, who has a history of [E1]a soft or quiet voi[/E1]ce. Examination also revealed a simple partial seizure. The underlying cause was traced to a mutation in [E2]the [/E2]POLG gene.",the ,GENE_VARIANT,181,185,a soft or quiet voi,HPO_TERM,57,76,0.254326,0.745674,0.49134803,1
line741,"We report the case of Patient Y141, who has a history of a soft or quiet voice. Examination also revealed a simple partial seizure. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Y141, who has a history of a soft or quiet voice. Examination also reveale[E1]d a simple partial sei[/E1]zure. The underlying cause was traced to a mutation in [E2]the [/E2]POLG gene.",the ,GENE_VARIANT,181,185,d a simple partial sei,HPO_TERM,104,126,0.4990942,0.5009058,0.0018116236,1
line742,Patient Y142 was evaluated for a focal bright signal on T2 MRI of the thalamus. The patient also presented with a partial seizure and a weak voice. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y142 was evaluated for [E1]a focal bright signal on T2 MRI of the thala[/E1]mus. The patient also presented with a partial seizure and a weak voice. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,173,177,a focal bright signal on T2 MRI of the thala,HPO_TERM,31,75,0.7908195,0.20918043,-0.5816391,0
line742,Patient Y142 was evaluated for a focal bright signal on T2 MRI of the thalamus. The patient also presented with a partial seizure and a weak voice. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y142 was evaluated for a focal bright signal on T2 MRI of the thalamus. The patient also presented wi[E1]th a partial sei[/E1]zure and a weak voice. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,173,177,th a partial sei,HPO_TERM,109,125,0.84035814,0.15964185,-0.6807163,0
line742,Patient Y142 was evaluated for a focal bright signal on T2 MRI of the thalamus. The patient also presented with a partial seizure and a weak voice. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y142 was evaluated for a focal bright signal on T2 MRI of the thalamus. The patient also presented with a partial seizure [E1]and a weak v[/E1]oice. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,173,177,and a weak v,HPO_TERM,130,142,0.80466104,0.19533898,-0.6093221,0
line743,Patient Y143 was evaluated for bilateral grand mal seizures. The patient also presented with a focal bright signal on T2 MRI of the thalamus and a history of significant weight loss. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y143 was evaluated for [E1]bilateral grand mal seizures[/E1]. The patient also presented with a focal bright signal on T2 MRI of the thalamus and a history of significant weight loss. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,208,212,bilateral grand mal seizures,HPO_TERM,31,59,0.7501405,0.24985947,-0.50028104,0
line743,Patient Y143 was evaluated for bilateral grand mal seizures. The patient also presented with a focal bright signal on T2 MRI of the thalamus and a history of significant weight loss. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y143 was evaluated for bilateral grand mal seizures. The patient also presented with [E1]a focal bright signal on T2 MRI of the thala[/E1]mus and a history of significant weight loss. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,208,212,a focal bright signal on T2 MRI of the thala,HPO_TERM,93,137,0.7160959,0.28390408,-0.43219185,0
line743,Patient Y143 was evaluated for bilateral grand mal seizures. The patient also presented with a focal bright signal on T2 MRI of the thalamus and a history of significant weight loss. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y143 was evaluated for bilateral grand mal seizures. The patient also presented with a focal bright signal on T2 MRI of the thalamus a[E1]nd a history of significant weight [/E1]loss. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,208,212,nd a history of significant weight ,HPO_TERM,142,177,0.7745887,0.22541137,-0.54917735,0
line744,"We report the case of Patient Y144, who has a history of a focal bright signal on T2 MRI of the thalamus. Examination also revealed a focal-onset seizure. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Y144, who has a history of [E1]a focal bright signal on T2 MRI of the thala[/E1]mus. Examination also revealed a focal-onset seizure. The underlying cause was traced to a mutation in [E2]the [/E2]POLG gene.",the ,GENE_VARIANT,204,208,a focal bright signal on T2 MRI of the thala,HPO_TERM,57,101,0.13309906,0.86690086,0.7338018,1
line744,"We report the case of Patient Y144, who has a history of a focal bright signal on T2 MRI of the thalamus. Examination also revealed a focal-onset seizure. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Y144, who has a history of a focal bright signal on T2 MRI of the thalamus. Examination also reveal[E1]ed a focal-onset sei[/E1]zure. The underlying cause was traced to a mutation in [E2]the [/E2]POLG gene.",the ,GENE_VARIANT,204,208,ed a focal-onset sei,HPO_TERM,129,149,0.25959396,0.74040604,0.48081207,1
line745,"We report the case of Patient Y145, who has a history of a weak voice. Examination also revealed a decrease in body mass. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Y145, who has a history of [E1]a weak voice[/E1]. Examination also revealed a decrease in body mass. The underlying cause was traced to a mutation in the [E2]POLG[/E2] gene.",POLG,GENE_VARIANT,175,179,a weak voice,HPO_TERM,57,69,0.37943473,0.6205653,0.24113056,1
line745,"We report the case of Patient Y145, who has a history of a weak voice. Examination also revealed a decrease in body mass. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Y145, who has a history of a weak voice. Examination also revealed [E1]a decrease in body mass[/E1]. The underlying cause was traced to a mutation in the [E2]POLG[/E2] gene.",POLG,GENE_VARIANT,175,179,a decrease in body mass,HPO_TERM,97,120,0.26398796,0.7360121,0.47202414,1
line746,The primary symptoms for Patient Y146 were a focal-onset seizure and a focal bright signal on T2 MRI of the thalamus. Analysis of the POLG gene was performed.,The primary symptoms for Patient Y146 were a [E1]focal-onset seizure [/E1]and a focal bright signal on T2 MRI of the thalamus. Analysis of the POLG g[E2]ene [/E2]was performed.,ene ,GENE_VARIANT,140,144,focal-onset seizure ,HPO_TERM,45,65,0.7993555,0.20064451,-0.598711,0
line746,The primary symptoms for Patient Y146 were a focal-onset seizure and a focal bright signal on T2 MRI of the thalamus. Analysis of the POLG gene was performed.,The primary symptoms for Patient Y146 were a focal-onset seizure and a[E1] focal bright signal on T2 MRI of the thalam[/E1]us. Analysis of the POLG g[E2]ene [/E2]was performed.,ene ,GENE_VARIANT,140,144, focal bright signal on T2 MRI of the thalam,HPO_TERM,70,114,0.8245783,0.17542176,-0.6491565,0
line747,The clinical profile for Patient Y147 includes a weak voice and a tremor. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Y147 includes [E1]a weak voice[/E1] and a tremor. Genetic analysis of the[E2] POL[/E2]G gene confirmed the diagnosis., POL,GENE_VARIANT,97,101,a weak voice,HPO_TERM,47,59,0.8363994,0.16360064,-0.67279875,0
line747,The clinical profile for Patient Y147 includes a weak voice and a tremor. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Y147 includes a weak voice and [E1]a tremo[/E1]r. Genetic analysis of the[E2] POL[/E2]G gene confirmed the diagnosis., POL,GENE_VARIANT,97,101,a tremo,HPO_TERM,64,71,0.86079055,0.13920946,-0.7215811,0
line748,"This report details Patient Y148, a patient with a weak voice. Further investigation showed a focal-onset seizure and decreased liver function. A known variant in the POLG gene was identified.","This report details Patient Y148, a patient with [E1]a weak voice[/E1]. Further investigation showed a focal-onset seizure and decreased liver function. A known variant in the[E2] POL[/E2]G gene was identified.", POL,GENE_VARIANT,166,170,a weak voice,HPO_TERM,49,61,0.78703755,0.21296246,-0.5740751,0
line748,"This report details Patient Y148, a patient with a weak voice. Further investigation showed a focal-onset seizure and decreased liver function. A known variant in the POLG gene was identified.","This report details Patient Y148, a patient with a weak voice. Further investigation showed [E1]a focal-onset seizur[/E1]e and decreased liver function. A known variant in the[E2] POL[/E2]G gene was identified.", POL,GENE_VARIANT,166,170,a focal-onset seizur,HPO_TERM,92,112,0.80282176,0.19717829,-0.60564345,0
line748,"This report details Patient Y148, a patient with a weak voice. Further investigation showed a focal-onset seizure and decreased liver function. A known variant in the POLG gene was identified.","This report details Patient Y148, a patient with a weak voice. Further investigation showed a focal-onset seizure and[E1] decreased liver functio[/E1]n. A known variant in the[E2] POL[/E2]G gene was identified.", POL,GENE_VARIANT,166,170, decreased liver functio,HPO_TERM,117,141,0.8356909,0.16430904,-0.6713819,0
line749,The primary symptoms for Patient Y149 were a focal bright signal on T2 MRI of the thalamus and a decrease in body mass. Analysis of the POLG gene was performed.,The primary symptoms for Patient Y149 were a [E1]focal bright signal on T2 MRI of the thalamu[/E1]s and a decrease in body mass. Analysis of the POLG ge[E2]ne w[/E2]as performed.,ne w,GENE_VARIANT,143,147,focal bright signal on T2 MRI of the thalamu,HPO_TERM,45,89,0.80423063,0.19576941,-0.6084612,0
line749,The primary symptoms for Patient Y149 were a focal bright signal on T2 MRI of the thalamus and a decrease in body mass. Analysis of the POLG gene was performed.,The primary symptoms for Patient Y149 were a focal bright signal on T2 MRI of the thalamus and[E1] a decrease in body mas[/E1]s. Analysis of the POLG ge[E2]ne w[/E2]as performed.,ne w,GENE_VARIANT,143,147, a decrease in body mas,HPO_TERM,94,117,0.8286785,0.17132145,-0.65735704,0
line750,"We report the case of Patient Y150, who has a history of a soft or quiet voice. Examination also revealed a focal-onset seizure. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Y150, who has a history of [E1]a soft or quiet voi[/E1]ce. Examination also revealed a focal-onset seizure. The underlying cause was traced to a mutation in t[E2]he P[/E2]OLG gene.",he P,GENE_VARIANT,179,183,a soft or quiet voi,HPO_TERM,57,76,0.31287986,0.68712014,0.37424028,1
line750,"We report the case of Patient Y150, who has a history of a soft or quiet voice. Examination also revealed a focal-onset seizure. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Y150, who has a history of a soft or quiet voice. Examination also reveale[E1]d a focal-onset seiz[/E1]ure. The underlying cause was traced to a mutation in t[E2]he P[/E2]OLG gene.",he P,GENE_VARIANT,179,183,d a focal-onset seiz,HPO_TERM,104,124,0.342301,0.6576989,0.31539792,1
line751,Patient Y151 was evaluated for a weak voice. The patient also presented with impaired liver function and a focal-onset seizure. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y151 was evaluated for [E1]a weak voice[/E1]. The patient also presented with impaired liver function and a focal-onset seizure. Subsequent sequencing of the[E2] POL[/E2]G gene revealed a pathogenic variant., POL,GENE_VARIANT,156,160,a weak voice,HPO_TERM,31,43,0.84102744,0.15897256,-0.6820549,0
line751,Patient Y151 was evaluated for a weak voice. The patient also presented with impaired liver function and a focal-onset seizure. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y151 was evaluated for a weak voice. The patient also presented with [E1]impaired liver function[/E1] and a focal-onset seizure. Subsequent sequencing of the[E2] POL[/E2]G gene revealed a pathogenic variant., POL,GENE_VARIANT,156,160,impaired liver function,HPO_TERM,77,100,0.83275974,0.16724028,-0.6655195,0
line751,Patient Y151 was evaluated for a weak voice. The patient also presented with impaired liver function and a focal-onset seizure. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y151 was evaluated for a weak voice. The patient also presented with impaired liver function and [E1]a focal-onset seizur[/E1]e. Subsequent sequencing of the[E2] POL[/E2]G gene revealed a pathogenic variant., POL,GENE_VARIANT,156,160,a focal-onset seizur,HPO_TERM,105,125,0.855294,0.14470598,-0.710588,0
line752,The clinical profile for Patient Y152 includes a partial seizure and a soft or quiet voice. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Y152 includes [E1]a partial seizur[/E1]e and a soft or quiet voice. Genetic analysis of t[E2]he P[/E2]OLG gene confirmed the diagnosis.,he P,GENE_VARIANT,113,117,a partial seizur,HPO_TERM,47,63,0.84380907,0.15619089,-0.6876182,0
line752,The clinical profile for Patient Y152 includes a partial seizure and a soft or quiet voice. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Y152 includes a partial seizure and[E1] a soft or quiet vo[/E1]ice. Genetic analysis of t[E2]he P[/E2]OLG gene confirmed the diagnosis.,he P,GENE_VARIANT,113,117, a soft or quiet vo,HPO_TERM,68,87,0.837566,0.162434,-0.67513204,0
line753,The primary symptoms for Patient Y153 were a focal bright signal on T2 MRI of the thalamus and anxiety. Analysis of the POLG gene was performed.,The primary symptoms for Patient Y153 were a[E1] focal bright signal on T2 MRI of the thalam[/E1]us and anxiety. Analysis of the POLG g[E2]ene [/E2]was performed.,ene ,GENE_VARIANT,126,130, focal bright signal on T2 MRI of the thalam,HPO_TERM,44,88,0.810059,0.18994105,-0.62011796,0
line753,The primary symptoms for Patient Y153 were a focal bright signal on T2 MRI of the thalamus and anxiety. Analysis of the POLG gene was performed.,The primary symptoms for Patient Y153 were a focal bright signal on T2 MRI of the thalamus an[E1]d anxie[/E1]ty. Analysis of the POLG g[E2]ene [/E2]was performed.,ene ,GENE_VARIANT,126,130,d anxie,HPO_TERM,93,100,0.83855224,0.16144784,-0.6771044,0
line754,Patient Y154 was evaluated for a resting tremor. The patient also presented with bilateral grand mal seizures and a focal-onset seizure. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y154 was evaluated for [E1]a resting tremo[/E1]r. The patient also presented with bilateral grand mal seizures and a focal-onset seizure. Subsequent sequencing of th[E2]e PO[/E2]LG gene revealed a pathogenic variant.,e PO,GENE_VARIANT,164,168,a resting tremo,HPO_TERM,31,46,0.85513645,0.14486353,-0.7102729,0
line754,Patient Y154 was evaluated for a resting tremor. The patient also presented with bilateral grand mal seizures and a focal-onset seizure. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y154 was evaluated for a resting tremor. The patient also presented with[E1] bilateral grand mal seizure[/E1]s and a focal-onset seizure. Subsequent sequencing of th[E2]e PO[/E2]LG gene revealed a pathogenic variant.,e PO,GENE_VARIANT,164,168, bilateral grand mal seizure,HPO_TERM,80,108,0.8548696,0.14513043,-0.7097392,0
line754,Patient Y154 was evaluated for a resting tremor. The patient also presented with bilateral grand mal seizures and a focal-onset seizure. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y154 was evaluated for a resting tremor. The patient also presented with bilateral grand mal seizures and[E1] a focal-onset seizu[/E1]re. Subsequent sequencing of th[E2]e PO[/E2]LG gene revealed a pathogenic variant.,e PO,GENE_VARIANT,164,168, a focal-onset seizu,HPO_TERM,113,133,0.8303785,0.16962148,-0.660757,0
line755,The clinical profile for Patient Y155 includes a weak voice and seizures originating in one area of the brain. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Y155 includes [E1]a weak voice[/E1] and seizures originating in one area of the brain. Genetic analysis of t[E2]he P[/E2]OLG gene confirmed the diagnosis.,he P,GENE_VARIANT,132,136,a weak voice,HPO_TERM,47,59,0.84001887,0.15998112,-0.68003774,0
line755,The clinical profile for Patient Y155 includes a weak voice and seizures originating in one area of the brain. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Y155 includes a weak voice and [E1]seizures originating in one area of the br[/E1]ain. Genetic analysis of t[E2]he P[/E2]OLG gene confirmed the diagnosis.,he P,GENE_VARIANT,132,136,seizures originating in one area of the br,HPO_TERM,64,106,0.8456144,0.15438567,-0.6912287,0
line756,Patient Y156 was evaluated for poor liver function. The patient also presented with seizures with a localized origin and a focal T2 hyperintense thalamic lesion. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y156 was evaluated for [E1]poor liver functio[/E1]n. The patient also presented with seizures with a localized origin and a focal T2 hyperintense thalamic lesion. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,188,192,poor liver functio,HPO_TERM,31,49,0.85971105,0.14028893,-0.7194221,0
line756,Patient Y156 was evaluated for poor liver function. The patient also presented with seizures with a localized origin and a focal T2 hyperintense thalamic lesion. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y156 was evaluated for poor liver function. The patient also presented with[E1] seizures with a localized orig[/E1]in and a focal T2 hyperintense thalamic lesion. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,188,192, seizures with a localized orig,HPO_TERM,83,114,0.76563656,0.23436348,-0.53127307,0
line756,Patient Y156 was evaluated for poor liver function. The patient also presented with seizures with a localized origin and a focal T2 hyperintense thalamic lesion. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y156 was evaluated for poor liver function. The patient also presented with seizures with a localized origin an[E1]d a focal T2 hyperintense thalamic les[/E1]ion. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,188,192,d a focal T2 hyperintense thalamic les,HPO_TERM,119,157,0.8364449,0.16355507,-0.6728898,0
line757,"This report details Patient Y157, a patient with a weak voice. Further investigation showed a focal T2 hyperintense thalamic lesion and a focal-onset seizure. A known variant in the POLG gene was identified.","This report details Patient Y157, a patient with [E1]a weak voice[/E1]. Further investigation showed a focal T2 hyperintense thalamic lesion and a focal-onset seizure. A known variant in th[E2]e PO[/E2]LG gene was identified.",e PO,GENE_VARIANT,180,184,a weak voice,HPO_TERM,49,61,0.768719,0.23128092,-0.5374381,0
line757,"This report details Patient Y157, a patient with a weak voice. Further investigation showed a focal T2 hyperintense thalamic lesion and a focal-onset seizure. A known variant in the POLG gene was identified.","This report details Patient Y157, a patient with a weak voice. Further investigation showed [E1]a focal T2 hyperintense thalamic lesio[/E1]n and a focal-onset seizure. A known variant in th[E2]e PO[/E2]LG gene was identified.",e PO,GENE_VARIANT,180,184,a focal T2 hyperintense thalamic lesio,HPO_TERM,92,130,0.79702854,0.20297149,-0.5940571,0
line757,"This report details Patient Y157, a patient with a weak voice. Further investigation showed a focal T2 hyperintense thalamic lesion and a focal-onset seizure. A known variant in the POLG gene was identified.","This report details Patient Y157, a patient with a weak voice. Further investigation showed a focal T2 hyperintense thalamic lesion and[E1] a focal-onset seizu[/E1]re. A known variant in th[E2]e PO[/E2]LG gene was identified.",e PO,GENE_VARIANT,180,184, a focal-onset seizu,HPO_TERM,135,155,0.7955658,0.20443419,-0.59113157,0
line758,The clinical profile for Patient Y158 includes a focal-onset seizure and poor liver function. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Y158 includes [E1]a focal-onset seizur[/E1]e and poor liver function. Genetic analysis of th[E2]e PO[/E2]LG gene confirmed the diagnosis.,e PO,GENE_VARIANT,116,120,a focal-onset seizur,HPO_TERM,47,67,0.87449044,0.1255096,-0.7489808,0
line758,The clinical profile for Patient Y158 includes a focal-onset seizure and poor liver function. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Y158 includes a focal-onset seizure and[E1] poor liver functi[/E1]on. Genetic analysis of th[E2]e PO[/E2]LG gene confirmed the diagnosis.,e PO,GENE_VARIANT,116,120, poor liver functi,HPO_TERM,72,90,0.8577972,0.14220282,-0.7155944,0
line759,The primary symptoms for Patient Y159 were a simple partial seizure and a history of anxiety. Analysis of the POLG gene was performed.,The primary symptoms for Patient Y159 were a [E1]simple partial seizure[/E1] and a history of anxiety. Analysis of the POLG ge[E2]ne w[/E2]as performed.,ne w,GENE_VARIANT,117,121,simple partial seizure,HPO_TERM,45,67,0.7997232,0.20027679,-0.5994464,0
line759,The primary symptoms for Patient Y159 were a simple partial seizure and a history of anxiety. Analysis of the POLG gene was performed.,The primary symptoms for Patient Y159 were a simple partial seizure and [E1]a history of anxiet[/E1]y. Analysis of the POLG ge[E2]ne w[/E2]as performed.,ne w,GENE_VARIANT,117,121,a history of anxiet,HPO_TERM,72,91,0.82788587,0.17211415,-0.65577173,0
line760,The clinical profile for Patient Y160 includes a focal T2 hyperintense thalamic lesion and a partial seizure. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Y160 includes [E1]a focal T2 hyperintense thalamic lesio[/E1]n and a partial seizure. Genetic analysis of th[E2]e PO[/E2]LG gene confirmed the diagnosis.,e PO,GENE_VARIANT,132,136,a focal T2 hyperintense thalamic lesio,HPO_TERM,47,85,0.83667666,0.16332337,-0.6733533,0
line760,The clinical profile for Patient Y160 includes a focal T2 hyperintense thalamic lesion and a partial seizure. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Y160 includes a focal T2 hyperintense thalamic lesion and[E1] a partial seizu[/E1]re. Genetic analysis of th[E2]e PO[/E2]LG gene confirmed the diagnosis.,e PO,GENE_VARIANT,132,136, a partial seizu,HPO_TERM,90,106,0.8511063,0.14889374,-0.7022126,0
line761,Patient Y161 was evaluated for a focal bright signal on T2 MRI of the thalamus. The patient also presented with a partial seizure and a weak voice. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y161 was evaluated for [E1]a focal bright signal on T2 MRI of the thala[/E1]mus. The patient also presented with a partial seizure and a weak voice. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,173,177,a focal bright signal on T2 MRI of the thala,HPO_TERM,31,75,0.79408526,0.2059147,-0.5881705,0
line761,Patient Y161 was evaluated for a focal bright signal on T2 MRI of the thalamus. The patient also presented with a partial seizure and a weak voice. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y161 was evaluated for a focal bright signal on T2 MRI of the thalamus. The patient also presented wi[E1]th a partial sei[/E1]zure and a weak voice. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,173,177,th a partial sei,HPO_TERM,109,125,0.84581226,0.15418774,-0.6916245,0
line761,Patient Y161 was evaluated for a focal bright signal on T2 MRI of the thalamus. The patient also presented with a partial seizure and a weak voice. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y161 was evaluated for a focal bright signal on T2 MRI of the thalamus. The patient also presented with a partial seizure [E1]and a weak v[/E1]oice. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,173,177,and a weak v,HPO_TERM,130,142,0.8069975,0.19300252,-0.61399496,0
line762,The primary symptoms for Patient Y162 were difficulty projecting the voice and a focal-onset seizure. Analysis of the POLG gene was performed.,The primary symptoms for Patient Y162 were d[E1]ifficulty projecting the voi[/E1]ce and a focal-onset seizure. Analysis of the POLG [E2]gene[/E2] was performed.,gene,GENE_VARIANT,123,127,ifficulty projecting the voi,HPO_TERM,44,72,0.8215691,0.17843089,-0.6431382,0
line762,The primary symptoms for Patient Y162 were difficulty projecting the voice and a focal-onset seizure. Analysis of the POLG gene was performed.,The primary symptoms for Patient Y162 were difficulty projecting the voice an[E1]d a focal-onset seiz[/E1]ure. Analysis of the POLG [E2]gene[/E2] was performed.,gene,GENE_VARIANT,123,127,d a focal-onset seiz,HPO_TERM,77,97,0.81849813,0.18150191,-0.6369962,0
line763,The primary symptoms for Patient Y163 were a history of anxiety and a focal bright signal on T2 MRI of the thalamus. Analysis of the POLG gene was performed.,The primary symptoms for Patient Y163 were a[E1] history of anxiety[/E1] and a focal bright signal on T2 MRI of the thalamus. Analysis of the POLG [E2]gene[/E2] was performed.,gene,GENE_VARIANT,138,142, history of anxiety,HPO_TERM,44,63,0.81985444,0.18014556,-0.6397089,0
line763,The primary symptoms for Patient Y163 were a history of anxiety and a focal bright signal on T2 MRI of the thalamus. Analysis of the POLG gene was performed.,The primary symptoms for Patient Y163 were a history of anxiety and [E1]a focal bright signal on T2 MRI of the thala[/E1]mus. Analysis of the POLG [E2]gene[/E2] was performed.,gene,GENE_VARIANT,138,142,a focal bright signal on T2 MRI of the thala,HPO_TERM,68,112,0.8131068,0.18689327,-0.6262135,0
line764,The primary symptoms for Patient Y164 were a focal-onset seizure and a focal T2 hyperintense thalamic lesion. Analysis of the POLG gene was performed.,The primary symptoms for Patient Y164 were a[E1] focal-onset seizure[/E1] and a focal T2 hyperintense thalamic lesion. Analysis of the POLG ge[E2]ne w[/E2]as performed.,ne w,GENE_VARIANT,133,137, focal-onset seizure,HPO_TERM,44,64,0.7738818,0.22611816,-0.54776365,0
line764,The primary symptoms for Patient Y164 were a focal-onset seizure and a focal T2 hyperintense thalamic lesion. Analysis of the POLG gene was performed.,The primary symptoms for Patient Y164 were a focal-onset seizure and [E1]a focal T2 hyperintense thalamic lesio[/E1]n. Analysis of the POLG ge[E2]ne w[/E2]as performed.,ne w,GENE_VARIANT,133,137,a focal T2 hyperintense thalamic lesio,HPO_TERM,69,107,0.849336,0.15066403,-0.698672,0
line765,Patient Y165 was evaluated for seizures with a localized origin. The patient also presented with a focal T2 hyperintense thalamic lesion and anxiety. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y165 was evaluated for [E1]seizures with a localized origi[/E1]n. The patient also presented with a focal T2 hyperintense thalamic lesion and anxiety. Subsequent sequencing of th[E2]e PO[/E2]LG gene revealed a pathogenic variant.,e PO,GENE_VARIANT,177,181,seizures with a localized origi,HPO_TERM,31,62,0.8483011,0.15169886,-0.6966022,0
line765,Patient Y165 was evaluated for seizures with a localized origin. The patient also presented with a focal T2 hyperintense thalamic lesion and anxiety. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y165 was evaluated for seizures with a localized origin. The patient also presented with[E1] a focal T2 hyperintense thalamic lesi[/E1]on and anxiety. Subsequent sequencing of th[E2]e PO[/E2]LG gene revealed a pathogenic variant.,e PO,GENE_VARIANT,177,181, a focal T2 hyperintense thalamic lesi,HPO_TERM,96,134,0.83810115,0.16189887,-0.6762023,0
line765,Patient Y165 was evaluated for seizures with a localized origin. The patient also presented with a focal T2 hyperintense thalamic lesion and anxiety. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y165 was evaluated for seizures with a localized origin. The patient also presented with a focal T2 hyperintense thalamic lesion an[E1]d anxie[/E1]ty. Subsequent sequencing of th[E2]e PO[/E2]LG gene revealed a pathogenic variant.,e PO,GENE_VARIANT,177,181,d anxie,HPO_TERM,139,146,0.8598251,0.14017497,-0.7196501,0
line766,Patient Y166 was evaluated for difficulty projecting the voice. The patient also presented with a focal-onset seizure and a tremor. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y166 was evaluated for [E1]difficulty projecting the vo[/E1]ice. The patient also presented with a focal-onset seizure and a tremor. Subsequent sequencing of[E2] the[/E2] POLG gene revealed a pathogenic variant., the,GENE_VARIANT,156,160,difficulty projecting the vo,HPO_TERM,31,59,0.7680396,0.23196045,-0.53607917,0
line766,Patient Y166 was evaluated for difficulty projecting the voice. The patient also presented with a focal-onset seizure and a tremor. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y166 was evaluated for difficulty projecting the voice. The patient also presented wi[E1]th a focal-onset sei[/E1]zure and a tremor. Subsequent sequencing of[E2] the[/E2] POLG gene revealed a pathogenic variant., the,GENE_VARIANT,156,160,th a focal-onset sei,HPO_TERM,93,113,0.82473946,0.17526059,-0.64947885,0
line766,Patient Y166 was evaluated for difficulty projecting the voice. The patient also presented with a focal-onset seizure and a tremor. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y166 was evaluated for difficulty projecting the voice. The patient also presented with a focal-onset seizure [E1]and a t[/E1]remor. Subsequent sequencing of[E2] the[/E2] POLG gene revealed a pathogenic variant., the,GENE_VARIANT,156,160,and a t,HPO_TERM,118,125,0.7979281,0.20207189,-0.5958562,0
line767,"We report the case of Patient Y167, who has a history of a focal bright signal on T2 MRI of the thalamus. Examination also revealed a history of anxiety. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Y167, who has a history of [E1]a focal bright signal on T2 MRI of the thala[/E1]mus. Examination also revealed a history of anxiety. The underlying cause was traced to a mutation in [E2]the [/E2]POLG gene.",the ,GENE_VARIANT,203,207,a focal bright signal on T2 MRI of the thala,HPO_TERM,57,101,0.25763914,0.7423609,0.48472175,1
line767,"We report the case of Patient Y167, who has a history of a focal bright signal on T2 MRI of the thalamus. Examination also revealed a history of anxiety. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Y167, who has a history of a focal bright signal on T2 MRI of the thalamus. Examination also reveal[E1]ed a history of anx[/E1]iety. The underlying cause was traced to a mutation in [E2]the [/E2]POLG gene.",the ,GENE_VARIANT,203,207,ed a history of anx,HPO_TERM,129,148,0.3465915,0.6534085,0.30681702,1
line768,"This report details Patient Y168, a patient with difficulty projecting the voice. Further investigation showed a focal-onset seizure and a soft or quiet voice. A known variant in the POLG gene was identified.","This report details Patient Y168, a patient with [E1]difficulty projecting the vo[/E1]ice. Further investigation showed a focal-onset seizure and a soft or quiet voice. A known variant i[E2]n th[/E2]e POLG gene was identified.",n th,GENE_VARIANT,177,181,difficulty projecting the vo,HPO_TERM,49,77,0.79675806,0.20324197,-0.5935161,0
line768,"This report details Patient Y168, a patient with difficulty projecting the voice. Further investigation showed a focal-onset seizure and a soft or quiet voice. A known variant in the POLG gene was identified.","This report details Patient Y168, a patient with difficulty projecting the voice. Further investigation show[E1]ed a focal-onset sei[/E1]zure and a soft or quiet voice. A known variant i[E2]n th[/E2]e POLG gene was identified.",n th,GENE_VARIANT,177,181,ed a focal-onset sei,HPO_TERM,108,128,0.8190629,0.18093705,-0.63812584,0
line768,"This report details Patient Y168, a patient with difficulty projecting the voice. Further investigation showed a focal-onset seizure and a soft or quiet voice. A known variant in the POLG gene was identified.","This report details Patient Y168, a patient with difficulty projecting the voice. Further investigation showed a focal-onset seizure [E1]and a soft or quiet[/E1] voice. A known variant i[E2]n th[/E2]e POLG gene was identified.",n th,GENE_VARIANT,177,181,and a soft or quiet,HPO_TERM,133,152,0.81326556,0.18673441,-0.6265311,0
line769,Patient Y169 was evaluated for seizures with a localized origin. The patient also presented with a focal bright signal on T2 MRI of the thalamus and a focal-onset seizure. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y169 was evaluated for [E1]seizures with a localized origi[/E1]n. The patient also presented with a focal bright signal on T2 MRI of the thalamus and a focal-onset seizure. Subsequent sequencing of[E2] the[/E2] POLG gene revealed a pathogenic variant., the,GENE_VARIANT,196,200,seizures with a localized origi,HPO_TERM,31,62,0.7698131,0.23018688,-0.53962624,0
line769,Patient Y169 was evaluated for seizures with a localized origin. The patient also presented with a focal bright signal on T2 MRI of the thalamus and a focal-onset seizure. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y169 was evaluated for seizures with a localized origin. The patient also presented with[E1] a focal bright signal on T2 MRI of the thal[/E1]amus and a focal-onset seizure. Subsequent sequencing of[E2] the[/E2] POLG gene revealed a pathogenic variant., the,GENE_VARIANT,196,200, a focal bright signal on T2 MRI of the thal,HPO_TERM,96,140,0.7779854,0.22201459,-0.5559708,0
line769,Patient Y169 was evaluated for seizures with a localized origin. The patient also presented with a focal bright signal on T2 MRI of the thalamus and a focal-onset seizure. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y169 was evaluated for seizures with a localized origin. The patient also presented with a focal bright signal on T2 MRI of the thalamus [E1]and a focal-onset se[/E1]izure. Subsequent sequencing of[E2] the[/E2] POLG gene revealed a pathogenic variant., the,GENE_VARIANT,196,200,and a focal-onset se,HPO_TERM,145,165,0.7796141,0.22038591,-0.5592282,0
line770,"This report details Patient Y170, a patient with a focal-onset seizure. Further investigation showed a focal bright signal on T2 MRI of the thalamus and a tremor. A known variant in the POLG gene was identified.","This report details Patient Y170, a patient with [E1]a focal-onset seizur[/E1]e. Further investigation showed a focal bright signal on T2 MRI of the thalamus and a tremor. A known variant in[E2] the[/E2] POLG gene was identified.", the,GENE_VARIANT,181,185,a focal-onset seizur,HPO_TERM,49,69,0.6404356,0.35956442,-0.28087115,0
line770,"This report details Patient Y170, a patient with a focal-onset seizure. Further investigation showed a focal bright signal on T2 MRI of the thalamus and a tremor. A known variant in the POLG gene was identified.","This report details Patient Y170, a patient with a focal-onset seizure. Further investigation showed[E1] a focal bright signal on T2 MRI of the thal[/E1]amus and a tremor. A known variant in[E2] the[/E2] POLG gene was identified.", the,GENE_VARIANT,181,185, a focal bright signal on T2 MRI of the thal,HPO_TERM,100,144,0.6874088,0.31259117,-0.37481764,0
line770,"This report details Patient Y170, a patient with a focal-onset seizure. Further investigation showed a focal bright signal on T2 MRI of the thalamus and a tremor. A known variant in the POLG gene was identified.","This report details Patient Y170, a patient with a focal-onset seizure. Further investigation showed a focal bright signal on T2 MRI of the thalamus [E1]and a t[/E1]remor. A known variant in[E2] the[/E2] POLG gene was identified.", the,GENE_VARIANT,181,185,and a t,HPO_TERM,149,156,0.6853065,0.31469345,-0.37061304,0
line771,"This report details Patient Y171, a patient with a weak voice. Further investigation showed a focal-onset seizure and a focal T2 hyperintense thalamic lesion. A known variant in the POLG gene was identified.","This report details Patient Y171, a patient with [E1]a weak voice[/E1]. Further investigation showed a focal-onset seizure and a focal T2 hyperintense thalamic lesion. A known variant in th[E2]e PO[/E2]LG gene was identified.",e PO,GENE_VARIANT,180,184,a weak voice,HPO_TERM,49,61,0.7948063,0.20519376,-0.58961254,0
line771,"This report details Patient Y171, a patient with a weak voice. Further investigation showed a focal-onset seizure and a focal T2 hyperintense thalamic lesion. A known variant in the POLG gene was identified.","This report details Patient Y171, a patient with a weak voice. Further investigation showed [E1]a focal-onset seizur[/E1]e and a focal T2 hyperintense thalamic lesion. A known variant in th[E2]e PO[/E2]LG gene was identified.",e PO,GENE_VARIANT,180,184,a focal-onset seizur,HPO_TERM,92,112,0.795268,0.20473202,-0.590536,0
line771,"This report details Patient Y171, a patient with a weak voice. Further investigation showed a focal-onset seizure and a focal T2 hyperintense thalamic lesion. A known variant in the POLG gene was identified.","This report details Patient Y171, a patient with a weak voice. Further investigation showed a focal-onset seizure and[E1] a focal T2 hyperintense thalamic lesi[/E1]on. A known variant in th[E2]e PO[/E2]LG gene was identified.",e PO,GENE_VARIANT,180,184, a focal T2 hyperintense thalamic lesi,HPO_TERM,117,155,0.8104302,0.18956973,-0.6208605,0
line772,The primary symptoms for Patient Y172 were a tremor and poor liver function. Analysis of the POLG gene was performed.,The primary symptoms for Patient Y172 were a [E1]tremor [/E1]and poor liver function. Analysis of the POLG gen[E2]e wa[/E2]s performed.,e wa,GENE_VARIANT,101,105,tremor ,HPO_TERM,45,52,0.7628913,0.23710872,-0.5257826,0
line772,The primary symptoms for Patient Y172 were a tremor and poor liver function. Analysis of the POLG gene was performed.,The primary symptoms for Patient Y172 were a tremor and p[E1]oor liver function[/E1]. Analysis of the POLG gen[E2]e wa[/E2]s performed.,e wa,GENE_VARIANT,101,105,oor liver function,HPO_TERM,57,75,0.77742165,0.22257838,-0.5548433,0
line773,The clinical profile for Patient Y173 includes focal seizures and a focal-onset seizure. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Y173 includes [E1]focal seizures[/E1] and a focal-onset seizure. Genetic analysis of the[E2] POL[/E2]G gene confirmed the diagnosis., POL,GENE_VARIANT,112,116,focal seizures,HPO_TERM,47,61,0.81407434,0.18592569,-0.6281487,0
line773,The clinical profile for Patient Y173 includes focal seizures and a focal-onset seizure. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Y173 includes focal seizures and [E1]a focal-onset seizur[/E1]e. Genetic analysis of the[E2] POL[/E2]G gene confirmed the diagnosis., POL,GENE_VARIANT,112,116,a focal-onset seizur,HPO_TERM,66,86,0.8452962,0.15470381,-0.6905924,0
line774,"We report the case of Patient Y174, who has a history of a reduction in facial animation. Examination also revealed a weak voice. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Y174, who has a history of [E1]a reduction in facial animatio[/E1]n. Examination also revealed a weak voice. The underlying cause was traced to a mutation in the[E2] POL[/E2]G gene.", POL,GENE_VARIANT,182,186,a reduction in facial animatio,HPO_TERM,57,87,0.53972673,0.46027324,-0.0794535,0
line774,"We report the case of Patient Y174, who has a history of a reduction in facial animation. Examination also revealed a weak voice. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Y174, who has a history of a reduction in facial animation. Examination also revealed[E1] a weak voic[/E1]e. The underlying cause was traced to a mutation in the[E2] POL[/E2]G gene.", POL,GENE_VARIANT,182,186, a weak voic,HPO_TERM,115,127,0.40528467,0.59471536,0.18943068,1
line775,Patient Y175 was evaluated for a resting tremor. The patient also presented with a soft or quiet voice and a focal-onset seizure. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y175 was evaluated for [E1]a resting tremo[/E1]r. The patient also presented with a soft or quiet voice and a focal-onset seizure. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,155,159,a resting tremo,HPO_TERM,31,46,0.81775606,0.18224394,-0.6355121,0
line775,Patient Y175 was evaluated for a resting tremor. The patient also presented with a soft or quiet voice and a focal-onset seizure. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y175 was evaluated for a resting tremor. The patient also presented with[E1] a soft or quiet vo[/E1]ice and a focal-onset seizure. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,155,159, a soft or quiet vo,HPO_TERM,80,99,0.7780091,0.22199091,-0.55601823,0
line775,Patient Y175 was evaluated for a resting tremor. The patient also presented with a soft or quiet voice and a focal-onset seizure. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y175 was evaluated for a resting tremor. The patient also presented with a soft or quiet voice a[E1]nd a focal-onset sei[/E1]zure. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,155,159,nd a focal-onset sei,HPO_TERM,104,124,0.8269927,0.17300728,-0.6539854,0
line776,"This report details Patient Y176, a patient with a focal bright signal on T2 MRI of the thalamus. Further investigation showed a focal-onset seizure and a weak voice. A known variant in the POLG gene was identified.","This report details Patient Y176, a patient with [E1]a focal bright signal on T2 MRI of the thala[/E1]mus. Further investigation showed a focal-onset seizure and a weak voice. A known variant in [E2]the [/E2]POLG gene was identified.",the ,GENE_VARIANT,186,190,a focal bright signal on T2 MRI of the thala,HPO_TERM,49,93,0.6910612,0.3089388,-0.3821224,0
line776,"This report details Patient Y176, a patient with a focal bright signal on T2 MRI of the thalamus. Further investigation showed a focal-onset seizure and a weak voice. A known variant in the POLG gene was identified.","This report details Patient Y176, a patient with a focal bright signal on T2 MRI of the thalamus. Further investigation show[E1]ed a focal-onset sei[/E1]zure and a weak voice. A known variant in [E2]the [/E2]POLG gene was identified.",the ,GENE_VARIANT,186,190,ed a focal-onset sei,HPO_TERM,124,144,0.74712753,0.25287253,-0.494255,0
line776,"This report details Patient Y176, a patient with a focal bright signal on T2 MRI of the thalamus. Further investigation showed a focal-onset seizure and a weak voice. A known variant in the POLG gene was identified.","This report details Patient Y176, a patient with a focal bright signal on T2 MRI of the thalamus. Further investigation showed a focal-onset seizure [E1]and a weak v[/E1]oice. A known variant in [E2]the [/E2]POLG gene was identified.",the ,GENE_VARIANT,186,190,and a weak v,HPO_TERM,149,161,0.7258035,0.27419654,-0.45160696,0
line777,"We report the case of Patient Y177, who has a history of a focal-onset seizure. Examination also revealed a focal T2 hyperintense thalamic lesion. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Y177, who has a history of [E1]a focal-onset seizur[/E1]e. Examination also revealed a focal T2 hyperintense thalamic lesion. The underlying cause was traced to a mutation in th[E2]e PO[/E2]LG gene.",e PO,GENE_VARIANT,198,202,a focal-onset seizur,HPO_TERM,57,77,0.33678406,0.6632159,0.3264318,1
line777,"We report the case of Patient Y177, who has a history of a focal-onset seizure. Examination also revealed a focal T2 hyperintense thalamic lesion. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Y177, who has a history of a focal-onset seizure. Examination also revealed[E1] a focal T2 hyperintense thalamic lesi[/E1]on. The underlying cause was traced to a mutation in th[E2]e PO[/E2]LG gene.",e PO,GENE_VARIANT,198,202, a focal T2 hyperintense thalamic lesi,HPO_TERM,105,143,0.31061456,0.6893854,0.37877086,1
line778,The primary symptoms for Patient Y178 were seizures with a localized origin and a focal bright signal on T2 MRI of the thalamus. Analysis of the POLG gene was performed.,The primary symptoms for Patient Y178 were se[E1]izures with a localized origin [/E1]and a focal bright signal on T2 MRI of the thalamus. Analysis of the POLG g[E2]ene [/E2]was performed.,ene ,GENE_VARIANT,151,155,izures with a localized origin ,HPO_TERM,45,76,0.83110696,0.16889302,-0.6622139,0
line778,The primary symptoms for Patient Y178 were seizures with a localized origin and a focal bright signal on T2 MRI of the thalamus. Analysis of the POLG gene was performed.,The primary symptoms for Patient Y178 were seizures with a localized origin and a[E1] focal bright signal on T2 MRI of the thalam[/E1]us. Analysis of the POLG g[E2]ene [/E2]was performed.,ene ,GENE_VARIANT,151,155, focal bright signal on T2 MRI of the thalam,HPO_TERM,81,125,0.82707137,0.1729286,-0.65414274,0
line779,Patient Y179 was evaluated for a soft or quiet voice. The patient also presented with a partial seizure and seizures with a localized origin. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y179 was evaluated for [E1]a soft or quiet voi[/E1]ce. The patient also presented with a partial seizure and seizures with a localized origin. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,167,171,a soft or quiet voi,HPO_TERM,31,50,0.8350033,0.16499668,-0.67000663,0
line779,Patient Y179 was evaluated for a soft or quiet voice. The patient also presented with a partial seizure and seizures with a localized origin. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y179 was evaluated for a soft or quiet voice. The patient also presented wit[E1]h a partial seiz[/E1]ure and seizures with a localized origin. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,167,171,h a partial seiz,HPO_TERM,84,100,0.83076435,0.16923565,-0.6615287,0
line779,Patient Y179 was evaluated for a soft or quiet voice. The patient also presented with a partial seizure and seizures with a localized origin. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y179 was evaluated for a soft or quiet voice. The patient also presented with a partial seizure a[E1]nd seizures with a localized or[/E1]igin. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,167,171,nd seizures with a localized or,HPO_TERM,105,136,0.81838185,0.18161814,-0.6367637,0
line780,The primary symptoms for Patient Y180 were a decrease in body mass and a focal bright signal on T2 MRI of the thalamus. Analysis of the POLG gene was performed.,The primary symptoms for Patient Y180 were a[E1] decrease in body mass [/E1]and a focal bright signal on T2 MRI of the thalamus. Analysis of the POLG g[E2]ene [/E2]was performed.,ene ,GENE_VARIANT,142,146, decrease in body mass ,HPO_TERM,44,67,0.8060446,0.19395542,-0.61208916,0
line780,The primary symptoms for Patient Y180 were a decrease in body mass and a focal bright signal on T2 MRI of the thalamus. Analysis of the POLG gene was performed.,The primary symptoms for Patient Y180 were a decrease in body mass and a[E1] focal bright signal on T2 MRI of the thalam[/E1]us. Analysis of the POLG g[E2]ene [/E2]was performed.,ene ,GENE_VARIANT,142,146, focal bright signal on T2 MRI of the thalam,HPO_TERM,72,116,0.8221013,0.17789878,-0.64420253,0
line781,"We report the case of Patient Y181, who has a history of a focal T2 hyperintense thalamic lesion. Examination also revealed a weak voice. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Y181, who has a history of [E1]a focal T2 hyperintense thalamic lesio[/E1]n. Examination also revealed a weak voice. The underlying cause was traced to a mutation in the[E2] POL[/E2]G gene.", POL,GENE_VARIANT,190,194,a focal T2 hyperintense thalamic lesio,HPO_TERM,57,95,0.57186604,0.42813393,-0.1437321,0
line781,"We report the case of Patient Y181, who has a history of a focal T2 hyperintense thalamic lesion. Examination also revealed a weak voice. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Y181, who has a history of a focal T2 hyperintense thalamic lesion. Examination also revealed[E1] a weak voic[/E1]e. The underlying cause was traced to a mutation in the[E2] POL[/E2]G gene.", POL,GENE_VARIANT,190,194, a weak voic,HPO_TERM,123,135,0.51396567,0.48603442,-0.027931243,0
line782,"We report the case of Patient Y182, who has a history of a focal-onset seizure. Examination also revealed a weak voice. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Y182, who has a history of [E1]a focal-onset seizur[/E1]e. Examination also revealed a weak voice. The underlying cause was traced to a mutation in the[E2] POL[/E2]G gene.", POL,GENE_VARIANT,172,176,a focal-onset seizur,HPO_TERM,57,77,0.3714702,0.6285298,0.25705957,1
line782,"We report the case of Patient Y182, who has a history of a focal-onset seizure. Examination also revealed a weak voice. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Y182, who has a history of a focal-onset seizure. Examination also revealed[E1] a weak voic[/E1]e. The underlying cause was traced to a mutation in the[E2] POL[/E2]G gene.", POL,GENE_VARIANT,172,176, a weak voic,HPO_TERM,105,117,0.40022746,0.5997726,0.19954512,1
line783,"This report details Patient Y183, a patient with impaired liver function. Further investigation showed a focal-onset seizure and a focal bright signal on T2 MRI of the thalamus. A known variant in the POLG gene was identified.","This report details Patient Y183, a patient with [E1]impaired liver function[/E1]. Further investigation showed a focal-onset seizure and a focal bright signal on T2 MRI of the thalamus. A known variant in [E2]the [/E2]POLG gene was identified.",the ,GENE_VARIANT,197,201,impaired liver function,HPO_TERM,49,72,0.71910214,0.28089783,-0.43820432,0
line783,"This report details Patient Y183, a patient with impaired liver function. Further investigation showed a focal-onset seizure and a focal bright signal on T2 MRI of the thalamus. A known variant in the POLG gene was identified.","This report details Patient Y183, a patient with impaired liver function. Further investigation showed [E1]a focal-onset seizur[/E1]e and a focal bright signal on T2 MRI of the thalamus. A known variant in [E2]the [/E2]POLG gene was identified.",the ,GENE_VARIANT,197,201,a focal-onset seizur,HPO_TERM,103,123,0.72293574,0.2770643,-0.44587144,0
line783,"This report details Patient Y183, a patient with impaired liver function. Further investigation showed a focal-onset seizure and a focal bright signal on T2 MRI of the thalamus. A known variant in the POLG gene was identified.","This report details Patient Y183, a patient with impaired liver function. Further investigation showed a focal-onset seizure and[E1] a focal bright signal on T2 MRI of the thal[/E1]amus. A known variant in [E2]the [/E2]POLG gene was identified.",the ,GENE_VARIANT,197,201, a focal bright signal on T2 MRI of the thal,HPO_TERM,128,172,0.74300224,0.25699773,-0.4860045,0
line784,Patient Y184 was evaluated for anxiety. The patient also presented with a weak voice and a focal bright signal on T2 MRI of the thalamus. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y184 was evaluated for [E1]anxiety[/E1]. The patient also presented with a weak voice and a focal bright signal on T2 MRI of the thalamus. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,164,168,anxiety,HPO_TERM,31,38,0.82518613,0.17481382,-0.6503723,0
line784,Patient Y184 was evaluated for anxiety. The patient also presented with a weak voice and a focal bright signal on T2 MRI of the thalamus. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y184 was evaluated for anxiety. The patient also presented with [E1]a weak voice[/E1] and a focal bright signal on T2 MRI of the thalamus. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,164,168,a weak voice,HPO_TERM,72,84,0.82076055,0.17923947,-0.6415211,0
line784,Patient Y184 was evaluated for anxiety. The patient also presented with a weak voice and a focal bright signal on T2 MRI of the thalamus. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y184 was evaluated for anxiety. The patient also presented with a weak voice and [E1]a focal bright signal on T2 MRI of the thala[/E1]mus. Subsequent sequencing of t[E2]he P[/E2]OLG gene revealed a pathogenic variant.,he P,GENE_VARIANT,164,168,a focal bright signal on T2 MRI of the thala,HPO_TERM,89,133,0.8436882,0.15631182,-0.6873764,0
line785,Patient Y185 was evaluated for seizures with a localized origin. The patient also presented with a partial seizure and a soft or quiet voice. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y185 was evaluated for [E1]seizures with a localized origi[/E1]n. The patient also presented with a partial seizure and a soft or quiet voice. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,167,171,seizures with a localized origi,HPO_TERM,31,62,0.8225211,0.17747895,-0.6450421,0
line785,Patient Y185 was evaluated for seizures with a localized origin. The patient also presented with a partial seizure and a soft or quiet voice. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y185 was evaluated for seizures with a localized origin. The patient also presented with[E1] a partial seizu[/E1]re and a soft or quiet voice. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,167,171, a partial seizu,HPO_TERM,96,112,0.8005492,0.19945079,-0.6010984,0
line785,Patient Y185 was evaluated for seizures with a localized origin. The patient also presented with a partial seizure and a soft or quiet voice. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y185 was evaluated for seizures with a localized origin. The patient also presented with a partial seizure an[E1]d a soft or quiet v[/E1]oice. Subsequent sequencing of [E2]the [/E2]POLG gene revealed a pathogenic variant.,the ,GENE_VARIANT,167,171,d a soft or quiet v,HPO_TERM,117,136,0.83189285,0.16810708,-0.66378576,0
line786,"We report the case of Patient Y186, who has a history of a focal T2 hyperintense thalamic lesion. Examination also revealed a tremor. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Y186, who has a history of [E1]a focal T2 hyperintense thalamic lesio[/E1]n. Examination also revealed a tremor. The underlying cause was traced to a mutation in th[E2]e PO[/E2]LG gene.",e PO,GENE_VARIANT,185,189,a focal T2 hyperintense thalamic lesio,HPO_TERM,57,95,0.6238989,0.3761011,-0.24779782,0
line786,"We report the case of Patient Y186, who has a history of a focal T2 hyperintense thalamic lesion. Examination also revealed a tremor. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Y186, who has a history of a focal T2 hyperintense thalamic lesion. Examination also revealed[E1] a trem[/E1]or. The underlying cause was traced to a mutation in th[E2]e PO[/E2]LG gene.",e PO,GENE_VARIANT,185,189, a trem,HPO_TERM,123,130,0.49572617,0.5042739,0.008547723,1
line787,"We report the case of Patient Y187, who has a history of a soft or quiet voice. Examination also revealed a focal-onset seizure. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Y187, who has a history of [E1]a soft or quiet voi[/E1]ce. Examination also revealed a focal-onset seizure. The underlying cause was traced to a mutation in t[E2]he P[/E2]OLG gene.",he P,GENE_VARIANT,179,183,a soft or quiet voi,HPO_TERM,57,76,0.31457675,0.6854233,0.37084657,1
line787,"We report the case of Patient Y187, who has a history of a soft or quiet voice. Examination also revealed a focal-onset seizure. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Y187, who has a history of a soft or quiet voice. Examination also reveale[E1]d a focal-onset seiz[/E1]ure. The underlying cause was traced to a mutation in t[E2]he P[/E2]OLG gene.",he P,GENE_VARIANT,179,183,d a focal-onset seiz,HPO_TERM,104,124,0.35041595,0.64958405,0.2991681,1
line788,The primary symptoms for Patient Y188 were seizures with a localized origin and a focal bright signal on T2 MRI of the thalamus. Analysis of the POLG gene was performed.,The primary symptoms for Patient Y188 were s[E1]eizures with a localized origin[/E1] and a focal bright signal on T2 MRI of the thalamus. Analysis of the POLG [E2]gene[/E2] was performed.,gene,GENE_VARIANT,150,154,eizures with a localized origin,HPO_TERM,44,75,0.8171896,0.18281041,-0.63437915,0
line788,The primary symptoms for Patient Y188 were seizures with a localized origin and a focal bright signal on T2 MRI of the thalamus. Analysis of the POLG gene was performed.,The primary symptoms for Patient Y188 were seizures with a localized origin and [E1]a focal bright signal on T2 MRI of the thala[/E1]mus. Analysis of the POLG [E2]gene[/E2] was performed.,gene,GENE_VARIANT,150,154,a focal bright signal on T2 MRI of the thala,HPO_TERM,80,124,0.8215158,0.17848414,-0.64303166,0
line789,The primary symptoms for Patient Y189 were anxiety and a focal T2 hyperintense thalamic lesion. Analysis of the POLG gene was performed.,The primary symptoms for Patient Y189 were an[E1]xiety a[/E1]nd a focal T2 hyperintense thalamic lesion. Analysis of the POLG gene[E2] was[/E2] performed., was,GENE_VARIANT,121,125,xiety a,HPO_TERM,45,52,0.83272374,0.16727632,-0.6654474,0
line790,Patient Y190 was evaluated for a partial seizure. The patient also presented with a focal bright signal on T2 MRI of the thalamus and a focal-onset seizure. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y190 was evaluated for [E1]a partial seizur[/E1]e. The patient also presented with a focal bright signal on T2 MRI of the thalamus and a focal-onset seizure. Subsequent sequencing of[E2] the[/E2] POLG gene revealed a pathogenic variant., the,GENE_VARIANT,181,185,a partial seizur,HPO_TERM,31,47,0.8043417,0.1956583,-0.60868335,0
line790,Patient Y190 was evaluated for a partial seizure. The patient also presented with a focal bright signal on T2 MRI of the thalamus and a focal-onset seizure. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y190 was evaluated for a partial seizure. The patient also presented with[E1] a focal bright signal on T2 MRI of the thal[/E1]amus and a focal-onset seizure. Subsequent sequencing of[E2] the[/E2] POLG gene revealed a pathogenic variant., the,GENE_VARIANT,181,185, a focal bright signal on T2 MRI of the thal,HPO_TERM,81,125,0.75784916,0.24215086,-0.5156983,0
line790,Patient Y190 was evaluated for a partial seizure. The patient also presented with a focal bright signal on T2 MRI of the thalamus and a focal-onset seizure. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y190 was evaluated for a partial seizure. The patient also presented with a focal bright signal on T2 MRI of the thalamus [E1]and a focal-onset se[/E1]izure. Subsequent sequencing of[E2] the[/E2] POLG gene revealed a pathogenic variant., the,GENE_VARIANT,181,185,and a focal-onset se,HPO_TERM,130,150,0.7414139,0.2585861,-0.48282778,0
line791,"This report details Patient Y191, a patient with a weak voice. Further investigation showed a focal T2 hyperintense thalamic lesion and a focal-onset seizure. A known variant in the POLG gene was identified.","This report details Patient Y191, a patient with [E1]a weak voice[/E1]. Further investigation showed a focal T2 hyperintense thalamic lesion and a focal-onset seizure. A known variant in th[E2]e PO[/E2]LG gene was identified.",e PO,GENE_VARIANT,180,184,a weak voice,HPO_TERM,49,61,0.7946582,0.20534185,-0.58931637,0
line791,"This report details Patient Y191, a patient with a weak voice. Further investigation showed a focal T2 hyperintense thalamic lesion and a focal-onset seizure. A known variant in the POLG gene was identified.","This report details Patient Y191, a patient with a weak voice. Further investigation showed [E1]a focal T2 hyperintense thalamic lesio[/E1]n and a focal-onset seizure. A known variant in th[E2]e PO[/E2]LG gene was identified.",e PO,GENE_VARIANT,180,184,a focal T2 hyperintense thalamic lesio,HPO_TERM,92,130,0.81395406,0.18604594,-0.6279081,0
line791,"This report details Patient Y191, a patient with a weak voice. Further investigation showed a focal T2 hyperintense thalamic lesion and a focal-onset seizure. A known variant in the POLG gene was identified.","This report details Patient Y191, a patient with a weak voice. Further investigation showed a focal T2 hyperintense thalamic lesion and[E1] a focal-onset seizu[/E1]re. A known variant in th[E2]e PO[/E2]LG gene was identified.",e PO,GENE_VARIANT,180,184, a focal-onset seizu,HPO_TERM,135,155,0.8171224,0.18287757,-0.6342448,0
line792,The clinical profile for Patient Y192 includes a focal T2 hyperintense thalamic lesion and impaired liver function. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Y192 includes [E1]a focal T2 hyperintense thalamic lesio[/E1]n and impaired liver function. Genetic analysis of the[E2] POL[/E2]G gene confirmed the diagnosis., POL,GENE_VARIANT,139,143,a focal T2 hyperintense thalamic lesio,HPO_TERM,47,85,0.8225538,0.1774462,-0.6451076,0
line792,The clinical profile for Patient Y192 includes a focal T2 hyperintense thalamic lesion and impaired liver function. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Y192 includes a focal T2 hyperintense thalamic lesion and[E1] impaired liver functio[/E1]n. Genetic analysis of the[E2] POL[/E2]G gene confirmed the diagnosis., POL,GENE_VARIANT,139,143, impaired liver functio,HPO_TERM,90,113,0.8482615,0.15173855,-0.69652295,0
line793,Patient Y193 was evaluated for seizures originating in one area of the brain. The patient also presented with a focal-onset seizure and a focal T2 hyperintense thalamic lesion. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y193 was evaluated for [E1]seizures originating in one area of the br[/E1]ain. The patient also presented with a focal-onset seizure and a focal T2 hyperintense thalamic lesion. Subsequent sequencing of[E2] the[/E2] POLG gene revealed a pathogenic variant., the,GENE_VARIANT,201,205,seizures originating in one area of the br,HPO_TERM,31,73,0.7200539,0.27994603,-0.44010788,0
line793,Patient Y193 was evaluated for seizures originating in one area of the brain. The patient also presented with a focal-onset seizure and a focal T2 hyperintense thalamic lesion. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y193 was evaluated for seizures originating in one area of the brain. The patient also presented wi[E1]th a focal-onset sei[/E1]zure and a focal T2 hyperintense thalamic lesion. Subsequent sequencing of[E2] the[/E2] POLG gene revealed a pathogenic variant., the,GENE_VARIANT,201,205,th a focal-onset sei,HPO_TERM,107,127,0.81400573,0.1859943,-0.62801147,0
line793,Patient Y193 was evaluated for seizures originating in one area of the brain. The patient also presented with a focal-onset seizure and a focal T2 hyperintense thalamic lesion. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y193 was evaluated for seizures originating in one area of the brain. The patient also presented with a focal-onset seizure [E1]and a focal T2 hyperintense thalamic l[/E1]esion. Subsequent sequencing of[E2] the[/E2] POLG gene revealed a pathogenic variant., the,GENE_VARIANT,201,205,and a focal T2 hyperintense thalamic l,HPO_TERM,132,170,0.7414942,0.25850582,-0.48298836,0
line794,The primary symptoms for Patient Y194 were a partial seizure and a focal T2 hyperintense thalamic lesion. Analysis of the POLG gene was performed.,The primary symptoms for Patient Y194 were a [E1]partial seizure [/E1]and a focal T2 hyperintense thalamic lesion. Analysis of the POLG gen[E2]e wa[/E2]s performed.,e wa,GENE_VARIANT,130,134,partial seizure ,HPO_TERM,45,61,0.79208076,0.20791923,-0.5841615,0
line794,The primary symptoms for Patient Y194 were a partial seizure and a focal T2 hyperintense thalamic lesion. Analysis of the POLG gene was performed.,The primary symptoms for Patient Y194 were a partial seizure and a[E1] focal T2 hyperintense thalamic lesion[/E1]. Analysis of the POLG gen[E2]e wa[/E2]s performed.,e wa,GENE_VARIANT,130,134, focal T2 hyperintense thalamic lesion,HPO_TERM,66,104,0.79996324,0.20003682,-0.5999264,0
line795,Patient Y195 was evaluated for seizures with a localized origin. The patient also presented with a tremor and a weak voice. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y195 was evaluated for [E1]seizures with a localized origi[/E1]n. The patient also presented with a tremor and a weak voice. Subsequent sequencing of th[E2]e PO[/E2]LG gene revealed a pathogenic variant.,e PO,GENE_VARIANT,151,155,seizures with a localized origi,HPO_TERM,31,62,0.87403476,0.12596525,-0.7480695,0
line795,Patient Y195 was evaluated for seizures with a localized origin. The patient also presented with a tremor and a weak voice. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y195 was evaluated for seizures with a localized origin. The patient also presented with[E1] a trem[/E1]or and a weak voice. Subsequent sequencing of th[E2]e PO[/E2]LG gene revealed a pathogenic variant.,e PO,GENE_VARIANT,151,155, a trem,HPO_TERM,96,103,0.86459047,0.13540955,-0.72918093,0
line795,Patient Y195 was evaluated for seizures with a localized origin. The patient also presented with a tremor and a weak voice. Subsequent sequencing of the POLG gene revealed a pathogenic variant.,Patient Y195 was evaluated for seizures with a localized origin. The patient also presented with a tremor an[E1]d a weak voi[/E1]ce. Subsequent sequencing of th[E2]e PO[/E2]LG gene revealed a pathogenic variant.,e PO,GENE_VARIANT,151,155,d a weak voi,HPO_TERM,108,120,0.879764,0.120235965,-0.75952804,0
line796,"We report the case of Patient Y196, who has a history of reduced vocal volume. Examination also revealed unintentional weight loss. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Y196, who has a history of [E1]reduced vocal volume[/E1]. Examination also revealed unintentional weight loss. The underlying cause was traced to a mutation in the [E2]POLG[/E2] gene.",POLG,GENE_VARIANT,185,189,reduced vocal volume,HPO_TERM,57,77,0.47100785,0.5289922,0.057984322,1
line796,"We report the case of Patient Y196, who has a history of reduced vocal volume. Examination also revealed unintentional weight loss. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Y196, who has a history of reduced vocal volume. Examination also revealed [E1]unintentional weight loss[/E1]. The underlying cause was traced to a mutation in the [E2]POLG[/E2] gene.",POLG,GENE_VARIANT,185,189,unintentional weight loss,HPO_TERM,105,130,0.43318957,0.5668105,0.13362092,1
line797,The clinical profile for Patient Y197 includes bilateral grand mal seizures and weight loss. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Y197 includes [E1]bilateral grand mal seizures[/E1] and weight loss. Genetic analysis of the [E2]POLG[/E2] gene confirmed the diagnosis.,POLG,GENE_VARIANT,117,121,bilateral grand mal seizures,HPO_TERM,47,75,0.7865762,0.21342379,-0.5731524,0
line797,The clinical profile for Patient Y197 includes bilateral grand mal seizures and weight loss. Genetic analysis of the POLG gene confirmed the diagnosis.,The clinical profile for Patient Y197 includes bilateral grand mal seizures and [E1]weight loss[/E1]. Genetic analysis of the [E2]POLG[/E2] gene confirmed the diagnosis.,POLG,GENE_VARIANT,117,121,weight loss,HPO_TERM,80,91,0.78355134,0.21644872,-0.5671026,0
line798,"We report the case of Patient Y198, who has a history of reduced vocal volume. Examination also revealed a diagnosis of focal-onset seizures. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Y198, who has a history of [E1]reduced vocal volume[/E1]. Examination also revealed a diagnosis of focal-onset seizures. The underlying cause was traced to a mutation in the [E2]POLG[/E2] gene.",POLG,GENE_VARIANT,195,199,reduced vocal volume,HPO_TERM,57,77,0.43462092,0.565379,0.1307581,1
line798,"We report the case of Patient Y198, who has a history of reduced vocal volume. Examination also revealed a diagnosis of focal-onset seizures. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient Y198, who has a history of reduced vocal volume. Examination also revealed [E1]a diagnosis of focal-onset seizures[/E1]. The underlying cause was traced to a mutation in the [E2]POLG[/E2] gene.",POLG,GENE_VARIANT,195,199,a diagnosis of focal-onset seizures,HPO_TERM,105,140,0.46079516,0.5392049,0.07840973,1
line799,The primary symptoms for Patient Y199 were a tremor and bilateral tonic-clonic seizures. Analysis of the POLG gene was performed.,The primary symptoms for Patient Y199 were a [E1]tremor [/E1]and bilateral tonic-clonic seizures. Analysis of the POLG gene[E2] was[/E2] performed., was,GENE_VARIANT,114,118,tremor ,HPO_TERM,45,52,0.82493776,0.17506224,-0.6498755,0
line800,Patient V0 was evaluated for pallhypesthesia. The patient also presented with a decrease in tendon reflexes and unilateral motor seizure activity. Subsequent sequencing of c.1156C>T p.R386C revealed a pathogenic variant.,Patient V0 was evaluated for [E1]pallhypesthesia[/E1]. The patient also presented with a decrease in tendon reflexes and unilateral motor seizure activity. Subsequent sequencing of [E2]c.1156C>T p.R386C[/E2] revealed a pathogenic variant.,c.1156C>T p.R386C,GENE_VARIANT,172,189,pallhypesthesia,HPO_TERM,29,44,0.8855168,0.11448314,-0.7710337,0
line800,Patient V0 was evaluated for pallhypesthesia. The patient also presented with a decrease in tendon reflexes and unilateral motor seizure activity. Subsequent sequencing of c.1156C>T p.R386C revealed a pathogenic variant.,Patient V0 was evaluated for pallhypesthesia. The patient also presented with [E1]a decrease in tendon reflexes[/E1] and unilateral motor seizure activity. Subsequent sequencing of [E2]c.1156C>T p.R386C[/E2] revealed a pathogenic variant.,c.1156C>T p.R386C,GENE_VARIANT,172,189,a decrease in tendon reflexes,HPO_TERM,78,107,0.8829942,0.11700584,-0.76598835,0
line800,Patient V0 was evaluated for pallhypesthesia. The patient also presented with a decrease in tendon reflexes and unilateral motor seizure activity. Subsequent sequencing of c.1156C>T p.R386C revealed a pathogenic variant.,Patient V0 was evaluated for pallhypesthesia. The patient also presented with a decrease in tendon reflexes and [E1]unilateral motor seizure activity[/E1]. Subsequent sequencing of [E2]c.1156C>T p.R386C[/E2] revealed a pathogenic variant.,c.1156C>T p.R386C,GENE_VARIANT,172,189,unilateral motor seizure activity,HPO_TERM,112,145,0.88526505,0.11473497,-0.7705301,0
line801,"This report details Patient V1, a patient with tendon reflexes were difficult to elicit. Further investigation showed impaired coordination during walking and a kinetic tremor. A known variant in 1868T>G L623W was identified.","This report details Patient V1, a patient with [E1]tendon reflexes were difficult to elicit[/E1]. Further investigation showed impaired coordination during walking and a kinetic tremor. A known variant in [E2]1868T>G L623W[/E2] was identified.",1868T>G L623W,GENE_VARIANT,196,209,tendon reflexes were difficult to elicit,HPO_TERM,47,87,0.8667059,0.13329406,-0.73341185,0
line801,"This report details Patient V1, a patient with tendon reflexes were difficult to elicit. Further investigation showed impaired coordination during walking and a kinetic tremor. A known variant in 1868T>G L623W was identified.","This report details Patient V1, a patient with tendon reflexes were difficult to elicit. Further investigation showed [E1]impaired coordination during walking[/E1] and a kinetic tremor. A known variant in [E2]1868T>G L623W[/E2] was identified.",1868T>G L623W,GENE_VARIANT,196,209,impaired coordination during walking,HPO_TERM,118,154,0.86478037,0.13521966,-0.72956073,0
line801,"This report details Patient V1, a patient with tendon reflexes were difficult to elicit. Further investigation showed impaired coordination during walking and a kinetic tremor. A known variant in 1868T>G L623W was identified.","This report details Patient V1, a patient with tendon reflexes were difficult to elicit. Further investigation showed impaired coordination during walking and [E1]a kinetic tremor[/E1]. A known variant in [E2]1868T>G L623W[/E2] was identified.",1868T>G L623W,GENE_VARIANT,196,209,a kinetic tremor,HPO_TERM,159,175,0.86558163,0.13441832,-0.7311633,0
line802,Patient V2 was evaluated for a focal seizure with motor signs. The patient also presented with pallhypesthesia and a coagulopathy. Subsequent sequencing of R853W revealed a pathogenic variant.,Patient V2 was evaluated for [E1]a focal seizure with motor sign[/E1]s. The patient also presented with pallhypesthesia and a coagulopathy. Subsequent sequencing o[E2]f R85[/E2]3W revealed a pathogenic variant.,f R85,GENE_VARIANT,154,159,a focal seizure with motor sign,HPO_TERM,29,60,0.88247025,0.11752975,-0.7649405,0
line802,Patient V2 was evaluated for a focal seizure with motor signs. The patient also presented with pallhypesthesia and a coagulopathy. Subsequent sequencing of R853W revealed a pathogenic variant.,Patient V2 was evaluated for a focal seizure with motor signs. The patient also presented with[E1] pallhypesthesi[/E1]a and a coagulopathy. Subsequent sequencing o[E2]f R85[/E2]3W revealed a pathogenic variant.,f R85,GENE_VARIANT,154,159, pallhypesthesi,HPO_TERM,94,109,0.8877488,0.11225128,-0.7754975,0
line802,Patient V2 was evaluated for a focal seizure with motor signs. The patient also presented with pallhypesthesia and a coagulopathy. Subsequent sequencing of R853W revealed a pathogenic variant.,Patient V2 was evaluated for a focal seizure with motor signs. The patient also presented with pallhypesthesia and[E1] a coagulopat[/E1]hy. Subsequent sequencing o[E2]f R85[/E2]3W revealed a pathogenic variant.,f R85,GENE_VARIANT,154,159, a coagulopat,HPO_TERM,114,127,0.88683355,0.11316645,-0.7736671,0
line805,The clinical profile for Patient V5 includes sluggish tendon reflexes and a stooped posture. Genetic analysis of G737R confirmed the diagnosis.,The clinical profile for Patient V5 includes [E1]sluggish tendon reflexe[/E1]s and a stooped posture. Genetic analysis o[E2]f G73[/E2]7R confirmed the diagnosis.,f G73,GENE_VARIANT,111,116,sluggish tendon reflexe,HPO_TERM,45,68,0.86705106,0.13294896,-0.73410213,0
line805,The clinical profile for Patient V5 includes sluggish tendon reflexes and a stooped posture. Genetic analysis of G737R confirmed the diagnosis.,The clinical profile for Patient V5 includes sluggish tendon reflexes and[E1] a stooped postu[/E1]re. Genetic analysis o[E2]f G73[/E2]7R confirmed the diagnosis.,f G73,GENE_VARIANT,111,116, a stooped postu,HPO_TERM,73,89,0.87189746,0.12810257,-0.7437949,0
line807,Patient V7 was evaluated for an ataxic gait. The patient also presented with impaired vibratory sensation and a focal motor seizure. Subsequent sequencing of 2263A>G K755E revealed a pathogenic variant.,Patient V7 was evaluated for [E1]an ataxic gai[/E1]t. The patient also presented with impaired vibratory sensation and a focal motor seizure. Subsequent sequencing[E2] of 2263A>G K[/E2]755E revealed a pathogenic variant., of 2263A>G K,GENE_VARIANT,154,167,an ataxic gai,HPO_TERM,29,42,0.8884239,0.11157609,-0.77684784,0
line807,Patient V7 was evaluated for an ataxic gait. The patient also presented with impaired vibratory sensation and a focal motor seizure. Subsequent sequencing of 2263A>G K755E revealed a pathogenic variant.,Patient V7 was evaluated for an ataxic gait. The patient also presented with[E1] impaired vibratory sensat[/E1]ion and a focal motor seizure. Subsequent sequencing[E2] of 2263A>G K[/E2]755E revealed a pathogenic variant., of 2263A>G K,GENE_VARIANT,154,167, impaired vibratory sensat,HPO_TERM,76,102,0.8818386,0.11816137,-0.76367724,0
line807,Patient V7 was evaluated for an ataxic gait. The patient also presented with impaired vibratory sensation and a focal motor seizure. Subsequent sequencing of 2263A>G K755E revealed a pathogenic variant.,Patient V7 was evaluated for an ataxic gait. The patient also presented with impaired vibratory sensation a[E1]nd a focal motor sei[/E1]zure. Subsequent sequencing[E2] of 2263A>G K[/E2]755E revealed a pathogenic variant., of 2263A>G K,GENE_VARIANT,154,167,nd a focal motor sei,HPO_TERM,107,127,0.8864732,0.113526836,-0.77294636,0
line808,Patient V8 was evaluated for a focal motor seizure. The patient also presented with a language disorder and a tremor. Subsequent sequencing of c.3643+2T>C revealed a pathogenic variant.,Patient V8 was evaluated for [E1]a focal motor seizur[/E1]e. The patient also presented with a language disorder and a tremor. Subsequent sequencing of[E2] c.3643+2T>C[/E2] revealed a pathogenic variant., c.3643+2T>C,GENE_VARIANT,142,154,a focal motor seizur,HPO_TERM,29,49,0.89079666,0.10920333,-0.7815933,0
line808,Patient V8 was evaluated for a focal motor seizure. The patient also presented with a language disorder and a tremor. Subsequent sequencing of c.3643+2T>C revealed a pathogenic variant.,Patient V8 was evaluated for a focal motor seizure. The patient also presented with[E1] a language disorde[/E1]r and a tremor. Subsequent sequencing of[E2] c.3643+2T>C[/E2] revealed a pathogenic variant., c.3643+2T>C,GENE_VARIANT,142,154, a language disorde,HPO_TERM,83,102,0.8795112,0.12048883,-0.75902236,0
line808,Patient V8 was evaluated for a focal motor seizure. The patient also presented with a language disorder and a tremor. Subsequent sequencing of c.3643+2T>C revealed a pathogenic variant.,Patient V8 was evaluated for a focal motor seizure. The patient also presented with a language disorder and[E1] a tremo[/E1]r. Subsequent sequencing of[E2] c.3643+2T>C[/E2] revealed a pathogenic variant., c.3643+2T>C,GENE_VARIANT,142,154, a tremo,HPO_TERM,107,115,0.8872814,0.112718605,-0.77456284,0
line809,"This report details Patient V9, a patient with a postural or kinetic tremor. Further investigation showed a kinetic tremor and parietal sharp waves on electroencephalogram. A known variant in G737R was identified.","This report details Patient V9, a patient with [E1]a postural or kinetic tremo[/E1]r. Further investigation showed a kinetic tremor and parietal sharp waves on electroencephalogram. A known variant [E2]in G7[/E2]37R was identified.",in G7,GENE_VARIANT,189,194,a postural or kinetic tremo,HPO_TERM,47,74,0.8499184,0.15008157,-0.69983685,0
line809,"This report details Patient V9, a patient with a postural or kinetic tremor. Further investigation showed a kinetic tremor and parietal sharp waves on electroencephalogram. A known variant in G737R was identified.","This report details Patient V9, a patient with a postural or kinetic tremor. Further investigation showed[E1] a kinetic tremo[/E1]r and parietal sharp waves on electroencephalogram. A known variant [E2]in G7[/E2]37R was identified.",in G7,GENE_VARIANT,189,194, a kinetic tremo,HPO_TERM,105,121,0.8549822,0.14501788,-0.70996433,0
line809,"This report details Patient V9, a patient with a postural or kinetic tremor. Further investigation showed a kinetic tremor and parietal sharp waves on electroencephalogram. A known variant in G737R was identified.","This report details Patient V9, a patient with a postural or kinetic tremor. Further investigation showed a kinetic tremor and[E1] parietal sharp waves on electroencephalog[/E1]ram. A known variant [E2]in G7[/E2]37R was identified.",in G7,GENE_VARIANT,189,194, parietal sharp waves on electroencephalog,HPO_TERM,126,168,0.8471885,0.15281156,-0.69437695,0
line811,The primary symptoms for Patient V11 were an ataxic gait and a coagulation disorder. Analysis of the c.1156C>T p.R386C was performed.,The primary symptoms for Patient V11 were an[E1] ataxic gait [/E1]and a coagulation disorder. Analysis of the c.11[E2]56C>T p.R386C was[/E2] performed.,56C>T p.R386C was,GENE_VARIANT,105,122, ataxic gait ,HPO_TERM,44,57,0.87997997,0.12002003,-0.75995994,0
line812,Patient V12 was evaluated for a forward-leaning posture. The patient also presented with a focal motor seizure and a decrease in tendon reflexes. Subsequent sequencing of c.1156C>T p.R386C revealed a pathogenic variant.,Patient V12 was evaluated for [E1]a forward-leaning postur[/E1]e. The patient also presented with a focal motor seizure and a decrease in tendon reflexes. Subsequent sequencing o[E2]f c.1156C>T p.R38[/E2]6C revealed a pathogenic variant.,f c.1156C>T p.R38,GENE_VARIANT,169,186,a forward-leaning postur,HPO_TERM,30,54,0.8927238,0.10727617,-0.7854476,0
line812,Patient V12 was evaluated for a forward-leaning posture. The patient also presented with a focal motor seizure and a decrease in tendon reflexes. Subsequent sequencing of c.1156C>T p.R386C revealed a pathogenic variant.,Patient V12 was evaluated for a forward-leaning posture. The patient also presented with[E1] a focal motor seizu[/E1]re and a decrease in tendon reflexes. Subsequent sequencing o[E2]f c.1156C>T p.R38[/E2]6C revealed a pathogenic variant.,f c.1156C>T p.R38,GENE_VARIANT,169,186, a focal motor seizu,HPO_TERM,88,108,0.8857975,0.11420251,-0.771595,0
line812,Patient V12 was evaluated for a forward-leaning posture. The patient also presented with a focal motor seizure and a decrease in tendon reflexes. Subsequent sequencing of c.1156C>T p.R386C revealed a pathogenic variant.,Patient V12 was evaluated for a forward-leaning posture. The patient also presented with a focal motor seizure an[E1]d a decrease in tendon reflex[/E1]es. Subsequent sequencing o[E2]f c.1156C>T p.R38[/E2]6C revealed a pathogenic variant.,f c.1156C>T p.R38,GENE_VARIANT,169,186,d a decrease in tendon reflex,HPO_TERM,113,142,0.8891036,0.11089642,-0.7782072,0
line814,Patient V14 was evaluated for a postural or kinetic tremor. The patient also presented with impaired vibratory sensation and a kinetic tremor. Subsequent sequencing of 1868T>G L623W revealed a pathogenic variant.,Patient V14 was evaluated for [E1]a postural or kinetic tremo[/E1]r. The patient also presented with impaired vibratory sensation and a kinetic tremor. Subsequent sequencing [E2]of 1868T>G L6[/E2]23W revealed a pathogenic variant.,of 1868T>G L6,GENE_VARIANT,165,178,a postural or kinetic tremo,HPO_TERM,30,57,0.89503324,0.10496676,-0.7900665,0
line814,Patient V14 was evaluated for a postural or kinetic tremor. The patient also presented with impaired vibratory sensation and a kinetic tremor. Subsequent sequencing of 1868T>G L623W revealed a pathogenic variant.,Patient V14 was evaluated for a postural or kinetic tremor. The patient also presented with[E1] impaired vibratory sensat[/E1]ion and a kinetic tremor. Subsequent sequencing [E2]of 1868T>G L6[/E2]23W revealed a pathogenic variant.,of 1868T>G L6,GENE_VARIANT,165,178, impaired vibratory sensat,HPO_TERM,91,117,0.88839287,0.11160708,-0.7767858,0
line814,Patient V14 was evaluated for a postural or kinetic tremor. The patient also presented with impaired vibratory sensation and a kinetic tremor. Subsequent sequencing of 1868T>G L623W revealed a pathogenic variant.,Patient V14 was evaluated for a postural or kinetic tremor. The patient also presented with impaired vibratory sensation a[E1]nd a kinetic tre[/E1]mor. Subsequent sequencing [E2]of 1868T>G L6[/E2]23W revealed a pathogenic variant.,of 1868T>G L6,GENE_VARIANT,165,178,nd a kinetic tre,HPO_TERM,122,138,0.8933474,0.10665261,-0.78669477,0
line816,The primary symptoms for Patient V16 were reduced vibration sense and a language disorder. Analysis of the c.1156C>T p.R386C was performed.,The primary symptoms for Patient V16 were re[E1]duced vibration sense [/E1]and a language disorder. Analysis of the c.1[E2]156C>T p.R386C wa[/E2]s performed.,156C>T p.R386C wa,GENE_VARIANT,110,127,duced vibration sense ,HPO_TERM,44,66,0.85773194,0.14226806,-0.7154639,0
line816,The primary symptoms for Patient V16 were reduced vibration sense and a language disorder. Analysis of the c.1156C>T p.R386C was performed.,The primary symptoms for Patient V16 were reduced vibration sense and a[E1] language disorder[/E1]. Analysis of the c.1[E2]156C>T p.R386C wa[/E2]s performed.,156C>T p.R386C wa,GENE_VARIANT,110,127, language disorder,HPO_TERM,71,89,0.8466104,0.15338956,-0.69322085,0
line819,The clinical profile for Patient V19 includes an ataxic gait and reduced reflexes on examination. Genetic analysis of R853W confirmed the diagnosis.,The clinical profile for Patient V19 includes [E1]an ataxic gai[/E1]t and reduced reflexes on examination. Genetic analysis[E2] of R[/E2]853W confirmed the diagnosis., of R,GENE_VARIANT,114,119,an ataxic gai,HPO_TERM,46,59,0.8715292,0.12847075,-0.74305844,0
line819,The clinical profile for Patient V19 includes an ataxic gait and reduced reflexes on examination. Genetic analysis of R853W confirmed the diagnosis.,The clinical profile for Patient V19 includes an ataxic gait and[E1] reduced reflexes on examina[/E1]tion. Genetic analysis[E2] of R[/E2]853W confirmed the diagnosis., of R,GENE_VARIANT,114,119, reduced reflexes on examina,HPO_TERM,64,92,0.87205505,0.12794495,-0.7441101,0
line821,The clinical profile for Patient V21 includes focal motor seizures and gait ataxia. Genetic analysis of c.1156C>T p.R386C confirmed the diagnosis.,The clinical profile for Patient V21 includes [E1]focal motor seizures[/E1] and gait ataxia. Genetic analysis of [E2]c.1156C>T p.R386C[/E2] confirmed the diagnosis.,c.1156C>T p.R386C,GENE_VARIANT,104,121,focal motor seizures,HPO_TERM,46,66,0.87320054,0.12679942,-0.74640113,0
line821,The clinical profile for Patient V21 includes focal motor seizures and gait ataxia. Genetic analysis of c.1156C>T p.R386C confirmed the diagnosis.,The clinical profile for Patient V21 includes focal motor seizures and [E1]gait ataxia[/E1]. Genetic analysis of [E2]c.1156C>T p.R386C[/E2] confirmed the diagnosis.,c.1156C>T p.R386C,GENE_VARIANT,104,121,gait ataxia,HPO_TERM,71,82,0.8810646,0.11893539,-0.7621292,0
line822,The clinical profile for Patient V22 includes parietal epileptiform discharges on EEG and a blood clotting disorder. Genetic analysis of c.2794C>T p.H932Y confirmed the diagnosis.,The clinical profile for Patient V22 includes [E1]parietal epileptiform discharges on EEG[/E1] and a blood clotting disorder. Genetic analysis of [E2]c.2794C>T p.H932Y c[/E2]onfirmed the diagnosis.,c.2794C>T p.H932Y c,GENE_VARIANT,137,156,parietal epileptiform discharges on EEG,HPO_TERM,46,85,0.88001174,0.119988225,-0.76002353,0
line822,The clinical profile for Patient V22 includes parietal epileptiform discharges on EEG and a blood clotting disorder. Genetic analysis of c.2794C>T p.H932Y confirmed the diagnosis.,The clinical profile for Patient V22 includes parietal epileptiform discharges on EEG and [E1]a blood clotting disorder[/E1]. Genetic analysis of [E2]c.2794C>T p.H932Y c[/E2]onfirmed the diagnosis.,c.2794C>T p.H932Y c,GENE_VARIANT,137,156,a blood clotting disorder,HPO_TERM,90,115,0.8842441,0.11575586,-0.7684882,0
line825,Patient V25 was evaluated for an ataxic gait. The patient also presented with hyporeflexia and an inability to coordinate gait. Subsequent sequencing of R853W revealed a pathogenic variant.,Patient V25 was evaluated for [E1]an ataxic gai[/E1]t. The patient also presented with hyporeflexia and an inability to coordinate gait. Subsequent sequenci[E2]ng of[/E2] R853W revealed a pathogenic variant.,ng of,GENE_VARIANT,147,152,an ataxic gai,HPO_TERM,30,43,0.8831986,0.116801344,-0.7663973,0
line825,Patient V25 was evaluated for an ataxic gait. The patient also presented with hyporeflexia and an inability to coordinate gait. Subsequent sequencing of R853W revealed a pathogenic variant.,Patient V25 was evaluated for an ataxic gait. The patient also presented with[E1] hyporeflex[/E1]ia and an inability to coordinate gait. Subsequent sequenci[E2]ng of[/E2] R853W revealed a pathogenic variant.,ng of,GENE_VARIANT,147,152, hyporeflex,HPO_TERM,77,88,0.86637175,0.13362831,-0.73274344,0
line825,Patient V25 was evaluated for an ataxic gait. The patient also presented with hyporeflexia and an inability to coordinate gait. Subsequent sequencing of R853W revealed a pathogenic variant.,Patient V25 was evaluated for an ataxic gait. The patient also presented with hyporeflexia an[E1]d an inability to coordinat[/E1]e gait. Subsequent sequenci[E2]ng of[/E2] R853W revealed a pathogenic variant.,ng of,GENE_VARIANT,147,152,d an inability to coordinat,HPO_TERM,93,120,0.8707172,0.12928277,-0.74143445,0
line826,The primary symptoms for Patient V26 were hyporeflexia and impaired coordination during walking. Analysis of the W748S was performed.,The primary symptoms for Patient V26 were hy[E1]poreflexia [/E1]and impaired coordination during walking. Analysis of the W7[E2]48S w[/E2]as performed.,48S w,GENE_VARIANT,115,120,poreflexia ,HPO_TERM,44,55,0.7707875,0.22921254,-0.54157495,0
line826,The primary symptoms for Patient V26 were hyporeflexia and impaired coordination during walking. Analysis of the W748S was performed.,The primary symptoms for Patient V26 were hyporeflexia and i[E1]mpaired coordination during walkin[/E1]g. Analysis of the W7[E2]48S w[/E2]as performed.,48S w,GENE_VARIANT,115,120,mpaired coordination during walkin,HPO_TERM,60,94,0.8135826,0.18641733,-0.62716526,0
line827,"This report details Patient V27, a patient with a communication disorder. Further investigation showed a focal motor seizure and an action tremor. A known variant in G737R was identified.","This report details Patient V27, a patient with [E1]a communication disorde[/E1]r. Further investigation showed a focal motor seizure and an action tremor. A known variant [E2]in G7[/E2]37R was identified.",in G7,GENE_VARIANT,163,168,a communication disorde,HPO_TERM,48,71,0.8571727,0.14282721,-0.7143455,0
line827,"This report details Patient V27, a patient with a communication disorder. Further investigation showed a focal motor seizure and an action tremor. A known variant in G737R was identified.","This report details Patient V27, a patient with a communication disorder. Further investigation showed[E1] a focal motor seizu[/E1]re and an action tremor. A known variant [E2]in G7[/E2]37R was identified.",in G7,GENE_VARIANT,163,168, a focal motor seizu,HPO_TERM,102,122,0.8476624,0.15233761,-0.6953248,0
line827,"This report details Patient V27, a patient with a communication disorder. Further investigation showed a focal motor seizure and an action tremor. A known variant in G737R was identified.","This report details Patient V27, a patient with a communication disorder. Further investigation showed a focal motor seizure an[E1]d an action tre[/E1]mor. A known variant [E2]in G7[/E2]37R was identified.",in G7,GENE_VARIANT,163,168,d an action tre,HPO_TERM,127,142,0.87309885,0.12690121,-0.74619764,0
line828,"This report details Patient V28, a patient with a stooped posture. Further investigation showed parietal epileptiform discharges on EEG and impaired vibratory sensation. A known variant in W748S was identified.","This report details Patient V28, a patient with [E1]a stooped postur[/E1]e. Further investigation showed parietal epileptiform discharges on EEG and impaired vibratory sensation. A known variant [E2]in W7[/E2]48S was identified.",in W7,GENE_VARIANT,186,191,a stooped postur,HPO_TERM,48,64,0.8168537,0.18314628,-0.6337074,0
line828,"This report details Patient V28, a patient with a stooped posture. Further investigation showed parietal epileptiform discharges on EEG and impaired vibratory sensation. A known variant in W748S was identified.","This report details Patient V28, a patient with a stooped posture. Further investigation showed[E1] parietal epileptiform discharges on EE[/E1]G and impaired vibratory sensation. A known variant [E2]in W7[/E2]48S was identified.",in W7,GENE_VARIANT,186,191, parietal epileptiform discharges on EE,HPO_TERM,95,134,0.81026274,0.1897373,-0.6205254,0
line828,"This report details Patient V28, a patient with a stooped posture. Further investigation showed parietal epileptiform discharges on EEG and impaired vibratory sensation. A known variant in W748S was identified.","This report details Patient V28, a patient with a stooped posture. Further investigation showed parietal epileptiform discharges on EEG and[E1] impaired vibratory sensat[/E1]ion. A known variant [E2]in W7[/E2]48S was identified.",in W7,GENE_VARIANT,186,191, impaired vibratory sensat,HPO_TERM,139,165,0.812672,0.18732794,-0.6253441,0
line830,Patient V30 was evaluated for a deficit in vibratory sense. The patient also presented with a stooped posture and a communication disorder. Subsequent sequencing of c.2794C>T p.H932Y revealed a pathogenic variant.,Patient V30 was evaluated for [E1]a deficit in vibratory sen[/E1]se. The patient also presented with a stooped posture and a communication disorder. Subsequent sequencing[E2] of c.2794C>T p.H93[/E2]2Y revealed a pathogenic variant., of c.2794C>T p.H93,GENE_VARIANT,161,180,a deficit in vibratory sen,HPO_TERM,30,56,0.890003,0.10999693,-0.7800061,0
line830,Patient V30 was evaluated for a deficit in vibratory sense. The patient also presented with a stooped posture and a communication disorder. Subsequent sequencing of c.2794C>T p.H932Y revealed a pathogenic variant.,Patient V30 was evaluated for a deficit in vibratory sense. The patient also presented wit[E1]h a stooped post[/E1]ure and a communication disorder. Subsequent sequencing[E2] of c.2794C>T p.H93[/E2]2Y revealed a pathogenic variant., of c.2794C>T p.H93,GENE_VARIANT,161,180,h a stooped post,HPO_TERM,90,106,0.8940654,0.1059346,-0.78813076,0
line830,Patient V30 was evaluated for a deficit in vibratory sense. The patient also presented with a stooped posture and a communication disorder. Subsequent sequencing of c.2794C>T p.H932Y revealed a pathogenic variant.,Patient V30 was evaluated for a deficit in vibratory sense. The patient also presented with a stooped posture a[E1]nd a communication diso[/E1]rder. Subsequent sequencing[E2] of c.2794C>T p.H93[/E2]2Y revealed a pathogenic variant., of c.2794C>T p.H93,GENE_VARIANT,161,180,nd a communication diso,HPO_TERM,111,134,0.8969751,0.10302487,-0.7939502,0
line832,The primary symptoms for Patient V32 were an ataxic gait and an action tremor. Analysis of the c.1156C>T p.R386C was performed.,The primary symptoms for Patient V32 were an[E1] ataxic gait [/E1]and an action tremor. Analysis of the c.1[E2]156C>T p.R386C wa[/E2]s performed.,156C>T p.R386C wa,GENE_VARIANT,98,115, ataxic gait ,HPO_TERM,44,57,0.8543119,0.14568815,-0.70862377,0
line832,The primary symptoms for Patient V32 were an ataxic gait and an action tremor. Analysis of the c.1156C>T p.R386C was performed.,The primary symptoms for Patient V32 were an ataxic gait and a[E1]n action tremor[/E1]. Analysis of the c.1[E2]156C>T p.R386C wa[/E2]s performed.,156C>T p.R386C wa,GENE_VARIANT,98,115,n action tremor,HPO_TERM,62,77,0.85872555,0.14127447,-0.7174511,0
line835,"This report details Patient V35, a patient with EEG with parietal epileptiform discharges. Further investigation showed a kinetic tremor and an action tremor. A known variant in 15q26 118 kb deletion involving POLG1 gene and FANCI gene was identified.","This report details Patient V35, a patient with [E1]EEG with parietal epileptiform discharge[/E1]s. Further investigation showed a kinetic tremor and an action tremor. A known variant i[E2]n 15q26 118 kb deletion involving POLG1 gene and FANCI gene [/E2]was identified.",n 15q26 118 kb deletion involving POLG1 gene and FANCI gene ,GENE_VARIANT,176,236,EEG with parietal epileptiform discharge,HPO_TERM,48,88,0.804859,0.19514106,-0.6097179,0
line835,"This report details Patient V35, a patient with EEG with parietal epileptiform discharges. Further investigation showed a kinetic tremor and an action tremor. A known variant in 15q26 118 kb deletion involving POLG1 gene and FANCI gene was identified.","This report details Patient V35, a patient with EEG with parietal epileptiform discharges. Further investigation showed[E1] a kinetic tremo[/E1]r and an action tremor. A known variant i[E2]n 15q26 118 kb deletion involving POLG1 gene and FANCI gene [/E2]was identified.",n 15q26 118 kb deletion involving POLG1 gene and FANCI gene ,GENE_VARIANT,176,236, a kinetic tremo,HPO_TERM,119,135,0.79338634,0.20661364,-0.5867727,0
line835,"This report details Patient V35, a patient with EEG with parietal epileptiform discharges. Further investigation showed a kinetic tremor and an action tremor. A known variant in 15q26 118 kb deletion involving POLG1 gene and FANCI gene was identified.","This report details Patient V35, a patient with EEG with parietal epileptiform discharges. Further investigation showed a kinetic tremor and[E1] an action trem[/E1]or. A known variant i[E2]n 15q26 118 kb deletion involving POLG1 gene and FANCI gene [/E2]was identified.",n 15q26 118 kb deletion involving POLG1 gene and FANCI gene ,GENE_VARIANT,176,236, an action trem,HPO_TERM,140,155,0.80659133,0.19340871,-0.6131826,0
line839,The clinical profile for Patient V39 includes a focal seizure with motor signs and reduced tendon reflexes. Genetic analysis of 2263A>G K755E confirmed the diagnosis.,The clinical profile for Patient V39 includes [E1]a focal seizure with motor sign[/E1]s and reduced tendon reflexes. Genetic analysis of[E2] 2263A>G K755[/E2]E confirmed the diagnosis., 2263A>G K755,GENE_VARIANT,127,140,a focal seizure with motor sign,HPO_TERM,46,77,0.8803397,0.11966034,-0.76067936,0
line839,The clinical profile for Patient V39 includes a focal seizure with motor signs and reduced tendon reflexes. Genetic analysis of 2263A>G K755E confirmed the diagnosis.,The clinical profile for Patient V39 includes a focal seizure with motor signs and[E1] reduced tendon reflexe[/E1]s. Genetic analysis of[E2] 2263A>G K755[/E2]E confirmed the diagnosis., 2263A>G K755,GENE_VARIANT,127,140, reduced tendon reflexe,HPO_TERM,82,105,0.8855154,0.11448456,-0.77103084,0
line840,The clinical profile for Patient V40 includes a focal motor seizure and a stooped posture. Genetic analysis of W748S confirmed the diagnosis.,The clinical profile for Patient V40 includes [E1]a focal motor seizur[/E1]e and a stooped posture. Genetic analysis o[E2]f W74[/E2]8S confirmed the diagnosis.,f W74,GENE_VARIANT,109,114,a focal motor seizur,HPO_TERM,46,66,0.87141514,0.12858482,-0.74283034,0
line840,The clinical profile for Patient V40 includes a focal motor seizure and a stooped posture. Genetic analysis of W748S confirmed the diagnosis.,The clinical profile for Patient V40 includes a focal motor seizure and[E1] a stooped postu[/E1]re. Genetic analysis o[E2]f W74[/E2]8S confirmed the diagnosis.,f W74,GENE_VARIANT,109,114, a stooped postu,HPO_TERM,71,87,0.8740465,0.12595351,-0.748093,0
line841,The primary symptoms for Patient V41 were focal motor seizures and impaired vibratory sensation. Analysis of the c.1156C>T p.R386C was performed.,The primary symptoms for Patient V41 were fo[E1]cal motor seizures a[/E1]nd impaired vibratory sensation. Analysis of the c.1[E2]156C>T p.R386C wa[/E2]s performed.,156C>T p.R386C wa,GENE_VARIANT,116,133,cal motor seizures a,HPO_TERM,44,64,0.8554163,0.14458372,-0.7108326,0
line841,The primary symptoms for Patient V41 were focal motor seizures and impaired vibratory sensation. Analysis of the c.1156C>T p.R386C was performed.,The primary symptoms for Patient V41 were focal motor seizures and im[E1]paired vibratory sensation[/E1]. Analysis of the c.1[E2]156C>T p.R386C wa[/E2]s performed.,156C>T p.R386C wa,GENE_VARIANT,116,133,paired vibratory sensation,HPO_TERM,69,95,0.83871746,0.16128257,-0.6774349,0
line842,Patient V42 was evaluated for an ataxic gait. The patient also presented with reduced tendon reflexes and a postural or kinetic tremor. Subsequent sequencing of A467T revealed a pathogenic variant.,Patient V42 was evaluated for [E1]an ataxic gai[/E1]t. The patient also presented with reduced tendon reflexes and a postural or kinetic tremor. Subsequent sequencing o[E2]f A46[/E2]7T revealed a pathogenic variant.,f A46,GENE_VARIANT,159,164,an ataxic gai,HPO_TERM,30,43,0.8922038,0.10779622,-0.7844076,0
line842,Patient V42 was evaluated for an ataxic gait. The patient also presented with reduced tendon reflexes and a postural or kinetic tremor. Subsequent sequencing of A467T revealed a pathogenic variant.,Patient V42 was evaluated for an ataxic gait. The patient also presented with[E1] reduced tendon reflexe[/E1]s and a postural or kinetic tremor. Subsequent sequencing o[E2]f A46[/E2]7T revealed a pathogenic variant.,f A46,GENE_VARIANT,159,164, reduced tendon reflexe,HPO_TERM,77,100,0.88340807,0.116591886,-0.7668162,0
line842,Patient V42 was evaluated for an ataxic gait. The patient also presented with reduced tendon reflexes and a postural or kinetic tremor. Subsequent sequencing of A467T revealed a pathogenic variant.,Patient V42 was evaluated for an ataxic gait. The patient also presented with reduced tendon reflexes and[E1] a postural or kinetic trem[/E1]or. Subsequent sequencing o[E2]f A46[/E2]7T revealed a pathogenic variant.,f A46,GENE_VARIANT,159,164, a postural or kinetic trem,HPO_TERM,105,132,0.8813702,0.11862988,-0.7627403,0
line844,The clinical profile for Patient V44 includes parietal epileptiform discharges on EEG and a postural or kinetic tremor. Genetic analysis of 2263A>G K755E confirmed the diagnosis.,The clinical profile for Patient V44 includes [E1]parietal epileptiform discharges on EEG[/E1] and a postural or kinetic tremor. Genetic analysis of[E2] 2263A>G K755[/E2]E confirmed the diagnosis., 2263A>G K755,GENE_VARIANT,139,152,parietal epileptiform discharges on EEG,HPO_TERM,46,85,0.87731063,0.12268944,-0.7546212,0
line844,The clinical profile for Patient V44 includes parietal epileptiform discharges on EEG and a postural or kinetic tremor. Genetic analysis of 2263A>G K755E confirmed the diagnosis.,The clinical profile for Patient V44 includes parietal epileptiform discharges on EEG and [E1]a postural or kinetic tremo[/E1]r. Genetic analysis of[E2] 2263A>G K755[/E2]E confirmed the diagnosis., 2263A>G K755,GENE_VARIANT,139,152,a postural or kinetic tremo,HPO_TERM,90,117,0.885794,0.11420603,-0.77158797,0
line845,The clinical profile for Patient V45 includes reduced vibration sense and a language disorder. Genetic analysis of c.2794C>T p.H932Y confirmed the diagnosis.,The clinical profile for Patient V45 includes [E1]reduced vibration sens[/E1]e and a language disorder. Genetic analysis o[E2]f c.2794C>T p.H932Y[/E2] confirmed the diagnosis.,f c.2794C>T p.H932Y,GENE_VARIANT,113,132,reduced vibration sens,HPO_TERM,46,68,0.8671059,0.13289408,-0.7342118,0
line845,The clinical profile for Patient V45 includes reduced vibration sense and a language disorder. Genetic analysis of c.2794C>T p.H932Y confirmed the diagnosis.,The clinical profile for Patient V45 includes reduced vibration sense and[E1] a language disord[/E1]er. Genetic analysis o[E2]f c.2794C>T p.H932Y[/E2] confirmed the diagnosis.,f c.2794C>T p.H932Y,GENE_VARIANT,113,132, a language disord,HPO_TERM,73,91,0.87510794,0.12489201,-0.75021595,0
line846,The clinical profile for Patient V46 includes aphasia and a deficit in vibratory sense. Genetic analysis of W748S confirmed the diagnosis.,The clinical profile for Patient V46 includes [E1]aphasia[/E1] and a deficit in vibratory sense. Genetic analysis o[E2]f W74[/E2]8S confirmed the diagnosis.,f W74,GENE_VARIANT,106,111,aphasia,HPO_TERM,46,53,0.87125474,0.12874523,-0.7425095,0
line846,The clinical profile for Patient V46 includes aphasia and a deficit in vibratory sense. Genetic analysis of W748S confirmed the diagnosis.,The clinical profile for Patient V46 includes aphasia and [E1]a deficit in vibratory sen[/E1]se. Genetic analysis o[E2]f W74[/E2]8S confirmed the diagnosis.,f W74,GENE_VARIANT,106,111,a deficit in vibratory sen,HPO_TERM,58,84,0.878543,0.12145703,-0.757086,0
line848,The primary symptoms for Patient V48 were an elevated GGT and a forward-leaning posture. Analysis of the W748S was performed.,The primary symptoms for Patient V48 were an[E1] elevated GGT [/E1]and a forward-leaning posture. Analysis of the W74[E2]8S wa[/E2]s performed.,8S wa,GENE_VARIANT,108,113, elevated GGT ,HPO_TERM,44,58,0.74421614,0.2557839,-0.48843226,0
line848,The primary symptoms for Patient V48 were an elevated GGT and a forward-leaning posture. Analysis of the W748S was performed.,The primary symptoms for Patient V48 were an elevated GGT and a[E1] forward-leaning posture[/E1]. Analysis of the W74[E2]8S wa[/E2]s performed.,8S wa,GENE_VARIANT,108,113, forward-leaning posture,HPO_TERM,63,87,0.7477492,0.25225076,-0.49549845,0
line849,Patient V49 was evaluated for an abnormality of coagulation. The patient also presented with parietal sharp waves on electroencephalogram and reduced tendon reflexes. Subsequent sequencing of c3239G>C p.Ser1080Thr revealed a pathogenic variant.,Patient V49 was evaluated for [E1]an abnormality of coagulatio[/E1]n. The patient also presented with parietal sharp waves on electroencephalogram and reduced tendon reflexes. Subsequent sequencing [E2]of c3239G>C p.Ser1080[/E2]Thr revealed a pathogenic variant.,of c3239G>C p.Ser1080,GENE_VARIANT,189,210,an abnormality of coagulatio,HPO_TERM,30,58,0.90454113,0.09545889,-0.80908227,0
line849,Patient V49 was evaluated for an abnormality of coagulation. The patient also presented with parietal sharp waves on electroencephalogram and reduced tendon reflexes. Subsequent sequencing of c3239G>C p.Ser1080Thr revealed a pathogenic variant.,Patient V49 was evaluated for an abnormality of coagulation. The patient also presented with[E1] parietal sharp waves on electroencephalog[/E1]ram and reduced tendon reflexes. Subsequent sequencing [E2]of c3239G>C p.Ser1080[/E2]Thr revealed a pathogenic variant.,of c3239G>C p.Ser1080,GENE_VARIANT,189,210, parietal sharp waves on electroencephalog,HPO_TERM,92,134,0.89020354,0.109796435,-0.7804071,0
line849,Patient V49 was evaluated for an abnormality of coagulation. The patient also presented with parietal sharp waves on electroencephalogram and reduced tendon reflexes. Subsequent sequencing of c3239G>C p.Ser1080Thr revealed a pathogenic variant.,Patient V49 was evaluated for an abnormality of coagulation. The patient also presented with parietal sharp waves on electroencephalogram a[E1]nd reduced tendon refle[/E1]xes. Subsequent sequencing [E2]of c3239G>C p.Ser1080[/E2]Thr revealed a pathogenic variant.,of c3239G>C p.Ser1080,GENE_VARIANT,189,210,nd reduced tendon refle,HPO_TERM,139,162,0.9015407,0.09845931,-0.8030814,0
line850,The primary symptoms for Patient V50 were a stooped posture and aphasia. Analysis of the c.1156C>T p.R386C was performed.,The primary symptoms for Patient V50 were a [E1]stooped posture [/E1]and aphasia. Analysis of the c.11[E2]56C>T p.R386C was[/E2] performed.,56C>T p.R386C was,GENE_VARIANT,93,110,stooped posture ,HPO_TERM,44,60,0.8812394,0.11876061,-0.7624788,0
line851,Patient V51 was evaluated for a deficit in vibratory sense. The patient also presented with an elevated GGT and a communication disorder. Subsequent sequencing of R853W revealed a pathogenic variant.,Patient V51 was evaluated for [E1]a deficit in vibratory sen[/E1]se. The patient also presented with an elevated GGT and a communication disorder. Subsequent sequencing[E2] of R[/E2]853W revealed a pathogenic variant., of R,GENE_VARIANT,159,164,a deficit in vibratory sen,HPO_TERM,30,56,0.8762039,0.12379606,-0.75240785,0
line851,Patient V51 was evaluated for a deficit in vibratory sense. The patient also presented with an elevated GGT and a communication disorder. Subsequent sequencing of R853W revealed a pathogenic variant.,Patient V51 was evaluated for a deficit in vibratory sense. The patient also presented wit[E1]h an elevated [/E1]GGT and a communication disorder. Subsequent sequencing[E2] of R[/E2]853W revealed a pathogenic variant., of R,GENE_VARIANT,159,164,h an elevated ,HPO_TERM,90,104,0.87731785,0.12268212,-0.75463575,0
line851,Patient V51 was evaluated for a deficit in vibratory sense. The patient also presented with an elevated GGT and a communication disorder. Subsequent sequencing of R853W revealed a pathogenic variant.,Patient V51 was evaluated for a deficit in vibratory sense. The patient also presented with an elevated GGT a[E1]nd a communication diso[/E1]rder. Subsequent sequencing[E2] of R[/E2]853W revealed a pathogenic variant., of R,GENE_VARIANT,159,164,nd a communication diso,HPO_TERM,109,132,0.88996714,0.110032864,-0.7799343,0
line852,Patient V52 was evaluated for parietal epileptiform discharges on EEG. The patient also presented with a coagulation disorder and reduced vibration sense. Subsequent sequencing of G737R revealed a pathogenic variant.,Patient V52 was evaluated for [E1]parietal epileptiform discharges on EEG[/E1]. The patient also presented with a coagulation disorder and reduced vibration sense. Subsequent sequencing of[E2] G737[/E2]R revealed a pathogenic variant., G737,GENE_VARIANT,179,184,parietal epileptiform discharges on EEG,HPO_TERM,30,69,0.87528753,0.124712415,-0.7505751,0
line852,Patient V52 was evaluated for parietal epileptiform discharges on EEG. The patient also presented with a coagulation disorder and reduced vibration sense. Subsequent sequencing of G737R revealed a pathogenic variant.,Patient V52 was evaluated for parietal epileptiform discharges on EEG. The patient also presented with [E1]a coagulation disorder[/E1] and reduced vibration sense. Subsequent sequencing of[E2] G737[/E2]R revealed a pathogenic variant., G737,GENE_VARIANT,179,184,a coagulation disorder,HPO_TERM,103,125,0.885067,0.114933096,-0.7701339,0
line852,Patient V52 was evaluated for parietal epileptiform discharges on EEG. The patient also presented with a coagulation disorder and reduced vibration sense. Subsequent sequencing of G737R revealed a pathogenic variant.,Patient V52 was evaluated for parietal epileptiform discharges on EEG. The patient also presented with a coagulation disorder and [E1]reduced vibration sens[/E1]e. Subsequent sequencing of[E2] G737[/E2]R revealed a pathogenic variant., G737,GENE_VARIANT,179,184,reduced vibration sens,HPO_TERM,130,152,0.88975203,0.110247985,-0.77950406,0
line853,"This report details Patient V53, a patient with unsteady walking. Further investigation showed a kinetic tremor and reduced tendon reflexes. A known variant in c.2794C>T p.H932Y was identified.","This report details Patient V53, a patient with [E1]unsteady walkin[/E1]g. Further investigation showed a kinetic tremor and reduced tendon reflexes. A known variant in[E2] c.2794C>T p.H932Y [/E2]was identified.", c.2794C>T p.H932Y ,GENE_VARIANT,159,178,unsteady walkin,HPO_TERM,48,63,0.8440751,0.15592495,-0.68815017,0
line853,"This report details Patient V53, a patient with unsteady walking. Further investigation showed a kinetic tremor and reduced tendon reflexes. A known variant in c.2794C>T p.H932Y was identified.","This report details Patient V53, a patient with unsteady walking. Further investigation showed[E1] a kinetic tremo[/E1]r and reduced tendon reflexes. A known variant in[E2] c.2794C>T p.H932Y [/E2]was identified.", c.2794C>T p.H932Y ,GENE_VARIANT,159,178, a kinetic tremo,HPO_TERM,94,110,0.8393572,0.16064285,-0.67871433,0
line853,"This report details Patient V53, a patient with unsteady walking. Further investigation showed a kinetic tremor and reduced tendon reflexes. A known variant in c.2794C>T p.H932Y was identified.","This report details Patient V53, a patient with unsteady walking. Further investigation showed a kinetic tremor and[E1] reduced tendon reflexe[/E1]s. A known variant in[E2] c.2794C>T p.H932Y [/E2]was identified.", c.2794C>T p.H932Y ,GENE_VARIANT,159,178, reduced tendon reflexe,HPO_TERM,115,138,0.8467793,0.15322076,-0.6935585,0
line855,The primary symptoms for Patient V55 were parietal epileptiform discharges on EEG and gait ataxia. Analysis of the c.1156C>T p.R386C was performed.,The primary symptoms for Patient V55 were pa[E1]rietal epileptiform discharges on EEG a[/E1]nd gait ataxia. Analysis of the c.115[E2]6C>T p.R386C was [/E2]performed.,6C>T p.R386C was ,GENE_VARIANT,120,137,rietal epileptiform discharges on EEG a,HPO_TERM,44,83,0.87727875,0.1227212,-0.75455755,0
line857,"This report details Patient V57, a patient with a language disorder. Further investigation showed a coagulation disorder and reduced tendon reflexes. A known variant in G737R was identified.","This report details Patient V57, a patient with [E1]a language disorde[/E1]r. Further investigation showed a coagulation disorder and reduced tendon reflexes. A known variant in[E2] G737[/E2]R was identified.", G737,GENE_VARIANT,168,173,a language disorde,HPO_TERM,48,66,0.8706457,0.1293543,-0.7412914,0
line857,"This report details Patient V57, a patient with a language disorder. Further investigation showed a coagulation disorder and reduced tendon reflexes. A known variant in G737R was identified.","This report details Patient V57, a patient with a language disorder. Further investigation showed[E1] a coagulation disorde[/E1]r and reduced tendon reflexes. A known variant in[E2] G737[/E2]R was identified.", G737,GENE_VARIANT,168,173, a coagulation disorde,HPO_TERM,97,119,0.87157047,0.12842952,-0.74314094,0
line857,"This report details Patient V57, a patient with a language disorder. Further investigation showed a coagulation disorder and reduced tendon reflexes. A known variant in G737R was identified.","This report details Patient V57, a patient with a language disorder. Further investigation showed a coagulation disorder and[E1] reduced tendon reflexe[/E1]s. A known variant in[E2] G737[/E2]R was identified.", G737,GENE_VARIANT,168,173, reduced tendon reflexe,HPO_TERM,124,147,0.8719661,0.12803389,-0.74393225,0
line858,"We report the case of Patient V58, who has a history of a deficit in vibratory sense. Examination also revealed a forward-leaning posture. The underlying cause was traced to a mutation in G737R.","We report the case of Patient V58, who has a history of [E1]a deficit in vibratory sen[/E1]se. Examination also revealed a forward-leaning posture. The underlying cause was traced to a mutation in G[E2]737R.[/E2]",737R.,GENE_VARIANT,189,194,a deficit in vibratory sen,HPO_TERM,56,82,0.7952701,0.20472993,-0.5905402,0
line858,"We report the case of Patient V58, who has a history of a deficit in vibratory sense. Examination also revealed a forward-leaning posture. The underlying cause was traced to a mutation in G737R.","We report the case of Patient V58, who has a history of a deficit in vibratory sense. Examination also reveale[E1]d a forward-leaning post[/E1]ure. The underlying cause was traced to a mutation in G[E2]737R.[/E2]",737R.,GENE_VARIANT,189,194,d a forward-leaning post,HPO_TERM,110,134,0.8016051,0.19839492,-0.6032102,0
line859,Patient V59 was evaluated for a focal motor seizure. The patient also presented with gait ataxia and parietal sharp waves on electroencephalogram. Subsequent sequencing of c.1156C>T p.R386C revealed a pathogenic variant.,Patient V59 was evaluated for [E1]a focal motor seizur[/E1]e. The patient also presented with gait ataxia and parietal sharp waves on electroencephalogram. Subsequent sequencing [E2]of c.1156C>T p.R3[/E2]86C revealed a pathogenic variant.,of c.1156C>T p.R3,GENE_VARIANT,169,186,a focal motor seizur,HPO_TERM,30,50,0.89057857,0.109421395,-0.7811572,0
line859,Patient V59 was evaluated for a focal motor seizure. The patient also presented with gait ataxia and parietal sharp waves on electroencephalogram. Subsequent sequencing of c.1156C>T p.R386C revealed a pathogenic variant.,Patient V59 was evaluated for a focal motor seizure. The patient also presented with[E1] gait ataxi[/E1]a and parietal sharp waves on electroencephalogram. Subsequent sequencing [E2]of c.1156C>T p.R3[/E2]86C revealed a pathogenic variant.,of c.1156C>T p.R3,GENE_VARIANT,169,186, gait ataxi,HPO_TERM,84,95,0.88501954,0.11498049,-0.7700391,0
line859,Patient V59 was evaluated for a focal motor seizure. The patient also presented with gait ataxia and parietal sharp waves on electroencephalogram. Subsequent sequencing of c.1156C>T p.R386C revealed a pathogenic variant.,Patient V59 was evaluated for a focal motor seizure. The patient also presented with gait ataxia and[E1] parietal sharp waves on electroencephalog[/E1]ram. Subsequent sequencing [E2]of c.1156C>T p.R3[/E2]86C revealed a pathogenic variant.,of c.1156C>T p.R3,GENE_VARIANT,169,186, parietal sharp waves on electroencephalog,HPO_TERM,100,142,0.88319814,0.11680186,-0.7663963,0
line861,Patient V61 was evaluated for reduced tendon reflexes. The patient also presented with an elevated GGT and a forward-leaning posture. Subsequent sequencing of W748S revealed a pathogenic variant.,Patient V61 was evaluated for [E1]reduced tendon reflexes[/E1]. The patient also presented with an elevated GGT and a forward-leaning posture. Subsequent sequencing o[E2]f W74[/E2]8S revealed a pathogenic variant.,f W74,GENE_VARIANT,157,162,reduced tendon reflexes,HPO_TERM,30,53,0.8822067,0.11779329,-0.76441336,0
line861,Patient V61 was evaluated for reduced tendon reflexes. The patient also presented with an elevated GGT and a forward-leaning posture. Subsequent sequencing of W748S revealed a pathogenic variant.,Patient V61 was evaluated for reduced tendon reflexes. The patient also presented with [E1]an elevated GG[/E1]T and a forward-leaning posture. Subsequent sequencing o[E2]f W74[/E2]8S revealed a pathogenic variant.,f W74,GENE_VARIANT,157,162,an elevated GG,HPO_TERM,87,101,0.8770102,0.12298973,-0.7540205,0
line861,Patient V61 was evaluated for reduced tendon reflexes. The patient also presented with an elevated GGT and a forward-leaning posture. Subsequent sequencing of W748S revealed a pathogenic variant.,Patient V61 was evaluated for reduced tendon reflexes. The patient also presented with an elevated GGT and[E1] a forward-leaning postu[/E1]re. Subsequent sequencing o[E2]f W74[/E2]8S revealed a pathogenic variant.,f W74,GENE_VARIANT,157,162, a forward-leaning postu,HPO_TERM,106,130,0.8750652,0.12493478,-0.7501304,0
line862,Patient V62 was evaluated for focal motor seizures. The patient also presented with an elevated GGT and impaired vibratory sensation. Subsequent sequencing of R853W revealed a pathogenic variant.,Patient V62 was evaluated for [E1]focal motor seizures[/E1]. The patient also presented with an elevated GGT and impaired vibratory sensation. Subsequent sequencing [E2]of R8[/E2]53W revealed a pathogenic variant.,of R8,GENE_VARIANT,156,161,focal motor seizures,HPO_TERM,30,50,0.862047,0.13795301,-0.72409403,0
line862,Patient V62 was evaluated for focal motor seizures. The patient also presented with an elevated GGT and impaired vibratory sensation. Subsequent sequencing of R853W revealed a pathogenic variant.,Patient V62 was evaluated for focal motor seizures. The patient also presented with [E1]an elevated GG[/E1]T and impaired vibratory sensation. Subsequent sequencing [E2]of R8[/E2]53W revealed a pathogenic variant.,of R8,GENE_VARIANT,156,161,an elevated GG,HPO_TERM,84,98,0.86148876,0.13851129,-0.72297746,0
line862,Patient V62 was evaluated for focal motor seizures. The patient also presented with an elevated GGT and impaired vibratory sensation. Subsequent sequencing of R853W revealed a pathogenic variant.,Patient V62 was evaluated for focal motor seizures. The patient also presented with an elevated GGT and[E1] impaired vibratory sensat[/E1]ion. Subsequent sequencing [E2]of R8[/E2]53W revealed a pathogenic variant.,of R8,GENE_VARIANT,156,161, impaired vibratory sensat,HPO_TERM,103,129,0.8631019,0.13689816,-0.72620374,0
line863,Patient V63 was evaluated for an ataxic gait. The patient also presented with reduced tendon reflexes and a stooped posture. Subsequent sequencing of A467T revealed a pathogenic variant.,Patient V63 was evaluated for [E1]an ataxic gai[/E1]t. The patient also presented with reduced tendon reflexes and a stooped posture. Subsequent sequencing o[E2]f A46[/E2]7T revealed a pathogenic variant.,f A46,GENE_VARIANT,148,153,an ataxic gai,HPO_TERM,30,43,0.8916707,0.10832934,-0.78334135,0
line863,Patient V63 was evaluated for an ataxic gait. The patient also presented with reduced tendon reflexes and a stooped posture. Subsequent sequencing of A467T revealed a pathogenic variant.,Patient V63 was evaluated for an ataxic gait. The patient also presented with[E1] reduced tendon reflexe[/E1]s and a stooped posture. Subsequent sequencing o[E2]f A46[/E2]7T revealed a pathogenic variant.,f A46,GENE_VARIANT,148,153, reduced tendon reflexe,HPO_TERM,77,100,0.8840737,0.11592634,-0.76814735,0
line863,Patient V63 was evaluated for an ataxic gait. The patient also presented with reduced tendon reflexes and a stooped posture. Subsequent sequencing of A467T revealed a pathogenic variant.,Patient V63 was evaluated for an ataxic gait. The patient also presented with reduced tendon reflexes and[E1] a stooped postu[/E1]re. Subsequent sequencing o[E2]f A46[/E2]7T revealed a pathogenic variant.,f A46,GENE_VARIANT,148,153, a stooped postu,HPO_TERM,105,121,0.88122797,0.118772045,-0.76245594,0
line864,Patient V64 was evaluated for an ataxic gait. The patient also presented with aphasia and a focal motor seizure. Subsequent sequencing of W748S revealed a pathogenic variant.,Patient V64 was evaluated for [E1]an ataxic gai[/E1]t. The patient also presented with aphasia and a focal motor seizure. Subsequent sequencing o[E2]f W74[/E2]8S revealed a pathogenic variant.,f W74,GENE_VARIANT,136,141,an ataxic gai,HPO_TERM,30,43,0.8838468,0.11615322,-0.7676936,0
line864,Patient V64 was evaluated for an ataxic gait. The patient also presented with aphasia and a focal motor seizure. Subsequent sequencing of W748S revealed a pathogenic variant.,Patient V64 was evaluated for an ataxic gait. The patient also presented with[E1] aphasi[/E1]a and a focal motor seizure. Subsequent sequencing o[E2]f W74[/E2]8S revealed a pathogenic variant.,f W74,GENE_VARIANT,136,141, aphasi,HPO_TERM,77,84,0.8736972,0.12630285,-0.7473944,0
line864,Patient V64 was evaluated for an ataxic gait. The patient also presented with aphasia and a focal motor seizure. Subsequent sequencing of W748S revealed a pathogenic variant.,Patient V64 was evaluated for an ataxic gait. The patient also presented with aphasia and[E1] a focal motor seizu[/E1]re. Subsequent sequencing o[E2]f W74[/E2]8S revealed a pathogenic variant.,f W74,GENE_VARIANT,136,141, a focal motor seizu,HPO_TERM,89,109,0.87467206,0.12532796,-0.7493441,0
line866,Patient V66 was evaluated for parietal epileptiform discharges on EEG. The patient also presented with an elevated GGT and an action tremor. Subsequent sequencing of c3239G>C p.Ser1080Thr revealed a pathogenic variant.,Patient V66 was evaluated for [E1]parietal epileptiform discharges on EEG[/E1]. The patient also presented with an elevated GGT and an action tremor. Subsequent sequencing o[E2]f c3239G>C p.Ser1080T[/E2]hr revealed a pathogenic variant.,f c3239G>C p.Ser1080T,GENE_VARIANT,164,185,parietal epileptiform discharges on EEG,HPO_TERM,30,69,0.8853722,0.11462775,-0.77074444,0
line866,Patient V66 was evaluated for parietal epileptiform discharges on EEG. The patient also presented with an elevated GGT and an action tremor. Subsequent sequencing of c3239G>C p.Ser1080Thr revealed a pathogenic variant.,Patient V66 was evaluated for parietal epileptiform discharges on EEG. The patient also presented with [E1]an elevated GG[/E1]T and an action tremor. Subsequent sequencing o[E2]f c3239G>C p.Ser1080T[/E2]hr revealed a pathogenic variant.,f c3239G>C p.Ser1080T,GENE_VARIANT,164,185,an elevated GG,HPO_TERM,103,117,0.89536446,0.104635544,-0.7907289,0
line866,Patient V66 was evaluated for parietal epileptiform discharges on EEG. The patient also presented with an elevated GGT and an action tremor. Subsequent sequencing of c3239G>C p.Ser1080Thr revealed a pathogenic variant.,Patient V66 was evaluated for parietal epileptiform discharges on EEG. The patient also presented with an elevated GGT and[E1] an action trem[/E1]or. Subsequent sequencing o[E2]f c3239G>C p.Ser1080T[/E2]hr revealed a pathogenic variant.,f c3239G>C p.Ser1080T,GENE_VARIANT,164,185, an action trem,HPO_TERM,122,137,0.8972812,0.102718756,-0.79456246,0
line867,The primary symptoms for Patient V67 were a language disorder and a forward-leaning posture. Analysis of the 15q26 118 kb deletion involving POLG1 gene and FANCI gene was performed.,The primary symptoms for Patient V67 were a [E1]language disorder [/E1]and a forward-leaning posture. Analysis of the 15q[E2]26 118 kb deletion involving POLG1 gene and FANCI gene was p[/E2]erformed.,26 118 kb deletion involving POLG1 gene and FANCI gene was p,GENE_VARIANT,112,172,language disorder ,HPO_TERM,44,62,0.81467813,0.1853219,-0.62935627,0
line867,The primary symptoms for Patient V67 were a language disorder and a forward-leaning posture. Analysis of the 15q26 118 kb deletion involving POLG1 gene and FANCI gene was performed.,The primary symptoms for Patient V67 were a language disorder and a[E1] forward-leaning posture[/E1]. Analysis of the 15q[E2]26 118 kb deletion involving POLG1 gene and FANCI gene was p[/E2]erformed.,26 118 kb deletion involving POLG1 gene and FANCI gene was p,GENE_VARIANT,112,172, forward-leaning posture,HPO_TERM,67,91,0.8292028,0.17079724,-0.65840554,0
line868,Patient V68 was evaluated for hyporeflexia. The patient also presented with an elevated GGT and parietal epileptiform discharges on EEG. Subsequent sequencing of 15q26 118 kb deletion involving POLG1 gene and FANCI gene revealed a pathogenic variant.,Patient V68 was evaluated for [E1]hyporeflexi[/E1]a. The patient also presented with an elevated GGT and parietal epileptiform discharges on EEG. Subsequent sequencing o[E2]f 15q26 118 kb deletion involving POLG1 gene and FANCI gene [/E2]revealed a pathogenic variant.,f 15q26 118 kb deletion involving POLG1 gene and FANCI gene ,GENE_VARIANT,160,220,hyporeflexi,HPO_TERM,30,41,0.85626614,0.1437339,-0.7125322,0
line868,Patient V68 was evaluated for hyporeflexia. The patient also presented with an elevated GGT and parietal epileptiform discharges on EEG. Subsequent sequencing of 15q26 118 kb deletion involving POLG1 gene and FANCI gene revealed a pathogenic variant.,Patient V68 was evaluated for hyporeflexia. The patient also presented with[E1] an elevated G[/E1]GT and parietal epileptiform discharges on EEG. Subsequent sequencing o[E2]f 15q26 118 kb deletion involving POLG1 gene and FANCI gene [/E2]revealed a pathogenic variant.,f 15q26 118 kb deletion involving POLG1 gene and FANCI gene ,GENE_VARIANT,160,220, an elevated G,HPO_TERM,75,89,0.8328383,0.1671617,-0.6656766,0
line868,Patient V68 was evaluated for hyporeflexia. The patient also presented with an elevated GGT and parietal epileptiform discharges on EEG. Subsequent sequencing of 15q26 118 kb deletion involving POLG1 gene and FANCI gene revealed a pathogenic variant.,Patient V68 was evaluated for hyporeflexia. The patient also presented with an elevated GGT an[E1]d parietal epileptiform discharges on E[/E1]EG. Subsequent sequencing o[E2]f 15q26 118 kb deletion involving POLG1 gene and FANCI gene [/E2]revealed a pathogenic variant.,f 15q26 118 kb deletion involving POLG1 gene and FANCI gene ,GENE_VARIANT,160,220,d parietal epileptiform discharges on E,HPO_TERM,94,133,0.848744,0.15125602,-0.69748795,0
line869,The primary symptoms for Patient V69 were aphasia and EEG with parietal epileptiform discharges. Analysis of the A467T was performed.,The primary symptoms for Patient V69 were ap[E1]hasia a[/E1]nd EEG with parietal epileptiform discharges. Analysis of the A467[E2]T was[/E2] performed.,T was,GENE_VARIANT,117,122,hasia a,HPO_TERM,44,51,0.86259377,0.13740624,-0.72518754,0
line870,Patient V70 was evaluated for a stooped posture. The patient also presented with a kinetic tremor and a language disorder. Subsequent sequencing of c.2794C>T p.H932Y revealed a pathogenic variant.,Patient V70 was evaluated for [E1]a stooped postur[/E1]e. The patient also presented with a kinetic tremor and a language disorder. Subsequent sequencing o[E2]f c.2794C>T p.H932Y[/E2] revealed a pathogenic variant.,f c.2794C>T p.H932Y,GENE_VARIANT,146,165,a stooped postur,HPO_TERM,30,46,0.88790125,0.112098746,-0.7758025,0
line870,Patient V70 was evaluated for a stooped posture. The patient also presented with a kinetic tremor and a language disorder. Subsequent sequencing of c.2794C>T p.H932Y revealed a pathogenic variant.,Patient V70 was evaluated for a stooped posture. The patient also presented with[E1] a kinetic tremo[/E1]r and a language disorder. Subsequent sequencing o[E2]f c.2794C>T p.H932Y[/E2] revealed a pathogenic variant.,f c.2794C>T p.H932Y,GENE_VARIANT,146,165, a kinetic tremo,HPO_TERM,80,96,0.87754035,0.12245966,-0.7550807,0
line870,Patient V70 was evaluated for a stooped posture. The patient also presented with a kinetic tremor and a language disorder. Subsequent sequencing of c.2794C>T p.H932Y revealed a pathogenic variant.,Patient V70 was evaluated for a stooped posture. The patient also presented with a kinetic tremor and[E1] a language disord[/E1]er. Subsequent sequencing o[E2]f c.2794C>T p.H932Y[/E2] revealed a pathogenic variant.,f c.2794C>T p.H932Y,GENE_VARIANT,146,165, a language disord,HPO_TERM,101,119,0.8815289,0.11847107,-0.7630578,0
line871,The primary symptoms for Patient V71 were parietal epileptiform discharges on EEG and a postural or kinetic tremor. Analysis of the c.1156C>T p.R386C was performed.,The primary symptoms for Patient V71 were pa[E1]rietal epileptiform discharges on EEG a[/E1]nd a postural or kinetic tremor. Analysis of the c.11[E2]56C>T p.R386C was[/E2] performed.,56C>T p.R386C was,GENE_VARIANT,136,153,rietal epileptiform discharges on EEG a,HPO_TERM,44,83,0.8726204,0.12737961,-0.7452408,0
line872,The primary symptoms for Patient V72 were a language disorder and a postural or kinetic tremor. Analysis of the c.1156C>T p.R386C was performed.,The primary symptoms for Patient V72 were a [E1]language disorder [/E1]and a postural or kinetic tremor. Analysis of the c.1[E2]156C>T p.R386C wa[/E2]s performed.,156C>T p.R386C wa,GENE_VARIANT,115,132,language disorder ,HPO_TERM,44,62,0.8529614,0.14703856,-0.70592284,0
line872,The primary symptoms for Patient V72 were a language disorder and a postural or kinetic tremor. Analysis of the c.1156C>T p.R386C was performed.,The primary symptoms for Patient V72 were a language disorder and a[E1] postural or kinetic tremor[/E1]. Analysis of the c.1[E2]156C>T p.R386C wa[/E2]s performed.,156C>T p.R386C wa,GENE_VARIANT,115,132, postural or kinetic tremor,HPO_TERM,67,94,0.8562679,0.14373203,-0.7125359,0
line873,Patient V73 was evaluated for an elevated GGT. The patient also presented with a focal motor seizure and a language disorder. Subsequent sequencing of c.2794C>T p.H932Y revealed a pathogenic variant.,Patient V73 was evaluated for [E1]an elevated GG[/E1]T. The patient also presented with a focal motor seizure and a language disorder. Subsequent sequencing [E2]of c.2794C>T p.H932[/E2]Y revealed a pathogenic variant.,of c.2794C>T p.H932,GENE_VARIANT,148,167,an elevated GG,HPO_TERM,30,44,0.8923974,0.10760256,-0.78479487,0
line873,Patient V73 was evaluated for an elevated GGT. The patient also presented with a focal motor seizure and a language disorder. Subsequent sequencing of c.2794C>T p.H932Y revealed a pathogenic variant.,Patient V73 was evaluated for an elevated GGT. The patient also presented with[E1] a focal motor seizu[/E1]re and a language disorder. Subsequent sequencing [E2]of c.2794C>T p.H932[/E2]Y revealed a pathogenic variant.,of c.2794C>T p.H932,GENE_VARIANT,148,167, a focal motor seizu,HPO_TERM,78,98,0.8825544,0.11744565,-0.76510876,0
line873,Patient V73 was evaluated for an elevated GGT. The patient also presented with a focal motor seizure and a language disorder. Subsequent sequencing of c.2794C>T p.H932Y revealed a pathogenic variant.,Patient V73 was evaluated for an elevated GGT. The patient also presented with a focal motor seizure an[E1]d a language disor[/E1]der. Subsequent sequencing [E2]of c.2794C>T p.H932[/E2]Y revealed a pathogenic variant.,of c.2794C>T p.H932,GENE_VARIANT,148,167,d a language disor,HPO_TERM,103,121,0.89453685,0.1054631,-0.78907377,0
line875,Patient V75 was evaluated for an ataxic gait. The patient also presented with a kinetic tremor and a stooped posture. Subsequent sequencing of 15q26 118 kb deletion involving POLG1 gene and FANCI gene revealed a pathogenic variant.,Patient V75 was evaluated for [E1]an ataxic gai[/E1]t. The patient also presented with a kinetic tremor and a stooped posture. Subsequent sequencing o[E2]f 15q26 118 kb deletion involving POLG1 gene and FANCI gene [/E2]revealed a pathogenic variant.,f 15q26 118 kb deletion involving POLG1 gene and FANCI gene ,GENE_VARIANT,141,201,an ataxic gai,HPO_TERM,30,43,0.86492765,0.13507241,-0.72985524,0
line875,Patient V75 was evaluated for an ataxic gait. The patient also presented with a kinetic tremor and a stooped posture. Subsequent sequencing of 15q26 118 kb deletion involving POLG1 gene and FANCI gene revealed a pathogenic variant.,Patient V75 was evaluated for an ataxic gait. The patient also presented with[E1] a kinetic tremo[/E1]r and a stooped posture. Subsequent sequencing o[E2]f 15q26 118 kb deletion involving POLG1 gene and FANCI gene [/E2]revealed a pathogenic variant.,f 15q26 118 kb deletion involving POLG1 gene and FANCI gene ,GENE_VARIANT,141,201, a kinetic tremo,HPO_TERM,77,93,0.8394606,0.16053945,-0.67892116,0
line875,Patient V75 was evaluated for an ataxic gait. The patient also presented with a kinetic tremor and a stooped posture. Subsequent sequencing of 15q26 118 kb deletion involving POLG1 gene and FANCI gene revealed a pathogenic variant.,Patient V75 was evaluated for an ataxic gait. The patient also presented with a kinetic tremor and[E1] a stooped postu[/E1]re. Subsequent sequencing o[E2]f 15q26 118 kb deletion involving POLG1 gene and FANCI gene [/E2]revealed a pathogenic variant.,f 15q26 118 kb deletion involving POLG1 gene and FANCI gene ,GENE_VARIANT,141,201, a stooped postu,HPO_TERM,98,114,0.84816194,0.15183812,-0.6963238,0
line876,The primary symptoms for Patient V76 were an elevated GGT and a forward-leaning posture. Analysis of the G737R was performed.,The primary symptoms for Patient V76 were an[E1] elevated GGT [/E1]and a forward-leaning posture. Analysis of the G73[E2]7R wa[/E2]s performed.,7R wa,GENE_VARIANT,108,113, elevated GGT ,HPO_TERM,44,58,0.78172904,0.21827097,-0.5634581,0
line876,The primary symptoms for Patient V76 were an elevated GGT and a forward-leaning posture. Analysis of the G737R was performed.,The primary symptoms for Patient V76 were an elevated GGT and a[E1] forward-leaning posture[/E1]. Analysis of the G73[E2]7R wa[/E2]s performed.,7R wa,GENE_VARIANT,108,113, forward-leaning posture,HPO_TERM,63,87,0.78689283,0.21310723,-0.5737856,0
line879,The clinical profile for Patient V79 includes an elevated GGT and a forward-leaning posture. Genetic analysis of c.3643+2T>C confirmed the diagnosis.,The clinical profile for Patient V79 includes [E1]an elevated GG[/E1]T and a forward-leaning posture. Genetic analysis o[E2]f c.3643+2T>[/E2]C confirmed the diagnosis.,f c.3643+2T>,GENE_VARIANT,111,123,an elevated GG,HPO_TERM,46,60,0.8783466,0.12165342,-0.7566932,0
line879,The clinical profile for Patient V79 includes an elevated GGT and a forward-leaning posture. Genetic analysis of c.3643+2T>C confirmed the diagnosis.,The clinical profile for Patient V79 includes an elevated GGT and[E1] a forward-leaning postu[/E1]re. Genetic analysis o[E2]f c.3643+2T>[/E2]C confirmed the diagnosis.,f c.3643+2T>,GENE_VARIANT,111,123, a forward-leaning postu,HPO_TERM,65,89,0.88154846,0.1184515,-0.763097,0
line881,Patient V81 was evaluated for a kinetic tremor. The patient also presented with impaired vibratory sensation and a deficit in vibratory sense. Subsequent sequencing of A467T revealed a pathogenic variant.,Patient V81 was evaluated for [E1]a kinetic tremor[/E1]. The patient also presented with impaired vibratory sensation and a deficit in vibratory sense. Subsequent sequencing[E2] of A[/E2]467T revealed a pathogenic variant., of A,GENE_VARIANT,164,169,a kinetic tremor,HPO_TERM,30,46,0.8775815,0.1224185,-0.75516295,0
line881,Patient V81 was evaluated for a kinetic tremor. The patient also presented with impaired vibratory sensation and a deficit in vibratory sense. Subsequent sequencing of A467T revealed a pathogenic variant.,Patient V81 was evaluated for a kinetic tremor. The patient also presented with [E1]impaired vibratory sensati[/E1]on and a deficit in vibratory sense. Subsequent sequencing[E2] of A[/E2]467T revealed a pathogenic variant., of A,GENE_VARIANT,164,169,impaired vibratory sensati,HPO_TERM,80,106,0.87845385,0.12154617,-0.7569077,0
line881,Patient V81 was evaluated for a kinetic tremor. The patient also presented with impaired vibratory sensation and a deficit in vibratory sense. Subsequent sequencing of A467T revealed a pathogenic variant.,Patient V81 was evaluated for a kinetic tremor. The patient also presented with impaired vibratory sensation an[E1]d a deficit in vibratory s[/E1]ense. Subsequent sequencing[E2] of A[/E2]467T revealed a pathogenic variant., of A,GENE_VARIANT,164,169,d a deficit in vibratory s,HPO_TERM,111,137,0.876297,0.123702966,-0.75259405,0
line882,Patient V82 was evaluated for an ataxic gait. The patient also presented with parietal epileptiform discharges on EEG and a forward-leaning posture. Subsequent sequencing of R853W revealed a pathogenic variant.,Patient V82 was evaluated for [E1]an ataxic gai[/E1]t. The patient also presented with parietal epileptiform discharges on EEG and a forward-leaning posture. Subsequent sequencing o[E2]f R85[/E2]3W revealed a pathogenic variant.,f R85,GENE_VARIANT,172,177,an ataxic gai,HPO_TERM,30,43,0.8802653,0.11973471,-0.7605306,0
line882,Patient V82 was evaluated for an ataxic gait. The patient also presented with parietal epileptiform discharges on EEG and a forward-leaning posture. Subsequent sequencing of R853W revealed a pathogenic variant.,Patient V82 was evaluated for an ataxic gait. The patient also presented with[E1] parietal epileptiform discharges on EE[/E1]G and a forward-leaning posture. Subsequent sequencing o[E2]f R85[/E2]3W revealed a pathogenic variant.,f R85,GENE_VARIANT,172,177, parietal epileptiform discharges on EE,HPO_TERM,77,116,0.8697946,0.13020541,-0.7395892,0
line882,Patient V82 was evaluated for an ataxic gait. The patient also presented with parietal epileptiform discharges on EEG and a forward-leaning posture. Subsequent sequencing of R853W revealed a pathogenic variant.,Patient V82 was evaluated for an ataxic gait. The patient also presented with parietal epileptiform discharges on EEG and[E1] a forward-leaning postu[/E1]re. Subsequent sequencing o[E2]f R85[/E2]3W revealed a pathogenic variant.,f R85,GENE_VARIANT,172,177, a forward-leaning postu,HPO_TERM,121,145,0.8697322,0.1302678,-0.7394644,0
line883,Patient V83 was evaluated for reduced tendon reflexes. The patient also presented with a language disorder and an ataxic gait. Subsequent sequencing of c3239G>C p.Ser1080Thr revealed a pathogenic variant.,Patient V83 was evaluated for [E1]reduced tendon reflexes[/E1]. The patient also presented with a language disorder and an ataxic gait. Subsequent sequencing o[E2]f c3239G>C p.Ser1080T[/E2]hr revealed a pathogenic variant.,f c3239G>C p.Ser1080T,GENE_VARIANT,150,171,reduced tendon reflexes,HPO_TERM,30,53,0.8937094,0.10629055,-0.78741884,0
line883,Patient V83 was evaluated for reduced tendon reflexes. The patient also presented with a language disorder and an ataxic gait. Subsequent sequencing of c3239G>C p.Ser1080Thr revealed a pathogenic variant.,Patient V83 was evaluated for reduced tendon reflexes. The patient also presented with [E1]a language disorde[/E1]r and an ataxic gait. Subsequent sequencing o[E2]f c3239G>C p.Ser1080T[/E2]hr revealed a pathogenic variant.,f c3239G>C p.Ser1080T,GENE_VARIANT,150,171,a language disorde,HPO_TERM,87,105,0.8872337,0.112766296,-0.77446735,0
line883,Patient V83 was evaluated for reduced tendon reflexes. The patient also presented with a language disorder and an ataxic gait. Subsequent sequencing of c3239G>C p.Ser1080Thr revealed a pathogenic variant.,Patient V83 was evaluated for reduced tendon reflexes. The patient also presented with a language disorder and[E1] an ataxic ga[/E1]it. Subsequent sequencing o[E2]f c3239G>C p.Ser1080T[/E2]hr revealed a pathogenic variant.,f c3239G>C p.Ser1080T,GENE_VARIANT,150,171, an ataxic ga,HPO_TERM,110,123,0.8909022,0.10909781,-0.78180444,0
line885,Patient V85 was evaluated for a forward-leaning posture. The patient also presented with a stooped posture and parietal epileptiform discharges on EEG. Subsequent sequencing of 2263A>G K755E revealed a pathogenic variant.,Patient V85 was evaluated for [E1]a forward-leaning postur[/E1]e. The patient also presented with a stooped posture and parietal epileptiform discharges on EEG. Subsequent sequencing o[E2]f 2263A>G K75[/E2]5E revealed a pathogenic variant.,f 2263A>G K75,GENE_VARIANT,175,188,a forward-leaning postur,HPO_TERM,30,54,0.8851968,0.11480326,-0.77039355,0
line885,Patient V85 was evaluated for a forward-leaning posture. The patient also presented with a stooped posture and parietal epileptiform discharges on EEG. Subsequent sequencing of 2263A>G K755E revealed a pathogenic variant.,Patient V85 was evaluated for a forward-leaning posture. The patient also presented with[E1] a stooped postu[/E1]re and parietal epileptiform discharges on EEG. Subsequent sequencing o[E2]f 2263A>G K75[/E2]5E revealed a pathogenic variant.,f 2263A>G K75,GENE_VARIANT,175,188, a stooped postu,HPO_TERM,88,104,0.87213874,0.12786128,-0.7442775,0
line885,Patient V85 was evaluated for a forward-leaning posture. The patient also presented with a stooped posture and parietal epileptiform discharges on EEG. Subsequent sequencing of 2263A>G K755E revealed a pathogenic variant.,Patient V85 was evaluated for a forward-leaning posture. The patient also presented with a stooped posture an[E1]d parietal epileptiform discharges on E[/E1]EG. Subsequent sequencing o[E2]f 2263A>G K75[/E2]5E revealed a pathogenic variant.,f 2263A>G K75,GENE_VARIANT,175,188,d parietal epileptiform discharges on E,HPO_TERM,109,148,0.88343513,0.1165649,-0.76687026,0
line886,The clinical profile for Patient V86 includes an ataxic gait and a focal motor seizure. Genetic analysis of 2263A>G K755E confirmed the diagnosis.,The clinical profile for Patient V86 includes [E1]an ataxic gai[/E1]t and a focal motor seizure. Genetic analysis o[E2]f 2263A>G K75[/E2]5E confirmed the diagnosis.,f 2263A>G K75,GENE_VARIANT,106,119,an ataxic gai,HPO_TERM,46,59,0.8676781,0.13232183,-0.7353563,0
line886,The clinical profile for Patient V86 includes an ataxic gait and a focal motor seizure. Genetic analysis of 2263A>G K755E confirmed the diagnosis.,The clinical profile for Patient V86 includes an ataxic gait and[E1] a focal motor seizu[/E1]re. Genetic analysis o[E2]f 2263A>G K75[/E2]5E confirmed the diagnosis.,f 2263A>G K75,GENE_VARIANT,106,119, a focal motor seizu,HPO_TERM,64,84,0.86794114,0.1320588,-0.73588234,0
line887,The clinical profile for Patient V87 includes an ataxic gait and parietal epileptiform discharges on EEG. Genetic analysis of W748S confirmed the diagnosis.,The clinical profile for Patient V87 includes [E1]an ataxic gai[/E1]t and parietal epileptiform discharges on EEG. Genetic analysis of[E2] W748[/E2]S confirmed the diagnosis., W748,GENE_VARIANT,125,130,an ataxic gai,HPO_TERM,46,59,0.8713256,0.12867439,-0.7426512,0
line887,The clinical profile for Patient V87 includes an ataxic gait and parietal epileptiform discharges on EEG. Genetic analysis of W748S confirmed the diagnosis.,The clinical profile for Patient V87 includes an ataxic gait and[E1] parietal epileptiform discharges on EE[/E1]G. Genetic analysis of[E2] W748[/E2]S confirmed the diagnosis., W748,GENE_VARIANT,125,130, parietal epileptiform discharges on EE,HPO_TERM,64,103,0.864088,0.13591199,-0.728176,0
line888,The clinical profile for Patient V88 includes an elevated GGT and a hunched-over stance. Genetic analysis of c.2794C>T p.H932Y confirmed the diagnosis.,The clinical profile for Patient V88 includes [E1]an elevated GG[/E1]T and a hunched-over stance. Genetic analysis o[E2]f c.2794C>T p.H932Y[/E2] confirmed the diagnosis.,f c.2794C>T p.H932Y,GENE_VARIANT,107,126,an elevated GG,HPO_TERM,46,60,0.884407,0.11559304,-0.76881397,0
line888,The clinical profile for Patient V88 includes an elevated GGT and a hunched-over stance. Genetic analysis of c.2794C>T p.H932Y confirmed the diagnosis.,The clinical profile for Patient V88 includes an elevated GGT and[E1] a hunched-over stan[/E1]ce. Genetic analysis o[E2]f c.2794C>T p.H932Y[/E2] confirmed the diagnosis.,f c.2794C>T p.H932Y,GENE_VARIANT,107,126, a hunched-over stan,HPO_TERM,65,85,0.89999145,0.10000856,-0.7999829,0
line889,The primary symptoms for Patient V89 were reduced vibration sense and focal motor seizures. Analysis of the c.1156C>T p.R386C was performed.,The primary symptoms for Patient V89 were re[E1]duced vibration sense [/E1]and focal motor seizures. Analysis of the c.11[E2]56C>T p.R386C was[/E2] performed.,56C>T p.R386C was,GENE_VARIANT,112,129,duced vibration sense ,HPO_TERM,44,66,0.87995595,0.12004399,-0.75991195,0
line892,Patient V92 was evaluated for impaired vibratory sensation. The patient also presented with reduced tendon reflexes and a forward-leaning posture. Subsequent sequencing of A467T revealed a pathogenic variant.,Patient V92 was evaluated for [E1]impaired vibratory sensati[/E1]on. The patient also presented with reduced tendon reflexes and a forward-leaning posture. Subsequent sequencing [E2]of A4[/E2]67T revealed a pathogenic variant.,of A4,GENE_VARIANT,169,174,impaired vibratory sensati,HPO_TERM,30,56,0.8845253,0.11547474,-0.76905054,0
line892,Patient V92 was evaluated for impaired vibratory sensation. The patient also presented with reduced tendon reflexes and a forward-leaning posture. Subsequent sequencing of A467T revealed a pathogenic variant.,Patient V92 was evaluated for impaired vibratory sensation. The patient also presented wit[E1]h reduced tendon reflex[/E1]es and a forward-leaning posture. Subsequent sequencing [E2]of A4[/E2]67T revealed a pathogenic variant.,of A4,GENE_VARIANT,169,174,h reduced tendon reflex,HPO_TERM,90,113,0.8804366,0.11956344,-0.76087314,0
line892,Patient V92 was evaluated for impaired vibratory sensation. The patient also presented with reduced tendon reflexes and a forward-leaning posture. Subsequent sequencing of A467T revealed a pathogenic variant.,Patient V92 was evaluated for impaired vibratory sensation. The patient also presented with reduced tendon reflexes an[E1]d a forward-leaning post[/E1]ure. Subsequent sequencing [E2]of A4[/E2]67T revealed a pathogenic variant.,of A4,GENE_VARIANT,169,174,d a forward-leaning post,HPO_TERM,118,142,0.87858564,0.12141437,-0.7571713,0
line893,The primary symptoms for Patient V93 were a stooped posture and a postural or kinetic tremor. Analysis of the 15q26 118 kb deletion involving POLG1 gene and FANCI gene was performed.,The primary symptoms for Patient V93 were a [E1]stooped posture [/E1]and a postural or kinetic tremor. Analysis of the 15q[E2]26 118 kb deletion involving POLG1 gene and FANCI gene was p[/E2]erformed.,26 118 kb deletion involving POLG1 gene and FANCI gene was p,GENE_VARIANT,113,173,stooped posture ,HPO_TERM,44,60,0.81436604,0.18563391,-0.62873214,0
line893,The primary symptoms for Patient V93 were a stooped posture and a postural or kinetic tremor. Analysis of the 15q26 118 kb deletion involving POLG1 gene and FANCI gene was performed.,The primary symptoms for Patient V93 were a stooped posture and a[E1] postural or kinetic tremor[/E1]. Analysis of the 15q[E2]26 118 kb deletion involving POLG1 gene and FANCI gene was p[/E2]erformed.,26 118 kb deletion involving POLG1 gene and FANCI gene was p,GENE_VARIANT,113,173, postural or kinetic tremor,HPO_TERM,65,92,0.8162292,0.18377076,-0.63245845,0
line894,"This report details Patient V94, a patient with reduced reflexes on examination. Further investigation showed an ataxic gait and a forward-leaning posture. A known variant in G737R was identified.","This report details Patient V94, a patient with [E1]reduced reflexes on examinat[/E1]ion. Further investigation showed an ataxic gait and a forward-leaning posture. A known varian[E2]t in [/E2]G737R was identified.",t in ,GENE_VARIANT,170,175,reduced reflexes on examinat,HPO_TERM,48,76,0.873687,0.12631297,-0.74737406,0
line894,"This report details Patient V94, a patient with reduced reflexes on examination. Further investigation showed an ataxic gait and a forward-leaning posture. A known variant in G737R was identified.","This report details Patient V94, a patient with reduced reflexes on examination. Further investigation show[E1]ed an ataxic [/E1]gait and a forward-leaning posture. A known varian[E2]t in [/E2]G737R was identified.",t in ,GENE_VARIANT,170,175,ed an ataxic ,HPO_TERM,107,120,0.85526687,0.14473318,-0.7105337,0
line894,"This report details Patient V94, a patient with reduced reflexes on examination. Further investigation showed an ataxic gait and a forward-leaning posture. A known variant in G737R was identified.","This report details Patient V94, a patient with reduced reflexes on examination. Further investigation showed an ataxic gait [E1]and a forward-leaning po[/E1]sture. A known varian[E2]t in [/E2]G737R was identified.",t in ,GENE_VARIANT,170,175,and a forward-leaning po,HPO_TERM,125,149,0.86983365,0.13016638,-0.7396673,0
line896,The primary symptoms for Patient V96 were aphasia and a focal motor seizure. Analysis of the R853W was performed.,The primary symptoms for Patient V96 were ap[E1]hasia a[/E1]nd a focal motor seizure. Analysis of the R853[E2]W was[/E2] performed.,W was,GENE_VARIANT,97,102,hasia a,HPO_TERM,44,51,0.8687952,0.1312048,-0.73759043,0
line899,Patient V99 was evaluated for an ataxic gait. The patient also presented with a coagulation disorder and reduced vibration sense. Subsequent sequencing of 2263A>G K755E revealed a pathogenic variant.,Patient V99 was evaluated for [E1]an ataxic gai[/E1]t. The patient also presented with a coagulation disorder and reduced vibration sense. Subsequent sequencing o[E2]f 2263A>G K75[/E2]5E revealed a pathogenic variant.,f 2263A>G K75,GENE_VARIANT,153,166,an ataxic gai,HPO_TERM,30,43,0.8919959,0.10800404,-0.7839919,0
line899,Patient V99 was evaluated for an ataxic gait. The patient also presented with a coagulation disorder and reduced vibration sense. Subsequent sequencing of 2263A>G K755E revealed a pathogenic variant.,Patient V99 was evaluated for an ataxic gait. The patient also presented with[E1] a coagulation disorde[/E1]r and reduced vibration sense. Subsequent sequencing o[E2]f 2263A>G K75[/E2]5E revealed a pathogenic variant.,f 2263A>G K75,GENE_VARIANT,153,166, a coagulation disorde,HPO_TERM,77,99,0.88365066,0.11634933,-0.7673013,0
line899,Patient V99 was evaluated for an ataxic gait. The patient also presented with a coagulation disorder and reduced vibration sense. Subsequent sequencing of 2263A>G K755E revealed a pathogenic variant.,Patient V99 was evaluated for an ataxic gait. The patient also presented with a coagulation disorder and[E1] reduced vibration sen[/E1]se. Subsequent sequencing o[E2]f 2263A>G K75[/E2]5E revealed a pathogenic variant.,f 2263A>G K75,GENE_VARIANT,153,166, reduced vibration sen,HPO_TERM,104,126,0.8898051,0.11019496,-0.7796101,0
line900,Patient V100 was evaluated for a deficit in vibratory sense. The patient also presented with a forward-leaning posture and an ataxic gait. Subsequent sequencing of c3239G>C p.Ser1080Thr revealed a pathogenic variant.,Patient V100 was evaluated for [E1]a deficit in vibratory sen[/E1]se. The patient also presented with a forward-leaning posture and an ataxic gait. Subsequent sequencing[E2] of c3239G>C p.Ser108[/E2]0Thr revealed a pathogenic variant., of c3239G>C p.Ser108,GENE_VARIANT,160,181,a deficit in vibratory sen,HPO_TERM,31,57,0.8931467,0.106853336,-0.7862934,0
line900,Patient V100 was evaluated for a deficit in vibratory sense. The patient also presented with a forward-leaning posture and an ataxic gait. Subsequent sequencing of c3239G>C p.Ser1080Thr revealed a pathogenic variant.,Patient V100 was evaluated for a deficit in vibratory sense. The patient also presented wit[E1]h a forward-leaning post[/E1]ure and an ataxic gait. Subsequent sequencing[E2] of c3239G>C p.Ser108[/E2]0Thr revealed a pathogenic variant., of c3239G>C p.Ser108,GENE_VARIANT,160,181,h a forward-leaning post,HPO_TERM,91,115,0.8917834,0.108216584,-0.78356683,0
line900,Patient V100 was evaluated for a deficit in vibratory sense. The patient also presented with a forward-leaning posture and an ataxic gait. Subsequent sequencing of c3239G>C p.Ser1080Thr revealed a pathogenic variant.,Patient V100 was evaluated for a deficit in vibratory sense. The patient also presented with a forward-leaning posture a[E1]nd an ataxic [/E1]gait. Subsequent sequencing[E2] of c3239G>C p.Ser108[/E2]0Thr revealed a pathogenic variant., of c3239G>C p.Ser108,GENE_VARIANT,160,181,nd an ataxic ,HPO_TERM,120,133,0.8923584,0.10764161,-0.78471684,0
line902,The primary symptoms for Patient V102 were a stooped posture and aphasia. Analysis of the c.1156C>T p.R386C was performed.,The primary symptoms for Patient V102 were a [E1]stooped posture [/E1]and aphasia. Analysis of the c.11[E2]56C>T p.R386C was[/E2] performed.,56C>T p.R386C was,GENE_VARIANT,94,111,stooped posture ,HPO_TERM,45,61,0.8819091,0.11809091,-0.76381814,0
line903,Patient V103 was evaluated for an elevated GGT. The patient also presented with an ataxic gait and a coagulation disorder. Subsequent sequencing of W748S revealed a pathogenic variant.,Patient V103 was evaluated for [E1]an elevated GG[/E1]T. The patient also presented with an ataxic gait and a coagulation disorder. Subsequent sequencing o[E2]f W74[/E2]8S revealed a pathogenic variant.,f W74,GENE_VARIANT,146,151,an elevated GG,HPO_TERM,31,45,0.88506824,0.11493172,-0.77013654,0
line903,Patient V103 was evaluated for an elevated GGT. The patient also presented with an ataxic gait and a coagulation disorder. Subsequent sequencing of W748S revealed a pathogenic variant.,Patient V103 was evaluated for an elevated GGT. The patient also presented with[E1] an ataxic ga[/E1]it and a coagulation disorder. Subsequent sequencing o[E2]f W74[/E2]8S revealed a pathogenic variant.,f W74,GENE_VARIANT,146,151, an ataxic ga,HPO_TERM,79,92,0.88409394,0.11590606,-0.7681879,0
line903,Patient V103 was evaluated for an elevated GGT. The patient also presented with an ataxic gait and a coagulation disorder. Subsequent sequencing of W748S revealed a pathogenic variant.,Patient V103 was evaluated for an elevated GGT. The patient also presented with an ataxic gait an[E1]d a coagulation disord[/E1]er. Subsequent sequencing o[E2]f W74[/E2]8S revealed a pathogenic variant.,f W74,GENE_VARIANT,146,151,d a coagulation disord,HPO_TERM,97,119,0.89178,0.10822002,-0.78356,0
line904,Patient V104 was evaluated for a language disorder. The patient also presented with a coagulation disorder and reduced tendon reflexes. Subsequent sequencing of W748S revealed a pathogenic variant.,Patient V104 was evaluated for [E1]a language disorde[/E1]r. The patient also presented with a coagulation disorder and reduced tendon reflexes. Subsequent sequencing of[E2] W748[/E2]S revealed a pathogenic variant., W748,GENE_VARIANT,160,165,a language disorde,HPO_TERM,31,49,0.8746703,0.1253297,-0.74934065,0
line904,Patient V104 was evaluated for a language disorder. The patient also presented with a coagulation disorder and reduced tendon reflexes. Subsequent sequencing of W748S revealed a pathogenic variant.,Patient V104 was evaluated for a language disorder. The patient also presented with[E1] a coagulation disorde[/E1]r and reduced tendon reflexes. Subsequent sequencing of[E2] W748[/E2]S revealed a pathogenic variant., W748,GENE_VARIANT,160,165, a coagulation disorde,HPO_TERM,83,105,0.8705775,0.12942244,-0.7411551,0
line904,Patient V104 was evaluated for a language disorder. The patient also presented with a coagulation disorder and reduced tendon reflexes. Subsequent sequencing of W748S revealed a pathogenic variant.,Patient V104 was evaluated for a language disorder. The patient also presented with a coagulation disorder and[E1] reduced tendon reflexe[/E1]s. Subsequent sequencing of[E2] W748[/E2]S revealed a pathogenic variant., W748,GENE_VARIANT,160,165, reduced tendon reflexe,HPO_TERM,110,133,0.87939465,0.12060539,-0.75878924,0
line907,The primary symptoms for Patient V107 were reduced tendon reflexes and a forward-leaning posture. Analysis of the 1868T>G L623W was performed.,The primary symptoms for Patient V107 were re[E1]duced tendon reflexes a[/E1]nd a forward-leaning posture. Analysis of the 1868[E2]T>G L623W was[/E2] performed.,T>G L623W was,GENE_VARIANT,118,131,duced tendon reflexes a,HPO_TERM,45,68,0.8423182,0.1576818,-0.68463635,0
line908,Patient V108 was evaluated for parietal epileptiform discharges on EEG. The patient also presented with an ataxic gait and a focal motor seizure. Subsequent sequencing of A467T revealed a pathogenic variant.,Patient V108 was evaluated for [E1]parietal epileptiform discharges on EEG[/E1]. The patient also presented with an ataxic gait and a focal motor seizure. Subsequent sequencing o[E2]f A46[/E2]7T revealed a pathogenic variant.,f A46,GENE_VARIANT,169,174,parietal epileptiform discharges on EEG,HPO_TERM,31,70,0.87841,0.12159006,-0.7568199,0
line908,Patient V108 was evaluated for parietal epileptiform discharges on EEG. The patient also presented with an ataxic gait and a focal motor seizure. Subsequent sequencing of A467T revealed a pathogenic variant.,Patient V108 was evaluated for parietal epileptiform discharges on EEG. The patient also presented with [E1]an ataxic gai[/E1]t and a focal motor seizure. Subsequent sequencing o[E2]f A46[/E2]7T revealed a pathogenic variant.,f A46,GENE_VARIANT,169,174,an ataxic gai,HPO_TERM,104,117,0.88583475,0.11416523,-0.7716695,0
line908,Patient V108 was evaluated for parietal epileptiform discharges on EEG. The patient also presented with an ataxic gait and a focal motor seizure. Subsequent sequencing of A467T revealed a pathogenic variant.,Patient V108 was evaluated for parietal epileptiform discharges on EEG. The patient also presented with an ataxic gait and[E1] a focal motor seizu[/E1]re. Subsequent sequencing o[E2]f A46[/E2]7T revealed a pathogenic variant.,f A46,GENE_VARIANT,169,174, a focal motor seizu,HPO_TERM,122,142,0.88583773,0.11416226,-0.77167547,0
line909,The primary symptoms for Patient V109 were an elevated GGT and a focal motor seizure. Analysis of the c.1156C>T p.R386C was performed.,The primary symptoms for Patient V109 were an[E1] elevated GGT [/E1]and a focal motor seizure. Analysis of the c.1[E2]156C>T p.R386C wa[/E2]s performed.,156C>T p.R386C wa,GENE_VARIANT,105,122, elevated GGT ,HPO_TERM,45,59,0.867214,0.13278598,-0.73442805,0
line909,The primary symptoms for Patient V109 were an elevated GGT and a focal motor seizure. Analysis of the c.1156C>T p.R386C was performed.,The primary symptoms for Patient V109 were an elevated GGT and a[E1] focal motor seizure[/E1]. Analysis of the c.1[E2]156C>T p.R386C wa[/E2]s performed.,156C>T p.R386C wa,GENE_VARIANT,105,122, focal motor seizure,HPO_TERM,64,84,0.8644239,0.13557607,-0.7288478,0
line912,"This report details Patient V112, a patient with a forward-leaning posture. Further investigation showed a kinetic tremor and parietal sharp waves on electroencephalogram. A known variant in c.2794C>T p.H932Y was identified.","This report details Patient V112, a patient with [E1]a forward-leaning postur[/E1]e. Further investigation showed a kinetic tremor and parietal sharp waves on electroencephalogram. A known variant [E2]in c.2794C>T p.H932[/E2]Y was identified.",in c.2794C>T p.H932,GENE_VARIANT,188,207,a forward-leaning postur,HPO_TERM,49,73,0.8706963,0.1293037,-0.7413926,0
line912,"This report details Patient V112, a patient with a forward-leaning posture. Further investigation showed a kinetic tremor and parietal sharp waves on electroencephalogram. A known variant in c.2794C>T p.H932Y was identified.","This report details Patient V112, a patient with a forward-leaning posture. Further investigation showed[E1] a kinetic tremo[/E1]r and parietal sharp waves on electroencephalogram. A known variant [E2]in c.2794C>T p.H932[/E2]Y was identified.",in c.2794C>T p.H932,GENE_VARIANT,188,207, a kinetic tremo,HPO_TERM,104,120,0.8611581,0.13884191,-0.72231615,0
line912,"This report details Patient V112, a patient with a forward-leaning posture. Further investigation showed a kinetic tremor and parietal sharp waves on electroencephalogram. A known variant in c.2794C>T p.H932Y was identified.","This report details Patient V112, a patient with a forward-leaning posture. Further investigation showed a kinetic tremor and[E1] parietal sharp waves on electroencephalog[/E1]ram. A known variant [E2]in c.2794C>T p.H932[/E2]Y was identified.",in c.2794C>T p.H932,GENE_VARIANT,188,207, parietal sharp waves on electroencephalog,HPO_TERM,125,167,0.85727715,0.14272279,-0.71455437,0
line913,The primary symptoms for Patient V113 were a coagulation disorder and parietal epileptiform discharges on EEG. Analysis of the G737R was performed.,The primary symptoms for Patient V113 were a [E1]coagulation disorder a[/E1]nd parietal epileptiform discharges on EEG. Analysis of the G737R[E2] was [/E2]performed., was ,GENE_VARIANT,132,137,coagulation disorder a,HPO_TERM,45,67,0.8670361,0.13296391,-0.7340722,0
line916,The clinical profile for Patient V116 includes a focal motor seizure and a forward-leaning posture. Genetic analysis of R853W confirmed the diagnosis.,The clinical profile for Patient V116 includes [E1]a focal motor seizur[/E1]e and a forward-leaning posture. Genetic analysis o[E2]f R85[/E2]3W confirmed the diagnosis.,f R85,GENE_VARIANT,118,123,a focal motor seizur,HPO_TERM,47,67,0.8721847,0.12781525,-0.74436945,0
line916,The clinical profile for Patient V116 includes a focal motor seizure and a forward-leaning posture. Genetic analysis of R853W confirmed the diagnosis.,The clinical profile for Patient V116 includes a focal motor seizure and[E1] a forward-leaning postu[/E1]re. Genetic analysis o[E2]f R85[/E2]3W confirmed the diagnosis.,f R85,GENE_VARIANT,118,123, a forward-leaning postu,HPO_TERM,72,96,0.87119836,0.1288016,-0.7423968,0
line917,Patient V117 was evaluated for a language disorder. The patient also presented with a forward-leaning posture and an ataxic gait. Subsequent sequencing of 2263A>G K755E revealed a pathogenic variant.,Patient V117 was evaluated for [E1]a language disorde[/E1]r. The patient also presented with a forward-leaning posture and an ataxic gait. Subsequent sequencing [E2]of 2263A>G K7[/E2]55E revealed a pathogenic variant.,of 2263A>G K7,GENE_VARIANT,152,165,a language disorde,HPO_TERM,31,49,0.8827621,0.11723792,-0.76552415,0
line917,Patient V117 was evaluated for a language disorder. The patient also presented with a forward-leaning posture and an ataxic gait. Subsequent sequencing of 2263A>G K755E revealed a pathogenic variant.,Patient V117 was evaluated for a language disorder. The patient also presented with[E1] a forward-leaning postu[/E1]re and an ataxic gait. Subsequent sequencing [E2]of 2263A>G K7[/E2]55E revealed a pathogenic variant.,of 2263A>G K7,GENE_VARIANT,152,165, a forward-leaning postu,HPO_TERM,83,107,0.8734739,0.12652612,-0.74694777,0
line917,Patient V117 was evaluated for a language disorder. The patient also presented with a forward-leaning posture and an ataxic gait. Subsequent sequencing of 2263A>G K755E revealed a pathogenic variant.,Patient V117 was evaluated for a language disorder. The patient also presented with a forward-leaning posture an[E1]d an ataxic g[/E1]ait. Subsequent sequencing [E2]of 2263A>G K7[/E2]55E revealed a pathogenic variant.,of 2263A>G K7,GENE_VARIANT,152,165,d an ataxic g,HPO_TERM,112,125,0.8851242,0.11487582,-0.7702484,0
line918,The primary symptoms for Patient V118 were an ataxic gait and a deficit in vibratory sense. Analysis of the c.1156C>T p.R386C was performed.,The primary symptoms for Patient V118 were an[E1] ataxic gait [/E1]and a deficit in vibratory sense. Analysis of the c.[E2]1156C>T p.R386C w[/E2]as performed.,1156C>T p.R386C w,GENE_VARIANT,110,127, ataxic gait ,HPO_TERM,45,58,0.85687923,0.14312069,-0.7137585,0
line918,The primary symptoms for Patient V118 were an ataxic gait and a deficit in vibratory sense. Analysis of the c.1156C>T p.R386C was performed.,The primary symptoms for Patient V118 were an ataxic gait and a[E1] deficit in vibratory sens[/E1]e. Analysis of the c.[E2]1156C>T p.R386C w[/E2]as performed.,1156C>T p.R386C w,GENE_VARIANT,110,127, deficit in vibratory sens,HPO_TERM,63,89,0.88991034,0.110089704,-0.7798206,0
line919,Patient V119 was evaluated for an ataxic gait. The patient also presented with a hunched-over stance and a language disorder. Subsequent sequencing of 15q26 118 kb deletion involving POLG1 gene and FANCI gene revealed a pathogenic variant.,Patient V119 was evaluated for [E1]an ataxic gai[/E1]t. The patient also presented with a hunched-over stance and a language disorder. Subsequent sequencing [E2]of 15q26 118 kb deletion involving POLG1 gene and FANCI gene[/E2] revealed a pathogenic variant.,of 15q26 118 kb deletion involving POLG1 gene and FANCI gene,GENE_VARIANT,148,208,an ataxic gai,HPO_TERM,31,44,0.841487,0.15851298,-0.682974,0
line919,Patient V119 was evaluated for an ataxic gait. The patient also presented with a hunched-over stance and a language disorder. Subsequent sequencing of 15q26 118 kb deletion involving POLG1 gene and FANCI gene revealed a pathogenic variant.,Patient V119 was evaluated for an ataxic gait. The patient also presented with[E1] a hunched-over stan[/E1]ce and a language disorder. Subsequent sequencing [E2]of 15q26 118 kb deletion involving POLG1 gene and FANCI gene[/E2] revealed a pathogenic variant.,of 15q26 118 kb deletion involving POLG1 gene and FANCI gene,GENE_VARIANT,148,208, a hunched-over stan,HPO_TERM,78,98,0.81492543,0.18507458,-0.62985086,0
line919,Patient V119 was evaluated for an ataxic gait. The patient also presented with a hunched-over stance and a language disorder. Subsequent sequencing of 15q26 118 kb deletion involving POLG1 gene and FANCI gene revealed a pathogenic variant.,Patient V119 was evaluated for an ataxic gait. The patient also presented with a hunched-over stance an[E1]d a language disor[/E1]der. Subsequent sequencing [E2]of 15q26 118 kb deletion involving POLG1 gene and FANCI gene[/E2] revealed a pathogenic variant.,of 15q26 118 kb deletion involving POLG1 gene and FANCI gene,GENE_VARIANT,148,208,d a language disor,HPO_TERM,103,121,0.8476474,0.15235254,-0.69529486,0
line920,The clinical profile for Patient V120 includes a language disorder and a forward-leaning posture. Genetic analysis of 2263A>G K755E confirmed the diagnosis.,The clinical profile for Patient V120 includes [E1]a language disorde[/E1]r and a forward-leaning posture. Genetic analysis o[E2]f 2263A>G K75[/E2]5E confirmed the diagnosis.,f 2263A>G K75,GENE_VARIANT,116,129,a language disorde,HPO_TERM,47,65,0.874347,0.12565307,-0.7486939,0
line920,The clinical profile for Patient V120 includes a language disorder and a forward-leaning posture. Genetic analysis of 2263A>G K755E confirmed the diagnosis.,The clinical profile for Patient V120 includes a language disorder and[E1] a forward-leaning postu[/E1]re. Genetic analysis o[E2]f 2263A>G K75[/E2]5E confirmed the diagnosis.,f 2263A>G K75,GENE_VARIANT,116,129, a forward-leaning postu,HPO_TERM,70,94,0.8779299,0.12207005,-0.75585985,0
line921,Patient V121 was evaluated for an ataxic gait. The patient also presented with a stooped posture and parietal epileptiform discharges on EEG. Subsequent sequencing of 1868T>G L623W revealed a pathogenic variant.,Patient V121 was evaluated for [E1]an ataxic gai[/E1]t. The patient also presented with a stooped posture and parietal epileptiform discharges on EEG. Subsequent sequencing o[E2]f 1868T>G L62[/E2]3W revealed a pathogenic variant.,f 1868T>G L62,GENE_VARIANT,165,178,an ataxic gai,HPO_TERM,31,44,0.8950968,0.104903184,-0.7901936,0
line921,Patient V121 was evaluated for an ataxic gait. The patient also presented with a stooped posture and parietal epileptiform discharges on EEG. Subsequent sequencing of 1868T>G L623W revealed a pathogenic variant.,Patient V121 was evaluated for an ataxic gait. The patient also presented with[E1] a stooped postu[/E1]re and parietal epileptiform discharges on EEG. Subsequent sequencing o[E2]f 1868T>G L62[/E2]3W revealed a pathogenic variant.,f 1868T>G L62,GENE_VARIANT,165,178, a stooped postu,HPO_TERM,78,94,0.87845856,0.12154148,-0.75691706,0
line921,Patient V121 was evaluated for an ataxic gait. The patient also presented with a stooped posture and parietal epileptiform discharges on EEG. Subsequent sequencing of 1868T>G L623W revealed a pathogenic variant.,Patient V121 was evaluated for an ataxic gait. The patient also presented with a stooped posture an[E1]d parietal epileptiform discharges on E[/E1]EG. Subsequent sequencing o[E2]f 1868T>G L62[/E2]3W revealed a pathogenic variant.,f 1868T>G L62,GENE_VARIANT,165,178,d parietal epileptiform discharges on E,HPO_TERM,99,138,0.88856554,0.1114344,-0.77713114,0
line922,"This report details Patient V122, a patient with impaired vibratory sensation. Further investigation showed an elevated GGT and a forward-leaning posture. A known variant in A467T was identified.","This report details Patient V122, a patient with [E1]impaired vibratory sensati[/E1]on. Further investigation showed an elevated GGT and a forward-leaning posture. A known variant[E2] in A[/E2]467T was identified.", in A,GENE_VARIANT,170,175,impaired vibratory sensati,HPO_TERM,49,75,0.8649865,0.13501346,-0.729973,0
line922,"This report details Patient V122, a patient with impaired vibratory sensation. Further investigation showed an elevated GGT and a forward-leaning posture. A known variant in A467T was identified.","This report details Patient V122, a patient with impaired vibratory sensation. Further investigation showe[E1]d an elevated [/E1]GGT and a forward-leaning posture. A known variant[E2] in A[/E2]467T was identified.", in A,GENE_VARIANT,170,175,d an elevated ,HPO_TERM,106,120,0.85898,0.14102,-0.71796,0
line922,"This report details Patient V122, a patient with impaired vibratory sensation. Further investigation showed an elevated GGT and a forward-leaning posture. A known variant in A467T was identified.","This report details Patient V122, a patient with impaired vibratory sensation. Further investigation showed an elevated GGT a[E1]nd a forward-leaning pos[/E1]ture. A known variant[E2] in A[/E2]467T was identified.", in A,GENE_VARIANT,170,175,nd a forward-leaning pos,HPO_TERM,125,149,0.8826209,0.11737914,-0.76524174,0
line923,The clinical profile for Patient V123 includes an elevated GGT and a kinetic tremor. Genetic analysis of W748S confirmed the diagnosis.,The clinical profile for Patient V123 includes [E1]an elevated GG[/E1]T and a kinetic tremor. Genetic analysis of[E2] W748[/E2]S confirmed the diagnosis., W748,GENE_VARIANT,104,109,an elevated GG,HPO_TERM,47,61,0.8719381,0.12806192,-0.7438762,0
line923,The clinical profile for Patient V123 includes an elevated GGT and a kinetic tremor. Genetic analysis of W748S confirmed the diagnosis.,The clinical profile for Patient V123 includes an elevated GGT and[E1] a kinetic tremo[/E1]r. Genetic analysis of[E2] W748[/E2]S confirmed the diagnosis., W748,GENE_VARIANT,104,109, a kinetic tremo,HPO_TERM,66,82,0.8811331,0.11886696,-0.7622661,0
line924,The primary symptoms for Patient V124 were aphasia and a language disorder. Analysis of the c.3643+2T>C was performed.,The primary symptoms for Patient V124 were ap[E1]hasia a[/E1]nd a language disorder. Analysis of the c.36[E2]43+2T>C was [/E2]performed.,43+2T>C was ,GENE_VARIANT,96,108,hasia a,HPO_TERM,45,52,0.8692619,0.13073803,-0.7385239,0
line925,The primary symptoms for Patient V125 were an ataxic gait and a coagulation disorder. Analysis of the W748S was performed.,The primary symptoms for Patient V125 were an[E1] ataxic gait [/E1]and a coagulation disorder. Analysis of the W748[E2]S was[/E2] performed.,S was,GENE_VARIANT,106,111, ataxic gait ,HPO_TERM,45,58,0.83278924,0.16721073,-0.6655785,0
line926,Patient V126 was evaluated for a forward-leaning posture. The patient also presented with aphasia and a focal motor seizure. Subsequent sequencing of W748S revealed a pathogenic variant.,Patient V126 was evaluated for [E1]a forward-leaning postur[/E1]e. The patient also presented with aphasia and a focal motor seizure. Subsequent sequencing o[E2]f W74[/E2]8S revealed a pathogenic variant.,f W74,GENE_VARIANT,148,153,a forward-leaning postur,HPO_TERM,31,55,0.8785557,0.121444255,-0.75711143,0
line926,Patient V126 was evaluated for a forward-leaning posture. The patient also presented with aphasia and a focal motor seizure. Subsequent sequencing of W748S revealed a pathogenic variant.,Patient V126 was evaluated for a forward-leaning posture. The patient also presented with[E1] aphasi[/E1]a and a focal motor seizure. Subsequent sequencing o[E2]f W74[/E2]8S revealed a pathogenic variant.,f W74,GENE_VARIANT,148,153, aphasi,HPO_TERM,89,96,0.87551385,0.124486126,-0.7510277,0
line926,Patient V126 was evaluated for a forward-leaning posture. The patient also presented with aphasia and a focal motor seizure. Subsequent sequencing of W748S revealed a pathogenic variant.,Patient V126 was evaluated for a forward-leaning posture. The patient also presented with aphasia and[E1] a focal motor seizu[/E1]re. Subsequent sequencing o[E2]f W74[/E2]8S revealed a pathogenic variant.,f W74,GENE_VARIANT,148,153, a focal motor seizu,HPO_TERM,101,121,0.8771087,0.12289124,-0.75421745,0
line927,The clinical profile for Patient V127 includes a coagulation disorder and reduced vibration sense. Genetic analysis of R853W confirmed the diagnosis.,The clinical profile for Patient V127 includes [E1]a coagulation disorder[/E1] and reduced vibration sense. Genetic analysis of[E2] R853[/E2]W confirmed the diagnosis., R853,GENE_VARIANT,118,123,a coagulation disorder,HPO_TERM,47,69,0.871568,0.12843192,-0.7431361,0
line927,The clinical profile for Patient V127 includes a coagulation disorder and reduced vibration sense. Genetic analysis of R853W confirmed the diagnosis.,The clinical profile for Patient V127 includes a coagulation disorder and [E1]reduced vibration sens[/E1]e. Genetic analysis of[E2] R853[/E2]W confirmed the diagnosis., R853,GENE_VARIANT,118,123,reduced vibration sens,HPO_TERM,74,96,0.8886232,0.11137687,-0.7772463,0
line929,The primary symptoms for Patient V129 were an elevated GGT and a deficit in vibratory sense. Analysis of the G737R was performed.,The primary symptoms for Patient V129 were an[E1] elevated GGT [/E1]and a deficit in vibratory sense. Analysis of the G7[E2]37R w[/E2]as performed.,37R w,GENE_VARIANT,111,116, elevated GGT ,HPO_TERM,45,59,0.82264537,0.17735462,-0.64529073,0
line929,The primary symptoms for Patient V129 were an elevated GGT and a deficit in vibratory sense. Analysis of the G737R was performed.,The primary symptoms for Patient V129 were an elevated GGT and a[E1] deficit in vibratory sens[/E1]e. Analysis of the G7[E2]37R w[/E2]as performed.,37R w,GENE_VARIANT,111,116, deficit in vibratory sens,HPO_TERM,64,90,0.8625898,0.1374102,-0.72517955,0
line930,"We report the case of Patient V130, who has a history of a focal motor seizure. Examination also revealed a deficit in vibratory sense. The underlying cause was traced to a mutation in G737R.","We report the case of Patient V130, who has a history of [E1]a focal motor seizur[/E1]e. Examination also revealed a deficit in vibratory sense. The underlying cause was traced to a mutation in G[E2]737R.[/E2]",737R.,GENE_VARIANT,186,191,a focal motor seizur,HPO_TERM,57,77,0.76782817,0.2321718,-0.53565633,0
line930,"We report the case of Patient V130, who has a history of a focal motor seizure. Examination also revealed a deficit in vibratory sense. The underlying cause was traced to a mutation in G737R.","We report the case of Patient V130, who has a history of a focal motor seizure. Examination also revealed[E1] a deficit in vibratory se[/E1]nse. The underlying cause was traced to a mutation in G[E2]737R.[/E2]",737R.,GENE_VARIANT,186,191, a deficit in vibratory se,HPO_TERM,105,131,0.7706437,0.22935623,-0.5412875,0
line932,"We report the case of Patient V132, who has a history of impaired vibratory sensation. Examination also revealed a focal motor seizure. The underlying cause was traced to a mutation in 1868T>G L623W.","We report the case of Patient V132, who has a history of [E1]impaired vibratory sensati[/E1]on. Examination also revealed a focal motor seizure. The underlying cause was traced to a mutation in 1[E2]868T>G L623W.[/E2]",868T>G L623W.,GENE_VARIANT,186,199,impaired vibratory sensati,HPO_TERM,57,83,0.83793724,0.16206282,-0.6758744,0
line932,"We report the case of Patient V132, who has a history of impaired vibratory sensation. Examination also revealed a focal motor seizure. The underlying cause was traced to a mutation in 1868T>G L623W.","We report the case of Patient V132, who has a history of impaired vibratory sensation. Examination also reveale[E1]d a focal motor seiz[/E1]ure. The underlying cause was traced to a mutation in 1[E2]868T>G L623W.[/E2]",868T>G L623W.,GENE_VARIANT,186,199,d a focal motor seiz,HPO_TERM,111,131,0.82681835,0.17318162,-0.6536367,0
line936,The clinical profile for Patient V136 includes aphasia and a stooped posture. Genetic analysis of G737R confirmed the diagnosis.,The clinical profile for Patient V136 includes [E1]aphasia[/E1] and a stooped posture. Genetic analysis of[E2] G737[/E2]R confirmed the diagnosis., G737,GENE_VARIANT,97,102,aphasia,HPO_TERM,47,54,0.88029164,0.11970839,-0.7605833,0
line936,The clinical profile for Patient V136 includes aphasia and a stooped posture. Genetic analysis of G737R confirmed the diagnosis.,The clinical profile for Patient V136 includes aphasia and [E1]a stooped postur[/E1]e. Genetic analysis of[E2] G737[/E2]R confirmed the diagnosis., G737,GENE_VARIANT,97,102,a stooped postur,HPO_TERM,59,75,0.8869645,0.113035515,-0.773929,0
line938,The clinical profile for Patient V138 includes a stooped posture and a deficit in vibratory sense. Genetic analysis of A467T confirmed the diagnosis.,The clinical profile for Patient V138 includes [E1]a stooped postur[/E1]e and a deficit in vibratory sense. Genetic analysis [E2]of A4[/E2]67T confirmed the diagnosis.,of A4,GENE_VARIANT,116,121,a stooped postur,HPO_TERM,47,63,0.8851936,0.11480639,-0.7703872,0
line938,The clinical profile for Patient V138 includes a stooped posture and a deficit in vibratory sense. Genetic analysis of A467T confirmed the diagnosis.,The clinical profile for Patient V138 includes a stooped posture and[E1] a deficit in vibratory se[/E1]nse. Genetic analysis [E2]of A4[/E2]67T confirmed the diagnosis.,of A4,GENE_VARIANT,116,121, a deficit in vibratory se,HPO_TERM,68,94,0.886371,0.11362895,-0.77274203,0
line939,The clinical profile for Patient V139 includes hyporeflexia and parietal epileptiform discharges on EEG. Genetic analysis of c.2794C>T p.H932Y confirmed the diagnosis.,The clinical profile for Patient V139 includes [E1]hyporeflexi[/E1]a and parietal epileptiform discharges on EEG. Genetic analysis of[E2] c.2794C>T p.H932Y [/E2]confirmed the diagnosis., c.2794C>T p.H932Y ,GENE_VARIANT,124,143,hyporeflexi,HPO_TERM,47,58,0.89132255,0.108677514,-0.78264505,0
line939,The clinical profile for Patient V139 includes hyporeflexia and parietal epileptiform discharges on EEG. Genetic analysis of c.2794C>T p.H932Y confirmed the diagnosis.,The clinical profile for Patient V139 includes hyporeflexia and[E1] parietal epileptiform discharges on EE[/E1]G. Genetic analysis of[E2] c.2794C>T p.H932Y [/E2]confirmed the diagnosis., c.2794C>T p.H932Y ,GENE_VARIANT,124,143, parietal epileptiform discharges on EE,HPO_TERM,63,102,0.8843143,0.11568572,-0.7686286,0
line943,Patient V143 was evaluated for an elevated GGT. The patient also presented with a coagulation disorder and reduced tendon reflexes. Subsequent sequencing of 2263A>G K755E revealed a pathogenic variant.,Patient V143 was evaluated for [E1]an elevated GG[/E1]T. The patient also presented with a coagulation disorder and reduced tendon reflexes. Subsequent sequencing of[E2] 2263A>G K755[/E2]E revealed a pathogenic variant., 2263A>G K755,GENE_VARIANT,156,169,an elevated GG,HPO_TERM,31,45,0.89735335,0.10264666,-0.7947067,0
line943,Patient V143 was evaluated for an elevated GGT. The patient also presented with a coagulation disorder and reduced tendon reflexes. Subsequent sequencing of 2263A>G K755E revealed a pathogenic variant.,Patient V143 was evaluated for an elevated GGT. The patient also presented with[E1] a coagulation disorde[/E1]r and reduced tendon reflexes. Subsequent sequencing of[E2] 2263A>G K755[/E2]E revealed a pathogenic variant., 2263A>G K755,GENE_VARIANT,156,169, a coagulation disorde,HPO_TERM,79,101,0.8936796,0.106320314,-0.7873593,0
line943,Patient V143 was evaluated for an elevated GGT. The patient also presented with a coagulation disorder and reduced tendon reflexes. Subsequent sequencing of 2263A>G K755E revealed a pathogenic variant.,Patient V143 was evaluated for an elevated GGT. The patient also presented with a coagulation disorder and[E1] reduced tendon reflexe[/E1]s. Subsequent sequencing of[E2] 2263A>G K755[/E2]E revealed a pathogenic variant., 2263A>G K755,GENE_VARIANT,156,169, reduced tendon reflexe,HPO_TERM,106,129,0.8999741,0.1000259,-0.7999482,0
line944,The clinical profile for Patient V144 includes an ataxic gait and a coagulation disorder. Genetic analysis of c.2794C>T p.H932Y confirmed the diagnosis.,The clinical profile for Patient V144 includes [E1]an ataxic gai[/E1]t and a coagulation disorder. Genetic analysis of[E2] c.2794C>T p.H932Y [/E2]confirmed the diagnosis., c.2794C>T p.H932Y ,GENE_VARIANT,109,128,an ataxic gai,HPO_TERM,47,60,0.8772385,0.12276147,-0.754477,0
line944,The clinical profile for Patient V144 includes an ataxic gait and a coagulation disorder. Genetic analysis of c.2794C>T p.H932Y confirmed the diagnosis.,The clinical profile for Patient V144 includes an ataxic gait and[E1] a coagulation disorde[/E1]r. Genetic analysis of[E2] c.2794C>T p.H932Y [/E2]confirmed the diagnosis., c.2794C>T p.H932Y ,GENE_VARIANT,109,128, a coagulation disorde,HPO_TERM,65,87,0.89264745,0.10735257,-0.7852949,0
line946,Patient V146 was evaluated for parietal sharp waves on electroencephalogram. The patient also presented with a forward-leaning posture and an ataxic gait. Subsequent sequencing of 15q26 118 kb deletion involving POLG1 gene and FANCI gene revealed a pathogenic variant.,Patient V146 was evaluated for [E1]parietal sharp waves on electroencephalogr[/E1]am. The patient also presented with a forward-leaning posture and an ataxic gait. Subsequent sequencing[E2] of 15q26 118 kb deletion involving POLG1 gene and FANCI gen[/E2]e revealed a pathogenic variant., of 15q26 118 kb deletion involving POLG1 gene and FANCI gen,GENE_VARIANT,176,236,parietal sharp waves on electroencephalogr,HPO_TERM,31,73,0.86429846,0.13570149,-0.728597,0
line946,Patient V146 was evaluated for parietal sharp waves on electroencephalogram. The patient also presented with a forward-leaning posture and an ataxic gait. Subsequent sequencing of 15q26 118 kb deletion involving POLG1 gene and FANCI gene revealed a pathogenic variant.,Patient V146 was evaluated for parietal sharp waves on electroencephalogram. The patient also presented wit[E1]h a forward-leaning post[/E1]ure and an ataxic gait. Subsequent sequencing[E2] of 15q26 118 kb deletion involving POLG1 gene and FANCI gen[/E2]e revealed a pathogenic variant., of 15q26 118 kb deletion involving POLG1 gene and FANCI gen,GENE_VARIANT,176,236,h a forward-leaning post,HPO_TERM,107,131,0.8645252,0.13547482,-0.7290504,0
line946,Patient V146 was evaluated for parietal sharp waves on electroencephalogram. The patient also presented with a forward-leaning posture and an ataxic gait. Subsequent sequencing of 15q26 118 kb deletion involving POLG1 gene and FANCI gene revealed a pathogenic variant.,Patient V146 was evaluated for parietal sharp waves on electroencephalogram. The patient also presented with a forward-leaning posture a[E1]nd an ataxic [/E1]gait. Subsequent sequencing[E2] of 15q26 118 kb deletion involving POLG1 gene and FANCI gen[/E2]e revealed a pathogenic variant., of 15q26 118 kb deletion involving POLG1 gene and FANCI gen,GENE_VARIANT,176,236,nd an ataxic ,HPO_TERM,136,149,0.87055385,0.12944613,-0.7411077,0
line947,The clinical profile for Patient V147 includes reduced vibration sense and a postural or kinetic tremor. Genetic analysis of c.2794C>T p.H932Y confirmed the diagnosis.,The clinical profile for Patient V147 includes [E1]reduced vibration sens[/E1]e and a postural or kinetic tremor. Genetic analysis o[E2]f c.2794C>T p.H932Y[/E2] confirmed the diagnosis.,f c.2794C>T p.H932Y,GENE_VARIANT,123,142,reduced vibration sens,HPO_TERM,47,69,0.87834245,0.121657476,-0.75668496,0
line947,The clinical profile for Patient V147 includes reduced vibration sense and a postural or kinetic tremor. Genetic analysis of c.2794C>T p.H932Y confirmed the diagnosis.,The clinical profile for Patient V147 includes reduced vibration sense and[E1] a postural or kinetic trem[/E1]or. Genetic analysis o[E2]f c.2794C>T p.H932Y[/E2] confirmed the diagnosis.,f c.2794C>T p.H932Y,GENE_VARIANT,123,142, a postural or kinetic trem,HPO_TERM,74,101,0.8783014,0.12169862,-0.75660276,0
line949,The primary symptoms for Patient V149 were an action tremor and an ataxic gait. Analysis of the R853W was performed.,The primary symptoms for Patient V149 were an[E1] action tremor [/E1]and an ataxic gait. Analysis of the R85[E2]3W wa[/E2]s performed.,3W wa,GENE_VARIANT,99,104, action tremor ,HPO_TERM,45,60,0.80261755,0.19738248,-0.6052351,0
line949,The primary symptoms for Patient V149 were an action tremor and an ataxic gait. Analysis of the R853W was performed.,The primary symptoms for Patient V149 were an action tremor and a[E1]n ataxic gait[/E1]. Analysis of the R85[E2]3W wa[/E2]s performed.,3W wa,GENE_VARIANT,99,104,n ataxic gait,HPO_TERM,65,78,0.7767328,0.2232672,-0.5534656,0
line950,Patient V150 was evaluated for a deficit in vibratory sense. The patient also presented with an elevated GGT and an ataxic gait. Subsequent sequencing of c.2794C>T p.H932Y revealed a pathogenic variant.,Patient V150 was evaluated for [E1]a deficit in vibratory sen[/E1]se. The patient also presented with an elevated GGT and an ataxic gait. Subsequent sequencing[E2] of c.2794C>T p.H93[/E2]2Y revealed a pathogenic variant., of c.2794C>T p.H93,GENE_VARIANT,150,169,a deficit in vibratory sen,HPO_TERM,31,57,0.8864945,0.11350541,-0.7729891,0
line950,Patient V150 was evaluated for a deficit in vibratory sense. The patient also presented with an elevated GGT and an ataxic gait. Subsequent sequencing of c.2794C>T p.H932Y revealed a pathogenic variant.,Patient V150 was evaluated for a deficit in vibratory sense. The patient also presented wit[E1]h an elevated [/E1]GGT and an ataxic gait. Subsequent sequencing[E2] of c.2794C>T p.H93[/E2]2Y revealed a pathogenic variant., of c.2794C>T p.H93,GENE_VARIANT,150,169,h an elevated ,HPO_TERM,91,105,0.8893699,0.110630155,-0.77873975,0
line950,Patient V150 was evaluated for a deficit in vibratory sense. The patient also presented with an elevated GGT and an ataxic gait. Subsequent sequencing of c.2794C>T p.H932Y revealed a pathogenic variant.,Patient V150 was evaluated for a deficit in vibratory sense. The patient also presented with an elevated GGT a[E1]nd an ataxic [/E1]gait. Subsequent sequencing[E2] of c.2794C>T p.H93[/E2]2Y revealed a pathogenic variant., of c.2794C>T p.H93,GENE_VARIANT,150,169,nd an ataxic ,HPO_TERM,110,123,0.89193255,0.10806747,-0.7838651,0
line951,Patient V151 was evaluated for a forward-leaning posture. The patient also presented with an elevated GGT and parietal sharp waves on electroencephalogram. Subsequent sequencing of 2263A>G K755E revealed a pathogenic variant.,Patient V151 was evaluated for [E1]a forward-leaning postur[/E1]e. The patient also presented with an elevated GGT and parietal sharp waves on electroencephalogram. Subsequent sequencing[E2] of 2263A>G K[/E2]755E revealed a pathogenic variant., of 2263A>G K,GENE_VARIANT,177,190,a forward-leaning postur,HPO_TERM,31,55,0.88946474,0.11053522,-0.77892953,0
line951,Patient V151 was evaluated for a forward-leaning posture. The patient also presented with an elevated GGT and parietal sharp waves on electroencephalogram. Subsequent sequencing of 2263A>G K755E revealed a pathogenic variant.,Patient V151 was evaluated for a forward-leaning posture. The patient also presented with[E1] an elevated G[/E1]GT and parietal sharp waves on electroencephalogram. Subsequent sequencing[E2] of 2263A>G K[/E2]755E revealed a pathogenic variant., of 2263A>G K,GENE_VARIANT,177,190, an elevated G,HPO_TERM,89,103,0.885622,0.11437797,-0.77124405,0
line951,Patient V151 was evaluated for a forward-leaning posture. The patient also presented with an elevated GGT and parietal sharp waves on electroencephalogram. Subsequent sequencing of 2263A>G K755E revealed a pathogenic variant.,Patient V151 was evaluated for a forward-leaning posture. The patient also presented with an elevated GGT an[E1]d parietal sharp waves on electroencephalo[/E1]gram. Subsequent sequencing[E2] of 2263A>G K[/E2]755E revealed a pathogenic variant., of 2263A>G K,GENE_VARIANT,177,190,d parietal sharp waves on electroencephalo,HPO_TERM,108,150,0.889523,0.11047691,-0.7790461,0
line952,"We report the case of Patient V152, who has a history of impaired coordination during walking. Examination also revealed a focal motor seizure. The underlying cause was traced to a mutation in W748S.","We report the case of Patient V152, who has a history of [E1]impaired coordination during walki[/E1]ng. Examination also revealed a focal motor seizure. The underlying cause was traced to a mutation in W[E2]748S.[/E2]",748S.,GENE_VARIANT,194,199,impaired coordination during walki,HPO_TERM,57,91,0.75520194,0.24479805,-0.5104039,0
line952,"We report the case of Patient V152, who has a history of impaired coordination during walking. Examination also revealed a focal motor seizure. The underlying cause was traced to a mutation in W748S.","We report the case of Patient V152, who has a history of impaired coordination during walking. Examination also reveale[E1]d a focal motor seiz[/E1]ure. The underlying cause was traced to a mutation in W[E2]748S.[/E2]",748S.,GENE_VARIANT,194,199,d a focal motor seiz,HPO_TERM,119,139,0.74243796,0.25756204,-0.48487592,0
line954,Patient V154 was evaluated for an ataxic gait. The patient also presented with aphasia and reduced vibration sense. Subsequent sequencing of c3239G>C p.Ser1080Thr revealed a pathogenic variant.,Patient V154 was evaluated for [E1]an ataxic gai[/E1]t. The patient also presented with aphasia and reduced vibration sense. Subsequent sequencing o[E2]f c3239G>C p.Ser1080T[/E2]hr revealed a pathogenic variant.,f c3239G>C p.Ser1080T,GENE_VARIANT,139,160,an ataxic gai,HPO_TERM,31,44,0.8967916,0.103208415,-0.79358315,0
line954,Patient V154 was evaluated for an ataxic gait. The patient also presented with aphasia and reduced vibration sense. Subsequent sequencing of c3239G>C p.Ser1080Thr revealed a pathogenic variant.,Patient V154 was evaluated for an ataxic gait. The patient also presented with[E1] aphasi[/E1]a and reduced vibration sense. Subsequent sequencing o[E2]f c3239G>C p.Ser1080T[/E2]hr revealed a pathogenic variant.,f c3239G>C p.Ser1080T,GENE_VARIANT,139,160, aphasi,HPO_TERM,78,85,0.8934296,0.10657042,-0.78685915,0
line954,Patient V154 was evaluated for an ataxic gait. The patient also presented with aphasia and reduced vibration sense. Subsequent sequencing of c3239G>C p.Ser1080Thr revealed a pathogenic variant.,Patient V154 was evaluated for an ataxic gait. The patient also presented with aphasia and[E1] reduced vibration sen[/E1]se. Subsequent sequencing o[E2]f c3239G>C p.Ser1080T[/E2]hr revealed a pathogenic variant.,f c3239G>C p.Ser1080T,GENE_VARIANT,139,160, reduced vibration sen,HPO_TERM,90,112,0.8957314,0.10426856,-0.79146284,0
line955,The primary symptoms for Patient V155 were a language disorder and a forward-leaning posture. Analysis of the W748S was performed.,The primary symptoms for Patient V155 were a [E1]language disorder [/E1]and a forward-leaning posture. Analysis of the W74[E2]8S wa[/E2]s performed.,8S wa,GENE_VARIANT,113,118,language disorder ,HPO_TERM,45,63,0.7336261,0.26637387,-0.46725225,0
line955,The primary symptoms for Patient V155 were a language disorder and a forward-leaning posture. Analysis of the W748S was performed.,The primary symptoms for Patient V155 were a language disorder and a[E1] forward-leaning posture[/E1]. Analysis of the W74[E2]8S wa[/E2]s performed.,8S wa,GENE_VARIANT,113,118, forward-leaning posture,HPO_TERM,68,92,0.74761283,0.25238714,-0.4952257,0
line956,The primary symptoms for Patient V156 were parietal epileptiform discharges on EEG and a stooped posture. Analysis of the 2263A>G K755E was performed.,The primary symptoms for Patient V156 were pa[E1]rietal epileptiform discharges on EEG a[/E1]nd a stooped posture. Analysis of the 2263[E2]A>G K755E was[/E2] performed.,A>G K755E was,GENE_VARIANT,126,139,rietal epileptiform discharges on EEG a,HPO_TERM,45,84,0.8475292,0.1524709,-0.6950583,0
line957,The clinical profile for Patient V157 includes an ataxic gait and a coagulation disorder. Genetic analysis of G737R confirmed the diagnosis.,The clinical profile for Patient V157 includes [E1]an ataxic gai[/E1]t and a coagulation disorder. Genetic analysis of[E2] G737[/E2]R confirmed the diagnosis., G737,GENE_VARIANT,109,114,an ataxic gai,HPO_TERM,47,60,0.87755144,0.12244856,-0.7551029,0
line957,The clinical profile for Patient V157 includes an ataxic gait and a coagulation disorder. Genetic analysis of G737R confirmed the diagnosis.,The clinical profile for Patient V157 includes an ataxic gait and[E1] a coagulation disorde[/E1]r. Genetic analysis of[E2] G737[/E2]R confirmed the diagnosis., G737,GENE_VARIANT,109,114, a coagulation disorde,HPO_TERM,65,87,0.8853883,0.11461166,-0.7707766,0
line959,Patient V159 was evaluated for a stooped posture. The patient also presented with parietal sharp waves on electroencephalogram and reduced tendon reflexes. Subsequent sequencing of A467T revealed a pathogenic variant.,Patient V159 was evaluated for [E1]a stooped postur[/E1]e. The patient also presented with parietal sharp waves on electroencephalogram and reduced tendon reflexes. Subsequent sequencing [E2]of A4[/E2]67T revealed a pathogenic variant.,of A4,GENE_VARIANT,178,183,a stooped postur,HPO_TERM,31,47,0.88677806,0.11322192,-0.7735561,0
line959,Patient V159 was evaluated for a stooped posture. The patient also presented with parietal sharp waves on electroencephalogram and reduced tendon reflexes. Subsequent sequencing of A467T revealed a pathogenic variant.,Patient V159 was evaluated for a stooped posture. The patient also presented with[E1] parietal sharp waves on electroencephalog[/E1]ram and reduced tendon reflexes. Subsequent sequencing [E2]of A4[/E2]67T revealed a pathogenic variant.,of A4,GENE_VARIANT,178,183, parietal sharp waves on electroencephalog,HPO_TERM,81,123,0.87524086,0.12475914,-0.7504817,0
line959,Patient V159 was evaluated for a stooped posture. The patient also presented with parietal sharp waves on electroencephalogram and reduced tendon reflexes. Subsequent sequencing of A467T revealed a pathogenic variant.,Patient V159 was evaluated for a stooped posture. The patient also presented with parietal sharp waves on electroencephalogram a[E1]nd reduced tendon refle[/E1]xes. Subsequent sequencing [E2]of A4[/E2]67T revealed a pathogenic variant.,of A4,GENE_VARIANT,178,183,nd reduced tendon refle,HPO_TERM,128,151,0.88610005,0.113900006,-0.77220005,0
line962,The primary symptoms for Patient V162 were a hunched-over stance and an action tremor. Analysis of the c.1156C>T p.R386C was performed.,The primary symptoms for Patient V162 were a [E1]hunched-over stance [/E1]and an action tremor. Analysis of the c.1[E2]156C>T p.R386C wa[/E2]s performed.,156C>T p.R386C wa,GENE_VARIANT,106,123,hunched-over stance ,HPO_TERM,45,65,0.8454242,0.15457584,-0.69084835,0
line962,The primary symptoms for Patient V162 were a hunched-over stance and an action tremor. Analysis of the c.1156C>T p.R386C was performed.,The primary symptoms for Patient V162 were a hunched-over stance and a[E1]n action tremor[/E1]. Analysis of the c.1[E2]156C>T p.R386C wa[/E2]s performed.,156C>T p.R386C wa,GENE_VARIANT,106,123,n action tremor,HPO_TERM,70,85,0.8490083,0.15099171,-0.69801664,0
line963,The clinical profile for Patient V163 includes aphasia and a focal motor seizure. Genetic analysis of 15q26 118 kb deletion involving POLG1 gene and FANCI gene confirmed the diagnosis.,The clinical profile for Patient V163 includes [E1]aphasia[/E1] and a focal motor seizure. Genetic analysis of[E2] 15q26 118 kb deletion involving POLG1 gene and FANCI gene c[/E2]onfirmed the diagnosis., 15q26 118 kb deletion involving POLG1 gene and FANCI gene c,GENE_VARIANT,101,161,aphasia,HPO_TERM,47,54,0.84851235,0.15148765,-0.6970247,0
line963,The clinical profile for Patient V163 includes aphasia and a focal motor seizure. Genetic analysis of 15q26 118 kb deletion involving POLG1 gene and FANCI gene confirmed the diagnosis.,The clinical profile for Patient V163 includes aphasia and [E1]a focal motor seizur[/E1]e. Genetic analysis of[E2] 15q26 118 kb deletion involving POLG1 gene and FANCI gene c[/E2]onfirmed the diagnosis., 15q26 118 kb deletion involving POLG1 gene and FANCI gene c,GENE_VARIANT,101,161,a focal motor seizur,HPO_TERM,59,79,0.8551042,0.14489587,-0.71020836,0
line966,The primary symptoms for Patient V166 were focal motor seizures and an elevated GGT. Analysis of the c.3643+2T>C was performed.,The primary symptoms for Patient V166 were fo[E1]cal motor seizures a[/E1]nd an elevated GGT. Analysis of the c.36[E2]43+2T>C was [/E2]performed.,43+2T>C was ,GENE_VARIANT,105,117,cal motor seizures a,HPO_TERM,45,65,0.88229233,0.117707655,-0.76458466,0
line968,The clinical profile for Patient V168 includes a stooped posture and a postural or kinetic tremor. Genetic analysis of c.2794C>T p.H932Y confirmed the diagnosis.,The clinical profile for Patient V168 includes [E1]a stooped postur[/E1]e and a postural or kinetic tremor. Genetic analysis o[E2]f c.2794C>T p.H932Y[/E2] confirmed the diagnosis.,f c.2794C>T p.H932Y,GENE_VARIANT,117,136,a stooped postur,HPO_TERM,47,63,0.884507,0.11549295,-0.76901406,0
line968,The clinical profile for Patient V168 includes a stooped posture and a postural or kinetic tremor. Genetic analysis of c.2794C>T p.H932Y confirmed the diagnosis.,The clinical profile for Patient V168 includes a stooped posture and[E1] a postural or kinetic trem[/E1]or. Genetic analysis o[E2]f c.2794C>T p.H932Y[/E2] confirmed the diagnosis.,f c.2794C>T p.H932Y,GENE_VARIANT,117,136, a postural or kinetic trem,HPO_TERM,68,95,0.8846003,0.1153997,-0.76920056,0
line970,Patient V170 was evaluated for parietal epileptiform discharges on EEG. The patient also presented with an ataxic gait and a focal motor seizure. Subsequent sequencing of 15q26 118 kb deletion involving POLG1 gene and FANCI gene revealed a pathogenic variant.,Patient V170 was evaluated for [E1]parietal epileptiform discharges on EEG[/E1]. The patient also presented with an ataxic gait and a focal motor seizure. Subsequent sequencing o[E2]f 15q26 118 kb deletion involving POLG1 gene and FANCI gene [/E2]revealed a pathogenic variant.,f 15q26 118 kb deletion involving POLG1 gene and FANCI gene ,GENE_VARIANT,169,229,parietal epileptiform discharges on EEG,HPO_TERM,31,70,0.81524545,0.18475457,-0.6304909,0
line970,Patient V170 was evaluated for parietal epileptiform discharges on EEG. The patient also presented with an ataxic gait and a focal motor seizure. Subsequent sequencing of 15q26 118 kb deletion involving POLG1 gene and FANCI gene revealed a pathogenic variant.,Patient V170 was evaluated for parietal epileptiform discharges on EEG. The patient also presented with [E1]an ataxic gai[/E1]t and a focal motor seizure. Subsequent sequencing o[E2]f 15q26 118 kb deletion involving POLG1 gene and FANCI gene [/E2]revealed a pathogenic variant.,f 15q26 118 kb deletion involving POLG1 gene and FANCI gene ,GENE_VARIANT,169,229,an ataxic gai,HPO_TERM,104,117,0.8342965,0.16570343,-0.6685931,0
line970,Patient V170 was evaluated for parietal epileptiform discharges on EEG. The patient also presented with an ataxic gait and a focal motor seizure. Subsequent sequencing of 15q26 118 kb deletion involving POLG1 gene and FANCI gene revealed a pathogenic variant.,Patient V170 was evaluated for parietal epileptiform discharges on EEG. The patient also presented with an ataxic gait and[E1] a focal motor seizu[/E1]re. Subsequent sequencing o[E2]f 15q26 118 kb deletion involving POLG1 gene and FANCI gene [/E2]revealed a pathogenic variant.,f 15q26 118 kb deletion involving POLG1 gene and FANCI gene ,GENE_VARIANT,169,229, a focal motor seizu,HPO_TERM,122,142,0.8153329,0.18466707,-0.63066584,0
line971,The clinical profile for Patient V171 includes reduced tendon reflexes and a stooped posture. Genetic analysis of 2263A>G K755E confirmed the diagnosis.,The clinical profile for Patient V171 includes [E1]reduced tendon reflexes[/E1] and a stooped posture. Genetic analysis of[E2] 2263A>G K755[/E2]E confirmed the diagnosis., 2263A>G K755,GENE_VARIANT,113,126,reduced tendon reflexes,HPO_TERM,47,70,0.8823325,0.117667444,-0.76466507,0
line971,The clinical profile for Patient V171 includes reduced tendon reflexes and a stooped posture. Genetic analysis of 2263A>G K755E confirmed the diagnosis.,The clinical profile for Patient V171 includes reduced tendon reflexes and [E1]a stooped postur[/E1]e. Genetic analysis of[E2] 2263A>G K755[/E2]E confirmed the diagnosis., 2263A>G K755,GENE_VARIANT,113,126,a stooped postur,HPO_TERM,75,91,0.89203095,0.10796908,-0.78406185,0
line972,"This report details Patient V172, a patient with a postural or kinetic tremor. Further investigation showed aphasia and a deficit in vibratory sense. A known variant in c3239G>C p.Ser1080Thr was identified.","This report details Patient V172, a patient with [E1]a postural or kinetic tremo[/E1]r. Further investigation showed aphasia and a deficit in vibratory sense. A known variant [E2]in c3239G>C p.Ser1080[/E2]Thr was identified.",in c3239G>C p.Ser1080,GENE_VARIANT,166,187,a postural or kinetic tremo,HPO_TERM,49,76,0.8786483,0.12135177,-0.7572965,0
line972,"This report details Patient V172, a patient with a postural or kinetic tremor. Further investigation showed aphasia and a deficit in vibratory sense. A known variant in c3239G>C p.Ser1080Thr was identified.","This report details Patient V172, a patient with a postural or kinetic tremor. Further investigation showed[E1] aphasi[/E1]a and a deficit in vibratory sense. A known variant [E2]in c3239G>C p.Ser1080[/E2]Thr was identified.",in c3239G>C p.Ser1080,GENE_VARIANT,166,187, aphasi,HPO_TERM,107,114,0.8717108,0.12828922,-0.74342155,0
line972,"This report details Patient V172, a patient with a postural or kinetic tremor. Further investigation showed aphasia and a deficit in vibratory sense. A known variant in c3239G>C p.Ser1080Thr was identified.","This report details Patient V172, a patient with a postural or kinetic tremor. Further investigation showed aphasia and[E1] a deficit in vibratory se[/E1]nse. A known variant [E2]in c3239G>C p.Ser1080[/E2]Thr was identified.",in c3239G>C p.Ser1080,GENE_VARIANT,166,187, a deficit in vibratory se,HPO_TERM,119,145,0.8692517,0.13074824,-0.73850346,0
line973,Patient V173 was evaluated for an ataxic gait. The patient also presented with a coagulation disorder and reduced vibration sense. Subsequent sequencing of A467T revealed a pathogenic variant.,Patient V173 was evaluated for [E1]an ataxic gai[/E1]t. The patient also presented with a coagulation disorder and reduced vibration sense. Subsequent sequencing o[E2]f A46[/E2]7T revealed a pathogenic variant.,f A46,GENE_VARIANT,154,159,an ataxic gai,HPO_TERM,31,44,0.893082,0.10691794,-0.7861641,0
line973,Patient V173 was evaluated for an ataxic gait. The patient also presented with a coagulation disorder and reduced vibration sense. Subsequent sequencing of A467T revealed a pathogenic variant.,Patient V173 was evaluated for an ataxic gait. The patient also presented with[E1] a coagulation disorde[/E1]r and reduced vibration sense. Subsequent sequencing o[E2]f A46[/E2]7T revealed a pathogenic variant.,f A46,GENE_VARIANT,154,159, a coagulation disorde,HPO_TERM,78,100,0.8873191,0.11268096,-0.7746381,0
line973,Patient V173 was evaluated for an ataxic gait. The patient also presented with a coagulation disorder and reduced vibration sense. Subsequent sequencing of A467T revealed a pathogenic variant.,Patient V173 was evaluated for an ataxic gait. The patient also presented with a coagulation disorder and[E1] reduced vibration sen[/E1]se. Subsequent sequencing o[E2]f A46[/E2]7T revealed a pathogenic variant.,f A46,GENE_VARIANT,154,159, reduced vibration sen,HPO_TERM,105,127,0.88961804,0.110381916,-0.77923614,0
line974,Patient V174 was evaluated for a deficit in vibratory sense. The patient also presented with a language disorder and parietal epileptiform discharges on EEG. Subsequent sequencing of c.2794C>T p.H932Y revealed a pathogenic variant.,Patient V174 was evaluated for [E1]a deficit in vibratory sen[/E1]se. The patient also presented with a language disorder and parietal epileptiform discharges on EEG. Subsequent sequencing [E2]of c.2794C>T p.H932[/E2]Y revealed a pathogenic variant.,of c.2794C>T p.H932,GENE_VARIANT,180,199,a deficit in vibratory sen,HPO_TERM,31,57,0.8917502,0.10824976,-0.78350043,0
line974,Patient V174 was evaluated for a deficit in vibratory sense. The patient also presented with a language disorder and parietal epileptiform discharges on EEG. Subsequent sequencing of c.2794C>T p.H932Y revealed a pathogenic variant.,Patient V174 was evaluated for a deficit in vibratory sense. The patient also presented wit[E1]h a language disor[/E1]der and parietal epileptiform discharges on EEG. Subsequent sequencing [E2]of c.2794C>T p.H932[/E2]Y revealed a pathogenic variant.,of c.2794C>T p.H932,GENE_VARIANT,180,199,h a language disor,HPO_TERM,91,109,0.8897053,0.11029472,-0.7794106,0
line974,Patient V174 was evaluated for a deficit in vibratory sense. The patient also presented with a language disorder and parietal epileptiform discharges on EEG. Subsequent sequencing of c.2794C>T p.H932Y revealed a pathogenic variant.,Patient V174 was evaluated for a deficit in vibratory sense. The patient also presented with a language disorder a[E1]nd parietal epileptiform discharges on [/E1]EEG. Subsequent sequencing [E2]of c.2794C>T p.H932[/E2]Y revealed a pathogenic variant.,of c.2794C>T p.H932,GENE_VARIANT,180,199,nd parietal epileptiform discharges on ,HPO_TERM,114,153,0.89276505,0.10723489,-0.78553015,0
line975,The primary symptoms for Patient V175 were an ataxic gait and a coagulation disorder. Analysis of the 15q26 118 kb deletion involving POLG1 gene and FANCI gene was performed.,The primary symptoms for Patient V175 were an[E1] ataxic gait [/E1]and a coagulation disorder. Analysis of the 15q2[E2]6 118 kb deletion involving POLG1 gene and FANCI gene was pe[/E2]rformed.,6 118 kb deletion involving POLG1 gene and FANCI gene was pe,GENE_VARIANT,106,166, ataxic gait ,HPO_TERM,45,58,0.811442,0.18855797,-0.62288404,0
line976,The clinical profile for Patient V176 includes an elevated GGT and a forward-leaning posture. Genetic analysis of W748S confirmed the diagnosis.,The clinical profile for Patient V176 includes [E1]an elevated GG[/E1]T and a forward-leaning posture. Genetic analysis o[E2]f W74[/E2]8S confirmed the diagnosis.,f W74,GENE_VARIANT,112,117,an elevated GG,HPO_TERM,47,61,0.8820964,0.11790365,-0.76419276,0
line976,The clinical profile for Patient V176 includes an elevated GGT and a forward-leaning posture. Genetic analysis of W748S confirmed the diagnosis.,The clinical profile for Patient V176 includes an elevated GGT and[E1] a forward-leaning postu[/E1]re. Genetic analysis o[E2]f W74[/E2]8S confirmed the diagnosis.,f W74,GENE_VARIANT,112,117, a forward-leaning postu,HPO_TERM,66,90,0.88336515,0.11663478,-0.76673037,0
line977,Patient V177 was evaluated for a forward-leaning posture. The patient also presented with aphasia and a focal motor seizure. Subsequent sequencing of c.3643+2T>C revealed a pathogenic variant.,Patient V177 was evaluated for [E1]a forward-leaning postur[/E1]e. The patient also presented with aphasia and a focal motor seizure. Subsequent sequencing o[E2]f c.3643+2T>[/E2]C revealed a pathogenic variant.,f c.3643+2T>,GENE_VARIANT,148,160,a forward-leaning postur,HPO_TERM,31,55,0.88878626,0.111213796,-0.77757245,0
line977,Patient V177 was evaluated for a forward-leaning posture. The patient also presented with aphasia and a focal motor seizure. Subsequent sequencing of c.3643+2T>C revealed a pathogenic variant.,Patient V177 was evaluated for a forward-leaning posture. The patient also presented with[E1] aphasi[/E1]a and a focal motor seizure. Subsequent sequencing o[E2]f c.3643+2T>[/E2]C revealed a pathogenic variant.,f c.3643+2T>,GENE_VARIANT,148,160, aphasi,HPO_TERM,89,96,0.88844407,0.11155593,-0.77688813,0
line977,Patient V177 was evaluated for a forward-leaning posture. The patient also presented with aphasia and a focal motor seizure. Subsequent sequencing of c.3643+2T>C revealed a pathogenic variant.,Patient V177 was evaluated for a forward-leaning posture. The patient also presented with aphasia and[E1] a focal motor seizu[/E1]re. Subsequent sequencing o[E2]f c.3643+2T>[/E2]C revealed a pathogenic variant.,f c.3643+2T>,GENE_VARIANT,148,160, a focal motor seizu,HPO_TERM,101,121,0.88691527,0.11308471,-0.77383053,0
line978,The primary symptoms for Patient V178 were reduced tendon reflexes and a postural or kinetic tremor. Analysis of the c.2794C>T p.H932Y was performed.,The primary symptoms for Patient V178 were re[E1]duced tendon reflexes a[/E1]nd a postural or kinetic tremor. Analysis of the c.27[E2]94C>T p.H932Y was p[/E2]erformed.,94C>T p.H932Y was p,GENE_VARIANT,121,140,duced tendon reflexes a,HPO_TERM,45,68,0.87231225,0.12768777,-0.7446245,0
line981,Patient V181 was evaluated for a postural or kinetic tremor. The patient also presented with a coagulation disorder and reduced tendon reflexes. Subsequent sequencing of c.3643+2T>C revealed a pathogenic variant.,Patient V181 was evaluated for [E1]a postural or kinetic tremo[/E1]r. The patient also presented with a coagulation disorder and reduced tendon reflexes. Subsequent sequencing of[E2] c.3643+2T>C[/E2] revealed a pathogenic variant., c.3643+2T>C,GENE_VARIANT,169,181,a postural or kinetic tremo,HPO_TERM,31,58,0.8893429,0.11065706,-0.77868587,0
line981,Patient V181 was evaluated for a postural or kinetic tremor. The patient also presented with a coagulation disorder and reduced tendon reflexes. Subsequent sequencing of c.3643+2T>C revealed a pathogenic variant.,Patient V181 was evaluated for a postural or kinetic tremor. The patient also presented with[E1] a coagulation disorde[/E1]r and reduced tendon reflexes. Subsequent sequencing of[E2] c.3643+2T>C[/E2] revealed a pathogenic variant., c.3643+2T>C,GENE_VARIANT,169,181, a coagulation disorde,HPO_TERM,92,114,0.8861493,0.11385079,-0.7722985,0
line981,Patient V181 was evaluated for a postural or kinetic tremor. The patient also presented with a coagulation disorder and reduced tendon reflexes. Subsequent sequencing of c.3643+2T>C revealed a pathogenic variant.,Patient V181 was evaluated for a postural or kinetic tremor. The patient also presented with a coagulation disorder and[E1] reduced tendon reflexe[/E1]s. Subsequent sequencing of[E2] c.3643+2T>C[/E2] revealed a pathogenic variant., c.3643+2T>C,GENE_VARIANT,169,181, reduced tendon reflexe,HPO_TERM,119,142,0.8905076,0.10949242,-0.78101516,0
line983,The clinical profile for Patient V183 includes a forward-leaning posture and an ataxic gait. Genetic analysis of c.2794C>T p.H932Y confirmed the diagnosis.,The clinical profile for Patient V183 includes [E1]a forward-leaning postur[/E1]e and an ataxic gait. Genetic analysis o[E2]f c.2794C>T p.H932Y[/E2] confirmed the diagnosis.,f c.2794C>T p.H932Y,GENE_VARIANT,111,130,a forward-leaning postur,HPO_TERM,47,71,0.87415516,0.12584478,-0.7483104,0
line983,The clinical profile for Patient V183 includes a forward-leaning posture and an ataxic gait. Genetic analysis of c.2794C>T p.H932Y confirmed the diagnosis.,The clinical profile for Patient V183 includes a forward-leaning posture and[E1] an ataxic ga[/E1]it. Genetic analysis o[E2]f c.2794C>T p.H932Y[/E2] confirmed the diagnosis.,f c.2794C>T p.H932Y,GENE_VARIANT,111,130, an ataxic ga,HPO_TERM,76,89,0.8789602,0.12103983,-0.7579204,0
line984,"This report details Patient V184, a patient with focal motor seizures. Further investigation showed a forward-leaning posture and a language disorder. A known variant in G737R was identified.","This report details Patient V184, a patient with [E1]focal motor seizures[/E1]. Further investigation showed a forward-leaning posture and a language disorder. A known variant i[E2]n G73[/E2]7R was identified.",n G73,GENE_VARIANT,168,173,focal motor seizures,HPO_TERM,49,69,0.8816848,0.11831522,-0.76336956,0
line984,"This report details Patient V184, a patient with focal motor seizures. Further investigation showed a forward-leaning posture and a language disorder. A known variant in G737R was identified.","This report details Patient V184, a patient with focal motor seizures. Further investigation showed [E1]a forward-leaning postur[/E1]e and a language disorder. A known variant i[E2]n G73[/E2]7R was identified.",n G73,GENE_VARIANT,168,173,a forward-leaning postur,HPO_TERM,100,124,0.8831173,0.116882704,-0.76623464,0
line984,"This report details Patient V184, a patient with focal motor seizures. Further investigation showed a forward-leaning posture and a language disorder. A known variant in G737R was identified.","This report details Patient V184, a patient with focal motor seizures. Further investigation showed a forward-leaning posture and[E1] a language disord[/E1]er. A known variant i[E2]n G73[/E2]7R was identified.",n G73,GENE_VARIANT,168,173, a language disord,HPO_TERM,129,147,0.8929658,0.1070342,-0.7859316,0
line985,The primary symptoms for Patient V185 were a forward-leaning posture and a focal motor seizure. Analysis of the R853W was performed.,The primary symptoms for Patient V185 were a [E1]forward-leaning posture [/E1]and a focal motor seizure. Analysis of the R85[E2]3W wa[/E2]s performed.,3W wa,GENE_VARIANT,115,120,forward-leaning posture ,HPO_TERM,45,69,0.80868924,0.19131075,-0.6173785,0
line985,The primary symptoms for Patient V185 were a forward-leaning posture and a focal motor seizure. Analysis of the R853W was performed.,The primary symptoms for Patient V185 were a forward-leaning posture and a[E1] focal motor seizure[/E1]. Analysis of the R85[E2]3W wa[/E2]s performed.,3W wa,GENE_VARIANT,115,120, focal motor seizure,HPO_TERM,74,94,0.79896086,0.20103912,-0.5979217,0
line987,The clinical profile for Patient V187 includes an ataxic gait and an elevated GGT. Genetic analysis of c.3643+2T>C confirmed the diagnosis.,The clinical profile for Patient V187 includes [E1]an ataxic gai[/E1]t and an elevated GGT. Genetic analysis o[E2]f c.3643+2T>[/E2]C confirmed the diagnosis.,f c.3643+2T>,GENE_VARIANT,101,113,an ataxic gai,HPO_TERM,47,60,0.8905762,0.109423764,-0.7811524,0
line987,The clinical profile for Patient V187 includes an ataxic gait and an elevated GGT. Genetic analysis of c.3643+2T>C confirmed the diagnosis.,The clinical profile for Patient V187 includes an ataxic gait and[E1] an elevated G[/E1]GT. Genetic analysis o[E2]f c.3643+2T>[/E2]C confirmed the diagnosis.,f c.3643+2T>,GENE_VARIANT,101,113, an elevated G,HPO_TERM,65,79,0.889441,0.11055905,-0.77888197,0
line988,Patient V188 was evaluated for a language disorder. The patient also presented with a stooped posture and reduced tendon reflexes. Subsequent sequencing of A467T revealed a pathogenic variant.,Patient V188 was evaluated for [E1]a language disorde[/E1]r. The patient also presented with a stooped posture and reduced tendon reflexes. Subsequent sequencing o[E2]f A46[/E2]7T revealed a pathogenic variant.,f A46,GENE_VARIANT,154,159,a language disorde,HPO_TERM,31,49,0.8863507,0.11364937,-0.7727013,0
line988,Patient V188 was evaluated for a language disorder. The patient also presented with a stooped posture and reduced tendon reflexes. Subsequent sequencing of A467T revealed a pathogenic variant.,Patient V188 was evaluated for a language disorder. The patient also presented with[E1] a stooped postu[/E1]re and reduced tendon reflexes. Subsequent sequencing o[E2]f A46[/E2]7T revealed a pathogenic variant.,f A46,GENE_VARIANT,154,159, a stooped postu,HPO_TERM,83,99,0.8778332,0.12216687,-0.7556663,0
line988,Patient V188 was evaluated for a language disorder. The patient also presented with a stooped posture and reduced tendon reflexes. Subsequent sequencing of A467T revealed a pathogenic variant.,Patient V188 was evaluated for a language disorder. The patient also presented with a stooped posture an[E1]d reduced tendon reflex[/E1]es. Subsequent sequencing o[E2]f A46[/E2]7T revealed a pathogenic variant.,f A46,GENE_VARIANT,154,159,d reduced tendon reflex,HPO_TERM,104,127,0.8846661,0.11533396,-0.7693321,0
line990,Patient V190 was evaluated for a deficit in vibratory sense. The patient also presented with an ataxic gait and a hunched-over stance. Subsequent sequencing of 2263A>G K755E revealed a pathogenic variant.,Patient V190 was evaluated for [E1]a deficit in vibratory sen[/E1]se. The patient also presented with an ataxic gait and a hunched-over stance. Subsequent sequencing[E2] of 2263A>G K[/E2]755E revealed a pathogenic variant., of 2263A>G K,GENE_VARIANT,156,169,a deficit in vibratory sen,HPO_TERM,31,57,0.881271,0.118729,-0.762542,0
line990,Patient V190 was evaluated for a deficit in vibratory sense. The patient also presented with an ataxic gait and a hunched-over stance. Subsequent sequencing of 2263A>G K755E revealed a pathogenic variant.,Patient V190 was evaluated for a deficit in vibratory sense. The patient also presented wit[E1]h an ataxic g[/E1]ait and a hunched-over stance. Subsequent sequencing[E2] of 2263A>G K[/E2]755E revealed a pathogenic variant., of 2263A>G K,GENE_VARIANT,156,169,h an ataxic g,HPO_TERM,91,104,0.87882876,0.121171206,-0.7576575,0
line990,Patient V190 was evaluated for a deficit in vibratory sense. The patient also presented with an ataxic gait and a hunched-over stance. Subsequent sequencing of 2263A>G K755E revealed a pathogenic variant.,Patient V190 was evaluated for a deficit in vibratory sense. The patient also presented with an ataxic gait a[E1]nd a hunched-over st[/E1]ance. Subsequent sequencing[E2] of 2263A>G K[/E2]755E revealed a pathogenic variant., of 2263A>G K,GENE_VARIANT,156,169,nd a hunched-over st,HPO_TERM,109,129,0.8861024,0.11389765,-0.77220476,0
line991,The primary symptoms for Patient V191 were aphasia and a focal motor seizure. Analysis of the c3239G>C p.Ser1080Thr was performed.,The primary symptoms for Patient V191 were ap[E1]hasia a[/E1]nd a focal motor seizure. Analysis of the c323[E2]9G>C p.Ser1080Thr was[/E2] performed.,9G>C p.Ser1080Thr was,GENE_VARIANT,98,119,hasia a,HPO_TERM,45,52,0.88187087,0.118129104,-0.76374173,0
line993,The clinical profile for Patient V193 includes a focal motor seizure and a forward-leaning posture. Genetic analysis of 1868T>G L623W confirmed the diagnosis.,The clinical profile for Patient V193 includes [E1]a focal motor seizur[/E1]e and a forward-leaning posture. Genetic analysis o[E2]f 1868T>G L62[/E2]3W confirmed the diagnosis.,f 1868T>G L62,GENE_VARIANT,118,131,a focal motor seizur,HPO_TERM,47,67,0.8778736,0.12212641,-0.7557472,0
line993,The clinical profile for Patient V193 includes a focal motor seizure and a forward-leaning posture. Genetic analysis of 1868T>G L623W confirmed the diagnosis.,The clinical profile for Patient V193 includes a focal motor seizure and[E1] a forward-leaning postu[/E1]re. Genetic analysis o[E2]f 1868T>G L62[/E2]3W confirmed the diagnosis.,f 1868T>G L62,GENE_VARIANT,118,131, a forward-leaning postu,HPO_TERM,72,96,0.8767727,0.12322728,-0.7535454,0
line994,The clinical profile for Patient V194 includes reduced vibration sense and a coagulation disorder. Genetic analysis of 15q26 118 kb deletion involving POLG1 gene and FANCI gene confirmed the diagnosis.,The clinical profile for Patient V194 includes [E1]reduced vibration sens[/E1]e and a coagulation disorder. Genetic analysis of[E2] 15q26 118 kb deletion involving POLG1 gene and FANCI gene c[/E2]onfirmed the diagnosis., 15q26 118 kb deletion involving POLG1 gene and FANCI gene c,GENE_VARIANT,118,178,reduced vibration sens,HPO_TERM,47,69,0.86402136,0.13597864,-0.7280427,0
line994,The clinical profile for Patient V194 includes reduced vibration sense and a coagulation disorder. Genetic analysis of 15q26 118 kb deletion involving POLG1 gene and FANCI gene confirmed the diagnosis.,The clinical profile for Patient V194 includes reduced vibration sense and[E1] a coagulation disorde[/E1]r. Genetic analysis of[E2] 15q26 118 kb deletion involving POLG1 gene and FANCI gene c[/E2]onfirmed the diagnosis., 15q26 118 kb deletion involving POLG1 gene and FANCI gene c,GENE_VARIANT,118,178, a coagulation disorde,HPO_TERM,74,96,0.86547947,0.13452053,-0.73095894,0
line995,Patient V195 was evaluated for a focal motor seizure. The patient also presented with a coagulation disorder and reduced vibration sense. Subsequent sequencing of 2263A>G K755E revealed a pathogenic variant.,Patient V195 was evaluated for [E1]a focal motor seizur[/E1]e. The patient also presented with a coagulation disorder and reduced vibration sense. Subsequent sequencing o[E2]f 2263A>G K75[/E2]5E revealed a pathogenic variant.,f 2263A>G K75,GENE_VARIANT,161,174,a focal motor seizur,HPO_TERM,31,51,0.8960987,0.103901364,-0.7921973,0
line995,Patient V195 was evaluated for a focal motor seizure. The patient also presented with a coagulation disorder and reduced vibration sense. Subsequent sequencing of 2263A>G K755E revealed a pathogenic variant.,Patient V195 was evaluated for a focal motor seizure. The patient also presented with[E1] a coagulation disorde[/E1]r and reduced vibration sense. Subsequent sequencing o[E2]f 2263A>G K75[/E2]5E revealed a pathogenic variant.,f 2263A>G K75,GENE_VARIANT,161,174, a coagulation disorde,HPO_TERM,85,107,0.8901437,0.109856345,-0.7802873,0
line995,Patient V195 was evaluated for a focal motor seizure. The patient also presented with a coagulation disorder and reduced vibration sense. Subsequent sequencing of 2263A>G K755E revealed a pathogenic variant.,Patient V195 was evaluated for a focal motor seizure. The patient also presented with a coagulation disorder and[E1] reduced vibration sen[/E1]se. Subsequent sequencing o[E2]f 2263A>G K75[/E2]5E revealed a pathogenic variant.,f 2263A>G K75,GENE_VARIANT,161,174, reduced vibration sen,HPO_TERM,112,134,0.89354753,0.10645251,-0.787095,0
line997,The clinical profile for Patient V197 includes bilateral grand mal seizures and weight loss. Genetic analysis of c3239G>C p.Ser1080Thr confirmed the diagnosis.,The clinical profile for Patient V197 includes [E1]bilateral grand mal seizures[/E1] and weight loss. Genetic analysis of c323[E2]9G>C p.Ser1080Thr con[/E2]firmed the diagnosis.,9G>C p.Ser1080Thr con,GENE_VARIANT,117,138,bilateral grand mal seizures,HPO_TERM,47,75,0.884543,0.11545701,-0.769086,0
line997,The clinical profile for Patient V197 includes bilateral grand mal seizures and weight loss. Genetic analysis of c3239G>C p.Ser1080Thr confirmed the diagnosis.,The clinical profile for Patient V197 includes bilateral grand mal seizures and [E1]weight loss[/E1]. Genetic analysis of c323[E2]9G>C p.Ser1080Thr con[/E2]firmed the diagnosis.,9G>C p.Ser1080Thr con,GENE_VARIANT,117,138,weight loss,HPO_TERM,80,91,0.8858029,0.11419708,-0.77160585,0
line998,"We report the case of Patient V198, who has a history of reduced vocal volume. Examination also revealed a diagnosis of focal-onset seizures. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient V198, who has a history of [E1]reduced vocal volume[/E1]. Examination also revealed a diagnosis of focal-onset seizures. The underlying cause was traced to a mutation in the [E2]POLG[/E2] gene.",POLG,GENE_VARIANT,195,199,reduced vocal volume,HPO_TERM,57,77,0.5780665,0.4219335,-0.15613303,0
line998,"We report the case of Patient V198, who has a history of reduced vocal volume. Examination also revealed a diagnosis of focal-onset seizures. The underlying cause was traced to a mutation in the POLG gene.","We report the case of Patient V198, who has a history of reduced vocal volume. Examination also revealed [E1]a diagnosis of focal-onset seizures[/E1]. The underlying cause was traced to a mutation in the [E2]POLG[/E2] gene.",POLG,GENE_VARIANT,195,199,a diagnosis of focal-onset seizures,HPO_TERM,105,140,0.5996355,0.4003645,-0.199271,0
line999,Patient V199 was evaluated for an action tremor. The patient also presented with a focal motor seizure and aphasia. Subsequent sequencing of c.2794C>T p.H932Y revealed a pathogenic variant.,Patient V199 was evaluated for [E1]an action tremo[/E1]r. The patient also presented with a focal motor seizure and aphasia. Subsequent sequencing o[E2]f c.2794C>T p.H932Y[/E2] revealed a pathogenic variant.,f c.2794C>T p.H932Y,GENE_VARIANT,139,158,an action tremo,HPO_TERM,31,46,0.8790183,0.12098165,-0.7580367,0
line999,Patient V199 was evaluated for an action tremor. The patient also presented with a focal motor seizure and aphasia. Subsequent sequencing of c.2794C>T p.H932Y revealed a pathogenic variant.,Patient V199 was evaluated for an action tremor. The patient also presented with[E1] a focal motor seizu[/E1]re and aphasia. Subsequent sequencing o[E2]f c.2794C>T p.H932Y[/E2] revealed a pathogenic variant.,f c.2794C>T p.H932Y,GENE_VARIANT,139,158, a focal motor seizu,HPO_TERM,80,100,0.87155294,0.12844713,-0.7431058,0
line999,Patient V199 was evaluated for an action tremor. The patient also presented with a focal motor seizure and aphasia. Subsequent sequencing of c.2794C>T p.H932Y revealed a pathogenic variant.,Patient V199 was evaluated for an action tremor. The patient also presented with a focal motor seizure an[E1]d aphas[/E1]ia. Subsequent sequencing o[E2]f c.2794C>T p.H932Y[/E2] revealed a pathogenic variant.,f c.2794C>T p.H932Y,GENE_VARIANT,139,158,d aphas,HPO_TERM,105,112,0.8880154,0.11198458,-0.7760308,0
